Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	O
Drugs	B-TREATMENT

Chief	O
Complaint:	O
recent	B-PROBLEM
mild	I-PROBLEM
angina	I-PROBLEM
with	O
exertion	O

emergency	B-TREATMENT
CABG	I-TREATMENT
X	O
3	O
(	O
2017-06-13	O
)(	O
LIMA	B-TREATMENT
to	I-TREATMENT
LAD	I-TREATMENT
,	O
SVG	B-TREATMENT
to	I-TREATMENT
ramus	I-TREATMENT
,	O
SVG	B-TREATMENT
to	I-TREATMENT
OM	I-TREATMENT
)	O

61	O
yo	O
African-American-Hispanic	O
male	O
had	O
abnormal	B-PROBLEM
EKG	I-PROBLEM
found	O
as	O
part	O
of	O
pre-op	B-TEST
eval.	I-TEST
for	O
ventral	B-TREATMENT
hernia	I-TREATMENT
repair	I-TREATMENT
.	O

Had	O
subsequent	O
abnormal	B-PROBLEM
stress	I-PROBLEM
test	I-PROBLEM
and	O
pefusion	B-TEST
imaging	I-TEST
showed	O
EF	B-TEST
38%	O
with	O
perfusion	B-PROBLEM
defects	I-PROBLEM
.	O

Echo	B-TEST
prior	O
to	O
scheduled	B-TEST
cath	I-TEST
showed	O
mild	B-PROBLEM
LVH	I-PROBLEM
,	O
inferior	B-PROBLEM
HK	I-PROBLEM
,	O
EF	B-TEST
40%	O
,	O
mild	B-PROBLEM
MR	I-PROBLEM
,	O
mild	B-PROBLEM
LAE	I-PROBLEM
.	O

Cath	B-TEST
at	O
Kindred/North	O
Shore	O
today	O
showed	O
80%	B-PROBLEM
LM	I-PROBLEM
lesion	I-PROBLEM
with	O
normal	O
LAD	O
,	O
CX	O
,	O
RCA	O
.	O

Severe	B-PROBLEM
systolic	I-PROBLEM
HTN	I-PROBLEM
also	O
noted	O
.	O

Transferred	O
in	O
urgently	O
for	O
cabg	B-TREATMENT
with	O
Dr.	O
Howard	O
.	O

ventral	B-PROBLEM
hernia	I-PROBLEM

HTN	B-PROBLEM
elev.	B-PROBLEM
chol.	I-PROBLEM
right	B-PROBLEM
facial	I-PROBLEM
droop	I-PROBLEM
with	O
metal	B-TREATMENT
plate	I-TREATMENT
secondary	O
to	O
GSW	B-PROBLEM
to	O
face	B-TREATMENT
right	I-TREATMENT
nephrectomy	I-TREATMENT

2017-06-14	O
02:06AM	O
BLOOD	B-TEST

WBC	B-TEST
-	O
9.4	O
RBC	B-TEST
-	O
3.61*	O
Hgb	B-TEST
-	O
10.4*	O
Hct	B-TEST
-	O
29.9*	O
MCV	B-TEST
-	O
83	O
MCH	B-TEST
-	O
28.8	O
MCHC	B-TEST
-	O
34.8	O
RDW	B-TEST
-	O
14.3	O
Plt	B-TEST
Ct	I-TEST
-	O
154	O

2017-06-17	O
05:14AM	O
BLOOD	B-TEST

Hct	B-TEST
-	O
25.2*	O

2017-06-14	O
02:06AM	O
BLOOD	B-TEST

Plt	B-TEST
Ct	I-TEST
-	O
154	O

2017-06-13	O
08:05PM	O
BLOOD	B-TEST

PT	B-TEST
-	O
13.6*	O
PTT	B-TEST
-	O
33.3	O
INR	B-TEST
(	O
PT	B-TEST
)	O
-	O
1.2*	O

2017-06-17	O
05:14AM	O
BLOOD	B-TEST

UreaN	B-TEST
-	O
25*	O
Creat	B-TEST
-	O
1.0	O
K	B-TEST
-	O
3.9	O

2017-06-15	O
02:02PM	O
BLOOD	B-TEST

Mg	B-TEST
-	O
2.1	O

TWO	B-TEST
VIEW	I-TEST
CHEST	I-TEST
,	O
2017-06-17	O

Status	O
post	O
coronary	B-TREATMENT
bypass	I-TREATMENT
surgery	I-TREATMENT
.	O

There	O
has	O
been	O
removal	O
of	O
a	B-TREATMENT
Swan-Ganz	I-TREATMENT
catheter	I-TREATMENT
and	O
placement	O
of	O
a	B-TREATMENT
right	I-TREATMENT
internal	I-TREATMENT
jugular	I-TREATMENT
vascular	I-TREATMENT
catheter	I-TREATMENT
,	O
with	O
the	O
tip	O
terminating	O
in	O
the	O
proximal	O
right	O
atrium	O
just	O
below	O
the	O
junction	O
with	O
the	O
superior	O
vena	O
cava	O
.	O

Previously	O
reported	O
interstitial	B-PROBLEM
edema	I-PROBLEM
has	O
resolved	O
.	O

There	O
has	O
been	O
interval	O
improvement	O
in	O
left	B-PROBLEM
basilar	I-PROBLEM
atelectasis	I-PROBLEM
.	O

Right	B-PROBLEM
basilar	I-PROBLEM
atelectasis	I-PROBLEM
has	O
slightly	O
worsened	O
.	O

Bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
are	O
unchanged	O
.	O

1.	O
Vascular	B-TREATMENT
catheter	I-TREATMENT
tip	I-TREATMENT
terminates	O
in	O
proximal	O
right	O
atrium	O
.	O

2.	O
Bibasilar	B-PROBLEM
minor	I-PROBLEM
atelectasis	I-PROBLEM
,	O
worse	O
on	O
the	O
right	O
and	O
improved	O
on	O
the	O
left	O
.	O

Persistent	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
.	O

The	O
left	O
atrium	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

No	O
spontaneous	B-PROBLEM
echo	I-PROBLEM
contrast	I-PROBLEM
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
.	O

No	O
spontaneous	B-PROBLEM
echo	I-PROBLEM
contrast	I-PROBLEM
or	O
thrombus	B-PROBLEM
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O

No	O
mass/thrombus	B-PROBLEM
is	O
seen	O
in	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O

No	O
atrial	B-PROBLEM
septal	I-PROBLEM
defect	I-PROBLEM
is	O
seen	O
by	O
2D	B-TEST
or	O
color	B-TEST
Doppler	I-TEST
.	O

There	O
is	O
mild	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
with	O
normal	O
cavity	O
size	O
.	O

There	O
is	O
mild	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
.	O

No	O
left	B-PROBLEM
ventricular	I-PROBLEM
aneurysm	I-PROBLEM
is	O
seen	O
.	O

There	O
is	O
mild	B-PROBLEM
regional	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
systolic	I-PROBLEM
dysfunction	I-PROBLEM
.	O

Overall	B-TEST
left	I-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
mildly	B-PROBLEM
depressed	I-PROBLEM
.	O

There	O
is	O
no	O
ventricular	B-PROBLEM
septal	I-PROBLEM
defect	I-PROBLEM
.	O

Resting	B-PROBLEM
regional	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
include	O
mild	B-PROBLEM
inferior	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

The	O
right	O
ventricular	O
cavity	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

There	O
are	O
simple	B-PROBLEM
atheroma	I-PROBLEM
in	O
the	O
aortic	O
root	O
.	O

There	O
are	O
simple	B-PROBLEM
atheroma	I-PROBLEM
in	O
the	O
ascending	O
aorta	O
.	O

There	O
are	O
simple	B-PROBLEM
atheroma	I-PROBLEM
in	O
the	O
aortic	O
arch	O
.	O

There	O
are	O
simple	B-PROBLEM
atheroma	I-PROBLEM
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O

The	O
aortic	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

No	O
masses	B-PROBLEM
or	O
vegetations	B-PROBLEM
are	O
seen	O
on	O
the	O
aortic	O
valve	O
.	O

There	O
is	O
no	O
aortic	B-PROBLEM
valve	I-PROBLEM
stenosis	I-PROBLEM
.	O

Trace	B-PROBLEM
aortic	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

No	O
mass	B-PROBLEM
or	O
vegetation	B-PROBLEM
is	O
seen	O
on	O
the	O
mitral	O
valve	O
.	O

Trivial	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

There	O
is	O
no	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
.	O

Preserved	O
LV	O
systolic	O
function	O
on	O
phenylephrine	B-TREATMENT
.	O

LVEF	B-TEST
now	O
50%	O
.	O

Trace	B-PROBLEM
MR	I-PROBLEM
,	O
AI	B-PROBLEM
as	O
described	O
.	O

I	O
certify	O
that	O
I	O
was	O
present	O
for	O
this	B-TREATMENT
procedure	I-TREATMENT
in	O
compliance	O
with	O
HCFA	O
regulations	O
.	O

Admitted	O
directly	O
to	O
OR	O
from	O
ambulance	O
transfer	O
and	O
underwent	O
cabg	B-TREATMENT
x3	O
with	O
Dr.	O
Howard	O
on	O
06-13	O
.	O

Transferred	O
to	O
the	O
CSRU	O
in	O
stable	O
condition	O
on	O
phenylephrine	B-TREATMENT
and	O
propofol	B-TREATMENT
drips	I-TREATMENT
.	O

Extubated	O
early	O
the	O
next	O
morning	O
and	O
chest	B-TREATMENT
tubes	I-TREATMENT
removed	O
.	O

Gentle	B-TREATMENT
diuresis	I-TREATMENT
and	O
beta	B-TREATMENT
blockade	I-TREATMENT
started	O
,	O
and	O
he	O
was	O
transferred	O
to	O
the	O
floor	O
to	O
begin	O
increasing	O
his	O
activity	O
level	O
.	O

Foley	B-TREATMENT
removed	O
on	O
POD	O
#2	O
and	O
had	O
scattered	B-PROBLEM
rales	I-PROBLEM
with	O
temp	B-TEST
101.2	O
.	O

Afebrile	B-PROBLEM
the	O
next	O
day	O
and	O
pacing	B-TREATMENT
wires	I-TREATMENT
removed	O
without	O
incident	O
.	O

bisoprolol	B-TREATMENT
5	O
mg	O
daily	O
crestor	B-TREATMENT
20	O
mg	O
daily	O

HCTZ	B-TREATMENT
25	O
mg	O
daily	O
lisinopril	B-TREATMENT
40	O
mg	O
daily	O

1.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

2.	O
Potassium	B-TREATMENT
Chloride	I-TREATMENT
10	O
mEq	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
7	O
days	O
.	O

3.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

4.	O
Ranitidine	B-TREATMENT
HCl	I-TREATMENT
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

5.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Oxycodone-Acetaminophen	B-TREATMENT
5-325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
every	O
4-6	O
hours	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

7.	O
Rosuvastatin	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

8.	O
Furosemide	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
7	O
days	O
.	O

CAD	B-PROBLEM

HTN	B-PROBLEM
ventral	B-PROBLEM
hernia	I-PROBLEM
right	B-TREATMENT
nephrectomy	I-TREATMENT
s/p	O
right	B-TREATMENT
facial	I-TREATMENT
plating	I-TREATMENT

Discharge	O
Instructions	O
:	O
may	O
shower	O
,	O
no	O
bathing	O
or	O
swimming	O
for	O
1	O
month	O
no	O
creams	B-TREATMENT
,	O
lotions	B-TREATMENT
or	O
powders	B-TREATMENT
to	O
any	B-PROBLEM
incisions	I-PROBLEM
no	O
driving	O
for	O
1	O
month	O
no	O
lifting	O
>	O
10	O
#	O
for	O
10	O
weeks	O

Chest	B-PROBLEM
pain	I-PROBLEM

The	O
patient	O
is	O
a	O
91	O
yo	O
woman	O
with	O
h/o	O
HTN	B-PROBLEM
who	O
came	O
from	O
Bridgewater	O
State	O
Hospital	O
Rehab	O
with	O
substernal	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
after	O
exercise	O
.	O

After	O
returning	O
to	O
her	O
room	O
she	O
w	O
noted	O
SSCP	B-PROBLEM
without	O
radiation	O
.	O

No	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
diaphoresis	B-PROBLEM
.	O

They	O
did	O
an	B-TEST
ECG	I-TEST
at	O
Bridgewater	O
State	O
Hospital	O
rehab	O
which	O
demonstarted	O
new	B-PROBLEM
ST	I-PROBLEM
depressions	I-PROBLEM
in	I-PROBLEM
V1-V4	I-PROBLEM
.	O

She	O
received	O
ASA	B-TREATMENT
81	O
mg	O
x	O
2	O
and	O
nitro	B-TREATMENT
SL	I-TREATMENT
x	O
2	O
with	O
partial	O
relief	O
at	O
nursing	O
home	O
.	O

On	O
presentation	O
to	O
Providence	O
Behavioral	O
Health	O
Hospital	O
Amanda	O
,	O
her	B-TEST
vitals	I-TEST
were	O
HR	B-TEST
68	O
,	O
BP	B-TEST
142/68	O
,	O
RR	B-TEST
28	O
,	O
O2	B-TEST
sat	I-TEST
100%	O
RA	O
.	O

Exam	B-TEST
was	O
notable	O
for	O
RRR	O
with	O
no	O
murmur	B-PROBLEM
,	O
bibasilar	B-PROBLEM
crackles	I-PROBLEM
,	O
guaiac	B-TEST
negative	O
.	O

EKG	B-TEST
showed	O
sinus	B-PROBLEM
brady	I-PROBLEM
,	O
with	O
old	B-PROBLEM
LAD	I-PROBLEM
and	I-PROBLEM
new	I-PROBLEM
ST	I-PROBLEM
depressions	I-PROBLEM
in	I-PROBLEM
V1-V4	I-PROBLEM
.	O

Troponin	B-TEST
was	O
0.07	O
.	O

She	O
received	O
ASA	B-TREATMENT
,	O
nitro	B-TREATMENT
SL	I-TREATMENT
then	O
gtt	O
,	O
morphine	B-TREATMENT
,	O
metoprolol	B-TREATMENT
,	O
and	O
heparin	B-TREATMENT
gtt	I-TREATMENT
.	O

Cardiology	O
discussed	O
cath	B-TEST
however	O
,	O
patient	O
's	O
family	O
turned	O
down	O
.	O

Transferred	O
to	O
CCU	O
for	O
further	B-TREATMENT
management	I-TREATMENT
and	O
observation	O
.	O

HTN	B-PROBLEM

Hearing	B-PROBLEM
difficulty	I-PROBLEM

Blindness	B-PROBLEM
02-26	O
macular	B-PROBLEM
degeneration	I-PROBLEM

R	B-PROBLEM
ankle	I-PROBLEM
fx	I-PROBLEM
2002	O

S/p	O
hysterectomy	B-TREATMENT

T	B-TEST
97.8	O
,	O
HR	B-TEST
53	O
,	O
BP	B-TEST
156/58	O
,	O
RR	B-TEST
16	O
,	O
O2	B-TEST
sat	I-TEST
94%	O
on	O
2.5	O
L	O

NAD	B-PROBLEM
,	O
awake	O
,	O
alert	O
,	O
blind	B-PROBLEM
,	O
able	O
to	O
hear	O
loud	O
voices	O
at	O
L	O
ear	O

JVP	B-TEST
11	O
cm	O

Reg	O
rate	O
,	O
nl	O
S1	O
&	O
S2	O
,	O
no	O
m/r/g	B-PROBLEM

Crackles	B-PROBLEM
at	I-PROBLEM
base	I-PROBLEM
and	I-PROBLEM
mid-lungs	I-PROBLEM
bilaterally	I-PROBLEM

Soft	O
,	O
NT	B-PROBLEM
,	O
ND	B-PROBLEM
,	O
BS	O
present	O
,	O
no	O
masses	B-PROBLEM

Trace	B-PROBLEM
ankle	I-PROBLEM
edema	I-PROBLEM
bilaterally	I-PROBLEM

WBC	B-TEST
-	O
11.4*	O
RBC	B-TEST
-	O
3.61*	O
Hgb	B-TEST
-	O
11.4*	O
Hct	B-TEST
-	O
32.6*	O
MCV	B-TEST
-	O
90	O
MCH	B-TEST
-	O
31.7	O

MCHC	B-TEST
-	O
35.1*	O
RDW	B-TEST
-	O
14.7	O
Plt	B-TEST
Ct	I-TEST
-	O
281	O

Glucose	B-TEST
-	O
124*	O
UreaN	B-TEST
-	O
30*	O
Creat	B-TEST
-	O
1.3*	O
Na	B-TEST
-	O
137	O
K	B-TEST
-	O
4.2	O
Cl	B-TEST
-	O
102	O
HCO3	B-TEST
-	O
27	O

AnGap	B-TEST
-	O
12	O

CK	B-TEST
(	O
CPK	B-TEST
)	O
-	O
42	O
cTropnT	B-TEST
-	O
0.07*	O

EKG	B-TEST
:	O

sinus	B-PROBLEM
brady	I-PROBLEM
@	O
48	O
bpm	O
,	O
LAD	O
,	O
LVH	B-PROBLEM
,	O
RBBB	B-PROBLEM
,	O
Q	B-PROBLEM
wave	I-PROBLEM
in	I-PROBLEM
I	I-PROBLEM
,	O
ST	B-PROBLEM
depressions	I-PROBLEM
in	I-PROBLEM
V1-V4	I-PROBLEM
,	O
ST	B-PROBLEM
elevation	I-PROBLEM
in	I-PROBLEM
III	I-PROBLEM
,	O
aVF	B-PROBLEM
,	O
TWI	B-PROBLEM
in	I-PROBLEM
III	I-PROBLEM
,	O
V5	O
.	O

CXR	B-TEST
10-07	O
:	O

There	O
is	O
slight	B-PROBLEM
worsening	I-PROBLEM
of	O
the	B-PROBLEM
still	I-PROBLEM
mild	I-PROBLEM
pulmonary	I-PROBLEM
edema	I-PROBLEM
.	O

There	O
is	O
no	O
pneumothorax	B-PROBLEM
.	O

Small	B-PROBLEM
right	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
is	O
stable	O
.	O

Echo	B-TEST
:	O

LVEF	B-TEST
>70%	O
,	O
LA	B-TEST
6.1	O
cm	O
,	O
no	O
regional	B-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormality	I-PROBLEM
.	O

Cardiac	B-TEST
Enzymes	I-TEST

2015-10-05	O
09:00PM	O
BLOOD	B-TEST

CK	B-TEST
(	O
CPK	B-TEST
)	O
-	O
1471*	O
CK-MB	B-TEST
-	O
207*	O
MB	B-TEST
Indx	I-TEST
-	O
14.1*	O
cTropnT	B-TEST
-	O
6.00*	O

2015-10-06	O
04:47PM	O
BLOOD	B-TEST

CK	B-TEST
(	O
CPK	B-TEST
)	O
-	O
1288*	O
CK-MB	B-TEST
-	O
158*	O
MB	B-TEST
Indx	I-TEST
-	O
12.3*	O
cTropnT	B-TEST
-	O
6.88*	O

2015-10-07	O
07:30AM	O
BLOOD	B-TEST

CK	B-TEST
(	O
CPK	B-TEST
)	O
-	O
627*	O
CK-MB	B-TEST
-	O
55*	O
MB	B-TEST
Indx	I-TEST
-	O
8.8*	O
cTropnT	B-TEST
-	O
4.46*	O

Labs	B-TEST
on	O
Discharge	O
2015-10-08	O
08:35AM	O

WBC	B-TEST
-	O
13.8*	O
RBC	B-TEST
-	O
3.39*	O
Hgb	B-TEST
-	O
10.7*	O
Hct	B-TEST
-	O
30.2*	O
MCV	B-TEST
-	O
89	O
MCH	B-TEST
-	O
31.5	O

MCHC	B-TEST
-	O
35.3*	O
RDW	B-TEST
-	O
14.8	O
Plt	B-TEST
Ct	I-TEST
-	O
214	O

Glucose	B-TEST
-	O
120*	O
UreaN	B-TEST
-	O
30*	O
Creat	B-TEST
-	O
1.2*	O
Na	B-TEST
-	O
134	O
K	B-TEST
-	O
4.2	O
Cl	B-TEST
-	O
100	O
HCO3	B-TEST
-	O
25	O

AnGap	B-TEST
-	O
13	O

Calcium	B-TEST
-	O
8.7	O
Phos	B-TEST
-	O
2.5*	O
Mg	B-TEST
-	O
2.1	O

90	O
year-old	O
woman	O
with	O
h/o	O
of	O
HTN	B-PROBLEM
p/w	O
substernal	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
shortly	O
after	O
exercise	O
at	O
nursing	O
home	O
,	O
with	O
EKG	B-TEST
showing	O
ST	B-PROBLEM
depressions	I-PROBLEM
in	I-PROBLEM
V1-V4	I-PROBLEM
and	O
troponin	B-TEST
0.07.	O

Likely	O
NSTEMI	B-PROBLEM
.	O

The	O
patient	O
's	O
family	O
refused	O
coronary	B-TREATMENT
artery	I-TREATMENT
catheterization	I-TREATMENT
.	O

The	O
patient	O
was	O
given	O
ASA	B-TREATMENT
,	O
Plavix	B-TREATMENT
,	O
heparin	B-TREATMENT
drip	I-TREATMENT
x	O
24	O
hours	O
,	O
nitro	B-TREATMENT
drip	I-TREATMENT
,	O
atorvastatin	B-TREATMENT
,	O
metoprolol	B-TREATMENT
,	O
and	O
lisinopril	B-TREATMENT
.	O

Her	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
was	O
controlled	O
with	O
morphine	B-TREATMENT
.	O

Her	B-TEST
SBP	I-TEST
remained	O
in	O
the	O
160s-170s	O
on	O
hospital	O
day	O
1	O
and	O
she	O
was	O
gently	O
diuresed	O
.	O

On	O
hospital	O
day	O
2	O
she	O
experienced	O
atrial	B-PROBLEM
fibrillation	I-PROBLEM
with	O
HR	B-TEST
in	O
the	O
140s	O
.	O

Her	B-TREATMENT
metoprolol	I-TREATMENT
dose	I-TREATMENT
was	O
increased	O
from	O
25	O
mg	O
PO	O
bid	O
to	O
50	O
mg	O
PO	O
bid	O
then	O
75	O
mg	O
PO	O
tid	O
.	O

Her	B-TEST
HR	I-TEST
decreased	O
to	O
70s-80s	O
.	O

Her	B-TEST
BP	I-TEST
remained	O
stable	O
.	O

An	B-TEST
ECHO	I-TEST
showed	O
that	O
she	O
had	O
preserved	O
EF	O
and	O
no	O
wall	B-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
.	O

We	O
decided	O
given	O
her	O
age	O
that	O
she	O
would	O
not	O
be	O
a	O
good	O
candidate	O
for	O
cardioversion	B-TREATMENT
for	O
her	B-PROBLEM
afib	I-PROBLEM
nor	O
would	O
she	O
be	O
a	O
good	O
candidate	O
for	O
coumadin	B-TREATMENT
.	O

Therefore	O
we	O
will	O
continue	O
rate	O
control	O
with	O
metoprolol	B-TREATMENT
this	O
can	O
be	O
titrated	O
if	O
needed	O
,	O
and	O
aspirin	B-TREATMENT
and	O
plavix	B-TREATMENT
for	O
anti-coagulation	B-TREATMENT
.	O

She	O
should	O
also	O
continue	O
on	O
lipitor	B-TREATMENT
and	O
lisinopril	B-TREATMENT
.	O

She	O
should	O
have	O
her	B-TEST
chem	I-TEST
7	I-TEST
checked	O
next	O
week	O
given	O
the	O
start	O
of	O
her	B-TREATMENT
new	I-TREATMENT
meds	I-TREATMENT
.	O

Will	O
also	O
need	O
LFT	B-TEST
's	I-TEST
checked	O
in	O
3-6	O
months	O
.	O

Bilateral	B-PROBLEM
crackles	I-PROBLEM
at	I-PROBLEM
bases	I-PROBLEM
and	I-PROBLEM
midlungs	I-PROBLEM
,	O
elevated	B-PROBLEM
JVP	I-PROBLEM
,	O
trace	B-PROBLEM
bilateral	I-PROBLEM
ankle	I-PROBLEM
edema	I-PROBLEM
,	O
and	O
CXR	B-TEST
with	O
diffuse	B-PROBLEM
opacities	I-PROBLEM
suggest	O
possible	O
pulmonary	B-PROBLEM
edema	I-PROBLEM
,	O
likely	O
secondary	O
to	O
acute	B-PROBLEM
MI	I-PROBLEM
.	O

Her	B-TEST
O2	I-TEST
sat	I-TEST
was	O
stable	O
at	O
94-97%	O
on	O
2.5L	O
of	O
supplemental	B-TREATMENT
O2	I-TREATMENT
.	O

She	O
experienced	O
no	O
respiratory	B-PROBLEM
difficulty	I-PROBLEM
during	O
the	O
hospital	O
stay	O
.	O

Her	B-TEST
CXR	I-TEST
prior	O
to	O
discharge	O
showed	O
mild	B-PROBLEM
pulm	I-PROBLEM
edema	I-PROBLEM
and	O
thus	O
was	O
given	O
40	O
of	O
lasix	B-TREATMENT
prior	O
to	O
going	O
to	O
rehab	O
.	O

She	O
can	O
be	O
given	O
prn	O
lasix	B-TREATMENT
for	O
weight	B-PROBLEM
gain	I-PROBLEM
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

*	O
Leukocytosis-	B-PROBLEM
She	O
developed	O
mild	B-PROBLEM
elevated	I-PROBLEM
WBC	I-PROBLEM
.	O

UA	B-TEST
had	O
12-14	O

WBC	B-TEST
's	I-TEST
,	O
few	B-PROBLEM
bacteria	I-PROBLEM
.	O

She	O
was	O
initially	O
started	O
on	O
Bactrim	B-TREATMENT
,	O
but	O
this	O
was	O
stopped	O
as	O
she	O
was	O
afebrile	B-PROBLEM
.	O

SHe	O
has	O
a	B-TEST
culture	I-TEST
pending	O
which	O
needs	O
to	O
be	O
followed	O
up	O
at	O
the	O
nursing	O
home	O
and	O
treated	O
if	O
positive	B-PROBLEM
.	O

tylenol	B-TREATMENT
PRN	O
lisinopril	B-TREATMENT
5	O
mg	O
PO	O
qd	O
protonix	B-TREATMENT
20	O
mg	O
PO	O
qd	O
artifical	B-TREATMENT
tears	I-TREATMENT
bid	O
metoprolol	B-TREATMENT
25	O
mg	O
PO	O
bid	O

1.	O
Senna	B-TREATMENT
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

2.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

3.	O
Aspirin	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

4.	O
Clopidogrel	B-TREATMENT
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

5.	O
Atorvastatin	B-TREATMENT
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
0.5	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O

7.	O
Polyvinyl	B-TREATMENT
Alcohol	I-TREATMENT
1.4	O
%	O
Drops	O
Sig	O
:	O
1-2	O
Drops	O
Ophthalmic	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

8.	O
Lisinopril	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

9.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O

10.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

11.	O
Maalox	B-TREATMENT
225-200	O
mg/5	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
mL	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
indigestion	B-PROBLEM
.	O

12.	O
Lasix	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
or	O
wheezing	B-PROBLEM
:	O

Can	O
give	O
40	O
lasix	B-TREATMENT
PO	O
if	O
having	O
any	O
weight	B-PROBLEM
gain	I-PROBLEM
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

NSTEMI	B-PROBLEM

Atrial	B-PROBLEM
Fibrillation	I-PROBLEM

HTN	B-PROBLEM

Patient	O
without	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
heart	B-TEST
rate	I-TEST
and	O
BP	B-TEST
stable	O
.	O

Please	O
take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
instructed	O
.	O

She	O
has	O
been	O
started	O
on	O
several	B-TREATMENT
new	I-TREATMENT
medications	I-TREATMENT
which	O
are	O
important	O
to	O
protect	O
her	O
heart	O
.	O

If	O
the	O
patient	O
experiences	O
any	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
please	O
return	O
to	O
the	O
emergency	O
room	O
.	O

The	O
patient	O
is	O
a	O
1,770	O
gram	O
male	O
infant	O
born	O
by	O
stat	B-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
for	O
fetal	B-PROBLEM
bradycardia	I-PROBLEM
at	O
30-6/7	O
weeks	O
gestation	O
to	O
a	O
29-year-old	O
gravida	O
3	O
,	O
para	O
0	O
now	O
1	O
mother	O
.	O

The	O
pregnancy	O
was	O
unremarkable	O
until	O
2015-06-01	O
when	O
the	O
mother	O
presented	O
to	O
Shriner	O
's	O
Hospital	O
for	O
Crippled	O
Children	O
for	O
increased	B-PROBLEM
blood	I-PROBLEM
pressure	I-PROBLEM
and	O
proteinuria	B-PROBLEM
.	O

She	O
was	O
transferred	O
to	O
Charles	O
River	O
Hospital	O
and	O
was	O
treated	O
with	O
magnesium	B-TREATMENT
sulfate	I-TREATMENT
and	O
betamethasone	B-TREATMENT
.	O

The	O
morning	O
of	O
admission	O
the	O
mother	O
developed	O
vaginal	B-PROBLEM
bleeding	I-PROBLEM
and	O
fetal	B-PROBLEM
bradycardia	I-PROBLEM
was	O
noted	O
.	O

Therefore	O
,	O
a	B-TREATMENT
stat	I-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
was	O
performed	O
.	O

The	O
infant	O
emerged	O
limp	B-PROBLEM
and	O
without	O
spontaneous	B-PROBLEM
respiratory	I-PROBLEM
effort	I-PROBLEM
.	O

He	O
was	O
given	O
bag	B-TREATMENT
mask	I-TREATMENT
ventilation	I-TREATMENT
with	O
good	O
response	O
.	O

Apgar	B-TEST
scores	I-TEST
were	O
6	O
at	O
one	O
minute	O
and	O
8	O
at	O
five	O
minutes	O
.	O

O+	O
,	O
hepatitis	B-TEST
B	I-TEST
surface	I-TEST
antigen	I-TEST
negative	O
,	O

RPR	B-TEST
nonreactive	O
,	O
rubella	B-PROBLEM
immune	O
.	O

The	O
patient	O
was	O
in	O
mild	B-PROBLEM
to	I-PROBLEM
moderate	I-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
.	O

Neck	O
was	O
supple	O
without	O
masses	B-PROBLEM
or	O
defects	B-PROBLEM
.	O

The	O
lungs	O
were	O
coarse	B-PROBLEM
bilaterally	I-PROBLEM
with	O
moderate	B-PROBLEM
retractions	I-PROBLEM
.	O

The	B-TEST
cardiovascular	I-TEST
examination	I-TEST
revealed	O
S1	B-TEST
and	O
S2	B-TEST
regular	O
,	O
no	O
murmurs	B-PROBLEM
,	O
2+	B-TEST
femoral	I-TEST
pulses	I-TEST
.	O

The	O
abdomen	O
was	O
benign	O
,	O
flat	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
no	O
hepatosplenomegaly	B-PROBLEM
.	O

Hips	O
were	O
stable	O
without	O
clunk	B-PROBLEM
.	O

The	O
skin	O
was	O
without	O
lesions	B-PROBLEM
.	O

The	B-TEST
neurological	I-TEST
examination	I-TEST
was	O
appropriate	O
for	O
age	O
with	O
normal	O
tone	O
and	O
strength	O
and	O
appropriate	O
reflexes	O
.	O

He	O
was	O
noted	O
to	O
have	O
some	B-PROBLEM
apnea	I-PROBLEM
and	O
bradycardic	B-PROBLEM
spells	I-PROBLEM
of	I-PROBLEM
prematurity	I-PROBLEM
and	O
was	O
therefore	O
started	O
on	O
caffeine	B-TREATMENT
.	O

With	O
the	O
initiation	O
of	O
caffeine	B-TREATMENT
therapy	I-TREATMENT
the	O
patient	O
has	O
had	O
no	O
more	O
apnea	B-PROBLEM
or	O
bradycardic	B-PROBLEM
events	I-PROBLEM
.	O

The	O
patient	O
was	O
initially	O
started	O
on	O
nasal	B-TREATMENT
prong	I-TREATMENT
CPAP	I-TREATMENT
at	O
6	O
and	O
required	O
additional	B-TREATMENT
oxygen	I-TREATMENT
to	O
35%	O
.	O

However	O
by	O
24	O
hours	O
he	O
transitioned	O
to	O
low-flow	B-TREATMENT
nasal	I-TREATMENT
cannula	I-TREATMENT
and	O
on	O
day	O
of	O
life	O
five	O
transitioned	O
to	O
room	O
air	O
where	O
he	O
currently	O
remains	O
.	O

The	O
patient	O
was	O
initially	O
maintained	O
on	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
only	O
and	O
when	O
his	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
resolved	O
he	O
was	O
transitioned	O
to	O
enteral	B-TREATMENT
feeds	I-TREATMENT
.	O

The	O
morning	O
of	O
transfer	O
his	B-TREATMENT
IV	I-TREATMENT
came	O
out	O
so	O
he	O
has	O
just	O
been	O
advanced	O
to	O
120	O
cc	O
per	O
kg	O
per	O
day	O
of	O
PE-20	B-TREATMENT
and	O
his	O
tolerating	O
these	B-TREATMENT
PG	I-TREATMENT
feedings	I-TREATMENT
without	O
difficulty	O
.	O

Last	B-TEST
set	I-TEST
of	I-TEST
electrolytes	I-TEST
on	O
06-08	O
,	O
DOL3	O
:	O

Na	B-TEST
145	O
,	O
K	B-TEST
4.3	O
,	O
Cl	B-TEST
110	O
,	O
tCO2	B-TEST
25	O
.	O

His	B-TEST
admission	I-TEST
complete	I-TEST
blood	I-TEST
count	I-TEST
was	O
notable	O
for	O
a	B-TEST
white	I-TEST
count	I-TEST
of	O
11.8	O
,	O
25	B-TEST
polys	I-TEST
and	O
no	O
bands	B-PROBLEM
.	O

Hematocrit	B-TEST
was	O
45	O
,	O
platelet	B-TEST
count	I-TEST
270	O
.	O

He	O
developed	O
physiologic	B-PROBLEM
hyperbilirubinemia	I-PROBLEM
(	O
peak	B-TEST
bili	I-TEST
8.6/0.3	O
on	O
06-08	O
,	O
DOL3	O
)	O
for	O
which	O
he	O
was	O
treated	O
with	O
a	B-TREATMENT
single	I-TREATMENT
phototherapy	I-TREATMENT
.	O

His	B-TEST
most	I-TEST
recent	I-TEST
bilirubin	I-TEST
was	O
6.6	O
on	O
day	O
of	O
life	O
six	O
,	O
the	O
day	O
of	O
discharge	O
,	O
and	O
his	B-TREATMENT
phototherapy	I-TREATMENT
was	O
discontinued.	O
He	O
will	O
need	O
a	B-TEST
rebound	I-TEST
bilirubin	I-TEST
level	I-TEST
in	O
am	O
.	O

Blood	B-TEST
culture	I-TEST
was	O
sent	O
but	O
he	O
was	O
never	O
started	O
on	O
antibiotics	B-TREATMENT
.	O

The	B-TEST
blood	I-TEST
culture	I-TEST
remained	O
sterile	O
.	O

He	O
was	O
noted	O
to	O
have	O
an	B-PROBLEM
erythematous	I-PROBLEM
perianal	I-PROBLEM
rash	I-PROBLEM
and	O
for	O
this	O
was	O
started	O
on	O
Nystatin	B-TREATMENT
powder	I-TREATMENT
.	O

The	O
patient	O
has	O
not	O
had	O
an	O
CMED	B-TEST
examination	I-TEST
or	O
hearing	B-TEST
test	I-TEST
.	O

Feeds	B-TREATMENT
at	O
discharge	O
are	O
PE-20	B-TREATMENT
currently	O
at	O
120	O
cc	O
per	O
kg	O
per	O
day	O
due	O
to	O
advance	O
15	O
cc	O
per	O
kg	O
per	O
day	O
to	O
a	O
total	O
of	O
150	O
cc	O
per	O
kg	O
per	O
day	O
.	O

Caffeine	B-TREATMENT
12	O
mg	O
pg	O
q	O
day.	O
He	O
has	O
not	O
had	O
his	O
06-10	O
dose	O
.	O

He	O
is	O
due	O
to	O
have	O
his	B-TEST
state	I-TEST
screen	I-TEST
sent	O
today	O
.	O

Synagis	B-TREATMENT
RSV	I-TREATMENT
prophylaxis	I-TREATMENT
should	O
be	O
considered	O
from	O
October	O
through	O
April	O
for	O
infants	O
who	O
meet	O
any	O
of	O
the	O
following	O
criteria	O
:	O

3.	O
With	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
.	O

Influenza	B-TREATMENT
vaccination	I-TREATMENT
should	O
be	O
considered	O
annually	O
in	O
the	O
fall	O
for	O
preterm	O
infants	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
once	O
they	O
reach	O
six	O
months	O
of	O
age	O
.	O

Before	O
this	O
age	O
,	O
the	O
family	O
and	O
other	O
caregivers	O
should	O
be	O
considered	O
for	O
immunization	B-TREATMENT
against	O
influenza	B-PROBLEM
to	O
protect	O
the	O
infant	O
.	O

1.	O
Prematurity	B-PROBLEM
at	O
30-6/7	O
weeks	O
.	O

2.	O
Rule	O
out	O
sepsis	B-PROBLEM
,	O
off	O
antibiotics	B-TREATMENT
.	O

3.	O
Apnea	B-PROBLEM
and	O
bradycardia	B-PROBLEM
of	O
prematurity	B-PROBLEM
.	O

4.	O
Hyperbilirubinemia	B-PROBLEM
.	O

5.	O
Feeding	B-PROBLEM
immaturity	I-PROBLEM
.	O

Sulfonamides	B-TREATMENT
/	O
Penicillins	B-TREATMENT
/	O
Tetracyclines	B-TREATMENT
/	O
Azithromycin	B-TREATMENT
/	O
Iodine	B-TREATMENT
/	O
Shellfish	O
/	O
Ace	B-TREATMENT
Inhibitors	I-TREATMENT
/	O
Ciprofloxacin	B-TREATMENT

Chronic	B-PROBLEM
prostatitis	I-PROBLEM

TURP	B-TREATMENT

Justin	O
Searle	O
a	O
60-year-old	O
man	O
with	O
a	O
long	O
history	O
of	O
chronic	B-PROBLEM
prostatitis	I-PROBLEM
status	O
post	O
two	B-TREATMENT
transurethral	I-TREATMENT
resection	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
prostate	I-TREATMENT
procedures	O
in	O
2007	O
and	O
1998	O
.	O

He	O
also	O
has	O
a	O
diagnosis	O
of	O
interstitial	B-PROBLEM
cystitis	I-PROBLEM
and	O
more	O
significantly	O
has	O
a	O
history	O
of	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
with	O
a	B-TEST
recent	I-TEST
catheterization	I-TEST
,	O
supraventricular	B-PROBLEM
tachycardia	I-PROBLEM
,	O
and	O
a	B-PROBLEM
progressive	I-PROBLEM
mitochondrial	I-PROBLEM
myopathy	I-PROBLEM
.	O

He	O
has	O
had	O
symptoms	B-PROBLEM
of	O
dribbling	B-PROBLEM
,	O
stress	B-PROBLEM
incontinence	I-PROBLEM
,	O
hematuria	B-PROBLEM
,	O
but	O
has	O
no	O
dysuria	B-PROBLEM
.	O

1.	O
Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
(	O
s/p	O
stents	B-TREATMENT
to	I-TREATMENT
LAD	I-TREATMENT
and	I-TREATMENT
3rd	I-TREATMENT
OM	I-TREATMENT
)	O

2.	O
Supraventricular	B-PROBLEM
tachycardia	I-PROBLEM
(	O
on	O
a	B-TREATMENT
beta	I-TREATMENT
blocker	I-TREATMENT
)	O
.	O

3.	O
Mitochondrial	B-PROBLEM
myopathy	I-PROBLEM
.	O

4.	O
History	O
of	O
orthostasis	B-PROBLEM
with	O
tilt	B-TEST
table	I-TEST
testing	I-TEST
done	O
in	O
the	O
past	O
.	O

5.	O
Status	O
post	O
transurethral	B-TREATMENT
resection	I-TREATMENT
of	I-TREATMENT
prostate	I-TREATMENT
times	O
two	O
(	O
in	O
2007	O
and	O
1998	O
)	O
.	O

6.	O
Interstitial	B-PROBLEM
cystitis	I-PROBLEM
.	O

7.	O
Pericarditis	B-PROBLEM
.	O

8.	O
Hypertension	B-PROBLEM
.	O

9.	O
Hypercholesterolemia	B-PROBLEM
.	O

10.	O
Gastrointestinal	B-PROBLEM
bleed	I-PROBLEM

Father	O
had	O
MI	B-PROBLEM
at	O
42	O

Mother	O
died	O
of	O
MI	B-PROBLEM
at	O
76	O

NAD	B-PROBLEM

RRR	O
,	O
no	O
m/r/g	B-PROBLEM

Abd	O
:	O
soft	O
,	O
+distension	B-PROBLEM
with	O
tympany	B-PROBLEM
,	O
no	O
HSM	B-PROBLEM
,	O
hyperactive	B-PROBLEM
BS	I-PROBLEM

Ext	O
:	O
no	O
c/c/e	B-PROBLEM

ECG	B-TEST
:	O

NSR	B-TEST
at	O
62	O
,	O
nl	O
axis	O
,	O
nl	O
intervals	O
,	O
Q	B-PROBLEM
waves	I-PROBLEM
in	I-PROBLEM
III	I-PROBLEM
,	O
avR	B-TEST
,	I-TEST
V1	B-TEST
.	O

TWI	B-PROBLEM
's	O
in	O
III	O
,	O
V1	O
.	O

GLUCOSE	B-TEST
-	O
94	O
UREA	B-TEST
N	I-TEST
-	O
22*	O
CREAT	B-TEST
-	O
1.4*	O
SODIUM	B-TEST
-	O
142	O

POTASSIUM	B-TEST
-	O
5.9*	O
CHLORIDE	B-TEST
-	O
108	O
TOTAL	B-TEST
CO2	I-TEST
-	O
23	O
ANION	B-TEST
GAP	I-TEST
-	O
17	O

CALCIUM	B-TEST
-	O
9.7	O
PHOSPHATE	B-TEST
-	O
3.9	O
MAGNESIUM	B-TEST
-	O
1.9	O

WBC	B-TEST
-	O
7.5	O
RBC	B-TEST
-	O
5.09	O
HGB	B-TEST
-	O
15.4	O
HCT	B-TEST
-	O
43.7	O
MCV	B-TEST
-	O
86	O

MCH	B-TEST
-	O
30.2	O
MCHC	B-TEST
-	O
35.2*	O
RDW	B-TEST
-	O
13.6	O

PLT	B-TEST
COUNT	I-TEST
-	O
257#	O

PT	B-TEST
-	O
12.2	O
PTT	B-TEST
-	O
23.8	O
INR	B-TEST
(	I-TEST
PT	I-TEST
)	I-TEST
-	O
0.9	O

On	O
HD2	O
,	O
cardiac	B-TEST
clearance	I-TEST
was	O
obtained	O
by	O
Dr.	O
Sanchez	O
.	O

Patient	O
tolerated	O
procedure	B-TREATMENT
on	O
2018-03-05	O
and	O
was	O
transferred	O
to	O

ICU	O
for	O
24hr	O
post-op	O
cardiac	B-TEST
monitoring	I-TEST
.	O

Catheter	B-TREATMENT
was	O
removed	O
.	O

He	O
was	O
started	O
on	O
Pyridium	B-TREATMENT
.	O

1.	O
Hydroxyzine	B-TREATMENT
HCl	I-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

2.	O
Atorvastatin	B-TREATMENT
Calcium	I-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

3.	O
Ezetimibe	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

4.	O
Simethicone	B-TREATMENT
80	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
0.5-1	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
indigestion/gas	B-PROBLEM
pain	I-PROBLEM
.	O

5.	O
Aluminum-Magnesium	B-TREATMENT
Hydroxide	I-TREATMENT
225-200	O
mg/5	O
mL	O
Suspension	O
Sig	O
:	O
15-30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
indigestion	B-PROBLEM
.	O

6.	O
Atenolol	B-TREATMENT
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

7.	O
Hyoscyamine	B-TREATMENT
Sulfate	I-TREATMENT
0.125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O

8.	O
Phenazopyridine	B-TREATMENT
HCl	I-TREATMENT
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
for	O
3	O
days	O
.	O

Chronic	B-PROBLEM
prostatitis	I-PROBLEM

Interstitial	B-PROBLEM
cystitis	I-PROBLEM

Go	O
to	O
an	O
Emergency	O
Room	O
if	O
you	O
experience	O
symptoms	B-PROBLEM
including	O
,	O
but	O
not	O
necessarily	O
limited	O
to	O
:	O
new	B-PROBLEM
and	I-PROBLEM
continuing	I-PROBLEM
nausea	I-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
fevers	B-PROBLEM
(	O
>101.5	O
F	O
)	O
,	O
chills	B-PROBLEM
,	O
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

Proceed	O
to	O
the	O
ER/EW/Monica	O
if	O
your	B-PROBLEM
wound	I-PROBLEM
becomes	O
red	B-PROBLEM
,	O
swollen	B-PROBLEM
,	O
warm	B-PROBLEM
,	O
or	O
produces	O
pus	B-PROBLEM
.	O

You	O
may	O
remove	O
your	B-TREATMENT
dressings	I-TREATMENT
2	O
days	O
after	O
your	B-TREATMENT
surgery	I-TREATMENT
if	O
they	O
were	O
not	O
removed	O
in	O
the	O
hospital	O
.	O

Leave	O
the	B-TREATMENT
steri	I-TREATMENT
strips	I-TREATMENT
on	O
until	O
they	O
begin	O
to	O
peel	O
,	O
then	O
you	O
may	O
remove	O
them.	O
Staples	B-TREATMENT
and	O
stitches	B-TREATMENT
will	O
remain	O
until	O
your	O
follow-up	O
appointment	O
.	O

If	O
you	O
experience	O
clear	B-PROBLEM
drainage	I-PROBLEM
from	O
your	B-PROBLEM
wounds	I-PROBLEM
,	O
cover	O
them	O
with	O
a	B-TREATMENT
clean	I-TREATMENT
dressing	I-TREATMENT
and	O
stop	O
showering	O
until	O
the	B-PROBLEM
drainage	I-PROBLEM
subsides	O
for	O
at	O
least	O
2	O
days	O
.	O

No	O
driving	O
while	O
taking	O
pain	B-TREATMENT
medications	I-TREATMENT
.	O

Narcotics	B-TREATMENT
can	O
cause	O
constipation	B-PROBLEM
.	O

Please	O
take	O
an	B-TREATMENT
over	I-TREATMENT
the	I-TREATMENT
counter	I-TREATMENT
stool	I-TREATMENT
softener	I-TREATMENT
such	O
as	O
Colace	B-TREATMENT
or	O
a	B-TREATMENT
gentle	I-TREATMENT
laxative	I-TREATMENT
such	O
as	O
Milk	B-TREATMENT
of	I-TREATMENT
Magnesia	I-TREATMENT
if	O
you	O
experience	O
constipation	B-PROBLEM
.	O

You	O
may	O
take	O
showers	O
(	O
no	O
baths	O
)	O
after	O
your	B-TREATMENT
dressings	I-TREATMENT
have	O
been	O
removed	O
from	O
your	B-PROBLEM
wounds	I-PROBLEM
.	O

Continue	O
taking	O
your	B-TREATMENT
home	I-TREATMENT
medications	I-TREATMENT
unless	O
otherwise	O
contraindicated	O
and	O
follow	O
up	O
with	O
PCP	O
.	O

Mr.	O
Jackson	O
is	O
a	O
63-year-old	O
male	O
with	O
squamous	B-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM
of	O
the	O
floor	O
of	O
mouth	O
(	O
stage	B-PROBLEM
T2	I-PROBLEM
N0	I-PROBLEM
)	O
that	O
was	O
biopsied	O
by	O
his	O
dentist	O
.	O

Pathology	B-TEST
was	O
reviewed	O
revealing	O
invasive	B-PROBLEM
squamous	I-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM
.	O

He	O
presented	O
on	O
2016-11-21	O
for	O
resection	B-TREATMENT
.	O

He	O
was	O
admitted	O
on	O
2016-11-21	O
following	O
his	B-TREATMENT
surgery	I-TREATMENT
.	O

He	O
underwent	O
a	B-TREATMENT
joint	I-TREATMENT
procedure	I-TREATMENT
by	O
Otolaryngology	O
and	O
Plastic	O
Surgery	O
.	O

Includes	O
hypertension	B-PROBLEM
and	O
chronic	B-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
.	O

Polypectomy	B-TREATMENT
in	O
2011	O
,	O
tooth	B-TREATMENT
extraction	I-TREATMENT
(	O
all	O
)	O
in	O
1980	O
,	O
and	O
hernia	B-PROBLEM
in	O
1977	O
.	O

TOMATO	O
(	O
causing	O
anaphylaxis	B-PROBLEM
)	O
and	O
TETANUS	B-TREATMENT
SHOT	I-TREATMENT
.	O

Triamterene/hydrochlorothiazide	B-TREATMENT
37.5/25	O
mg	O
one	O
tablet	O
by	O
mouth	O
once	O
daily	O
and	O
lorazepam	B-TREATMENT
1	O
mg	O
three	O
times	O
daily	O
as	O
needed	O
(	O
for	O
anxiety	B-PROBLEM
)	O
.	O

1.	O
Tracheostomy	B-TREATMENT
.	O

2.	O
Diagnostic	B-TEST
laryngoscopy	I-TEST
and	O
biopsy	B-TEST
.	O

3.	O
Bilateral	B-TREATMENT
supraomohyoid	I-TREATMENT
neck	I-TREATMENT
dissection	I-TREATMENT
.	O

4.	O
Resection	B-TREATMENT
of	O
floor	O
of	O
mouth	B-PROBLEM
tumor	I-PROBLEM
.	O

Frozen	B-TEST
section	I-TEST
sent	O
to	O
pathology	O
revealing	O
invasive	B-PROBLEM
squamous	I-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM
.	O

No	O
complications	B-PROBLEM
.	O

The	O
Plastic	O
Team	O
then	O
took	O
over	O
for	O
reconstruction	B-TREATMENT
consisting	O
of	O
radial	B-TREATMENT
forearm	I-TREATMENT
free	I-TREATMENT
flap	I-TREATMENT
to	O
floor	O
of	O
mouth	O
.	O

Total	B-TREATMENT
intravenous	I-TREATMENT
fluids	I-TREATMENT
of	O
7300	O
cc	O
.	O

Estimated	B-PROBLEM
blood	I-PROBLEM
loss	I-PROBLEM
of	O
300	O
cc	O
.	O

Urine	B-TEST
output	I-TEST
of	O
900	O
cc	O
.	O

No	O
complications	B-PROBLEM
.	O

In	O
addition	O
,	O
the	O
patient	O
was	O
prepared	O
for	O
an	B-TREATMENT
attempted	I-TREATMENT
percutaneous	I-TREATMENT
endoscopic	I-TREATMENT
gastrostomy	I-TREATMENT
tube	I-TREATMENT
.	O

The	B-TREATMENT
percutaneous	I-TREATMENT
endoscopic	I-TREATMENT
gastrostomy	I-TREATMENT
was	O
unsuccessful	O
,	O
and	O
the	B-TREATMENT
procedure	I-TREATMENT
was	O
converted	O
to	O
an	B-TREATMENT
open	I-TREATMENT
gastrostomy	I-TREATMENT
tube	I-TREATMENT
which	O
then	O
proceeded	O
without	O
complications	B-PROBLEM
.	O

He	O
was	O
sedated	O
and	O
ventilated	O
by	O
his	B-TREATMENT
tracheostomy	I-TREATMENT
6	I-TREATMENT
cuff	I-TREATMENT
Shiley	I-TREATMENT
tube	I-TREATMENT
.	O

He	O
had	O
three	O
Westwood-Pocasset	B-TREATMENT
drains	I-TREATMENT
-	O
two	O
in	O
the	O
neck	O
and	O
one	O
in	O
his	O
right	O
arm	O
.	O

G-tube	B-TREATMENT
was	O
to	O
gravity	O
,	O
Foley	B-TREATMENT
to	O
gravity	O
,	O
left	B-TREATMENT
radial	I-TREATMENT
A-line	I-TREATMENT
.	O

The	B-TREATMENT
flap	I-TREATMENT
was	O
pink	O
with	O
a	B-TEST
strong	I-TEST
Doppler	I-TEST
signal	I-TEST
.	O

He	O
underwent	O
flap	B-TEST
checks	I-TEST
every	O
15	O
minutes	O
initially	O
with	O
a	B-TREATMENT
dextran	I-TREATMENT
infusion	I-TREATMENT
.	O

He	O
was	O
placed	O
on	O
Unasyn	B-TREATMENT
3	O
grams	O
IV	B-TREATMENT
q.6h.	O

Nothing	O
by	O
mouth	O
initially	O
with	O
morphine	B-TREATMENT
as	O
needed	O
for	O
pain	B-PROBLEM
and	O
Ativan	B-TREATMENT
around	O
the	O
clock	O
for	O
delirium	B-TREATMENT
tremens	I-TREATMENT
prophylaxis	I-TREATMENT
.	O

In	O
addition	O
,	O
he	O
received	O
metoprolol	B-TREATMENT
q.4.h.	O
,	O
a	B-TREATMENT
regular	I-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
,	O
and	O
adequate	O
gastrointestinal	O
prophylaxis	O
with	O
Protonix	B-TREATMENT
.	O

Postoperative	B-TEST
laboratories	I-TEST
revealed	O
sodium	B-TEST
was	O
134	O
,	O
potassium	B-TEST
was	O
4.1	O
,	O
chloride	B-TEST
was	O
102	O
,	O
bicarbonate	B-TEST
was	O
28	O
,	O
blood	B-TEST
urea	I-TEST
nitrogen	I-TEST
was	O
18	O
,	O
creatinine	B-TEST
was	O
0.8	O
,	O
and	O
glucose	B-TEST
was	O
148	O
.	O

Calcium	B-TEST
was	O
7.6	O
.	O

Magnesium	B-TEST
was	O
2.2	O
.	O

Complete	B-TEST
blood	I-TEST
count	I-TEST
revealed	O
white	B-TEST
count	I-TEST
was	O
5.4	O
,	O
hematocrit	B-TEST
was	O
31.3	O
,	O
and	O
platelets	B-TEST
were	O
160	O
.	O

ALT	B-TEST
was	O
14	O
,	O
AST	B-TEST
was	O
31	O
,	O
alkaline	B-TEST
phosphatase	I-TEST
was	O
42	O
,	O
total	B-TEST
bilirubin	I-TEST
was	O
0.9	O
,	O
albumin	B-TEST
was	O
2.2	O
.	O

A	B-TEST
chest	I-TEST
x-ray	I-TEST
postoperatively	O
showed	O
clear	O
lung	O
fields	O
.	O

Tracheostomy	B-TREATMENT
tube	I-TREATMENT
in	O
good	O
position	O
.	O

No	O
pneumothorax	B-PROBLEM
.	O

CMED	O
CSRU	O
and	O
Plastic	O
Surgery	O
flap	B-TEST
checks	I-TEST
,	O
tracheostomy	B-TREATMENT
care	I-TREATMENT
,	O
and	O
Westwood-Pocasset	B-TREATMENT
management.	I-TREATMENT

Lopressor	B-TREATMENT
5	O
intravenously	O
q.4.h.	O

Nebulizers	B-TREATMENT
as	O
needed	O
,	O
weaning	O
from	O
ventilation	B-TREATMENT
.	O

Medications	B-TREATMENT
per	O
gastrostomy	B-TREATMENT
tube	I-TREATMENT
on	O
postoperative	O
day	O
one	O
.	O

Foley	B-TREATMENT
catheter	I-TREATMENT
for	O
strict	B-TEST
monitoring	I-TEST
of	I-TEST
ins	I-TEST
and	I-TEST
outs	I-TEST
.	O

Hematocrit	B-TEST
stable	O
.	O

Unasyn	B-TREATMENT
for	O
antibiotic	B-TREATMENT
coverage	I-TREATMENT
.	O

Flap	B-TEST
checks	I-TEST
carried	O
out	O
q.2h.	O
initially	O
in	O
the	O
Surgical	O
Intensive	O
Care	O
Unit	O
showing	O
positive	B-PROBLEM
biphasic	I-PROBLEM
Doppler	I-PROBLEM
signals	I-PROBLEM
.	O

He	O
was	O
weaned	O
from	O
ventilation	B-TREATMENT
on	O
postoperative	O
day	O
one	O
to	O
pressure	B-TREATMENT
support	I-TREATMENT
ventilation	I-TREATMENT
and	O
then	O
to	O
spontaneous	O
breathing	O
on	O
postoperative	O
day	O
two	O
.	O

His	B-TEST
Westwood-Pocasset	I-TEST
output	I-TEST
for	O
postoperative	O
day	O
one	O
on	O
the	O
left	O
was	O
60	O
,	O
right	O
neck	O
93	O
,	O
in	O
the	O
arm	O
20	O
.	O

Tube	B-TREATMENT
feedings	I-TREATMENT
were	O
started	O
48	O
hours	O
after	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

The	O
cuff	O
on	O
his	B-TREATMENT
tracheostomy	I-TREATMENT
tube	I-TREATMENT
was	O
put	O
down	O
on	O
11-23	O
,	O
postoperative	O
day	O
two	O
which	O
he	O
tolerated	O
well	O
with	O
minimal	B-PROBLEM
secretions	I-PROBLEM
and	O
a	O
strong	O
adequate	O
cough	O
.	O

His	B-TREATMENT
tube	I-TREATMENT
feedings	I-TREATMENT
were	O
advanced	O
.	O

He	O
continued	O
with	O
pulmonary	B-TREATMENT
toilet	I-TREATMENT
and	O
q.2h.	B-TEST
flap	I-TEST
checks	I-TEST
.	O

The	B-TREATMENT
Westwood-Pocasset	I-TREATMENT
in	I-TREATMENT
his	I-TREATMENT
right	I-TREATMENT
arm	I-TREATMENT
was	O
removed	O
on	O
2016-11-25	O
.	O

His	B-TREATMENT
tracheostomy	I-TREATMENT
was	O
changed	O
to	O
a	B-TREATMENT
6	I-TREATMENT
cuffless	I-TREATMENT
Shiley	I-TREATMENT
on	O
2016-11-26	O
and	O
sutures	B-TREATMENT
in	O
place	O
with	O
a	B-TREATMENT
3-0	I-TREATMENT
silk	I-TREATMENT
.	O

The	O
patient	O
tolerated	O
this	B-TREATMENT
procedure	I-TREATMENT
well	O
.	O

Mrs.	O
Wisniewski	O
is	O
a	O
45-year-old	O
woman	O
with	O
multiple	B-PROBLEM
familial	I-PROBLEM
cavernous	I-PROBLEM
hemangiomas	I-PROBLEM
.	O

She	O
developed	O
an	B-PROBLEM
ear	I-PROBLEM
ache	I-PROBLEM
,	O
for	O
which	O
she	O
saw	O
her	O
primary	O
care	O
physician	O
,	O
Evelyn	O
was	O
prescribed	O
cortisone	B-TREATMENT
drops	I-TREATMENT
.	O

A	O
few	O
days	O
later	O
she	O
complained	O
of	O
dizziness	B-PROBLEM
.	O

This	O
was	O
mostly	O
described	O
as	O
feeling	O
unsteady	B-PROBLEM
on	I-PROBLEM
her	I-PROBLEM
feet	I-PROBLEM
.	O

She	O
was	O
seen	O
again	O
by	O
primary	O
care	O
physician	O
,	O
Roderick	O
since	O
she	O
had	O
complaints	O
of	O
dizziness	B-PROBLEM
,	O
as	O
well	O
as	O
a	O
new	O
complaint	O
of	O
decreased	B-PROBLEM
hearing	I-PROBLEM
and	O
the	O
sensation	O
of	O
static	B-PROBLEM
in	I-PROBLEM
her	I-PROBLEM
ears	I-PROBLEM
,	O
meniere	B-PROBLEM
's	I-PROBLEM
disease	I-PROBLEM
was	O
considered	O
.	O

She	O
was	O
given	O
an	B-TREATMENT
oral	I-TREATMENT
prednisone	I-TREATMENT
taper	I-TREATMENT
.	O

This	B-PROBLEM
unsteady	I-PROBLEM
gait	I-PROBLEM
progressed	O
,	O
and	O
then	O
she	O
subsequently	O
started	O
to	O
develop	O
a	B-PROBLEM
pins	I-PROBLEM
and	I-PROBLEM
needle	I-PROBLEM
feeling	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
face	I-PROBLEM
,	I-PROBLEM
hands	I-PROBLEM
and	I-PROBLEM
feet	I-PROBLEM
bilaterally	I-PROBLEM
.	O

Her	O
hearing	O
got	O
progressively	B-PROBLEM
worse	I-PROBLEM
and	O
the	B-PROBLEM
sound	I-PROBLEM
of	I-PROBLEM
static	I-PROBLEM
increased	O
.	O

She	O
was	O
very	B-PROBLEM
fatigued	I-PROBLEM
.	O

At	O
an	O
outside	O
hospital	O
,	O
head	B-TEST
CT	I-TEST
revealed	O
a	B-PROBLEM
1.5	I-PROBLEM
cm	I-PROBLEM
diameter	I-PROBLEM
hyperdense	I-PROBLEM
mass	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
pons	I-PROBLEM
,	O
slightly	O
off	O
center	O
to	O
the	O
right	O
.	O

Notable	O
for	O
multiple	B-PROBLEM
cavernous	I-PROBLEM
hemangiomas	I-PROBLEM
.	O

She	O
has	O
had	O
at	B-PROBLEM
least	I-PROBLEM
two	I-PROBLEM
bleeding	I-PROBLEM
episodes	I-PROBLEM
in	O
the	O
past	O
,	O
mostly	O
described	O
as	O
being	O
accompanied	O
by	O
generalized	B-PROBLEM
weakness	I-PROBLEM
.	O

She	O
has	O
had	O
at	B-PROBLEM
least	I-PROBLEM
two	I-PROBLEM
generalized	I-PROBLEM
seizures	I-PROBLEM
in	O
the	O
past	O
,	O
but	O
she	O
has	O
not	O
had	O
one	O
since	O
she	O
was	O
26	O
years	O
old	O
.	O

She	O
was	O
never	O
on	O
an	B-TREATMENT
anticonvulsant	I-TREATMENT
due	O
to	O
her	O
former	O
beliefs	O
as	O
N.	O
Derk	O
Scientist	O
.	O

Prednisone	B-TREATMENT
taper	I-TREATMENT
as	O
above	O
.	O

Strong	O
maternal	O
history	O
of	O
hemangiomas	B-PROBLEM
.	O

Temperature	B-TEST
99.2	O
.	O

Pulse	B-TEST
60	O
.	O

Blood	B-TEST
pressure	I-TEST
120/80	O
.	O

Respiratory	B-TEST
rate	I-TEST
14	O
.	O

In	O
general	O
,	O
she	O
was	O
a	O
thin	O
well-appearing	O
woman	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Sclera	O
were	O
anicteric	B-PROBLEM
.	O

Cardiovascular	B-TEST
exam	I-TEST
revealed	O
a	O
regular	O
rate	O
and	O
rhythm	O
with	O
no	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
.	O

Abdomen	O
soft	O
,	O
nontender	B-PROBLEM
and	O
distended	B-PROBLEM
.	O

Extremities	O
showed	O
no	O
edema	B-PROBLEM
.	O

Neurologically	O
,	O
she	O
was	O
awoken	O
from	O
sleep	O
by	O
voice	O
,	O
cooperative	O
,	O
but	O
mildly	B-PROBLEM
drowsy	I-PROBLEM
.	O

She	O
became	O
more	O
alert	O
during	O
the	O
remainder	O
of	O
the	B-TEST
exam	I-TEST
.	O

Speech	O
was	O
fluent	O
but	O
slow	B-PROBLEM
,	O
and	O
there	O
was	O
long	B-PROBLEM
response	I-PROBLEM
latencies	I-PROBLEM
before	O
she	O
would	O
initiate	O
speech	O
.	O

She	O
otherwise	O
had	O
normal	O
spontaneous	O
movements	O
and	O
facial	O
expression	O
and	O
did	O
not	O
appear	O
to	O
be	O
abulic	B-PROBLEM
.	O

There	O
was	O
no	O
dysarthria	B-PROBLEM
.	O

There	O
was	O
no	O
evidence	O
of	O
any	B-PROBLEM
special	I-PROBLEM
neglect	I-PROBLEM
.	O

She	O
had	O
sustained	B-PROBLEM
gaze	I-PROBLEM
holding	I-PROBLEM
nystagmus	I-PROBLEM
in	O
both	O
horizontal	O
directions	O
.	O

There	O
was	O
no	O
rotary	B-PROBLEM
component	I-PROBLEM
.	O

She	O
had	O
a	B-PROBLEM
mildly	I-PROBLEM
widened	I-PROBLEM
right	I-PROBLEM
palpable	I-PROBLEM
fissure	I-PROBLEM
.	O

There	O
was	O
decreased	B-PROBLEM
excursion	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
mouth	I-PROBLEM
and	O
flattening	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
nasolabial	I-PROBLEM
fold	I-PROBLEM
(	I-PROBLEM
mild	I-PROBLEM
)	I-PROBLEM
.	O

Light	O
touch	O
was	O
subjectively	B-PROBLEM
abnormal	I-PROBLEM
on	O
both	O
sides	O
of	O
the	O
face	O
.	O

Hearing	O
was	O
diminished	B-PROBLEM
for	O
conversational	O
speech	O
.	O

There	O
was	O
a	B-PROBLEM
mild	I-PROBLEM
left	I-PROBLEM
pronator	I-PROBLEM
drift	I-PROBLEM
.	O

Finger	B-TEST
tapping	I-TEST
and	O
rapid	B-TEST
alternating	I-TEST
movements	I-TEST
were	O
slow	B-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
and	O
she	O
had	O
trouble	B-PROBLEM
isolating	I-PROBLEM
individual	I-PROBLEM
finger	I-PROBLEM
movements	I-PROBLEM
.	O

There	O
was	O
mild	B-PROBLEM
finger-to-nose	I-PROBLEM
dysmetria	I-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
.	O

Power	O
was	O
mildly	B-PROBLEM
diminished	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
finger	I-PROBLEM
extensors	I-PROBLEM
and	O
hand	O
intrinsics	O
on	O
the	O
left	O
,	O
otherwise	O
,	O
power	O
was	O
full	O
throughout	O
.	O

Reflexes	B-TEST
were	O
brisk	O
in	O
the	O
legs	O
with	O
4-5	O
beats	O
of	O
clonus	B-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
ankles	I-PROBLEM
bilaterally	I-PROBLEM
.	O

She	O
had	O
bilateral	B-PROBLEM
upgoing	I-PROBLEM
toes	I-PROBLEM
.	O

She	O
made	O
mistakes	B-PROBLEM
with	I-PROBLEM
position	I-PROBLEM
sense	I-PROBLEM
,	O
roughly	O
at	O
chance	O
level	O
with	O
both	O
great	O
toes	O
and	O
the	O
left	O
first	O
finger	O
,	O
position	O
sense	O
in	O
the	O
right	O
limb	O
seems	O
preserved	O
.	O

Gait	O
was	O
wide	B-PROBLEM
based	I-PROBLEM
,	O
very	B-PROBLEM
unsteady	I-PROBLEM
,	O
veering	O
to	O
the	O
left	O
and	O
to	O
the	O
right	O
.	O

She	O
retropulsed	B-PROBLEM
and	O
would	O
have	O
pitched	O
backwards	O
without	O
the	O
assistance	O
of	O
the	O
examiner	O
.	O

White	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
7.8	O
with	O
86%	O
polymorphonuclear	B-TEST
cells	I-TEST
,	O
11.1	O
lymphocytes	B-TEST
,	O
hemoglobin	B-TEST
14.3	O
,	O
hematocrit	B-TEST
40.5	O
,	O
MCV	B-TEST
88	O
,	O
INR	B-TEST
1.0	O
,	O
PTT	B-TEST
24.7	O
,	O
PT	B-TEST
12.3	O
,	O
platelet	B-TEST
count	I-TEST
295,000	O
,	O
glucose	B-TEST
81	O
,	O
BUN	B-TEST
15	O
,	O
creatinine	B-TEST
0.8	O
,	O
sodium	B-TEST
142	O
,	O
potassium	B-TEST
4.2	O
,	O
chloride	B-TEST
104	O
,	O
CO2	B-TEST
26	O
,	O
calcium	B-TEST
9.3	O
,	O
phosphate	B-TEST
4.8	O
,	O
magnesium	B-TEST
2.3	O
.	O

MRI	B-TEST
of	I-TEST
the	I-TEST
brain	I-TEST
revealed	O
multiple	B-PROBLEM
foci	I-PROBLEM
susceptibility	I-PROBLEM
artifact	I-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
brain	I-PROBLEM
.	O

These	O
were	O
seen	O
best	O
in	O
gradient	B-TEST
echocardiogram	I-TEST
images	I-TEST
.	O

There	O
was	O
a	O
large	O
focus	O
of	O
subacute	B-PROBLEM
blood	I-PROBLEM
products	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
mid	I-PROBLEM
to	I-PROBLEM
low	I-PROBLEM
pons	I-PROBLEM
suggesting	O
recent	B-PROBLEM
hemorrhage	I-PROBLEM
into	I-PROBLEM
a	I-PROBLEM
cavernous	I-PROBLEM
angioma	I-PROBLEM
.	O

There	O
was	O
some	B-PROBLEM
mild	I-PROBLEM
surrounding	I-PROBLEM
edema	I-PROBLEM
.	O

There	O
are	O
also	O
tiny	B-PROBLEM
foci	I-PROBLEM
artifact	I-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
cerebellum	I-PROBLEM
and	I-PROBLEM
base	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
pons	I-PROBLEM
.	O

There	O
was	O
a	O
larger	O
area	O
of	O
susceptibility	B-PROBLEM
artifact	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
temporal	I-PROBLEM
lobe	I-PROBLEM
,	I-PROBLEM
right	I-PROBLEM
frontal	I-PROBLEM
lobe	I-PROBLEM
,	I-PROBLEM
and	I-PROBLEM
the	I-PROBLEM
splenius	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
corpus	I-PROBLEM
collasum	I-PROBLEM
.	O

There	O
was	O
mild	B-PROBLEM
enhancement	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
pontine	I-PROBLEM
hemorrhagic	I-PROBLEM
mass	I-PROBLEM
but	O
none	O
elsewhere	O
.	O

There	O
was	O
no	O
areas	B-PROBLEM
of	I-PROBLEM
restricted	I-PROBLEM
diffusion	I-PROBLEM
to	O
indicate	O
infarction	B-PROBLEM
.	O

MRA	B-TEST
of	I-TEST
the	I-TEST
brain	I-TEST
was	O
unremarkable	O
.	O

There	O
was	O
no	O
communication	O
>.......<	O
in	O
the	O
visualized	O
vessels	O
and	O
the	O
angiomas	B-PROBLEM
.	O

Follow-up	B-TEST
CT	I-TEST
was	O
obtained	O
the	O
second	O
day	O
of	O
admission	O
.	O

There	O
was	O
no	O
evidence	O
of	O
developing	B-PROBLEM
hydrocephalus	I-PROBLEM
,	O
which	O
was	O
a	O
concern	O
due	O
to	O
the	B-PROBLEM
surrounding	I-PROBLEM
edema	I-PROBLEM
,	O
and	O
possible	O
suppression	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
fourth	I-PROBLEM
ventricle	I-PROBLEM
.	O

There	O
was	O
no	O
significant	B-PROBLEM
change	I-PROBLEM
in	I-PROBLEM
size	I-PROBLEM
of	O
the	B-PROBLEM
subacute	I-PROBLEM
pontine	I-PROBLEM
hemorrhage	I-PROBLEM
.	O

Mrs.	O
Wisniewski	O
is	O
a	O
45	O
-	O
year-old	O
woman	O
with	O
a	O
strong	O
family	O
history	O
of	O
cavernous	B-PROBLEM
angiomas	I-PROBLEM
.	O

She	O
has	O
had	O
several	B-PROBLEM
prior	I-PROBLEM
bleeding	I-PROBLEM
events	I-PROBLEM
and	O
presented	O
with	O
a	B-PROBLEM
subacute	I-PROBLEM
bleed	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
mid	I-PROBLEM
to	I-PROBLEM
lower	I-PROBLEM
pons	I-PROBLEM
.	O

There	O
was	O
relatively	O
central	O
in	O
location	O
,	O
with	O
only	O
a	B-PROBLEM
slight	I-PROBLEM
right-sided	I-PROBLEM
predominance	I-PROBLEM
.	O

Her	B-TEST
physical	I-TEST
examination	I-TEST
remained	O
relatively	O
unchanged	O
,	O
with	O
resolution	O
of	O
the	B-PROBLEM
subtle	I-PROBLEM
left	I-PROBLEM
hand	I-PROBLEM
weakness	I-PROBLEM
and	O
right	B-PROBLEM
facial	I-PROBLEM
weakness	I-PROBLEM
.	O

Her	O
gait	O
remained	O
severely	B-PROBLEM
ataxic	I-PROBLEM
,	O
likely	O
secondary	O
to	O
sensory	B-PROBLEM
deafferentation	I-PROBLEM
,	O
as	O
well	O
as	O
involvement	O
of	O
crossing	B-PROBLEM
pontine	I-PROBLEM
cerebellar	I-PROBLEM
fibers	I-PROBLEM
.	O

Therefore	O
,	O
it	O
was	O
recommended	O
that	O
she	O
have	O
aggressive	B-TREATMENT
Physical	I-TREATMENT
Therapy	I-TREATMENT
at	O
an	O
Acute	O
Rehabilitation	O
Center	O
.	O

We	O
will	O
arrange	O
to	O
have	O
a	O
copy	O
of	O
the	B-TEST
MRI	I-TEST
scans	I-TEST
sent	O
to	O
him	O
.	O

1.	O
Familial	B-PROBLEM
cavernous	I-PROBLEM
hemangiomas	I-PROBLEM
,	O
status	O
post	O
a	B-PROBLEM
subacute	I-PROBLEM
pontine	I-PROBLEM
hemorrhage	I-PROBLEM
.	O

2.	O
Severe	B-PROBLEM
gait	I-PROBLEM
ataxia	I-PROBLEM
.	O

1.	O
Gabapentin	B-TREATMENT
100	O
mg	O
po	O
t.i.d.	O
for	O
paresthesias	B-PROBLEM
.	O

2.	O
Colace	B-TREATMENT
100	O
mg	O
po	O
b.i.d.	O

3.	O
Zantac	B-TREATMENT
150	O
mg	O
po	O
b.i.d.	O

4.	O
Prednisone	B-TREATMENT
taper	I-TREATMENT
completed	O
.	O

This	O
is	O
an	O
85	O
year	O
old	O
man	O
initially	O
admitted	O
to	O
the	O
Plastic	O
Surgery	O
Service	O
for	O
evaluation	B-TEST
of	O
a	B-PROBLEM
left	I-PROBLEM
facial	I-PROBLEM
mass	I-PROBLEM
.	O

His	O
past	O
medical	O
history	O
is	O
significant	O
for	O
prostate	B-PROBLEM
cancer	I-PROBLEM
,	O
benign	B-PROBLEM
prostatic	I-PROBLEM
hypertrophy	I-PROBLEM
,	O
hypothyroidism	B-PROBLEM
,	O
status	O
post	O
radiation	B-TREATMENT
for	O
non	B-PROBLEM
Hodgkin	I-PROBLEM
's	I-PROBLEM
lymphoma	I-PROBLEM
,	O
chronic	B-PROBLEM
painless	I-PROBLEM
hematuria	I-PROBLEM
,	O
degenerative	B-PROBLEM
joint	I-PROBLEM
disease	I-PROBLEM
and	O
history	O
of	O
a	B-PROBLEM
murmur	I-PROBLEM
.	O

Last	O
colonoscopy	B-TEST
,	O
five	O
years	O
ago	O
.	O

Dementia	B-PROBLEM
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

1.	O
Levothyroxine	B-TREATMENT
.	O

2.	O
Lasix	B-TREATMENT
.	O

3.	O
Proscar	B-TREATMENT
.	O

4.	O
Aeroseb	B-TREATMENT
.	O

5.	O
Ancef	B-TREATMENT
.	O

On	O
examination	B-TEST
,	O
he	O
is	O
afebrile	B-PROBLEM
.	O

Vital	B-TEST
signs	I-TEST
,	O
stable	O
.	O

Elderly	O
man	O
,	O
somewhat	B-PROBLEM
cachectic	I-PROBLEM
.	O

Head	O
,	O
eyes	O
,	O
ears	O
,	O
nose	O
and	O
throat	O
,	O
polypoid	B-PROBLEM
lesion	I-PROBLEM
just	O
inferior	O
to	O
the	O
left	O
zygoma	O
,	O
elevated	O
superiorly	O
,	O
with	O
visible	B-PROBLEM
bone	I-PROBLEM
.	O

No	O
exudate	B-PROBLEM
.	O

Minimal	B-PROBLEM
bleeding	I-PROBLEM
.	O

Clear	O
to	O
auscultation	B-TEST
.	O

Nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
.	O

He	O
was	O
initially	O
admitted	O
to	O
CMED	O
for	O
resection	B-TREATMENT
and	O
repair	B-TREATMENT
of	O
this	B-PROBLEM
left	I-PROBLEM
facial	I-PROBLEM
lesion	I-PROBLEM
.	O

He	O
also	O
had	O
consults	O
from	O
Urology	O
for	O
his	B-PROBLEM
hematuria	I-PROBLEM
as	O
well	O
as	O
Medicine	O
preoperatively	O
and	O
CMED	O
CCU	O
.	O

He	O
went	O
to	O
the	O
Operating	O
Room	O
on	O
2016-03-10	O
with	O
Urology	O
for	O
hematuria	B-PROBLEM
where	O
he	O
had	O
a	B-TREATMENT
cystoscopy	I-TREATMENT
transurethral	I-TREATMENT
resection	I-TREATMENT
of	I-TREATMENT
prostate	I-TREATMENT
placement	I-TREATMENT
.	O

He	O
then	O
went	O
to	O
the	O
Operating	O
Room	O
on	O
2016-03-14	O
where	O
he	O
had	O
resection	B-TREATMENT
of	O
the	B-PROBLEM
left	I-PROBLEM
face	I-PROBLEM
squamous	I-PROBLEM
cell	I-PROBLEM
cancer	I-PROBLEM
by	O
Dr.	O
Langhorne	O
and	O
split	B-TREATMENT
thickness	I-TREATMENT
and	I-TREATMENT
full	I-TREATMENT
thickness	I-TREATMENT
skin	I-TREATMENT
grafting	I-TREATMENT
of	O
the	B-PROBLEM
defects	I-PROBLEM
on	O
2016-03-14	O
.	O

He	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
with	O
no	O
complications	B-PROBLEM
except	O
postoperatively	O
,	O
his	O
voice	O
was	O
hoarse	B-PROBLEM
.	O

On	O
scoping	B-TEST
him	O
he	O
had	O
significant	B-PROBLEM
supraglottic	I-PROBLEM
edema	I-PROBLEM
.	O

He	O
was	O
kept	O
in	O
the	O
Unit	O
for	O
observation	B-TEST
of	I-TEST
his	I-TEST
airway	I-TEST
and	O
b.i.d.	O
laryngoscopy	B-TEST
.	O

This	O
revealed	O
some	B-PROBLEM
supraglottic	I-PROBLEM
edema	I-PROBLEM
which	O
revealed	O
with	O
time	O
,	O
without	O
further	B-TREATMENT
intervention	I-TREATMENT
.	O

He	O
was	O
followed	O
by	O
Plastic	O
Surgery	O
for	O
his	B-TREATMENT
split	I-TREATMENT
thickness	I-TREATMENT
skin	I-TREATMENT
graft	I-TREATMENT
and	O
his	B-TREATMENT
bolster	I-TREATMENT
was	O
discontinued	O
on	O
postoperative	O
day	O
#5	O
with	O
good	O
take	O
up	O
of	O
his	B-TREATMENT
skin	I-TREATMENT
graft	I-TREATMENT
.	O

Urology	O
also	O
followed	O
him	O
and	O
kept	O
him	O
on	O
antibiotics	B-TREATMENT
until	O
postoperative	O
day	O
#7	O
at	O
which	O
point	O
antibiotics	B-TREATMENT
were	O
discontinued	O
.	O

Foley	B-TREATMENT
was	O
also	O
discontinued	O
.	O

He	O
is	O
being	O
discharged	O
to	O
rehabilitation	O
to	O
follow	O
up	O
for	O
XRT	B-TREATMENT
given	O
the	O
fact	O
that	O
his	B-TEST
pathology	I-TEST
revealed	O
squamous	B-PROBLEM
cell	I-PROBLEM
cancer	I-PROBLEM
extending	O
deep	O
to	O
the	O
margin	O
as	O
well	O
as	O
positive	B-PROBLEM
level	I-PROBLEM
II	I-PROBLEM
nodes	I-PROBLEM
.	O

Dr.	O
Navarrete	O
has	O
been	O
e-mailed	O
and	O
his	O
secretary	O
contacted	O
for	O
as	O
soon	O
as	O
possible	O
appointment	O
for	O
XRT	B-TREATMENT
follow	O
up	O
.	O

Keflex	B-TREATMENT
/	O
Heparin	B-TREATMENT
Agents	I-TREATMENT

Chief	O
Complaint	O
:	O
pt	O
sent	O
to	O
ER	O
after	O
routine	O
F/U	O
for	O
UE	B-PROBLEM
DVT	I-PROBLEM
with	O
vascular	O
surgery	O
.	O

In	O
ER	O
c/o	O
dyspnea	B-PROBLEM
and	O
was	O
noted	O
to	O
have	O
mental	B-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
.	O

AVR	B-TREATMENT
(	I-TREATMENT
tissue	I-TREATMENT
)	I-TREATMENT
05-14	O

s/p	O
AVR	B-TREATMENT
05-14	O
.	O

Postop	O
course	O
c/b	O
right	B-PROBLEM
upper	I-PROBLEM
extremity	I-PROBLEM
DVT	I-PROBLEM
and	O
postop	B-PROBLEM
Afib	I-PROBLEM
.	O

At	O
that	O
time	O
had	O
UE	B-TEST
duplex	I-TEST
which	O
revealed	O
RUE	B-PROBLEM
DVT	I-PROBLEM
involving	O
IJ	O
,	O
Axillary	O
,	O
subclav	O
,	O
brachial	O
,	O
and	O
basilic	O
veins	O
.	O

Then	O
referred	O
to	O
ER	O
for	O
Tx	B-TREATMENT

s/p	O
AVR	B-TREATMENT
(	O
#27	O
pericardial	O
)	O

post-op	B-PROBLEM
Afib	I-PROBLEM

HTN	B-PROBLEM

renal	B-PROBLEM
calculi	I-PROBLEM

?	O
sleep	B-PROBLEM
apnea	I-PROBLEM

seasonal	B-PROBLEM
allergies	I-PROBLEM

s/p	O
2	B-TREATMENT
surgs.	I-TREATMENT
for	O
spermatocele	B-PROBLEM

s/p	O
oral	B-TREATMENT
surgery	I-TREATMENT

non-contributory	O
for	O
premature	B-PROBLEM
CAD	I-PROBLEM
;	O
father	O
had	O
MI	B-PROBLEM
in	O
his	O
70	O
's	O

admission	B-TEST
PE	I-TEST

VS	B-TEST
:	O
HR	B-TEST
103	O
BP	B-TEST
162/69	O
RR	B-TEST
14	O
Sat	B-TEST
92%	O
RA	O

Neuro	O
:	O
MAE	O
,	O
Follows	O
commands	O
,	O
slightly	B-PROBLEM
confused	I-PROBLEM

Heent	O
:	O
PERRL/EOMI	O
,	O
no	O
JVD	B-PROBLEM

CV	O
:	O
RRR	O
S1-S2	O
,	O
no	O
murmur	B-PROBLEM
.	O

Abdm	O
:	O
soft	O
NT	B-PROBLEM
/	O
ND	B-PROBLEM
/	O
NABS	O

Ext	O
:	O
+	O
distal	B-TEST
pulses	I-TEST
,	O
no	O
edema	B-PROBLEM

Discharge	B-TEST
PE	I-TEST

VS	B-TEST
:	O
T	B-TEST
99	O
HR	B-TEST
68	O
BP	B-TEST
113/72	O
RR	B-TEST
18	O
Sat	B-TEST
98%	O
RA	O

CV:RRR	O
S1-S2	O
,	O
no	O
MRG	B-PROBLEM

Abdm	O
:	O
soft	O
,	O
NT/ND/NABS	B-PROBLEM

Ext	O
:	O
warm	O
well	O
perfused	O
No	O
CCE	B-PROBLEM

GLUCOSE	B-TEST
-	O
193	O
*	O
UREA	B-TEST
N	I-TEST
-	O
23	O
*	O
CREAT	B-TEST
-	O
1.2	O
SODIUM	B-TEST
-	O
138	O
POTASSIUM	B-TEST
-	O
4.6	O
CHLORIDE	B-TEST
-	O
101	O
TOTAL	B-TEST
CO2	I-TEST
-	O
21	O
*	O
ANION	B-TEST
GAP	I-TEST
-	O
21	O
*	O

CALCIUM	B-TEST
-	O
8.8	O
PHOSPHATE	B-TEST
-	O
3.9	O
MAGNESIUM	B-TEST
-	O
2.4	O

PT	B-TEST
-	O
15.0	O
*	O
PTT	B-TEST
-	O
107.1	O
*	O
INR	B-TEST
(	I-TEST
PT	I-TEST
)-	I-TEST
1.3	O
*	O

WBC	B-TEST
-	O
13.3	O
*#	O
RBC	B-TEST
-	O
3.45	O
*	O
HGB	B-TEST
-	O
10.6	O
*	O
HCT	B-TEST
-	O
30.5	O
*	O
MCV	B-TEST
-	O
88	O
MCH	B-TEST
-	O
30.6	O
MCHC	B-TEST
-	O
34.7	O
RDW	B-TEST
-	O
12.7	O

BLOOD	B-TEST
WBC	I-TEST
-	O
12.9	O
*	O
RBC	B-TEST
-	O
3.37	O
*	O
Hgb	B-TEST
-	O
10.4	O
*	O
Hct	B-TEST
-	O
29.4	O
*	O
MCV	B-TEST
-	O
87	O
MCH	B-TEST
-	O
30.8	O
MCHC	B-TEST
-	O
35.3	O
*	O
RDW	B-TEST
-	O
13.3	O
Plt	B-TEST
Ct	I-TEST
-	O
345	O

BLOOD	B-TEST
PT	I-TEST
-	O
39.1	O
*	O
INR	B-TEST
(	I-TEST
PT	I-TEST
)-	I-TEST
4.4	O
*	O

BLOOD	B-TEST
HEPARIN	I-TEST
DEPENDENT	I-TEST
ANTIBODIES	I-TEST
-	O
positive	O

Pt	O
admitted	O
05-24	O
from	O
ER	O
after	O
positive	B-PROBLEM
RUE	I-PROBLEM
DVT	I-PROBLEM
finding	O
in	O
vascular	O
lab	O
.	O

During	O
ER	B-TEST
evaluation	I-TEST
pt	O
was	O
noted	O
to	O
have	O
some	O
degree	O
of	O
dyspnea	B-PROBLEM
as	O
well	O
as	O
mental	B-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
,	O
including	O
loss	B-PROBLEM
of	I-PROBLEM
short	I-PROBLEM
term	I-PROBLEM
memory	I-PROBLEM
and	O
brief	B-PROBLEM
unresponsive	I-PROBLEM
period	I-PROBLEM
after	O
one	O
dose	O
of	O
IV	B-TREATMENT
Benadry	I-TREATMENT
and	O
steroids	B-TREATMENT
prior	O
to	O
CT	B-TEST
scan	I-TEST
.	O

The	B-TEST
CT	I-TEST
was	O
negative	O
for	O
CVA	B-PROBLEM
but	O
positive	O
for	O
Pulmonary	B-PROBLEM
embolism	I-PROBLEM
.	O

He	O
was	O
transferred	O
to	O
CSRU	O
for	O
evaluation	B-TEST
.	O

Neurology	O
was	O
consulted	O
and	O
the	O
pt	O
also	O
had	O
MRI	B-TEST
which	O
was	O
negative	O
.	O

The	O
pt	O
was	O
begun	O
on	O
heparin	B-TREATMENT
gtt	I-TREATMENT
and	O
was	O
noted	O
to	O
have	O
platelet	B-PROBLEM
drop	I-PROBLEM
>	O
50%	O
after	O
infusion	B-TREATMENT
began	O
,	O
hepain	B-TREATMENT
was	O
d/c	O
'd.	O

Argatroban	B-TREATMENT
was	O
started	O
abd	O
a	B-TEST
HIT	I-TEST
panel	I-TEST
was	O
sent	O
,	O
HIT	B-TEST
panel	I-TEST
was	O
positive	B-PROBLEM
.	O

By	O
the	O
following	O
mornig	O
all	B-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
had	O
cleared	O
and	O
the	O
pt	O
was	O
transferred	O
to	O
the	O
floors	O
for	O
continued	O
care	O
.	O

Over	O
the	O
next	O
several	O
days	O
the	O
patient	O
was	O
maintained	O
on	O
Argatrobanwhile	B-TREATMENT
coumadin	B-TREATMENT
therapy	I-TREATMENT
was	O
initiated	O
.	O

On	O
HD#6	O
the	O
pt	O
had	O
a	B-TEST
therapeudic	I-TEST
INR	I-TEST
(	O
4.4	O
)	O
off	O
Argatroban	B-TREATMENT
and	O
wad	O
discharged	O
home	O
.	O

He	O
was	O
to	O
have	O
f/u	O
INR	B-TEST
check	I-TEST
with	O
Dr	O
Lewis	O
on	O
05-31	O
.	O

ASA	B-TREATMENT
81	O
'	O

Atorvastatin	B-TREATMENT
10	O
'	O

Lisinopril	B-TREATMENT
5	O
'	O

Lopressor	B-TREATMENT
50	O
"	O

Amiodarone	B-TREATMENT
200	O
'	O

1.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

2.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

3.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
50	O
mg	O
Tablet	O
Sig	O
:One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

4.	O
Amoxicillin-Pot	B-TREATMENT
Clavulanate	I-TREATMENT
875-125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
10	O
days	O
.	O

5.	O
Amiodarone	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Warfarin	B-TREATMENT
2	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
as	O
directed	O
:	O
3	O
mg	O
1943-05-29	O
and	O
6/1	O
then	O
as	O
directed	O
by	O
Dr	O
Mace	O
.	O

Discharge	O
Diagnosis	O
:	O
s/p	O
AVR	B-TREATMENT
05-14	O
(	O
tissue	O
)	O
readmitted	O
05-24	O
w/	O
pulmonary	B-PROBLEM
embolism	I-PROBLEM
,	O
RUE	B-PROBLEM
DVT	I-PROBLEM
,	O
HIT	B-PROBLEM
positive	I-PROBLEM

PMH	O
:	O
HTN	B-PROBLEM
,	O
Renal	B-PROBLEM
calculi	I-PROBLEM
,	O
sleep	B-PROBLEM
apnea	I-PROBLEM
,	O

Discharge	O
Instructions	O
:	O
keep	O
wounds	B-PROBLEM
clean	O
and	O
dry	O
.	O

Take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

Follow-up	B-TEST
INR	I-TEST
to	O
be	O
drawn	O
06-01	O
,	O
by	O
Dr	O
Lewis	O
@	O
597-4427	O

Haldol	B-TREATMENT
/	O
Compazine	B-TREATMENT
/	O
Phenergan	B-TREATMENT
/	O
Tigan	B-TREATMENT
/	O
Flagyl	B-TREATMENT

Chest	B-PROBLEM
Pain	I-PROBLEM

Removal	B-TREATMENT
of	I-TREATMENT
tunneled	I-TREATMENT
cath	I-TREATMENT
(	O
previously	O
used	O
for	O
tPN	B-TREATMENT
)	O

54	O
yo	O
F	O
with	O
Crohn	B-PROBLEM
's	I-PROBLEM
s/p	O
ileostomy	B-TREATMENT
and	O
subsequent	O
short	B-PROBLEM
gut	I-PROBLEM
syndrome	I-PROBLEM
with	O
port-a-cath	B-TREATMENT
placement	I-TREATMENT
for	O
TPN	B-TREATMENT
who	O
presents	O
with	O
progressive	B-PROBLEM
right	I-PROBLEM
sided	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
that	O
comes	O
in	O
waves	O
.	O

The	O
pt	O
reports	O
sharp	B-PROBLEM
10/10	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
under	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
breast	I-PROBLEM
which	O
is	O
getting	O
progressively	O
worse	O
.	O

The	B-PROBLEM
pain	I-PROBLEM
is	O
worsened	O
with	O
deep	O
inspiration	O
or	O
movement	O
.	O

It	O
is	O
associated	O
with	O
SOB	B-PROBLEM
as	O
well	O
as	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
.	O

The	O
pt	O
denies	O
abd	B-PROBLEM
pain	I-PROBLEM
,	O
n/v	B-PROBLEM
or	O
increased	B-PROBLEM
ostomy	I-PROBLEM
output	I-PROBLEM
.	O

Given	O
her	B-PROBLEM
fever	I-PROBLEM
,	O
sx	B-PROBLEM
of	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
and	O
SOB	B-PROBLEM
as	O
well	O
as	O
an	B-PROBLEM
elevated	I-PROBLEM
WBC	I-PROBLEM
count	I-PROBLEM
,	O
she	O
was	O
initially	O
thought	O
to	O
have	O
a	B-PROBLEM
PNA	I-PROBLEM
.	O

She	O
was	O
therefore	O
given	O
ceftriaxone	B-TREATMENT
1	O
g	O
IV	O
x1	O
and	O
azithromycin	B-TREATMENT
500	O
mg	O
PO	O
x1	O
in	O
the	O
Deanna	O
.	O

As	O
the	B-TEST
CXR	I-TEST
was	O
without	O
any	O
evidence	O
of	O
PNA	B-PROBLEM
,	O
or	O
PTX	B-PROBLEM
,	O
the	O
pt	O
subsequently	O
received	O
a	B-TEST
CTA	I-TEST
to	O
evaluate	O
for	O
PE	B-PROBLEM
which	O
revealed	O
multifocal	B-PROBLEM
bilateral	I-PROBLEM
PNA	I-PROBLEM
but	O
no	O
PE	B-PROBLEM
.	O

At	O
this	O
time	O
,	O
she	O
was	O
given	O
Vancomycin	B-TREATMENT
1	O
g	O
IV	O
x1	O
.	O

She	O
was	O
also	O
given	O
morphine	B-TREATMENT
2	O
mg	O
x3	O
,	O
4	O
mg	O
IV	O
x2	O
,	O
dolasetron	B-TREATMENT
12.5	O
mg	O
x2	O
and	O
ativan	B-TREATMENT
1	O
mg	O
IV	O
x1	O
.	O

1.	O
Crohn	B-PROBLEM
's	I-PROBLEM
disease	I-PROBLEM
,	O
dx	O
1974	O
s/p	O
three	B-TREATMENT
bowel	I-TREATMENT
resections	I-TREATMENT
and	O
eventual	B-TREATMENT
ileostomy	I-TREATMENT
,	O
resulting	O
in	O
short	B-PROBLEM
gut	I-PROBLEM
syndrome	I-PROBLEM

2.	O
Restless	B-PROBLEM
leg	I-PROBLEM
syndrome	I-PROBLEM

3.	O
?	O
Parkinsons	B-PROBLEM
vs.	O
EPS	B-PROBLEM
side	I-PROBLEM
effects	I-PROBLEM
from	O
risperdal	B-TREATMENT

4.	O
Chronic	B-PROBLEM
idiopathic	I-PROBLEM
pancreatitis	I-PROBLEM
,	O
as	O
demonstrated	O
on	O
CT	B-TEST
in	O
09-01	O

5.	O
Arthritis	B-PROBLEM
s/p	O
"	B-TREATMENT
pin	I-TREATMENT
placement	I-TREATMENT
"	I-TREATMENT
in	I-TREATMENT
left	I-TREATMENT
foot	I-TREATMENT
05-01	O

6.	O
Degenerative	B-PROBLEM
disc	I-PROBLEM
disease	I-PROBLEM
s/p	O
two	B-TREATMENT
back	I-TREATMENT
surgeries	I-TREATMENT
in	O
80	O
's	O

7.	O
Benzo	B-TREATMENT
and	O
opiod	B-TREATMENT
addiction	O

8.	O
Paranoia	B-PROBLEM
/	O
Depression	B-PROBLEM
,	O
h/o	O
auditory	B-PROBLEM
hallucinations	I-PROBLEM
,	O
?	O
mania	B-PROBLEM

9.	O
Port-a-Cath	B-TREATMENT
placement	I-TREATMENT
for	O
IV	B-TREATMENT
hydration	I-TREATMENT
in	O
setting	O
of	O
short	B-PROBLEM
gut	I-PROBLEM
syndrome	I-PROBLEM
,	O
complicated	O
by	O
clotting	B-PROBLEM
x	O
4	O
,	O
requiring	O
replacement	B-TREATMENT

Abd	B-TEST
CT	I-TEST
performed	O
09-01	O
showed	O
multiple	B-PROBLEM
calcifications	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
body	I-PROBLEM
and	I-PROBLEM
tail	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
pancreas	I-PROBLEM
with	O
a	B-PROBLEM
larger	I-PROBLEM
cystic	I-PROBLEM
lesion	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
tail	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
pancreas	I-PROBLEM
.	O

A	B-PROBLEM
second	I-PROBLEM
9	I-PROBLEM
mm	I-PROBLEM
cystic	I-PROBLEM
lesion	I-PROBLEM
is	O
seen	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
chronic	B-PROBLEM
pancreatitis	I-PROBLEM
with	O
pseudocyst	B-PROBLEM
formation	I-PROBLEM

Social	O
History:	O
lives	O
w/	O
her	O
husband	O
in	O
John	O
area	O
;	O
smokes	O
05-04	O
cig	O
/d	O
(	O
30	O
pack	O
year	O
history	O
);	O
no	O
alcohol	O
or	O
recreational	O
drug	O
use	O
,	O
has	O
had	O
addiction	O
to	O
benzodiazepines	B-TREATMENT
and	O
opioids	B-TREATMENT
in	O
the	O
past	O

Mother-Crohn	B-PROBLEM
's	I-PROBLEM
;	O
Daugher-IBS	B-PROBLEM
,	O
colitis	B-PROBLEM
;	O
Mother	O
--	O
breast	B-PROBLEM
CA	I-PROBLEM
,;	O

Father	O
-	O
Stephanie	B-PROBLEM
tumor	I-PROBLEM
,	O
no	O
DM	B-PROBLEM
,	O
no	O
CAD	B-PROBLEM

V	B-TEST
:	O
101.4	O
,	O
102	O
,	O
167/54	O
->	O
159/77	O
,	O
24	O
->	O
16	O
,	O
98%	O
RA	O
->	O
96%	O
RA	O

CV	O
:	O
RRR	O
,	O
s1	O
,	O
s2	B-PROBLEM
distant	I-PROBLEM

Chest	O
:	O
crackles	B-PROBLEM
at	I-PROBLEM
right	I-PROBLEM
base	I-PROBLEM
with	O
dec.	B-PROBLEM
air	I-PROBLEM
movement	I-PROBLEM
.	O

tender	B-PROBLEM
over	I-PROBLEM
right	I-PROBLEM
chest	I-PROBLEM

Abd	O
:	O
obese	B-PROBLEM
,	O
multiple	B-PROBLEM
surgical	I-PROBLEM
scars	I-PROBLEM
.	O

Ileostomy	B-TREATMENT
bag	I-TREATMENT
present	O
with	O
gas	O
and	O
stool	O
.	O

absomen	O
soft	O
,	O
tender	B-PROBLEM
to	O
palpation	B-TEST
over	I-TEST
RUQ	I-TEST
,	O
but	O
no	O
guarding	B-PROBLEM
or	O
rebound	B-PROBLEM

Ext	O
:	O
tr	B-PROBLEM
edema	I-PROBLEM
,	O
2+	O
DP	B-TEST
bilaterally	I-TEST

GLUCOSE	B-TEST
-	O
208	O
*	O
UREA	B-TEST
N	I-TEST
-	O
21	O
*	O
CREAT	B-TEST
-	O
1.3	O
*	O
SODIUM	B-TEST
-	O
138	O
POTASSIUM	B-TEST
-	O
4.2	O
CHLORIDE	B-TEST
-	O
104	O
TOTAL	B-TEST
CO2	I-TEST
-	O
23	O
ANION	B-TEST
GAP	I-TEST
-	O
15	O

CK	B-TEST
(	I-TEST
CPK	I-TEST
)-	I-TEST
31	O

cTropnT	B-TEST
-<	O
0.01	O

WBC	B-TEST
-	O
14.4	O
*#	O
RBC	B-TEST
-	O
3.82	O
*	O
HGB	B-TEST
-	O
11.5	O
*	O
HCT	B-TEST
-	O
33.5	O
*	O
MCV	B-TEST
-	O
88	O
MCH	B-TEST
-	O
30.2	O
MCHC	B-TEST
-	O
34.5	O
RDW	B-TEST
-	O
14.7	O

NEUTS	B-TEST
-	O
78.0	O
*	O
LYMPHS	B-TEST
-	O
17.0	O
*	O
MONOS	B-TEST
-	O
4.6	O
EOS	B-TEST
-	O
0.3	O
BASOS	B-TEST
-	O
0.1	O

PLT	B-TEST
COUNT	I-TEST
-	O
128	O
*	O

PT	B-TEST
-	O
12.3	O
PTT	B-TEST
-	O
26.1	O
INR	B-TEST
(	I-TEST
PT	I-TEST
)-	I-TEST
1.0	O

CTA	B-TEST
2013-12-24	O
-	O
IMPRESSION	O
:	O

1.	O
No	O
definite	B-PROBLEM
pulmonary	I-PROBLEM
embolism	I-PROBLEM
is	O
identified	O
.	O

2.	O
Peripheral	B-PROBLEM
patchy	I-PROBLEM
opacities	I-PROBLEM
are	O
seen	O
bilaterally	O
,	O
most	O
consistent	O
with	O
multifocal	B-PROBLEM
pneumonia	I-PROBLEM
.	O

CXR	B-TEST
2013-12-24	O
-	O
There	O
are	O
faint	B-PROBLEM
ill-defined	I-PROBLEM
opacities	I-PROBLEM
within	O
the	O
right	O
lower	O
lung	O
zone	O
and	O
left	O
upper	O
lung	O
zone	O
could	O
represent	O
a	B-PROBLEM
multifocal	I-PROBLEM
pneumonic	I-PROBLEM
process	I-PROBLEM
.	O

CXR	B-TEST
2014-01-02	O
-	O
IMPRESSION	O
:	O

Multilobar	B-PROBLEM
pneumonia	I-PROBLEM
with	O
interval	B-PROBLEM
worsening	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
lung	I-PROBLEM
but	O
slight	O
improvement	O
in	O
the	O
right	O
lower	O
lobe	O
.	O

Head	B-TEST
CT	I-TEST
2014-01-09	O
-	O
Ordered	O
to	O
evaluate	O
for	O
changes	O
to	O
explain	O
delta	B-PROBLEM
MS	I-PROBLEM

Left	B-PROBLEM
parietal	I-PROBLEM
subcortical	I-PROBLEM
hypodensity	I-PROBLEM
,	O
likely	O
ischemic	B-PROBLEM
.	O

No	O
definite	B-PROBLEM
changes	I-PROBLEM
since	O
the	B-TEST
MR	I-TEST
of	O
in	O
2011-05-15	O
.	O

CXR	B-TEST
2014-01-09	O

54	O
yo	O
F	O
with	O
Crohn	B-PROBLEM
's	I-PROBLEM
disease	I-PROBLEM
s/p	O
ileostomy	B-TREATMENT
with	O
subsequent	O
short	B-PROBLEM
gut	I-PROBLEM
syndrome	I-PROBLEM
with	O
port-o-cath	B-TREATMENT
for	O
TPN	B-TREATMENT
presents	O
with	O
acute	B-PROBLEM
onset	I-PROBLEM
pleuritic	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
with	O
fever	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
and	O
sob	B-PROBLEM
.	O

1.	O
Chest	B-PROBLEM
pain	I-PROBLEM
/	O
Fever	B-PROBLEM
/	O
Chills	B-PROBLEM
:	O

The	B-PROBLEM
acute	I-PROBLEM
onset	I-PROBLEM
of	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
was	O
initially	O
very	O
concerning	O
for	O
a	B-PROBLEM
PE	I-PROBLEM
,	O
however	O
the	B-TEST
Chest	I-TEST
CT	I-TEST
demonstrated	O
multifocal	B-PROBLEM
consolidation	I-PROBLEM
consistent	O
with	O
a	B-PROBLEM
bacterial	I-PROBLEM
PNA	I-PROBLEM
.	O

This	O
is	O
consistent	O
with	O
the	O
remainder	O
of	O
the	O
pt	O
's	O
history	O
including	O
fever	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
sob	B-PROBLEM
and	O
an	B-PROBLEM
elevated	I-PROBLEM
WBC	I-PROBLEM
count	I-PROBLEM
.	O

The	O
pt	O
was	O
given	O
ceftriaxone	B-TREATMENT
/	O
azithromycin	B-TREATMENT
/	O
vancomycin	B-TREATMENT
in	O
Deanna	O
.	O

Blood	B-TEST
,	I-TEST
urine	I-TEST
and	I-TEST
sputum	I-TEST
culutres	I-TEST
were	O
sent	O
.	O

Pt	B-TEST
's	I-TEST
blood	I-TEST
cultures	I-TEST
came	O
back	O
positive	O
for	O
Staph	B-PROBLEM
Aureus	I-PROBLEM
and	O
Enterococcus	B-PROBLEM
,	O
both	O
were	O
pansensitive	O
.	O

Sputum	B-TEST
culture	I-TEST
also	O
returned	O
with	O
Staph.	B-PROBLEM
Aureus	I-PROBLEM
.	O

Ceftriaxone	B-TREATMENT
and	O
azithro	B-TREATMENT
were	O
discontinued	O
,	O
and	O
Vacomycin	B-TREATMENT
was	O
continued	O
.	O

Pt	O
initially	O
was	O
hypoxic	B-PROBLEM
requiring	O
NRB	B-TREATMENT
for	O
O2	B-TEST
sat	I-TEST
of	O
94%	O
,	O
with	O
any	O
attempt	O
to	O
wean	O
she	O
would	O
desat	O
.	O

Pt	O
was	O
intubated	O
prior	O
to	O
tunneled	B-TREATMENT
catheter	I-TREATMENT
removal	I-TREATMENT
,	O
see	O
below	O
.	O

(	O
The	B-TREATMENT
tunneled	I-TREATMENT
catheter	I-TREATMENT
later	O
came	O
back	O
for	O
negative	O
for	O
culture.	B-TEST
)	O

Earlier	O
that	O
day	O
pt	O
had	O
a	B-TEST
chest	I-TEST
x	I-TEST
ray	I-TEST
which	O
showed	O
diffuse	B-PROBLEM
infiltrative	I-PROBLEM
process	I-PROBLEM
concerning	O
for	O
ARDS	B-PROBLEM
.	O

Post	O
procedure	B-TREATMENT
pt	O
remained	O
intubated	B-TREATMENT
on	O
ARDSnet	B-TREATMENT
protocol	I-TREATMENT
.	O

She	O
self	O
extubated	O
the	O
first	O
day	O
and	O
was	O
reintubated	O
without	O
any	B-PROBLEM
complications	I-PROBLEM
.	O

Her	B-PROBLEM
O2	I-PROBLEM
requirement	I-PROBLEM
improved	O
on	O
the	B-TREATMENT
vent	I-TREATMENT
over	O
the	O
next	O
few	O
days	O
and	O
she	O
was	O
weaned	O
off	O
the	B-TREATMENT
vent	I-TREATMENT
on	O
2013-01-01	O
.	O

After	O
extubation	O
her	B-PROBLEM
o2	I-PROBLEM
requirement	I-PROBLEM
was	O
down	O
to	O
1L	B-TREATMENT
NC	I-TREATMENT
with	O
sats	B-TEST
in	O
mid	O
90s	O
.	O

The	O
patient	O
remained	O
afebrile	B-PROBLEM
when	O
she	O
transferred	O
to	O
the	O
medicine	O
service	O
.	O

She	O
was	O
weaned	O
off	O
the	B-TREATMENT
oxygen	I-TREATMENT
and	O
for	O
the	O
remainder	O
of	O
her	O
course	O
her	B-TEST
O2sats	I-TEST
were	O
stable	O
on	O
room	O
air	O
.	O

The	O
patient	O
had	O
completed	O
her	B-TREATMENT
antibiotic	I-TREATMENT
course	I-TREATMENT
while	O
in	O
house	O
.	O

2.	O
Hx	O
of	O
multiple	B-PROBLEM
port-o-cath	I-PROBLEM
clots	I-PROBLEM
:	O

Although	O
the	O
pt	O
is	O
on	O
warfarin	B-TREATMENT
chronically	O
,	O
her	B-TEST
INR	I-TEST
was	O
subtherapeutic	O
.	O

Goal	O
INR	B-TEST
01-31	O
.	O

Initially	O
coumadin	B-TREATMENT
was	O
increased	O
,	O
however	O
given	O
concern	O
for	O
infected	B-PROBLEM
line	I-PROBLEM
,	O
general	O
surgery	O
was	O
consulted	O
who	O
removed	O
the	B-TREATMENT
line	I-TREATMENT
in	O
the	O
ICU	O
.	O

3.	O
ARF	B-PROBLEM
:	O

Pt	O
initially	O
with	O
mild	B-PROBLEM
ARI	I-PROBLEM
,	O
this	O
was	O
thought	O
to	O
be	O
due	O
to	O
dehydration	B-PROBLEM
,	O
after	O
initial	B-TREATMENT
volume	I-TREATMENT
repletion	I-TREATMENT
her	O
renal	O
function	O
improved	O
to	O
her	O
baseline	O
.	O

The	O
pt	O
has	O
a	O
history	O
of	O
paranoia	B-PROBLEM
/	O
depression	B-PROBLEM
.	O

ON	O
admission	O
she	O
was	O
taking	O
Quetiapine	B-TREATMENT
300	O
mg	O
QHS	O
and	O
Clonazepam	B-TREATMENT
1	O
mg	O
QAM	O
,	O
1	O
mg	O
Q3PM	O
,	O
2	O
mg	O
PO	O
QHS	O
.	O

Quetiapine	B-TREATMENT
was	O
continued	O
however	O
clonipin	B-TREATMENT
was	O
initially	O
held	O
when	O
she	O
was	O
intubated	B-TREATMENT
on	O
fentynyl	B-TREATMENT
/	O
versed	B-TREATMENT
.	O

This	O
was	O
restarted	O
post	O
extubation	B-TREATMENT
.	O

Her	O
course	O
later	O
became	O
complicated	O
by	O
visual	B-PROBLEM
and	I-PROBLEM
auditory	I-PROBLEM
hallucinations	I-PROBLEM
.	O

She	O
was	O
unable	B-PROBLEM
to	I-PROBLEM
sleep	I-PROBLEM
at	O
night	O
,	O
often	O
pacing	O
the	O
halls	O
.	O

She	O
required	O
a	B-TREATMENT
1:1	I-TREATMENT
sitter	I-TREATMENT
.	O

They	O
felt	O
that	O
her	O
presentation	O
was	O
secondary	O
to	O
delirium	B-PROBLEM
and	O
was	O
multifactorial	O
.	O

They	O
attributed	O
it	O
to	O
polypharmacy	B-PROBLEM
,	O
recent	B-PROBLEM
infection	I-PROBLEM
(	I-PROBLEM
pneumonia	I-PROBLEM
)	I-PROBLEM
and	O
insomnia	B-PROBLEM
.	O

A	B-TEST
head	I-TEST
CT	I-TEST
was	O
done	O
which	O
ruled	O
out	O
any	B-PROBLEM
acute	I-PROBLEM
processes	I-PROBLEM
.	O

The	O
patient	O
refused	O
an	B-TEST
LP	I-TEST
.	O

They	O
made	O
recommendations	O
for	O
adjustments	O
to	O
her	B-TREATMENT
anti-psychotic	I-TREATMENT
medications	I-TREATMENT
.	O

At	O
discharge	O
the	O
patient	O
was	O
on	O
clonazepam	B-TREATMENT
1	O
mg	O
tid	O
,	O
seroquel	B-TREATMENT
300	O
BID	O
and	O
neurontin	B-TREATMENT
600	O
QAM	O
,	O
1200	O
QPM	O
and	O
1200	O
QHS	O
.	O

The	O
Kindred	O
Hospital	O
hospital	O
course	O
was	O
prolonged	O
because	O
of	O
her	B-PROBLEM
delirium	I-PROBLEM
.	O

5.	O
?	O
Parkinson	B-PROBLEM
's	I-PROBLEM
Disease	I-PROBLEM
/	O
Akithesia	B-PROBLEM
:	O

The	O
patient	O
was	O
maintained	O
Sinemet	B-TREATMENT
.	O

6.	O
Pain	B-PROBLEM
:	O

In	O
addition	O
to	O
her	B-PROBLEM
usual	I-PROBLEM
neuropathy	I-PROBLEM
pain	I-PROBLEM
,	O
the	O
pt	O
initially	O
appeared	O
to	O
have	O
significant	B-PROBLEM
pain	I-PROBLEM
from	O
the	B-PROBLEM
multi-focal	I-PROBLEM
PNA	I-PROBLEM
as	O
well	O
.	O

(	O
Home	B-TREATMENT
regimen	I-TREATMENT
,	O
Gabapentin	B-TREATMENT
800	O
mg	O
PO	O
QAM	O
,	O
1600	O
mg	O
PO	O
Q3PM	O
,	O
1600	O
mg	O
PO	O
QHS	O
.	O

This	O
was	O
held	O
in	O
the	O
ICU	O
and	O
she	O
was	O
given	O
diluadid	B-TREATMENT
prn	O
for	O
pain	B-TREATMENT
control	I-TREATMENT
.	O

The	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
narcotic	I-TREATMENT
and	O
CMED	B-TREATMENT
CCU	I-TREATMENT
regimen	I-TREATMENT
was	O
evaluated	O
by	O
psychiatry	O
during	O
her	B-PROBLEM
delirium	I-PROBLEM
.	O

Given	O
her	O
hx	O
of	O
ileostomy	B-TREATMENT
secondary	O
to	O
crohn	B-PROBLEM
's	I-PROBLEM
disease	I-PROBLEM
and	O
resultant	O
short	B-PROBLEM
gut	I-PROBLEM
syndrome	I-PROBLEM
,	O
the	O
pt	O
requires	O
nutritional	B-TREATMENT
support	I-TREATMENT
via	O
TPN	B-TREATMENT
.	O

After	O
removal	O
of	O
tunneled	B-TREATMENT
line	I-TREATMENT
pt	O
was	O
given	O
tube	B-TREATMENT
feeds	I-TREATMENT
while	O
she	O
was	O
intubated	B-TREATMENT
.	O

The	O
patient	O
was	O
transitioned	O
to	O
a	B-TREATMENT
low	I-TREATMENT
fat	I-TREATMENT
,	I-TREATMENT
low	I-TREATMENT
residue	I-TREATMENT
diet	I-TREATMENT
.	O

PPX	O
:	O
PPI	B-TREATMENT
and	O
heparin	B-TREATMENT
SC	I-TREATMENT

1.	O
Quetiapine	B-TREATMENT
300	O
mg	O
QHS	O

2.	O
Clonazepam	B-TREATMENT
1	O
mg	O
QAM	O
,	O
1	O
mg	O
Q3PM	O
,	O
2	O
mg	O
PO	O
QHS	O

3.	O
Ferrous	B-TREATMENT
Sulfate	I-TREATMENT
325	O
PO	O
Daily	O

4.	O
Carbidopa-Levodopa	B-TREATMENT
25-250	O
mg	O
PO	O
5	O
TIMES	O
PER	O
DAY	O
.	O

5.	O
Gabapentin	B-TREATMENT
800	O
mg	O
PO	O
QAM	O
,	O
1600	O
mg	O
PO	O
Q3PM	O
,	O
1600	O
mg	O
PO	O
QHS	O

6.	O
Heparin	B-TREATMENT
Lock	I-TREATMENT
Flush	I-TREATMENT
10	O
unit	O
/	O
mL	O
Daily	O
as	O
needed	O
.	O

7.	O
Saline	B-TREATMENT
Flush	I-TREATMENT

8.	O
Prevacid	B-TREATMENT
30	O
mg	O
PO	O
twice	O
a	O
day	O
.	O

9.	O
Vistaril	B-TREATMENT
50	O
mg	O
once	O
a	O
day	O
as	O
needed	O
for	O
nausea	B-PROBLEM
.	O

10.	O
Zofran	B-TREATMENT
4	O
mg	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
nausea	B-PROBLEM
.	O

11.	O
Vitamin	B-TREATMENT
B-12	I-TREATMENT
1,000	O
mcg	O
/	O
mL	O
One	O
Injection	O
every	O
other	O
week	O
.	O

12.	O
Vicodin	B-TREATMENT
5-500	O
mg	O
1-2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
PRN	O

13.	O
Warfarin	B-TREATMENT
1	O
mg	O
PO	O
HS	O
.	O

14.	O
TPN	B-TREATMENT

1.	O
Amylase-Lipase-Protease	B-TREATMENT
33,200	O
-	O
10,000	O
-	O
37,500	O
unit	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Cap	O
PO	O
W/	O
MEALS	O
AND	O
SNACKS	O
(	O
)	O
.	O

2.	O
Carbidopa-Levodopa	B-TREATMENT
25	O
-	O
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
5	O
TIMES	O
A	O
DAY	O
(	O
)	O
.	O

3.	O
Pramipexole	B-TREATMENT
0.125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O

4.	O
Clonazepam	B-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O

5.	O
Ferrous	B-TREATMENT
Sulfate	I-TREATMENT
300	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Nystatin	B-TREATMENT
100,000	O
unit	O
/	O
g	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

7.	O
Lansoprazole	B-TREATMENT
30	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

8.	O
Quetiapine	B-TREATMENT
100	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

9.	O
Propranolol	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

10.	O
Neurontin	B-TREATMENT
300	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
three	O
times	O
a	O
day	O
:	O
take	O
2	O
tabs	O
in	O
the	O
morining	O
,	O
4	O
tabs	O
in	O
the	O
afternoon	O
,	O
and	O
4	O
tabs	O
in	O
the	O
evening	O
.	O

Pneumonia	B-PROBLEM

You	O
are	O
to	O
return	O
to	O
the	O
hospital	O
immediately	O
if	O
you	O
should	O
experience	O
any	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
fevers	B-PROBLEM
or	O
any	B-PROBLEM
other	I-PROBLEM
worrisome	I-PROBLEM
symptom	I-PROBLEM
.	O

Please	O
continue	O
taking	O
your	B-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	O
Drugs	B-TREATMENT

Shortness	B-PROBLEM
of	I-PROBLEM
Breath	I-PROBLEM

Coronary	B-TREATMENT
Artery	I-TREATMENT
Bypass	I-TREATMENT
Graft	I-TREATMENT
x3	O
(	O
Left	B-TREATMENT
internal	I-TREATMENT
mammary	I-TREATMENT
->	I-TREATMENT
left	I-TREATMENT
anterior	I-TREATMENT
descending	I-TREATMENT
,	O
saphaneous	B-TREATMENT
vein	I-TREATMENT
graft	I-TREATMENT
->	I-TREATMENT
obtuse	I-TREATMENT
marginal	I-TREATMENT
,	O
saphaneous	B-TREATMENT
vein	I-TREATMENT
graft	I-TREATMENT
->	I-TREATMENT
posterior	I-TREATMENT
descending	I-TREATMENT
artery	I-TREATMENT
)	O
2018-10-25	O

67	O
y/o	O
male	O
with	O
worsening	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath.	I-PROBLEM
Had	O
abnormal	B-PROBLEM
ETT	I-PROBLEM
and	O
referred	O
for	O
cath	B-TEST
.	O

Cath	B-TEST
revealed	O
severe	B-PROBLEM
3	I-PROBLEM
vessel	I-PROBLEM
disease	I-PROBLEM
.	O

Then	O
referred	O
for	O
surgical	B-TREATMENT
intervention	I-TREATMENT
.	O

Carpal	B-PROBLEM
tunnel	I-PROBLEM
syndrome	I-PROBLEM
,	O
Hypertension	B-PROBLEM
,	O
Hyperlipidemia	B-PROBLEM
,	O
Arthritis	B-PROBLEM
,	O
h/o	O
Bell's	B-PROBLEM
Palsy	I-PROBLEM
,	O
HOH	B-PROBLEM
,	O
s/p	O
Tonsillectomy	B-TREATMENT

Father	O
with	O
MI	B-PROBLEM
in	O
50	O
's	O
and	O
underwent	O
CABG	B-TREATMENT
.	O

VS	B-TEST
:	O
65	O
20	O
160/100	O
5	O
'	O
7	O
"	O
180	O
#	O

General	O
:	O
WD/WN	O
male	O
in	O
NAD	B-PROBLEM

HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
NC/AT	B-PROBLEM

Neck	O
:	O
Supple	O
,	O
FROM	O
,	O
-	O
JVD	B-PROBLEM
,	O
-	O
carotid	B-PROBLEM
bruits	I-PROBLEM

Chest	O
:	O
CTAB	O
-	O
w/r/r	B-PROBLEM

Heart	O
:	O
RRR	O
-	O
c/r/m/g	B-PROBLEM

Abd	O
:	O
Soft	O
,	O
NT/ND	B-PROBLEM
+BS	O

Ext	O
:	O
Warm	O
,	O
well-perfused	O
-	O
edema	B-PROBLEM
,	O
-	O
varicosities	B-PROBLEM

Echo	B-TEST
10-25	O
:	O
PRE-BYPASS	O
:	O
Left	B-TEST
ventricular	I-TEST
wall	I-TEST
thicknesses	I-TEST
are	O
normal	O
.	O

The	B-TEST
left	I-TEST
ventricular	I-TEST
cavity	I-TEST
size	I-TEST
is	O
normal	O
.	O

There	O
is	O
mild	B-PROBLEM
inferior	I-PROBLEM
wall	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

There	O
is	O
akinesis	B-PROBLEM
/	O
dyskinesis	B-PROBLEM
and	O
thinning	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
mid	I-PROBLEM
to	I-PROBLEM
distal	I-PROBLEM
inferior	I-PROBLEM
septum	I-PROBLEM
and	O
the	O
apex	O
.	O

Overall	B-TEST
left	I-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
mildly	B-PROBLEM
depressed	I-PROBLEM
.	O

Right	B-TEST
ventricular	I-TEST
chamber	I-TEST
size	I-TEST
and	O
free	B-TEST
wall	I-TEST
motion	I-TEST
are	O
normal	O
.	O

The	O
descending	O
thoracic	O
aorta	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

There	O
are	O
simple	B-PROBLEM
atheroma	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
descending	I-PROBLEM
thoracic	I-PROBLEM
aorta	I-PROBLEM
.	O

There	O
is	O
no	O
aortic	B-PROBLEM
valve	I-PROBLEM
stenosis	I-PROBLEM
.	O

No	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

Trivial	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

POST-BYPASS	B-TREATMENT
:	O
LV	B-TEST
and	I-TEST
RV	I-TEST
function	I-TEST
is	O
unchanged	O
.	O

CXR	B-TEST
10-30	O
:	O
Left	B-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
atelectasis	I-PROBLEM
has	O
partially	O
cleared	O
.	O

Mild	B-PROBLEM
postoperative	I-PROBLEM
widening	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
cardiomediastinal	I-PROBLEM
silhouette	I-PROBLEM
is	O
stable	O
.	O

No	O
pneumothorax	B-PROBLEM
.	O

2018-10-25	O
11:15	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
18.3	O
*#	O
RBC	B-TEST
-	O
3.42	O
*	O
Hgb	B-TEST
-	O
10.9	O
*	O
Hct	B-TEST
-	O
31.6	O
*	O
MCV	B-TEST
-	O
92	O
MCH	B-TEST
-	O
31.7	O
MCHC	B-TEST
-	O
34.4	O
RDW	B-TEST
-	O
13.3	O
Plt	B-TEST
Ct	I-TEST
-	O
134	O
*	O

2018-10-31	O
06:25	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
13.6	O
*	O
RBC	B-TEST
-	O
2.72	O
*	O
Hgb	B-TEST
-	O
8.6	O
*	O
Hct	B-TEST
-	O
24.6	O
*	O
MCV	B-TEST
-	O
91	O
MCH	B-TEST
-	O
31.7	O
MCHC	B-TEST
-	O
35.0	O
RDW	B-TEST
-	O
14.0	O
Plt	B-TEST
Ct	I-TEST
-	O
314	O

2018-10-25	O
11:15	O
AM	O
BLOOD	B-TEST
PT	B-TEST
-	O
13.3	O
*	O
PTT	B-TEST
-	O
30.0	O
INR(PT)	B-TEST
-	O
1.2	O
*	O

2018-10-29	O
06:50	O
AM	O
BLOOD	B-TEST
PT	B-TEST
-	O
11.9	O
INR(PT)	B-TEST
-	O
1.0	O

2018-10-25	O
12:36	O
PM	O
BLOOD	B-TEST
UreaN	B-TEST
-	O
17	O
Creat	B-TEST
-	O
0.7	O
Cl	B-TEST
-	O
111	O
*	O
HCO3	B-TEST
-	O
23	O

2018-10-31	O
06:25	O
AM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
91	O
UreaN	B-TEST
-	O
19	O
Creat	B-TEST
-	O
0.8	O
Na	B-TEST
-	O
134	O
K	B-TEST
-	O
4.0	O
Cl	B-TEST
-	O
98	O
HCO3	B-TEST
-	O
26	O
AnGap	B-TEST
-	O
14	O

Mr.	O
Kammerer	O
was	O
a	O
same	O
day	O
admit	O
and	O
on	O
10-25	O
was	O
brought	O
to	O
the	O
operating	O
room	O
where	O
he	O
underwent	O
a	B-TREATMENT
coronary	I-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
graft	I-TREATMENT
x	O
3	O
.	O

He	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
was	O
transferred	O
to	O
the	O
CSRU	O
for	O
invasive	B-TEST
monitoring	I-TEST
in	O
stable	O
condition	O
.	O

Later	O
on	O
op	O
day	O
he	O
was	O
weaned	O
from	O
sedation	B-TREATMENT
,	O
awoke	O
neurologically	O
intact	O
,	O
and	O

Beta	B-TREATMENT
blockers	I-TREATMENT
and	O
diuretics	B-TREATMENT
were	O
initiated	O
on	O
post-op	O
day	O
one	O
.	O

He	O
was	O
diuresed	B-TREATMENT
towards	O
his	B-TEST
pre-op	I-TEST
weight	I-TEST
.	O

He	O
did	O
have	O
burst	B-PROBLEM
of	I-PROBLEM
atrial	I-PROBLEM
fibrillation	I-PROBLEM
and	O
was	O
started	O
on	O
a	B-TREATMENT
Amiodarone	I-TREATMENT
gtt	I-TREATMENT
.	O

His	B-TREATMENT
beta	I-TREATMENT
blockers	I-TREATMENT
were	O
also	O
titrated	O
for	O
maximal	B-TREATMENT
BP	I-TREATMENT
and	I-TREATMENT
HR	I-TREATMENT
control	I-TREATMENT
.	O

Chest	B-TREATMENT
tubes	I-TREATMENT
were	O
removed	O
on	O
post-op	O
day	O
two	O
and	O
epicardial	B-TREATMENT
pacing	I-TREATMENT
wires	I-TREATMENT
on	O
post-op	O
day	O
three	O
.	O

Over	O
the	O
next	O
several	O
days	O
he	O
continued	O
to	O
improve	O
his	O
ambulation	O
and	O
mobility	O
with	O
physical	B-TREATMENT
therapy	I-TREATMENT
.	O

He	O
had	O
no	O
further	B-PROBLEM
episodes	I-PROBLEM
of	I-PROBLEM
AFIB	I-PROBLEM
while	O
on	O
po	B-TREATMENT
Amiodarone	I-TREATMENT
.	O

On	O
post-op	O
day	O
five	O
he	O
appeared	O
to	O
have	O
left	B-PROBLEM
arm	I-PROBLEM
phlebitis	I-PROBLEM
and	O
was	O
started	O
on	O
antibiotics	B-TREATMENT
.	O

He	O
was	O
discharged	O
home	O
on	O
post-op	O
day	O
six	O
with	O
antibiotics	B-TREATMENT
and	O
appropriate	B-TREATMENT
meds	I-TREATMENT
.	O

He	O
will	O
have	O
VNA	B-TREATMENT
services	I-TREATMENT
and	O
make	O
the	O
appropriate	O
follow-up	O
appointments	O
.	O

Aspirin	B-TREATMENT
81	O
mg	O
qd	O
,	O
Toprol	B-TREATMENT
XL	O
50	O
mg	O
qd	O
,	O
MVI	B-TREATMENT
,	O
Flexeril	B-TREATMENT
10	O
mg	O
qhs	O
,	O
Plavix	B-TREATMENT
75	O
mg	O
qd	O
(	O
last	O
on	O
10-18	O
)	O

1.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

2.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

3.	O
Ranitidine	B-TREATMENT
HCl	I-TREATMENT
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

4.	O
Oxycodone	B-TREATMENT
-	I-TREATMENT
Acetaminophen	I-TREATMENT
5-325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

5.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

6.	O
Amiodarone	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
):	O
please	O
take	O
400	O
mg	O
twice	O
a	O
day	O
until	O
11-02	O
then	O
decrease	O
to	O
400	O
mg	O
once	O
a	O
day	O
for	O
1	O
week	O
and	O
then	O
decrease	O
to	O
200	O
mg	O
once	O
a	O
day	O
.	O

7.	O
Metoprolol	B-TREATMENT
Succinate	I-TREATMENT
50	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
).	O

8.	O
Ferrous	B-TREATMENT
Gluconate	I-TREATMENT
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

9.	O
Ascorbic	B-TREATMENT
Acid	I-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

10.	O
Cephalexin	B-TREATMENT
500	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
6	O
days	O
:	O
please	O
complete	O
full	O
course	O
.	O

11.	O
Furosemide	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
2	O
weeks	O
.	O

12.	O
Potassium	B-TREATMENT
Chloride	I-TREATMENT
10	O
mEq	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
2	O
weeks	O
.	O

13.	O
Lisinopril	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
s/p	O
Coronary	B-TREATMENT
Artery	I-TREATMENT
Bypass	I-TREATMENT
Graft	I-TREATMENT
x3	O

PMH	O
:	O
Carpal	B-PROBLEM
tunnel	I-PROBLEM
syndrome	I-PROBLEM
,	O
Hypertension	B-PROBLEM
,	O
Hyperlipidemia	B-PROBLEM
,	O
Arthritis	B-PROBLEM

Monitor	O
wounds	B-PROBLEM
for	O
infection	B-PROBLEM
-	O
redness	B-PROBLEM
,	O
drainage	B-PROBLEM
,	O
or	O
increased	B-PROBLEM
pain	I-PROBLEM

Report	O
any	B-PROBLEM
fever	I-PROBLEM
greater	I-PROBLEM
than	I-PROBLEM
101	I-PROBLEM

Report	O
any	B-PROBLEM
weight	I-PROBLEM
gain	I-PROBLEM
of	O
greater	O
than	O
2	O
pounds	O
in	O
24	O
hours	O
or	O
5	O
pounds	O
in	O
a	O
week	O

No	O
creams	B-TREATMENT
,	O
lotions	B-TREATMENT
,	O
powders	B-TREATMENT
,	O
or	O
ointments	B-TREATMENT
to	O
incisions	B-PROBLEM

Left	O
Arm	O
continue	O
with	O
elevation	B-TREATMENT
,	O
ice	B-TREATMENT
,	O
and	O
complete	O
all	B-TREATMENT
antibiotics	I-TREATMENT

For	O
surgical	B-PROBLEM
incision	I-PROBLEM
and	O
left	O
arm	O

This	O
is	O
an	O
83	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
hypertension	B-PROBLEM
who	O
presents	O
with	O
slurred	B-PROBLEM
speech	I-PROBLEM
when	O
dehydrated	B-PROBLEM
.	O

She	O
has	O
paraplegia	B-PROBLEM
secondary	O
to	O
HTLV	B-PROBLEM
exposure	I-PROBLEM
while	O
on	O
vacation	O
in	O
the	O
Bahamas	O
six	O
years	O
ago	O
.	O

She	O
presented	O
with	O
three	O
days	O
of	O
general	B-PROBLEM
malaise	I-PROBLEM
,	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
cough	B-PROBLEM
productive	O
of	O
white	B-PROBLEM
sputum	I-PROBLEM
.	O

She	O
awoke	O
with	O
nausea	B-PROBLEM
on	O
the	O
day	O
of	O
admission	O
and	O
pleuritic	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
.	O

The	O
patient	O
has	O
some	B-PROBLEM
difficulty	I-PROBLEM
talking	O
and	O
grasping	O
right	O
hand	O
.	O

She	O
came	O
to	O
the	O
Emergency	O
Department	O
on	O
the	O
2011-03-10	O
,	O
with	O
temperature	B-TEST
of	O
99.0	O
F	O
.;	O
blood	B-TEST
pressure	I-TEST
of	O
97/50	O
;	O
heart	B-TEST
rate	I-TEST
100	O
;	O
respirations	B-TEST
27	O
;	O
O2	B-TEST
saturation	I-TEST
84%	O
on	O
room	O
air	O
and	O
94%	O
on	O
two	O
liters	O
.	O

The	O
patient	O
had	O
coarse	B-PROBLEM
rhonchi	I-PROBLEM
on	O
examination	B-TEST
.	O

Chest	B-TEST
x-ray	I-TEST
revealed	O
mild	B-PROBLEM
pulmonary	I-PROBLEM
edema	I-PROBLEM
.	O

Chest	B-TEST
CT	I-TEST
scan	I-TEST
was	O
negative	O
for	O
pulmonary	B-PROBLEM
embolism	I-PROBLEM
but	O
positive	O
for	O
consolidation	B-PROBLEM
.	O

She	O
was	O
started	O
on	O
Levofloxacin	B-TREATMENT
but	O
the	O
patient	O
became	O
hypotensive	B-PROBLEM
at	O
that	O
point	O
with	O
blood	B-TEST
pressure	I-TEST
of	O
70/45	O
and	O
received	O
a	B-TREATMENT
normal	I-TREATMENT
saline	I-TREATMENT
bolus	I-TREATMENT
to	O
boost	O
her	B-TEST
blood	I-TEST
pressure	I-TEST
to	O
99/60	O
;	O
however	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Medical	O
Intensive	O
Care	O
Unit	O
for	O
overnight	B-TEST
observation	I-TEST
because	O
of	O
her	B-PROBLEM
somnolence	I-PROBLEM
and	O
hypotension	B-PROBLEM
.	O

1.	O
Positive	B-PROBLEM
lupus	I-PROBLEM
anti-coagulant	I-PROBLEM
.	O

2.	O
Basilar	B-PROBLEM
stenosis	I-PROBLEM
.	O

3.	O
Prior	B-PROBLEM
transient	I-PROBLEM
ischemic	I-PROBLEM
attacks	I-PROBLEM
.	O

4.	O
Right	B-TREATMENT
medial	I-TREATMENT
malleolus	I-TREATMENT
repair	I-TREATMENT
in	O
2004-08-05	O
.	O

5.	O
Paraplegia	B-PROBLEM
secondary	O
to	O
HTLV	B-PROBLEM
from	O
a	O
trip	O
to	O
the	O
Bahamas	O
five	O
to	O
six	O
years	O
ago	O
.	O

6.	O
Hypertension	B-PROBLEM
.	O

7.	O
Chronic	B-PROBLEM
diarrhea	I-PROBLEM
with	O
multiple	O
admissions	O
for	O
dehydration	B-PROBLEM
with	O
most	O
recent	O
one	O
on	O
2011-02-26	O
.	O

8.	O
Venous	B-PROBLEM
stasis	I-PROBLEM
.	O

9.	O
Depression	B-PROBLEM
.	O

10.	O
Seizure	B-PROBLEM
history	I-PROBLEM
on	O
Neurontin	B-TREATMENT
.	O

11.	O
Left	B-TREATMENT
CMED	I-TREATMENT
cataract	I-TREATMENT
surgery	I-TREATMENT
in	O
2009-10-05	O
.	O

12.	O
Chronic	B-PROBLEM
muscle	I-PROBLEM
spasms	I-PROBLEM
.	O

Penicillin	B-TREATMENT
for	O
which	O
she	O
reports	O
a	B-PROBLEM
rash	I-PROBLEM
and	O
dyspepsia	B-PROBLEM
when	O
taking	O
uncoated	B-TREATMENT
aspirin	I-TREATMENT
.	O

She	O
has	O
a	O
questionable	O
sensitivity	B-PROBLEM
to	O
iodine	B-TREATMENT
.	O

1.	O
Enteric-coated	B-TREATMENT
aspirin	I-TREATMENT
.	O

2.	O
Aggrenox	B-TREATMENT
.	O

3.	O
Zanaflex	B-TREATMENT
.	O

4.	O
Neurontin	B-TREATMENT
300	O
mg	O
three	O
times	O
a	O
day	O
.	O

5.	O
Celexa	B-TREATMENT
10	O
mg	O
daily	O
.	O

On	O
admission	B-TEST
examination	I-TEST
she	O
was	O
a	O
well	O
developed	O
,	O
well	O
nourished	O
female	O
in	O
no	O
apparent	B-PROBLEM
distress	I-PROBLEM
.	O

Her	O
lungs	O
revealed	O
coarse	B-PROBLEM
bilateral	I-PROBLEM
rhonchi	I-PROBLEM
from	O
base	O
to	O
midline	O
.	O

Cardiovascular	B-TEST
examination	I-TEST
is	O
notable	O
for	O
a	O
regular	O
rate	O
and	O
rhythm	O
;	O
no	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
.	O

Abdomen	O
is	O
soft	O
and	O
obese	B-PROBLEM
,	O
nontender	B-PROBLEM
.	O

Extremities	O
notable	O
for	O
two	B-PROBLEM
plus	I-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
edema	I-PROBLEM
and	O
the	O
ankles	O
were	O
noted	O
to	O
be	O
in	O
pressure	B-TREATMENT
stockings	I-TREATMENT
.	O

White	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
were	O
11.8	O
,	O
hematocrit	B-TEST
31.5	O
,	O
platelets	B-TEST
151	O
.	O

Chem-7	B-TEST
was	O
a	B-TEST
sodium	I-TEST
of	O
140	O
,	O
potassium	B-TEST
of	O
3.0	O
,	O
chloride	B-TEST
108	O
,	O
bicarbonate	B-TEST
24	O
,	O
BUN	B-TEST
22	O
,	O
creatinine	B-TEST
1.0	O
and	O
glucose	B-TEST
117	O
.	O

The	O
patient	O
also	O
had	O
a	B-TEST
head	I-TEST
CT	I-TEST
scan	I-TEST
in	O
the	O
Emergency	O
Department	O
before	O
coming	O
to	O
the	O
Unit	O
which	O
reported	O
no	O
recent	B-PROBLEM
bleed	I-PROBLEM
and	O
no	O
change	B-PROBLEM
from	O
a	B-TEST
prior	I-TEST
CT	I-TEST
scan	I-TEST
done	O
on	O
2011-03-04	O
.	O

EKG	B-TEST
is	O
notable	O
for	O
sinus	B-PROBLEM
tachycardia	I-PROBLEM
at	O
100	O
beats	O
per	O
minute	O
,	O
normal	O
axis	O
.	O

.....	O
done	O
on	O
02-24	O
,	O
notable	O
for	O
mid-basilar	B-PROBLEM
artery	I-PROBLEM
high-grade	I-PROBLEM
stenosis	I-PROBLEM
.	O

After	O
transfer	O
to	O
the	O
Floor	O
,	O
the	O
patient	O
was	O
continued	O
on	O
Levofloxacin	B-TREATMENT
for	O
a	O
ten	O
to	O
14	O
day	O
course	O
for	O
presumptive	O
pneumonia	B-PROBLEM
.	O

Due	O
to	O
her	B-PROBLEM
chronic	I-PROBLEM
diarrhea	I-PROBLEM
she	O
was	O
repleted	O
with	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
.	O

For	O
her	B-PROBLEM
depression	I-PROBLEM
,	O
continued	O
on	O
Citalopram	B-TREATMENT
10	O
mg	O
daily	O
.	O

For	O
her	B-PROBLEM
paraplegia	I-PROBLEM
and	O
associated	O
muscle	B-PROBLEM
spasticity	I-PROBLEM
she	O
was	O
continued	O
on	O
her	B-TREATMENT
Zanaflex	I-TREATMENT
.	O

For	O
deep	B-TREATMENT
vein	I-TREATMENT
thrombosis	I-TREATMENT
prophylaxis	I-TREATMENT
she	O
was	O
treated	O
with	O
subcutaneous	B-TREATMENT
heparin	I-TREATMENT
and	O
for	O
gastrointestinal	B-TREATMENT
prophylaxis	I-TREATMENT
she	O
was	O
treated	O
with	O
Protonix	B-TREATMENT
.	O

She	O
was	O
also	O
evaluated	O
by	O
Physical	B-TREATMENT
Therapy	I-TREATMENT
and	O
Speech	B-TREATMENT
and	O
Swallow	B-TREATMENT
because	O
of	O
some	O
report	O
of	O
dysphagia	B-PROBLEM
.	O

Physical	B-TREATMENT
Therapy	I-TREATMENT
felt	O
that	O
the	O
patient	O
was	O
cleared	O
for	O
transfer	O
home	O
with	O
services	O
.	O

Occupational	B-TREATMENT
Therapy	I-TREATMENT
was	O
also	O
in	O
agreement	O
with	O
the	O
patient	O
's	O
disposition	O
home	O
with	O
services	O
.	O

The	O
patient	O
was	O
able	O
to	O
advance	O
her	O
diet	O
well	O
from	O
liquids	O
to	O
solids	O
,	O
however	O
,	O
she	O
was	O
plagued	O
with	O
a	B-PROBLEM
persistent	I-PROBLEM
cough	I-PROBLEM
and	O
some	B-PROBLEM
low	I-PROBLEM
grade	I-PROBLEM
fevers	I-PROBLEM
to	O
99.0	O
F	O
.	O

Speech	B-TREATMENT
and	O
Swallow	B-TREATMENT
evaluated	O
the	O
patient	O
at	O
bedside	O
and	O
recommended	O
advancing	O
to	O
regular	O
diet	O
with	O
regular	O
consistency	O
and	O
saw	O
no	O
evidence	O
of	O
any	B-PROBLEM
dysphagia	I-PROBLEM
.	O

There	O
was	O
some	O
question	O
regarding	O
restarting	O
of	O
the	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
Coumadin	I-TREATMENT
given	O
her	B-PROBLEM
positive	I-PROBLEM
lupus	I-PROBLEM
anti-coagulant	I-PROBLEM
status	I-PROBLEM
as	O
well	O
as	O
the	O
presence	O
of	O
her	B-PROBLEM
basilar	I-PROBLEM
artery	I-PROBLEM
stenosis	I-PROBLEM
.	O

The	O
patient	O
was	O
discharged	O
on	O
the	O
2011-03-15	O
on	O
the	B-TREATMENT
following	I-TREATMENT
medications	I-TREATMENT
.	O

1.	O
Levofloxacin	B-TREATMENT
250	O
mg	O
q.	O
day	O
for	O
ten	O
days	O
.	O

2.	O
Aspirin	B-TREATMENT
/	O
dipyridamole	B-TREATMENT
25/200	O
mg	O
capsules	O
taken	O
two	O
times	O
a	O
day	O
.	O

3.	O
Neurontin	B-TREATMENT
300	O
mg	O
taken	O
three	O
times	O
a	O
day	O
.	O

4.	O
Subcutaneous	B-TREATMENT
heparin	I-TREATMENT
taken	O
5000	O
units	O
twice	O
a	O
day	O
.	O

5.	O
Albuterol	B-TREATMENT
multiple	I-TREATMENT
dose	I-TREATMENT
inhalers	I-TREATMENT
,	O
one	O
to	O
two	O
puffs	O
q.	O
six	O
hours	O
as	O
needed	O
.	O

6.	O
Atrovent	B-TREATMENT
multiple	I-TREATMENT
dose	I-TREATMENT
inhalers	I-TREATMENT
,	O
one	O
to	O
two	O
puffs	O
q.	O
six	O
hours	O
as	O
needed	O
.	O

7.	O
Citalopram	B-TREATMENT
10	O
mg	O
q.	O
day	O
.	O

8.	O
Lisinopril	B-TREATMENT
2.5	O
mg	O
once	O
a	O
day	O
.	O

9.	O
Trazodone	B-TREATMENT
25	O
mg	O
q.	O
h.s.	O
p.r.n.	O

10.	O
Protonix	B-TREATMENT
40	O
mg	O
q.	O
day	O
.	O

11.	O
Zanaflex	B-TREATMENT
2	O
mg	O
twice	O
a	O
day	O
.	O

12.	O
Tylenol	B-TREATMENT
325	O
mg	O
,	O
one	O
to	O
two	O
tablets	O
q.	O
four	O
to	O
six	O
hours	O
p.r.n.	O

13.	O
The	O
patient	O
was	O
also	O
discharged	O
with	O
the	O
restarting	O
of	O
warfarin	B-TREATMENT
2	O
mg	O
daily	O
.	O

1.	O
She	O
was	O
instructed	O
to	O
have	O
blood	B-TEST
drawn	O
by	O
the	O
Visiting	O
Nurses	O
Association	O
the	O
day	O
after	O
discharge	O
and	O
then	O
a	O
few	O
days	O
after	O
discharge	O
the	O
same	O
week	O
to	O
have	O
INR	B-TEST
.	O

Will	O
also	O
have	O
INR	B-TEST
checked	O
at	O
once	O
weekly	O
until	O
target	O
of	O
INR	B-TEST
of	O
2.0	O
to	O
3.0	O
is	O
reached	O
.	O

2.	O
The	O
patient	O
was	O
instructed	O
to	O
contact	O
Dr.	O
Ralph	O
at	O
(	O
428	O
)	O
678-6930	O
,	O
who	O
is	O
covering	O
for	O
her	O
primary	O
care	O
physician	O
,	O
Dr.	O
Erika	O
Witt	O
,	O
to	O
adjust	O
her	B-TREATMENT
dosages	I-TREATMENT
based	O
on	O
the	B-TEST
INR	I-TEST
levels	I-TEST
.	O

4.	O
She	O
was	O
also	O
instructed	O
to	O
follow-up	O
with	O
Dr.	O
Reid	O
from	O
Neurology	O
within	O
a	O
month	O
at	O
(	O
382	O
)	O
716	O
4151	O
,	O
given	O
her	B-PROBLEM
neurological	I-PROBLEM
deficits	I-PROBLEM
during	O
this	O
presentation	O
.	O

The	O
patient	O
is	O
a	O
47	O
-	O
year-old	O
male	O
with	O
a	O
past	O
medical	O
history	O
of	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
status	B-TREATMENT
post	I-TREATMENT
2-vessel	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
in	O
2005	O
,	O
3-vessel	B-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
in	O
2009	O
,	O
hypertension	B-PROBLEM
,	O
new	B-PROBLEM
onset	I-PROBLEM
type	I-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
,	O
and	O
hypercholesterolemia	B-PROBLEM
who	O
presents	O
with	O
the	O
sudden	O
onset	O
of	O
substernal	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
status	O
post	O
exercise	O
.	O

The	O
patient	O
presented	O
to	O
Bournewood	O
Hospital	O
on	O
the	O
morning	O
of	O
admission	O
with	O
a	O
chief	O
complaint	O
of	O
substernal	B-PROBLEM
burning	I-PROBLEM
without	O
radiation	O
which	O
developed	O
while	O
doing	O
exercise	O
.	O

The	B-PROBLEM
pain	I-PROBLEM
became	O
worse	O
over	O
the	O
next	O
few	O
minutes	O
to	O
07-12	O
and	O
increased	O
to	O
10-12	O
while	O
he	O
was	O
in	O
the	O
ambulance	O
.	O

His	B-TREATMENT
nitroglycerin	I-TREATMENT
patch	I-TREATMENT
did	O
not	O
help	O
,	O
and	O
he	O
only	O
had	O
slight	O
relief	O
with	O
sublingual	B-TREATMENT
nitroglycerin	I-TREATMENT
times	O
three	O
.	O

In	O
addition	O
,	O
he	O
had	O
slight	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
but	O
denies	O
headache	B-PROBLEM
,	O
change	B-PROBLEM
in	I-PROBLEM
vision	I-PROBLEM
,	O
dizziness	B-PROBLEM
,	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
change	B-PROBLEM
in	I-PROBLEM
bowel	I-PROBLEM
or	I-PROBLEM
urinary	I-PROBLEM
habits	I-PROBLEM
,	O
or	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
and	O
sweats	B-PROBLEM
.	O

In	O
the	O
Emergency	O
Department	O
he	O
received	O
aspirin	B-TREATMENT
,	O
nitroglycerin	B-TREATMENT
drip	I-TREATMENT
,	O
heparin	B-TREATMENT
drip	I-TREATMENT
,	O
Dilaudid	B-TREATMENT
,	O
and	O
TNK	B-TREATMENT
with	O
decreased	O
in	O
his	B-PROBLEM
pain	I-PROBLEM
but	O
without	O
resolution	O
of	O
symptoms	B-PROBLEM
.	O

Electrocardiogram	B-TEST
at	O
that	O
time	O
showed	O
ST	B-PROBLEM
elevations	I-PROBLEM
and	O
J	B-PROBLEM
point	I-PROBLEM
elevations	I-PROBLEM
in	I-PROBLEM
V2	I-PROBLEM
through	I-PROBLEM
V4	I-PROBLEM
.	O

The	O
patient	O
was	O
transferred	O
to	O
Sturdy	O
Memorial	O
where	O
he	O
underwent	O
catheterization	B-TEST
.	O

Catheterization	B-TEST
results	I-TEST
showed	O
100%	B-PROBLEM
occlusion	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
proximal	I-PROBLEM
left	I-PROBLEM
anterior	I-PROBLEM
descending	I-PROBLEM
artery	I-PROBLEM
and	O
50%	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
first	I-PROBLEM
diagonal	I-PROBLEM
.	O

Angio-Jet	B-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
and	O
stenting	B-TREATMENT
was	O
performed	O
on	O
proximal	O
left	O
anterior	O
descending	O
artery	O
and	O
the	B-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
was	O
performed	O
on	O
first	O
diagonal	O
with	O
good	O
results	O
.	O

An	B-TREATMENT
intra-aortic	I-TREATMENT
balloon	I-TREATMENT
pump	I-TREATMENT
was	O
placed	O
at	O
this	O
time	O
as	O
well	O
.	O

1.	O
Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
;	O
the	O
patient	O
is	O
status	B-TREATMENT
post	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
times	O
three	O
in	O
2009	O
at	O
Clinton	O
Hospital	O
;	O
the	O
patient	O
is	O
status	B-TREATMENT
post	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
times	O
two	O
in	O
2005	O
at	O
Waltham/Weston	O
Hospital	O
.	O

2.	O
Type	B-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
.	O

3.	O
Hypercholesterolemia	B-PROBLEM
.	O

4.	O
Hypertension	B-PROBLEM
.	O

The	O
patient	O
's	O
father	O
died	O
of	O
a	B-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
at	O
age	O
40	O
,	O
and	O
a	O
brother	O
who	O
died	O
of	O
a	B-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
at	O
age	O
40	O
.	O

Diltiazem	B-TREATMENT
180	O
mg	O
p.o.	O
q.d.	O
,	O
Lipitor	B-TREATMENT
10	O
mg	O
p.o.	O
q.d.	O
,	O
Glyset	B-TREATMENT
25	O
mg	O
p.o.	O
q.d.	O
,	O
Prevacid	B-TREATMENT
30	O
mg	O
p.o.	O
q.d.	O
,	O
metoprolol	B-TREATMENT
50	O
mg	O
p.o.	O
b.i.d.	O
,	O
Glucophage	B-TREATMENT
500	O
mg	O
p.o.	O
q.d.	O

Allergies	B-PROBLEM
included	O
PENICILLIN	B-TREATMENT
and	O
IODINE	B-TREATMENT
.	O

Temperature	B-TEST
maximum	I-TEST
98.7	O
,	O
temperature	B-TEST
current	I-TEST
98.3	O
,	O
pulse	B-TEST
ranged	O
from	O
82	O
to	O
92	O
,	O
blood	B-TEST
pressure	I-TEST
104	O
to	O
124/67	O
to	O
74	O
with	O
a	O
mean	O
of	O
86	O
to	O
99	O
,	O
respiratory	B-TEST
rate	I-TEST
of	O
11	O
to	O
16	O
,	O
oxygen	B-TEST
saturation	I-TEST
94%	O
to	O
98%	O
on	O
2	O
liters	O
.	O

Pulmonary	B-TEST
artery	I-TEST
pressure	I-TEST
was	O
29/15	O
with	O
a	O
mean	O
of	O
22	O
.	O

Cardiac	B-TEST
output	I-TEST
was	O
7	O
(	O
that	O
was	O
on	O
6	O
of	O
dopamine	B-TREATMENT
)	O
.	O

Intra-aortic	B-TEST
balloon	I-TEST
pump	I-TEST
augmented	I-TEST
systole	I-TEST
was	O
109	O
,	O
augmented	B-TEST
diastole	I-TEST
was	O
111	O
.	O

The	O
patient	O
was	O
lying	O
flat	O
in	O
no	O
apparent	B-PROBLEM
distress	I-PROBLEM
.	O

No	O
lymphadenopathy	B-PROBLEM
.	O

Lungs	O
were	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
,	O
anteriorly	O
and	O
laterally	O
.	O

Cardiovascular	O
revealed	O
jugular	B-PROBLEM
venous	I-PROBLEM
distention	I-PROBLEM
not	O
appreciated	O
.	O

Carotids	O
had	O
normal	O
upstroke	O
and	O
normal	O
volume	O
with	O
bilateral	B-PROBLEM
bruits	I-PROBLEM
.	O

No	O
S3	B-PROBLEM
or	O
S4	B-PROBLEM
.	O

No	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
.	O

Abdomen	O
had	O
decreased	B-PROBLEM
bowel	I-PROBLEM
sounds	I-PROBLEM
,	O
soft	O
,	O
nontender	B-PROBLEM
,	O
and	O
nondistended	B-PROBLEM
.	O

No	O
hepatosplenomegaly	B-PROBLEM
.	O

Extremities	O
had	O
no	O
edema	B-PROBLEM
.	O

The	O
right	O
groin	O
revealed	O
intra-aortic	B-TREATMENT
balloon	I-TREATMENT
pump	I-TREATMENT
site	O
and	O
pulmonary	B-TREATMENT
artery	I-TREATMENT
catheterization	I-TREATMENT
site	O
were	O
clean	O
,	O
dry	O
and	O
intact	O
without	O
tenderness	B-PROBLEM
.	O

Dorsalis	B-TEST
pedis	I-TEST
pulses	I-TEST
were	O
2+	O
bilaterally	O
.	O

Neurologic	B-TEST
examination	I-TEST
revealed	O
alert	O
and	O
oriented	O
times	O
three	O
.	O

Laboratories	B-TEST
on	O
admission	O
revealed	O
white	B-TEST
count	I-TEST
7.8	O
,	O
hematocrit	B-TEST
was	O
41.7	O
,	O
platelets	B-TEST
of	O
252	O
,	O
MCV	B-TEST
89	O
,	O
RDW	B-TEST
12.7	O
.	O

Chem-7	B-TEST
revealed	O
sodium	B-TEST
of	O
136	O
,	O
potassium	B-TEST
4.7	O
,	O
chloride	B-TEST
103	O
,	O
bicarbonate	B-TEST
22	O
,	O
BUN	B-TEST
16	O
,	O
creatinine	B-TEST
0.8	O
,	O
glucose	B-TEST
284	O
.	O

PT	B-TEST
14.2	O
,	O
PTT	B-TEST
108.5	O
,	O
INR	B-TEST
1.3	O
.	O

Creatine	B-TEST
kinase	I-TEST
at	O
11	O
a.m.	O
was	O
83	O
,	O
at	O
5	O
p.m.	O
was	O
3021	O
.	O

Arterial	B-TEST
blood	I-TEST
gas	I-TEST
at	O
11	O
a.m.	O
was	O
7.33/46/115	O
.	O

Creatine	B-TEST
kinases	I-TEST
trended	O
from	O
11:15	O
on	O
the	O
day	O
of	O
admission	O
from	O
83	O
to	O
3021	O
at	O
5	O
p.m.	O
to	O
3450	O
at	O
11	O
p.m.	O
,	O
to	O
1734	O
at	O
5:30	O
a.m.	O
on	O
11-07	O
,	O
to	O
1277	O
at	O
11:30	O
a.m.	O
on	O
11-07	O
,	O
to	O
83	O
at	O
9:30	O
a.m.	O
on	O
11-11	O
.	O

Electrocardiogram	B-TEST
post	O
catheterization	B-TEST
showed	O
continued	B-PROBLEM
ST	I-PROBLEM
elevations	I-PROBLEM
and	O
J	B-PROBLEM
point	I-PROBLEM
elevations	I-PROBLEM
in	I-PROBLEM
V2	I-PROBLEM
through	I-PROBLEM
V3	I-PROBLEM
.	O

Post	B-TEST
catheterization	I-TEST
echocardiogram	I-TEST
showed	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
30%	O
,	O
moderate	B-PROBLEM
systolic	I-PROBLEM
dysfunction	I-PROBLEM
,	O
basal	B-PROBLEM
anterior	I-PROBLEM
hypokinesis	I-PROBLEM
,	O
mid	B-PROBLEM
anterior	I-PROBLEM
akinesis	I-PROBLEM
,	O
basal	B-PROBLEM
anteroseptal	I-PROBLEM
hypokinesis	I-PROBLEM
,	O
mid	B-PROBLEM
anteroseptal	I-PROBLEM
akinesis	I-PROBLEM
.	O

Anterior	B-PROBLEM
apex	I-PROBLEM
akinesis	I-PROBLEM
,	O
inferior	B-PROBLEM
apex	I-PROBLEM
akinesis	I-PROBLEM
,	O
and	O
apex	B-PROBLEM
akinesis	I-PROBLEM
.	O

The	O
was	O
trace	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
and	O
trace	B-PROBLEM
tricuspid	I-PROBLEM
regurgitation	I-PROBLEM
.	O

This	O
is	O
a	O
47	O
-	O
year-old	O
male	O
with	O
a	O
past	O
medical	O
history	O
of	O
type	B-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
,	O
high	B-PROBLEM
cholesterol	I-PROBLEM
,	O
hypertension	B-PROBLEM
,	O
and	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
status	B-TREATMENT
post	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
times	O
two	O
,	O
who	O
presented	O
with	O
acute	B-PROBLEM
coronary	I-PROBLEM
syndrome	I-PROBLEM
refractory	O
to	O
medical	B-TREATMENT
treatment	I-TREATMENT
and	O
TNK	B-TREATMENT
,	O
now	O
status	B-TREATMENT
post	I-TREATMENT
Angio-Jet	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
and	O
stent	B-TREATMENT
of	I-TREATMENT
proximal	I-TREATMENT
left	I-TREATMENT
anterior	I-TREATMENT
descending	I-TREATMENT
artery	I-TREATMENT
and	O
percutaneous	B-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
of	O
first	O
diagonal	O
with	O
intra-aortic	B-TREATMENT
balloon	I-TREATMENT
pump	I-TREATMENT
placement	I-TREATMENT
.	O

Dopamine	B-TREATMENT
was	O
discontinued	O
on	O
day	O
one	O
.	O

The	B-TREATMENT
intra-aortic	I-TREATMENT
balloon	I-TREATMENT
pump	I-TREATMENT
was	O
discontinued	O
on	O
day	O
two	O
.	O

The	O
patient	O
was	O
continued	O
on	O
heparin	B-TREATMENT
throughout	O
his	O
hospital	O
course	O
and	O
transitioned	O
to	O
Coumadin	B-TREATMENT
on	O
hospital	O
day	O
four	O
.	O

The	O
patient	O
was	O
continued	O
on	O
Lipitor	B-TREATMENT
and	O
aspirin	B-TREATMENT
,	O
and	O
Plavix	B-TREATMENT
was	O
added	O
and	O
will	O
be	O
continued	O
for	O
30	O
days	O
post	O
catheterization	B-TEST
.	O

The	O
patient	O
was	O
continued	O
on	O
Lopressor	B-TREATMENT
and	O
captopril	B-TREATMENT
throughout	O
his	O
hospital	O
course	O
,	O
and	O
changed	O
to	O

Zestril	B-TREATMENT
10	O
mg	O
q.d.	O
and	O
atenolol	B-TREATMENT
25	O
mg	O
q.d.	O
at	O
discharge	O
.	O

The	O
patient	O
was	O
discharged	O
to	O
the	O
medical	O
floor	O
on	O
hospital	O
day	O
three	O
and	O
discharged	O
from	O
the	O
hospital	O
once	O
his	B-TEST
INR	I-TEST
was	O
within	O
the	O
2	O
to	O
2.5	O
range	O
.	O

Primary	O
care	O
physician	O
was	O
to	O
check	O
INR	B-TEST
and	O
titrate	O
Zestril	B-TREATMENT
up	O
and	O
atenolol	B-TREATMENT
as	O
tolerated	O
.	O

1.	O
Lipitor	B-TREATMENT
10	O
mg	O
p.o.	O
q.d.	O

2.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.d.	O

3.	O
Plavix	B-TREATMENT
75	O
mg	O
p.o.	O
q.d.	O
times	O
30	O
days	O
.	O

4.	O
Prevacid	B-TREATMENT
30	O
mg	O
p.o.	O
q.d.	O

5.	O
Atenolol	B-TREATMENT
25	O
mg	O
p.o.	O
q.d.	O

6.	O
Zestril	B-TREATMENT
10	O
mg	O
p.o.	O
q.d.	O

7.	O
Glyset	B-TREATMENT
25	O
mg	O
p.o.	O
q.d.	O

8.	O
Glucophage	B-TREATMENT
500	O
mg	O
p.o.	O
q.d.	O

9.	O
Coumadin	B-TREATMENT
5	O
mg	O
p.o.	O
q.d.	O

MEDICINE	B-TREATMENT

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

Shortness	B-PROBLEM
of	I-PROBLEM
Breath	I-PROBLEM

Endotracheal	B-TREATMENT
Intubation	I-TREATMENT

Central	B-TREATMENT
Venous	I-TREATMENT
Catheter	I-TREATMENT
and	O
Swan	B-TREATMENT
Ganz	I-TREATMENT
catheter	I-TREATMENT
placement	I-TREATMENT

Arterial	B-TREATMENT
Line	I-TREATMENT
Placement	I-TREATMENT

Right	B-TREATMENT
sided	I-TREATMENT
thoracentesis	I-TREATMENT

70	O
y/o	O
male	O
with	O
h/o	O
CAD	B-PROBLEM
s/p	B-TREATMENT
LAD	I-TREATMENT
PTCA	I-TREATMENT
33	O
yrs	O
ago	O
,	O
COPD	B-PROBLEM
,	O
T2DM	B-PROBLEM
,	O
and	O
AICD	B-PROBLEM
pocket	I-PROBLEM
infection	I-PROBLEM
who	O
presented	O
to	O
the	O
Juan	O
on	O
2017-09-03	O
with	O
worsening	B-PROBLEM
SOB	I-PROBLEM
x	O
5	O
days	O
and	O
feeling	O
"	O
cloudy	O
."	O

The	O
patient	O
was	O
currently	O
at	O
Hubbard	O
Regional	O
Hospital	O
and	O
began	O
to	O
develop	O
worsening	B-PROBLEM
SOB	I-PROBLEM
for	O
the	O
past	O
5	O
days	O
.	O

This	O
AM	O
while	O
talking	O
with	O
his	O
daughter	O
on	O
the	O
phone	O
,	O
he	O
was	O
noted	O
to	O
desaturate	O
into	O
the	O
high	O
80s	O
and	O
he	O
was	O
brought	O
to	O
the	O
The	O
Hospital	O
for	O
Orthopedics	O
Juan	O
for	O
further	B-TEST
evaluation	I-TEST
.	O

The	O
patient	O
states	O
that	O
he	O
has	O
felt	O
"	O
cloudy	B-PROBLEM
"	O
of	O
late	O
which	O
seems	O
to	O
relate	O
to	O
his	B-PROBLEM
worsening	I-PROBLEM
SOB	I-PROBLEM
.	O

He	O
is	O
not	O
ambulatory	O
and	O
is	O
very	B-PROBLEM
deconditioned	I-PROBLEM
secondary	O
to	O
several	B-PROBLEM
complications	I-PROBLEM
within	O
the	O
past	O
two	O
months	O
related	O
to	O
an	B-PROBLEM
AICD	I-PROBLEM
pocket	I-PROBLEM
infection	I-PROBLEM
.	O

He	O
denies	O
any	B-PROBLEM
CP	I-PROBLEM
,	O
N/V/D	B-PROBLEM
,	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
or	O
HA	B-PROBLEM
.	O

In	O
the	O
Juan	O
,	O
his	B-TEST
VS	I-TEST
were	O
97.8	O
150/80	O
88	O
12	O
89-94%	O
3L	B-TREATMENT
NC	I-TREATMENT
.	O

He	O
was	O
given	O
Percocet	B-TREATMENT
for	O
back	B-PROBLEM
pain	I-PROBLEM
,	O
Lasix	B-TREATMENT
80	O
mg	O
IV	O
,	O
and	O
Combivent	B-TREATMENT
neb	I-TREATMENT
.	O

For	O
unclear	O
reasons	O
,	O
he	O
was	O
placed	O
on	O
a	B-TREATMENT
NRB	I-TREATMENT
in	O
the	O
Juan	O
.	O

He	O
was	O
quickly	O
weaned	O
to	O
3L	B-TREATMENT
O2	I-TREATMENT
via	O
NC	B-TREATMENT
,	O
O2	B-TEST
sats	I-TEST
100%	O
.	O

-	O
AICD	B-PROBLEM
Pocket	I-PROBLEM
infection	I-PROBLEM
c/b	O
MSSA	B-PROBLEM
bacteremia	I-PROBLEM
,	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
s/p	B-TEST
mediastinal	I-TEST
exploration	I-TEST
,	O
evacuation	B-TREATMENT
of	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
&	O
hematoma	B-PROBLEM
(	O
2017-07-24	O
)	O

-	O
Ischemic	B-PROBLEM
colitis	I-PROBLEM
and	O
ischemic	B-PROBLEM
liver	I-PROBLEM
2017-06-22	O
(	O
post	O
air	B-PROBLEM
embolism	I-PROBLEM
from	O
post	O
mediastinal	B-TEST
exploration	I-TEST
)	O

-	O
CAD	B-PROBLEM
s/p	B-TREATMENT
LAD	I-TREATMENT
PTCA	I-TREATMENT
33	O
years	O
ago	O

-	O
T2DM	B-PROBLEM
c/b	O
neuropathy	B-PROBLEM
and	O
nephropathy	B-PROBLEM

-	O
COPD	B-PROBLEM

-	O
Hypothyroidism	B-PROBLEM

-	O
CVA	B-PROBLEM

-	O
s/p	B-TREATMENT
Bovine	I-TREATMENT
AVR	I-TREATMENT
1999	O

-	O
Hyperlipidemia	B-PROBLEM

-	O
GERD	B-PROBLEM

-	O
Chronic	B-PROBLEM
LBP	I-PROBLEM

-	O
Lumbar	B-PROBLEM
sympathectomy	I-PROBLEM

Sister	O
with	O
diabetes	B-PROBLEM
.	O

97.6	O
95/48	O
71	O
98%	O
4L	B-TREATMENT
NC	I-TREATMENT

Slight	B-PROBLEM
confustion	I-PROBLEM
with	O
place	O
but	O
oriented	O
with	O
some	O
re-direction	O
.	O

JVD	B-PROBLEM
difficult	O
to	O
access	O
02-23	O
increased	B-PROBLEM
neck	I-PROBLEM
girth	I-PROBLEM
.	O

S1	O
,	O
S2	O
with	O
Grade	B-PROBLEM
II/VI	I-PROBLEM
SEM	I-PROBLEM
.	O
+S3	B-PROBLEM
.	O

Crackles	B-PROBLEM
halfway	I-PROBLEM
up	I-PROBLEM
lung	I-PROBLEM
fields	I-PROBLEM
B/L	I-PROBLEM
.	O

Soft	O
,	O
NT/ND	B-PROBLEM
with	O
normoactive	O
BS	O
.	O

2+	O
pitting	B-PROBLEM
edema	I-PROBLEM
to	I-PROBLEM
knees	I-PROBLEM
B/L	I-PROBLEM
.	O

2017-09-03	O
PT	B-TEST
-	O
13.8	O
*	O
PTT	B-TEST
-	O
33.1	O
INR	B-TEST
(	I-TEST
PT	I-TEST
)-	I-TEST
1.2	O
*	O

2017-09-03	O
PLT	B-TEST
COUNT	I-TEST
-	O
124	O
*	O

2017-09-03	O
HYPOCHROM	B-TEST
-	O
2+	O
ANISOCYT	B-TEST
-	O
1+	O
MACROCYT	B-TEST
-	O
2+	O

2017-09-03	O
NEUTS	B-TEST
-	O
79.5	O
*	O
LYMPHS	B-TEST
-	O
9.9	O
*	O
MONOS	B-TEST
-	O
4.9	O
EOS	B-TEST
-	O
5.4	O
*	O
BASOS	B-TEST
-	O
0.2	O

2017-09-03	O
WBC	B-TEST
-	O
9.1	O
RBC	B-TEST
-	O
2.77	O
*	O
HGB	B-TEST
-	O
8.8	O
*	O
HCT	B-TEST
-	O
27.2	O
*	O
MCV	B-TEST
-	O
99	O
*	O
MCH	B-TEST
-	O
31.9	O
MCHC	B-TEST
-	O
32.4	O
RDW	B-TEST
-	O
18.0	O
*	O

2017-09-03	O
CK	B-TEST
-	I-TEST
MB	I-TEST
-	O
Not	O
Done	O
proBNP	B-TEST
-	O
2656	O
*	O

2017-09-03	O
CK	B-TEST
(	I-TEST
CPK	I-TEST
)-	I-TEST
16	O
*	O

2017-09-03	O
GLUCOSE	B-TEST
-	O
206	O
*	O
UREA	B-TEST
N	I-TEST
-	O
28	O
*	O
CREAT	B-TEST
-	O
1.8	O
*	O
SODIUM	B-TEST
-	O
135	O
POTASSIUM	B-TEST
-	O
4.1	O
CHLORIDE	B-TEST
-	O
85	O
*	O
TOTAL	B-TEST
CO2	I-TEST
-	O
42	O
*	O
ANION	B-TEST
GAP	I-TEST
-	O
12	O

2017-09-03	O
CK	B-TEST
-	I-TEST
MB	I-TEST
-	O
Not	O
Done	O
cTropnT	B-TEST
-	O
0.22	O
*	O

2017-09-03	O
CK	B-TEST
(	I-TEST
CPK	I-TEST
)-	I-TEST
38	O

INR	B-TEST
3.5	O
,	O
PT	B-TEST
32.5	O
,	O
PTT	B-TEST
41	O

1.	O
CXR	B-TEST
(	I-TEST
PA/Lateral	I-TEST
)	I-TEST
2017-09-03	O

Congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
with	O
bilateral	B-PROBLEM
effusions	I-PROBLEM
(	O
R	O
>	O
L	O
)	O
,	O
with	O
possible	O
underlying	B-PROBLEM
consolidation	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
RLL	I-PROBLEM
and	O
to	O
a	O
lesser	O
degree	O
the	O
RML	O
and	O
LLL	O
.	O

2.	O
CXR	B-TEST
2017-09-04	O

Compared	O
to	O
PA	B-TEST
and	I-TEST
lateral	I-TEST
chest	I-TEST
of	O
the	O
prior	O
day	O
.	O

Right-sided	B-TREATMENT
PICC	I-TREATMENT
line	I-TREATMENT
with	O
its	O
tip	O
in	O
the	O
distal	O
SVC	O
.	O

The	O
heart	O
is	O
markedly	B-PROBLEM
enlarged	I-PROBLEM
.	O

There	O
remains	O
a	B-PROBLEM
large	I-PROBLEM
right	I-PROBLEM
and	I-PROBLEM
small	I-PROBLEM
left	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
,	O
not	O
significantly	O
changed	O
.	O

Patient	O
remains	O
in	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
,	O
though	O
it	O
may	O
be	O
slightly	O
improved	O
compared	O
to	O
the	B-TEST
prior	I-TEST
study	I-TEST
.	O

Underlying	B-PROBLEM
infectious	I-PROBLEM
consolidation	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
not	O
excluded	O
.	O

3.	O
Echo	B-TEST
2017-09-04	O

The	O
left	O
atrium	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

There	O
is	O
mild	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
.	O

LV	B-TEST
systolic	I-TEST
function	I-TEST
appears	O
depressed	B-PROBLEM
.	O

Resting	B-PROBLEM
regional	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
include	O
inferior	B-PROBLEM
and	I-PROBLEM
inferolateral	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
and	O
free	O
wall	O
motion	O
may	O
be	O
mildly	B-PROBLEM
impaired	I-PROBLEM
.	O

The	O
aortic	O
root	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

The	O
ascending	O
aorta	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

The	O
aortic	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

A	B-TREATMENT
bioprosthetic	I-TREATMENT
aortic	I-TREATMENT
valve	I-TREATMENT
prosthesis	I-TREATMENT
is	O
present	O
.	O

The	B-TREATMENT
aortic	I-TREATMENT
prosthesis	I-TREATMENT
leaflets	I-TREATMENT
appear	O
to	O
move	O
normally	O
.	O

The	O
transaortic	O
gradient	O
is	O
normal	O
for	O
this	B-TREATMENT
prosthesis	I-TREATMENT
.	O

The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

The	B-TEST
left	I-TEST
ventricular	I-TEST
inflow	I-TEST
pattern	I-TEST
suggests	O
a	B-PROBLEM
restrictive	I-PROBLEM
filling	I-PROBLEM
abnormality	I-PROBLEM
,	O
with	O
elevated	B-PROBLEM
left	I-PROBLEM
atrial	I-PROBLEM
pressure	I-PROBLEM
.	O

Transmitral	B-TEST
Doppler	I-TEST
and	O
tissue	B-TEST
velocity	I-TEST
imaging	I-TEST
are	O
consistent	O
with	O
Grade	B-PROBLEM
III/IV	I-PROBLEM
(	I-PROBLEM
severe	I-PROBLEM
)	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
diastolic	I-PROBLEM
dysfunction	I-PROBLEM
.	O

The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

There	O
is	O
mild	B-PROBLEM
pulmonary	I-PROBLEM
artery	I-PROBLEM
systolic	I-PROBLEM
hypertension	I-PROBLEM
.	O

There	O
is	O
no	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
.	O

Compared	O
with	O
the	B-TEST
prior	I-TEST
study	I-TEST
(	O
images	O
reviewed	O
)	O
of	O
2017-08-14	O
,	O
ventricular	O
function	O
is	O
now	O
similar.	O

EF	B-TEST
35-40%	O
.	O

4.	O
Echo	B-TEST
2017-09-14	O

The	O
left	O
atrium	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

Overall	B-TEST
left	I-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
cannot	O
be	O
reliably	O
assessed	O
.	O

The	O
aortic	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

There	O
is	O
no	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
.	O

Compared	O
with	O
the	B-TEST
prior	I-TEST
study	I-TEST
(	O
images	O
reviewed	O
)	O
of	O
2017-09-04	O
,	O
there	O
is	O
probably	O
no	O
significant	O
change	O
.	O

All	B-TEST
cultures	I-TEST
,	O
including	O
BCx	B-TEST
,	O
UCx	B-TEST
,	O
pleural	B-TEST
fluid	I-TEST
culture	I-TEST
,	O
and	O
wound	B-TEST
culture	I-TEST
have	O
been	O
negative	O
.	O

5.	O
CT	B-TEST
Chest	I-TEST
2017-09-16	O
:	O

1.	O
Increasing	B-PROBLEM
large	I-PROBLEM
right-sided	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
and	O
pulmonary	B-PROBLEM
edema	I-PROBLEM
.	O

Scattered	B-PROBLEM
parenchymal	I-PROBLEM
opacities	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
represent	O
superimposed	B-PROBLEM
infection	I-PROBLEM
vs	O
atelectasis	B-PROBLEM
.	O

There	O
is	O
no	O
evidence	O
of	O
abscess	B-PROBLEM
.	O

6.	O
2017-09-28	O
Chest	B-TEST
X	I-TEST
Ray	I-TEST
:	O

SINGLE	B-TEST
AP	I-TEST
VIEW	I-TEST
OF	I-TEST
THE	I-TEST
CHEST	I-TEST
.	O

There	O
has	O
been	O
almost	O
complete	O
resolution	O
of	O
pulmonary	B-PROBLEM
edema	I-PROBLEM
.	O

A	B-PROBLEM
small	I-PROBLEM
right	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
has	O
decreased	O
in	O
size	O
.	O

Mild	B-PROBLEM
cardiomegaly	I-PROBLEM
is	O
stable	O
.	O

There	O
is	O
no	O
pneumothorax	B-PROBLEM
.	O

Right	B-TREATMENT
PIC	I-TREATMENT
catheter	I-TREATMENT
tip	I-TREATMENT
ends	O
in	O
the	O
lower	O
SVC	O
.	O

Patient	O
is	O
post	O
median	B-TREATMENT
sternotomy	I-TREATMENT
.	O

Almost	O
complete	O
resolution	O
of	O
pulmonary	B-PROBLEM
edema	I-PROBLEM
.	O

7.	O
2017-09-29	O
CT	B-TEST
Head	I-TEST
:	O

There	O
is	O
no	O
evidence	O
of	O
intraaxial	B-PROBLEM
or	I-PROBLEM
extraaxial	I-PROBLEM
hemorrhage	I-PROBLEM
,	O
mass	B-PROBLEM
effect	I-PROBLEM
,	O
shift	B-PROBLEM
of	I-PROBLEM
normally	I-PROBLEM
midline	I-PROBLEM
structures	I-PROBLEM
,	O
or	O
acute	B-PROBLEM
major	I-PROBLEM
or	I-PROBLEM
minor	I-PROBLEM
vascular	I-PROBLEM
territorial	I-PROBLEM
infarction	I-PROBLEM
.	O

The	O
ventricles	O
and	O
sulci	O
are	O
mildly	B-PROBLEM
prominent	I-PROBLEM
,	O
but	O
stable	O
in	O
size	O
and	O
appearance	O
.	O

Again	O
seen	O
are	O
subtle	B-PROBLEM
hypodensities	I-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
periventricular	I-PROBLEM
white	I-PROBLEM
matter	I-PROBLEM
which	O
is	O
an	O
indication	O
of	O
chronic	B-PROBLEM
microvascular	I-PROBLEM
ischemic	I-PROBLEM
changes	I-PROBLEM
,	O
stable	O
.	O

Extensive	B-PROBLEM
carotid	I-PROBLEM
artery	I-PROBLEM
calcifications	I-PROBLEM
are	O
identified	O
.	O

No	O
evidence	O
of	O
acute	B-PROBLEM
or	I-PROBLEM
chronic	I-PROBLEM
infarction	I-PROBLEM
.	O

Stable	B-PROBLEM
microvascular	I-PROBLEM
ischemic	I-PROBLEM
changes	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
periventricular	I-PROBLEM
white	I-PROBLEM
matter	I-PROBLEM
.	O

8.	O
2017-09-30	O
EEG	B-TEST
:	O

Abnormal	B-PROBLEM
EEG	I-PROBLEM
due	O
to	O
the	B-PROBLEM
moderately	I-PROBLEM
slow	I-PROBLEM
posterior	I-PROBLEM
background	I-PROBLEM
and	O
occasional	O
bursts	O
of	O
generalized	B-PROBLEM
slowing	I-PROBLEM
.	O

These	O
findings	O
indicate	O
a	B-PROBLEM
widespread	I-PROBLEM
encephalopathic	I-PROBLEM
condition	I-PROBLEM
affecting	O
both	O
cortical	O
and	O
subcortical	O
structures	O
.	O

Medications	B-TREATMENT
,	O
metabolic	B-PROBLEM
disturbances	I-PROBLEM
,	O
and	O
infection	B-PROBLEM
are	O
among	O
the	O
most	O
common	O
causes	O
.	O

No	O
prominent	B-PROBLEM
focal	I-PROBLEM
abnormalities	I-PROBLEM
were	O
evident	O
,	O
and	O
there	O
were	O
no	O
epileptiform	B-PROBLEM
features	I-PROBLEM
.	O

The	B-TEST
cardiac	I-TEST
monitor	I-TEST
showed	O
occasional	B-PROBLEM
irregularities	I-PROBLEM
in	O
a	B-TREATMENT
PACED	I-TREATMENT
rhythm	I-TREATMENT
.	O

70	O
y/o	O
male	O
with	O
h/o	O
CAD	B-PROBLEM
,	O
T2DM	B-PROBLEM
,	O
hyperlipidemia	B-PROBLEM
,	O
and	O
COPD	B-PROBLEM
who	O
presented	O
to	O
the	O
Juan	O
on	O
2017-09-03	O
with	O
worsening	B-PROBLEM
SOB	I-PROBLEM
x	O
5	O
days	O
from	O
Morton	O
Hospital	O
&	O
Medical	O
Center	O
.	O

Pt.	O
was	O
initially	O
admitted	O
to	O
CCU	O
on	O
2017-09-03	O
,	O
transferred	O
to	O
Pendleton	O
on	O
2017-09-05	O
,	O
triggered	O
on	O
2017-09-10	O
for	O
hypotension	B-PROBLEM
with	O
BP	B-TEST
67/38	O
and	O
transferred	O
back	O
to	O
CCU	O
on	O
2017-09-10	O
.	O

He	O
remained	O
fluid	B-PROBLEM
overloaded	I-PROBLEM
and	O
a	B-TREATMENT
swan	I-TREATMENT
catheter	I-TREATMENT
was	O
placed	O
.	O

Pump	B-TREATMENT

The	O
patient	O
was	O
initially	O
admitted	O
for	O
likely	O
CHF	B-PROBLEM
exacerbation	I-PROBLEM
.	O

He	O
was	O
started	O
on	O
a	B-TREATMENT
lasix	I-TREATMENT
gtt	I-TREATMENT
the	O
night	O
of	O
admission	O
with	O
a	O
good	O
response	O
.	O

After	O
several	O
days	O
,	O
he	O
became	O
hypotensive	B-PROBLEM
and	O
triggered	O
for	O
BPs	B-TEST
60s/30s	O
.	O

He	O
was	O
given	O
IVF	B-TREATMENT
without	O
an	O
adequate	O
response	O
in	O
his	B-TEST
pressures	I-TEST
.	O

He	O
was	O
transferred	O
back	O
to	O
the	O
CCU	O
and	O
started	O
on	O
a	B-TREATMENT
dopamine	I-TREATMENT
gtt	I-TREATMENT
.	O

He	O
diuresed	O
well	O
on	O
the	B-TREATMENT
dopamine	I-TREATMENT
gtt	I-TREATMENT
and	O
his	B-TEST
BP	I-TEST
was	O
supported	O
.	O

Gradually	O
,	O
the	B-TREATMENT
dopamine	I-TREATMENT
gtt	I-TREATMENT
was	O
weaned	O
.	O

However	O
,	O
he	O
still	O
appeared	O
volume	B-PROBLEM
overloaded	I-PROBLEM
with	O
minimal	O
improvement	O
in	O
his	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
.	O

A	B-TEST
swan	I-TEST
was	O
placed	O
for	O
a	O
more	O
accurate	O
picture	O
of	O
his	O
volume	O
status	O
and	O
he	O
was	O
volume	B-PROBLEM
overloaded	I-PROBLEM
by	O
swan	B-TEST
numbers	I-TEST
with	O
an	B-PROBLEM
elevated	I-PROBLEM
PAD	I-PROBLEM
and	O
elevated	B-PROBLEM
CVP	I-PROBLEM
without	O
an	B-TEST
obtainable	I-TEST
wedge	I-TEST
pressure	I-TEST
.	O

He	O
also	O
had	O
a	B-PROBLEM
high	I-PROBLEM
CO	I-PROBLEM
and	O
low	B-PROBLEM
SVR	I-PROBLEM
suggestive	O
of	O
sepsis	B-PROBLEM
,	O
but	O
he	O
never	O
had	O
an	B-PROBLEM
elevated	I-PROBLEM
WBC	I-PROBLEM
and	O
was	O
afebrile	B-PROBLEM
during	O
his	O
entire	O
hospital	O
admission	O
with	O
negative	O
blood	B-TEST
,	I-TEST
urine	I-TEST
,	I-TEST
wound	I-TEST
,	I-TEST
and	I-TEST
pleural	I-TEST
fluid	I-TEST
cultures	I-TEST
.	O

The	B-TREATMENT
Lasix	I-TREATMENT
drip	I-TREATMENT
was	O
eventually	O
changed	O
to	O
IV	B-TREATMENT
Lasix	I-TREATMENT
boluses	I-TREATMENT
,	O
with	O
a	B-TREATMENT
net	I-TREATMENT
diuresis	I-TREATMENT
of	O
over	O
36	O
liters	O
for	O
the	O
hospital	O
stay	O
.	O

He	O
was	O
then	O
transitioned	O
to	O
oral	B-TREATMENT
Lasix	I-TREATMENT
for	O
maintainence	O
.	O

The	O
patient	O
had	O
an	B-TEST
echo	I-TEST
on	O
2017-09-04	O
with	O
the	O
results	O
above	O
in	O
detail	O
.	O

It	O
was	O
unchanged	O
in	O
comparison	O
to	O
2017-08-14	O
with	O
similar	O
ventricular	B-TEST
function	I-TEST
and	O
inferior	B-PROBLEM
and	I-PROBLEM
inferolateral	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

The	O
patient	O
had	O
another	B-TEST
echo	I-TEST
on	O
2017-09-14	O
with	O
no	O
new	O
changes	O
.	O

At	O
discharge	O
the	O
patient	O
was	O
thought	O
to	O
be	O
euvolemic	O
,	O
satting	O
well	O
on	O
room	O
air	O
and	O
without	O
peripheral	B-PROBLEM
edema	I-PROBLEM
.	O

His	B-TEST
dry	I-TEST
weight	I-TEST
is	O
70.4	O
kg	O
.	O

Ischemia	B-PROBLEM

The	O
patient	O
had	O
an	B-PROBLEM
initial	I-PROBLEM
troponin	I-PROBLEM
bump	I-PROBLEM
on	O
admission	O
which	O
was	O
most	O
likely	O
secondary	O
to	O
CHF	B-PROBLEM
exacerbation	I-PROBLEM
.	O

He	O
was	O
continued	O
on	O
Aspirin	B-TREATMENT
,	O
Metoprolol	B-TREATMENT
and	O
Lipitor	B-TREATMENT
with	O
no	O
further	B-PROBLEM
issues	I-PROBLEM
.	O

Rhythm	B-TEST

The	O
patient	O
is	O
completely	B-PROBLEM
pacer-dependent	I-PROBLEM
,	O
being	O
epicardially	B-TREATMENT
paced	I-TREATMENT
at	O
70	O
.	O

He	O
is	O
on	O
Amiodarone	B-TREATMENT
for	O
post-op	B-PROBLEM
afib	I-PROBLEM
and	O
this	O
was	O
continued	O
this	O
entire	O
admission	O
.	O

His	B-TEST
underlying	I-TEST
rhythm	I-TEST
is	O
atrial	B-PROBLEM
flutter	I-PROBLEM
;	O
it	O
was	O
unclear	O
whether	O
he	O
had	O
previously	O
been	O
cardioverted	O
.	O

Anti-coagulation	B-TREATMENT
was	O
started	O
with	O
Warfarin	B-TREATMENT
5	O
mg	O
with	O
a	O
goal	O
of	O
2-3	O
and	O
a	O
plan	O
for	O
cardioversion	B-TREATMENT
in	O
6	O
weeks	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
INR	I-TEST
became	O
supratherapeutic	B-PROBLEM
and	O
Coumadin	B-TREATMENT
was	O
held	O
.	O

His	B-TREATMENT
coumadin	I-TREATMENT
was	O
transitioned	O
to	O
2	O
mg	O
and	O
then	O
1	O
mg	O
.	O

His	B-TEST
INR	I-TEST
continued	O
to	O
flucuate	O
.	O

His	B-TEST
INR	I-TEST
will	O
have	O
to	O
be	O
monitored	O
closely	O
unitl	O
his	B-TEST
levels	I-TEST
are	O
stable	O
.	O

His	O
INR	B-TEST
goal	O
is	O
02-24	O
.	O

2#	O
SOB	B-PROBLEM
on	O
admission	O
:	O

Likely	O
due	O
to	O
CHF	B-PROBLEM
exacerbation	I-PROBLEM
,	O
with	O
diuresis	B-TREATMENT
of	O
over	O
36	O
L	O
during	O
his	O
admission	O
.	O

He	O
had	O
4	B-TREATMENT
surgeries	I-TREATMENT
(	O
3	B-TREATMENT
cardiac	I-TREATMENT
surgeries	I-TREATMENT
)	O
earlier	O
in	O
the	O
summer	O
,	O
so	O
it	O
is	O
likely	O
that	O
he	O
required	O
copious	B-TREATMENT
IVF	I-TREATMENT
hydration	I-TREATMENT
surrounding	O
these	B-TREATMENT
procedures	I-TREATMENT
which	O
may	O
have	O
been	O
the	O
cause	O
of	O
his	B-PROBLEM
massive	I-PROBLEM
fluid	I-PROBLEM
overload	I-PROBLEM
.	O

It	O
appears	O
that	O
his	O
diet	O
was	O
regulated	O
at	O
rehab	O
but	O
there	O
is	O
concern	O
for	O
medication	B-PROBLEM
non-compliance	I-PROBLEM
at	O
rehab	O
,	O
per	O
previous	O
discharge	O
summaries	O
.	O

On	O
discharge	O
,	O
the	O
patient	O
was	O
maintained	O
on	O
standing	B-TREATMENT
diuretics	I-TREATMENT
as	O
well	O
as	O
PRN	B-TREATMENT
nebs	I-TREATMENT
and	O
INH	B-TREATMENT
COPD	I-TREATMENT
meds	I-TREATMENT
.	O

3#	O
Metabolic	B-PROBLEM
Alkalosis	I-PROBLEM
/	O
Hypochloremia	B-PROBLEM
:	O

Etiology	O
most	O
likely	O
a	O
combination	O
of	O
contraction	B-PROBLEM
alkalosis	I-PROBLEM
and	O
/	O
or	O
post-hypercapnia	B-PROBLEM
.	O

This	O
acutely	O
worsened	O
on	O
2017-09-18	O
,	O
when	O
the	O
patient	O
was	O
found	O
to	O
have	O
mental	B-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
and	O
an	B-TEST
ABG	I-TEST
revealed	O
a	B-TEST
CO2	I-TEST
of	O
over	O
100	O
,	O
likley	O
due	O
to	O
a	B-PROBLEM
depressed	I-PROBLEM
respiratory	I-PROBLEM
drive	I-PROBLEM
secondary	O
to	O
sedatives	B-TREATMENT
given	O
for	O
agitation	B-PROBLEM
on	O
top	O
of	O
a	B-PROBLEM
preexisting	I-PROBLEM
alkalosis	I-PROBLEM
.	O

The	O
patient	O
was	O
therefore	O
intubated	B-TREATMENT
for	O
ventilation	B-TREATMENT
,	O
and	O
continued	O
to	O
be	O
diuresed	O
.	O

His	B-TEST
CO2	I-TEST
improved	O
and	O
he	O
was	O
extubated	B-TREATMENT
after	O
a	O
few	O
days	O
.	O

All	B-TREATMENT
sedating	I-TREATMENT
medications	I-TREATMENT
were	O
held	O
and	O
serial	B-TEST
ABGs	I-TEST
were	O
trended	O
to	O
follow	O
the	O
resolution	O
of	O
the	B-PROBLEM
metabolic	I-PROBLEM
alkalosis	I-PROBLEM
.	O

4#	O
Pleural	B-PROBLEM
effusions	I-PROBLEM
:	O
s/p	B-TREATMENT
right	I-TREATMENT
thoracentesis	I-TREATMENT
on	O
2017-09-06	O
,	O
1600	O
mL	O
of	O
serosanguinous	B-PROBLEM
fluid	I-PROBLEM
removed	O
from	O
right	O
pleural	O
space	O
.	O

Gram	B-TEST
stain	I-TEST
and	O
cultures	B-TEST
were	O
negative	O
,	O
cytology	B-TEST
was	O
negative	O
.	O

The	B-PROBLEM
right	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
slowly	O
re-accumulated	O
after	O
tap	B-TREATMENT
but	O
resolved	O
after	O
continued	B-TREATMENT
diuresis	I-TREATMENT
.	O

Repeat	B-TEST
CXR	I-TEST
showed	O
improvement	O
of	O
the	B-PROBLEM
effusion	I-PROBLEM
and	O
on	O
discharge	O
he	O
had	O
been	O
breathing	O
well	O
on	O
room	O
air	O
without	O
complications	B-PROBLEM

5#	O
T2DM	B-PROBLEM
:	O

The	O
patient	O
was	O
started	O
on	O
Glargine	B-TREATMENT
for	O
tighter	O
glycemic	O
control	O
and	O
was	O
covered	O
with	O
an	B-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
.	O

He	O
was	O
monitored	O
with	O
QID	B-TEST
fingersticks	I-TEST
.	O

His	B-TEST
blood	I-TEST
sugars	I-TEST
were	O
in	O
the	O
100s	O
on	O
discharge	O
.	O

6#	O
Hyperlipidemia	B-PROBLEM
:	O

The	O
patient	O
was	O
continued	O
on	O
his	B-TREATMENT
statin	I-TREATMENT
.	O

7#	O
COPD	B-PROBLEM
:	O

The	O
patient	O
was	O
continued	O
on	O
nebs	B-TREATMENT

8#	O
MS	B-PROBLEM
changes	I-PROBLEM
:	O

The	O
patient	O
has	O
a	O
history	O
of	O
baseline	B-PROBLEM
dementia	I-PROBLEM
which	O
was	O
confounded	O
by	O
delerium	B-PROBLEM
in	O
the	O
face	O
of	O
metabolic	B-PROBLEM
abnormalities	I-PROBLEM
.	O

Neurology	O
was	O
also	O
consulted	O
and	O
a	B-TEST
head	I-TEST
CT	I-TEST
showed	O
old	B-PROBLEM
lacunar	I-PROBLEM
infarcts	I-PROBLEM
but	O
no	O
acute	O
causes	O
for	O
a	B-PROBLEM
change	I-PROBLEM
in	I-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
.	O

An	B-TEST
EEG	I-TEST
showed	O
mild	B-PROBLEM
encephalopathy	I-PROBLEM
,	O
but	O
no	O
other	O
findings	O
.	O

His	O
mental	O
status	O
did	O
clear	O
somewhat	O
with	O
the	O
addition	O
of	O
standing	B-TREATMENT
lactulose	I-TREATMENT
;	O
he	O
was	O
discharged	O
on	O
this	B-TREATMENT
medication	I-TREATMENT
.	O

9#	O
Hypothyroidism	B-PROBLEM
:	O

The	O
patient	O
was	O
continued	O
on	O
his	O
outpatient	O
dose	O
of	O
Levothyroxine	B-TREATMENT
.	O

10#	O
?	O
UTI	B-PROBLEM
:	O

The	O
patient	O
was	O
started	O
on	O
levofloxacin	B-TREATMENT
at	O
Newton-Wellesley	O
Hospital	O
for	O
a	O
question	O
of	O
UTI	B-PROBLEM
based	O
on	O
U/A	B-TEST
positive	O
for	O
WBC	B-TEST
.	O

UCx	B-TEST
during	O
this	O
hospitalization	O
were	O
negative	O
and	O
Levofloxacin	B-TREATMENT
was	O
d/c	O
'd	O
.	O

11#	O
Chronic	B-PROBLEM
lower	I-PROBLEM
back	I-PROBLEM
pain	I-PROBLEM
:	O

The	O
patient	O
was	O
treated	O
with	O
a	B-TREATMENT
Lidocaine	I-TREATMENT
patch	I-TREATMENT
and	O
Percocet	B-TREATMENT
prn	O
.	O

Stronger	B-TREATMENT
narcotics	I-TREATMENT
were	O
avoided	O
given	O
somnolence	B-PROBLEM
and	O
MS	B-PROBLEM
changes	I-PROBLEM
.	O

12#	O
Wound	B-TREATMENT
Care	I-TREATMENT
:	O

The	O
patient	O
has	O
left	B-PROBLEM
chest	I-PROBLEM
wound	I-PROBLEM
and	O
left	B-PROBLEM
gluteal	I-PROBLEM
pressure	I-PROBLEM
ulcer	I-PROBLEM
.	O

For	O
the	B-PROBLEM
left	I-PROBLEM
gluteal	I-PROBLEM
pressure	I-PROBLEM
ulcer	I-PROBLEM
,	O
they	O
recommended	O
gentle	B-TREATMENT
cleansing	I-TREATMENT
with	O
normal	B-TREATMENT
saline	I-TREATMENT
or	O
commercial	B-TREATMENT
wound	I-TREATMENT
cleaner	I-TREATMENT
,	O
thin	O
layer	O
of	O
Duoderm	B-TREATMENT
gel	I-TREATMENT
,	O
air	O
dry	O
,	O
allevyn	B-TREATMENT
foam	I-TREATMENT
adhesive	I-TREATMENT
over	O
the	O
site	O
,	O
and	O
change	O
every	O
2	O
days	O
or	O
prn	O
.	O

For	O
the	B-PROBLEM
left	I-PROBLEM
chest	I-PROBLEM
wound	I-PROBLEM
,	O
they	O
recommended	O
cleansing	O
with	O
commercial	B-TREATMENT
wound	I-TREATMENT
cleanser	I-TREATMENT
,	O
pat	O
dry	O
,	O
pack	B-TREATMENT
aquacel	I-TREATMENT
AG	I-TREATMENT
rope	I-TREATMENT
and	O
moisten	O
with	O
saline	B-TREATMENT
,	O
cover	O
with	O
dry	B-TREATMENT
gauze	I-TREATMENT
and	O
change	O
daily	O
.	O

He	O
was	O
started	O
on	O
finsateride	B-TREATMENT
on	O
the	O
day	O
prior	O
to	O
admission	O
.	O

Until	O
then	O
,	O
his	B-TREATMENT
foley	I-TREATMENT
should	O
remain	O
in	O
place	O
.	O

Levothyroxine	B-TREATMENT
100	O
mcg	O
PO	O
daily	O

Duloxetine	B-TREATMENT
20	O
mg	O
PO	O
QHS	O

Ondansetron	B-TREATMENT
PRN	O

Percocet	B-TREATMENT
1	O
tab	O
PRN	O

Senna	B-TREATMENT
PRN	O

Colace	B-TREATMENT
PRN	O

Lasix	B-TREATMENT
80	O
mg	O
PO	O
BID	O

Lactulose	B-TREATMENT
PRN	O

Lidocaine	B-TREATMENT
patch	I-TREATMENT

Nystatin	B-TREATMENT
powder	I-TREATMENT

Gabapentin	B-TREATMENT
300	O
mg	O
PO	O
TID	O

Alb	B-TREATMENT
nebs	I-TREATMENT

Fluticasone	B-TREATMENT
/	O
Salmeterol	B-TREATMENT

Tiotropium	B-TREATMENT
Bromide	I-TREATMENT

Spironolactone	B-TREATMENT
25	O
mg	O
PO	O
daily	O

Epoetin	B-TREATMENT
4000	O
units	O
MWF	O

RISS	B-TREATMENT

Amiodarone	B-TREATMENT
200	O
mg	O
PO	O
daily	O

Calcium	B-TREATMENT
Acetate	I-TREATMENT
667	O
mg	O
PO	O
TID	O

SubQ	B-TREATMENT
Heparin	I-TREATMENT

Pantoprazole	B-TREATMENT
40	O
mg	O
PO	O
daily	O

Simvastatin	B-TREATMENT
40	O
mg	O
PO	O
QHS	O

ASA	B-TREATMENT
81	O
mg	O
PO	O
daily	O

MVI	B-TREATMENT

Tylenol	B-TREATMENT
PRN	O

1.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	B-PROBLEM
.	O

2.	O
Levothyroxine	B-TREATMENT
100	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

3.	O
Duloxetine	B-TREATMENT
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O

4.	O
Lactulose	B-TREATMENT
10	O
g	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

5.	O
Fluticasone	B-TREATMENT
-	O
Salmeterol	B-TREATMENT
100-50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

6.	O
Tiotropium	B-TREATMENT
Bromide	I-TREATMENT
18	O
mcg	O
Capsule	O
,	O
w/	O
Inhalation	B-TREATMENT
Device	I-TREATMENT
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
Inhalation	O
DAILY	O
(	O
Daily	O
)	O
.	O

7.	O
Amiodarone	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

8.	O
Calcium	B-TREATMENT
Acetate	I-TREATMENT
667	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
W/MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O

9.	O
Oxycodone	B-TREATMENT
-	O
Acetaminophen	B-TREATMENT
5-325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

10.	O
Multivitamin	B-TREATMENT
Capsule	I-TREATMENT
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

11.	O
Miconazole	B-TREATMENT
Nitrate	I-TREATMENT
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

12.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

13.	O
Simvastatin	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O

14.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

15.	O
Lidocaine	B-TREATMENT
5	O
%(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O

16.	O
Furosemide	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

17.	O
Ferrous	B-TREATMENT
Sulfate	I-TREATMENT
325	O
(	O
65	O
)	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

18.	O
Epoetin	B-TREATMENT
Alfa	I-TREATMENT
4,000	O
unit/mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
QMOWEFR	O
(	O
Monday	O
-	O
Wednesday	O
-	O
Friday	O
)	O
.	O

19.	O
Spironolactone	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

20.	O
Albuterol	B-TREATMENT
90	O
mcg/Actuation	O
Aerosol	O
Sig	O
:	O
4-6	O
Puffs	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O

21.	O
Metoprolol	B-TREATMENT
Succinate	I-TREATMENT
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

22.	O
Finasteride	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

23.	O
Gabapentin	B-TREATMENT
300	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

24.	O
Warfarin	B-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
:	O
Please	O
monitor	O
INR	B-TEST
with	O
goal	O
02-24	O
.	O

Congestive	B-PROBLEM
Heart	I-PROBLEM
Failure	I-PROBLEM
exacerbation	I-PROBLEM

Coronary	B-PROBLEM
Artery	I-PROBLEM
Disease	I-PROBLEM

Hypertension	B-PROBLEM

Type	B-PROBLEM
2	I-PROBLEM
Diabetes	I-PROBLEM
Mellitus	I-PROBLEM

Chronic	B-PROBLEM
Obstructive	I-PROBLEM
Pulmonary	I-PROBLEM
Disease	I-PROBLEM

The	O
patient	O
was	O
discharged	O
hemodynamicallly	O
stable	O
,	O
afebrile	B-PROBLEM
with	O
appropriate	O
follow	O
up	O
.	O

During	O
this	O
admission	O
you	O
have	O
been	O
treated	O
for	O
a	B-PROBLEM
CHF	I-PROBLEM
exacerbation	I-PROBLEM
.	O

1.	O
Please	O
take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

3.	O
Please	O
call	O
your	O
PCP	O
C.	O
Lettinga	O
or	O
seek	O
medical	O
attention	O
in	O
the	O
Juan	O
if	O
you	O
experience	O
worsening	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
dizziness	B-PROBLEM
,	O
passing	B-PROBLEM
out	I-PROBLEM
,	O
or	O
any	B-PROBLEM
other	I-PROBLEM
concerning	I-PROBLEM
symptom	I-PROBLEM
.	O

MEDICINE	B-TREATMENT

Sulfonamides	B-TREATMENT

Transfer	O
from	O
Athol	O
Memorial	O
Hospital	O
for	O
acute	O
on	O
chronic	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
.	O

Lumbar	B-TEST
puncture	I-TEST
on	O
08-16	O

Mr.	O
Lockley	O
is	O
a	O
73	O
yo	O
male	O
with	O
a	O
complicated	O
past	O
medical	O
history	O
,	O
recently	O
discharged	O
from	O
St.	O
Margaret	O
's	O
Center	O
for	O
Women	O
&	O
Infants	O
on	O
08-02	O
following	O
a	O
prolonged	O
admission	O
for	O
STEMI	B-PROBLEM
,	O
respiratory	B-PROBLEM
failure	I-PROBLEM
felt	O
secondary	O
to	O
pulmonary	B-PROBLEM
edema	I-PROBLEM
requiring	O
intubation	O
and	O
subsequent	B-TREATMENT
tracheostomy	I-TREATMENT
02-22	O
failure	B-PROBLEM
to	I-PROBLEM
wean	I-PROBLEM
,	O
sepsis	B-PROBLEM
and	O
C.difficile	B-PROBLEM
colitis	I-PROBLEM
treated	O
with	O
Vancomycin	B-TREATMENT
and	O
Flagyl	B-TREATMENT
with	O
a	O
course	O
of	O
Levophed	B-TREATMENT
.	O

He	O
was	O
discharged	O
to	O
Athol	O
Memorial	O
Hospital	O
for	O
continued	B-TREATMENT
weaning	I-TREATMENT
.	O

Per	O
Dr.	O
John	O
C.	O
Corrigan	O
Mental	O
Health	O
Center	O
,	O
patient	O
remained	O
ventilator	B-PROBLEM
dependent	I-PROBLEM
,	O
intermittently	O
on	O
PS	B-TREATMENT
20/5	O
and	O
back	O
on	O
AC	B-TREATMENT
15/5/500/0.35	O
on	O
08-08	O
.	O

At	O
OSH	O
,	O
sputum	B-TEST
cultures	I-TEST
grew	O
Pseudomonas	B-PROBLEM
and	O
MRSA	B-PROBLEM
,	O
and	O
he	O
was	O
restarted	O
on	O
Zosyn	B-TREATMENT
(	O
08-08	O
)	O
and	O
Vancomycin	B-TREATMENT
(	O
08-09	O
).	O

He	O
completed	O
his	O
course	O
of	O
Vancomycin	B-TREATMENT
on	O
2017-08-10	O
.	O

However	O
,	O
today	O
around	O
17:45	O
,	O
while	O
being	O
moved	O
by	O
the	O
nursing	O
staff	O
,	O
Mr.	O
Lockley	O
Bosche	O
started	O
coughing	B-PROBLEM
.	O

He	O
then	O
became	O
dusky	B-PROBLEM
and	O
cyanotic	B-PROBLEM
,	O
and	O
stopped	B-PROBLEM
breathing	I-PROBLEM
on	O
his	O
own	O
.	O

A	O
code	O
was	O
called	O
,	O
+	O
pulse	B-TEST
.	O

Patient	O
placed	O
on	O
FiO2	B-TREATMENT
100%	O
.	O

Vitals	B-TEST
reportedly	O
HR	B-TEST
88-98	O
,	O
BP	B-TEST
150/80	O
.	O

ABG	B-TEST
done	O
on	O
FiO2	B-TREATMENT
100%	O
7.36/66/417/98%	O
.	O

At	O
Vencor	O
Hospital	O
,	O
BP	B-PROBLEM
dropped	I-PROBLEM
to	O
90	O
,	O
and	O
patient	O
was	O
started	O
on	O
NS	B-TREATMENT
IVF	I-TREATMENT
,	O
with	O
improvement	O
in	O
BP	B-TEST
.	O

EKG	B-TEST
without	O
acute	B-PROBLEM
changes	I-PROBLEM
.	O

He	O
was	O
transferred	O
to	O
St.	O
Margaret	O
's	O
Center	O
for	O
Women	O
&	O
Infants	O
John	O
for	O
further	B-TREATMENT
management	I-TREATMENT
on	O
AC	B-TEST
,	O
RR	B-TEST
15	O
,	O
PEEP	B-TEST
5	O
,	O
Vt	B-TEST
500	O
,	O
Fi02	B-TEST
1.0	O
.	O

In	O
John	O
,	O
BP	B-TEST
80/60	O
,	O
HR	B-TEST
80	O
.	O

Continued	O
on	O
IVF	B-TREATMENT
(	O
received	O
total	O
2300	O
cc	O
)	O
,	O
with	O
improved	O
BP	B-TEST
to	O
SBP	B-TEST
105-118	O
.	O

Stool	B-TEST
sent	O
for	O
C.diff	B-PROBLEM
and	O
given	O
Flagyl	B-TREATMENT
500	O
mg	O
PO	O
X	O
1	O
dose	O
.	O

1.	O
Non-small	B-PROBLEM
cell	I-PROBLEM
lung	I-PROBLEM
cancer	I-PROBLEM
s/p	B-TREATMENT
XRT	I-TREATMENT
and	O
chemotherapy	B-TREATMENT
in	O
French	O
Guiana	O
,	O
s/p	B-TREATMENT
right	I-TREATMENT
pneumonectomy	I-TREATMENT
in	O
2016-09-21	O
for	O
recurrence	B-PROBLEM
.	O

Chronic	B-PROBLEM
left	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

2.	O
SSS	B-PROBLEM
status	B-TREATMENT
post	I-TREATMENT
PM/ICD	I-TREATMENT
placement	I-TREATMENT

3.	O
COPD/bronchiectasis	B-PROBLEM

4.	O
Hypertension	B-PROBLEM

5.	O
CAD	B-PROBLEM
,	O
with	O
known	O
TO	O
RCA	O
.	O

6.	O
CHF	B-PROBLEM
with	O
EF	B-TEST
25%	O
on	O
last	B-TEST
echo	I-TEST
on	O
2017-07-19	O

7.	O
BPH	B-PROBLEM

8.	O
Depression	B-PROBLEM

9.	O
Left	B-PROBLEM
femoral	I-PROBLEM
AV	I-PROBLEM
fistula	I-PROBLEM
2017-04-19	O

10.	O
Recent	B-PROBLEM
MRSA	I-PROBLEM
pneumonia	I-PROBLEM
and	O
sepsis	B-PROBLEM
2017-07-21	O
,	O
treated	O
with	O
Vancomycin	B-TREATMENT

11.	O
C.	B-PROBLEM
difficile	I-PROBLEM
colitis	I-PROBLEM
treated	O
with	O
Flagyl	B-TREATMENT
(	O
completed	O
08-10	O
)	O

12.	O
Status	B-TREATMENT
post	I-TREATMENT
PEG	I-TREATMENT
tube	I-TREATMENT
placement	I-TREATMENT
2017-07-21	O

13.	O
Status	B-TREATMENT
post	I-TREATMENT
tracheostomy	I-TREATMENT
2017-07-21	O
02-22	O
failure	B-PROBLEM
to	I-PROBLEM
wean	I-PROBLEM

14.	O
Status	B-TREATMENT
post	I-TREATMENT
partial	I-TREATMENT
colectomy	I-TREATMENT
1972	O

Opens	O
eyes	O
spontaneously	O
,	O
withdraws	O
to	O
painful	B-TEST
stimulus	I-TEST
.	O

BP	B-TEST
90s-118/47-59	O
,	O
HR	B-TEST
80-90s	O
.	O

AC	B-TEST
,	O
RR	B-TEST
15	O
,	O
PEEP	B-TEST
5	O
,	O
Vt	B-TEST
500	O
cc	O
,	O
FiO2	B-TEST
1.0	O
.	O

Intubated	B-TREATMENT
,	O
opens	O
eyes	O
,	O
responds	O
to	O
painful	B-TEST
stimulus	I-TEST
.	O

Pupils	B-PROBLEM
minimally	I-PROBLEM
reactive	I-PROBLEM
.	O

Sclera	B-PROBLEM
anicteric	I-PROBLEM
.	O

Unable	O
to	O
assess	O
JVP	B-TEST
.	O

Bronchial	B-PROBLEM
breathing	I-PROBLEM
over	I-PROBLEM
right	I-PROBLEM
hemithorax	I-PROBLEM
.	O

Ronchorous	B-PROBLEM
breath	I-PROBLEM
sounds	I-PROBLEM
left	I-PROBLEM
chest	I-PROBLEM
.	O

Limited	B-TEST
examination	I-TEST
.	O

+	O
S4	B-PROBLEM
.	O

No	O
murmur	B-PROBLEM
appreciated	O
.	O

PEG	B-TREATMENT
in	O
place	O
,	O
site	O
without	O
drainage	B-PROBLEM
.	O

BS	O
present	O
,	O
hypoactive	B-PROBLEM
.	O

No	O
grimacing	B-PROBLEM
with	O
palpation	B-TEST
.	O

Foley	B-TREATMENT
in	O
place	O
.	O

2+	B-PROBLEM
edema	I-PROBLEM
both	I-PROBLEM
upper	I-PROBLEM
extremities	I-PROBLEM
,	O
sacral	B-PROBLEM
edema	I-PROBLEM
.	O

Cool	B-PROBLEM
extremities	I-PROBLEM
.	O

Limited	B-TEST
examination	I-TEST
.	O

Withdraws	O
to	O
painful	B-TEST
stimulus	I-TEST
.	O

WBC	B-TEST
-	O
4.9	O
RBC	B-TEST
-	O
2.92	O
*	O
HGB	B-TEST
-	O
8.8	O
*	O
HCT	B-TEST
-	O
26.2	O
*	O
MCV	B-TEST
-	O
90	O
MCH	B-TEST
-	O
30.1	O
MCHC	B-TEST
-	O
33.5	O
RDW	B-TEST
-	O
18.5	O
*	O
NEUTS	B-TEST
-	O
86.5	O
*	O
LYMPHS	B-TEST
-	O
7.5	O
*	O
MONOS	B-TEST
-	O
4.7	O
EOS	B-TEST
-	O
1.2	O
BASOS	B-TEST
-	O
0.1	O
PLT	B-TEST
COUNT	I-TEST
-	O
145	O
*	O
GLUCOSE	B-TEST
-	O
91	O
UREA	B-TEST
N	I-TEST
-	O
21	O
*	O
CREAT	B-TEST
-	O
0.6	O
SODIUM	B-TEST
-	O
143	O
POTASSIUM	B-TEST
-	O
4.2	O
CHLORIDE	B-TEST
-	O
106	O
TOTAL	B-TEST
CO2	I-TEST
-	O
32	O
ANION	B-TEST
GAP	I-TEST
-	O
9	O
LACTATE	B-TEST
-	O
1.4	O
K+	B-TEST
-	O
3.9	O

ABG	B-TEST
:	O

2017-08-14	O
07:30	O
PM	O
TYPE	O
-	O
ART	B-TEST
PO2	I-TEST
-	O
468	O
*	O
PCO2	B-TEST
-	O
44	O
PH	B-TEST
-	O
7.50	O
*	O
TOTAL	B-TEST
CO2	I-TEST
-	O
36	O
*	O
BASE	B-TEST
XS	I-TEST
-	O
10	O
INTUBATED	B-TREATMENT
-	O
INTUBATED	B-TREATMENT

EKG	B-TEST
(	O
at	O
Athol	O
Memorial	O
Hospital	O
,	O
17:11	O
)	O
:	O

Atrial	B-PROBLEM
fibrillation	I-PROBLEM
,	O
occasional	B-TREATMENT
V-paced	I-TREATMENT
,	O
rate	B-TEST
74	O
.	O

Old	B-PROBLEM
TWI	I-PROBLEM
V4-6	I-PROBLEM
.	O

EKG	B-TEST
in	O
John	O
:	O

Afib	B-PROBLEM
,	O
occasional	B-TREATMENT
V-paced	I-TREATMENT
,	O
rate	B-TEST
83	O
bpm	O
.	O

Long	B-PROBLEM
QT	I-PROBLEM
interval	I-PROBLEM
(	O
QTc	B-TEST
462	O
ms	O
).	O

ST	B-PROBLEM
depressions	I-PROBLEM
V4	I-PROBLEM
,	I-PROBLEM
5	I-PROBLEM
.	O

Mild	B-PROBLEM
ST	I-PROBLEM
elevation	I-PROBLEM
in	I-PROBLEM
V3	I-PROBLEM
.	O

Old	B-PROBLEM
TWI	I-PROBLEM
V4-6	I-PROBLEM
.	O

2017-08-14	O
CXR	B-TEST
:	O

ETT	B-TREATMENT
in	O
correct	O
position	O
.	O

PM	B-TREATMENT
wires	I-TREATMENT
in	O
good	O
position	O
.	O

S/p	B-TREATMENT
right	I-TREATMENT
pneumonectomy	I-TREATMENT
.	O

Blunting	B-PROBLEM
of	I-PROBLEM
left	I-PROBLEM
CPA	I-PROBLEM
likely	O
effusion	B-PROBLEM
.	O

New	B-PROBLEM
lower	I-PROBLEM
left	I-PROBLEM
lateral	I-PROBLEM
CW	I-PROBLEM
opacity	I-PROBLEM
,	O
likely	O
loculated	B-PROBLEM
pleural	I-PROBLEM
fluid	I-PROBLEM
.	O

2017-07-19	O
ECHO	B-TEST
:	O

Left-to-right	B-PROBLEM
shunt	I-PROBLEM
across	I-PROBLEM
the	I-PROBLEM
interatrial	I-PROBLEM
septum	I-PROBLEM
.	O

LVEF	B-TEST
25%	O
.	O

Resting	B-TEST
WMA	I-TEST
include	O
mid	B-PROBLEM
to	I-PROBLEM
distal	I-PROBLEM
septal	I-PROBLEM
akinesis	I-PROBLEM
,	O
apical	B-PROBLEM
akinesis	I-PROBLEM
,	O
inferior	B-PROBLEM
akinesis/hypokinesis	I-PROBLEM
,	O
and	O
mid	B-PROBLEM
to	I-PROBLEM
distal	I-PROBLEM
anterolateral	I-PROBLEM
hypokinesis	I-PROBLEM
/	O
akinesis	B-PROBLEM
.	O

No	O
definite	O
apical	B-PROBLEM
thrombus	I-PROBLEM
seen	O
(	O
cannot	O
exclude	O
).	O

01-22+	O
AR	B-PROBLEM
.	O

Trivial	B-PROBLEM
MR	I-PROBLEM
.	O

1+	O
TR	B-PROBLEM
.	O

2017-08-16	O
CT	B-TEST
head	I-TEST
:	O

New	B-PROBLEM
rounded	I-PROBLEM
low-density	I-PROBLEM
area	I-PROBLEM
measuring	O
2.5	O
cm	O
in	O
left	O
basal	O
ganglia	O
,	O
which	O
partially	O
extends	O
to	O
the	O
left	O
thalamus	O
,	O
probably	O
representing	O
subacute	B-PROBLEM
infarction	I-PROBLEM
.	O

On	O
this	B-TEST
head	I-TEST
CT	I-TEST
without	O
contrast	O
,	O
the	B-TEST
evaluation	I-TEST
is	O
limited	O
.	O

2017-08-16	O
CTA	B-TEST
chest	I-TEST
:	O

No	O
evidence	O
for	O
pulmonary	B-PROBLEM
embolism	I-PROBLEM
.	O

Findings	O
consistent	O
with	O
failure	B-PROBLEM
or	O
fluid	B-PROBLEM
overload	I-PROBLEM
.	O

Development	O
of	O
small	B-PROBLEM
loculated	I-PROBLEM
pleural	I-PROBLEM
fluid	I-PROBLEM
collection	I-PROBLEM
along	I-PROBLEM
the	I-PROBLEM
periphery	I-PROBLEM
of	O
the	O
left	O
major	O
fissure	O
or	O
so-called	B-PROBLEM
pseudotumor	I-PROBLEM
,	O
consistent	O
with	O
the	B-TEST
recent	I-TEST
chest	I-TEST
x-ray	I-TEST
.	O

Unchanged	O
appearance	O
of	O
right	B-TREATMENT
pneumonectomy	I-TREATMENT
.	O

2017-08-16	O
ECHO	B-TEST
:	O

Overall	B-TEST
LVEF	I-TEST
is	O
difficult	O
to	O
assess	O
due	O
to	O
poor	O
echo	B-TEST
windows	I-TEST
although	O
the	B-TEST
basal	I-TEST
LV	I-TEST
appeas	O
hyperdynamic	B-PROBLEM
without	O
regional	B-PROBLEM
contraction	I-PROBLEM
abnormality	I-PROBLEM
(	O
suspect	O
significant	O
improvement	O
compared	O
to	O
prior	B-TEST
study	I-TEST
dated	O
2017-07-18	O
).	O

No	O
masses	B-PROBLEM
or	O
thrombi	B-PROBLEM
are	O
seen	O
in	O
the	O
left	O
ventricle	O
(	O
due	O
to	O
poor	O
echo	B-TEST
windows	I-TEST
cannot	O
fully	O
exclude	O
).	O

The	O
ascending	O
aorta	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

There	O
is	O
no	O
aortic	B-PROBLEM
valve	I-PROBLEM
stenosis	I-PROBLEM
.	O

Mild	B-PROBLEM
(	I-PROBLEM
1+	I-PROBLEM
)	I-PROBLEM
aortic	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

Trivial	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

The	B-TEST
left	I-TEST
ventricular	I-TEST
inflow	I-TEST
pattern	I-TEST
suggests	O
impaired	B-PROBLEM
relaxation	I-PROBLEM
.	O

There	O
is	O
a	B-PROBLEM
small	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
.	O

There	O
are	O
no	O
echocardiographic	B-TEST
signs	I-TEST
of	O
tamponade	B-PROBLEM

2017-08-17	O
EEG	B-TEST
:	O

Markedly	B-PROBLEM
abnormal	I-PROBLEM
portable	I-PROBLEM
EEG	I-PROBLEM
due	O
to	O
the	B-PROBLEM
voltage	I-PROBLEM
suppression	I-PROBLEM
over	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
hemisphere	I-PROBLEM
and	O
due	O
to	O
the	B-PROBLEM
bursts	I-PROBLEM
of	I-PROBLEM
generalized	I-PROBLEM
slowing	I-PROBLEM
and	O
right	B-PROBLEM
hemisphere	I-PROBLEM
slowing	I-PROBLEM
.	O

The	B-PROBLEM
first	I-PROBLEM
abnormality	I-PROBLEM
raises	O
the	O
possibility	O
of	O
material	B-PROBLEM
(	I-PROBLEM
such	I-PROBLEM
as	I-PROBLEM
subdural	I-PROBLEM
fluid	I-PROBLEM
)	I-PROBLEM
interposed	I-PROBLEM
between	I-PROBLEM
the	I-PROBLEM
brain	I-PROBLEM
and	O
recording	O
electrodes	O
or	O
widespread	B-PROBLEM
cortical	I-PROBLEM
dysfunction	I-PROBLEM
on	I-PROBLEM
that	I-PROBLEM
side	I-PROBLEM
.	O

The	B-PROBLEM
generalized	I-PROBLEM
slowing	I-PROBLEM
indicates	O
a	B-PROBLEM
non	I-PROBLEM
specific	I-PROBLEM
dysfunction	I-PROBLEM
in	I-PROBLEM
midline	I-PROBLEM
structures	I-PROBLEM
.	O

There	O
was	O
also	O
evidence	O
of	O
subcortical	B-PROBLEM
dysfunction	I-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
side	I-PROBLEM
.	O

No	O
epileptiform	B-PROBLEM
features	I-PROBLEM
were	O
seen	O
.	O

2017-08-17	O
STOOL	B-TEST
CLOSTRIDIUM	I-TEST
DIFFICILE	I-TEST
TOXIN	I-TEST
ASSAY	I-TEST
-	O
PENDING	O

2017-08-16	O
CSF	O
;	O
SPINAL	B-TEST
FLUID	I-TEST
GRAM	I-TEST
STAIN	I-TEST
-	O
neg	O
FLUID	B-TEST
CULTURE	I-TEST
-	O
neg	O
;	O
FUNGAL	B-TEST
CULTURE	I-TEST
-	O
PENDING	O
;	O
ACID	B-TEST
FAST	I-TEST
CULTURE	I-TEST
-	O
PENDING	O
;	O
VIRAL	B-TEST
CULTURE	I-TEST
-	O
PENDING	O

2017-08-15	O
SPUTUM	B-TEST
CULTURE	I-TEST
-	O
PRELIMINARY	O
{	O
PSEUDOMONAS	B-PROBLEM
AERUGINOSA	I-PROBLEM
}	O

2017-08-15	O
BLOOD	B-TEST
CULTURE	I-TEST
NGTD	O

2017-08-15	O
URINE	B-TEST
CULTURE	I-TEST
-	O
FINAL	O

2017-08-15	O
BLOOD	B-TEST
CULTURE	I-TEST
NGTD	O

Mr.	O
Lockley	O
was	O
admitted	O
with	O
respiratory	B-PROBLEM
failure	I-PROBLEM
,	O
thought	O
to	O
be	O
related	O
to	O
mucus	B-PROBLEM
plugging	I-PROBLEM
as	O
well	O
as	O
a	B-PROBLEM
pseudomonal	I-PROBLEM
pneumonia	I-PROBLEM
.	O

However	O
,	O
the	O
issue	O
that	O
dominated	O
the	O
admission	O
was	O
his	B-PROBLEM
recent	I-PROBLEM
acute	I-PROBLEM
decline	I-PROBLEM
in	I-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
.	O

He	O
was	O
thoroughly	O
evaluated	O
by	O
neurology	O
and	O
underwent	O
head	B-TEST
CT	I-TEST
,	O
MRI	B-TEST
,	O
LP	B-TEST
,	O
and	O
EEG	B-TEST
.	O

This	B-TEST
work-up	I-TEST
demonstrated	O
a	B-PROBLEM
small	I-PROBLEM
left	I-PROBLEM
basal	I-PROBLEM
ganglia	I-PROBLEM
infarct	I-PROBLEM
,	O
likely	O
cardioembolic	B-PROBLEM
.	O

However	O
,	O
they	O
felt	O
this	O
event	O
could	O
not	O
account	O
for	O
his	B-PROBLEM
new	I-PROBLEM
,	I-PROBLEM
severe	I-PROBLEM
global	I-PROBLEM
deficit	I-PROBLEM
;	O
this	O
was	O
thought	O
to	O
be	O
secondary	O
to	O
a	B-PROBLEM
more	I-PROBLEM
pervasive	I-PROBLEM
process	I-PROBLEM
,	O
likely	O
anoxic	B-PROBLEM
encephalopathy	I-PROBLEM
,	O
for	O
which	O
the	O
prognosis	O
is	O
extremely	O
grim	O
.	O

The	O
end	O
result	O
of	O
these	O
discussion	O
was	O
that	O
the	O
patient	O
's	O
wishes	O
would	O
not	O
be	O
consistent	O
with	O
this	O
new	O
level	O
of	O
functioning	O
from	O
which	O
he	O
had	O
little	O
hope	O
of	O
recovery	O
;	O
the	O
family	O
decided	O
to	O
make	O
him	O
comfort	B-TREATMENT
measures	I-TREATMENT
only	I-TREATMENT
.	O

He	O
was	O
disconnected	O
from	O
the	B-TREATMENT
ventilator	I-TREATMENT
and	O
all	B-TREATMENT
medications	I-TREATMENT
beyond	O
a	B-TREATMENT
morphine	I-TREATMENT
drip	I-TREATMENT
were	O
stopped	O
,	O
and	O
he	O
expired	O
shortly	O
thereafter	O
.	O

Jevity	B-TREATMENT
1.2	O
65	O
mL	O
/	O
hour	O
continuous	O
with	O
water	O
240	O
cc	O
q	O
8	O
hours	O

Lasix	B-TREATMENT
40	O
mg	O
IV	O
QAM	O
(	O
given	O
08-14	O
)	O

Vancomycin	B-TREATMENT
1	O
gm	O
IV	O
q	O
36	O
hours	O
(	O
last	O
dose	O
at	O
2000	O
on	O
08-13	O
)	O
.	O

ASA	B-TREATMENT
325	O
mg	O
PO	O
QD	O

Lansoprazole	B-TREATMENT
30	O
mg	O
PO	O
QAM	O

Heparin	B-TREATMENT
5000	O
units	O
SC	O
TID	O

Zosyn	B-TREATMENT
4.5	O
gm	O
IV	O
q	O
8	O
hours	O
(	O
last	O
dose	O
on	O
08-14	O
at	O
1400	O
)	O
,	O
started	O
08-08	O
.	O

Metoprolol	B-TREATMENT
37.5	O
mg	O
q	O
12	O
hours	O
(	O
last	O
dose	O
07/25	O
in	O
AM	O
)	O

Protein	B-TREATMENT
/	I-TREATMENT
Soy	I-TREATMENT
supplement	I-TREATMENT
2	O
scoops	O
q	O
12	O
hours	O

Ipratropium	B-TREATMENT
/	O
Albuterol	B-TREATMENT
inhaler	I-TREATMENT
4	O
puffs	O
QID	O

Completed	O
course	O
of	O
Flagyl	B-TREATMENT
07-25	O
-->	O
08-10	O
.	O

Anoxic	B-PROBLEM
encephalopathy	I-PROBLEM

Acute	B-PROBLEM
respiratory	I-PROBLEM
failure	I-PROBLEM

Chronic	B-PROBLEM
respiratory	I-PROBLEM
failure	I-PROBLEM

Pseudomonal	B-PROBLEM
pneumonia	I-PROBLEM

Volume	B-PROBLEM
overload	I-PROBLEM

Chronic	B-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM

Bronchiectasis	B-PROBLEM

Hyponatremia	B-PROBLEM

Anemia	B-PROBLEM
of	I-PROBLEM
chronic	I-PROBLEM
disease	I-PROBLEM

1.	O
Non-small	B-PROBLEM
cell	I-PROBLEM
lung	I-PROBLEM
cancer	I-PROBLEM
s/p	B-TREATMENT
XRT	I-TREATMENT
and	O
chemotherapy	B-TREATMENT
in	O
Western	O
Sahara	O
,	O
s/p	B-TREATMENT
right	I-TREATMENT
pneumonectomy	I-TREATMENT
in	O
2016-09-21	O
for	O
recurrence	B-PROBLEM
.	O

Chronic	B-PROBLEM
left	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

2.	O
Sick	B-PROBLEM
Sinus	I-PROBLEM
Syndrome	I-PROBLEM
status	B-TREATMENT
post	I-TREATMENT
PM/ICD	I-TREATMENT
placement	I-TREATMENT

3.	O
COPD/bronchiectasis	B-PROBLEM

4.	O
Hypertension	B-PROBLEM

5.	O
CAD	B-PROBLEM
,	O
with	O
known	O
TO	O
RCA	O
.	O

6.	O
CHF	B-PROBLEM
with	O
EF	B-TEST
25%	O
on	O
last	B-TEST
echo	I-TEST
on	O
2017-07-19	O

7.	O
BPH	B-PROBLEM

8.	O
Depression	B-PROBLEM

9.	O
Left	B-PROBLEM
femoral	I-PROBLEM
AV	I-PROBLEM
fistula	I-PROBLEM
2017-04-19	O

10.	O
Recent	B-PROBLEM
MRSA	I-PROBLEM
pneumonia	I-PROBLEM
and	O
sepsis	B-PROBLEM
2017-07-21	O
,	O
treated	O
with	O
Vancomycin	B-TREATMENT

11.	O
C.	B-PROBLEM
difficile	I-PROBLEM
colitis	I-PROBLEM
treated	O
with	O
Flagyl	B-TREATMENT
(	O
completed	O
08-10	O
)	O

12.	O
Status	B-TREATMENT
post	I-TREATMENT
PEG	I-TREATMENT
tube	I-TREATMENT
placement	I-TREATMENT
2017-07-21	O

13.	O
Status	B-TREATMENT
post	I-TREATMENT
tracheostomy	I-TREATMENT
2017-07-21	O
02-22	O
failure	B-PROBLEM
to	I-PROBLEM
wean	I-PROBLEM

14.	O
Status	B-TREATMENT
post	I-TREATMENT
partial	I-TREATMENT
colectomy	I-TREATMENT
1972	O

MEDICINE	B-TREATMENT

Losartan	B-TREATMENT
/	O
Aspirin	B-TREATMENT
/	O
Lisinopril-Hctz	B-TREATMENT

Chief	O
Complaint	O
:	O
fever	B-PROBLEM

Intubation	B-TREATMENT
for	O
airway	B-TREATMENT
protection	I-TREATMENT
tunneled	B-TREATMENT
line	I-TREATMENT
change	I-TREATMENT
over	I-TREATMENT
wire	I-TREATMENT
2019-01-08	O

69	O
y/o	O
female	O
wtih	O
PMH	O
significant	O
for	O
ESRD	B-PROBLEM
on	O
HD	B-TREATMENT
,	O
type	B-PROBLEM
2	I-PROBLEM
DM	I-PROBLEM
,	O
and	O
recent	B-PROBLEM
PE	I-PROBLEM
resulting	O
in	O
PEA	B-PROBLEM
arrest	I-PROBLEM
admitted	O
through	O
the	O
Juan	O
with	O
sepsis	B-PROBLEM
of	O
unknown	O
etiology	O
.	O

Pt	O
was	O
recently	O
admitted	O
to	O
The	O
Hospital	O
for	O
Orthopedics	O
from	O
12-07	O
thorugh	O
12-14	O
with	O
hypotension	B-PROBLEM
thought	O
to	O
be	O
secondary	O
to	O
overdiuresis	B-PROBLEM
at	O
HD.	B-TREATMENT

However	O
,	O
a	B-PROBLEM
septic	I-PROBLEM
component	I-PROBLEM
to	O
the	B-PROBLEM
hypotension	I-PROBLEM
was	O
also	O
considered	O
as	O
the	O
pt	O
was	O
found	O
to	O
have	O
citrobacter	B-PROBLEM
in	I-PROBLEM
her	I-PROBLEM
urine	I-PROBLEM
and	O
C	B-PROBLEM
diff	I-PROBLEM
in	I-PROBLEM
her	I-PROBLEM
stool	I-PROBLEM
.	O

Her	O
son	O
reports	O
that	O
she	O
then	O
developed	O
a	B-PROBLEM
headache	I-PROBLEM
and	O
fevers	B-PROBLEM
started	O
three	O
days	O
ago	O
which	O
were	O
treated	O
with	O
tylenol	B-TREATMENT
.	O

Then	O
,	O
this	O
morning	O
she	O
developed	O
fatigue	B-PROBLEM
and	O
did	O
not	O
eat	O
well	O
.	O

He	O
son	O
also	O
notes	O
that	O
she	O
appeared	O
to	O
be	O
working	B-PROBLEM
hard	I-PROBLEM
to	I-PROBLEM
breath	I-PROBLEM
.	O

She	O
was	O
found	O
to	O
be	O
febrile	B-PROBLEM
to	O
101.9	O
and	O
received	O
levoflox	B-TREATMENT
and	O
vancomycin	B-TREATMENT
.	O

Pt	O
was	O
then	O
sent	O
to	O
the	O
The	O
Hospital	O
for	O
Orthopedics	O
Juan	O
for	O
further	B-TEST
evaluation	I-TEST
.	O

Per	O
notes	O
,	O
pt	O
denied	O
SOB	B-PROBLEM
,	O
CP	B-PROBLEM
,	O
and	O
abdominal	B-PROBLEM
pain	I-PROBLEM
prior	O
to	O
intubation	B-TREATMENT
.	O

She	O
did	O
complain	O
of	O
a	B-PROBLEM
left	I-PROBLEM
frontal	I-PROBLEM
headache	I-PROBLEM
.	O

In	O
the	O
Juan	O
,	O
the	B-TEST
pt	I-TEST
's	I-TEST
VS	I-TEST
were	O
singificant	O
for	O
a	B-PROBLEM
fever	I-PROBLEM
of	O
103.8	O
,	O
tachycardia	B-PROBLEM
in	O
the	O
130s-150s	O
,	O
and	O
initial	B-PROBLEM
hypertensive	I-PROBLEM
in	O
the	O
140s	O
.	O

Her	B-TEST
oxygen	I-TEST
saturation	I-TEST
was	O
96%	O
on	O
RA	O
but	O
she	O
was	O
tachypneic	B-PROBLEM
to	O
31	O
.	O

She	O
was	O
obtunded	B-PROBLEM
and	O
was	O
thus	O
intubated	B-TREATMENT
for	O
airway	B-TREATMENT
protection	I-TREATMENT
.	O

Post-intubation	O
,	O
the	B-TEST
pt	I-TEST
's	I-TEST
BP	I-TEST
acutely	O
dropped	O
to	O
58/19	O
in	O
the	O
setting	O
of	O
propofol	B-TREATMENT
.	O

When	O
this	B-TREATMENT
medication	I-TREATMENT
was	O
discontinued	O
,	O
her	B-TEST
BP	I-TEST
came	O
back	O
up	O
to	O
the	O
70s-90s	O
/	O
30s-50s	O
.	O

Pt	O
was	O
then	O
initiated	O
on	O
the	B-TREATMENT
sepsis	I-TREATMENT
protocol	I-TREATMENT
.	O

In	O
the	O
Juan	O
,	O
she	O
received	O
vancomycin	B-TREATMENT
,	O
levofloxacin	B-TREATMENT
,	O
flagyl	B-TREATMENT
,	O
and	O
cefepime	B-TREATMENT
(	O
2	O
gm	O
).	O

She	O
received	O
a	O
total	O
of	O
4	O
liters	O
of	O
NS	B-TREATMENT
then	O
was	O
started	O
on	O
levophed	B-TREATMENT
for	O
continued	B-PROBLEM
hypotension	I-PROBLEM
.	O

Pt	O
is	O
now	O
transferred	O
to	O
the	O
FICU	O
for	O
further	B-TREATMENT
care	I-TREATMENT
.	O

Per	O
pt	O
's	O
son	O
,	O
she	O
is	O
bedbound	B-PROBLEM
at	O
baseline	O
due	O
to	O
her	B-PROBLEM
multiple	I-PROBLEM
LE	I-PROBLEM
femur	I-PROBLEM
fractures	I-PROBLEM
.	O

1.	O
Type	B-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM

2.	O
Diabetic	B-PROBLEM
nephropathy	I-PROBLEM
resulting	O
in	O
ESRD	B-PROBLEM
for	O
which	O
she	O
is	O
on	O
HD	B-TREATMENT
.	O

Pt	O
was	O
due	O
for	O
HD	B-TREATMENT
but	O
missed	O
it	O
secondary	O
to	O
her	B-PROBLEM
illness	I-PROBLEM
.	O

She	O
normally	O
receives	O
HD	B-TREATMENT
on	O
Mon	O
,	O
Wed	O
,	O
and	O
Fri	O
.	O

3.	O
Status	B-PROBLEM
post	I-PROBLEM
left	I-PROBLEM
femur	I-PROBLEM
fracture	I-PROBLEM

4.	O
Hyponatremia	B-PROBLEM

5.	O
Hypercholesterolemia	B-PROBLEM

6.	O
Unsteady	B-PROBLEM
gait	I-PROBLEM

7.	O
Cataracts	B-PROBLEM

8.	O
Back	B-PROBLEM
pain	I-PROBLEM

9.	O
Hypertension	B-PROBLEM

10.	O
Anemia	B-PROBLEM
of	I-PROBLEM
chronic	I-PROBLEM
disease	I-PROBLEM

11.	O
S/P	B-TREATMENT
L	I-TREATMENT
shoulder	I-TREATMENT
hemiarthroplasty	I-TREATMENT
following	O
a	B-PROBLEM
left	I-PROBLEM
humeral	I-PROBLEM
fracuture	I-PROBLEM
in	O
2018-11-10-	O
Dumas	O
was	O
complicated	O
by	O
a	B-PROBLEM
PEA	I-PROBLEM
arrest	I-PROBLEM
secondary	O
to	O
PE	B-PROBLEM
.	O

12.	O
PE	B-PROBLEM
2018-11-17	O
leading	O
to	O
PEA	B-PROBLEM
arrest	I-PROBLEM

AC	O
500	O
/	O
15	O
/	O
.50	O
/	O
PEEP	B-TREATMENT
5	O

Gen	O
-	O
Sedated	B-TREATMENT
and	O
intubated	B-TREATMENT
.	O

Anicteric	B-PROBLEM
sclera	I-PROBLEM
.	O

No	O
m,r,g	B-PROBLEM
.	O

Abdomen	O
-	O
Obese	B-PROBLEM
.	O

NT	B-PROBLEM
.	O

ND	B-PROBLEM
.	O

Extremities	O
-	O
Feet	B-PROBLEM
mildly	I-PROBLEM
cool	I-PROBLEM
.	O

2+	B-TEST
DP	I-TEST
pulses	I-TEST
bilaterally	I-TEST
.	O

2+	B-PROBLEM
pitting	I-PROBLEM
edema	I-PROBLEM
bilateral	I-PROBLEM
LE	I-PROBLEM
.	O

Skin	B-PROBLEM
breakdown	I-PROBLEM
between	I-PROBLEM
toes	I-PROBLEM
.	O

Pressure	B-PROBLEM
ulcers	I-PROBLEM
under	I-PROBLEM
bilateral	I-PROBLEM
LE	I-PROBLEM
right	O
above	O
the	O
ankles	O
.	O

Do	O
not	O
appear	O
infected	B-PROBLEM
.	O

Question	O
mild	B-PROBLEM
erythema	I-PROBLEM
and	O
warmth	B-PROBLEM
of	I-PROBLEM
left	I-PROBLEM
LE	I-PROBLEM
.	O

Neuro	O
-	O
Sedated	B-PROBLEM
.	O

LACTATE	B-TEST
-	O
1.8	O

CRP	B-TEST
-	O
46.2	O
*	O

SED	B-TEST
RATE	I-TEST
-	O
33	O
*	O

TYPE	O
-	O
MIX	B-TEST
TEMP	I-TEST
-	O
35.6	O
RATES	B-TEST
-/	O
15	O
TIDAL	B-TEST
VOL	I-TEST
-	O
500	O
PEEP	B-TREATMENT
-	O
5	O
O2	B-TEST
-	O
50	O
PO2	B-TEST
-	O
34	O
*	O
PCO2	B-TEST
-	O
39	O
PH	B-TEST
-	O
7.32	O
*	O
TOTAL	B-TEST
CO2	I-TEST
-	O
21	O
BASE	B-TEST
XS	I-TEST
-	O
-6	O

-	O
ASSIST	O
/	O
CON	O
INTUBATED	B-TREATMENT
-	O
INTUBATED	B-TREATMENT

LACTATE	B-TEST
-	O
1.6	O

GLUCOSE	B-TEST
-	O
210	O
*	O
UREA	B-TEST
N	I-TEST
-	O
29	O
*	O
CREAT	B-TEST
-	O
3.2	O
*	O
SODIUM	B-TEST
-	O
139	O
POTASSIUM	B-TEST
-	O
3.9	O
CHLORIDE	B-TEST
-	O
112	O
*	O
TOTAL	B-TEST
CO2	I-TEST
-	O
17	O
*	O
ANION	B-TEST
GAP	I-TEST
-	O
14	O

CALCIUM	B-TEST
-	O
6.2	O
*	O
PHOSPHATE	B-TEST
-	O
1.7	O
*	O
MAGNESIUM	B-TEST
-	O
0.9	O
*	O

CORTISOL	B-TEST
-	O
10.3	O

WBC	B-TEST
-	O
9.0	O
RBC	B-TEST
-	O
2.93	O
*	O
HGB	B-TEST
-	O
9.0	O
*	O
HCT	B-TEST
-	O
29.7	O
*	O
MCV	B-TEST
-	O
101	O
*	O
MCH	B-TEST
-	O
30.8	O
MCHC	B-TEST
-	O
30.4	O
*	O
RDW	B-TEST
-	O
24.1	O
*	O

NEUTS	B-TEST
-	O
65.2	O
LYMPHS	B-TEST
-	O
25.2	O
MONOS	B-TEST
-	O
6.0	O
EOS	B-TEST
-	O
3.3	O
BASOS	B-TEST
-	O
0.4	O

HYPOCHROM	B-TEST
-	O
3+	O
ANISOCYT	B-TEST
-	O
3+	O
POIKILOCY	B-TEST
-	O
1+	O
MACROCYT	B-TEST
-	O
3+	O
MICROCYT	B-TEST
-	O
1+	O

PLT	B-TEST
COUNT	I-TEST
-	O
177	O

CORTISOL	B-TEST
-	O
9.3	O

2018-12-26	O
08:28	O
PM	B-TEST
URINE	I-TEST

COLOR	B-TEST
-	O
Yellow	O
APPEAR	B-TEST
-	O
SlHazy	O
SP	O
Barajas	O
-	O
1.005	O

2018-12-26	O
08:28	O
PM	B-TEST
URINE	I-TEST

BLOOD	B-TEST
-	O
LGE	B-TEST
NITRITE	I-TEST
-	O
NEG	O
PROTEIN	B-TEST
-	O
500	O
GLUCOSE	B-TEST
-	O
TR	O
KETONE	B-TEST
-	O
NEG	O
BILIRUBIN	B-TEST
-	O
NEG	O
UROBILNGN	B-TEST
-	O
NEG	O
PH	B-TEST
-	O
7.0	O
LEUK	B-TEST
-	O
NEG	O

2018-12-26	O
08:28	O
PM	B-TEST
URINE	I-TEST

RBC	B-TEST
-	O
225	O
*	O
WBC	B-TEST
-	O
8	O
*	O
BACTERIA	B-TEST
-	O
NONE	O
YEAST	B-TEST
-	O
NONE	O
EPI	B-TEST
-	O
<	O
1	O

CK	B-TEST
(	I-TEST
CPK	I-TEST
)-	I-TEST
350	O
*	O

CK	B-TEST
-	O
MB	B-TEST
-	O
3	O
cTropnT	B-TEST
-	O
0.40	O
*	O

MICRO	O
:	O
sputum	B-TEST
12-27	O
:	O
grm	B-TEST
stn	I-TEST
and	O
cx	B-TEST
negative	O

infl	B-TEST
A	I-TEST
and	I-TEST
B	I-TEST
12-27	O
:	O
negative	O

CSF	B-TEST
grm	I-TEST
stn	I-TEST
/	O
cx	B-TEST
:	O
negative	O

urine	B-TEST
cx	I-TEST
12-26	O
:	O
>	O
100K	O
VRE	B-PROBLEM
likely	O
colonized	O
,	O
01-03	O
yest	O
and	O
VRE	B-PROBLEM

c	B-TEST
diff	I-TEST
neg	O
:	O
12-28	O
,	O
12-31	O
,	O
01-01	O
,	O
01-02	O
.	O

bld	B-TEST
cx	I-TEST
12-26	O
,	O
12-27	O
,	O
12-28	O
,	O
12-31	O
-	O
NG	O
.	O

Catheter	B-TREATMENT
tip	I-TREATMENT
01-05	O
,	O
NG	B-TREATMENT
.	O

C.	B-TEST
Diff	I-TEST
B	I-TEST
-	O
negative	O

Tunnled	B-TREATMENT
catheter	I-TREATMENT
tip	I-TREATMENT
01-08	O
-	O
ngtd	O

HERPES	B-TEST
SIMPLEX	I-TEST
VIRUS	I-TEST
PCR	I-TEST
-	O
PND	O

69	O
y/o	O
female	O
wtih	O
PMH	B-PROBLEM
significant	O
for	O
ESRD	B-PROBLEM
on	O
HD	B-TREATMENT
,	O
type	B-PROBLEM
2	I-PROBLEM
DM	I-PROBLEM
,	O
and	O
recent	B-PROBLEM
PE	I-PROBLEM
resulting	O
in	O
PEA	B-PROBLEM
arrest	I-PROBLEM
admitted	O
through	O
the	O
Juan	O
with	O
sepsis	B-PROBLEM
of	O
unknown	O
etiology	O
.	O

1.	O
Sepsis	B-PROBLEM
/	O
ID-	O
Started	O
on	O
sepsis	B-TREATMENT
protocol	I-TREATMENT
.	O

Unclear	O
etiology	O
headache	B-PROBLEM
over	O
the	O
three	O
days	O
prior	O
to	O
admission	O
in	O
association	O
with	O
fever	B-PROBLEM
was	O
concerning	O
for	O
a	O
CNS	O
etiology	O
.	O

Covered	O
broadly	O
with	O
vancomycin	B-TREATMENT
,	O
flagyl	B-TREATMENT
,	O
and	O
cefipime	B-TREATMENT
.	O

Given	O
stress	B-TREATMENT
dose	I-TREATMENT
steroids	I-TREATMENT
empirically	O
and	O
Sanchez	B-TEST
stim	I-TEST
showed	O
cortisol	B-TEST
of	O
9.3	O
-->	O
10.3	O
therefore	O
steroids	B-TREATMENT
continued	O
.	O

CXR	B-TEST
,	O
LP	B-TEST
,	O
UA	B-TEST
and	O
abdominal	B-TEST
CT	I-TEST
showed	O
no	O
sign	O
of	O
infection	B-PROBLEM
.	O

PICC	B-TREATMENT
line	I-TREATMENT
was	O
removed	O
empirically	O
.	O

Tip	B-TREATMENT
could	O
not	O
be	O
cultured	O
due	O
to	O
contamination	B-PROBLEM
.	O

Cultures	B-TEST
drawn	O
off	O
the	B-TREATMENT
HD	I-TREATMENT
cath	I-TREATMENT
are	O
negative	O
to	O
date	O
.	O

Patient	B-PROBLEM
's	I-PROBLEM
LE	I-PROBLEM
ulcers	I-PROBLEM
appear	O
chronic	O
and	O
do	O
not	O
appear	O
to	O
be	O
the	O
source	O
of	O
infection	B-PROBLEM
.	O

Her	O
left	O
knee	O
is	O
slightly	B-PROBLEM
erythematous	I-PROBLEM
compared	O
to	O
the	O
right	O
but	O
not	O
impressive	O
.	O

Nasal	B-TEST
washings	I-TEST
for	O
influenza	B-PROBLEM
were	O
negative	O
;	O
culture	B-TEST
pending	O
.	O

Steroids	B-TREATMENT
were	O
discontinued	O
.	O

On	O
12-18	O
flagyl	B-TREATMENT
and	O
cefepime	B-TREATMENT
were	O
discontinued	O
as	O
all	B-TEST
culture	I-TEST
data	I-TEST
negative	O
to	O
date	O
.	O

Plan	O
to	O
continue	O
vancomycin	B-TREATMENT
for	O
08-19	O
day	O
course	O
to	O
treat	O
empiric	B-PROBLEM
line	I-PROBLEM
infection	I-PROBLEM
.	O

Urine	B-TEST
culture	I-TEST
came	O
back	O
positive	O
for	O
VRE	B-PROBLEM
,	O
however	O
,	O
since	O
patient	O
improved	O
without	O
treatement	B-TREATMENT
(	O
ie	O
Linezolid	B-TREATMENT
)	O
initially	O
.	O

On	O
the	O
floor	O
the	B-TREATMENT
Vancomycin	I-TREATMENT
was	O
discontinued	O
as	O
the	B-TEST
catheter	I-TEST
tip	I-TEST
culture	I-TEST
was	O
negative	O
.	O

ID	O
was	O
consulted	O
who	O
suggested	O
broad	B-TREATMENT
spectrum	I-TREATMENT
antibiotics	I-TREATMENT
if	O
she	O
were	O
to	O
spike	B-PROBLEM
.	O

When	O
pt	O
spiked	O
a	B-PROBLEM
temperature	I-PROBLEM
and	O
became	O
hypotensive	B-PROBLEM
she	O
was	O
started	O
on	O
Linezolid	B-TREATMENT
was	O
started	O
for	O
presumed	O
VRE	B-PROBLEM
infection	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
urine	I-PROBLEM
.	O

She	O
was	O
also	O
started	O
on	O
fluconazole	B-TREATMENT
for	O
yeast	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
urine	I-PROBLEM
,	O
to	O
be	O
treated	O
with	O
fluconazole	B-TREATMENT
for	O
total	O
7	O
days	O
.	O

She	O
was	O
given	O
Flagyl	B-TREATMENT
for	O
presumed	O
C.	B-PROBLEM
Diff.	I-PROBLEM
Colitis	I-PROBLEM
,	O
however	O
this	O
was	O
stopped	O
when	O
C.	B-TEST
Diff	I-TEST
B	I-TEST
toxin	I-TEST
came	O
back	O
negative	O
on	O
2019-01-10	O
.	O

The	B-TREATMENT
tunneled	I-TREATMENT
catheter	I-TREATMENT
line	I-TREATMENT
was	O
changed	O
over	O
a	B-TREATMENT
wire	I-TREATMENT
and	O
the	B-TEST
tip	I-TEST
was	O
also	O
negative	O
.	O

2.	O
Respiratory	O
-	O
Intubated	B-TREATMENT
for	O
airway	B-TREATMENT
protection	I-TREATMENT
due	O
to	O
change	B-PROBLEM
in	I-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
.	O

Extubated	B-TREATMENT
12-28	O
with	O
no	O
incident	O
.	O

3.	O
ECG	B-PROBLEM
changes	I-PROBLEM
-	O
Patient	O
had	O
an	O
episode	O
of	O
chest	B-PROBLEM
pain	I-PROBLEM
during	O
her	O
hospital	O
stay	O
that	O
was	O
both	O
right	O
and	O
left	O
sided	O
with	O
no	O
radiation	O
and	O
no	O
associated	B-PROBLEM
symptoms	I-PROBLEM
.	O

ECG	B-TEST
showed	O
new	B-PROBLEM
diffuse	I-PROBLEM
TWI	I-PROBLEM
in	I-PROBLEM
all	I-PROBLEM
leads	I-PROBLEM
.	O

Cardiac	B-TEST
enzymes	I-TEST
were	O
cycled	O
and	O
were	O
normal	O
.	O

Echo	B-TEST
was	O
obtained	O
which	O
showed	O
WMA	B-PROBLEM
and	O
EF	B-TEST
of	O
35-40%	O
.	O

Pt	O
was	O
note	O
started	O
on	O
ASA	B-TREATMENT
as	O
she	O
does	O
not	O
tolerate	O
this	O
well	O
,	O
BB	B-TREATMENT
was	O
also	O
not	O
started	O
given	O
SBPs	B-TEST
in	O
the	O
110s	O
.	O

Statin	B-TREATMENT
was	O
also	O
deffered	O
.	O

She	O
may	O
be	O
started	O
on	O
ASA	B-TREATMENT
,	O
BB	B-TREATMENT
,	O
statin	B-TREATMENT
by	O
PCP	O
as	O
Stephen	O
.	O

4.	O
Shoulder	B-PROBLEM
fracture	I-PROBLEM
-	O
Patient	O
is	O
s/p	B-PROBLEM
a	I-PROBLEM
left	I-PROBLEM
hip	I-PROBLEM
fracture	I-PROBLEM
(	O
decision	O
not	O
to	O
operate	O
)	O
and	O
a	B-PROBLEM
left	I-PROBLEM
shoulder	I-PROBLEM
fracture	I-PROBLEM
with	O
hemiarthroplasty	B-TREATMENT
11-14	O
.	O

Patient	O
was	O
found	O
to	O
have	O
a	B-PROBLEM
new	I-PROBLEM
humerus	I-PROBLEM
fracture	I-PROBLEM
distal	I-PROBLEM
to	I-PROBLEM
the	I-PROBLEM
hardware	I-PROBLEM
on	O
film	B-TEST
this	O
admission	O
.	O

Assumed	O
to	O
be	O
secondary	O
to	O
trauma	B-PROBLEM
when	O
moving	O
patient	O
into	O
ambulance	O
.	O

CMED	O
service	O
was	O
consulted	O
and	O
recommended	O
wtd	B-TREATMENT
woulnd	I-TREATMENT
care	I-TREATMENT
and	O
sling	B-TREATMENT
at	O
all	O
times	O
.	O

Wound	B-TREATMENT
care	I-TREATMENT
should	O
be	O
continued	O
as	O
described	O
after	O
discharge	O
.	O

5.	O
Type	B-PROBLEM
2	I-PROBLEM
DM	I-PROBLEM
-	O
Patient	O
was	O
initially	O
covered	O
with	O
an	B-TREATMENT
insulin	I-TREATMENT
drip	I-TREATMENT
while	O
septic	B-PROBLEM
and	O
then	O
transitioned	O
back	O
to	O
insulin	B-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
.	O

6.	O
ESRD	B-PROBLEM
on	O
HD	B-TREATMENT
-	O
Pt	O
has	O
ESRD	B-PROBLEM
secondary	O
to	O
her	B-PROBLEM
DM	I-PROBLEM
and	O
is	O
on	O
HD	B-TREATMENT
.	O

She	O
was	O
dialysed	O
but	O
was	O
slightly	B-PROBLEM
limited	I-PROBLEM
by	O
hypotension	B-PROBLEM
.	O

Her	B-TREATMENT
dialysis	I-TREATMENT
was	O
managed	O
by	O
renal	O
service	O
in	O
house	O
.	O

7.	O
PE	B-PROBLEM
(	O
11-14	O
)-	O
On	O
heparin	B-TREATMENT
drip	I-TREATMENT
.	O

Restared	O
coumadin	B-TREATMENT
on	O
12-29	O
.	O

Heparin	B-TREATMENT
discontinued	O
on	O
01-01	O
when	O
INR	B-TEST
was	O
2.0	O
.	O

Coumadin	B-TREATMENT
was	O
stopped	O
and	O
she	O
received	O
fFP	B-TREATMENT
for	O
tunneled	B-TREATMENT
line	I-TREATMENT
change	I-TREATMENT
over	I-TREATMENT
a	I-TREATMENT
wire	I-TREATMENT
.	O

Coumadin	B-TREATMENT
was	O
restarted	O
at	O
a	O
dose	O
of	O
2	O
mg	O
qhs	O
.	O

This	O
should	O
be	O
titrated	O
after	O
discharge	O
for	O
INR	B-TEST
goal	I-TEST
of	O
2-3	O
.	O

8.	O
PVD	B-PROBLEM
:	O

Dry	B-PROBLEM
gangrene	I-PROBLEM
of	I-PROBLEM
toes	I-PROBLEM
bilaterally	I-PROBLEM
w/	O
necrosis	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
heels	I-PROBLEM
and	I-PROBLEM
posterior	I-PROBLEM
calf	I-PROBLEM
.	O

Continue	O
to	O
monitor	B-TEST
for	O
sign	O
of	O
infection	B-PROBLEM
.	O

On	O
vit	B-TREATMENT
C.	I-TREATMENT
and	O
zinc	B-TREATMENT
as	O
well	O
to	O
aid	O
w/	O
wound	O
healing	O
.	O

Wound	O
care	O
consult	O
given	O
anasarca	B-TREATMENT
to	O
prevent	O
decub	B-PROBLEM
.	O

9.	O
Left	O
UE	O
markedly	O
more	B-PROBLEM
edematous	I-PROBLEM
than	O
right	O
UE	O
,	O
this	O
could	O
be	O
from	O
fracture	B-PROBLEM
,	O
or	O
there	O
could	O
be	O
a	B-PROBLEM
clot	I-PROBLEM
,	O
an	B-PROBLEM
abscess	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
area	I-PROBLEM
also	O
a	O
possiblity	O
.	O

Ultrasound	B-TEST
without	O
clot	B-PROBLEM
.	O

Continue	O
elevation	B-TREATMENT
and	O
tight	B-TREATMENT
dressing	I-TREATMENT
to	I-TREATMENT
LUE	I-TREATMENT
>	O

10.	O
Access	O
-	O
Left	B-TREATMENT
IJ	I-TREATMENT
placed	O
12-26	O
in	O
Juan	O
was	O
discontinued	O
during	O
the	O
hospitilization	O
.	O

Right	B-TREATMENT
dialysis	I-TREATMENT
catheter	I-TREATMENT
(	O
2018-11-05	O
)	O
was	O
changed	O
over	O
a	B-TREATMENT
wire	I-TREATMENT
2019-01-08	O
.	O

PICC	B-TREATMENT
line	I-TREATMENT
placed	O
2019-01-08	O
,	O
this	O
should	O
be	O
discontinued	O
immediately	O
after	O
pt	O
finishes	O
the	B-TREATMENT
linezolid	I-TREATMENT
course	I-TREATMENT
.	O

1.	O
Ascorbic	B-TREATMENT
acid	I-TREATMENT
500	O
mg	O
BID	O

2.	O
Folic	B-TREATMENT
acid	I-TREATMENT
1	O
mg	O
daily	O

3.	O
Humulin	B-TREATMENT
insulin	I-TREATMENT
2	O
units	O
QAM	O

4.	O
RISS	B-TREATMENT

5.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
BID	O

6.	O
Neutra	B-TREATMENT
phos	I-TREATMENT
2	O
tabs	O
BID	O

7.	O
Vitamin	B-TREATMENT
B	I-TREATMENT
complex	I-TREATMENT
1	O
tab	O
daily	O

8.	O
Coumadin	B-TREATMENT
-	O
Dose	O
unknown	O

9.	O
Tylenol	B-TREATMENT
650	O
mg	O
Q4H	O
PRN	O

10.	O
Ondansetron	B-TREATMENT
4	O
mg	O
Q6H	O
PRN	O

1.	O
Ascorbic	B-TREATMENT
Acid	I-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

2.	O
Folic	B-TREATMENT
Acid	I-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

3.	O
Zinc	B-TREATMENT
Sulfate	I-TREATMENT
220	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

4.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

5.	O
Papain	B-TREATMENT
-	I-TREATMENT
Urea	I-TREATMENT
544	O
287	O
0616	O
unit	O
-	O
mg	O
/	O
g	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Ipratropium	B-TREATMENT
Bromide	I-TREATMENT
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
.	O

7.	O
Calcium	B-TREATMENT
Acetate	I-TREATMENT
667	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
W/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O

8.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
Hold	O
for	O
SBP	O
<	O
100	O
,	O
HR	O
<	O
60	O
.	O

9.	O
Fluconazole	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
days	O
.	O

10.	O
Insulin	B-TREATMENT
Regular	I-TREATMENT
Human	I-TREATMENT
300	O
unit	O
/	O
3	O
mL	O
Insulin	O
Pen	O
Sig	O
:	O
as	O
directed	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
Please	O
administer	O
8	O
units	O
glargine	B-TREATMENT
at	O
dinner	O
and	O
regular	B-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
as	O
prescribed	O
.	O

11.	O
Warfarin	B-TREATMENT
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
:	O
Titrate	O
dose	O
to	O
Goal	O
INR	B-TEST
03-15	O
.	O

12.	O
Linezolid	B-TREATMENT
600	O
mg	O
IV	O
Q12H	O

13.	O
Heparin	B-TREATMENT
Flush	I-TREATMENT
PICC	I-TREATMENT
(	O
100	O
units	O
/	O
ml	O
)	O
2	O
ml	O
IV	O
DAILY	O
:	O
PRN	O
10	O
ml	O
NS	O
followed	O
by	O
2	O
ml	O
of	O
100	O
Units	O
/	O
ml	O
heparin	B-TREATMENT
(	O
200	O
units	O
heparin	B-TREATMENT
)	O
each	O
lumen	B-TREATMENT
Daily	O
and	O
PRN	O
.	O

14.	O
Heparin	B-TREATMENT
Flush	I-TREATMENT
CVL	I-TREATMENT
(	O
100	O
units	O
/	O
ml	O
)	O
1	O
ml	O
IV	O
DAILY	O
:	O
PRN	O

10ml	O
NS	B-TREATMENT
followed	O
by	O
1ml	O
of	O
100	O
units/ml	O
heparin	B-TREATMENT
(	O
100	O
units	O
heparin	B-TREATMENT
)	O
each	O
lumen	B-TREATMENT
QD	O
and	O
PRN	O
.	O

15.	O
Dolasetron	B-TREATMENT
Mesylate	I-TREATMENT
12.5	O
mg	O
IV	O
Q8H	O
:	O
PRN	O

16.	O
medication	B-TREATMENT

Please	O
complete	O
a	O
total	O
14	O
day	O
course	O
of	O
linezolid	B-TREATMENT
.	O

Stop	O
linezolid	B-TREATMENT
on	O
2019-01-17	O
.	O

The	B-TREATMENT
PICC	I-TREATMENT
line	I-TREATMENT
should	O
be	O
discontinued	O
promptly	O
after	O
the	B-TREATMENT
linezolid	I-TREATMENT
course	I-TREATMENT
is	O
completed	O
.	O

Sepsis	B-PROBLEM
-?	O
source	O

Chronic	B-PROBLEM
Kidney	I-PROBLEM
disease	I-PROBLEM
-	O
on	O
hemodialysis	B-TREATMENT
type	B-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
hypercholestrolemia	B-PROBLEM
anemia	B-PROBLEM
of	I-PROBLEM
chornic	I-PROBLEM
disease	I-PROBLEM
h/o	O
PE	B-PROBLEM
,	O
s/p	B-PROBLEM
PEA	I-PROBLEM
arrest	I-PROBLEM
11-14	O

You	O
were	O
admitted	O
with	O
low	B-PROBLEM
blood	I-PROBLEM
pressure	I-PROBLEM
and	O
fevers	B-PROBLEM
likely	O
due	O
to	O
an	B-PROBLEM
infection	I-PROBLEM
.	O

Although	O
there	O
was	O
never	O
any	B-PROBLEM
bacteria	I-PROBLEM
isolated	O
from	O
the	B-TEST
blood	I-TEST
you	O
had	O
some	B-PROBLEM
bacteria	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
urine	I-PROBLEM
which	O
you	O
are	O
being	O
treated	O
for	O
.	O

It	O
is	O
important	O
that	O
you	O
complete	O
the	B-TREATMENT
antibiotic	I-TREATMENT
course	I-TREATMENT
as	O
prescribed	O
.	O

Please	O
continue	O
to	O
take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
prescirbed	O
and	O
follow	O
up	O
with	O
all	O
your	O
appointments	O
.	O

If	O
you	O
have	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
diahrrea	B-PROBLEM
or	O
fevers	B-PROBLEM
please	O
contact	O
your	O
PCP	O
.	O

Robert	O
the	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
gets	O
worse	O
please	O
return	O
to	O
emergency	O
room	O
.	O

If	O
you	O
have	O
fevers	B-PROBLEM
please	O
contact	O
your	O
PCP	O
or	O
return	O
to	O
the	O
emergency	O
room	O
.	O

Medicine	B-TREATMENT

This	O
is	O
a	O
59	O
year	O
old	O
male	O
with	O
a	O
past	O
medical	O
history	O
significant	O
for	O
an	B-TREATMENT
atrioseptal	I-TREATMENT
defect	I-TREATMENT
repair	I-TREATMENT
at	O
age	O
18	O
,	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
with	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
45%	O
and	O
a	B-PROBLEM
recent	I-PROBLEM
cardiac	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
,	O
pulmonary	B-PROBLEM
hypertension	I-PROBLEM
and	O
mitral	B-PROBLEM
regurgitation	I-PROBLEM
,	O
and	O
atrial	B-PROBLEM
fibrillation	I-PROBLEM
.	O

He	O
was	O
seen	O
by	O
his	O
primary	O
care	O
physician	O
the	O
day	O
before	O
admission	O
and	O
complained	O
of	O
two	O
weeks	O
of	O
increasing	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
fatigue	B-PROBLEM
,	O
weight	B-PROBLEM
gain	I-PROBLEM
and	O
abdominal	B-PROBLEM
fullness	I-PROBLEM
.	O

He	O
was	O
sent	O
to	O
the	O
Emergency	O
Department	O
for	O
further	B-TEST
evaluation	I-TEST
.	O

The	O
patient	O
reported	O
feeling	O
at	O
his	O
baseline	O
with	O
chronic	B-PROBLEM
mild	I-PROBLEM
dyspnea	I-PROBLEM
on	O
exertion	O
until	O
two	O
weeks	O
prior	O
to	O
admission	O
.	O

During	O
this	O
period	O
he	O
had	O
also	O
been	O
weaned	O
off	O
of	O
his	B-TREATMENT
Digoxin	I-TREATMENT
starting	O
early	O
in	O
February	O
.	O

Over	O
the	O
two	O
weeks	O
prior	O
to	O
admission	O
he	O
had	O
noticed	O
an	B-PROBLEM
increasing	I-PROBLEM
heart	I-PROBLEM
rate	I-PROBLEM
from	O
his	O
baseline	O
in	O
the	O
60s	O
to	O
a	B-TEST
heart	I-TEST
rate	I-TEST
in	O
the	O
120s	O
.	O

He	O
had	O
also	O
some	B-PROBLEM
increased	I-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
a	B-PROBLEM
10	I-PROBLEM
pound	I-PROBLEM
weight	I-PROBLEM
gain	I-PROBLEM
and	O
new	O
three	O
to	O
four	O
pillow	B-PROBLEM
orthopnea	I-PROBLEM
with	O
a	B-PROBLEM
dry	I-PROBLEM
cough	I-PROBLEM
.	O

He	O
denied	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
nausea	B-PROBLEM
or	O
vomiting	B-PROBLEM
,	O
chest	B-PROBLEM
pain	I-PROBLEM
or	O
diaphoresis	B-PROBLEM
.	O

Atrioseptal	B-TREATMENT
defect	I-TREATMENT
repair	I-TREATMENT
in	O
1970	O
,	O
cardiomyopathy	B-PROBLEM
,	O
right-sided	B-PROBLEM
congestive	I-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
,	O
pulmonary	B-PROBLEM
hypertension	I-PROBLEM
,	O
history	O
of	O
atrial	B-PROBLEM
fibrillation	I-PROBLEM
and	O
atrial	B-PROBLEM
flutter	I-PROBLEM
,	O
history	O
of	O
prostate	B-PROBLEM
cancer	I-PROBLEM
,	O
status	B-TREATMENT
post	I-TREATMENT
brachytherapy	I-TREATMENT
,	O
history	O
of	O
rectal	B-PROBLEM
bleeding	I-PROBLEM
,	O
obstructive	B-PROBLEM
sleep	I-PROBLEM
apnea	I-PROBLEM
on	O
CPAP	B-TREATMENT
.	O

ACE	B-TREATMENT
inhibitors	I-TREATMENT
,	O
possible	O
allergy	B-PROBLEM
to	O
barium	B-TREATMENT
reported	O
by	O
the	O
patient	O
during	O
a	B-TREATMENT
barium	I-TREATMENT
swallow	I-TREATMENT
25	O
years	O
ago	O
.	O

Digoxin	B-TREATMENT
0.125	O
,	O
discontinued	O
one	O
month	O
prior	O
to	O
admission	O
,	O
Toprol	B-TREATMENT
XL	I-TREATMENT
100	O
mg	O
daily	O
,	O
Trazodone	B-TREATMENT
50	O
mg	O
once	O
daily	O
,	O
Lipitor	B-TREATMENT
10	O
mg	O
daily	O
,	O
Diovan	B-TREATMENT
40	O
mg	O
daily	O
,	O
Atrovent	B-TREATMENT
/	O
Albuterol	B-TREATMENT
prn	O
,	O
Pulmicort	B-TREATMENT
,	O
Coumadin	B-TREATMENT
2.5	O
mg	O
daily	O
,	O
Vitamin	B-TREATMENT
E	I-TREATMENT
,	O
Vitamin	B-TREATMENT
C	I-TREATMENT
,	O
iron	B-TREATMENT
supplement	I-TREATMENT
.	O

White	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
10.5	O
,	O
hematocrit	B-TEST
38.1	O
,	O
platelets	B-TEST
254	O
,	O
INR	B-TEST
1.8	O
.	O

Sodium	B-TEST
140	O
,	O
potassium	B-TEST
5.2	O
,	O
BUN	B-TEST
38	O
,	O
creatinine	B-TEST
.7	O
,	O
TSH	B-TEST
1.8	O
,	O
Digoxin	B-TEST
level	I-TEST
less	O
than	O
0.2	O
.	O

Serial	B-TEST
cardiac	I-TEST
enzymes	I-TEST
negative	O
.	O

ALT	B-TEST
14	O
,	O
AST	B-TEST
31	O
,	O
alkaline	B-TEST
phosphatase	I-TEST
283	O
,	O
total	B-TEST
bilirubin	I-TEST
1.0	O
,	O
amylase	B-TEST
71	O
,	O
glucose	B-TEST
tolerance	I-TEST
test	I-TEST
317	O
.	O

Electrocardiogram	B-TEST
showed	O
atrial	B-PROBLEM
fibrillation	I-PROBLEM
with	O
rapid	B-PROBLEM
ventricular	I-PROBLEM
response	I-PROBLEM
and	O
atrial	B-PROBLEM
flutter	I-PROBLEM
.	O

Echocardiogram	B-TEST
showed	O
moderate	B-PROBLEM
dilated	I-PROBLEM
left	I-PROBLEM
atrium	I-PROBLEM
,	O
no	O
atrioseptal	B-PROBLEM
defect	I-PROBLEM
,	O
severe	B-PROBLEM
global	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypokinesis	I-PROBLEM
with	O
severe	B-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
systolic	I-PROBLEM
function	I-PROBLEM
and	O
moderately	B-PROBLEM
dilated	I-PROBLEM
right	I-PROBLEM
ventricle	I-PROBLEM
.	O

There	O
was	O
global	B-PROBLEM
hypokinesis	I-PROBLEM
apical	I-PROBLEM
throughout	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
ventricle	I-PROBLEM
and	O
abnormal	B-PROBLEM
septal	I-PROBLEM
motion	I-PROBLEM
consistent	O
with	O
right	B-PROBLEM
ventricular	I-PROBLEM
volume	I-PROBLEM
overload	I-PROBLEM
.	O

Moderate	B-PROBLEM
to	I-PROBLEM
severe	I-PROBLEM
3+	I-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
and	O
3+	B-PROBLEM
tricuspid	I-PROBLEM
regurgitation	I-PROBLEM
along	O
with	O
moderate	B-PROBLEM
pulmonary	I-PROBLEM
early	I-PROBLEM
systolic	I-PROBLEM
hypertension	I-PROBLEM
.	O

Of	O
note	O
,	O
this	B-TEST
echocardiogram	I-TEST
was	O
performed	O
when	O
the	O
patient	O
was	O
tachycardiac	B-PROBLEM
.	O

1.	O
Hypotension	B-PROBLEM
-	O
The	O
patient	O
was	O
initially	O
mildly	B-PROBLEM
hypotensive	I-PROBLEM
with	O
systolic	B-TEST
blood	I-TEST
pressures	I-TEST
in	O
the	O
80s	O
.	O

Upon	O
admission	O
it	O
was	O
unclear	O
whether	O
or	O
not	O
the	O
patient	O
was	O
volume	B-PROBLEM
overloaded	I-PROBLEM
or	O
volume	B-PROBLEM
depleted	I-PROBLEM
.	O

Initially	O
he	O
was	O
treated	O
with	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
with	O
a	O
dramatic	O
response	O
in	O
his	B-TEST
systolic	I-TEST
blood	I-TEST
pressure	I-TEST
.	O

However	O
,	O
subsequent	O
it	O
was	O
determined	O
that	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
hypotension	I-PROBLEM
may	O
have	O
been	O
related	O
to	O
his	B-PROBLEM
rapid	I-PROBLEM
ventricular	I-PROBLEM
response	I-PROBLEM
and	O
right	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

Therefore	O
the	O
focus	O
of	O
treatment	B-TREATMENT
was	O
changed	O
to	O
controlling	O
his	B-TEST
rate	I-TEST
.	O

2.	O
Atrial	B-PROBLEM
fibrillation	I-PROBLEM
-	O
The	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
Digoxin	I-TREATMENT
had	O
been	O
weaned	O
off	O
prior	O
to	O
his	O
admission	O
.	O

It	O
was	O
felt	O
that	O
this	O
potentially	O
had	O
lead	O
to	O
his	B-PROBLEM
atrial	I-PROBLEM
flutter	I-PROBLEM
and	O
atrial	B-PROBLEM
fibrillation	I-PROBLEM
with	O
rapid	B-PROBLEM
ventricular	I-PROBLEM
response	I-PROBLEM
.	O

The	O
patient	O
was	O
loaded	O
once	O
again	O
with	O
Digoxin	B-TREATMENT
and	O
his	B-TREATMENT
beta	I-TREATMENT
blocker	I-TREATMENT
was	O
increased	O
to	O
100	O
mg	O
of	O
Lopressor	B-TREATMENT
,	O
three	O
times	O
a	O
day	O
.	O

In	O
addition	O
the	O
patient	O
was	O
started	O
on	O
Verapamil	B-TREATMENT
since	O
his	B-TEST
heart	I-TEST
rate	I-TEST
had	O
remained	O
mildly	B-PROBLEM
tachycardiac	I-PROBLEM
in	O
the	O
low	O
100s	O
.	O

3.	O
Congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
-	O
During	O
the	O
initial	O
course	O
of	O
the	O
patient	O
's	O
admission	O
,	O
it	O
was	O
unclear	O
as	O
to	O
whether	O
or	O
not	O
he	O
was	O
volume	B-PROBLEM
overloaded	I-PROBLEM
or	O
volume	B-PROBLEM
depleted	I-PROBLEM
.	O

The	O
patient	O
was	O
initially	O
treated	O
with	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
,	O
however	O
,	O
subsequently	O
he	O
was	O
diuresed	O
when	O
he	O
became	O
symptomatic	B-PROBLEM
and	O
short	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

Chest	B-TEST
x-rays	I-TEST
revealed	O
evidence	O
of	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

The	O
decision	O
was	O
made	O
to	O
have	O
the	O
patient	O
undergo	O
a	B-TEST
cardiac	I-TEST
catheterization	I-TEST
to	O
fully	O
evaluate	O
the	O
hemodynamics	O
to	O
determine	O
the	O
etiology	O
of	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

In	O
addition	O
,	O
plans	O
were	O
made	O
to	O
evaluate	O
the	O
patient	O
's	O
cardiac	O
arteries	O
to	O
determine	O
if	O
he	O
had	O
any	O
component	O
of	O
ischemic	B-PROBLEM
cardiomyopathy	I-PROBLEM
.	O

4.	O
Abnormal	B-TEST
liver	I-TEST
function	I-TEST
tests	I-TEST
-	O
The	O
patient	O
had	O
an	B-PROBLEM
isolated	I-PROBLEM
,	I-PROBLEM
elevated	I-PROBLEM
alkaline	I-PROBLEM
phosphatase	I-PROBLEM
with	O
a	B-PROBLEM
confirmatory	I-PROBLEM
elevation	I-PROBLEM
in	O
his	B-TEST
gamma	I-TEST
glutamyl	I-TEST
transferase	I-TEST
.	O

An	B-TEST
ultrasound	I-TEST
of	I-TEST
the	I-TEST
right	I-TEST
upper	I-TEST
quadrant	I-TEST
did	O
not	O
reveal	O
any	B-PROBLEM
cholelithiasis	I-PROBLEM
or	O
cholecystitis	B-PROBLEM
,	O
however	O
,	O
an	B-PROBLEM
irregular	I-PROBLEM
hepatic	I-PROBLEM
contour	I-PROBLEM
was	O
seen	O
which	O
is	O
suggestive	O
of	O
underlying	B-PROBLEM
chronic	I-PROBLEM
liver	I-PROBLEM
disease	I-PROBLEM
.	O

There	O
was	O
some	O
concern	O
that	O
the	O
patient	O
may	O
have	O
a	B-PROBLEM
partial	I-PROBLEM
biliary	I-PROBLEM
obstruction	I-PROBLEM
and	O
the	O
patient	O
was	O
sent	O
for	O
an	B-TEST
magnetic	I-TEST
resonance	I-TEST
cholangiopancreatography	I-TEST
to	O
further	O
evaluate	O
the	O
biliary	O
system	O
.	O

Magnetic	B-TEST
resonance	I-TEST
cholangiopancreatography	I-TEST
did	O
not	O
reveal	O
any	O
evidence	O
of	O
biliary	B-PROBLEM
dilatation	I-PROBLEM
or	O
of	O
any	B-PROBLEM
obstructing	I-PROBLEM
pancreatic	I-PROBLEM
mass	I-PROBLEM
.	O

Again	O
seen	O
was	O
a	B-PROBLEM
slightly	I-PROBLEM
irregular	I-PROBLEM
contour	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
liver	I-PROBLEM
with	O
dilated	B-PROBLEM
hepatic	I-PROBLEM
veins	I-PROBLEM
suggesting	O
chronic	B-PROBLEM
hepatic	I-PROBLEM
vascular	I-PROBLEM
congestion	I-PROBLEM
.	O

It	O
was	O
felt	O
that	O
he	O
may	O
have	O
had	O
some	O
component	O
of	O
vascular	B-PROBLEM
congestion	I-PROBLEM
from	O
his	B-PROBLEM
congestive	I-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
as	O
well	O
as	O
possibly	O
some	B-PROBLEM
mild	I-PROBLEM
cirrhotic	I-PROBLEM
changes	I-PROBLEM
secondary	O
to	O
his	O
previous	O
alcohol	O
use	O
.	O

He	O
did	O
not	O
sleep	O
at	O
all	O
the	O
night	O
before	O
and	O
was	O
extremely	B-PROBLEM
fatigued	I-PROBLEM
.	O

He	O
was	O
walking	O
in	O
the	O
hall	O
,	O
dragging	O
his	B-TREATMENT
intravenous	I-TREATMENT
pole	I-TREATMENT
when	O
he	O
tripped	O
over	O
the	O
foot	O
of	O
the	O
pole	O
and	O
lost	O
his	O
balance	O
.	O

His	B-TEST
neurological	I-TEST
examination	I-TEST
at	O
that	O
time	O
was	O
nonfocal	O
and	O
the	O
head	O
was	O
atraumatic	B-PROBLEM
without	O
any	O
evidence	O
of	O
a	B-PROBLEM
hematoma	I-PROBLEM
.	O

A	B-TEST
computerized	I-TEST
axial	I-TEST
tomography	I-TEST
scan	I-TEST
of	I-TEST
his	I-TEST
head	I-TEST
at	O
that	O
time	O
did	O
not	O
reveal	O
any	B-PROBLEM
extra	I-PROBLEM
or	I-PROBLEM
intracranial	I-PROBLEM
hemorrhage	I-PROBLEM
.	O

6.	O
Rectal	B-PROBLEM
bleeding	I-PROBLEM
-	O
The	O
patient	O
has	O
a	O
history	O
of	O
rectal	B-PROBLEM
bleeding	I-PROBLEM
,	O
ever	O
since	O
his	B-TREATMENT
brachytherapy	I-TREATMENT
for	O
his	B-PROBLEM
prostate	I-PROBLEM
cancer	I-PROBLEM
.	O

The	O
patient	O
has	O
been	O
treated	O
with	O
Argon	B-TREATMENT
laser	I-TREATMENT
therapy	I-TREATMENT
in	O
the	O
past	O
for	O
his	B-PROBLEM
rectal	I-PROBLEM
bleeding	I-PROBLEM
and	O
it	O
is	O
recommended	O
that	O
he	O
follow	O
up	O
with	O
his	O
gastroenterologist	O
for	O
repeat	B-TREATMENT
Argon	I-TREATMENT
laser	I-TREATMENT
therapy	I-TREATMENT
.	O

Internal	B-TREATMENT
Medicine	I-TREATMENT

Her	O
renal	O
function	O
significantly	O
improved	O
,	O
and	O
her	B-TEST
discharge	I-TEST
creatinine	I-TEST
was	O
3.1	O
.	O

Of	O
note	O
,	O
her	B-TEST
blood	I-TEST
pressure	I-TEST
significantly	O
improved	O
in	O
the	O
120s-130s	O
which	O
assured	O
better	O
perfusion	O
in	O
her	O
kidneys	O
.	O

She	O
received	O
intermittent	O
doses	O
of	O
Lasix	B-TREATMENT
to	O
assure	O
overall	O
negative	O
intakes	O
and	O
outputs	O
.	O

She	O
progressed	O
beautifully	O
with	O
physical	B-TREATMENT
therapy	I-TREATMENT
and	O
occupational	B-TREATMENT
therapy	I-TREATMENT
and	O
was	O
able	O
to	O
ambulate	O
with	O
assistance	O
.	O

She	O
has	O
very	B-PROBLEM
mild	I-PROBLEM
left	I-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
pain	I-PROBLEM
which	O
is	O
largely	O
unchanged	O
.	O

1.	O
Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

2.	O
Congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

3.	O
Acute	B-PROBLEM
renal	I-PROBLEM
failure	I-PROBLEM
.	O

4.	O
Acute	B-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
.	O

5.	O
Osteomyelitis	B-PROBLEM
.	O

6.	O
Diabetes	B-PROBLEM
mellitus	I-PROBLEM
.	O

1.	O
Amiodarone	B-TREATMENT
200	O
mg	O
p.o.	O
q	O
day	O
.	O

2.	O
Warfarin	B-TREATMENT
3	O
mg	O
p.o.	O
q	O
h.s.	O

3.	O
Renagel	B-TREATMENT
1600	O
mg	O
p.o.	O
t.i.d.	O

4.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q	O
day	O
.	O

5.	O
Miconazole	B-TREATMENT
powder	I-TREATMENT
2%	O
t.i.d.	O

6.	O
Levofloxacin	B-TREATMENT
250	O
mg	O
p.o.	O
q48	O
hours	O
for	O
the	O
next	O
five	O
weeks	O
for	O
osteomyelitis	B-PROBLEM
.	O

7.	O
Flagyl	B-TREATMENT
500	O
mg	O
p.o.	O
t.i.d.	O
for	O
the	O
next	O
five	O
weeks	O
for	O
osteomyelitis	B-PROBLEM
.	O

8.	O
Protonix	B-TREATMENT
40	O
mg	O
p.o.	O
q	O
day	O
.	O

9.	O
Magnesium	B-TREATMENT
Oxide	I-TREATMENT
800	O
mg	O
p.o.	O
b.i.d.	O

10.	O
Epogen	B-TREATMENT
5000	O
units	O
two	O
times	O
weekly	O
,	O
on	O
Monday	O
and	O
Thursday	O
.	O

11.	O
Colace	B-TREATMENT
100	O
mg	O
p.o.	O
b.i.d.	O

12.	O
Lasix	B-TREATMENT
80	O
mg	O
p.o.	O
b.i.d.	O

13.	O
NPH	B-TREATMENT
insulin	I-TREATMENT
7	O
units	O
in	O
the	O
morning	O
and	O
5	O
units	O
at	O
night	O
.	O

14.	O
Regular	B-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
.	O

Tape	O
/	O
Benadryl	B-TREATMENT

Chest	B-PROBLEM
discomfort	I-PROBLEM

2015-10-30	O
Left	B-TREATMENT
Carotid	I-TREATMENT
Stenting	I-TREATMENT

2015-11-02	O
Coronary	B-TREATMENT
Artery	I-TREATMENT
Bypass	I-TREATMENT
Graft	I-TREATMENT
x	O
2	O
(	O
Lima	B-TREATMENT
to	I-TREATMENT
LAD	I-TREATMENT
,	O
SVG	B-TREATMENT
to	I-TREATMENT
OM	I-TREATMENT
)	O

Ms.	O
Bridge	O
is	O
a	O
74	O
y/o	O
female	O
admitted	O
to	O
outside	O
hospital	O
on	O
2015-10-21	O
with	O
chest	B-PROBLEM
discomfort	I-PROBLEM
,	O
vomiting	B-PROBLEM
and	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

Initial	B-TEST
EKG	I-TEST
showed	O
ST	B-PROBLEM
depressions	I-PROBLEM
,	O
but	O
cardiac	B-TEST
enzymes	I-TEST
were	O
not	O
elevated	B-PROBLEM
.	O

She	O
eventually	O
underwent	O
a	B-TEST
cardiac	I-TEST
cath	I-TEST
to	O
assess	O
coronary	B-PROBLEM
disease	I-PROBLEM
which	O
revealed	O
three	B-PROBLEM
vessel	I-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

She	O
was	O
then	O
transferred	O
to	O
The	O
Hospital	O
for	O
Orthopedics	O
for	O
surgical	B-TREATMENT
intervention	I-TREATMENT
.	O

Coronary	B-PROBLEM
Artery	I-PROBLEM
Disease	I-PROBLEM
,	O
Hypertension	B-PROBLEM
,	O
Hyperlipidemia	B-PROBLEM
,	O
Diabetes	B-PROBLEM
Mellitus	I-PROBLEM
,	O
Hypothyroid	B-PROBLEM
,	O
h/o	O
Bilateral	B-PROBLEM
DVT	I-PROBLEM
's	I-PROBLEM
(	O
on	O
chronic	B-TREATMENT
coumadin	I-TREATMENT
therapy	I-TREATMENT
),	O
Pleural	B-PROBLEM
disorder	I-PROBLEM
?	O
Sarcoidosis	B-PROBLEM
,	O
Gastritis	B-PROBLEM
,	O
B12	B-PROBLEM
deficiency	I-PROBLEM
,	O
Chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
,	O
s/p	O
Appendectomy	B-TREATMENT
,	O
s/p	O
Lap	B-TREATMENT
cholectomy	I-TREATMENT
,	O
s/p	O
Total	B-TREATMENT
abdominal	I-TREATMENT
hysterectomy	I-TREATMENT

Mother	O
died	O
of	O
MI	B-PROBLEM
at	O
age	O
55	O
.	O

Brother	O
w/	O
CAD	B-PROBLEM
since	O
age	O
40	O
and	O
died	O
in	O
70	O
's	O
after	O
cardiac	B-TREATMENT
surgery	I-TREATMENT
.	O

Son	O
died	O
at	O
14	O
d/t	O
ASD	B-PROBLEM
.	O

Gen	O
:	O
NAD	B-PROBLEM

Neck	O
:	O
Supple	O
,	O
-	O
JVD	B-PROBLEM
,	O
-	O
Bruits	B-PROBLEM

Heart	O
:	O
RRR	O
-	O
c/r/m/g	B-PROBLEM

Lungs	O
:	O
CTAB	O
,	O
coarse	B-PROBLEM

Abd	O
:	O
Soft	O
,	O
NT/NT	B-PROBLEM
+	O
BS	O

Ext	O
:	O
Cool	O
,	O
1	O
+	O
pedal	B-TEST
pulses	I-TEST
,	O
-	O
varicosities	B-PROBLEM
,	O
-	O
edema	B-PROBLEM

Some	B-PROBLEM
rashes	I-PROBLEM
on	I-PROBLEM
ACW	I-PROBLEM
around	O
EKG	B-TREATMENT
leads	I-TREATMENT

CNIS	B-TEST
10-29	O
:	O

1.	O
60-69%	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
internal	I-PROBLEM
carotid	I-PROBLEM
artery	I-PROBLEM
.	O

2.	O
80-99%	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
internal	I-PROBLEM
carotid	I-PROBLEM
artery	I-PROBLEM
.	O

Echo	B-TEST
11-02	O
:	O
PRE-BYPASS	O
:	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF>55%	B-TEST
).	O

Resting	B-PROBLEM
regional	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
include	O
mild	B-PROBLEM
apical	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
.	O

The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
.	O

There	O
are	O
complex	B-PROBLEM
(>	I-PROBLEM
4	I-PROBLEM
mm	I-PROBLEM
)	I-PROBLEM
atheroma	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
descending	I-PROBLEM
thoracic	I-PROBLEM
aorta	I-PROBLEM
.	O

Mild	B-PROBLEM
tricuspid	I-PROBLEM
regurgitation	I-PROBLEM
.	O

Trivial	B-PROBLEM
MR	I-PROBLEM
.	O

CT	B-TEST
11-04	O
:	O
No	O
acute	B-PROBLEM
intracranial	I-PROBLEM
hemorrhage	I-PROBLEM
.	O

Findings	O
consistent	O
with	O
small	B-PROBLEM
vessel	I-PROBLEM
ischemic	I-PROBLEM
changes	I-PROBLEM
.	O

MRI	B-TEST
would	O
be	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
acute	B-PROBLEM
infarction	I-PROBLEM
.	O

CT	B-TEST
angiogram	I-TEST
demonstrates	O
no	O
stenosis	B-PROBLEM
or	O
aneurysm	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
intracranial	I-PROBLEM
circulation	I-PROBLEM
.	O

Slight	B-PROBLEM
irregularity	I-PROBLEM
of	O
the	O
origin	O
of	O
the	O
right	O
vertebral	O
artery	O
may	O
be	O
atherosclerotic	B-PROBLEM
in	O
nature	O
.	O

Normal	O
contrast	O
enhancement	O
seen	O
in	O
the	B-TREATMENT
left	I-TREATMENT
common/internal	I-TREATMENT
carotid	I-TREATMENT
artery	I-TREATMENT
stent	I-TREATMENT
.	O

Mild	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
proximal	I-PROBLEM
right	I-PROBLEM
internal	I-PROBLEM
carotid	I-PROBLEM
artery	I-PROBLEM
.	O

4	B-PROBLEM
mm	I-PROBLEM
left	I-PROBLEM
upper	I-PROBLEM
lobe	I-PROBLEM
lung	I-PROBLEM
nodule	I-PROBLEM
.	O

In	O
the	O
absence	O
of	O
history	O
of	O
malignancy	B-PROBLEM
,	O
this	O
is	O
statistically	O
benign	O
.	O

CXR	B-TEST
11-06	O
:	O
Allowing	O
for	O
technical	O
changes	O
,	O
no	O
major	B-PROBLEM
adverse	I-PROBLEM
interval	I-PROBLEM
change	I-PROBLEM
has	O
occurred	O
.	O

Bibasilar	B-PROBLEM
subsegmental	I-PROBLEM
atelectasis	I-PROBLEM
together	O
with	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
appear	O
relatively	O
unchanged	O
.	O

Left-sided	B-TREATMENT
subclavian	I-TREATMENT
line	I-TREATMENT
is	O
unchanged	O
in	O
position	O
.	O

There	O
is	O
evidence	O
of	O
prior	B-TREATMENT
cardiac	I-TREATMENT
surgery	I-TREATMENT
.	O

2015-11-13	O
06:15	O
AM	O
BLOOD	O
WBC	B-TEST
-	O
8.8	O
RBC	B-TEST
-	O
2.79	O
*	O
Hgb	B-TEST
-	O
8.6	O
*	O
Hct	B-TEST
-	O
25.4	O
*	O
MCV	B-TEST
-	O
91	O
MCH	B-TEST
-	O
30.9	O
MCHC	B-TEST
-	O
33.8	O
RDW	B-TEST
-	O
15.6	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
583	O
*	O

2015-11-12	O
06:00	O
AM	O
BLOOD	O
WBC	B-TEST
-	O
7.7	O
RBC	B-TEST
-	O
2.73	O
*	O
Hgb	B-TEST
-	O
8.3	O
*	O
Hct	B-TEST
-	I-TEST
25.1	O
*	O
MCV	B-TEST
-	O
92	O
MCH	B-TEST
-	O
30.4	O
MCHC	B-TEST
-	O
33.1	O
RDW	B-TEST
-	O
15.5	O
Plt	B-TEST
Ct	I-TEST
-	O
528	O
*	O

2015-11-13	O
06:15	O
AM	O
BLOOD	O
Plt	B-TEST
Ct	I-TEST
-	O
583	O
*	O

2015-11-13	O
06:15	O
AM	O
BLOOD	O
PT	B-TEST
-	O
18.0	O
*	O
PTT	B-TEST
-	O
62.3	O
*	O
INR(PT)	B-TEST
-	O
1.7	O
*	O

2015-11-12	O
06:00	O
AM	O
BLOOD	O
PT	B-TEST
-	O
15.5	O
*	O
PTT	B-TEST
-	O
62.4	O
*	O
INR(PT)	B-TEST
-	O
1.4	O
*	O

2015-11-11	O
05:45	O
AM	O
BLOOD	O
PT	B-TEST
-	O
14.5	O
*	O
PTT	B-TEST
-	O
51.4	O
*	O
INR(PT)	B-TEST
-	O
1.3	O
*	O

2015-11-13	O
06:15	O
AM	O
BLOOD	O
Glucose	B-TEST
-	O
96	O
UreaN	B-TEST
-	O
20	O
Creat	B-TEST
-	O
1.6	O
*	O
Na	B-TEST
-	O
141	O
K	B-TEST
-	O
4.3	O
Cl	B-TEST
-	O
106	O
HCO3	B-TEST
-	O
24	O
AnGap	B-TEST
-	O
15	O

2015-11-12	O
06:00	O
AM	O
BLOOD	O
Glucose	B-TEST
-	O
85	O
UreaN	B-TEST
-	O
19	O
Creat	B-TEST
-	O
1.6	O
*	O
Na	B-TEST
-	O
140	O
K	B-TEST
-	I-TEST
4.4	O
Cl	B-TEST
-	O
105	O
HCO3	B-TEST
-	O
24	O
AnGap	B-TEST
-	I-TEST
15	O

2015-11-11	O
05:45	O
AM	O
BLOOD	O
Creat	B-TEST
-	O
1.6	O
*	O
K	B-TEST
-	O
4.7	O

2015-10-28	O
03:30	O
PM	O
BLOOD	O
Glucose	B-TEST
-	O
98	O
UreaN	B-TEST
-	O
26	O
*	O
Creat	B-TEST
-	O
1.6	O
*	O
Na	B-TEST
-	O
140	O
K	B-TEST
-	O
4.6	O
Cl	B-TEST
-	O
104	O
HCO3	B-TEST
-	O
27	O
AnGap	B-TEST
-	O
14	O

Ms.	O
Bridge	O
was	O
admitted	O
from	O
OSH	O
for	O
coronary	B-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
surgery	I-TREATMENT
.	O

She	O
underwent	O
usual	B-TEST
pre-operative	I-TEST
testing	I-TEST
along	O
with	O
carotid	B-TEST
ultrasound	I-TEST
.	O

CNIS	B-TEST
revealed	O
carotid	B-PROBLEM
stenosis	I-PROBLEM
and	O
she	O
ultimately	O
underwent	O
left	B-TREATMENT
carotid	I-TREATMENT
stenting	I-TREATMENT
by	O
vascular	O
surgery	O
on	O
10-30	O
.	O

On	O
11-02	O
she	O
was	O
brought	O
to	O
the	O
operating	O
room	O
where	O
she	O
underwent	O
a	B-TREATMENT
coronary	I-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
graft	I-TREATMENT
x	O
2	O
.	O

She	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
was	O
transferred	O
to	O
the	O
CSRU	O
for	O
invasive	B-TEST
monitoring	I-TEST
in	O
stable	O
condition	O
.	O

Later	O
on	O
op	O
day	O
sedation	B-TREATMENT
was	O
weaned	O
,	O
she	O
awoke	O
neurologically	O
intact	O
and	O
was	O
extubated	B-TREATMENT
.	O

On	O
post-op	O
day	O
one	O
chest	B-TREATMENT
tubes	I-TREATMENT
were	O
removed	O
and	O
beta	B-TREATMENT
blockers	I-TREATMENT
and	O
diuretics	B-TREATMENT
were	O
initiated	O
.	O

Early	O
on	O
post-op	O
day	O
two	O
Ms.	O
Bridge	O
had	O
an	O
episode	O
of	O
aphasia	B-PROBLEM
.	O

She	O
underwent	O
an	B-TEST
immediate	I-TEST
head	I-TEST
CT	I-TEST
and	O
Neuro	O
consult	O
and	O
was	O
transferred	O
back	O
to	O
the	O
CSRU	O
.	O

CT	B-TEST
was	O
negative	O
and	O
she	O
returned	O
to	O
baseline	O
neuro	O
status	O
without	O
deficits	B-PROBLEM
by	O
arrival	O
to	O
CSRU	O
.	O

Neurology	O
concluded	O
episode	B-PROBLEM
was	O
most	O
concerning	O
for	O
TIA	B-PROBLEM
.	O

Epicardial	B-TREATMENT
pacing	I-TREATMENT
wires	I-TREATMENT
were	O
removed	O
on	O
post-op	O
day	O
four	O
.	O

After	O
remaining	O
stable	O
in	O
the	O
CSRU	O
for	O
several	O
days	O
without	O
change	B-PROBLEM
in	I-PROBLEM
neuro	I-PROBLEM
status	I-PROBLEM
she	O
was	O
transferred	O
back	O
to	O
the	O
SDU	O
on	O
post-op	O
day	O
four	O
.	O

She	O
was	O
then	O
started	O
on	O
Heparin	B-TREATMENT
with	O
transition	O
to	O
Coumadin	B-TREATMENT
(	O
goal	O
INR	B-TEST
of	O
2-3	O
secondary	O
to	O
h/o	O
bilateral	B-PROBLEM
DVT	I-PROBLEM
's).	O

complications	B-PROBLEM
.	O

Meds	B-TREATMENT
at	O
home	O
:	O
Coumadin	B-TREATMENT
,	O
Levoxyl	B-TREATMENT
,	O
Folate	B-TREATMENT
,	O
Colace	B-TREATMENT
,	O
Byetta	B-TREATMENT
,	O
Verapamil	B-TREATMENT
,	O
Lisinopril	B-TREATMENT
,	O
Pravachol	B-TREATMENT
,	O
Nexium	B-TREATMENT
,	O
Lasix	B-TREATMENT
,	O
Celexa	B-TREATMENT

Meds	B-TREATMENT
at	O
transfer	O
:	O
Levoxyl	B-TREATMENT
,	O
Celexa	B-TREATMENT
,	O
Folate	B-TREATMENT
,	O
Lopressor	B-TREATMENT
,	O
Colace	B-TREATMENT
,	O
RISS	B-TREATMENT
,	O
B12	B-TREATMENT
,	O
Protonix	B-TREATMENT
,	O
Lasix	B-TREATMENT
,	O
Zocor	B-TREATMENT
,	O
Verapamil	B-TREATMENT
,	O
Lovenox	B-TREATMENT
,	O
Lisinopril	B-TREATMENT

1.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
).	O

3.	O
Levothyroxine	B-TREATMENT
125	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

4.	O
Simvastatin	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

5.	O
Citalopram	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

6.	O
Clopidogrel	B-TREATMENT
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

7.	O
Ferrous	B-TREATMENT
Gluconate	I-TREATMENT
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

8.	O
Ascorbic	B-TREATMENT
Acid	I-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

9.	O
Folic	B-TREATMENT
Acid	I-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

10.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

11.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

12.	O
Coumadin	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Check	O
INR	B-TEST
11-15	O
with	O
results	O
called	O
to	O
Dr.	O
Lynn	O
.	O

13.	O
Tramadol	B-TREATMENT
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

14.	O
Lasix	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
40	O
mg	O
daily	O
x	O
1	O
week	O
then	O
40	O
mg	O
every	O
other	O
day	O
as	O
prior	O
to	O
surgery	B-TREATMENT
.	O

Coronary	B-PROBLEM
Artery	I-PROBLEM
Disease	I-PROBLEM
s/p	O
Coronary	B-TREATMENT
Artery	I-TREATMENT
Bypass	I-TREATMENT
Graft	I-TREATMENT
x	O
2	O

Post-operative	B-PROBLEM
Transient	I-PROBLEM
Ischemic	I-PROBLEM
Attack	I-PROBLEM

Carotid	B-PROBLEM
Stenosis	I-PROBLEM
s/p	O
Left	B-TREATMENT
Carotid	I-TREATMENT
Stenting	I-TREATMENT

PMH	O
:	O
Hypertension	B-PROBLEM
,	O
Hyperlipidemia	B-PROBLEM
,	O
Diabetes	B-PROBLEM
Mellitus	I-PROBLEM
,	O
Hypothyroid	B-PROBLEM
,	O
h/o	O
Bilateral	B-PROBLEM
DVT	I-PROBLEM
's,	I-PROBLEM
Pleural	B-PROBLEM
disorder	I-PROBLEM
?	O
Sarcoidosis	B-PROBLEM
,	O
Gastritis	B-PROBLEM
,	O
B12	B-PROBLEM
deficiency	I-PROBLEM
,	O
Chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
,	O
s/p	O
Appendectomy	B-TREATMENT
,	O
s/p	O
Lap	B-TREATMENT
cholectomy	I-TREATMENT
,	O
s/p	O
Total	B-TREATMENT
abdominal	I-TREATMENT
hysterectomy	I-TREATMENT

No	O
creams	B-TREATMENT
,	O
lotions	B-TREATMENT
or	O
ointments	B-TREATMENT
to	O
incisions	B-PROBLEM
.	O

No	O
lifting	O
more	O
than	O
10	O
lbs	O
for	O
at	O
least	O
10	O
weeks	O
from	O
the	O
date	O
of	O
surgery	B-TREATMENT
.	O

Monitor	O
wounds	B-PROBLEM
for	O
signs	B-PROBLEM
of	I-PROBLEM
infection	I-PROBLEM
.	O
Please	O
call	O
with	O
any	O
concerns	O
or	O
questions	O
.	O

Briefly	O
,	O
this	O
is	O
a	O
57-year-old	O
gentleman	O
with	O
a	O
history	O
of	O
COPD	B-PROBLEM
,	O
status	O
post	O
intubation	B-TREATMENT
six	O
years	O
ago	O
but	O
not	O
on	O
home	B-TREATMENT
02	I-TREATMENT
with	O
recent	O
FEV1	B-TEST
27%	O
of	O
predicted	O
value	O
,	O
and	O
FEV1/FVC	B-TEST
ratio	I-TEST
56%	O
of	O
hypercholesterolemia	B-PROBLEM
,	O
who	O
was	O
admitted	O
for	O
COPD	B-PROBLEM
exacerbation	I-PROBLEM
and	O
worsening	O
of	O
upper	B-PROBLEM
respiratory	I-PROBLEM
tract	I-PROBLEM
infection	I-PROBLEM
symptoms	I-PROBLEM
for	O
a	O
week	O
prior	O
to	O
admission	O
.	O

He	O
was	O
afebrile	B-PROBLEM
with	O
stable	O
vital	O
signs	O
on	O
presentation	O
to	O

He	O
was	O
started	O
on	O
p.o.	B-TREATMENT
steroids	I-TREATMENT
and	O
to	O
CMED	O
for	O
management	B-TREATMENT
of	O
COPD	B-PROBLEM
exacerbation	I-PROBLEM
but	O
he	O
appeared	O
in	O
more	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
overnight	O
and	O
was	O
started	O
on	O
IV	B-TREATMENT
Solu-Medrol	I-TREATMENT
and	O
more	B-TREATMENT
frequent	I-TREATMENT
nebulizers	I-TREATMENT
for	O
COPD	B-PROBLEM
.	O

He	O
was	O
also	O
started	O
on	O
antibiotics	B-TREATMENT
for	O
possible	O
bronchitis	B-PROBLEM
or	O
community-acquired	B-PROBLEM
pneumonia	I-PROBLEM
.	O

Given	O
his	B-PROBLEM
tenuous	I-PROBLEM
respiratory	I-PROBLEM
status	I-PROBLEM
,	O
he	O
was	O
transferred	O
to	O
the	O
FICU	O
with	O
closer	B-TEST
observation	I-TEST
.	O

He	O
did	O
not	O
require	O
intubation	B-TREATMENT
and	O
improved	O
with	O
q.	O
two	O
hour	O
nebulizers	B-TREATMENT
and	O
chest	B-TREATMENT
PT	I-TREATMENT
.	O

He	O
was	O
again	O
transferred	O
to	O
the	O
CMED	O
Service	O
for	O
further	B-TREATMENT
management	I-TREATMENT
of	O
his	B-PROBLEM
COPD	I-PROBLEM
exacerbation	I-PROBLEM
.	O

He	O
was	O
continued	O
on	O
p.o.	B-TREATMENT
prednisone	I-TREATMENT
and	O
frequent	B-TREATMENT
nebulizers	I-TREATMENT
for	O
COPD	B-PROBLEM
.	O

He	O
was	O
evaluated	O
by	O
the	O
physical	O
therapist	O
in	O
the	O
hospital	O
and	O
was	O
found	O
to	O
desaturate	B-PROBLEM
to	O
84%	O
with	O
ambulating	O
on	O
room	O
air	O
.	O

Therefore	O
,	O
home	B-TREATMENT
02	I-TREATMENT
was	O
recommended	O
on	O
discharge	O
.	O

1.	O
Chronic	B-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
exacerbation	I-PROBLEM
.	O

2.	O
Bronchitis	B-PROBLEM
.	O

3.	O
Community-acquired	B-PROBLEM
pneumonia	I-PROBLEM
.	O

4.	O
Rule	O
out	O
myocardial	B-PROBLEM
infarction	I-PROBLEM
.	O

1.	O
Flovent	B-TREATMENT
two	O
puffs	O
b.i.d.	O

2.	O
Levofloxacin	B-TREATMENT
500	O
mg	O
p.o.	O
q.d.	O
for	O
another	O
11	O
days	O
for	O
a	O
total	O
of	O
a	O
14	O
day	O
course	O
.	O

3.	O
Albuterol	B-TREATMENT
inhaler	I-TREATMENT
one	O
to	O
two	O
puffs	O
q.	O
four	O
to	O
six	O
hours	O
p.r.n.	O

4.	O
Aspirin	B-TREATMENT
81	O
mg	O
p.o.	O
q.d.	O

5.	O
Salmeterol	B-TREATMENT
one	O
to	O
two	O
puffs	O
b.i.d.	O

6.	O
Oxygen	B-TREATMENT
2	I-TREATMENT
liters	I-TREATMENT
nasal	I-TREATMENT
cannula	I-TREATMENT
with	O
ambulating	O
as	O
needed	O
.	O

7.	O
Prednisone	B-TREATMENT
taper	I-TREATMENT
with	O
40	O
mg	O
p.o.	O
q.d.	O
for	O
two	O
days	O
,	O
30	O
mg	O
p.o.	O
q.d.	O
for	O
two	O
days	O
,	O
20	O
mg	O
p.o.	O
q.d.	O
for	O
two	O
days	O
,	O
10	O
mg	O
p.o.	O
q.d.	O
for	O
two	O
days	O
.	O

The	O
patient	O
is	O
a	O
47	O
year	O
old	O
male	O
,	O
with	O
end	B-PROBLEM
stage	I-PROBLEM
liver	I-PROBLEM
disease	I-PROBLEM
secondary	O
to	O
hepatitis	B-PROBLEM
C	I-PROBLEM
cirrhosis	I-PROBLEM
diagnosed	O
about	O
5	O
years	O
prior	O
to	O
admission	O
.	O

The	O
patient	O
had	O
undergone	O
treatment	B-TREATMENT
with	O
interferon	B-TREATMENT
and	O
Ribavirin	B-TREATMENT
.	O

He	O
had	O
been	O
admitted	O
to	O
the	O
St.	O
Margaret	O
's	O
Center	O
for	O
Women	O
&	O
Infants	O
multiple	O
times	O
early	O
in	O
2013	O
for	O
management	B-TREATMENT
of	O
encephalopathy	B-PROBLEM
and	O
ascites	B-PROBLEM
.	O

The	O
patient	O
had	O
been	O
discharged	O
from	O
the	O
St.	O
Margaret	O
's	O
Center	O
for	O
Women	O
&	O
Infants	O
on	O
2013-05-06	O
,	O
but	O
was	O
readmitted	O
on	O
2013-05-09	O
when	O
noted	O
to	O
have	O
worsening	B-PROBLEM
renal	I-PROBLEM
function	I-PROBLEM
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
serum	I-TEST
creatinine	I-TEST
on	O
the	O
day	O
of	O
discharge	O
,	O
on	O
2013-05-06	O
,	O
was	O
1.9	O
,	O
but	O
was	O
noted	O
to	O
increase	O
to	O

3.2	O
on	O
2013-05-08	O
,	O
and	O
was	O
further	B-PROBLEM
elevated	I-PROBLEM
to	O
3.6	O
on	O
2013-05-09	O
.	O

The	O
patient	O
was	O
admitted	O
with	O
concern	O
for	O
hepatorenal	B-PROBLEM
syndrome	I-PROBLEM
.	O

1.	O
Hepatitis	B-PROBLEM
C	I-PROBLEM
cirrhosis	I-PROBLEM
for	O
which	O
the	O
patient	O
was	O
on	O
the	O
liver	O
transplant	O
list	O
.	O

2.	O
Hypertension	B-PROBLEM
.	O

3.	O
Nephrolithiasis	B-PROBLEM
.	O

4.	O
Hemorrhoids	B-PROBLEM
.	O

5.	O
Knee	B-TREATMENT
surgeries	I-TREATMENT
.	O

6.	O
Back	B-TREATMENT
surgery	I-TREATMENT
.	O

1.	O
Miconazole	B-TREATMENT
nitrate	I-TREATMENT
powder	I-TREATMENT
tid	O
prn	O
for	O
groin	B-PROBLEM
rash	I-PROBLEM
.	O

2.	O
Protonix	B-TREATMENT
40	O
mg	O
po	O
bid	O
.	O

3.	O
Lactulose	B-TREATMENT
30	O
ml	O
tid	O
(	O
titrated	O
to	O
4	O
to	O
5	O
bowel	O
movements	O
qd	O
)	O
.	O

4.	O
Vancomycin	B-TREATMENT
1	O
gm	O
IV	O
bid	O
.	O

As	O
previously	O
mentioned	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
creatinine	I-TEST
at	O
the	O
time	O
of	O
admission	O
was	O
up	O
to	O
3.6	O
from	O
1.9	O
at	O
the	O
time	O
of	O
his	O
discharge	O
3	O
days	O
prior	O
.	O

Over	O
the	O
following	O
5	O
days	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
creatinine	I-TEST
improved	O
marginally	O
to	O
2.7	O
.	O

Optimization	O
of	O
his	B-TEST
fluid	I-TEST
balance	I-TEST
was	O
managed	O
by	O
the	O
medical	O
service	O
in	O
consultation	O
with	O
hepatology	O
and	O
renal	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
INR	I-TEST
on	O
admission	O
was	O
2.4	O
,	O
with	O
his	B-TEST
PT	I-TEST
level	I-TEST
being	O
18.9	O
.	O

The	O
patient	O
periodically	O
required	O
transfusions	B-TREATMENT
of	O
fresh	B-TREATMENT
frozen	I-TREATMENT
plasma	I-TREATMENT
,	O
as	O
well	O
as	O
platelets	B-TREATMENT
and	O
red	B-TREATMENT
cells	I-TREATMENT
.	O

The	O
patient	O
was	O
thrombocytopenic	B-PROBLEM
with	O
a	B-TEST
platelet	I-TEST
count	I-TEST
of	O
49	O
on	O
the	O
23	O
.	O

The	O
patient	O
was	O
continued	O
on	O
vancomycin	B-TREATMENT
therapy	I-TREATMENT
for	O
his	B-PROBLEM
previously	I-PROBLEM
diagnosed	I-PROBLEM
Methicillin	I-PROBLEM
resistant	I-PROBLEM
,	I-PROBLEM
coagulase	I-PROBLEM
negative	I-PROBLEM
Staph	I-PROBLEM
bacteremia	I-PROBLEM
.	O

The	O
patient	O
's	O
nutrition	O
was	O
suboptimal	O
,	O
and	O
the	O
patient	O
was	O
started	O
on	O
tube	B-TREATMENT
feeding	I-TREATMENT
.	O

The	O
patient	O
underwent	O
diagnostic	O
and	O
therapeutic	B-TREATMENT
paracentesis	I-TREATMENT
on	O
2013-05-16	O
,	O
2013-05-21	O
,	O
and	O
2013-05-24	O
.	O

He	O
had	O
no	O
evidence	O
of	O
spontaneous	B-PROBLEM
bacterial	I-PROBLEM
peritonitis	I-PROBLEM
.	O

On	O
2013-05-25	O
,	O
a	O
liver	O
became	O
available	O
for	O
transplant	B-TREATMENT
to	O
the	O
patient	O
.	O

The	O
patient	O
was	O
taken	O
to	O
the	O
operating	O
room	O
and	O
underwent	O
an	B-TREATMENT
orthotopic	I-TREATMENT
liver	I-TREATMENT
transplant	I-TREATMENT
.	O

In	O
order	O
to	O
aid	O
in	O
optimization	O
of	O
the	B-TEST
patient	I-TEST
's	I-TEST
fluid	I-TEST
status	I-TEST
,	O
the	O
patient	O
was	O
on	O
continuous	B-TREATMENT
Baker	I-TREATMENT
Baker	I-TREATMENT
dialysis	I-TREATMENT
during	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

His	B-PROBLEM
estimated	I-PROBLEM
blood	I-PROBLEM
loss	I-PROBLEM
was	O
2	O
liters	O
.	O

The	O
patient	O
received	O
5	O
liters	O
of	O
crystalloid	B-TREATMENT
,	O
9	O
units	O
of	O
fresh	B-TREATMENT
frozen	I-TREATMENT
plasma	I-TREATMENT
,	O
9	O
units	O
of	O
red	B-TREATMENT
cells	I-TREATMENT
,	O
6	O
units	O
of	O
platelets	B-TREATMENT
,	O
as	O
well	O
as	O
1	O
liter	O
of	O
Cell	B-TREATMENT
Saver	I-TREATMENT
.	O

The	B-TREATMENT
procedure	I-TREATMENT
proceeded	O
without	O
complications	B-PROBLEM
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
while	O
still	O
intubated	B-TREATMENT
following	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

By	O
postop	O
day	O
1	O
,	O
the	O
patient	O
was	O
awake	O
,	O
in	O
no	O
distress	B-PROBLEM
,	O
and	O
appeared	O
lucid	O
prior	O
to	O
extubation	O
.	O

The	O
patient	O
was	O
extubated	O
on	O
postop	O
day	O
1	O
without	O
any	B-PROBLEM
problems	I-PROBLEM
.	O

The	O
patient	O
was	O
on	O
a	B-TREATMENT
Lasix	I-TREATMENT
drip	I-TREATMENT
to	O
aid	O
in	O
diuresis	B-TREATMENT
,	O
and	O
was	O
ultimately	O
converted	O
to	O
oral	B-TREATMENT
Lasix	I-TREATMENT
on	O
postop	O
day	O
1	O
.	O

The	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
pain	I-TREATMENT
control	I-TREATMENT
was	O
with	O
morphine	B-TREATMENT
.	O

The	O
patient	O
required	O
2	O
units	O
of	O
fresh	B-TREATMENT
frozen	I-TREATMENT
plasma	I-TREATMENT
on	O
the	O
night	O
following	O
surgery	B-TREATMENT
,	O
and	O
1	O
unit	O
of	O
platelets	B-TREATMENT
on	O
postop	O
day	O
1	O
,	O
but	O
otherwise	O
required	O
no	O
blood	B-TREATMENT
products	I-TREATMENT
following	O
the	B-TREATMENT
liver	I-TREATMENT
transplant	I-TREATMENT
.	O

The	O
patient	O
was	O
advanced	O
per	O
protocol	O
to	O
an	B-TREATMENT
immunosuppressive	I-TREATMENT
regimen	I-TREATMENT
of	O
prednisone	B-TREATMENT
,	O
Neoral	B-TREATMENT
,	O
and	O
CellCept	B-TREATMENT
.	O

The	O
patient	O
started	O
ambulating	O
with	O
the	O
assistance	O
of	O
physical	B-TREATMENT
therapy	I-TREATMENT
following	O
transfer	O
to	O
the	O
surgical	O
floor	O
.	O

The	O
patient	O
's	O
appetite	O
improved	O
significantly	O
,	O
and	O
at	O
the	O
time	O
of	O
discharge	O
the	O
patient	O
was	O
on	O
a	O
regular	O
diet	O
with	O
no	O
tube	B-TREATMENT
feed	I-TREATMENT
supplements	I-TREATMENT
deemed	O
necessary	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
liver	I-TEST
function	I-TEST
tests	I-TEST
all	O
improved	O
appropriately	O
by	O
the	O
time	O
of	O
discharge	O
.	O

The	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
surgical	I-PROBLEM
incision	I-PROBLEM
was	O
also	O
healing	O
well	O
by	O
the	O
time	O
of	O
discharge	O
with	O
no	O
evidence	O
of	O
infection	B-PROBLEM
.	O

1.	O
Bactrim	B-TREATMENT
single	I-TREATMENT
strength	I-TREATMENT
1	O
tablet	O
po	O
qd	O
.	O

2.	O
Protonix	B-TREATMENT
40	O
mg	O
po	O
qd	O
.	O

3.	O
Metoprolol	B-TREATMENT
25	O
mg	O
po	O
bid	O
.	O

4.	O
Fluconazole	B-TREATMENT
200	O
mg	O
po	O
qd	O
.	O

5.	O
CellCept	B-TREATMENT
1	O
gm	O
po	O
bid	O
.	O

6.	O
Prednisone	B-TREATMENT
20	O
mg	O
po	O
qd	O
.	O

7.	O
Dilaudid	B-TREATMENT
prn	O
.	O

8.	O
Neoral	B-TREATMENT
500	O
mg	O
po	O
bid	O
.	O

9.	O
Valcyte	B-TREATMENT
450	O
mg	O
po	O
qod	O
.	O

10.	O
Lasix	B-TREATMENT
40	O
mg	O
bid	O
x	O
21	O
days	O
.	O

11.	O
Colace	B-TREATMENT
100	O
mg	O
po	O
bid	O
.	O

Liver	B-TREATMENT
transplant	I-TREATMENT
on	O
2013-05-25	O
.	O

Cadaveric	B-TREATMENT
pancreas	I-TREATMENT
transplantation	I-TREATMENT
.	O

The	O
patient	O
is	O
a	O
37	O
year	O
old	O
lady	O
with	O
type	B-PROBLEM
1	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
,	O
who	O
is	O
four	O
months	O
postcadaveric	B-TREATMENT
kidney	I-TREATMENT
transplantation	I-TREATMENT
and	O
now	O
has	O
good	O
graft	O
function	O
.	O

She	O
presents	O
for	O
cadaveric	B-TREATMENT
pancreas	I-TREATMENT
transplantation	I-TREATMENT
.	O

Her	B-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
has	O
been	O
complicated	O
by	O
retinopathy	B-PROBLEM
and	O
nephropathy	B-PROBLEM
as	O
well	O
as	O
peripheral	B-PROBLEM
neuropathy	I-PROBLEM
.	O

She	O
takes	O
14	O
units	O
of	O
NPH	B-TREATMENT
insulin	I-TREATMENT
twice	O
a	O
day	O
supplementing	O
with	O
a	B-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
.	O

On	O
examination	B-TEST
,	O
she	O
is	O
in	O
no	O
apparent	B-PROBLEM
distress	I-PROBLEM
and	O
is	O
alert	O
and	O
oriented	O
.	O

Her	B-TEST
chest	I-TEST
and	I-TEST
cardiovascular	I-TEST
examinations	I-TEST
are	O
unremarkable	O
.	O

She	O
is	O
afebrile	B-PROBLEM
with	O
stable	O
vital	O
signs	O
.	O

Her	O
abdomen	O
is	O
soft	O
and	O
nontender	B-PROBLEM
with	O
a	B-PROBLEM
well	I-PROBLEM
healed	I-PROBLEM
left	I-PROBLEM
lower	I-PROBLEM
quadrant	I-PROBLEM
incision	I-PROBLEM
from	O
her	B-TREATMENT
kidney	I-TREATMENT
transplantation	I-TREATMENT
.	O

She	O
underwent	O
cadaveric	B-TREATMENT
pancreas	I-TREATMENT
transplantation	I-TREATMENT
without	O
complication	B-PROBLEM
.	O

She	O
received	O
induction	B-TREATMENT
therapy	I-TREATMENT
with	O
thymoglobulin	B-TREATMENT
intraoperative	O
and	O
postoperatively	O
for	O
five	O
days	O
.	O

She	O
was	O
kept	O
on	O
a	B-TREATMENT
similar	I-TREATMENT
immunosuppressive	I-TREATMENT
regimen	I-TREATMENT
as	O
with	O
her	B-TREATMENT
kidney	I-TREATMENT
transplant	I-TREATMENT
.	O

She	O
is	O
to	O
continue	O
monitoring	O
her	B-TEST
blood	I-TEST
sugar	I-TEST
twice	O
a	O
day	O
.	O

She	O
has	O
undergone	O
full	O
teaching	O
in	O
regards	O
to	O
immunosuppressant	B-TREATMENT
medications	I-TREATMENT
.	O

In	O
addition	O
,	O
she	O
will	O
take	O
Valganciclovir	B-TREATMENT
for	O
three	O
months	O
posttransplant	O
.	O

1.	O
Status	O
post	O
cadaveric	B-TREATMENT
pancreas	I-TREATMENT
transplant	I-TREATMENT
.	O

2.	O
Type	B-PROBLEM
1	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
.	O

3.	O
End	B-PROBLEM
stage	I-PROBLEM
renal	I-PROBLEM
disease	I-PROBLEM
,	O
status	O
post	O
kidney	B-TREATMENT
transplantation	I-TREATMENT
.	O

Penicillins	B-TREATMENT
/	O
Sulfonamides	B-TREATMENT

Benzo	B-PROBLEM
overdose	I-PROBLEM

Intubation	B-TREATMENT
for	I-TREATMENT
airway	I-TREATMENT
protection	I-TREATMENT

Ms.	O
Franklin	O
is	O
a	O
34	O
-	O
year-old	O
woman	O
with	O
Bipolar	B-PROBLEM
disorder	I-PROBLEM
and	O
group	O
home	O
resident	O
who	O
by	O
way	O
of	O
EMS	O
for	O
apparent	B-PROBLEM
alprazolam	I-PROBLEM
overdose	I-PROBLEM
.	O

In	O
the	O
St.	O
Margaret	O
's	O
Center	O
for	O
Women	O
&	O
Infants	O
,	O
the	O
patient	O
was	O
lethargic	B-PROBLEM
and	O
unable	O
to	O
give	O
a	O
history	O
.	O

She	O
was	O
promptly	O
intubated	O
for	O
airway	O
protection	O
and	O
in	O
order	O
to	O
administer	O
charcoal	B-TREATMENT
.	O

Patient	O
was	O
found	O
at	O
group	O
home	O
in	O
am	O
laying	O
on	O
floor	O
by	O
bed	O
unresponsive	B-PROBLEM
,	O
last	O
seen	O
awake	O
8	O
hours	O
prior	O
at	O
dinner	O
.	O

Group	O
home	O
states	O
that	O
patient	O
"	O
may	O
have	O
taken	O
too	O
many	O
Xanax	B-TREATMENT
.	O

Patient	O
has	O
a	O
history	O
of	O
suicidal	B-PROBLEM
ideations	I-PROBLEM
and	O
self	B-PROBLEM
mutilation	I-PROBLEM
.	O

Later	O
patient	O
told	O
CMED	O
CCU	O
that	O
she	O
was	O
feeling	O
down	O
and	O
impulsively	O
ingested	O
5	O
days	O
worth	O
of	O
medications	B-TREATMENT
,	O
she	O
states	O
that	O
her	O
intent	O
at	O
that	O
time	O
was	O
to	O
end	O
her	O
life	O
.	O

1.	O
Bipolar	B-PROBLEM
disorder	I-PROBLEM
.	O

2.	O
Asthma	B-PROBLEM
.	O

3.	O
Posttraumatic	B-PROBLEM
stress	I-PROBLEM
disorder	I-PROBLEM
.	O

4.	O
GERD	B-PROBLEM

5.	O
Chronic	B-PROBLEM
constipation	I-PROBLEM
from	O
laxative	B-PROBLEM
abuse	I-PROBLEM
.	O

Two	O
sisters	O
with	O
h/o	O
depression	B-PROBLEM
and	O
suicidality	B-PROBLEM
.	O

VS	B-TEST
95.4	O
HR	B-TEST
62	O
BP	B-TEST
99/70	O
RR	B-TEST
20	O
O2Sat	B-TEST
100%	O

Intubated	B-TREATMENT
and	O
sedated	B-TREATMENT

ATNC	B-PROBLEM
,	O
Pupils	O
dialted	O
at	O
5	O
mm	O
but	O
minimally	B-PROBLEM
reactive	I-PROBLEM
,	O
anicteric	B-PROBLEM

RR	O
nl	O
S1	O
S2	O
no	O
m	B-PROBLEM

Soft	O
,	O
nd	B-PROBLEM
,	O
hypoactive	B-PROBLEM
bowel	I-PROBLEM
sounds	I-PROBLEM

WWP	B-PROBLEM
,	O
multiple	B-PROBLEM
linear	I-PROBLEM
scars	I-PROBLEM
and	O
burns	B-PROBLEM
on	I-PROBLEM
hands	I-PROBLEM
and	I-PROBLEM
arms	I-PROBLEM

Sedated	B-TREATMENT
,	O
DTRs	B-TEST
:	O

No	O
rashes	B-PROBLEM
or	O
petechiae	B-PROBLEM
,	O
linear	B-PROBLEM
and	I-PROBLEM
burn	I-PROBLEM
scars	I-PROBLEM
as	O
above	O

WBC	B-TEST
-	O
9.4	O
#	O
RBC	B-TEST
-	O
4.75	O
HGB	B-TEST
-	O
14.7	O
HCT	B-TEST
-	O
42.2	O
MCV	B-TEST
-	O
89	O
MCH	B-TEST
-	O
30.9	O
MCHC	B-TEST
-	O
34.8	O
RDW	B-TEST
-	O
13.6	O

PLT	B-TEST
COUNT	I-TEST
-	O
330	O

NEUTS	B-TEST
-	O
73.0	O
*	O
LYMPHS	B-TEST
-	O
21.8	O
MONOS	B-TEST
-	O
3.8	O
EOS	B-TEST
-	O
1.1	O
BASOS	B-TEST
-	O
0.3	O

ASA	B-TEST
-	O
NEG	O
ETHANOL	B-TEST
-	O
NEG	O
ACETMNPHN	B-TEST
-	O
NEG	O
bnzodzpn	B-TEST
-	O
NEG	O
barbitrt	B-TEST
-	O
NEG	O
tricyclic	B-TEST
-	O
POS	O

LITHIUM	B-TEST
-	O
LESS	O
THAN	O

DIGOXIN	B-TEST
-<	O
0.2	O
*	O

GLUCOSE	B-TEST
-	O
116	O
*	O
UREA	B-TEST
N	I-TEST
-	O
14	O
CREAT	B-TEST
-	O
1.0	O
SODIUM	B-TEST
-	O
137	O
POTASSIUM	B-TEST
-	O
4.5	O
CHLORIDE	B-TEST
-	O
105	O
TOTAL	B-TEST
CO2	I-TEST
-	O
20	O
*	O
ANION	B-TEST
GAP	I-TEST
-	O
17	O

CALCIUM	B-TEST
-	O
9.7	O
PHOSPHATE	B-TEST
-	O
3.7	O
MAGNESIUM	B-TEST
-	O
2.1	O

ALT	B-TEST
(	I-TEST
SGPT	I-TEST
)-	I-TEST
21	O
AST	B-TEST
(	I-TEST
SGOT	I-TEST
)-	O
40	O
ALK	B-TEST
PHOS	I-TEST
-	O
70	O
AMYLASE	B-TEST
-	O
59	O
TOT	B-TEST
BILI	I-TEST
-	O
0.4	O

LIPASE	B-TEST
-	O
66	O
*	O

2014-04-23	O
08:00	O
AM	O
URINE	B-TEST

BLOOD	B-TEST
-	O
NEG	O
NITRITE	B-TEST
-	O
NEG	O
PROTEIN	B-TEST
-	O
NEG	O
GLUCOSE	B-TEST
-	O
NEG	O
KETONE	B-TEST
-	O
TR	O
BILIRUBIN	B-TEST
-	O
NEG	O
UROBILNGN	B-TEST
-	O
NEG	O
PH	B-TEST
-	O
6.5	O
LEUK	B-TEST
-	O
NEG	O

2014-04-23	O
08:13	O
AM	O
URINE	B-TEST
bnzodzpn	B-TEST
-	O
POS	O
barbitrt	B-TEST
-	O
NEG	O
opiates	B-TEST
-	O
NEG	O
cocaine	B-TEST
-	O
NEG	O
amphetmn	B-TEST
-	O
NEG	O
mthdone	B-TEST
-	O
NEG	O

CK	B-TEST
(	I-TEST
CPK	I-TEST
)-	I-TEST
4713	O
*	O

2014-04-23	O
03:45	O
PM	O
URINE	B-TEST

UCG	B-TEST
-	O
NEGATIVE	O

D-DIMER	B-TEST
-	O
7998	O
*	O

CXR	B-TEST
:	O

Probable	O
ateletasis	B-PROBLEM
of	I-PROBLEM
lingula	I-PROBLEM
,	O
consistent	O
with	O
pneumonitis	B-PROBLEM

EKG	B-TEST
:	O

NSR	O
R	B-TEST
60	O
Normal	O
axis	O
,	O
intervals	O
,	O
incomplete	B-PROBLEM
RBBB	I-PROBLEM
,	O
flat	B-PROBLEM
T	I-PROBLEM
aVL	I-PROBLEM
,	O
V2	O
,	O
TWI	B-PROBLEM
V1	I-PROBLEM

CT	B-TEST
Chest	I-TEST
-	O
shows	O
bilateral	B-PROBLEM
segmental	I-PROBLEM
,	I-PROBLEM
subsegmental	I-PROBLEM
PEs	I-PROBLEM

B/L	B-TEST
LE	I-TEST
LENIs	I-TEST
-	O
negative	O

Patient	O
was	O
intubated	O
in	O
John	O
for	O
airway	O
protection	O
and	O
administation	O
of	O
charcoal	B-TREATMENT
.	O

Toxicology	O
consulted	O
and	O
felt	O
that	O
patient	O
most	O
likely	O
had	O
benzo	B-PROBLEM
overdose	I-PROBLEM
.	O

ABG	B-TEST
revealed	O
widened	B-PROBLEM
A-a	I-PROBLEM
gradient	I-PROBLEM
so	O
a	B-TEST
d-dimer	I-TEST
was	O
sent	O
which	O
was	O
elevated	B-PROBLEM
.	O

Patient	O
had	O
CTA	B-TEST
which	O
showed	O
bilateral	B-PROBLEM
pulmonary	I-PROBLEM
embolisms	I-PROBLEM
.	O

Patient	O
was	O
started	O
on	O
heparin	B-TREATMENT
drip	I-TREATMENT
and	O
bilateral	B-TEST
lower	I-TEST
extremeties	I-TEST
were	O
done	O
which	O
were	O
negative	O
for	O
DVT	B-PROBLEM
.	O

Overnight	O
in	O
the	O
ICU	O
patient	O
was	O
noticed	O
to	O
have	O
painful	B-PROBLEM
bullae	I-PROBLEM
on	I-PROBLEM
hands	I-PROBLEM
and	I-PROBLEM
arm	I-PROBLEM
along	O
with	O
swelling	B-PROBLEM
.	O

Dermatology	O
and	O
plastic	O
surgery	O
were	O
consulted	O
who	O
felt	O
that	O
symptoms	B-PROBLEM
were	O
due	O
to	O
trauma	B-PROBLEM
;	O
it	O
was	O
not	O
felt	O
that	O
patient	O
had	O
compartment	B-PROBLEM
syndrome	I-PROBLEM
.	O

Patient	O
was	O
gradually	O
put	O
back	O
on	O
her	B-TREATMENT
outpatient	I-TREATMENT
xanax	I-TREATMENT
dose	I-TREATMENT
of	O
1	O
mg	O
qid	O
and	O
clozaril	B-TREATMENT
was	O
restarted	O
.	O

Plastic	O
did	O
not	O
feel	O
that	O
patient	O
had	O
any	B-PROBLEM
compartment	I-PROBLEM
syndrome	I-PROBLEM
and	O
recommended	O
aggresive	B-TREATMENT
upper	I-TREATMENT
extremity	I-TREATMENT
elevation	I-TREATMENT
for	O
swelling	B-TREATMENT
reduction	I-TREATMENT
.	O

While	O
on	O
the	O
floor	O
patient	O
's	O
hands	O
improved	O
with	O
good	O
range	O
of	O
motion	O
of	O
left	O
hand	O
,	O
however	O
Jones	O
some	B-PROBLEM
poor	I-PROBLEM
range	I-PROBLEM
of	I-PROBLEM
motion	I-PROBLEM
of	O
right	O
.	O

X-ray	B-TEST
of	I-TEST
the	I-TEST
hands	I-TEST
and	I-TEST
wrist	I-TEST
were	O
obtained	O
which	O
were	O
negative	O
.	O

Patient	O
seen	O
by	O
PT	O
and	O
OT	O
who	O
recommended	O
hand	B-TREATMENT
exercises	I-TREATMENT
and	O
splints	B-TREATMENT
for	O
patient	O
.	O

Patient	O
was	O
put	O
on	O
coumadin	B-TREATMENT
that	O
was	O
bridged	O
with	O
lovenox	B-TREATMENT
unti	O
lINR	B-TREATMENT
theraputic	I-TREATMENT
01-23	O
.	O

Patient	O
conitnued	O
to	O
have	O
SI	B-PROBLEM
while	O
on	O
floor	O
and	O
was	O
transferred	O
to	O
psychiatry	O
.	O

While	O
on	O
the	O
floor	O
patient	B-TEST
's	I-TEST
urinalysis	I-TEST
suggestive	O
of	O
UTI	B-PROBLEM
and	O
was	O
put	O
on	O
6	O
day	O
course	O
of	O
levofloxacin	B-TREATMENT
.	O

Propanolol	B-TREATMENT
XL	I-TREATMENT
80	O
mg	O
qd	O

Modifinal	B-TREATMENT
100	O
mg	O
po	O
qd	O

Lamictal	B-TREATMENT
100	O
mg	O
po	O
bid	O

Alprazolam	B-TREATMENT
1	O
mg	O
po	O
qid	O

Senna	B-TREATMENT

Trazadone	B-TREATMENT
200	O
mg	O
po	O
qhs	O

Clomipramine	B-TREATMENT
100	O
mg	O
po	O
qhs	O

Pantopraozle	B-TREATMENT
40	O
mg	O
po	O
qd	O

Clozapine	B-TREATMENT
300	O
mg	O
po	O
qhs	O

Folate	B-TREATMENT
1	O
mg	O
po	O
qd	O

Multivitamin	B-TREATMENT

1.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

2.	O
Lamotrigine	B-TREATMENT
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

3.	O
Pantoprazole	B-TREATMENT
Sodium	I-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O

4.	O
Folic	B-TREATMENT
Acid	I-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

5.	O
Multivitamin	B-TREATMENT
Capsule	I-TREATMENT
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O

6.	O
Senna	B-TREATMENT
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

7.	O
Clozapine	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O

8.	O
Warfarin	B-TREATMENT
Sodium	I-TREATMENT
3	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O

9.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O

10.	O
Trazodone	B-TREATMENT
HCl	I-TREATMENT
100	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O

11.	O
Alprazolam	B-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O

12.	O
Levofloxacin	B-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
3	O
days	O
.	O

13.	O
Bisacodyl	B-TREATMENT
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O

14.	O
Nicotine	B-TREATMENT
14	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
24	O
HR	O
Transdermal	O
DAILY	O
(	O
Daily	O
)	O
.	O

Benzodiazapine	B-PROBLEM
Overdose	I-PROBLEM

Traumatic	B-PROBLEM
/	I-PROBLEM
pressure	I-PROBLEM
bullae	I-PROBLEM

Bipolar	B-PROBLEM
Disorder	I-PROBLEM

Stable	O
-	O
Swelling	B-PROBLEM
in	I-PROBLEM
hands	I-PROBLEM
reduced	O
and	O
range	O
of	O
motion	O
continue	O
to	O
improve	O
.	O

Please	O
continue	O
to	O
take	O
coumadin	B-TREATMENT
as	O
directed	O
by	O
your	O
doctors	O
until	O
told	O
to	O
stop	O
for	O
clots	B-PROBLEM
found	O
in	O
your	O
lungs	O
.	O

Please	O
continue	O
to	O
take	O
antibiotics	B-TREATMENT
as	O
directed	O
for	O
urinary	B-PROBLEM
tract	I-PROBLEM
infection	I-PROBLEM
for	O
3	O
more	O
days	O
.	O

The	O
patient	O
is	O
a	O
55	O
-	O
year-old	O
male	O
with	O
recently	B-PROBLEM
diagnosed	I-PROBLEM
abdominal	I-PROBLEM
carcinomatosis	I-PROBLEM
.	O

The	O
patient	O
presented	O
with	O
abdominal	B-PROBLEM
pain	I-PROBLEM
and	O
bloating	B-PROBLEM
and	O
was	O
found	O
to	O
have	O
a	B-PROBLEM
large	I-PROBLEM
omental	I-PROBLEM
mass	I-PROBLEM
.	O

Biopsy	B-TEST
revealed	O
adenocarcinoma	B-PROBLEM
.	O

Histochemical	B-TEST
stains	I-TEST
are	O
consistent	O
with	O
hepatobiliary	O
origin	O
.	O

Endoscopies	B-TEST
were	O
negative	O
except	O
for	O
an	B-PROBLEM
extrinsic	I-PROBLEM
mass	I-PROBLEM
present	I-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
stomach	I-PROBLEM
.	O

The	O
patient	O
presents	O
with	O
increased	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
and	O
poor	B-PROBLEM
oral	I-PROBLEM
intake	I-PROBLEM
as	O
well	O
as	O
generalized	B-PROBLEM
weakness	I-PROBLEM
.	O

On	O
presentation	O
,	O
the	O
patient	O
denied	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
and	O
cough	B-PROBLEM
.	O

1.	O
Benign	B-PROBLEM
prostatic	I-PROBLEM
hypertrophy	I-PROBLEM
.	O

2.	O
Osteoarthritis	B-PROBLEM
.	O

3.	O
Gastrointestinal	B-PROBLEM
adenocarcinoma	I-PROBLEM
(	O
as	O
noted	O
in	O
History	O
of	O
Present	O
Illness	O
)	O
.	O

Colace	B-TREATMENT
,	O
Senna	B-TREATMENT
,	O
Dulcolax	B-TREATMENT
,	O
Tylenol	B-TREATMENT
,	O
oxycodone	B-TREATMENT
as	O
needed	O
,	O
Ambien	B-TREATMENT
,	O
and	O
Protonix	B-TREATMENT
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

Mother	O
had	O
adrenal	B-PROBLEM
cancer	I-PROBLEM
.	O

Father	O
had	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

Review	B-TEST
of	I-TEST
systems	I-TEST
was	O
significant	O
for	O
progressive	B-PROBLEM
abdominal	I-PROBLEM
discomfort	I-PROBLEM
,	O
decreased	B-PROBLEM
oral	I-PROBLEM
intake	I-PROBLEM
,	O
and	O
weakness	B-PROBLEM
in	O
the	O
past	O
nine	O
weeks	O
.	O

Physical	B-TEST
examination	I-TEST
revealed	O
temperature	B-TEST
was	O
96.9	O
,	O
heart	B-TEST
rate	I-TEST
was	O
121	O
,	O
blood	B-TEST
pressure	I-TEST
was	O
122/86	O
,	O
respiratory	B-TEST
rate	I-TEST
was	O
22	O
,	O
and	O
oxygen	B-TEST
saturation	I-TEST
was	O
96%	O
on	O
room	O
air	O
.	O

In	O
general	O
,	O
the	O
patient	O
looked	O
acutely	B-PROBLEM
and	I-PROBLEM
chronically	I-PROBLEM
ill	I-PROBLEM
.	O

Head	B-TEST
,	I-TEST
eyes	I-TEST
,	I-TEST
ears	I-TEST
,	I-TEST
nose	I-TEST
,	I-TEST
and	I-TEST
throat	I-TEST
examination	I-TEST
revealed	O
the	O
oropharynx	O
was	O
clear	O
.	O

Sclerae	O
were	O
anicteric	B-PROBLEM
.	O

Cardiovascular	B-TEST
examination	I-TEST
revealed	O
tachycardic	B-PROBLEM
first	I-PROBLEM
heart	I-PROBLEM
sound	I-PROBLEM
and	I-PROBLEM
second	I-PROBLEM
heart	I-PROBLEM
sound	I-PROBLEM
.	O

No	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
,	O
or	O
gallops	B-PROBLEM
.	O

Lungs	O
revealed	O
decreased	B-PROBLEM
breath	I-PROBLEM
sounds	I-PROBLEM
and	O
dullness	B-PROBLEM
to	O
percussion	B-TEST
in	O
the	O
left	O
lung	O
base	O
.	O

The	O
abdomen	O
was	O
distended	B-PROBLEM
and	O
firm	B-PROBLEM
.	O

Extremity	B-TEST
examination	I-TEST
revealed	O
no	O
clubbing	B-PROBLEM
,	O
cyanosis	B-PROBLEM
,	O
or	O
edema	B-PROBLEM
.	O

This	O
was	O
a	O
55	O
-	O
year-old	O
gentleman	O
with	O
recently	B-PROBLEM
diagnosed	I-PROBLEM
abdominal	I-PROBLEM
carcinomatosis	I-PROBLEM
admitted	O
with	O
increased	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
and	O
poor	B-PROBLEM
oral	I-PROBLEM
intake	I-PROBLEM
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
O-CMED	O
Service	O
for	O
further	B-TREATMENT
management	I-TREATMENT
.	O

He	O
was	O
placed	O
on	O
a	B-TREATMENT
patient-controlled	I-TREATMENT
analgesia	I-TREATMENT
for	O
pain	B-TREATMENT
control	I-TREATMENT
.	O

He	O
was	O
administered	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
and	O
oral	O
diet	O
as	O
tolerated	O
.	O

On	O
the	O
night	O
of	O
05-01	O
,	O
the	O
patient	O
complained	O
of	O
increased	B-PROBLEM
vomiting	I-PROBLEM
.	O

He	O
also	O
complained	O
of	O
increased	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
"	O
difficulty	B-PROBLEM
catching	I-PROBLEM
his	I-PROBLEM
breath	I-PROBLEM
."	O

On	O
room	O
air	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
oxygen	I-TEST
saturation	I-TEST
was	O
80%	O
.	O

His	B-TEST
saturation	I-TEST
increased	O
to	O
87%	O
on	O
a	B-TREATMENT
nonrebreather	I-TREATMENT
.	O

A	B-TEST
chest	I-TEST
x-ray	I-TEST
disclosed	O
a	B-PROBLEM
left	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

The	O
patient	O
was	O
bolused	O
with	O
intravenous	B-TREATMENT
heparin	I-TREATMENT
due	O
to	O
concern	O
for	O
pulmonary	B-PROBLEM
embolism	I-PROBLEM
.	O

The	O
patient	O
became	O
more	O
comfortable	O
being	O
seated	O
upright	O
with	O
nebulizer	B-TREATMENT
treatments	I-TREATMENT
.	O

An	B-TEST
angiogram	I-TEST
was	O
done	O
which	O
disclosed	O
possible	O
subsegmental	B-PROBLEM
pulmonary	I-PROBLEM
emboli	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
upper	I-PROBLEM
lobes	I-PROBLEM
as	O
well	O
as	O
infiltrates	B-PROBLEM
consistent	O
with	O
aspiration	B-PROBLEM
pneumonia	I-PROBLEM
.	O

The	O
patient	O
was	O
placed	O
on	O
Flagyl	B-TREATMENT
and	O
Levaquin	B-TREATMENT
for	O
treatment	B-TREATMENT
of	O
pneumonia	B-PROBLEM
.	O

He	O
was	O
continued	O
on	O
heparin	B-TREATMENT
for	O
treatment	B-TREATMENT
of	O
the	B-PROBLEM
pulmonary	I-PROBLEM
emboli	I-PROBLEM
.	O

While	O
in	O
the	O
Intensive	O
Care	O
Unit	O
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
increasing	B-PROBLEM
abdominal	I-PROBLEM
distention	I-PROBLEM
.	O

On	O
05-03	O
the	O
patient	O
underwent	O
an	B-TEST
abdominal	I-TEST
ultrasound	I-TEST
with	O
paracentesis	B-TREATMENT
,	O
and	O
5	O
liters	O
of	O
fluid	B-PROBLEM
were	O
removed	O
.	O

Due	O
to	O
persistent	B-PROBLEM
gastric	I-PROBLEM
secretions	I-PROBLEM
,	O
an	B-TREATMENT
nasogastric	I-TREATMENT
tube	I-TREATMENT
was	O
placed	O
for	O
decompression	B-TREATMENT
.	O

Octreotide	B-TREATMENT
was	O
initiated	O
in	O
an	O
attempt	O
to	O
decrease	O
the	B-PROBLEM
gastric	I-PROBLEM
secretions	I-PROBLEM
.	O

He	O
was	O
noted	O
not	O
have	O
an	B-PROBLEM
increasing	I-PROBLEM
left-sided	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

A	B-TREATMENT
thoracentesis	I-TREATMENT
was	O
done	O
with	O
removal	B-TREATMENT
of	O
1.5	O
liters	O
of	O
fluid	B-PROBLEM
.	O

A	B-TREATMENT
paracentesis	I-TREATMENT
was	O
repeated	O
with	O
removal	B-TREATMENT
of	O
2.5	O
liters	O
of	O
fluid	B-PROBLEM
.	O

The	O
family	O
decided	O
to	O
pursue	O
comfort	B-TREATMENT
measures	I-TREATMENT
.	O

Morphine	B-TREATMENT
was	O
administered	O
to	O
insure	O
patient	O
's	O
comfort	O
.	O

1.	O
Gastrointestinal	B-PROBLEM
adenocarcinoma	I-PROBLEM
;	O
primary	O
unknown	O
(	O
likely	O
hepatobiliary	O
)	O
.	O

2.	O
Aspiration	B-PROBLEM
pneumonia	I-PROBLEM
.	O

3.	O
Pulmonary	B-PROBLEM
emboli	I-PROBLEM
.	O

4.	O
Hypoxia	B-PROBLEM
.	O

5.	O
Dehydration	B-PROBLEM
.	O

6.	O
Ileus	B-PROBLEM
.	O

Erythromycin	B-TREATMENT
Base	I-TREATMENT

Syncope	B-PROBLEM
.	O

45M	O
w/no	O
PMH	O
presented	O
to	O
Chelseahospital	O
after	O
a	B-PROBLEM
syncopal	I-PROBLEM
episode	I-PROBLEM
on	O
the	O
morning	O
of	O
admission	O
.	O

Pt	O
was	O
preparing	O
lunch	O
when	O
suddenly	O
felt	O
lightheaded	B-PROBLEM
/	O
faint	B-PROBLEM
and	O
immediately	O
fell	O
to	O
the	O
kitchen	O
floor	O
face	O
first	O
.	O

He	O
denies	O
LOC	B-PROBLEM
.	O

Immediately	O
there	O
after	O
he	O
was	O
very	B-PROBLEM
short	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
felt	O
lightheaded	B-PROBLEM
again	O
and	O
called	O
911	O
.	O

At	O
Springfield	O
,	O
CT	B-TEST
chest	I-TEST
was	O
positive	O
for	O
saddle	B-PROBLEM
PE	I-PROBLEM
.	O

VS	B-TEST
were	O
with	O
stable	O
BPs	O
,	O
tachy	B-PROBLEM
to	O
110-120	O
,	O
sat	B-TEST
98%	O
RA	O
.	O

He	O
received	O
Lovenox	B-TREATMENT
91	O
mg	O
SC	O
prior	O
to	O
transport	O
and	O
was	O
transferred	O
to	O
Arbour	O
Hospital	O
for	O
further	O
care	O
.	O

He	O
was	O
essentially	B-PROBLEM
bed	I-PROBLEM
bound	I-PROBLEM
for	O
3	O
days	O
prior	O
to	O
admission	O
,	O
unable	B-PROBLEM
to	I-PROBLEM
ambulate	I-PROBLEM
.	O

He	O
started	O
to	O
notice	O
inflammation	B-PROBLEM
of	I-PROBLEM
his	I-PROBLEM
L	I-PROBLEM
calf	I-PROBLEM
/	I-PROBLEM
leg	I-PROBLEM
worse	O
2	O
days	O
prior	O
to	O
presentation	O
.	O

In	O
this	O
2	O
week	O
interval	O
he	O
denied	O
having	O
CP	B-PROBLEM
/	O
chest	B-PROBLEM
discomfort	I-PROBLEM
or	O
difficulty	B-PROBLEM
breathing	I-PROBLEM
,	O
no	O
cough	B-PROBLEM
or	O
hemoptysis	B-PROBLEM
.	O

No	O
f/c/	B-PROBLEM
sweats	B-PROBLEM
.	O

Pt	O
denied	O
any	B-PROBLEM
bleeding	I-PROBLEM
or	I-PROBLEM
clotting	I-PROBLEM
disorders	I-PROBLEM
and	O
has	O
never	O
had	O
a	B-PROBLEM
clot	I-PROBLEM
in	O
the	O
past	O
.	O

Left	B-PROBLEM
knee	I-PROBLEM
injury	I-PROBLEM
.	O

Seasonal	B-PROBLEM
allergies	I-PROBLEM
.	O

HTN	B-PROBLEM
,	O
DM	B-PROBLEM

COPD	B-PROBLEM
,	O
Prostate	B-PROBLEM
CA	I-PROBLEM

-	O
Grandfather	O
died	O
of	O
MI	B-PROBLEM
at	O
age	O
75	O

VS	B-TEST
:	O
99.4	O
HR	B-TEST
111	O
BP	B-TEST
110/64	O
RR16	B-TEST
97%	O
2LNC	B-TREATMENT

GEN	O
:	O
NAD	B-PROBLEM
,	O
pleasant	O
speaking	O
in	O
full	O
sentences	O

HEENT	O
:	O
MMM	O
,	O
OP	O
clear	O
,	O
dried	B-PROBLEM
blood	I-PROBLEM
in	I-PROBLEM
nasal	I-PROBLEM
mucosa	I-PROBLEM

RESP	O
:	O
CTABL	O
,	O
no	O
crackles	B-PROBLEM
,	O
no	O
wheezing	B-PROBLEM
or	O
rhonchi	B-PROBLEM

CV	O
:	O
Reg	O
,	O
tachy	B-PROBLEM
Nml	O
S1	O
,	O
S2	O
,	O
no	O
M/R/G	B-PROBLEM

ABD	O
:	O
soft	O
ND/NT	B-PROBLEM
+BS	O

EXT	O
:	O
L	B-PROBLEM
leg/calf	I-PROBLEM
swollen	I-PROBLEM
,	O
+	O
Johnson	B-TEST
sign	I-TEST
,	O
not	O
tense	B-PROBLEM
,	O
no	O
cord	O
palpable	O
,	O
L	O
knee	O
w/	O
medial	B-PROBLEM
meniscus	I-PROBLEM
area	I-PROBLEM
inflammed	I-PROBLEM
,	O
not	O
warm	B-PROBLEM
,	O
no	O
crepitus	B-PROBLEM
,	O
feet-2+DP	B-TEST
pulses	I-TEST
b/l	O

1.	O
CT	B-TEST
OF	I-TEST
HEAD	I-TEST
WITHOUT	I-TEST
CONTRAST	I-TEST
:	O

No	O
evidence	O
of	O
acute	B-PROBLEM
intracranial	I-PROBLEM
hemorrhage	I-PROBLEM
or	O
fractures	B-PROBLEM
.	O

2.	O
ECHO	B-TEST

The	B-TEST
estimated	I-TEST
right	I-TEST
atrial	I-TEST
pressure	I-TEST
is	O
16-20	O
mmHg	O
.	O

Left	B-TEST
ventricular	I-TEST
wall	I-TEST
thicknesses	I-TEST
are	O
normal	O
.	O

The	B-TEST
left	I-TEST
ventricular	I-TEST
cavity	I-TEST
is	O
small	O
.	O

Left	B-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
hyperdynamic	B-PROBLEM
(	O
EF	B-TEST
>	O
75%	O
)	O
.	O

There	O
is	O
no	O
ventricular	B-PROBLEM
septal	I-PROBLEM
defect	I-PROBLEM
.	O

The	O
right	O
ventricular	O
cavity	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
.	O

Right	B-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
borderline	O
normal	O
.	O

The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
.	O

There	O
is	O
no	O
mitral	B-PROBLEM
valve	I-PROBLEM
prolapse	I-PROBLEM
.	O

There	O
is	O
moderate	B-PROBLEM
pulmonary	I-PROBLEM
artery	I-PROBLEM
systolic	I-PROBLEM
hypertension	I-PROBLEM
.	O

There	O
is	O
no	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
.	O

Impression	O
:	O
mildly	B-PROBLEM
dilated	I-PROBLEM
right	I-PROBLEM
ventricle	I-PROBLEM
;	O
small	B-PROBLEM
,	I-PROBLEM
hyperdynamic	I-PROBLEM
left	I-PROBLEM
ventricle	I-PROBLEM
;	O
at	O
least	O
moderate	B-PROBLEM
pulmonary	I-PROBLEM
hypertension	I-PROBLEM

3.	O
BILATERAL	B-TEST
LENI	I-TEST
's	I-TEST

No	O
evidence	O
of	O
DVT	B-PROBLEM
in	I-PROBLEM
either	I-PROBLEM
lower	I-PROBLEM
limb	I-PROBLEM
.	O

OSH	B-TEST
IMAGING	I-TEST
:	O

-	O
saddle	B-PROBLEM
PE	I-PROBLEM
,	O
no	O
CD	O
or	O
report	O
sent	O

EKG	B-TEST
:	O

-	O
Sinus	B-PROBLEM
Tach	I-PROBLEM
,	O
normal	O
axis	O
HR	B-TEST
119	O
ST	B-PROBLEM
Depression	I-PROBLEM
V3-V5	I-PROBLEM
;	O
S1Q3T3	B-PROBLEM
,	O
p-pulmonale	B-PROBLEM
.	O

01-11	O
MRI	B-TEST
Left	I-TEST
Knee	I-TEST
w/o	I-TEST
Contrast	I-TEST

1.	O
Bucket	B-PROBLEM
handle	I-PROBLEM
medial	I-PROBLEM
meniscal	I-PROBLEM
tear	I-PROBLEM
with	O
flipped	B-PROBLEM
fragment	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
intercondylar	I-PROBLEM
notch	I-PROBLEM
.	O

Complex	B-PROBLEM
tear	I-PROBLEM
involving	O
the	O
posterior	O
Ellison	O
and	O
body	O
.	O

2.	O
Moderate	B-PROBLEM
knee	I-PROBLEM
joint	I-PROBLEM
effusion	I-PROBLEM
with	O
possible	O
ganglion	B-PROBLEM
cyst	I-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
insertion	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
PCL	I-PROBLEM
.	O

3.	O
Discoid	B-PROBLEM
lateral	I-PROBLEM
meniscus	I-PROBLEM
.	O

Mr.	O
Anders	O
was	O
admitted	O
for	O
anticoagulation	B-TREATMENT
and	O
hemodynamic	B-TEST
monitoring	I-TEST
in	O
the	O
setting	O
of	O
saddle	B-PROBLEM
pulmonary	I-PROBLEM
embolus	I-PROBLEM
and	O
left	B-PROBLEM
knee	I-PROBLEM
injury	I-PROBLEM
.	O

#.	O
PE	B-PROBLEM
:	O

Given	O
no	O
other	O
risk	O
factors	O
or	O
likely	O
causes	O
,	O
the	O
most	O
likely	O
etiology	O
for	O
his	B-PROBLEM
embolus	I-PROBLEM
is	O
DVT	B-PROBLEM
from	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
leg	I-PROBLEM
.	O

He	O
has	O
no	O
known	B-PROBLEM
clotting	I-PROBLEM
disorder	I-PROBLEM
but	O
did	O
have	O
trauma	B-PROBLEM
to	I-PROBLEM
leg	I-PROBLEM
prompting	O
immobility	B-PROBLEM
and	O
stasis	B-PROBLEM
.	O

He	O
remained	O
hemodynmically	O
stable	O
throughout	O
his	O
hospitalization	O
and	O
did	O
not	O
have	O
an	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
upon	O
discharge	O
.	O

Given	O
no	O
evidence	O
of	O
hemodynamic	B-PROBLEM
instability	I-PROBLEM
,	O
lysis	B-TREATMENT
was	O
not	O
required	O
.	O

He	O
was	O
anticoagulated	O
with	O
heparin	B-TREATMENT
and	O
coumadin	B-TREATMENT
.	O

He	O
will	O
need	O
to	O
follow	O
up	O
with	O
hematology	O
for	O
an	B-TEST
outpatient	I-TEST
thrombophilia	I-TEST
work-up	I-TEST
(	O
not	O
done	O
as	O
inpatient	O
as	O
results	O
would	O
not	O
change	O
acute	B-TREATMENT
management	I-TREATMENT
of	O
PE	B-PROBLEM
).	O

He	O
will	O
also	O
require	O
close	O
follow	O
up	O
with	O
his	O
primary	O
care	O
provider	O
for	O
coumadin	B-TREATMENT
management	I-TREATMENT
.	O

Duration	O
of	O
his	B-TREATMENT
coumadin	I-TREATMENT
therapy	I-TREATMENT
to	O
be	O
determined	O
by	O
hematology	O
,	O
but	O
likely	O
to	O
be	O
at	O
least	O
6	O
months	O
in	O
duration	O
.	O

#.	O
Syncope	B-PROBLEM
:	O

In	O
setting	O
of	O
PE	B-PROBLEM
.	O

Remainder	O
of	O
his	B-TEST
cardiac	I-TEST
workup	I-TEST
was	O
negative	O
.	O

He	O
did	O
have	O
a	B-PROBLEM
small	I-PROBLEM
troponin	I-PROBLEM
leak	I-PROBLEM
,	O
felt	O
to	O
be	O
related	O
to	O
right	B-PROBLEM
heart	I-PROBLEM
strain	I-PROBLEM
in	O
the	O
setting	O
of	O
P-pulmonale	B-PROBLEM
related	O
to	O
clot	B-PROBLEM
burden	I-PROBLEM
.	O

His	B-TEST
tronponin	I-TEST
quickly	O
trended	O
down	O
and	O
he	O
did	O
not	O
have	O
EKG	B-TEST
evidence	O
of	O
ischemia	B-PROBLEM
.	O

An	B-TEST
ECHO	I-TEST
did	O
not	O
reveal	O
any	B-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
related	O
to	O
ischemia	B-PROBLEM
.	O

#.	O
Hematocrit	B-TEST
:	O

Dropped	O
from	O
42.7	O
to	O
36	O
in	O
setting	O
of	O
anticoagulation	B-TREATMENT
for	O
saddle	B-PROBLEM
PE	I-PROBLEM
and	O
IV	B-TREATMENT
fluids	I-TREATMENT
.	O

No	O
active	B-PROBLEM
bleeding	I-PROBLEM
noted	O
.	O

Pt	O
asymptomatic	B-PROBLEM
.	O

#.	O
L	B-PROBLEM
knee	I-PROBLEM
injury	I-PROBLEM
:	O

Given	O
his	O
history	O
and	O
physical	B-TEST
exam	I-TEST
,	O
Mr.	O
Anders	O
presented	O
with	O
an	B-PROBLEM
injury	I-PROBLEM
most	O
consistent	O
with	O
meniscal	B-PROBLEM
tear	I-PROBLEM
.	O

In	O
order	O
to	O
facilitate	O
therapy	B-TREATMENT
and	O
to	O
promote	O
mobility	O
,	O
an	B-TEST
MRI	I-TEST
of	I-TEST
the	I-TEST
knee	I-TEST
was	O
done	O
.	O

He	O
was	O
seen	O
by	O
physical	O
therapy	O
and	O
will	O
need	O
to	O
follow	O
up	O
with	O
orthopaedics	O
upon	O
discharge	O
for	O
repeat	B-TEST
evaluation	I-TEST
.	O

-	O
Claritin	B-TREATMENT
prn	O

-	O
Flonase	B-TREATMENT
prn	O

Pulmonary	B-PROBLEM
embolus	I-PROBLEM

Left	B-PROBLEM
knee	I-PROBLEM
meniscal	I-PROBLEM
tear	I-PROBLEM

You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
a	B-PROBLEM
pulmonary	I-PROBLEM
embolism	I-PROBLEM
.	O

You	O
were	O
treated	O
with	O
blood	B-TREATMENT
thinners	I-TREATMENT
.	O

You	O
have	O
been	O
started	O
on	O
an	B-TREATMENT
oral	I-TREATMENT
blood	I-TREATMENT
thinner	I-TREATMENT
called	O
Coumadin	B-TREATMENT
(	I-TREATMENT
Warfarin	I-TREATMENT
).	O

Please	O
continue	O
to	O
take	O
this	B-TREATMENT
medication	I-TREATMENT
as	O
prescribed	O
.	O

You	O
must	O
have	O
your	B-TEST
INR	I-TEST
(	O
blood	B-TEST
levels	I-TEST
)	O
checked	O
on	O
a	O
regular	O
basis	O
until	O
your	B-TEST
INR	I-TEST
levels	I-TEST
remain	O
01-19	O
.	O

The	B-TEST
MRI	I-TEST
of	I-TEST
your	I-TEST
knee	I-TEST
showed	O
a	B-PROBLEM
meniscal	I-PROBLEM
tear	I-PROBLEM
.	O

Please	O
schedule	O
an	O
appointment	O
with	O
your	O
orthopedic	O
surgeon	O
to	O
determine	O
a	O
plan	O
for	O
treatment	B-TREATMENT
.	O

Please	O
return	O
to	O
the	O
hospital	O
if	O
you	O
experience	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
lightheadedness	B-PROBLEM
or	O
dizziness	B-PROBLEM
.	O

This	O
is	O
a	O
55-year-old	O
female	O
with	O
multiple	O
prior	O
admissions	O
for	O
pneumonia	B-PROBLEM
,	O
COPD	B-PROBLEM
,	O
asthma	B-PROBLEM
exacerbation	I-PROBLEM
,	O
over	O
3	O
weeks	O
of	O
upper	B-PROBLEM
respiratory	I-PROBLEM
like	I-PROBLEM
infection	I-PROBLEM
unremitting	O
with	O
increased	B-TREATMENT
nebulizer	I-TREATMENT
treatments	I-TREATMENT
at	O
home	O
.	O

The	O
patient	O
saw	O
her	O
PCP	O
and	O
was	O
known	O
to	O
have	O
an	B-TEST
oxygen	I-TEST
saturation	I-TEST
of	O
82	O
to	O
85	O
percent	O
on	O
room	O
air	O
.	O

In	O
the	O
Emergency	O
Department	O
,	O
the	O
patient	O
received	O
Zithromax	B-TREATMENT
,	O
ceftriaxone	B-TREATMENT
,	O
and	O
Flagyl	B-TREATMENT
.	O

Chest	B-TEST
x-ray	I-TEST
was	O
remarkable	O
for	O
a	O
questionable	O
left	B-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
infiltrate	I-PROBLEM
.	O

The	O
patient	O
received	O
nebulizer	B-TREATMENT
treatment	I-TREATMENT
with	O
oxygen	B-TEST
saturations	I-TEST
increasing	O
up	O
to	O
98	O
percent	O
on	O
room	O
air	O
.	O

Asthma	B-PROBLEM
/	O
COPD	B-PROBLEM
on	O
BiPAP	B-TREATMENT
,	O
history	O
of	O
intubation	B-TREATMENT
.	O

Restrictive	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
.	O

Chronic	B-PROBLEM
inflammatory	I-PROBLEM
demyelinating	I-PROBLEM
polyradiculopathy	I-PROBLEM
.	O

Gastritis	B-PROBLEM
and	O
duodenitis	B-PROBLEM
.	O

Question	O
of	O
Tyrone	B-PROBLEM
esophagus	I-PROBLEM
.	O

Chronic	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
.	O

Neurogenic	B-PROBLEM
bladder	I-PROBLEM
.	O

Chronic	B-PROBLEM
muscle	I-PROBLEM
spasms	I-PROBLEM
.	O

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
status	O
post	O
negative	O
stress	B-TEST
echo	I-TEST
on	O
10-12	O
.	O

History	O
of	O
syncope	B-PROBLEM
.	O

Adrenal	B-PROBLEM
insufficiency	I-PROBLEM
.	O

Hypercholesterolemia	B-PROBLEM
.	O

Depression	B-PROBLEM
and	O
anxiety	B-PROBLEM
.	O

Hyperthyroidism	B-PROBLEM
.	O

IgG	B-PROBLEM
deficiency	I-PROBLEM
.	O

Status	O
post	O
cholecystectomy	B-TREATMENT
and	O
appendectomy	B-TREATMENT
.	O

Anemia	B-PROBLEM
of	O
chronic	B-PROBLEM
disease	I-PROBLEM
.	O

AZMACORT	B-TREATMENT
,	O
CLINDAMYCIN	B-TREATMENT
,	O
VERSED	B-TREATMENT
,	O
FENTANYL	B-TREATMENT
,	O
and	O
MORPHINE	B-TREATMENT
.	O

Married	O
with	O
children	O
,	O
wheelchair	B-PROBLEM
bound	I-PROBLEM
mostly	O
.	O

From	O
admission	O
,	O
vital	B-TEST
signs	I-TEST
98.3	O
,	O
blood	B-TEST
pressure	I-TEST
128/74	O
,	O
68	O
to	O
112	O
is	O
her	B-TEST
heart	I-TEST
rate	I-TEST
,	O
respiratory	B-TEST
rate	I-TEST
24	O
,	O
100	O
percent	O
on	O
room	O
air	O
.	O

She	O
is	O
a	O
chronically	O
ill-appearing	O
female	O
,	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Cardiac	B-TEST
exam	I-TEST
:	O

Pulmonary	B-TEST
exam	I-TEST
:	O

Diffuse	B-PROBLEM
bronchial	I-PROBLEM
breath	I-PROBLEM
sounds	I-PROBLEM
,	O
no	O
wheezes	B-PROBLEM
.	O

Abdominal	B-TEST
exam	I-TEST
:	O

Extremity	B-TEST
exam	I-TEST
:	O

No	O
edema	B-PROBLEM
.	O

Left	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
and	I-PROBLEM
left	I-PROBLEM
upper	I-PROBLEM
extremity	I-PROBLEM
weaker	I-PROBLEM
at	O
3/5	O
compared	O
to	O
right	O
upper	O
extremity	O
and	O
right	O
lower	O
extremity	O
,	O
chronic	O
according	O
to	O
the	O
patient	O
.	O

1.	O
Vitamin	B-TREATMENT
D	I-TREATMENT
400	O
mg	O
q.d.	O

2.	O
Levoxyl	B-TREATMENT
50	O
mcg	O
q.d.	O

3.	O
Baclofen	B-TREATMENT
20	O
mg	O
p.o.	O
t.i.d.	O

4.	O
Florinef	B-TREATMENT
0.1	O
mg	O
p.o.	O
q.a.m.	O

5.	O
Klonopin	B-TREATMENT
2	O
mg	O
t.i.d.	O

6.	O
BuSpar	B-TREATMENT
10	O
mg	O
t.i.d.	O

7.	O
Zanaflex	B-TREATMENT
8	O
mg	O
q.4	O
h.	O

8.	O
Oxazepam	B-TREATMENT
30	O
mg	O
p.r.n.	O

9.	O
Singulair	B-TREATMENT
10	O
mg	O
q.p.m.	O

10.	O
Lipitor	B-TREATMENT
10	O
mg	O
q.p.m.	O

11.	O
Ativan	B-TREATMENT
2	O
mg	O
p.r.n.	O

12.	O
Protonix	B-TREATMENT
20	O
mg	O
p.o.	O
b.i.d.	O

13.	O
Sucralfate	B-TREATMENT
2	O
mg	O
b.i.d.	O

14.	O
Albuterol	B-TREATMENT
nebulizer	I-TREATMENT
q.03-14	O
h.	O
p.r.n.	O

15.	O
Pamidronate	B-TREATMENT
30	O
mg	O
IV	O
every	O
month	O
.	O

Shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

The	O
patient	O
was	O
maintained	O
on	O
albuterol	B-TREATMENT
nebulizer	I-TREATMENT
treatments	I-TREATMENT
and	O
Ipratropium	B-TREATMENT
nebulizer	I-TREATMENT
treatments	I-TREATMENT
,	O
as	O
this	O
was	O
apparently	O
thought	O
to	O
be	O
related	O
to	O
her	B-PROBLEM
chronic	I-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
.	O

Given	O
the	O
presence	O
of	O
consolidation	B-PROBLEM
on	O
chest	B-TEST
x-ray	I-TEST
,	O
however	O
,	O
and	O
previous	O
history	O
of	O
pneumonia	B-PROBLEM
,	O
the	O
patient	O
was	O
maintained	O
on	O
antibiotics	B-TREATMENT
of	O
Zithromax	B-TREATMENT
500	O
mg	O
daily	O
and	O
ceftriaxone	B-TREATMENT
.	O

The	O
patient	O
was	O
also	O
started	O
on	O
Solu-Medrol	B-TREATMENT
IV	I-TREATMENT
for	O
active	B-PROBLEM
airway	I-PROBLEM
disease	I-PROBLEM
component	I-PROBLEM
of	O
her	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

The	O
patient	O
was	O
maintained	O
on	O
supplemental	B-TREATMENT
oxygen	I-TREATMENT
and	O
sputum	O
production	O
was	O
maximized	O
with	O
the	O
help	O
of	O
an	B-TREATMENT
Acapella	I-TREATMENT
device	I-TREATMENT
and	O
respiratory	B-TREATMENT
therapy	I-TREATMENT
.	O

Mucomyst	B-TREATMENT
was	O
also	O
considered	O
as	O
a	B-TREATMENT
mucolytic	I-TREATMENT
component	I-TREATMENT
towards	O
secretions	B-PROBLEM
.	O

Adrenal	B-PROBLEM
insufficiency	I-PROBLEM
.	O

The	O
patient	O
was	O
maintained	O
on	O
IV	B-TREATMENT
Solu	I-TREATMENT
-	I-TREATMENT
Medrol	I-TREATMENT
60	O
mg	O
q.	O
8	O
h.	O

Chest	B-PROBLEM
soreness	I-PROBLEM
.	O

The	O
patient	O
describes	O
chest	B-PROBLEM
discomfort	I-PROBLEM
without	O
any	B-PROBLEM
significant	I-PROBLEM
EKG	I-PROBLEM
changes	I-PROBLEM
.	O

The	O
patient	O
was	O
maintained	O
on	O
Percocet	B-TREATMENT
p.r.n.	O
for	O
pain	B-TREATMENT
relief	I-TREATMENT
.	O

There	O
was	O
no	O
evidence	O
of	O
acute	B-PROBLEM
rib	I-PROBLEM
factors	I-PROBLEM
on	O
her	B-TEST
chest	I-TEST
x-ray	I-TEST
.	O

The	O
patient	O
was	O
maintained	O
on	O
PPI	B-TREATMENT
for	O
reflux	B-PROBLEM
disease	I-PROBLEM
and	O
known	B-PROBLEM
gastritis	I-PROBLEM
.	O

The	O
patient	O
has	O
a	O
history	O
of	O
neurogenic	B-PROBLEM
bladder	I-PROBLEM
and	O
,	O
therefore	O
,	O
she	O
required	O
a	B-TREATMENT
Foley	I-TREATMENT
catheterization	I-TREATMENT
.	O

The	O
patient	O
was	O
on	O
Levoxyl	B-TREATMENT
at	O
home	O
as	O
her	O
home	O
dose	O
for	O
hyperthyroidism	B-PROBLEM
.	O

The	O
patient	O
was	O
transferred	O
on	O
the	O
evening	O
of	O
2012-05-22	O
to	O
the	O
ICU	O
given	O
persistent	B-PROBLEM
carbon	I-PROBLEM
dioxide	I-PROBLEM
retention	I-PROBLEM
and	O
respiratory	B-PROBLEM
acidosis	I-PROBLEM
and	O
the	B-PROBLEM
intermittent	I-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
.	O

The	O
patient	O
had	O
had	O
ABG	B-TEST
on	O
the	O
floor	O
,	O
which	O
prompted	O
her	O
to	O
transfer	O
to	O
the	O
ICU	O
.	O

Her	B-TEST
pH	I-TEST
was	O
7.23	O
,	O
PCO2	B-TEST
73	O
,	O
PO2	B-TEST
146	O
on	O
a	B-TREATMENT
nonrebreather	I-TREATMENT
.	O

The	O
patient	O
had	O
BiPAP	B-TREATMENT
initiated	O
once	O
she	O
reached	O
the	O
unit	O
,	O
but	O
did	O
not	O
tolerate	O
it	O
,	O
becoming	O
apneic	B-PROBLEM
and	O
obstructing	B-PROBLEM
.	O

The	O
patient	O
was	O
switched	O
to	O
2	B-TREATMENT
liters	I-TREATMENT
nasal	I-TREATMENT
cannula	I-TREATMENT
and	O
oxygen	O
saturating	O
at	O
98	O
to	O
100	O
percent	O
.	O

After	O
BiPAP	B-TREATMENT
was	O
initiated	O
,	O
the	O
patient	O
became	O
hypotensive	B-PROBLEM
down	O
to	O
75/28	O
and	O
bradycardiac	B-PROBLEM
,	O
responding	O
to	O
3	B-TREATMENT
fluid	I-TREATMENT
boluses	I-TREATMENT
over	O
the	O
course	O
of	O
the	O
night	O
.	O

The	O
patient	O
was	O
started	O
on	O
Florinef	B-TREATMENT
for	O
concern	O
of	O
adrenal	B-PROBLEM
insufficiency	I-PROBLEM
;	O
however	O
,	O
she	O
was	O
hemodynamically	O
stable	O
that	O
morning	O
and	O
was	O
transferred	O
back	O
out	O
to	O
the	O
floor	O
.	O

It	O
was	O
thought	O
that	O
the	O
patient	O
may	O
have	O
been	O
mucous	B-PROBLEM
plugging	I-PROBLEM
during	O
her	O
stay	O
in	O
the	O
ICU	O
.	O

The	O
patient	O
has	O
a	O
history	O
of	O
high	B-PROBLEM
MCV	I-PROBLEM
and	O
megaloblastic	B-PROBLEM
cells	I-PROBLEM
on	O
smear	B-TEST
in	O
the	O
setting	O
of	O
anemia	B-PROBLEM
;	O
question	O
B12	B-PROBLEM
deficiency	I-PROBLEM
,	O
the	O
patient	O
also	O
has	O
a	O
history	O
of	O
borderline	B-PROBLEM
low	I-PROBLEM
B12	I-PROBLEM
levels	I-PROBLEM
.	O

The	O
patient	O
was	O
diagnosed	O
for	O
B12	B-PROBLEM
deficiency	I-PROBLEM
due	O
to	O
her	O
long	O
history	O
of	O
poor	B-PROBLEM
p.o.	I-PROBLEM
intake	I-PROBLEM
.	O

Methylmalonic	B-TEST
acid	I-TEST
levels	I-TEST
were	O
sent	O
,	O
the	O
results	O
are	O
pending	O
at	O
the	O
time	O
of	O
discharge	O
.	O

Asthma	B-PROBLEM
flare	I-PROBLEM
and	O
bronchitis	B-PROBLEM
.	O

Chronic	B-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
.	O

Demyelinating	B-PROBLEM
polyradiculopathy	I-PROBLEM
.	O

Anxiety	B-PROBLEM
disorder	I-PROBLEM
.	O

Chronic	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
.	O

The	O
patient	O
is	O
stable	O
without	O
an	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
.	O

1.	O
Cholecalciferol	B-TREATMENT
.	O

2.	O
Vitamin	B-TREATMENT
D	I-TREATMENT
.	O

3.	O
Levothyroxine	B-TREATMENT
50	O
mcg	O
p.o.	O
q.d.	O

4.	O
Baclofen	B-TREATMENT
10	O
mg	O
p.o.	O
t.i.d.	O

5.	O
Clonazepam	B-TREATMENT
1	O
mg	O
p.o.	O
t.i.d.	O

6.	O
Buspirone	B-TREATMENT
10	O
mg	O
p.o.	O
t.i.d.	O

7.	O
Montelukast	B-TREATMENT
sodium	I-TREATMENT
10	O
mg	O
p.o.	O
q.h.s.	O

8.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
p.o.	O
q.h.s.	O

9.	O
Protonix	B-TREATMENT
40	O
mg	O
p.o.	O
q.d.	O

10.	O
Albuterol	B-TREATMENT
sulfate	I-TREATMENT
solution	I-TREATMENT
q.05-15	O
h.	O
p.r.n.	O
for	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
.	O

11.	O
Tizanidine	B-TREATMENT
8	O
mg	O
p.o.	O
q.6	O
h.	O

12.	O
Acetaminophen	B-TREATMENT
p.r.n.	O

13.	O
Prednisone	B-TREATMENT
taper	I-TREATMENT
for	O
3	O
days	O
.	O

14.	O
Levofloxacin	B-TREATMENT
500	O
mg	O
p.o.	O
q.d.	O
for	O
10	O
more	O
days	O
.	O

15.	O
Florinef	B-TREATMENT
Acetate	I-TREATMENT
0.1	O
mg	O
p.o.	O
q.d.	O

MEDICINE	B-TREATMENT

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	O
Drugs	B-TREATMENT

Shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
fever	B-PROBLEM

Mr.	O
Mcelveen	O
is	O
a	O
51	O
year-old	O
male	O
with	O
metastatic	B-PROBLEM
RCC	I-PROBLEM
status	O
post	O
left	B-TREATMENT
radical	I-TREATMENT
nephrectomy	I-TREATMENT
in	O
2018-03-21	O
,	O
status	O
post	O
Avastin	B-TREATMENT
and	O
sorafenib	B-TREATMENT
,	O
most	O
recently	O
on	O
Sutent	B-TREATMENT
monotherapy	I-TREATMENT
since	O
2018-12-21	O
,	O
with	O
mild	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
,	O
who	O
presented	O
from	O
home	O
on	O
2019-06-14	O
with	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
fever	B-PROBLEM
.	O

Of	O
note	O
,	O
he	O
was	O
hospitalized	O
at	O
Dana-Farber	O
Cancer	O
Institute	O
from	O
9/25-10/6	O
with	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
at	O
which	O
time	O
he	O
reportedly	O
had	O
cardiac	B-TEST
enzymes	I-TEST
,	O
an	B-TEST
echocardiogram	I-TEST
and	O
a	B-TEST
pharmacological	I-TEST
stress	I-TEST
test	I-TEST
performed	O
.	O

It	O
is	O
unclear	O
from	O
history	O
what	O
these	B-TEST
studies	I-TEST
revealed	O
.	O

He	O
reports	O
that	O
he	O
felt	O
fatigued	B-PROBLEM
during	O
the	O
week	O
prior	O
to	O
the	O
current	O
admission	O
.	O

On	O
the	O
day	O
of	O
admission	O
,	O
he	O
felt	O
"	O
congested	B-PROBLEM
"	O
in	O
his	O
chest	O
,	O
and	O
had	O
a	B-PROBLEM
new	I-PROBLEM
fever	I-PROBLEM
.	O

Patrick	O
reports	O
a	B-PROBLEM
mild	I-PROBLEM
cough	I-PROBLEM
for	O
2	O
days	O
PTA	O
,	O
non-productive	B-PROBLEM
.	O

He	O
denies	O
a	O
history	O
of	O
aspiration	B-PROBLEM
events	I-PROBLEM
or	O
choking	B-PROBLEM
with	O
food	O
intake	O
.	O

He	O
describes	O
mild	B-PROBLEM
reflux	I-PROBLEM
symptoms	I-PROBLEM
at	O
night	O
.	O

Further	B-TEST
ROS	I-TEST
reveals	O
mild	B-PROBLEM
SOB	I-PROBLEM
in	O
the	O
days	O
preceding	O
admission	O
,	O
but	O
he	O
tells	O
me	O
that	O
he	O
was	O
surprised	O
to	O
find	O
out	O
about	O
his	B-PROBLEM
low	I-PROBLEM
oxygen	I-PROBLEM
saturation	I-PROBLEM
because	O
he	O
did	O
not	O
feel	O
that	O
bad	O
.	O

He	O
denies	O
chills	B-PROBLEM
,	O
no	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
no	O
LE	B-PROBLEM
swelling	I-PROBLEM
.	O

In	O
the	O
Deanna	O
,	O
Tmax	B-TEST
102.8	O
,	O
BP	B-TEST
100	O
-	O
140/60	O
s,	O
HR	B-TEST
80	O
s,	O
RR	B-TEST
20	O
s,	O
Sat	B-TEST
75%	O
on	O
RA	B-TREATMENT
in	O
triage	O
,	O
up	O
to	O
100%	O
on	O
NRB	B-TREATMENT
.	O

CXR	B-TEST
with	O
bibasilar	B-PROBLEM
consolidations	I-PROBLEM
.	O

He	O
was	O
given	O
Levo	B-TREATMENT
750	O
mg	O
PO	O
X1	O
,	O
and	O
Flagyl	B-TREATMENT
500	O
mg	O
PO	O
X1	O
.	O

His	B-TEST
BP	I-TEST
decreased	O
to	O
100	O
systolic	O
despite	O
hydration	B-TREATMENT
with	O
2L	O
of	O
NS	B-TREATMENT
.	O

He	O
was	O
subsquently	O
admitted	O
to	O
the	O
ICU	O
for	O
further	B-TREATMENT
care	I-TREATMENT
.	O

He	O
was	O
placed	O
on	O
Levo	B-TREATMENT
and	O
Ceftriaxone	B-TREATMENT
.	O

A	B-TEST
cosyntropin	I-TEST
stimulation	I-TEST
test	I-TEST
revealed	O
cortisol	B-TEST
32.1	O
-->	O
36.4	O
.	O

His	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
decreased	O
,	O
and	O
his	O
overall	O
status	O
improved	O
quickly	O
.	O

He	O
is	O
being	O
transferred	O
to	O
the	O
floor	O
for	O
ongoing	B-TREATMENT
care	I-TREATMENT
.	O

1.	O
Metastatic	B-PROBLEM
renal	I-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM
,	O
diagnosed	O
in	O
2018-03-21	O
,	O
status	O
post	O
left	B-TREATMENT
radical	I-TREATMENT
nephrectomy	I-TREATMENT
at	O
St.	O
Margaret's	O
Center	O
for	O
Women	O
&	O
Infants	O
in	O
03/2006	O
.	O

Path	O
consistent	O
with	O
renal	B-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM
of	I-PROBLEM
chromophobe	I-PROBLEM
type	I-PROBLEM
with	O
Carter	B-PROBLEM
nuclear	I-PROBLEM
grade	I-PROBLEM
of	O
4/4	O
.	O

Lymphovascular	B-PROBLEM
invasion	I-PROBLEM
was	O
present	O
.	O

He	O
later	O
presented	O
with	O
increasing	B-PROBLEM
back	I-PROBLEM
pain	I-PROBLEM
,	O
and	O
metastatic	B-PROBLEM
disease	I-PROBLEM
was	O
documented	O
.	O

He	O
is	O
status	O
post	O
Avastin	B-TREATMENT
plus	O
sorafenib	B-TREATMENT
,	O
protocol	O
#04-393	O
,	O
discontinued	O
in	O
the	O
setting	O
of	O

ongoing	B-PROBLEM
grade	I-PROBLEM
III	I-PROBLEM
rash	I-PROBLEM
,	O
involving	O
the	O
hands	O
and	O
feet	O
in	O
addition	O
proteinuria	B-PROBLEM
secondary	O
to	O
the	O
Avastin	B-TREATMENT
.	O

He	O
has	O
been	O
maintained	O
on	O
single	B-TREATMENT
Timlin	I-TREATMENT
therapy	I-TREATMENT
with	O
Sutent	B-TREATMENT
50	O
mg	O
daily	O
as	O
of	O
2018-12-21	O
and	O
has	O
completed	O
nearly	O
6	O
cycles	O
.	O

He	O
has	O
mild	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
in	O
the	O
setting	O
of	O
Sutent	B-TREATMENT
.	O

2.	O
Seasonal	B-PROBLEM
allergies	I-PROBLEM

VITALS	B-TEST
:	O
T	B-TEST
96.9	O
,	O
BP	B-TEST
110/70	O
,	O
HR	B-TEST
84	O
,	O
RR	B-TEST
20	O
,	O
Sat	B-TEST
97%	O
on	O
4L	O
.	O

GEN	O
:	O
In	O
NAD	B-PROBLEM
.	O

HEENT	O
:	O
Flushed	B-PROBLEM
cheeks	I-PROBLEM
.	O

Slightly	B-PROBLEM
dry	I-PROBLEM
MM	I-PROBLEM
.	O

NECK	O
:	O
JVP	B-TEST
not	O
elevated	B-PROBLEM
.	O

RESP	O
:	O
Decreased	B-PROBLEM
air	I-PROBLEM
entry	I-PROBLEM
and	O
crackles	B-PROBLEM
at	I-PROBLEM
both	I-PROBLEM
lung	I-PROBLEM
bases	I-PROBLEM
.	O

+	O
Egophony	B-PROBLEM
.	O

No	O
S3	B-PROBLEM
,	O
S4	B-PROBLEM
.	O

No	O
murmur	B-PROBLEM
or	O
rub	B-PROBLEM
.	O

Abdomen	O
soft	O
and	O
non-tender	B-PROBLEM
.	O

EXT	O
:	O
Without	O
edema	B-PROBLEM
.	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
WBC	B-TEST
-	O
8.0	O
RBC	B-TEST
-	O
4.22	O
*	O
Hgb	B-TEST
-	O
12.9	O
*	O
Hct	B-TEST
-	O
41.7	O
MCV	B-TEST
-	O
99	O
*	O
MCH	B-TEST
-	O
30.5	O
MCHC	B-TEST
-	O
30.8	O
*	O
RDW	B-TEST
-	O
16.8	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
797	O
*#	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
WBC	B-TEST
-	O
11.1	O
*	O
RBC	B-TEST
-	O
3.47	O
*	O
Hgb	B-TEST
-	O
10.9	O
*	O
Hct	B-TEST
-	O
34.1	O
*	O
MCV	B-TEST
-	O
98	O
MCH	B-TEST
-	O
31.3	O
MCHC	B-TEST
-	O
31.9	O
RDW	B-TEST
-	O
16.7	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
604	O
*	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
PT	B-TEST
-	O
11.2	O
PTT	B-TEST
-	O
23.9	O
INR(PT)	B-TEST
-	O
0.9	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
Plt	B-TEST
Ct	I-TEST
-	O
797	O
*#	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
Glucose	B-TEST
-	O
134	O
*	O
UreaN	B-TEST
-	O
39	O
*	O
Creat	B-TEST
-	O
2.1	O
*	O
Na	B-TEST
-	O
133	O
K	B-TEST
-	O
7.9	O
*	O
Cl	B-TEST
-	O
94	O
*	O
HCO3	B-TEST
-	O
28	O
AnGap	B-TEST
-	O
19	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
Glucose	B-TEST
-	O
73	O
UreaN	B-TEST
-	O
20	O
Creat	B-TEST
-	O
1.1	O
Na	B-TEST
-	O
136	O
K	B-TEST
-	O
5.0	O
Cl	B-TEST
-	O
101	O
HCO3	B-TEST
-	O
27	O
AnGap	B-TEST
-	O
13	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
ALT	B-TEST
-	O
34	O
AST	B-TEST
-	O
167	O
*	O
CK(CPK)	B-TEST
-	O
313	O
*	O
AlkPhos	B-TEST
-	O
383	O
*	O
Amylase	B-TEST
-	O
44	O
TotBili	B-TEST
-	O
0.7	O

2019-06-14	O
06:03	O
PM	O
BLOOD	O
CK(CPK)	B-TEST
-	O
194	O
*	O

2019-06-14	O
10:30	O
AM	O
BLOOD	O
CK-MB	B-TEST
-	O
3	O
cTropnT	B-TEST
-	O
0.05	O
*	O

2019-06-14	O
06:03	O
PM	O
BLOOD	O
CK-MB	B-TEST
-4	O
cTropnT	B-TEST
-	O
0.03	O
*	O

2019-06-17	O
05:30	O
AM	O
BLOOD	O
proBNP	B-TEST
-	O
258	O
*	O

2019-06-14	O
06:03	O
PM	O
BLOOD	O
Calcium	B-TEST
-	O
8.3	O
*	O
Phos	B-TEST
-	O
4.3	O
Mg	B-TEST
-	O
1.9	O

2019-06-18	O
07:55	O
AM	O
BLOOD	O
calTIBC	B-TEST
-	O
229	O
Ferritn	B-TEST
-	O
GREATER	O
TH	O
TRF	O
-	O
176	O
*	O

2019-06-16	O
07:35	O
AM	O
BLOOD	O
TSH	B-TEST
-	O
43	O
*	O

2019-06-16	O
07:35	O
AM	O
BLOOD	O
Free	B-TEST
T4	I-TEST
-	O
0.36	O
*	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
WBC	B-TEST
-	O
11.1	O
*	O
RBC	B-TEST
-	O
3.47	O
*	O
Hgb	B-TEST
-	O
10.9	O
*	O
Hct	B-TEST
-	O
34.1	O
*	O
MCV	B-TEST
-	O
98	O
MCH	B-TEST
-	O
31.3	O
MCHC	B-TEST
-	O
31.9	O
RDW	B-TEST
-	O
16.7	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
604	O
*	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
Neuts	B-TEST
-	O
77.0	O
*	O
Bands	B-TEST
-	O
5.0	O
Lymphs	B-TEST
-	O
11.0	O
*	O
Monos	B-TEST
-	O
3.0	O
Eos	B-TEST
-	O
0	O
Baso	B-TEST
-	O
0	O
Atyps	B-TEST
-	O
1.0	O
*	O
Metas	B-TEST
-	O
2.0	O
*	O
Myelos	B-TEST
-	O
1.0	O
*	O

2019-06-18	O
07:55	O
AM	O
BLOOD	O
PT	B-TEST
-	O
11.5	O
INR(PT)	B-TEST
-	O
1.0	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
Glucose	B-TEST
-	O
73	O
UreaN	B-TEST
-	O
20	O
Creat	B-TEST
-	O
1.1	O
Na	B-TEST
-	O
136	O
K	B-TEST
-	O
5.0	O
Cl	B-TEST
-	O
101	O
HCO3	B-TEST
-	O
27	O
AnGap	B-TEST
-	O
13	O

2019-06-19	O
07:20	O
AM	O
BLOOD	O
Calcium	B-TEST
-	O
8.0	O
*	O
Phos	B-TEST
-	O
3.3	O
Mg	B-TEST
-	O
2.0	O

1)	O
Bilateral	B-TEST
LE	I-TEST
doppler	I-TEST
(	O
06-14	O
):	O
No	O
evidence	O
of	O
deep	B-PROBLEM
venous	I-PROBLEM
thrombosis	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
lower	I-PROBLEM
extremities	I-PROBLEM
bilaterally	I-PROBLEM
.	O

2)	O
Cxray	B-TEST
(	O
06-14	O
):	O
New	B-PROBLEM
bibasilar	I-PROBLEM
consolidations	I-PROBLEM
are	O
demonstrated	O
accompanied	O
by	O
bilateral	B-PROBLEM
small	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

The	O
lung	O
volumes	O
are	O
slightly	B-PROBLEM
increased	I-PROBLEM
.	O

There	O
is	O
no	O
pneumothorax	B-PROBLEM
identified	O
.	O

3)	O
CT	B-TEST
Torso	I-TEST
(	O
06-17	O
):	O

1.	O
Marked	B-PROBLEM
interval	I-PROBLEM
enlargement	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
cardiac	I-PROBLEM
silhouette	I-PROBLEM
.	O

Together	O
with	O
the	O
interval	O
development	O
of	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
,	O
this	O
indicates	O
cardiac	B-PROBLEM
insufficiency	I-PROBLEM
(	O
or	O
alternatively	O
volume	B-PROBLEM
overload	I-PROBLEM
)	O
and	O
an	B-TEST
echocardiogram	I-TEST
may	O
be	O
indicated	O
for	O
further	B-TEST
evaluation	I-TEST
.	O

2.	O
Bilateral	B-PROBLEM
basilar	I-PROBLEM
compressive	I-PROBLEM
atelectasis	I-PROBLEM
.	O

Superimposed	B-PROBLEM
infectious	I-PROBLEM
consolidation	I-PROBLEM
is	O
likely	O
.	O

3.	O
Interval	O
development	O
of	O
tree-in-Eric	B-PROBLEM
nodular	I-PROBLEM
opacities	I-PROBLEM
and	O
scattered	B-PROBLEM
ground	I-PROBLEM
glass	I-PROBLEM
opacities	I-PROBLEM
involving	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
lung	I-PROBLEM
,	O
concerning	O
for	O
an	B-PROBLEM
infectious	I-PROBLEM
process	I-PROBLEM
.	O

The	O
differential	O
diagnosis	O
of	O
this	O
is	O
wide	O
including	O
viral	B-PROBLEM
,	I-PROBLEM
fungal	I-PROBLEM
and	I-PROBLEM
atypical	I-PROBLEM
mycobacterial	I-PROBLEM
infections	I-PROBLEM
.	O

Drug	B-PROBLEM
toxicity	I-PROBLEM
would	O
be	O
a	O
consideration	O
,	O
although	O
somewhat	O
less	O
likely	O
given	O
the	O
unilaterality	O
of	O
the	O
findings	O
.	O

4.	O
New	B-PROBLEM
jejunal	I-PROBLEM
wall	I-PROBLEM
thickening	I-PROBLEM
with	O
persistent	B-PROBLEM
distal	I-PROBLEM
ileal	I-PROBLEM
wall	I-PROBLEM
thickening	I-PROBLEM
and	O
diffuse	B-PROBLEM
mesenteric	I-PROBLEM
stranding	I-PROBLEM
,	O
most	O
likely	O
reflecting	O
an	B-PROBLEM
infectious	I-PROBLEM
etiology	I-PROBLEM
.	O

5.	O
Overall	O
stability	O
in	O
metastatic	B-PROBLEM
burden	I-PROBLEM
.	O

4)	O
ECHO	B-TEST
(	O
06-18	O
):	O
Mild	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
with	O
preserved	O
biventricular	O
systolic	O
function	O
.	O

Mild	B-PROBLEM
posterior	I-PROBLEM
mitral	I-PROBLEM
valve	I-PROBLEM
prolapse	I-PROBLEM
with	O
mild	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
.	O

Small	B-PROBLEM
(	I-PROBLEM
0.6	I-PROBLEM
cm	I-PROBLEM
)	I-PROBLEM
circumferential	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
,	O
largest	O
around	O
the	O
left	O
atrium	O
.	O

5)	O
L	B-TEST
femur	I-TEST
xray	I-TEST
(	O
06-18	O
):	O
Predominantly	B-PROBLEM
sclerotic	I-PROBLEM
lesion	I-PROBLEM
with	O
interval	B-PROBLEM
periosteal	I-PROBLEM
new	I-PROBLEM
bone	I-PROBLEM
formation	I-PROBLEM
involving	O
the	O
intertrochanteric	O
and	O
subtrochanteric	O
regions	O
.	O

No	O
displaced	B-PROBLEM
fracture	I-PROBLEM
is	O
demonstrated	O
.	O

Mr.	O
Mcelveen	O
51	O
year-old	O
male	O
with	O
metastatic	B-PROBLEM
RCC	I-PROBLEM
on	O
Sutent	B-TREATMENT
since	O
2018-12-21	O
,	O
admitted	O
with	O
fever	B-PROBLEM
,	O
hypoxemia	B-PROBLEM
,	O
and	O
bibasilar	B-PROBLEM
pneumonia	I-PROBLEM
.	O

1)	O
Bibasilar	B-PROBLEM
pneumonia	I-PROBLEM
:	O
Patient	O
was	O
treated	O
for	O
community-acquired	B-PROBLEM
pneumonia	I-PROBLEM
.	O

He	O
was	O
initially	O
placed	O
on	O
Ceftriaxone	B-TREATMENT
,	O
Levaquin	B-TREATMENT
,	O
and	O
Flagyl	B-TREATMENT
in	O
the	O
ICU	O
but	O
then	O
changed	O
to	O

Azithromycin	B-TREATMENT
&	O
CTX	B-TREATMENT
at	O
time	O
of	O
transfer	O
to	O
the	O
oncology	O
service	O
.	O

He	O
continued	O
to	O
have	O
an	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
and	O
CT	B-TEST
scan	I-TEST
suggested	O
ground	B-PROBLEM
glass	I-PROBLEM
opacities	I-PROBLEM
,	O
suggestive	O
of	O
an	B-PROBLEM
underlying	I-PROBLEM
infectious	I-PROBLEM
process	I-PROBLEM
.	O

ECHO	B-TEST
was	O
done	O
and	O
confirmed	O
normal	O
ejection	O
fraction	O
.	O

His	O
respiratory	O
status	O
improved	O
slowly	O
,	O
oxygen	B-TREATMENT
was	O
weaned	O
off	O
,	O
and	O
he	O
was	O
discharged	O
on	O
course	O
of	O
Levaquin	B-TREATMENT
.	O

2)	O
Metastatic	B-PROBLEM
RCC	I-PROBLEM
:	O
Sutent	B-TREATMENT
was	O
held	O
on	O
admission	O
in	O
light	O
of	O
acute	B-PROBLEM
infection	I-PROBLEM
.	O

He	O
underwent	O
a	B-TEST
staging	I-TEST
CT	I-TEST
scan	I-TEST
torso	I-TEST
which	O
suggested	O
no	O
significant	B-PROBLEM
increase	I-PROBLEM
in	I-PROBLEM
tumor	I-PROBLEM
burden	I-PROBLEM
.	O

Patient	O
was	O
also	O
found	O
to	O
have	O
abnormal	B-PROBLEM
TFTs	I-PROBLEM
on	O
Sutent	B-TREATMENT
and	O
was	O
started	O
on	O
replacement	B-TREATMENT

therapy	B-TREATMENT
.	O

He	O
will	O
need	O
follow-up	B-TEST
bloodwork	I-TEST
as	O
an	O
outpatient	O
.	O

Recent	B-TEST
CT	I-TEST
scan	I-TEST
showed	O
destruction	B-PROBLEM
of	I-PROBLEM
L	I-PROBLEM
femoral	I-PROBLEM
neck	I-PROBLEM
.	O

He	O
underwent	O
an	B-TEST
xray	I-TEST
of	I-TEST
the	I-TEST
L	I-TEST
femur	I-TEST
which	O
did	O
not	O
suggest	O
an	B-PROBLEM
acute	I-PROBLEM
fracture	I-PROBLEM
.	O

Patient	O
was	O
instructed	O
to	O
restart	O
Sutent	B-TREATMENT
next	O
Monday	O
.	O

3)	O
Renal	B-PROBLEM
insufficiency	I-PROBLEM
:	O
Creatinine	B-TEST
improved	O
from	O
2.1	O
to	O
1.3	O
at	O
time	O
of	O
discharge	O
.	O

Likely	O
related	O
to	O
underlying	B-PROBLEM
malignancy	I-PROBLEM
as	O
well	O
as	O
prerenal	B-PROBLEM
component	I-PROBLEM
given	O
improvement	O
with	O
gentle	B-TREATMENT
hydration	I-TREATMENT
.	O

MEDICATIONS	O
ON	O
ADMISSION	O
:	O
He	O
takes	O
Imodium	B-TREATMENT
and	O
Lomotil	B-TREATMENT
while	O
on	O
Sutent	B-TREATMENT
for	O
diarrhea	B-PROBLEM
.	O

He	O
is	O
also	O
on	O
MS	B-TREATMENT
Contin	I-TREATMENT
45	O
mg	O
PO	O
q12	O
hours	O
(	O
confirmed	O
with	O
wife	O
)	O
and	O
MSIR	B-TREATMENT
15	O
mg	O
every	O
4	O
hours	O
as	O
needed	O
.	O

Heparin	B-TREATMENT
5000	O
UNIT	O
SC	O
TID	O

Albuterol	B-TREATMENT
0.083%	O
Neb	O
Soln	O
1	O
NEB	O
IH	O
Q6H	O

Ipratropium	B-TREATMENT
Bromide	I-TREATMENT
Neb	I-TREATMENT
1	O
NEB	O
IH	O
Q6H	O

CeftriaXONE	B-TREATMENT
1	O
gm	O
IV	O
Q24H	O

Levofloxacin	B-TREATMENT
500	O
mg	O
PO	O
Q24H	O

Morphine	B-TREATMENT
Sulfate	I-TREATMENT
2-4	O
mg	O
IV	O
Q4H	O
:	O
PRN	O

Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
PO	O
BID	O

Pantoprazole	B-TREATMENT
40	O
mg	O
PO	O
Q24H	O

Fluticasone	B-TREATMENT
Propionate	I-TREATMENT
110mcg	O
2	O
PUFF	O
IH	O
BID	O

1.	O
Levothyroxine	B-TREATMENT
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Levofloxacin	B-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
4	O
days	O
:	O
last	O
dose	O
will	O
be	O
Nolen	O
,	O
06-23	O
.	O

3.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
):	O
Take	O
as	O
necessary	O
for	O
constipation	B-PROBLEM
.	O

4.	O
SUTENT	B-TREATMENT
50	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Every	O
other	O
day	O
:	O
Please	O
restart	O
on	O
Wallace	O
,	O
06-24	O
.	O

5.	O
Morphine	B-TREATMENT
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
Pain	B-PROBLEM
.	O

6.	O
Morphine	B-TREATMENT
15	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
).	O

1)	O
Pneumonia	B-PROBLEM

2)	O
Acute	B-PROBLEM
renal	I-PROBLEM
failure	I-PROBLEM

3)	O
Metastatic	B-PROBLEM
renal	I-PROBLEM
cell	I-PROBLEM
carcinoma	I-PROBLEM

4)	O
Hypoxemia	B-PROBLEM

1)	O
Please	O
take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
listed	O
in	O
the	O
discharge	O
instructions	O
.	O

2)	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
and	O
started	O
on	O
an	B-TREATMENT
antibiotic	I-TREATMENT
called	O
Levaquin	B-TREATMENT
for	O
a	B-PROBLEM
pneumonia	I-PROBLEM
.	O

You	O
should	O
continue	O
taking	O
this	B-TREATMENT
medication	I-TREATMENT
and	O
your	O
last	O
day	O
will	O
be	O
Nolen	O
,	O
06-23	O
.	O

3)	O
When	O
you	O
were	O
admitted	O
to	O
the	O
hospital	O
your	B-TREATMENT
Sutent	I-TREATMENT
was	O
stopped	O
.	O

You	O
should	O
resume	O
this	B-TREATMENT
medication	I-TREATMENT
starting	O
Wallace	O
,	O
06-24	O
.	O

You	O
should	O
take	O
this	B-TREATMENT
medication	I-TREATMENT
every	O
other	O
day	O
.	O

4)	O
During	O
your	O
hospital	O
stay	O
you	O
were	O
also	O
found	O
to	O
have	O
low	B-PROBLEM
thyroid	I-PROBLEM
hormone	I-PROBLEM
levels	I-PROBLEM
.	O

As	O
a	O
result	O
,	O
you	O
were	O
started	O
on	O
thyroid	B-TREATMENT
supplements	I-TREATMENT
.	O

You	O
should	O
have	O
follow-up	B-TEST
blood	I-TEST
tests	I-TEST
by	O
your	O
primary	O
care	O
physician	O
B	O
3	O
months	O
.	O

6)	O
If	O
you	O
experience	O
any	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
dizziness	B-PROBLEM
or	O
any	B-PROBLEM
other	I-PROBLEM
concerning	I-PROBLEM
symptoms	I-PROBLEM
please	O
return	O
to	O
the	O
emergency	O
department	O
.	O

Patient	O
was	O
discharged	O
to	O
rehabilitation	B-TREATMENT
on	O
2013-06-25	O
.	O

Discharge	O
was	O
delayed	O
by	O
one	O
day	O
to	O
ensure	O
patient	O
could	O
tolerate	O
P.O.	O
which	O
patient	O
did	O
without	O
difficulty	B-PROBLEM
.	O

Please	O
see	O
original	O
Discharge	O
Summary	O
for	O
discharge	B-TREATMENT
medications	I-TREATMENT
.	O

By	O
report	O
,	O
the	O
patient	O
was	O
noted	O
to	O
be	O
awake	O
,	O
but	O
confused	B-PROBLEM
at	O
the	O
scene	O
of	O
the	O
accident	O
with	O
no	O
memory	O
of	O
the	O
incident	O
.	O

She	O
was	O
immobilized	O
in	O
the	B-TREATMENT
C-spine	I-TREATMENT
collar	I-TREATMENT
at	O
the	O
scene	O
of	O
the	O
accident	O
and	O
subsequently	O
transported	O
by	O
EMS	O
to	O
the	O
New	O
England	O
Sinai	O
Hospital	O
&	O
Rehab	O
Center	O
Emergency	O
Department	O
for	O
further	B-TREATMENT
management	I-TREATMENT
.	O

Examination	B-TEST
on	O
presentation	O
to	O
the	O
emergency	O
room	O
revealed	O
the	O
following	O
:	O

Temperature	B-TEST
35.4	O
Celsius	O
,	O
blood	B-TEST
pressure	I-TEST
116/63	O
,	O
pulse	B-TEST
105	O
,	O
respiratory	B-TEST
rate	I-TEST
18	O
,	O
oxygen	B-TEST
saturation	I-TEST
98%	O
on	O
room	O
air	O
.	O

The	O
patient	O
was	O
alert	O
and	O
oriented	O
times	O
three	O
in	O
no	O
apparent	B-PROBLEM
distress	I-PROBLEM
.	O

Boston	B-TEST
Coma	I-TEST
Scale	I-TEST
of	O
15	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
lung	I-TEST
examination	I-TEST
revealed	O
the	O
lungs	O
to	O
be	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
,	O
no	O
crepitus	B-PROBLEM
,	O
and	O
a	B-PROBLEM
left	I-PROBLEM
clavicular	I-PROBLEM
deformity	I-PROBLEM
was	O
grossly	O
apparent	O
on	O
examination	B-TEST
.	O

Cardiac	B-TEST
examination	I-TEST
demonstrated	O
regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
,	O
or	O
gallops	B-PROBLEM
.	O

Soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
.	O

Examination	B-TEST
was	O
guaiac	B-TEST
negative	O
with	O
good	O
rectal	O
tone	O
.	O

The	O
patient	O
's	O
pelvis	O
was	O
stable	O
to	O
AP	B-TEST
and	I-TEST
lateral	I-TEST
compression	I-TEST
.	O

A	B-PROBLEM
5	I-PROBLEM
cm	I-PROBLEM
laceration	I-PROBLEM
was	O
noted	O
over	O
the	O
patient	O
's	O
occiput	O
on	O
further	B-TEST
inspection	I-TEST
with	O
no	O
exposed	B-PROBLEM
underlying	I-PROBLEM
bone	I-PROBLEM
.	O

Right	B-TEST
upper	I-TEST
extremity	I-TEST
examination	I-TEST
demonstrated	O
intact	O
motor	O
,	O
sensory	O
,	O
and	O
vascular	O
function	O
.	O

Left	B-TEST
upper	I-TEST
extremity	I-TEST
examination	I-TEST
demonstrated	O
no	O
gross	B-PROBLEM
deformities	I-PROBLEM
,	O
tenderness	B-PROBLEM
to	O
palpation	B-TEST
in	I-TEST
the	I-TEST
mid	I-TEST
forearm	I-TEST
,	O
intact	O
motor	O
function	O
in	O
the	O
median	O
,	O
radial	O
,	O
and	O
ulnar	O
nerve	O
distributions	O
,	O
intact	O
sensation	O
to	O
light	B-TEST
touch	I-TEST
in	O
the	O
median	O
and	O
radial	O
nerve	O
distributions	O
,	O
decreased	B-PROBLEM
sensation	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
ulnar-nerve	I-PROBLEM
distribution	I-PROBLEM
,	O
warm	O
and	O
well	O
perfused	O
limb	O
with	O
2+	O
radial	B-TEST
pulses	I-TEST
.	O

Right	B-TEST
lower	I-TEST
extremity	I-TEST
examination	I-TEST
demonstrated	O
mild	B-PROBLEM
swelling	I-PROBLEM
and	O
ecchymosis	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
posterior	I-PROBLEM
thigh	I-PROBLEM
and	O
approximately	O
a	B-PROBLEM
3	I-PROBLEM
cm	I-PROBLEM
laceration	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
lower	I-PROBLEM
leg	I-PROBLEM
,	O
expressive	O
of	O
moderate	O
amounts	O
of	O
standard	O
sterile	O

No	O
gross	B-PROBLEM
deformities	I-PROBLEM
.	O

Motor	B-TEST
,	I-TEST
sensory	I-TEST
,	I-TEST
and	I-TEST
vascular	I-TEST
examinations	I-TEST
were	O
intact	O
in	O
all	O
distributions	O
.	O

Left	B-TEST
lower	I-TEST
extremity	I-TEST
examination	I-TEST
demonstrated	O
no	O
gross	B-PROBLEM
deformities	I-PROBLEM
and	O
intact	O
motor	O
,	O
sensory	O
,	O
and	O
vascular	O
examinations	O
in	O
all	O
distributions	O
.	O

Radiographic	B-TEST
studies	I-TEST
demonstrated	O
an	B-PROBLEM
inferior	I-PROBLEM
displaced	I-PROBLEM
left	I-PROBLEM
midclavicular	I-PROBLEM
fracture	I-PROBLEM
,	O
no	O
evidence	O
of	O

pneumothorax	B-PROBLEM
.	O

Trauma	B-TEST
series	I-TEST
demonstrated	O
no	O
evidence	O
of	O
a	B-PROBLEM
pelvic	I-PROBLEM
fracture	I-PROBLEM
.	O

Head	B-TEST
CT	I-TEST
demonstrated	O
no	O
evidence	O
of	O
intracranial	B-PROBLEM
bleeding	I-PROBLEM
.	O

Trauma	B-TEST
CT	I-TEST
demonstrated	O
mild	B-PROBLEM
pulmonary	I-PROBLEM
contusions	I-PROBLEM
,	O
but	O
no	O
pelvic	B-PROBLEM
fracture	I-PROBLEM
.	O

Cervical	B-TEST
spine	I-TEST
imaging	I-TEST
demonstrated	O
no	O
evidence	O
of	O
cervical	B-PROBLEM
spine	I-PROBLEM
injury	I-PROBLEM
.	O

Right	B-TEST
tibial-fibular	I-TEST
film	I-TEST
series	I-TEST
demonstrated	O
no	O
evidence	O
of	O
fracture	B-PROBLEM
displacement	I-PROBLEM
.	O

Left	B-TEST
humerus	I-TEST
film	I-TEST
series	I-TEST
demonstrated	O
no	O
evidence	O
of	O
fracture	B-PROBLEM
or	O
displacement	B-PROBLEM
.	O

Right	B-TEST
foot	I-TEST
and	I-TEST
femur	I-TEST
series	I-TEST
demonstrated	O
no	O
evidence	O
of	O
fracture	B-PROBLEM
displacement	I-PROBLEM
.	O

Left	B-TEST
forearm	I-TEST
and	I-TEST
wrist	I-TEST
series	I-TEST
demonstrated	O
transverse	B-PROBLEM
mid	I-PROBLEM
shaft	I-PROBLEM
radial	I-PROBLEM
fracture	I-PROBLEM
with	O
ulnar	B-PROBLEM
displacement	I-PROBLEM
.	O

Diagnosis	B-TEST
peritoneum	I-TEST
lavage	I-TEST
times	O
two	O
was	O
negative	O
for	O
any	O
signs	O
of	O
intra-abdominal	B-PROBLEM
bleeding	I-PROBLEM
.	O

Studies	B-TEST
on	O
admission	O
revealed	O
the	O
following	O
:	O

White	B-TEST
blood	I-TEST
cell	I-TEST
12.9	O
,	O
hemoglobin	B-TEST
11.5	O
,	O
hematocrit	B-TEST
32.8	O
,	O
platelet	B-TEST
count	I-TEST
197,000	O
,	O
sodium	B-TEST
141	O
,	O
potassium	B-TEST
3.6	O
,	O
chloride	B-TEST
110	O
,	O
bicarbonate	B-TEST
21	O
,	O
BUN	B-TEST
20	O
,	O
creatinine	B-TEST
0.7	O
,	O
glucose	B-TEST
189	O
,	O
PT	B-TEST
13.3	O
,	O
INR	B-TEST
1.2	O
,	O
PTT	B-TEST
30.0	O
,	O
amylase	B-TEST
57	O
,	O
arterial	B-TEST
blood	I-TEST
gas	I-TEST
7.32	O
,	O
35	O
,	O
159	O
,	O
19	O
,	O
-7	O
.	O

Urinalysis	B-TEST
was	O
within	O
normal	O
limits	O
with	O
6	O
to	O
10	O
red	B-TEST
blood	I-TEST
cells	I-TEST
.	O

Toxicology	B-TEST
screen	I-TEST
was	O
negative	O
.	O

crystalloid	B-TREATMENT
and	O
four	O
units	O
packed	B-TREATMENT
red	I-TREATMENT
blood	I-TREATMENT
cells	I-TREATMENT
with	O
good	O
response	O
.	O

In	O
addition	O
,	O
the	O
patient	O
received	O
the	O
above-described	O
diagnostic	B-TEST
procedures	I-TEST
,	O
which	O
demonstrated	O
injuries	B-PROBLEM
limited	O
to	O
a	B-PROBLEM
posterior	I-PROBLEM
scalp	I-PROBLEM
laceration	I-PROBLEM
,	O
left	B-PROBLEM
fractured	I-PROBLEM
clavicle	I-PROBLEM
,	O
left	B-PROBLEM
fractured	I-PROBLEM
radius	I-PROBLEM
,	O
right	B-PROBLEM
thigh	I-PROBLEM
hematoma	I-PROBLEM
,	O
and	O
right	B-PROBLEM
leg	I-PROBLEM
laceration	I-PROBLEM
.	O

Given	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
right	I-PROBLEM
thigh	I-PROBLEM
hematoma	I-PROBLEM
,	O
a	B-TEST
duplex	I-TEST
evaluation	I-TEST
of	I-TEST
the	I-TEST
right	I-TEST
lower	I-TEST
extremity	I-TEST
was	O
performed	O
on	O
2010-06-28	O
and	O
demonstrated	O
no	O
evidence	O
of	O
major	B-PROBLEM
arterial	I-PROBLEM
or	I-PROBLEM
venous	I-PROBLEM
injury	I-PROBLEM
in	O
the	O
level	O
of	O

On	O
06-28	O
,	O
the	O
patient	O
was	O
also	O
cleared	O
for	O
removal	O
of	O
her	B-TREATMENT
C-spine	I-TREATMENT
collar	I-TREATMENT
and	O
deemed	O
stable	O
for	O
transfer	O
to	O
the	O
Orthopedic	O
Service	O
under	O
the	O
direction	O
of	O
Dr.	O
Ronda	O
Lopez	O
.	O

The	O
patient	O
remained	O
stable	O
through	O
2010-06-29	O
at	O
which	O
point	O
she	O
was	O
sent	O
to	O
the	O
operating	O
room	O
to	O
undergo	O
a	B-TREATMENT
left	I-TREATMENT
radial	I-TREATMENT
fracture	I-TREATMENT
open	I-TREATMENT
reduction	I-TREATMENT
and	O
internal	B-TREATMENT
fixation	I-TREATMENT
procedure	I-TREATMENT
.	O

The	O
patient	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
demonstrated	O
a	B-TEST
postoperative	I-TEST
hematocrit	I-TEST
of	O
40.9	O
.	O

Of	O
note	O
,	O
the	B-PROBLEM
scalp	I-PROBLEM
and	I-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
leg	I-PROBLEM
lacerations	I-PROBLEM
were	O
closed	O
primarily	O
by	O
the	O
trauma	O
team	O
on	O
admission	O
and	O
on	O
hospital	O
day	O
#1	O
were	O
noted	O
to	O
be	O
clean	O
,	O
dry	O
,	O
and	O
intact	O
.	O

Nonoperative	B-TREATMENT
treatment	I-TREATMENT
was	O
elected	O
for	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
left	I-PROBLEM
clavicular	I-PROBLEM
fracture	I-PROBLEM
.	O

On	O
postoperative	O
day	O
#1	O
,	O
2010-06-30	O
,	O
the	O
patient	O
was	O
noted	O
to	O
be	O
clinically	O
stable	O
,	O
tolerating	O
oral	O
intake	O
,	O
and	O
expressive	O
of	O
adequate	O
amounts	O
of	O
urine	O
independent	O
of	O
a	B-TREATMENT
Foley	I-TREATMENT
catheter	I-TREATMENT
.	O

The	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
head	I-PROBLEM
wound	I-PROBLEM
laceration	I-PROBLEM
was	O
noted	O
to	O
be	O
clean	O
and	O
dry	O
with	O
intact	B-TREATMENT
staples	I-TREATMENT
.	O

There	O
was	O
no	O
erythema	B-PROBLEM
or	O
purulence	B-PROBLEM
.	O

The	O
left	O
clavicle	O
was	O
noted	O
to	O
have	O
continued	B-PROBLEM
ecchymosis	I-PROBLEM
decreased	O
from	O
prior	B-TEST
examination	I-TEST
with	O
a	B-PROBLEM
minor	I-PROBLEM
stepoff	I-PROBLEM
and	O
mild	B-PROBLEM
tenderness	I-PROBLEM
to	O
palpation	B-TEST
decreased	O
from	O
prior	B-TEST
examinations	I-TEST
.	O

The	B-TREATMENT
left	I-TREATMENT
forearm	I-TREATMENT
dressing	I-TREATMENT
was	O
noted	O
to	O
be	O
in	O
place	O
,	O
clean	O
,	O
dry	O
,	O
and	O
intact	O
with	O
no	O
saturation	B-PROBLEM
.	O

Mild	B-PROBLEM
swelling	I-PROBLEM
was	O
noted	O
in	O
the	O
left	O
hand	O
.	O

Fingers	O
were	O
warm	O
and	O
well	O
perfused	O
with	O
capillary	B-TEST
refill	I-TEST
less	O
than	O
3	O
seconds	O
.	O

The	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
right	I-PROBLEM
anterior	I-PROBLEM
tibial	I-PROBLEM
wound	I-PROBLEM
was	O
noted	O
to	O
be	O
clean	O
,	O
dry	O
,	O
and	O
intact	O
with	O
sutures	B-TREATMENT
intact	O
and	O
no	O
erythema	B-PROBLEM
or	O
purulence	B-PROBLEM
noted	O
.	O

On	O
06-30	O
,	O
the	O
patient	O
was	O
evaluated	O
by	O
Occupational	O
Therapy	O
and	O
fitted	O
for	O
a	B-TREATMENT
left	I-TREATMENT
upper	I-TREATMENT
extremity	I-TREATMENT
splint	I-TREATMENT
.	O

The	O
patient	O
was	O
also	O
administered	O
adaptive	B-TREATMENT
training	I-TREATMENT
for	O
activities	B-TREATMENT
of	I-TREATMENT
daily	I-TREATMENT
life	I-TREATMENT
and	O
advised	O
regarding	O
wound	B-TREATMENT
care	I-TREATMENT
.	O

In	O
addition	O
,	O
the	O
patient	O
was	O
also	O
fitted	O
with	O
a	B-TREATMENT
figure-of-eight	I-TREATMENT
clavicular	I-TREATMENT
splint	I-TREATMENT
and	O
instructed	O
in	O
its	O

1.	O
Left	B-PROBLEM
transverse	I-PROBLEM
mid	I-PROBLEM
shaft	I-PROBLEM
radial	I-PROBLEM
fracture	I-PROBLEM
with	O
ulnar	B-PROBLEM
displacement	I-PROBLEM
status	O
post	O
left	B-TREATMENT
radial	I-TREATMENT
open	I-TREATMENT
reduction	I-TREATMENT
and	O
internal	B-TREATMENT
fixation	I-TREATMENT
.	O

2.	O
Left	B-PROBLEM
midclavicular	I-PROBLEM
fracture	I-PROBLEM
managed	O
nonoperatively	O
.	O

3.	O
Occipital	B-PROBLEM
scalp	I-PROBLEM
laceration	I-PROBLEM
.	O

4.	O
Right	B-PROBLEM
anterior	I-PROBLEM
tibial	I-PROBLEM
laceration	I-PROBLEM
.	O

Percocet	B-TREATMENT
one	O
to	O
two	O
tablets	O
PO	O
q.4h.	O
to	O
6h.p.r.n.	O
pain	B-PROBLEM
.	O

The	O
patient	O
is	O
to	O
maintain	O
her	B-TREATMENT
figure-of-eight	I-TREATMENT
clavicular	I-TREATMENT
splint	I-TREATMENT
and	O
left	B-TREATMENT
posterior	I-TREATMENT
forearm	I-TREATMENT
splint	I-TREATMENT
in	O
place	O
for	O
fourteen	O
days	O
following	O
discharge	O
.	O

The	B-PROBLEM
left	I-PROBLEM
forearm	I-PROBLEM
and	I-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
leg	I-PROBLEM
wound	I-PROBLEM
should	O
be	O
kept	O
clean	O
and	O
dry	O
with	O
regular	B-TREATMENT
dressing	I-TREATMENT
changes	I-TREATMENT
with	O
dry	B-TREATMENT
gauze	I-TREATMENT
once	O
per	O
day	O
.	O

Scalp	B-PROBLEM
laceration	I-PROBLEM
should	O
be	O
kept	O
clean	O
and	O
dry	O
for	O
five	O
days	O
following	O
discharge	O
after	O
which	O
point	O
the	O
patient	O
may	O
once	O
wash	O
her	O
hair	O
.	O

Percocet	B-TREATMENT
for	O
pain	B-PROBLEM
as	O
needed	O
.	O

The	O
patient	O
is	O
to	O
followup	O
with	O
an	O
orthopedist	O
in	O
the	O
United	O
Kingdom	O
fourteen	O
days	O
following	O
discharge	O
at	O
which	O
point	O
repeat	B-TEST
x-rays	I-TEST
of	I-TEST
her	I-TEST
left	I-TEST
forearm	I-TEST
should	O
be	O
obtained	O
and	O
her	B-TREATMENT
left	I-TREATMENT
forearm	I-TREATMENT
scalp	I-TREATMENT
and	I-TREATMENT
right	I-TREATMENT
lower	I-TREATMENT
leg	I-TREATMENT
sutures	I-TREATMENT
and	O
staples	B-TREATMENT
may	O
be	O
removed	O
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

Explained	O
to	O
pt	O
which	O
of	O
the	B-TREATMENT
meds	I-TREATMENT
he	O
should	O
no	O
longer	O
take	O
that	O
he	O
was	O
taking	O
pre-admission	O
.	O

Also	O
,	O
explained	O
which	O
meds	B-TREATMENT
are	O
new	O
.	O

1.	O
Diltiazem	B-TREATMENT
HCl	O
240	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Simvastatin	B-TREATMENT
40	O
mg	O
Tablet	O
Sig:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

3.	O
Albuterol-Ipratropium	B-TREATMENT
103-18	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
02-26	O
Puffs	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O

4.	O
Fluticasone-Salmeterol	B-TREATMENT
250-50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

5.	O
Terazosin	B-TREATMENT
1	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
HS	O
(	O
at	O
bedtime	O
).	O

6.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

7.	O
Nimodipine	B-TREATMENT
30	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
for	O
2	O
weeks	O
.	O

8.	O
Ferrous	B-TREATMENT
Sulfate	I-TREATMENT
325	O
(	O
65	O
)	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

9.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
).	O

10.	O
Ipratropium	B-TREATMENT
Bromide	I-TREATMENT
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
).	O

11.	O
Simvastatin	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

12.	O
Hydralazine	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

13.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

14.	O
Isosorbide	B-TREATMENT
Dinitrate	I-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

15.	O
Clopidogrel	B-TREATMENT
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

16.	O
Glipizide	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O

The	O
patient	O
was	O
initially	O
on	O
several	B-TREATMENT
antibiotics	I-TREATMENT
included	O
Cefepime	B-TREATMENT
,	O
Vancomycin	B-TREATMENT
,	O
Ciprofloxacin	B-TREATMENT
,	O
Ambazone	B-TREATMENT
and	O
Flagyl	B-TREATMENT
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
HSV	I-TEST
antibody	I-TEST
titer	I-TEST
was	O
found	O
to	O
be	O
negative	O
and	O
the	O
patient	O
's	O
Acyclovir	B-TREATMENT
was	O
not	O
restarted	O
.	O

Infectious	O
disease	O
continued	O
to	O
follow	O
and	O
on	O
2012-02-29	O
,	O
the	O
patient	O
spiked	O
again	O
which	O
at	O
that	O
time	O
was	O
felt	O
to	O
be	O
due	O
to	O
his	B-TREATMENT
central	I-TREATMENT
line	I-TREATMENT
and	O
the	B-TREATMENT
central	I-TREATMENT
line	I-TREATMENT
was	O
resited	O
on	O
the	O
left	O
side	O
and	O
the	O
patient	O
was	O
started	O
on	O
intravenous	B-TREATMENT
Vancomycin	I-TREATMENT
.	O

Over	O
the	O
following	O
days	O
until	O
discharge	O
,	O
the	O
patient	O
remained	O
afebrile	B-PROBLEM
and	O
on	O
2012-03-09	O
,	O
in	O
fact	O
all	O
the	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
antibiotics	I-TREATMENT
were	O
discontinued	O
.	O

As	O
for	O
the	O
patient	O
's	O
ALL	B-PROBLEM
and	O
AML	B-PROBLEM
,	O
the	O
patient	O
was	O
started	O
on	O
a	B-TREATMENT
new	I-TREATMENT
chemotherapy	I-TREATMENT
protocol	I-TREATMENT
called	O
hyper-CVAD	B-TREATMENT
on	O
2012-03-06	O
.	O

After	O
the	O
patient	O
began	O
on	O
this	B-TREATMENT
protocol	I-TREATMENT
,	O
his	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
steadily	O
began	O
to	O
climb	O
.	O

The	O
patient	O
became	O
no	O
longer	O
neutropenic	B-PROBLEM
.	O

The	O
patient	O
's	O
also	O
began	O
to	O
climb	O
and	O
the	B-TEST
percent	I-TEST
blasts	I-TEST
in	O
his	B-TEST
differential	I-TEST
decreased	O
significantly	O
.	O

The	O
patient	O
had	O
no	O
further	B-PROBLEM
complaints	I-PROBLEM
and	O
on	O
2012-03-10	O
,	O
his	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
was	O
2.3	O
,	O
neutrophils	B-TEST
50%	O
,	O
bands	B-TEST
2%	O
,	O
lymphocytes	B-TEST
5%	O
,	O
monocytes	B-TEST
40%	O
,	O
and	O
blasts	B-TEST
1%	O
.	O

Platelet	B-TEST
count	I-TEST
was	O
759,000	O
.	O

The	O
patient	O
was	O
discharged	O
to	O
home	O
with	O
instructions	O
to	O
return	O
to	O
the	O
hospital	O
on	O
Monday	O
,	O
2012-03-12	O
,	O
for	O
follow-up	O
and	O
laboratory	B-TEST
checks	I-TEST
.	O

The	O
patient	O
was	O
also	O
told	O
to	O
continue	O
on	O
a	B-TREATMENT
neutropenic	I-TREATMENT
diet	I-TREATMENT
.	O

The	O
patient	O
was	O
also	O
told	O
that	O
he	O
would	O
have	O
to	O
be	O
admitted	O
for	O
several	O
days	O
during	O
his	B-TREATMENT
next	I-TREATMENT
cycle	I-TREATMENT
of	I-TREATMENT
CVAD	I-TREATMENT
.	O

1.	O
Bactrim	B-TREATMENT
double	I-TREATMENT
strength	I-TREATMENT
one	O
tablet	O
q.	O
Monday	O
,	O
Wednesday	O
and	O
Friday	O
.	O

2.	O
Compazine	B-TREATMENT
10	O
mg	O
p.o.	O
q	O
6hours	O
p.r.n.	O
nausea	B-PROBLEM
.	O

3.	O
Anzemet	B-TREATMENT
100	O
mg	O
p.o.	O
once	O
daily	O
p.r.n.	O
nausea	B-PROBLEM
.	O

Mr.	O
Robert	O
Mackey	O
is	O
a	O
49	O
year	O
old	O
gentleman	O
with	O
a	O
22	O
year	O
history	O
of	O
diabetes	B-PROBLEM
mellitus	I-PROBLEM
.	O

He	O
has	O
a	O
history	O
of	O
peripheral	B-PROBLEM
neuropathy	I-PROBLEM
,	O
kidney	B-TREATMENT
transplantation	I-TREATMENT
in	O
2003	O
secondary	O
to	O
diabetic	B-PROBLEM
nephropathy	I-PROBLEM
,	O
as	O
well	O
as	O
throat	B-PROBLEM
cancer	I-PROBLEM
in	O
2004	O
treated	O
with	O
local	B-TREATMENT
resection	I-TREATMENT
and	O
radical	B-TREATMENT
neck	I-TREATMENT
dissection	I-TREATMENT
on	I-TREATMENT
the	I-TREATMENT
left	I-TREATMENT
as	O
well	O
as	O
postoperative	B-TREATMENT
radiation	I-TREATMENT
.	O

Mr.	O
Mackey	O
also	O
had	O
signs	B-PROBLEM
and	I-PROBLEM
symptoms	I-PROBLEM
consistent	O
with	O
cervical	B-PROBLEM
myelopathy	I-PROBLEM
;	O
a	B-TEST
cervical	I-TEST
MRI	I-TEST
scan	I-TEST
showed	O
very	O
impressive	B-PROBLEM
disc	I-PROBLEM
herniations	I-PROBLEM
at	I-PROBLEM
C5-C6	I-PROBLEM
,	O
less	O
so	O
at	O
C4-C5	O
,	O
with	O
clear	B-PROBLEM
cut	I-PROBLEM
cord	I-PROBLEM
compression	I-PROBLEM
,	O
particularly	O
on	O
the	O
right	O
side	O
C5-C6	O
.	O

Therefore	O
,	O
he	O
was	O
admitted	O
for	O
C4-C5	B-TREATMENT
and	I-TREATMENT
C5-C6	I-TREATMENT
anterior	I-TREATMENT
diskectomy	I-TREATMENT
with	O
autologous	B-TREATMENT
bone	I-TREATMENT
graft	I-TREATMENT
and	O
instrumented	B-TREATMENT
fusion	I-TREATMENT
.	O

Postoperative	B-TEST
physical	I-TEST
examination	I-TEST
demonstrated	O
that	O
he	O
was	O
afebrile	B-PROBLEM
at	O
97	O
degrees	O
;	O
blood	B-TEST
pressure	I-TEST
145/80	O
;	O
pulse	B-TEST
60	O
;	O
respiratory	B-TEST
rate	I-TEST
10	O
;	O
100%	O
on	O
a	B-TREATMENT
non-rebreather	I-TREATMENT
.	O

He	O
was	O
awake	O
,	O
alert	O
,	O
uncomfortable	B-PROBLEM
secondary	O
to	O
incisional	B-PROBLEM
tenderness	I-PROBLEM
at	O
neck	B-PROBLEM
site	I-PROBLEM
as	O
well	O
as	O
right	B-PROBLEM
iliac	I-PROBLEM
graft	I-PROBLEM
site	I-PROBLEM
.	O

The	B-PROBLEM
wounds	I-PROBLEM
were	O
clean	O
,	O
dry	O
and	O
intact	O
,	O
and	O
flat	O
.	O

While	O
in	O
the	O
PACU	O
,	O
Anesthesia	O
was	O
called	O
because	O
the	O
patient	O
became	O
dyspneic	B-PROBLEM
and	O
tachypneic	B-PROBLEM
and	O
his	B-TEST
SAO2	I-TEST
dropped	O
to	O
89%	O
.	O

His	B-TEST
respiratory	I-TEST
rate	I-TEST
was	O
30	O
on	O
face	B-TREATMENT
mask	I-TREATMENT
.	O

Interoperatively	O
,	O
he	O
was	O
positive	O
two	O
liters	O
with	O
a	O
stable	O
blood	O
pressure	O
and	O
heart	B-TEST
rate	I-TEST
,	O
although	O
requiring	O
some	B-TREATMENT
neo-synephrine	I-TREATMENT
interoperatively	O
.	O

He	O
responded	O
to	O
intravenous	B-TREATMENT
Lasix	I-TREATMENT
with	O
3.2	O
liters	O
of	O
urine	B-TEST
output	I-TEST
as	O
well	O
as	O
marked	O
clinical	O
improvement	O
.	O

The	O
etiology	O
for	O
his	B-PROBLEM
congestive	I-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
was	O
determined	O
likely	O
to	O
be	O
diastolic	B-PROBLEM
dysfunction	I-PROBLEM
from	O
increased	B-PROBLEM
heart	I-PROBLEM
rate	I-PROBLEM
as	O
well	O
as	O
excess	B-PROBLEM
volume	I-PROBLEM
.	O

No	O
definite	O
evidence	O
for	O
significant	B-PROBLEM
myocardial	I-PROBLEM
ischemia	I-PROBLEM
,	O
although	O
cardiac	B-TEST
enzymes	I-TEST
were	O
sent	O
and	O
he	O
ruled	O
out	O
for	O
myocardial	B-PROBLEM
infarction	I-PROBLEM
.	O

He	O
was	O
given	O
Lasix	B-TREATMENT
to	O
continue	O
to	O
diurese	O
the	B-PROBLEM
excess	I-PROBLEM
volume	I-PROBLEM
.	O

He	O
was	O
also	O
put	O
on	O
Lopressor	B-TREATMENT
150	O
mg	O
twice	O
a	O
day	O
.	O

Also	O
in	O
the	O
Intensive	O
Care	O
Unit	O
,	O
O2	B-TEST
saturation	I-TEST
was	O
closely	O
monitored	O
.	O

The	O
patient	O
became	O
agitated	B-PROBLEM
with	O
both	O
tent	B-TREATMENT
and	O
Bi-PAP	B-TREATMENT
machine	I-TREATMENT
,	O
although	O
continued	O
to	O
saturate	O
well	O
.	O

He	O
was	O
transferred	O
to	O
Medicine	O
the	O
morning	O
of	O
2010-08-30	O
,	O
for	O
continued	B-TREATMENT
medical	I-TREATMENT
management	I-TREATMENT
post	O
surgery	O
.	O

On	O
the	O
day	O
of	O
transfer	O
,	O
the	O
patient	O
was	O
noted	O
to	O
be	O
confused	B-PROBLEM
with	O
waxing	B-PROBLEM
and	I-PROBLEM
waning	I-PROBLEM
sensorium	I-PROBLEM
;	O
thus	O
,	O
a	B-TEST
delirium	I-TEST
work-up	I-TEST
was	O
initiated	O
looking	O
for	O
precipitants	O
.	O

1.	O
When	O
his	B-TEST
O2	I-TEST
saturation	I-TEST
was	O
monitored	O
,	O
his	B-TEST
pulse	I-TEST
oximetry	I-TEST
remained	O
in	O
the	O
90s	O
during	O
his	O
stay	O
.	O

2.	O
His	B-TREATMENT
non-essential	I-TREATMENT
medications	I-TREATMENT
that	O
may	O
have	O
been	O
contributing	O
to	O
his	B-PROBLEM
change	I-PROBLEM
in	I-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
were	O
discontinued	O
;	O
those	O
included	O
Temocillin	B-TREATMENT
,	O
Nortriptyline	B-TREATMENT
,	O
Haldol	B-TREATMENT
,	O
Lorazepam	B-TREATMENT
,	O
Venlafaxine	B-TREATMENT
,	O
Bupropion	B-TREATMENT
,	O
and	O
Gabapentin	B-TREATMENT
.	O

In	O
addition	O
,	O
his	B-TEST
cyclosporin	I-TEST
levels	I-TEST
were	O
checked	O
.	O

3.	O
Hypo	B-PROBLEM
or	I-PROBLEM
hyperglycemia	I-PROBLEM
:	O

Mahoney	O
had	O
been	O
following	O
with	O
their	O
appreciated	O
recommendations	O
on	O
glucose	B-TREATMENT
control	I-TREATMENT
.	O

Finger	B-TEST
sticks	I-TEST
were	O
in	O
the	O
150	O
s	O
when	O
acutely	B-PROBLEM
agitated	I-PROBLEM
,	O
therefore	O
,	O
it	O
was	O
not	O
determined	O
that	O
glucose	B-TEST
levels	I-TEST
were	O
contributory	O
.	O

4.	O
Infectious	B-PROBLEM
causes	I-PROBLEM
were	O
evaluated	O
.	O

He	O
was	O
febrile	B-PROBLEM
in	O
the	O
Intensive	O
Care	O
Unit	O
to	O
101.0	O
F.	O
;	O
yet	O
,	O
chest	B-TEST
x-ray	I-TEST
,	O
blood	B-TEST
cultures	I-TEST
,	O
urinalysis	B-TEST
and	O
urine	B-TEST
cultures	I-TEST
were	O
all	O
negative	O
for	O
sources	O
.	O

A	B-TEST
lumbar	I-TEST
puncture	I-TEST
was	O
considered	O
,	O
although	O
not	O
performed	O
due	O
to	O
the	O
fact	O
that	O
the	O
cerebrospinal	O
fluid	O
was	O
not	O
breached	O
during	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

5.	O
Mass	B-PROBLEM
effect	I-PROBLEM
was	O
considered	O
,	O
although	O
no	O
focal	B-PROBLEM
deficits	I-PROBLEM
were	O
ever	O
noted	O
on	O
examination	B-TEST
and	O
due	O
to	O
the	B-PROBLEM
fluctuating	I-PROBLEM
sensorium	I-PROBLEM
,	O
it	O
was	O
determined	O
that	O
there	O
was	O
no	O
severe	B-PROBLEM
underlying	I-PROBLEM
structural	I-PROBLEM
abnormality	I-PROBLEM
.	O

A	B-TEST
head	I-TEST
and	I-TEST
neck	I-TEST
CT	I-TEST
scan	I-TEST
,	I-TEST
non-contrast	I-TEST
,	O
were	O
ordered	O
though	O
to	O
evaluate	O
for	O
such	B-PROBLEM
processes	I-PROBLEM
.	O

No	O
acute	B-PROBLEM
intracranial	I-PROBLEM
hemorrhages	I-PROBLEM
or	O
midline	B-PROBLEM
shifts	I-PROBLEM
were	O
noted	O
,	O
although	O
a	B-PROBLEM
soft	I-PROBLEM
tissue	I-PROBLEM
mass	I-PROBLEM
was	O
noted	O
at	O
the	O
level	O
of	O
C2	O
.	O

6.	O
Trauma	B-PROBLEM
was	O
also	O
considered	O
.	O

The	O
patient	O
was	O
found	O
out	O
of	O
bed	O
but	O
no	O
signs	O
of	O
head	B-PROBLEM
trauma	I-PROBLEM
,	O
no	O
loss	B-PROBLEM
of	I-PROBLEM
consciousness	I-PROBLEM
.	O

Throughout	O
his	O
stay	O
,	O
Chem-10	B-TEST
was	O
monitored	O
.	O

There	O
were	O
no	O
electrolytes	B-PROBLEM
or	I-PROBLEM
mineral	I-PROBLEM
abnormalities	I-PROBLEM
that	O
could	O
explain	O
his	B-PROBLEM
delirium	I-PROBLEM
.	O

Liver	B-TEST
function	I-TEST
tests	I-TEST
were	O
checked	O
,	O
only	O
total	B-TEST
bilirubin	I-TEST
was	O
slightly	B-PROBLEM
elevated	I-PROBLEM
at	O
1.6	O
.	O

TSH	B-TEST
was	O
within	O
normal	O
limits	O
as	O
was	O
B12	B-TEST
and	O
folate	B-TEST
.	O

RPR	B-TEST
evaluating	I-TEST
for	O
possible	O
neurologic	B-PROBLEM
syphilis	I-PROBLEM
was	O
also	O
checked	O
.	O

The	B-TEST
assay	I-TEST
was	O
nonreactive	O
.	O

An	B-TEST
EEG	I-TEST
was	O
also	O
considered	O
to	O
rule	O
out	O
non-convulsive	B-PROBLEM
status	I-PROBLEM
epilepticus	I-PROBLEM
,	O
although	O
again	O
this	O
did	O
not	O
seem	O
to	O
be	O
a	O
likely	O
cause	O
.	O

On	O
the	O
evening	O
of	O
the	O
22nd	O
,	O
the	O
patient	O
became	O
acutely	B-PROBLEM
agitated	I-PROBLEM
,	O
threatening	O
to	O
leave	O
,	O
and	O
also	O
threatening	O
to	O
harm	O
those	O
nurses	O
and	O
physicians	O
that	O
were	O
attempting	O
to	O
prevent	O
him	O
from	O
leaving	O
.	O

restraints	B-TREATMENT
,	O
for	O
the	O
safety	O
of	O
both	O
the	O
patient	O
and	O
the	O
staff	O
of	O
the	O
hospital	O
.	O

The	B-TREATMENT
restraints	I-TREATMENT
were	O
weaned	O
off	O
overnight	O
although	O
he	O
became	O
acutely	B-PROBLEM
agitated	I-PROBLEM
and	O
they	O
were	O
replaced	O
early	O
on	O
08-31	O
.	O

Later	O
in	O
the	O
morning	O
on	O
08-31	O
,	O
the	O
patient	O
was	O
more	O
oriented	O
and	O
alert	O
,	O
and	O
asked	O
to	O
have	O
the	B-TREATMENT
restraints	I-TREATMENT
removed	O
.	O

The	O
patient	O
continued	O
to	O
do	O
well	O
and	O
did	O
not	O
require	O
restraints	B-TREATMENT
after	O
that	B-PROBLEM
event	I-PROBLEM
.	O

Intramuscular	B-TREATMENT
as	O
well	O
as	O
intravenous	B-TREATMENT
Haldol	I-TREATMENT
were	O
ordered	O
p.r.n.	O
for	O
emergency	O
use	O
should	O
he	O
become	O
acutely	B-PROBLEM
agitated	I-PROBLEM
.	O

haldol	B-TREATMENT
as	O
well	O
as	O
the	B-TREATMENT
restraints	I-TREATMENT
were	O
not	O
required	O
after	O
the	O
morning	O
of	O
the	O
23rd	O
.	O

Each	O
progressive	O
day,	O
Mr.	O
Donald	O
delirium	B-PROBLEM
abated	O
with	O
return	O
to	O
baseline	O
mental	O
status	O
early	O
on	O
09-01	O
.	O

The	O
likely	O
cause	O
of	O
the	B-PROBLEM
delirium	I-PROBLEM
was	O
a	O
combination	O
of	O
surgery	B-TREATMENT
and	O
Intensive	O
Care	O
Unit	O
stay	O
in	O
addition	O
to	O
poly-pharmacy	B-TREATMENT
.	O

Other	O
concerns	O
during	O
his	O
stay	O
was	O
his	B-TEST
kidney	I-TEST
function	I-TEST
,	O
due	O
to	O
his	B-TREATMENT
renal	I-TREATMENT
transplant	I-TREATMENT
in	O
2003	O
.	O

His	B-TREATMENT
immunosuppressive	I-TREATMENT
therapy	I-TREATMENT
was	O
continued	O
throughout	O
his	O
stay	O
;	O
his	B-TEST
creatinine	I-TEST
remained	O
approximately	O
2.3	O
to	O
2.4	O
;	O
he	O
has	O
a	B-PROBLEM
baseline	I-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
.	O

With	O
this	O
in	O
mind	O
,	O
when	O
obtaining	O
a	B-TEST
CT	I-TEST
scan	I-TEST
it	O
was	O
determined	O
that	O
contrast	B-TREATMENT
would	O
not	O
be	O
the	O
best	O
option	O
.	O

While	O
the	O
patient	O
was	O
in	O
restraints	B-TREATMENT
,	O
gentle	B-TREATMENT
hydration	I-TREATMENT
was	O
initiated	O
since	O
p.o.	B-TEST
intake	I-TEST
was	O
not	B-PROBLEM
adequate	I-PROBLEM
.	O

As	O
for	O
his	B-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
,	O
the	O
Mahoney	O
Team	O
provided	O
updated	O
recommendations	O
each	O
day	O
,	O
adjusting	O
for	O
the	O
changing	O
p.o.	O
intake	O
.	O

The	O
only	O
other	B-PROBLEM
complaints	I-PROBLEM
from	O
Mr.	O
Mackey	O
during	O
his	O
stay	O
were	O
:	O

Soreness	B-PROBLEM
at	O
his	B-PROBLEM
operative	I-PROBLEM
sites	I-PROBLEM
,	O
for	O
which	O
he	O
was	O
given	O
p.r.n.	B-TREATMENT
Tylenol	I-TREATMENT
once	O
his	B-PROBLEM
delirium	I-PROBLEM
had	O
resolved	O
.	O

In	O
addition	O
,	O
he	O
also	O
complained	O
of	O
difficulty	B-PROBLEM
with	I-PROBLEM
swallowing	I-PROBLEM
,	O
necessitating	O
only	O
soft	B-TREATMENT
and	I-TREATMENT
liquid	I-TREATMENT
diet	I-TREATMENT
.	O

This	O
was	O
attributed	O
to	O
postoperative	B-PROBLEM
swelling	I-PROBLEM
and	O
changes	O
from	O
his	B-TREATMENT
diskectomy	I-TREATMENT
performed	O
2010-08-27	O
.	O

3.	O
He	O
was	O
also	O
discharged	O
home	O
with	O
Visiting	O
Nurse	O
Association	O
for	O
Physical	B-TEST
Therapy	I-TEST
evaluation	I-TEST
of	O
home	O
safety	O
.	O

1.	O
Venlafaxine	B-TREATMENT
XR	I-TREATMENT
75	O
mg	O
q.	O
a.m.	O

2.	O
Furosemide	B-TREATMENT
20	O
mg	O
q.o.d.	O

3.	O
Metoprolol	B-TREATMENT
100	O
mg	O
twice	O
a	O
day	O
.	O

4.	O
Nitroglycerin	B-TREATMENT
sublingual	I-TREATMENT
0.3	O
mg	O
p.r.n.	O

5.	O
Cyclosporin	B-TREATMENT
microemulsion	I-TREATMENT
.	O

6.	O
Neoral	B-TREATMENT
100	O
mg	O
twice	O
a	O
day	O
.	O

7.	O
Zithropren	B-TREATMENT
50	O
mg	O
q.	O
day	O
.	O

8.	O
Prednisone	B-TREATMENT
10	O
mg	O
q.	O
day	O
.	O

9.	O
Minoxidil	B-TREATMENT
10	O
mg	O
twice	O
a	O
day	O
.	O

10.	O
Prilosec	B-TREATMENT
20	O
mg	O
q.	O
day	O
.	O

11.	O
NPH	B-TREATMENT
30	O
units	O
q.	O
a.m.	O
,	O
5	O
to	O
6	O
units	O
q.	O
p.m.	O

12.	O
Regular	B-TREATMENT
insulin	I-TREATMENT
5	O
units	O
q.	O
a.m.	O
and	O
3	O
to	O
5	O
units	O
q.	O
p.m.	O

13.	O
Wellbutrin	B-TREATMENT
100	O
mg	O
q.	O
day	O
.	O

14.	O
Zocor	B-TREATMENT
60	O
mg	O
q.	O
day	O
.	O

15.	O
Nitroglycerin	B-TREATMENT
SR	I-TREATMENT
2.5	O
mg	O
twice	O
a	O
day	O
.	O

He	O
was	O
instructed	O
to	O
hold	O
the	O
following	O
three	O
medications	B-TREATMENT
that	O
he	O
took	O
prior	O
to	O
admission	O
:	O

Nortriptyline	B-TREATMENT
10	O
mg	O
q.	O
h.s.	O
;	O
Flomax	B-TREATMENT
0.4	O
mg	O
q.	O
h.s.	O
;	O
Neurontin	B-TREATMENT
600	O
mg	O
three	O
times	O
a	O
day	O
.	O

1.	O
C4-C5	B-TREATMENT
,	I-TREATMENT
C5-C6	I-TREATMENT
,	I-TREATMENT
anterior	I-TREATMENT
microdiscectomy	I-TREATMENT
and	I-TREATMENT
fusion	I-TREATMENT
with	O
right	B-TREATMENT
iliac	I-TREATMENT
bone	I-TREATMENT
graft	I-TREATMENT
.	O

1.	O
End-stage	B-PROBLEM
renal	I-PROBLEM
disease	I-PROBLEM
secondary	O
to	O
type	B-PROBLEM
1	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
;	O
status	O
post	O
renal	B-TREATMENT
transplant	I-TREATMENT
in	O
2003	O
.	O

2.	O
History	O
of	O
multiple	B-PROBLEM
urinary	I-PROBLEM
tract	I-PROBLEM
infections	I-PROBLEM
.	O

3.	O
Pyelonephritis	B-PROBLEM
.	O

4.	O
Creatinine	B-TEST
2.2	O
to	O
2.5	O
.	O

5.	O
Right	B-TREATMENT
coronary	I-TREATMENT
artery	I-TREATMENT
stent	I-TREATMENT
in	O
2008	O
;	O
ejection	B-TEST
fraction	I-TEST
60	O
to	O
65%	O
.	O

6.	O
Type	B-PROBLEM
1	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
with	O
triopathy	B-PROBLEM
,	O
retinopathy	B-PROBLEM
,	O
neuropathy	B-PROBLEM
,	O
nephropathy	B-PROBLEM
.	O

7.	O
Benign	B-PROBLEM
prostatic	I-PROBLEM
hypertrophy	I-PROBLEM
status	O
post	O
transurethral	B-TREATMENT
resection	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
prostate	I-TREATMENT
;	O
self	B-TREATMENT
catheterization	I-TREATMENT
.	O

8.	O
Hypertension	B-PROBLEM
.	O

9.	O
Hypercholesterolemia	B-PROBLEM
.	O

10.	O
Hepatitis	B-PROBLEM
B	I-PROBLEM
.	O

11.	O
Throat	B-PROBLEM
cancer	I-PROBLEM
status	O
post	O
right	B-TREATMENT
neck	I-TREATMENT
dissection	I-TREATMENT
and	O
XRT	B-TREATMENT
in	O
2004	O
.	O

12.	O
Cerebral	B-PROBLEM
aneurysm	I-PROBLEM
.	O

13.	O
Left	B-TREATMENT
prosthetic	I-TREATMENT
CMED	O
CCU	O
.	O

Gentamicin	B-TREATMENT
,	O
and	O
ibuprofen	B-TREATMENT
.	O

Mr.	O
Cordano	O
is	O
a	O
58-year-old	O
gentlemen	O
with	O
a	O
past	O
medical	O
history	O
significant	O
for	O
primary	B-PROBLEM
sclerosing	I-PROBLEM
cholangitis	I-PROBLEM
who	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
and	O
percutaneous	B-TEST
transhepatic	I-TEST
cholangiogram	I-TEST
.	O

The	B-TREATMENT
most	I-TREATMENT
recent	I-TREATMENT
percutaneous	I-TREATMENT
transluminal	I-TREATMENT
coronary	I-TREATMENT
angioplasty	I-TREATMENT
was	O
done	O
in	O
2009-07-25	O
.	O

At	O
the	O
time	O
an	B-TREATMENT
8	I-TREATMENT
Caucasian	I-TREATMENT
catheter	I-TREATMENT
was	O
placed	O
in	O
the	O
common	O
hepatic/bioduct	O
for	O
external	B-TREATMENT
drainage	I-TREATMENT
.	O

The	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
also	O
showed	O
the	O
presence	O
proximal	O
common	O
bile	O
duct	O
.	O

Nodularities	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
common	I-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
visualized	O
by	O
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
was	O
also	O
worrisome	O
for	O
cholangiocarcinoma	B-PROBLEM
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Blue	O
General	O
Surgery	O
Service	O
for	O
possible	O
surgical	B-TREATMENT
interventions	I-TREATMENT
.	O

Ulcerative	B-PROBLEM
colitis	I-PROBLEM
,	O
primary	B-PROBLEM
sclerosing	I-PROBLEM
cholangitis	I-PROBLEM
.	O

Status	O
post	O
placement	B-TREATMENT
of	I-TREATMENT
percutaneous	I-TREATMENT
transhepatic	I-TREATMENT
biliary	I-TREATMENT
drainage	I-TREATMENT
with	O
placement	B-TREATMENT
of	I-TREATMENT
8	I-TREATMENT
Caucasian	I-TREATMENT
nephrostomy	I-TREATMENT
catheter	I-TREATMENT
in	O
the	O
common	O
bile	O
duct	O
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

1.	O
Ursodiol	B-TREATMENT
600	O
mg	O
t.i.d.	O

2.	O
Ambien	B-TREATMENT
5	O
mg	O
q.h.s.	O

The	O
patient	O
is	O
a	O
jaundiced	O
looking	O
gentlemen	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

The	O
head	O
is	O
normocephalic	O
,	O
atraumatic	B-PROBLEM
and	O
eyes	O
are	O
icteric	B-PROBLEM
.	O

The	O
neck	O
is	O
supple	O
with	O
no	O
lymphadenopathy	B-PROBLEM
.	O

The	O
chest	O
is	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

There	O
is	O
no	O
murmurs	B-PROBLEM
.	O

The	O
abdomen	O
was	O
soft	O
,	O
nontender	B-PROBLEM
,	O
no	O
masses	B-PROBLEM
and	O
nondistended	B-PROBLEM
.	O

There	O
is	O
no	O
hepatosplenomegaly	B-PROBLEM
.	O

Rectal	B-TEST
exam	I-TEST
showed	O
no	O
masses	B-PROBLEM
and	O
is	O
guaiac	B-TEST
negative	O
.	O

Neurological	B-TEST
exam	I-TEST
was	O
grossly	O
intact	O
.	O

A	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
of	O
14.2	O
,	O
hematocrit	B-TEST
of	O
35.3	O
,	O
platelet	B-TEST
count	I-TEST
of	O
449,000	O
.	O

Sodium	B-TEST
of	O
130	O
,	O
potassium	B-TEST
3.5	O
,	O
chloride	B-TEST
93	O
,	O
bicarbonate	B-TEST
28	O
,	O
BUN	B-TEST
15	O
,	O
creatinine	B-TEST
1.1,	O
prothrombin	B-TEST
time	I-TEST
14.1	O
,	O
partial	B-TEST
thrombin	I-TEST
time	I-TEST
29.7	O
.	O

INR	B-TEST
1.4	O
.	O

ALT	B-TEST
106	O
,	O
AST	B-TEST
149	O
,	O
alkaline	B-TEST
phosphatase	I-TEST
242	O
.	O

Total	B-TEST
bilirubin	I-TEST
10.1	O
,	O
amylase	B-TEST
90	O
and	O
lipase	B-TEST
112	O
.	O

Chest	B-TEST
x-ray	I-TEST
revealed	O
minimal	B-PROBLEM
left	I-PROBLEM
base	I-PROBLEM
atelectasis	I-PROBLEM
and	O
elevation	B-PROBLEM
of	I-PROBLEM
left	I-PROBLEM
hemidiaphragm	I-PROBLEM
.	O

A	B-TEST
CT	I-TEST
scan	I-TEST
with	I-TEST
po	I-TEST
contrast	I-TEST
showed	O
dilation	B-PROBLEM
of	I-PROBLEM
intrahepatic	I-PROBLEM
common	I-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
which	O
is	O
improved	O
from	O
previous	B-TEST
studies	I-TEST
.	O

It	O
is	O
also	O
noted	O
that	O
there	O
was	O
splenomegaly	B-PROBLEM
.	O

Mr.	O
Cordano	O
was	O
admitted	O
on	O
2009-08-17	O
for	O
a	B-TREATMENT
replacement	I-TREATMENT
of	I-TREATMENT
transhepatic	I-TREATMENT
biliary	I-TREATMENT
drainage	I-TREATMENT
catheter	I-TREATMENT
.	O

At	O
that	O
time	O
,	O
cholangiogram	B-TEST
confirmed	O
that	O
there	O
was	O
a	B-PROBLEM
distal	I-PROBLEM
stricture	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
common	I-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
.	O

An	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
also	O
demonstrated	O
similar	O
findings	O

and	O
it	O
is	O
noted	O
there	O
was	O
nodularity	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
common	I-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
which	O
is	O
worrisome	O
for	O
cholangiocarcinoma	B-PROBLEM
.	O

Therefore	O
,	O
the	O
patient	O
was	O
taken	O
to	O
the	O
Operating	O
Room	O
on	O
2009-08-24	O
for	O
a	B-TREATMENT
Whipple	I-TREATMENT
procedure	I-TREATMENT
versus	O
hepaticojejunostomy	B-TREATMENT
.	O

On	O
exploration	B-TEST
of	I-TEST
the	I-TEST
abdomen	I-TEST
revealed	O
significant	B-PROBLEM
nodularity	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
liver	I-PROBLEM
indicating	O
of	O
advanced	B-PROBLEM
cirrhosis	I-PROBLEM
.	O

region	B-PROBLEM
nodularity	I-PROBLEM
,	O
which	O
is	O
identified	O
previously	O
by	O
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
,	O
and	O
regional	O
lymph	O
nodes	O
were	O
all	O
sent	O
to	O
pathology	B-TEST
.	O

They	O
were	O
all	O
negative	O
for	O
malignancy	B-PROBLEM
and	O
therefore	O
a	B-TREATMENT
hepaticojejunostomy	I-TREATMENT

Cholangiogram	B-TEST
on	O
postoperative	O
day	O
number	O
two	O
showed	O
no	O
evidence	O
of	O
leakage	B-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
anastomosis	I-PROBLEM
site	I-PROBLEM
.	O

The	O
patient	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
he	O
was	O
sent	O
to	O
the	O
floor	O
in	O
stable	O
condition	O
.	O

The	O
patient	O
's	O
postoperative	O
course	O
was	O
notable	O
for	O
an	B-PROBLEM
elevation	I-PROBLEM
in	O
white	B-TEST
blood	I-TEST
cell	I-TEST
count	O
peaking	O
at	O
30.0	O
on	O
postoperative	O
day	O
number	O
two	O
.	O

He	O
was	O
given	O
Unasyn	B-TREATMENT
for	O
empiric	B-TREATMENT
antibiotic	I-TREATMENT
treatment	I-TREATMENT
.	O

At	O
the	O
time	O
,	O
blood	O
,	O
urine	O
and	O
bile	O
was	O
sent	O
for	O
culture	B-TEST
,	O
which	O
were	O
all	O
negative	O
.	O

A	B-TEST
chest	I-TEST
x-ray	I-TEST
was	O
also	O
negative	O
for	O
any	B-PROBLEM
pneumonia	I-PROBLEM
.	O

Postoperatively	O
,	O
Mr.	O
Cordano	O
also	O
suffered	O
from	O
low	B-PROBLEM
urine	I-PROBLEM
output	I-PROBLEM
ranges	O
between	O
25	O
to	O
30	O
cc	O
per	O
hour	O
.	O

Fractional	B-TEST
excretion	I-TEST
of	I-TEST
sodium	I-TEST
was	O
less	O
than	O
1%	O
suggesting	O
a	B-PROBLEM
prerenal	I-PROBLEM
etiology	I-PROBLEM
.	O

The	B-TEST
sodium	I-TEST
creatinine	I-TEST
peaked	O
at	O
2.0	O
and	O
the	O
patient	O
was	O
treated	O
with	O
boluses	B-TREATMENT
of	I-TREATMENT
intravenous	I-TREATMENT
fluid	I-TREATMENT
and	O
intravenous	B-TREATMENT
albumin	I-TREATMENT
infusion	I-TREATMENT
was	O
also	O
administered	O
.	O

He	O
responded	O
well	O
to	O
this	B-TREATMENT
regimen	I-TREATMENT
and	O
made	O
adequate	O
urine	O
output	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
patient	O
also	O
developed	O
distentions	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
abdomen	I-PROBLEM
consistent	O
with	O
accumulation	B-PROBLEM
of	I-PROBLEM
ascitic	I-PROBLEM
fluid	I-PROBLEM
.	O

He	O
also	O
had	O
significant	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
and	I-PROBLEM
scrotum	I-PROBLEM
edema	I-PROBLEM
.	O

On	O
postoperative	O
day	O
number	O
eight	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
oxygen	I-TEST
saturation	I-TEST
dropped	O
to	O
85%	O
on	O
room	O
air	O
and	O
he	O
was	O
transferred	O
to	O
the	O
Surgical	O
Intensive	O
Care	O
Unit	O
for	O
fluid	B-TREATMENT
management	I-TREATMENT
.	O

Chest	B-TEST
x-ray	I-TEST
and	O
sputum	B-TEST
culture	I-TEST
obtained	O
at	O
the	O
time	O
were	O
negative	O
and	O
the	O
patient	O
was	O
treated	O
with	O
100%	B-TREATMENT
nonrebreather	I-TREATMENT
which	O
improved	O
his	B-TEST
oxygenation	I-TEST
.	O

While	O
he	O
is	O
in	O
the	O
Surgical	O
Intensive	O
Care	O
Unit	O
,	O
paracentesis	B-TEST
was	O
performed	O
and	O
it	O

revealed	O
greater	O
than	O
24,000	O
white	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
in	O
the	B-PROBLEM
ascites	I-PROBLEM
which	O
is	O
consistent	O
with	O
SVT	B-PROBLEM
.	O

He	O
was	O
given	O
Zosyn	B-TREATMENT
for	O
empiric	B-TREATMENT
treatment	I-TREATMENT
.	O

Gram	B-TEST
stain	I-TEST
and	O
culture	B-TEST
of	O
the	B-PROBLEM
ascites	I-PROBLEM
failed	O
to	O
identify	O
any	B-PROBLEM
organism	I-PROBLEM
.	O

He	O
was	O
weaned	O
from	O
oxygen	B-PROBLEM
requirement	I-PROBLEM
and	O
was	O
continued	O
on	O
normal	B-TREATMENT
saline	I-TREATMENT
boluses	I-TREATMENT
and	O

intravenous	B-TREATMENT
albumin	I-TREATMENT
for	O
treatment	O
of	O
prerenal	B-PROBLEM
azotemia	I-PROBLEM
.	O

Somatostatin	B-TREATMENT
and	O
midodrine	B-TREATMENT
were	O
also	O
given	O
for	O
this	B-PROBLEM
condition	I-PROBLEM
and	O
he	O
also	O
received	O
packed	B-TREATMENT
red	I-TREATMENT
blood	I-TREATMENT
cells	I-TREATMENT
.	O

On	O
postoperative	O
day	O
number	O
ten	O
,	O
the	O
patient	O
returned	O
to	O
the	O
floor	O
with	O
improved	O
renal	O
function	O
and	O
without	O
oxygen	B-PROBLEM
requirement	I-PROBLEM
.	O

The	B-TREATMENT
somatostatin	I-TREATMENT
and	O
the	B-TREATMENT
midodrine	I-TREATMENT
were	O
discontinued	O
and	O
the	O
regimen	O
of	O
Lasix	B-TREATMENT
and	O
spironolactone	B-TREATMENT
was	O
started	O
for	O
diuresis	B-TREATMENT
.	O

His	B-TEST
creatinine	I-TEST
levels	I-TEST
trended	O
toward	O
normal	O
and	O
the	B-TEST
fractional	I-TEST
excretion	I-TEST
of	I-TEST
sodium	I-TEST
also	O
increased	O
indicating	O
a	O
resolution	O
of	O
the	B-PROBLEM
prerenal	I-PROBLEM
kidney	I-PROBLEM
failure	I-PROBLEM
.	O

He	O
has	O
a	B-TREATMENT
PICC	I-TREATMENT
line	I-TREATMENT
in	O
place	O
for	O
continued	O
treatment	O
with	O
Rocephin	B-TREATMENT
and	O
he	O
will	O
have	O
a	O
visiting	O
nurse	O
to	O
help	O
him	O
to	O
administer	O
these	B-TREATMENT
medications	I-TREATMENT
.	O

While	O
in	O
the	O
hospital	O
,	O
the	O
patient	O
received	O
initial	B-TEST
work-up	I-TEST
including	O
echocardiogram	B-TEST
,	O
electrocardiogram	B-TEST
and	O
serology	B-TEST
studies	I-TEST
to	O
be	O
listed	O
for	O
liver	B-TREATMENT
transplant	I-TREATMENT
.	O

1.	O
Rocephin	B-TREATMENT
1	O
gram	O
q.d.	O

2.	O
Furosemide	B-TREATMENT
10	O
mg	O
q.d.	O

3.	O
Spironolactone	B-TREATMENT
100	O
mg	O
q.d.	O

4.	O
Ursodiol	B-TREATMENT
600	O
mg	O
po	O
t.i.d.	O

PSC	B-PROBLEM
,	O
status	O
post	O
hepaticojejunostomy	B-TREATMENT
.	O

This	O
is	O
a	O
56	O
year	O
old	O
man	O
with	O
history	O
of	O
hypercholesterolemia	B-PROBLEM
and	O
type	B-PROBLEM
II	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
.	O

He	O
has	O
a	O
recent	O
history	O
of	O
dyspnea	B-PROBLEM
on	O
exertion	O
on	O
exertional	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
which	O
has	O
increased	O
over	O
the	O
last	O
several	O
weeks	O
and	O
is	O
relieved	O
by	O
sublingual	B-TREATMENT
nitroglycerin	I-TREATMENT
.	O

On	O
2016-06-26	O
,	O
he	O
had	O
a	B-PROBLEM
positive	I-PROBLEM
exercise	I-PROBLEM
tolerance	I-PROBLEM
test	I-PROBLEM
.	O

Cardiac	B-TEST
catheterization	I-TEST
at	O
the	O
end	O
of	O
October	O
revealed	O
a	B-PROBLEM
dilated	I-PROBLEM
aortic	I-PROBLEM
root	I-PROBLEM
to	O
4.4	O
cm	O
and	O
80%	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
mid	I-PROBLEM
left	I-PROBLEM
anterior	I-PROBLEM
descending	I-PROBLEM
at	O
the	O
bifurcation	O
involving	O
the	O
diagonal	O
branch	O
,	O
70%	B-PROBLEM
stenoses	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
circumflex	I-PROBLEM
and	I-PROBLEM
oblique	I-PROBLEM
marginal	I-PROBLEM
artery	I-PROBLEM
and	O
90%	B-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
posterior	I-PROBLEM
descending	I-PROBLEM
artery	I-PROBLEM
.	O

His	B-TEST
atrioventricular	I-TEST
valve	I-TEST
gradient	I-TEST
was	O
27	O
with	O
an	B-TEST
AV	I-TEST
surface	I-TEST
area	I-TEST
of	O
.91	O
.	O

Review	B-TEST
of	I-TEST
systems	I-TEST
shows	O
that	O
the	O
patient	O
denies	O
any	B-PROBLEM
orthopnea	I-PROBLEM
,	O
paroxysmal	B-PROBLEM
nocturnal	I-PROBLEM
dyspnea	I-PROBLEM
.	O

He	O
has	O
no	O
bleeding	B-PROBLEM
or	O
clotting	B-PROBLEM
problems	I-PROBLEM
.	O

Juanita	O
does	O
not	O
feel	O
any	B-PROBLEM
palpitations	I-PROBLEM
.	O

He	O
does	O
not	O
have	O
wheezing	B-PROBLEM
,	O
claudication	B-PROBLEM
or	O
gastrointestinal	B-PROBLEM
bleeding	I-PROBLEM
.	O

Nor	O
does	O
he	O
have	O
any	O
history	O
of	O
stroke	B-PROBLEM
like	I-PROBLEM
symptoms	I-PROBLEM
.	O

Hypercholesterolemia	B-PROBLEM
.	O

Type	B-PROBLEM
II	I-PROBLEM
diabetes	I-PROBLEM
.	O

Recent	B-PROBLEM
pneumonia	I-PROBLEM
.	O

Recent	B-PROBLEM
weight	I-PROBLEM
loss	I-PROBLEM
associated	O
with	O
the	B-PROBLEM
pneumonia	I-PROBLEM
.	O

Gastroesophageal	B-PROBLEM
reflux	I-PROBLEM
disease	I-PROBLEM
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

One	O
aspirin	B-TREATMENT
a	O
day	O
.	O

Nexium	B-TREATMENT
40	O
mg	O
a	O
day	O
.	O

Carvedilol	B-TREATMENT
6.125	O
mg	O
a	O
day	O
.	O

Glucophage	B-TREATMENT
25	O
mg	O
once	O
a	O
day	O
.	O

Lipitor	B-TREATMENT
10	O
mg	O
once	O
a	O
day	O
.	O

On	O
physical	B-TEST
examination	I-TEST
,	O
the	O
patient	O
is	O
afebrile	B-PROBLEM
.	O

Weight	B-TEST
is	O
82	O
kilograms	O
.	O

Blood	B-TEST
pressure	I-TEST
126/66	O
.	O

Head	B-TEST
and	I-TEST
neck	I-TEST
examination	I-TEST
:	O

No	O
bruits	B-PROBLEM
appreciated	O
.	O

Lungs	O
are	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

3/6	B-PROBLEM
systolic	I-PROBLEM
ejection	I-PROBLEM
murmur	I-PROBLEM
throughout	O
his	O
precordium	O
.	O

His	O
abdomen	O
is	O
soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
.	O

No	O
hepatosplenomegaly	B-PROBLEM
and	O
no	O
CVA	B-PROBLEM
tenderness	I-PROBLEM
.	O

Extremities	O
are	O
warm	O
,	O
well	O
perfused	O
,	O
no	O
cyanosis	B-PROBLEM
,	O
clubbing	B-PROBLEM
or	O

edema	B-PROBLEM
.	O

No	O
varicosities	B-PROBLEM
noted	O
.	O

He	O
was	O
admitted	O
to	O
the	O
cardiac	O
surgery	O
service	O
for	O
an	B-TREATMENT
elected	I-TREATMENT
Bental	I-TREATMENT
procedure	I-TREATMENT
with	O
homograft	B-TREATMENT
and	O
coronary	B-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
graft	I-TREATMENT
.	O

Once	O
consent	O
and	O
preoperative	B-TEST
evaluation	I-TEST
was	O
complete	O
,	O
he	O
was	O
taken	O
to	O
the	O
operating	O
room	O
.	O

Briefly	O
,	O
the	O
patient	O
was	O
taken	O
to	O
the	O
operating	O
room	O
to	O
repair	B-TREATMENT
his	B-PROBLEM
critical	I-PROBLEM
aortic	I-PROBLEM
stenosis	I-PROBLEM
,	O
his	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
and	O
his	B-PROBLEM
significantly	I-PROBLEM
dilated	I-PROBLEM
ascending	I-PROBLEM
aortic	I-PROBLEM
aneurysm	I-PROBLEM
.	O

The	B-TREATMENT
procedure	I-TREATMENT
was	O
an	B-TREATMENT
aortic	I-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
with	O
a	B-TREATMENT
tissue	I-TREATMENT
valve	I-TREATMENT
,	O
a	B-TREATMENT
coronary	I-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
graft	I-TREATMENT
procedure	I-TREATMENT
where	O
five	B-TREATMENT
grafts	I-TREATMENT
were	O
performed	O
.	O

The	O
left	O
internal	O
mammary	O
artery	O
was	O
connected	O
to	O
the	O
proximal	O
left	O
anterior	O
descending	O
and	O
saphenous	B-TREATMENT
vein	I-TREATMENT
grafts	I-TREATMENT
were	O
connected	O
to	O
the	O
posterior	O
descending	O
artery	O
,	O
diagonal	O
branch	O
,	O
obtuse	O
marginal	O
and	O
distal	O
left	O
anterior	O
descending	O
.	O

Finally	O
,	O
a	B-TREATMENT
super	I-TREATMENT
coronary	I-TREATMENT
arch	I-TREATMENT
graft	I-TREATMENT
was	O
implanted	O
.	O

This	O
was	O
a	B-TREATMENT
....................	I-TREATMENT
graft	I-TREATMENT
.	O

Cardiopulmonary	B-TREATMENT
bypass	I-TREATMENT
time	O
was	O
234	O
minutes	O
.	O

His	O
aorta	O
was	O
cross	B-TREATMENT
clamped	I-TREATMENT
for	O
168	O
minutes	O
.	O

He	O
had	O
pharmacologic	B-TREATMENT
circulatory	I-TREATMENT
arrest	I-TREATMENT
for	O
18	O
minutes	O
.	O

The	O
patient	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
was	O
transferred	O
to	O
the	O
unit	O
,	O
intubated	B-TREATMENT
on	O
Milrinone	B-TREATMENT
,	O
Levophed	B-TREATMENT
and	O
Propofol	B-TREATMENT
drips	I-TREATMENT
.	O

The	O
patient	O
remained	O
intubated	B-TREATMENT
until	O
postoperative	O
day	O
number	O
five	O
.	O

After	O
that	O
,	O
the	O
patient	O
had	O
no	O
major	B-PROBLEM
problems	I-PROBLEM
with	I-PROBLEM
his	I-PROBLEM
lungs	I-PROBLEM
.	O

His	B-TEST
oxygen	I-TEST
saturations	I-TEST
remained	O
good	O
and	O
he	O
did	O
not	O
require	O
supplemental	B-TREATMENT
oxygen	I-TREATMENT
more	O
than	O
a	O
couple	O
of	O
days	O
after	O
his	O
extubation	O
.	O

After	O
an	O
extended	O
stay	O
for	O
hemodynamic	B-TEST
monitoring	I-TEST
and	O
pressor	B-TREATMENT
support	I-TREATMENT
to	O
maintain	O
his	O
perfusion	O
.	O

The	B-PROBLEM
major	I-PROBLEM
neurologic	I-PROBLEM
event	I-PROBLEM
of	O
this	O
hospital	O
course	O
was	O
that	O
the	O
patient	O
was	O
slow	B-PROBLEM
to	I-PROBLEM
awake	I-PROBLEM
after	O
his	B-TREATMENT
Propofol	I-TREATMENT
drip	I-TREATMENT
was	O
discontinued	O
.	O

Because	O
of	O
his	B-PROBLEM
confusion	I-PROBLEM
,	O
a	O
neurology	O
consult	O
was	O
obtained	O
and	O
subsequent	B-TEST
radiographic	I-TEST
imaging	I-TEST
revealed	O
chronic	B-PROBLEM
appearing	I-PROBLEM
infarcts	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
occipital	I-PROBLEM
lobe	I-PROBLEM
as	O
well	O
as	O
both	O
cerebellar	O
hemispheres	O
,	O
suggestive	O
of	O
more	B-PROBLEM
chronic	I-PROBLEM
infarcts	I-PROBLEM
,	O
as	O
well	O
as	O
an	O
area	O
in	O
the	O
left	O
corona	O
radiata	O
,	O
adjacent	O
to	O
the	O
left	O
lateral	O
ventricle	O
which	O
may	O
or	O
may	O
not	O
be	O
an	B-PROBLEM
acute	I-PROBLEM
infarct	I-PROBLEM
.	O

This	O
was	O
seen	O
on	O
the	B-TEST
CAT	I-TEST
scan	I-TEST
on	O
postoperative	O
day	O
number	O
one	O
,	O
12-31	O
.	O

As	O
the	O
patient	O
became	O
more	O
awake	O
,	O
he	O
still	O
remained	O
somewhat	B-PROBLEM
confused	I-PROBLEM
and	O
a	B-PROBLEM
little	I-PROBLEM
bit	I-PROBLEM
out	I-PROBLEM
of	I-PROBLEM
it	I-PROBLEM
.	O

In	O
addition	O
,	O
he	O
was	O
noted	O
to	O
have	O
a	B-PROBLEM
right	I-PROBLEM
sided	I-PROBLEM
hemiplegia	I-PROBLEM
.	O

Over	O
his	O
postoperative	O
course	O
,	O
Mr.	O
Douglass	O
has	O
gradually	O
been	O
able	O
to	O
utilize	O
more	O
and	O
more	O
of	O
his	O
right	O
side	O
and	O
with	O
the	O
assistance	O
of	O
physical	B-TREATMENT
therapy	I-TREATMENT
and	O
occupational	B-TREATMENT
therapy	I-TREATMENT
,	O
he	O
has	O
4	O
to	O
5	O
+	O
strength	O
in	O
his	O
right	O
hand	O
and	O
arm	O
and	O
about	O
4	O
+	O
strength	O
in	O
his	O
right	O
leg	O
.	O

In	O
addition	O
,	O
Mr.	O
Douglass	O
is	O
given	O
Trazodone	B-TREATMENT
to	O
help	O
him	O
sleep	O
at	O
night	O
.	O

A	O
psychiatric	O
consult	O
was	O
also	O
obtained	O
due	O
to	O
his	O
mental	O
status	O
and	O
confusion	B-PROBLEM
postoperatively	O
but	O
his	B-PROBLEM
psychiatric	I-PROBLEM
issues	I-PROBLEM
are	O
mostly	O
related	O
to	O
his	B-PROBLEM
neurologic	I-PROBLEM
insults	I-PROBLEM
and	O
he	O
has	O
no	O
distinctive	B-PROBLEM
psychiatric	I-PROBLEM
disorder	I-PROBLEM
,	O
except	O
for	O
perhaps	O
postoperative	B-PROBLEM
delirium	I-PROBLEM
.	O

Cardiovascularly	O
,	O
the	O
patient	O
did	O
extremely	O
well	O
following	O
the	B-TREATMENT
surgery	I-TREATMENT
.	O

The	B-TREATMENT
Levophed	I-TREATMENT
drip	I-TREATMENT
was	O
continued	O
until	O
postoperative	O
day	O
number	O
one	O
.	O

Milrinone	B-TREATMENT
was	O
continued	O
until	O
postoperative	O
day	O
number	O
three	O
,	O
at	O
which	O
point	O
he	O
was	O
having	O
good	O
enough	O
cardiac	O
output	O
that	O
he	O
did	O
not	O
need	O
these	B-TREATMENT
drips	I-TREATMENT
to	O
help	O
maintain	O
his	B-TEST
blood	I-TEST
pressure	I-TEST
anymore	O
.	O

He	O
has	O
remained	O
without	O
any	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
following	O
this	B-TREATMENT
procedure	I-TREATMENT
and	O
his	B-PROBLEM
sternal	I-PROBLEM
wound	I-PROBLEM
is	O
clean	O
,	O
dry	O
and	O
intact	O
at	O
the	O
end	O
of	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

In	O
addition	O
,	O
he	O
has	O
hypertension	B-PROBLEM
,	O
for	O
which	O
he	O
receives	O
Metoprolol	B-TREATMENT
and	O
he	O
has	O
hypercholesterolemia	B-PROBLEM
,	O
for	O
which	O
he	O
receives	O
nothing	O
at	O
this	O
time	O
.	O

The	O
patient	O
remained	O
intubated	B-TREATMENT
until	O
postoperative	O
day	O
number	O
five	O
.	O

The	O
patient	O
has	O
gastroesophageal	B-PROBLEM
reflux	I-PROBLEM
disease	I-PROBLEM
,	O
for	O
which	O
he	O
has	O
been	O
receiving	O
Zantac	B-TREATMENT
as	O
an	O
inpatient	O
.	O

We	O
will	O
put	O
him	O
back	O
on	O
his	B-TREATMENT
Nexium	I-TREATMENT
.	O

In	O
addition	O
,	O
over	O
the	O
last	O
couple	O
of	O
days	O
prior	O
to	O
discharge	O
,	O
the	O
patient	O
did	O
appear	O
a	B-PROBLEM
little	I-PROBLEM
bit	I-PROBLEM
icteric	I-PROBLEM
.	O

Liver	B-TEST
function	I-TEST
tests	I-TEST
were	O
obtained	O
and	O
they	O
were	O
slightly	B-PROBLEM
elevated	I-PROBLEM
liver	I-PROBLEM
function	I-PROBLEM
tests	I-PROBLEM
and	O
ALT	B-TEST
was	O
44	O
,	O
AST	B-TEST
was	O
34	O
;	O
alkaline	B-TEST
phosphatase	I-TEST
was	O
199	O
,	O
within	O
normal	O
limits	O
.	O

Total	B-TEST
bilirubin	I-TEST
was	O
2.8	O
.	O

Amylase	B-TEST
was	O
108	O
and	O
lipase	B-TEST
was	O
213	O
.	O

A	B-TEST
right	I-TEST
upper	I-TEST
quadrant	I-TEST
ultrasound	I-TEST
did	O
not	O
reveal	O
any	B-PROBLEM
gallstones	I-PROBLEM
or	O
common	B-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
dilatation	I-PROBLEM
indicative	O
of	O
cholecystitis	B-PROBLEM
or	O
cholelithiasis	B-PROBLEM
.	O

In	O
addition	O
,	O
the	O
patient	O
did	O
have	O
slightly	B-PROBLEM
elevated	I-PROBLEM
blood	I-PROBLEM
sugars	I-PROBLEM
over	O
the	O
last	O
couple	O
of	O
days	O
and	O
has	O
required	O
an	B-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
and	O
basal	B-TREATMENT
insulin	I-TREATMENT
to	O
maintain	O
his	B-TEST
blood	I-TEST
sugars	I-TEST
at	O
a	O
more	O
appropriate	O
level	O
.	O

Please	O
stay	O
on	O
top	O
of	O
the	B-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
so	O
that	O
the	O
patient	O
can	O
keep	O
a	O
euglycemic	O
level	O
.	O

The	O
patient	O
,	O
during	O
this	O
admission	O
,	O
required	O
transfusion	O
of	O
three	O
units	O
of	O
packed	B-TREATMENT
red	I-TREATMENT
blood	I-TREATMENT
cells	I-TREATMENT
to	O
maintain	O
adequate	O
hematocrit	O
.	O

At	O
the	O
time	O
of	O
discharge	O
,	O
Mr.	O
Norman	O
hematocrit	B-TEST
is	O
at	O
40.7	O
.	O

The	O
patient	O
did	O
receive	O
a	O
significant	O
amount	O
of	O
diuresis	B-TREATMENT
postoperatively	O
and	O
is	O
well	O
below	O
his	O
baseline	O
with	O
weight	B-TEST
,	O
most	O
likely	O
because	O
of	O
his	B-PROBLEM
inability	I-PROBLEM
to	I-PROBLEM
eat	I-PROBLEM
because	O
of	O
his	B-PROBLEM
stroke	I-PROBLEM
.	O

declared	O
him	O
at	O
first	O
an	B-PROBLEM
aspiration	I-PROBLEM
risk	I-PROBLEM
.	O

As	O
Mr.	O
Douglass	O
has	O
improved	O
from	O
his	B-PROBLEM
initial	I-PROBLEM
stroke	I-PROBLEM
,	O
he	O
has	O
become	O
more	O
lucid	O

and	O
is	O
less	O
of	O
an	B-PROBLEM
aspiration	I-PROBLEM
risk	I-PROBLEM
.	O

He	O
is	O
going	O
out	O
on	O
a	B-TREATMENT
cardiac	I-TREATMENT
healthy	I-TREATMENT
,	I-TREATMENT
diabetic	I-TREATMENT
diet	I-TREATMENT
,	O
as	O
tolerated	O
with	O
Boost	B-TREATMENT
supplements	I-TREATMENT
.	O

The	O
patient	O
had	O
positive	B-PROBLEM
blood	I-PROBLEM
and	I-PROBLEM
urine	I-PROBLEM
cultures	I-PROBLEM
on	O
01-05	O
for	O
history	O
of	O
Methicillin	B-PROBLEM
resistant	I-PROBLEM
Staphylococcus	I-PROBLEM
aureus	I-PROBLEM
,	O
which	O
was	O
pan	B-TEST
sensitive	I-TEST
.	O

He	O
was	O
started	O
on	O
Oct.	O
25	O
for	O
this	B-PROBLEM
bug	I-PROBLEM
.	O

On	O
01-08	O
,	O
the	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
central	I-TREATMENT
venous	I-TREATMENT
line	I-TREATMENT
was	O
discontinued	O
.	O

The	B-TEST
catheterization	I-TEST
tip	I-TEST
also	O
grew	O
out	O
Serratia	B-PROBLEM
.	O

On	O
the	O
16th	O
,	O
a	B-TEST
urine	I-TEST
culture	I-TEST
was	O
obtained	O
and	O
did	O
grow	O
out	O
greater	O
than	O
100,000	O
colonies	O
of	O
E.	B-PROBLEM
coli	I-PROBLEM
which	O
was	O
intermittently	B-PROBLEM
resistant	I-PROBLEM
to	O
Ciprofloxacin	B-TREATMENT
.	O

He	O
was	O
started	O
on	O
Bactrim	B-TREATMENT
for	O
that	O
.	O

Please	O
continue	O
Mr.	O
David	O
Montero	O
for	O
one	O
month	O
to	O
fight	O
his	B-PROBLEM
blood	I-PROBLEM
borne	I-PROBLEM
infection	I-PROBLEM
,	O
to	O
prevent	O
seeding	O
of	O
his	B-TREATMENT
aortic	I-TREATMENT
graft	I-TREATMENT
and	O
continue	O
Bactrim	B-TREATMENT
for	O
ten	O
days	O
after	O
discharge	O
to	O
treat	O
the	B-PROBLEM
E.	I-PROBLEM
coli	I-PROBLEM
in	I-PROBLEM
his	I-PROBLEM
urine	I-PROBLEM
.	O

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
status	O
post	O
coronary	B-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
graft	I-TREATMENT
.	O

Critical	B-PROBLEM
aortic	I-PROBLEM
stenosis	I-PROBLEM
,	O
status	O
post	O
aortic	B-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
.	O

Aortic	B-PROBLEM
arch	I-PROBLEM
aneurysm	I-PROBLEM
,	O
status	O
post	O
aortic	B-TREATMENT
arch	I-TREATMENT
graft	I-TREATMENT
.	O

Acute	B-PROBLEM
postoperative	I-PROBLEM
delirium	I-PROBLEM
.	O

Perioperative	B-PROBLEM
stroke	I-PROBLEM
.	O

Chronic	B-PROBLEM
blood	I-PROBLEM
loss	I-PROBLEM
anemia	I-PROBLEM
and	O
chronic	B-TREATMENT
RBC	I-TREATMENT
transfusion	I-TREATMENT
.	O

Urinary	B-PROBLEM
tract	I-PROBLEM
infection	I-PROBLEM
.	O

Hypercholesterolemia	B-PROBLEM
.	O

Type	B-PROBLEM
II	I-PROBLEM
diabetes	I-PROBLEM
.	O

Gastroesophageal	B-PROBLEM
reflux	I-PROBLEM
disease	I-PROBLEM
.	O

Metoprolol	B-TREATMENT
75	O
mg	O
p.o.	O
twice	O
a	O
day	O
.	O

Captopril	B-TREATMENT
12.5	O
mg	O
p.o.	O
three	O
times	O
a	O
day	O
.	O

Aspirin	B-TREATMENT
81	O
mg	O
p.o.	O
q.	O
day	O
.	O

Plavix	B-TREATMENT
75	O
mg	O
p.o.	O
q.	O
day	O
.	O

Heparin	B-TREATMENT
5000	O
units	O
subcutaneous	O
twice	O
a	O
day	O
.	O

Metformin	B-TREATMENT
1000	O
mg	O
extended	O
release	O
p.o.	O
q.	O
day	O
.	O

Humalog	B-TREATMENT
Max	I-TREATMENT
75/25	O
,	O
20	O
units	O
subcutaneous	O
once	O
a	O
day	O
in	O
the	O
morning	O
.	O

Levofloxacin	B-TREATMENT
500	O
mg	O
p.o.	O
q.	O
day	O
.	O

Bactrim	B-TREATMENT
DS	I-TREATMENT
tabs	I-TREATMENT
,	O
one	O
tablet	O
p.o.	O
q.	O
day	O
for	O
ten	O
days	O
.	O

Colace	B-TREATMENT
100	O
mg	O
p.o.	O
twice	O
a	O
day	O
.	O

Hold	O
for	O
loose	B-PROBLEM
stools	I-PROBLEM
.	O

Nexium	B-TREATMENT
40	O
mg	O
p.o.	O
q.	O
day	O
.	O

Trazodone	B-TREATMENT
25	O
mg	O
p.o.	O
q	O
h.s.	O
as	O
needed	O
for	O
sleep	O
.	O

Lasix	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
day	O
for	O
one	O
week	O
.	O

KCl	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
day	O
for	O
one	O
week	O
.	O

Sulfa	B-TREATMENT
(	I-TREATMENT
Sulfonamides	I-TREATMENT
)	I-TREATMENT

Nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
Abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
distention	B-PROBLEM
.	O

1.	O
Subtotal	B-TREATMENT
colectomy	I-TREATMENT
,	O
end	B-TREATMENT
ileostomy	I-TREATMENT
,	O
Hartmann's	B-TREATMENT
pouch	I-TREATMENT
,	O
G-tube	B-TREATMENT

2.	O
Completion	B-TREATMENT
sigmoid	I-TREATMENT
colectomy	I-TREATMENT
,	O
repair	B-TREATMENT
of	O
colovesicular	B-PROBLEM
fistula	I-PROBLEM
,	O
small	B-TREATMENT
bowel	I-TREATMENT
repair	I-TREATMENT

Ms	O
Crossman	O
is	O
an	O
84	O
year	O
old	O
female	O
with	O
complaints	O
of	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
diarrhea	B-PROBLEM
,	O
nausea	B-PROBLEM
and	O
vomiting	B-PROBLEM
x	O
1	O
week	O
,	O
who	O
presented	O
to	O
an	O
outside	O
hospital	O
.	O

She	O
was	O
transferred	O
to	O
Arbour	O
Hospital	O
on	O
2015-02-21	O
for	O
bowel	B-PROBLEM
obstruction	I-PROBLEM
,	O
ischemia	B-PROBLEM
and	O
worsening	B-PROBLEM
abdominal	I-PROBLEM
distention	I-PROBLEM
and	O
pain	B-PROBLEM
.	O

CAD	B-PROBLEM
s/p	O
MI	B-PROBLEM
,	O
HTN	B-PROBLEM
,	O
DMII	B-PROBLEM

The	O
other	O
daughter	O
was	O
recently	O
in	O
a	O
car	O
accident	O
and	O
underwent	O
surgery	B-TREATMENT
at	O
Saint	O
Vincent	O
Hospital	O
.	O

Afebrile	B-PROBLEM
,	O
VSS	O

A&O	O
X	O
3	O
,	O
NAD	B-PROBLEM

CTAB	O
,	O
mildly	B-PROBLEM
decreased	I-PROBLEM
breath	I-PROBLEM
sounds	I-PROBLEM
b/l	I-PROBLEM

Abd	O
soft	O
,	O
NT/ND	B-PROBLEM
,	O
+	O
bs	O
,	O
no	O
masses	B-PROBLEM
,	O
ostomy	B-TREATMENT
in	I-TREATMENT
RLQ	I-TREATMENT
pink	O
,	O
with	O
stool	O

G-tube	B-TREATMENT
in	O
place	O

LE	B-PROBLEM
trace	I-PROBLEM
edema	I-PROBLEM

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
10.2	O
RBC	B-TEST
-	O
5.32	O
Hgb	B-TEST
-	O
14.9	O
Hct	B-TEST
-	O
43.4	O
MCV	B-TEST
-	O
82	O
MCH	B-TEST
-	O
28.0	O
MCHC	B-TEST
-	O
34.4	O
RDW	B-TEST
-	O
16.0	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
204	O

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
PT	B-TEST
-	O
12.9	O
PTT	B-TEST
-	O
32.5	O
INR(PT)	B-TEST
-	O
1.1	O

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
345	O
*	O
UreaN	B-TEST
-	O
34	O
*	O
Creat	B-TEST
-	O
1.0	O
Na	B-TEST
-	O
137	O
K	B-TEST
-	O
4.3	O
Cl	B-TEST
-	O
99	O
HCO3	B-TEST
-	O
24	O
AnGap	B-TEST
-	O
18	O

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
ALT	B-TEST
-	O
17	O
AST	B-TEST
-	O
27	O
AlkPhos	B-TEST
-	O
119	O
*	O
Amylase	B-TEST
-	O
27	O
TotBili	B-TEST
-	O
0.9	O

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
Lipase	B-TEST
-	O
11	O

2014-02-21	O
12:20	O
PM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
7	O
cTropnT	B-TEST
-<	O
0.01	O

2014-03-09	O
02:59	O
AM	O
BLOOD	B-TEST
cTropnT	B-TEST
-	O
0.21	O
*	O

2014-03-09	O
11:29	O
AM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
35	O
*	O
MB	B-TEST
Indx	I-TEST
-	O
25.5	O
*	O
cTropnT	B-TEST
-	O
0.45	O
*	O

2014-03-09	O
07:52	O
PM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
NotDone	O
cTropnT	B-TEST
-	O
0.55	O
*	O

2014-03-10	O
05:25	O
PM	O
BLOOD	B-TEST
cTropnT	B-TEST
-	O
0.42	O
*	O

2014-03-11	O
02:00	O
AM	O
BLOOD	B-TEST
cTropnT	B-TEST
-	O
0.45	O
*	O

2014-03-19	O
07:13	O
AM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
3	O
cTropnT	B-TEST
-	O
0.19	O
*	O

2014-03-19	O
01:33	O
PM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
NotDone	O
cTropnT	B-TEST
-	O
0.17	O
*	O

2014-03-21	O
09:58	O
AM	O
BLOOD	B-TEST
CK-MB	B-TEST
-	O
NotDone	O
cTropnT	B-TEST
-	O
0.06	O
*	O

03-07	O
wound	B-TEST
swab	I-TEST
:	O
VRE	B-PROBLEM

CT	B-TEST
Abd	I-TEST
02-21	O
:	O

1.	O
Markedly	B-PROBLEM
dilated	I-PROBLEM
colon	I-PROBLEM
throughout	O
ascending	O
,	O
transverse	O
,	O
and	O
descending	O
colon	O
with	O
air-fluid	B-PROBLEM
levels	I-PROBLEM
,	O
overall	O
unchanged	O
since	O
prior	B-TEST
study	I-TEST
performed	O
on	O
the	O
same	O
day	O
with	O
pneumatosis	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
ascending	I-PROBLEM
colon	I-PROBLEM
.	O

Sigmoid	B-PROBLEM
diverticulosis	I-PROBLEM
with	O
focal	B-PROBLEM
narrowing	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
sigmoid	I-PROBLEM
colon	I-PROBLEM
just	O
distal	O
to	O
the	B-PROBLEM
dilatation	I-PROBLEM
with	O
wall	B-PROBLEM
thickening	I-PROBLEM
,	O
due	O
to	O
diverticulitis	B-PROBLEM
.	O

This	O
area	O
can	O
be	O
a	O
leading	O
point	O
of	O
obstruction	B-PROBLEM
.	O

An	B-PROBLEM
underlying	I-PROBLEM
mass	I-PROBLEM
lesion	I-PROBLEM
or	O
cancer	B-PROBLEM
cannot	O
be	O
excluded	O
in	O
this	O
area	O
,	O
and	O
further	B-TEST
clinical	I-TEST
investigation	I-TEST
is	O
recommended	O
.	O

2.	O
Limited	B-TEST
evaluation	I-TEST
for	O
known	B-PROBLEM
sigmoid-vesicle	I-PROBLEM
fistula	I-PROBLEM
.	O

3.	O
Small	B-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
ascites	I-PROBLEM
,	O
somewhat	O
increased	O
anterior	O
to	O
the	O
liver	O
.	O

4.	O
Bilateral	B-PROBLEM
renal	I-PROBLEM
cysts	I-PROBLEM
.	O

5.	O
Heavy	B-PROBLEM
calcification	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
aorta	I-PROBLEM
and	I-PROBLEM
SMA	I-PROBLEM
and	I-PROBLEM
its	I-PROBLEM
branches	I-PROBLEM
.	O

Due	O
to	O
atherosclerosis	B-PROBLEM
,	O
assessment	B-TEST
of	I-TEST
the	I-TEST
intraluminal	I-TEST
process	I-TEST
of	O
these	O
branches	O
is	O
limited	O
.	O

CTA/CT	B-TEST
abd	I-TEST
03-07	O
:	O

1.	O
No	O
evidence	O
of	O
pulmonary	B-PROBLEM
embolism	I-PROBLEM
.	O

Small	B-PROBLEM
bilateral	I-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
with	O
compressive	B-PROBLEM
atelectasis	I-PROBLEM
.	O

2.	O
Left	B-PROBLEM
lower	I-PROBLEM
quadrant	I-PROBLEM
thick-walled	I-PROBLEM
peripherally	I-PROBLEM
enhancing	I-PROBLEM
fluid	I-PROBLEM
collection	I-PROBLEM
,	O
which	O
appears	O
to	O
communicate	O
with	O
the	O
sutured	O
end	O
of	O
the	O
proximal	O
sigmoid	O
colon	O
via	O
a	B-PROBLEM
small	I-PROBLEM
collection	I-PROBLEM
of	I-PROBLEM
extraluminal	I-PROBLEM
gas	I-PROBLEM
.	O

In	O
the	O
correct	O
clincial	O
setting	O
,	O
this	O
could	O
be	O
consistent	O
with	O
an	B-PROBLEM
abscess	I-PROBLEM
.	O

3.	O
Moderate	B-PROBLEM
intraabdominal	I-PROBLEM
ascites	I-PROBLEM
.	O

4.	O
Status	O
post	O
ileostomy	B-TREATMENT
without	O
evidence	O
of	O
small-bowel	B-PROBLEM
obstruction	I-PROBLEM
.	O

5.	O
Distended	B-PROBLEM
gallbladder	I-PROBLEM
.	O

6.	O
Diverticulosis	B-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
remnant	I-PROBLEM
sigmoid	I-PROBLEM
colon	I-PROBLEM
.	O

03-21	O
VCUG	B-TEST
-	O
no	O
leak	B-PROBLEM

Neuro	O
:	O
Developed	O
confusion	B-PROBLEM
during	O
her	O
first	O
5	O
days	O
in	O
the	O
ICU	O
.	O

Intermitent	B-PROBLEM
delirium	I-PROBLEM
throughout	O
admission	O
.	O

Required	O
restraints	B-TREATMENT
to	O
prevent	O
DC	O
of	O
pertinent	B-TREATMENT
therapies	I-TREATMENT
while	O
in	O
the	O
ICU	O
.	O

Cardiovascular	O
:	O
Complained	O
of	O
chest	B-PROBLEM
pain	I-PROBLEM
during	O
first	O
few	O
days	O
of	O
admission	O
,	O
a	O
cardiology	O
consult	O
was	O
obtained	O
.	O

She	O
recieved	O
serial	B-TEST
enzymes	I-TEST
and	O
EKGs	B-TEST
.	O

Troponins	B-TEST
remained	O
mildly	B-PROBLEM
elevated	I-PROBLEM
as	O
high	O
as	O
0.6	O
throughout	O
her	O
admission	O
,	O
and	O
most	O
recent	O
result	O
now	O
0.1	O
.	O

She	O
was	O
treated	O
in	O
IUC	O
for	O
unstable	B-PROBLEM
angina	I-PROBLEM
with	O
nitroglycerin	B-TREATMENT
.	O

It	O
was	O
recommended	O
to	O
maximize	O
her	B-TREATMENT
medical	I-TREATMENT
treatment	I-TREATMENT
with	O
Beta	B-TREATMENT
blockers	I-TREATMENT
,	O
aspirin	B-TREATMENT
,	O
a	B-TREATMENT
statin	I-TREATMENT
and	O
an	B-TREATMENT
ACE	I-TREATMENT
Inhibitor	I-TREATMENT
.	O

Required	O
diuresis	B-TREATMENT
of	O
>	O
9	O
L	O
while	O
in	O
the	O
ICU	O
,	O
after	O
2nd	B-TREATMENT
surgery	I-TREATMENT
.	O

Continues	O
to	O
have	O
trace	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
edema	I-PROBLEM
,	O
and	O
recieves	O
lasix	B-TREATMENT
po	I-TREATMENT
.	O

Respiratory	O
:	O
She	O
was	O
intubated	B-TREATMENT
briefly	O
post-op	O
subtotal	B-TREATMENT
colectomy	I-TREATMENT
and	O
again	O
for	O
several	O
days	O
after	O
second	B-TREATMENT
surgery	I-TREATMENT
.	O

Recieved	O
nebulizer	B-TREATMENT
treatments	I-TREATMENT
post-op	O
in	O
the	O
ICU	O
,	O
after	O
successfully	O
extubated	O
.	O

Gastrointestinal	O
:	O
Her	B-TEST
initial	I-TEST
CT	I-TEST
scan	I-TEST
showed	O
dilated	B-PROBLEM
Turner	I-PROBLEM
colon	I-PROBLEM
,	O
wall	B-PROBLEM
thickening	I-PROBLEM
and	O
pneumatosis	B-PROBLEM
see	O
pertinent	O
results	O
.	O

She	O
was	O
initially	O
treated	O
nonoperatively	O
with	O
IV	B-TREATMENT
fluids	I-TREATMENT
,	O
antibiotics	B-TREATMENT
,	O
serial	B-TEST
exams	I-TEST
and	O
NGT	B-TREATMENT
decompression	I-TREATMENT
.	O

On	O
HD#5	O
flexible	B-TEST
sigmoidoscopy	I-TEST
was	O
performed	O
for	O
colonic	B-TREATMENT
decompression	I-TREATMENT
.	O

On	O
HD#6	O
,	O
colonscopy	B-TEST
was	O
performed	O
for	O
decompression	B-TREATMENT
,	O
and	O
revealed	O
pseudomembrane	B-PROBLEM
and	O
friable	B-PROBLEM
colonic	I-PROBLEM
tissue	I-PROBLEM
.	O

Her	O
abdomen	O
remained	O
tender	B-PROBLEM
and	O
distended	B-PROBLEM
despite	O
attempted	O
decompression	B-TREATMENT
.	O

She	O
was	O
taken	O
to	O
the	O
OR	O
for	O
Subtotal	B-TREATMENT
Colectomy	I-TREATMENT
,	O
G	B-TREATMENT
tube	I-TREATMENT
and	O
ileostomy	B-TREATMENT
due	O
to	O
unresponsiveness	B-PROBLEM
to	O
non-operative	B-TREATMENT
treatment	I-TREATMENT
.	O

Ileostomy	B-TREATMENT
remains	O
pink	O
and	O
intact	O
,	O
draining	O
green-brown	O
soft	O
stool	O
.	O

She	O
developed	O
additional	B-PROBLEM
abdominal	I-PROBLEM
tenderness	I-PROBLEM
and	O
distention	B-PROBLEM
.	O

Her	B-TEST
HCT	I-TEST
dropped	O
and	O
she	O
recieved	O
1	B-TREATMENT
unit	I-TREATMENT
PRBCs	I-TREATMENT
.	O

On	O
POD#8	O
a	B-TEST
CT	I-TEST
scan	I-TEST
was	O
obtained	O
which	O
revealed	O
an	B-PROBLEM
abcess	I-PROBLEM
with	O
a	B-PROBLEM
colovesicular	I-PROBLEM
fistula	I-PROBLEM
.	O

She	O
was	O
taken	O
to	O
the	O
OR	O
for	O
exploration	B-TEST
and	O
drainage	B-TREATMENT
.	O

She	O
recieved	O
further	B-TREATMENT
resection	I-TREATMENT
of	I-TREATMENT
remaining	I-TREATMENT
colon	I-TREATMENT
,	O
repair	B-TREATMENT
of	O
a	B-PROBLEM
leak	I-PROBLEM
from	I-PROBLEM
Relaford	I-PROBLEM
pouch	I-PROBLEM
and	O
repair	B-TREATMENT
of	O
colovesicular	B-PROBLEM
fistula	I-PROBLEM
.	O

After	O
her	B-TREATMENT
2nd	I-TREATMENT
surgery	I-TREATMENT
she	O
returned	O
to	O
the	O
ICU	O
and	O
improved	O
steadily	O
.	O

Abdomen	O
remained	O
soft	O
and	O
nontender	B-PROBLEM
.	O

She	O
remained	O
on	O
IV	B-TREATMENT
antibiotics	I-TREATMENT
x	O
14	O
days	O
and	O
required	O
pressors	B-TREATMENT
for	O
the	O
first	O
few	O
days	O
post-op	O
.	O

Her	B-PROBLEM
incision	I-PROBLEM
has	O
remained	O
clean	O
,	O
dry	O
,	O
intact	O
,	O
with	O
staples	B-TREATMENT
removed	O
on	O
POD#	O
27/18	O
.	O

Genitourinary	O
:	O
She	O
had	O
a	B-TREATMENT
foley	I-TREATMENT
catheter	I-TREATMENT
from	O
the	O
time	O
of	O
admission	O
.	O

POD#	O
23/14	O
she	O
recieved	O
a	B-TEST
cystoscopy	I-TEST
which	O
revealed	O
no	O
leak	B-PROBLEM
.	O

Her	B-TREATMENT
foley	I-TREATMENT
was	O
subsequently	O
dc	O
'd	O
.	O

Musculoskeletal	O
:	O
Has	O
suffered	O
significant	B-PROBLEM
deconditioning	I-PROBLEM
since	O
admission	O
,	O
but	O
has	O
consisitently	O
recieved	O
PT	B-TREATMENT
.	O

See	O
PT	O
note	O
for	O
further	B-TEST
assessment	I-TEST
and	O
discussion	O
.	O

Nutrition	O
:	O
She	O
was	O
held	O
NPO	B-TREATMENT
at	O
admission	O
,	O
and	O
initiated	O
on	O
TPN	B-TREATMENT
by	O
HD#3	O
.	O

Post-operatively	O
she	O
began	O
on	O
TF	B-TREATMENT
s,	I-TREATMENT
and	O
the	B-TREATMENT
TPN	I-TREATMENT
was	O
weaned	O
down	O
.	O

By	O
POD#	O
05-29	O
she	O
was	O
having	O
high	B-PROBLEM
residuals	I-PROBLEM
on	O
TF	B-TREATMENT
s,	I-TREATMENT
so	O
TPN	B-TREATMENT
was	O
reinitiated	O
.	O

Tf	B-TREATMENT
's	I-TREATMENT
were	O
dc	O
'ed	O
prior	O
to	O
second	B-TREATMENT
surgery	I-TREATMENT
.	O

POD#	O
15/6	O
,	O
she	O
resumed	O
TF	B-TREATMENT
's	I-TREATMENT
and	O
TPN	B-TREATMENT
was	O
tapered	O
again	O
.	O

TF	O
goals	O
were	O
achieved	O
and	O
TPN	B-TREATMENT
dc	O
'ed.	O

At	O
time	O
of	O
discharge	O
she	O
is	O
tolerating	O
a	O
regular	O
diet	O
with	O
TF	B-TREATMENT
's	I-TREATMENT
at	O
goal	O
.	O

Patient	O
is	O
an	B-PROBLEM
insulin	I-PROBLEM
dependent	I-PROBLEM
diabetic	I-PROBLEM
.	O

She	O
was	O
followed	O
by	O
Cape	O
Cod	O
Hospital	O
Clinic	O
for	O
treatment	B-TREATMENT
of	O
persistent	B-PROBLEM
hyperglycemia	I-PROBLEM
.	O

Pain	B-PROBLEM
:	O
Her	B-PROBLEM
pain	I-PROBLEM
was	O
controlled	O
with	O
IV	B-TREATMENT
pain	I-TREATMENT
medicines	I-TREATMENT
while	O
in	O
ICU	O
.	O

She	O
has	O
been	O
adequately	O
controlled	O
with	O
Tylenol	B-TREATMENT
,	O
Motrin	B-TREATMENT
&	O
Oxycodone	B-TREATMENT
by	O
mouth	O
,	O
per	O
recommendations	O
by	O
Geriatrics	O
.	O

POD#	O
22/15	O
Ms	O
Crossman	O
was	O
transferred	O
to	O
3	O
North	O
where	O
she	O
continued	O
to	O
progress	O
well	O
with	O
PT	B-TREATMENT
,	O
increasing	O
PO	O
intake	O
,	O
tolerating	O
TF	B-TREATMENT
s,	I-TREATMENT
and	O
weaning	O
from	O
nasal	B-TREATMENT
cannula	I-TREATMENT
oxygen	I-TREATMENT
.	O

She	O
has	O
remained	O
stable	O
with	O
no	O
acute	B-PROBLEM
events	I-PROBLEM
.	O

Norvasc	B-TREATMENT

Atenolol	B-TREATMENT

Isosorbide	B-TREATMENT

Lasix	B-TREATMENT

Insulin	B-TREATMENT

1.	O
Heparin	B-TREATMENT
(	I-TREATMENT
Porcine	I-TREATMENT
)	I-TREATMENT
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
mL	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

2.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

3.	O
Polyvinyl	B-TREATMENT
Alcohol	I-TREATMENT
-	O
Povidone	B-TREATMENT
1.4-0.6	O
%	O
Dropperette	O
Sig	O
:	O
02-25	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
).	O

4.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

5.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
).	O

6.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

7.	O
Lisinopril	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

8.	O
Furosemide	B-TREATMENT
40	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

9.	O
Ipratropium	B-TREATMENT
Bromide	I-TREATMENT
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O

10.	O
Albuterol	B-TREATMENT
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1-2	O
Puffs	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O

11.	O
Oxycodone	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4-6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

12.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

13.	O
Potassium	B-TREATMENT
Chloride	I-TREATMENT
20	O
mEq	O
Tab	O
Sust	O
.	O
Rel	O
.	O
Particle	O
/	O
Crystal	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tab	O
Sust	O
.	O
Rel	O
.	O
Particle	O
/	O
Crystal	O
PO	O
once	O
a	O
day	O
.	O

14.	O
Glargine	B-TREATMENT
Sig	O
:	O
Twenty	O
Two	O
(	O
22	O
)	O
units	O
at	O
bedtime	O
.	O

15.	O
Miconazole	B-TREATMENT
Nitrate	I-TREATMENT
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

16.	O
Miconazole	B-TREATMENT
Nitrate	I-TREATMENT
2	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

17.	O
Ibuprofen	B-TREATMENT
100	O
mg/5	O
mL	O
Suspension	O
Sig	O
:	O
Twenty	O
(	O
20	O
)	O
mL	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
.	O

18.	O
Debrox	B-TREATMENT
6.5	O
%	O
Drops	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
Drop	O
Otic	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
5	O
days	O
:	O
both	O
ears	O
.	O

19.	O
Trazodone	B-TREATMENT
50	O
mg	O
Tablet	O
Sig	O
:	O
1	O
/	O
2-1	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
).	O

Hurtado	B-PROBLEM
Colon	I-PROBLEM

Diverticulitis	B-PROBLEM

S/P	O
Subtotal	B-TREATMENT
Colectomy	I-TREATMENT
,	O
Ileostomy	B-TREATMENT
,	O
Gastrostomy	B-TREATMENT
tube	I-TREATMENT

S/P	O
Exploratory	B-TEST
laparotomy	I-TEST
,	O
resection	B-TREATMENT
of	I-TREATMENT
small	I-TREATMENT
intestine	I-TREATMENT
with	O
primary	B-TREATMENT
anastomosis	I-TREATMENT
,	O
Sigmoid	B-TREATMENT
colectomy	I-TREATMENT
,	O
repair	B-TREATMENT
of	O
colovesicular	B-PROBLEM
fistula	I-PROBLEM

Unstable	B-PROBLEM
Angina	I-PROBLEM

Please	O
call	O
the	O
surgeon	O
or	O
return	O
to	O
the	O
Emergency	O
Department	O
if	O
you	O
develop	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
fever	B-PROBLEM
greater	I-PROBLEM
than	I-PROBLEM
101.5	I-PROBLEM
,	O
foul	B-PROBLEM
smelling	I-PROBLEM
or	I-PROBLEM
colorful	I-PROBLEM
drainage	I-PROBLEM
from	O
your	B-PROBLEM
incisions	I-PROBLEM
,	O
redness	B-PROBLEM
or	O
swelling	B-PROBLEM
,	O
severe	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
or	O
distention	B-PROBLEM
,	O
persistent	B-PROBLEM
nausea	I-PROBLEM
or	O
vomiting	B-PROBLEM
,	O
inability	B-PROBLEM
to	I-PROBLEM
eat	I-PROBLEM
or	I-PROBLEM
drink	I-PROBLEM
,	O
or	O
any	O

other	B-PROBLEM
symptoms	I-PROBLEM
which	O
are	O
concerning	O
to	O
you	O
.	O

If	O
there	O
is	O
clear	B-PROBLEM
drainage	I-PROBLEM
from	O
your	B-PROBLEM
incisions	I-PROBLEM
,	O
cover	O
with	O
a	B-TREATMENT
dry	I-TREATMENT
dressing	I-TREATMENT
.	O

Leave	O
white	B-TREATMENT
strips	I-TREATMENT
above	O
your	B-PROBLEM
incisions	I-PROBLEM
in	O
place	O
,	O
allow	O
them	O
to	O
fall	O
off	O
on	O
their	O
own	O
.	O

Medications	O
:	O
Resume	O
your	O
home	B-TREATMENT
medications	I-TREATMENT
.	O

You	O
should	O
take	O
a	B-TREATMENT
stool	I-TREATMENT
softener	I-TREATMENT
,	O
Colace	B-TREATMENT
100	O
mg	O
twice	O
daily	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

You	O
will	O
be	O
given	O
pain	B-TREATMENT
medication	I-TREATMENT
which	O
may	O
make	O
you	O
drowsy	B-PROBLEM
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

Overdose	B-PROBLEM

NG	B-TREATMENT
tube	I-TREATMENT

Mr.	O
Vazquez	O
is	O
a	O
48	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
hepatitis	B-PROBLEM
C	I-PROBLEM
,	O
bipolar	B-PROBLEM
disorder	I-PROBLEM
with	O
suicide	O
attempts	O
in	O
the	O
past	O
,	O
recent	O
CMED	O
admit	O
earlier	O
in	O
4/05	O
who	O
was	O
found	O
alert	O
approximately	O
one	O
hour	O
after	O
taking	O
an	O
unspecified	O
number	O
of	O
pills	B-TREATMENT
.	O

Per	O
report	O
,	O
there	O
were	O
empty	O
bottles	O
of	O
Inderal	B-TREATMENT
and	O
Klonopin	B-TREATMENT
found	O
at	O
bedside	O
,	O
as	O
well	O
as	O
02-26	O
full	O
bottles	O
of	O
geodon	B-TREATMENT
,	O
gabapentin	B-TREATMENT
,	O
Lescol	B-TREATMENT
and	O
paroxitine	B-TREATMENT
.	O

The	O
patient	O
was	O
reportedly	O
alert	O
at	O
scene	O
,	O
and	O
then	O
became	O
unresponsive	B-PROBLEM
in	O
route	O
to	O
the	O
hospital	O
.	O

In	O
the	O
Rita	O
,	O
the	O
patient	O
was	O
intubated	O
and	O
given	O
activated	B-TREATMENT
charcoal	I-TREATMENT
.	O

His	B-TEST
initial	I-TEST
BP	I-TEST
was	O
60/P	O
with	O
a	B-TEST
pulse	I-TEST
in	O
the	O
60	O
s.	O

He	O
was	O
given	O
4	O
amps	O
of	O
calcium	B-TREATMENT
gluconate	I-TREATMENT
,	O
and	O
started	O
on	O
a	B-TREATMENT
Calcium	I-TREATMENT
gtt	I-TREATMENT
.	O

He	O
was	O
also	O
given	O
5mg	O
of	O
glucagon	B-TREATMENT
and	O
started	O
on	O
a	B-TREATMENT
glucagon	I-TREATMENT
drip	I-TREATMENT
with	O
good	O
response	O
.	O

His	B-TEST
urine	I-TEST
and	O
serum	B-TEST
tox	I-TEST
screens	I-TEST
were	O
notable	O
only	O
for	O
benzos	B-TREATMENT
,	O
otherwise	O
negative	O
.	O

He	O
was	O
admitted	O
to	O
the	O
CMED	O
,	O
intubated	O
for	O
airway	B-TREATMENT
protection	I-TREATMENT
and	O
started	O
on	O
both	O
a	B-TREATMENT
calcium	I-TREATMENT
and	I-TREATMENT
glucagon	I-TREATMENT
drip	I-TREATMENT
.	O

There	O
was	O
evidence	O
of	O
possible	O
aspiration	B-PROBLEM
pneumonia	I-PROBLEM
on	O
CXR	B-TEST
,	O
though	O
he	O
was	O
extubated	O
without	O
incident	O
on	O
the	O
AM	O
of	O
transfer	O
to	O
the	O
medicine	O
floor	O
.	O

Hep	B-PROBLEM
C	I-PROBLEM

Bipolar	B-PROBLEM
D/O	I-PROBLEM
with	O
one	O
suicide	O
attempt	O
by	O
overdose	B-PROBLEM
several	O
years	O
ago	O

Agoraphobia	B-PROBLEM

Panic	B-PROBLEM
disorder	I-PROBLEM

Narcissism	B-PROBLEM

No	O
history	O
of	O
head	B-PROBLEM
trauma	I-PROBLEM
or	O
seizure	B-PROBLEM
disorder	I-PROBLEM

Reports	O
that	O
he	O
has	O
suffered	O
from	O
anxiety	B-PROBLEM
since	O
childhood	O
and	O
needed	O
to	O
drop	O
out	O
of	O
college	O
.	O

Vitals	B-TEST
:	O
99.3	O
67	O
(	O
60-70	O
)	O
99/53	O
(	O
90-100	O
s)	O
96%	O
on	O
RA	O
3.7L	O
+	O
LOS	O

Gen	O
:	O
caucasian	O
man	O
lying	O
in	O
bed	O
,	O
NAD	B-PROBLEM

HEENT	O
:	O
NCAT	O
,	O
PERRL	O
,	O
EOMI	O
,	O
no	O
icterus	B-PROBLEM
,	O
OP	O
clear	O
,	O
MMM	O
,	O
no	O
tongue	B-PROBLEM
fasciculations	I-PROBLEM

Neck	O
:	O
supple	O
,	O
no	O
LAD	B-PROBLEM
,	O
no	O
JVD	B-PROBLEM

CV	O
:	O
RRR	O
,	O
nl	O
s1	O
s2	O
,	O
no	O
m/g/r	B-PROBLEM

Lungs	O
:	O
?	O
decreased	B-PROBLEM
BS	I-PROBLEM
over	I-PROBLEM
left	I-PROBLEM
middle	I-PROBLEM
lung	I-PROBLEM
,	O
otherwise	O
CTA	O

Abd	O
:	O
normal	O
size	O
,	O
nd	B-PROBLEM
,	O
no	O
scars	B-PROBLEM
,	O
nl	O
bs	O
,	O
soft	O
,	O
nt	B-PROBLEM
,	O
palp	O
liver	O

Ext	O
:	O
no	O
c/c/e	B-PROBLEM
,	O
no	O
edema	B-PROBLEM

Neuro	O
:	O
no	O
asterixis	B-PROBLEM
,	O
CN	O
II-XII	O
intact	O
,	O
5/5	O
strength	O
throughout	O
,	O
sensation	O
to	O
LT	B-TEST
intact	O
throughout	O
,	O
gait	O
deferred	O

CMED	O
:	O
A+Ox3	O
,	O
mood	O
"	O
great	O
,"	O
affect	O
approp	O
,	O
speech	B-PROBLEM
stuttering	I-PROBLEM
,	O
linear	O
TP	O
,	O
no	O
SI	B-PROBLEM
or	O
HI	B-PROBLEM

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
8.9	O
RBC	B-TEST
-	O
4.94	O
Hgb	B-TEST
-	O
15.8	O
Hct	B-TEST
-	O
45.3	O
MCV	B-TEST
-	O
92	O
MCH	B-TEST
-	O
31.9	O
MCHC	B-TEST
-	O
34.8	O
RDW	B-TEST
-	O
12.4	O
Plt	B-TEST
Ct	I-TEST
-	O
175	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
Neuts	B-TEST
-	O
49.9	O
*	O
Lymphs	B-TEST
-	O
42.4	O
*	O
Monos	B-TEST
-	O
5.5	O
Eos	B-TEST
-	O
1.6	O
Baso	B-TEST
-	O
0.6	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
Plt	B-TEST
Ct	I-TEST
-	O
175	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
PT	B-TEST
-	O
12.8	O
PTT	B-TEST
-	O
25.7	O
INR(PT)	B-TEST
-	O
1.0	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
108	O
*	O
UreaN	B-TEST
-	O
13	O
Creat	B-TEST
-	O
0.7	O
Na	B-TEST
-	O
146	O
*	O
K	B-TEST
-	O
3.7	O
Cl	B-TEST
-	O
109	O
*	O
HCO3	B-TEST
-	O
30	O
*	O
AnGap	B-TEST
-	O
11	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
Albumin	B-TEST
-	O
3.9	O
Calcium	B-TEST
-	O
8.5	O
Phos	B-TEST
-	O
4.2	O
Mg	B-TEST
-	O
2.0	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
ALT	B-TEST
-	O
44	O
*	O
AST	B-TEST
-	O
31	O
AlkPhos	B-TEST
-	O
36	O
*	O
TotBili	B-TEST
-	O
0.2	O

2012-06-07	O
09:55	O
PM	O
BLOOD	B-TEST
ASA	B-TEST
-	O
NEG	O
Ethanol	B-TEST
-	O
NEG	O
Acetmnp	B-TEST
-	O
NEG	O
Bnzodzp	B-TEST
-	O
NEG	O
Barbitr	B-TEST
-	O
NEG	O
Tricycl	B-TEST
-	O
NEG	O

2012-06-08	O
09:30	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
10.1	O
RBC	B-TEST
-	O
4.35	O
*	O
Hgb	B-TEST
-	O
14.2	O
Hct	B-TEST
-	O
39.9	O
*	O
MCV	B-TEST
-	O
92	O
MCH	B-TEST
-	O
32.6	O
*	O
MCHC	B-TEST
-	O
35.6	O
*	O
RDW	B-TEST
-	O
12.4	O
Plt	B-TEST
Ct	I-TEST
-	O
151	O

2012-06-08	O
09:30	O
AM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
115	O
*	O
UreaN	B-TEST
-	O
14	O
Creat	B-TEST
-	O
0.8	O
Na	B-TEST
-	O
142	O
K	B-TEST
-	O
4.1	O
Cl	B-TEST
-	O
112	O
*	O
HCO3	B-TEST
-	O
26	O
AnGap	B-TEST
-	O
8	O

2012-06-08	O
09:30	O
AM	O
BLOOD	B-TEST
Calcium	B-TEST
-	O
10.4	O
*	O
Phos	B-TEST
-	O
2.8	O
Mg	B-TEST
-	O
1.8	O

CXR	B-TEST
:	O

An	B-TREATMENT
endotracheal	I-TREATMENT
tube	I-TREATMENT
terminates	O
just	O
above	O
the	O
thoracic	O
inlet	O
approximately	O
6.5	O
cm	O
above	O
the	O
carina	O
.	O

The	B-TREATMENT
nasogastric	I-TREATMENT
tube	I-TREATMENT
terminates	O
within	O
the	O
stomach	O
.	O

There	O
is	O
a	B-PROBLEM
patchy	I-PROBLEM
area	I-PROBLEM
of	I-PROBLEM
increased	I-PROBLEM
opacity	I-PROBLEM
in	O
the	O
left	O
retrocardiac	O
region	O
,	O
which	O
was	O
not	O
seen	O
on	O
the	B-TEST
earlier	I-TEST
study	I-TEST
.	O

Left	O
costophrenic	O
angle	O
has	O
been	O
excluded	O
from	O
the	B-TEST
study	I-TEST
and	O
cannot	O
be	O
assessed	O
.	O

There	O
is	O
no	O
evidence	O
of	O
right	B-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
or	O
right	B-PROBLEM
pneumothorax	I-PROBLEM
.	O

1)	O
Endotracheal	B-TREATMENT
tube	I-TREATMENT
is	O
slightly	O
proximal	O
in	O
location	O
,	O
and	O
could	O
be	O
advanced	O
approximately	O
1.5	O
cm	O
for	O
more	O
optimal	O
placement	O
.	O

2)	O
Patchy	B-PROBLEM
left	I-PROBLEM
retrocardiac	I-PROBLEM
opacity	I-PROBLEM
which	O
may	O
be	O
due	O
to	O
patchy	B-PROBLEM
atelectasis	I-PROBLEM
,	O
aspiration	B-PROBLEM
,	O
or	O
early	B-PROBLEM
pneumonia	I-PROBLEM
.	O

Followup	B-TEST
radiograph	I-TEST
suggested	O

A/P	O
:	O
48yo	O
man	O
with	O
h/o	O
HCV	B-PROBLEM
,	O
bipolar	B-PROBLEM
DO	I-PROBLEM
,	O
h/o	O
suicide	O
attempts	O
,	O
a/w	O
overdose	B-PROBLEM
of	O
Inderal	B-TREATMENT
,	O
Klonopin	B-TREATMENT
,	O
Geodon	B-TREATMENT
,	O
s/T	O
Jackson	O
stay	O
with	O
intubation	B-TREATMENT
for	O
airway	B-TREATMENT
protection	I-TREATMENT
,	O
with	O
question	O
of	O
L	B-PROBLEM
retrocardiac	I-PROBLEM
infiltrate	I-PROBLEM
,	O
now	O
doing	O
well	O
.	O

-	O
monitor	O
on	O
tele	B-TEST
overnight	O

-	O
if	O
HR	B-TEST
drops	O
,	O
restart	O
glucagon	B-TREATMENT
gtt	I-TREATMENT

-	O
watch	O
for	O
BZD	B-PROBLEM
withdrawal	I-PROBLEM
,	O
agitation	B-PROBLEM

Bipolar	B-PROBLEM
disorder	I-PROBLEM
:	O

-	O
suicide	B-TREATMENT
precautions	I-TREATMENT

PPX	O
:	O
SC	B-TREATMENT
heparin	I-TREATMENT
,	O
bowel	B-TREATMENT
regimen	I-TREATMENT
,	O
nicotine	B-TREATMENT
patch	I-TREATMENT

Neurontin	B-TREATMENT
800	O
mg	O
tid	O

Ziprasidone	B-TREATMENT
bid	O

Propanolol	B-TREATMENT
20	O
mg	O
tid	O

Klonopin	B-TREATMENT
2	O
mg	O
tid	O

Paxil	B-TREATMENT
30	O
mg	O
qd	O

Protonix	B-TREATMENT
40	O
mg	O
qd	O

Folate	B-TREATMENT
1	O
mg	O
qd	O

Lescol	B-TREATMENT
40	O
qd	O

Depression	B-PROBLEM

Depressed	B-PROBLEM

The	O
patient	O
was	O
referred	O
from	O
an	O
outside	O
hospital	O
with	O
a	O
chief	O
complaint	O
of	O
increasing	B-PROBLEM
shortness	I-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
tires	B-PROBLEM
easily	I-PROBLEM
with	O
exertion	O
.	O

Admitted	O
to	O
Bay	O
State	O
Medical	O
Center	O
Hospital	O
in	O
2012-10-22	O
in	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
at	O
that	O
time	O
.	O

Via	O
echocardiogram	B-TEST
,	O
found	O
to	O
have	O
aortic	B-PROBLEM
stenosis	I-PROBLEM
.	O

Referred	O
to	O
Memorial	O
Hospital	O
(	O
Worcester	O
)	O
for	O
cardiac	B-TEST
catheterization	I-TEST
to	O
further	O
evaluate	O
her	B-PROBLEM
aortic	I-PROBLEM
stenosis	I-PROBLEM
.	O

Cardiac	B-TEST
catheterization	I-TEST
done	O
on	O
01-07	O
showed	O
an	B-TEST
aortic	I-TEST
valve	I-TEST
area	I-TEST
of	O
.38	O
cm.sq.	O
,	O
with	O
a	B-TEST
mean	I-TEST
gradient	I-TEST
of	O
62	O
,	O
and	O
a	B-TEST
peak	I-TEST
gradient	I-TEST
of	O
85	O
.	O

Moderate	B-PROBLEM
pulmonary	I-PROBLEM
hypertension	I-PROBLEM
,	O
PA	B-TEST
pressure	I-TEST
48/24	O
,	O
1+	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
,	O
severe	B-PROBLEM
aortic	I-PROBLEM
stenosis	I-PROBLEM
with	O
an	B-TEST
LVEDP	I-TEST
of	O
19	O
and	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
43%	O
.	O

She	O
was	O
then	O
referred	O
to	O
Cardiothoracic	O
Surgery	O
for	O
aortic	B-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
.	O

1.	O
Aortic	B-PROBLEM
stenosis	I-PROBLEM

2.	O
Diabetes	B-PROBLEM
mellitus	I-PROBLEM
Type	I-PROBLEM
2	I-PROBLEM

3.	O
Right	B-TREATMENT
hip	I-TREATMENT
replacement	I-TREATMENT

4.	O
Noninsulin	B-PROBLEM
dependent	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM

Include	O
Glucovance	B-TREATMENT
5/500	O
one	O
tablet	O
twice	O
a	O
day	O
,	O
Univasc	B-TREATMENT
7.5	O
mg	O
once	O
daily	O
,	O
lasix	B-TREATMENT
20	O
mg	O
every	O
other	O
day	O
,	O
and	O
aspirin	B-TREATMENT
325	O
mg	O
once	O
daily	O
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

Significant	O
for	O
her	O
father	O
,	O
who	O
died	O
at	O
50	O
years	O
from	O
myocarditis	B-PROBLEM
.	O

Heart	B-TEST
rate	I-TEST
108	O
and	O
regular	O
,	O
blood	B-TEST
pressure	I-TEST
145/76	O
,	O
respiratory	B-TEST
rate	I-TEST
20	O
,	O
height	B-TEST
5'2"	O
,	O
weight	B-TEST
141	O
pounds	O
.	O

Healthy-appearing	O
woman	O
,	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

No	O
lesions	B-PROBLEM
or	O
rashes	B-PROBLEM
.	O

Pupils	O
equal	O
,	O
round	O
and	O
reactive	O
to	O
light	O
,	O
extraocular	O
movements	O
intact	O
,	O
anicteric	B-PROBLEM
,	O
not	O
injected	B-PROBLEM
.	O

Supple	O
,	O
no	O
lymphadenopathy	B-PROBLEM
,	O
no	O
jugular	B-PROBLEM
venous	I-PROBLEM
distention	I-PROBLEM
,	O
no	O
thyromegaly	B-PROBLEM
.	O

Clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Regular	O
rate	O
and	O
rhythm	O
,	O
S1	O
,	O
S2	O
,	O
with	O
III/VI	B-PROBLEM
blowing	I-PROBLEM
murmur	I-PROBLEM
.	O

Soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
normal	O
active	O
bowel	O
sounds	O
,	O
no	O
hepatosplenomegaly	B-PROBLEM
.	O

Warm	O
and	O
well	O
perfused	O
,	O
with	O
no	O
cyanosis	B-PROBLEM
,	O
clubbing	B-PROBLEM
or	O
edema	B-PROBLEM
,	O
no	O
varicosities	B-PROBLEM
.	O

Strength	B-TEST
5/5	O
in	O
upper	O
and	O
lower	O
extremities	O
.	O

Pulses	B-TEST
:	O

Femoral	B-TEST
2	O
+	O
bilaterally	O
,	O
dorsalis	B-TEST
pedis	I-TEST
1	O
+	O
bilaterally	O
,	O
posterior	B-TEST
tibial	I-TEST
1	O
+	O
bilaterally	O
,	O
and	O
radial	B-TEST
2	O
+	O
bilaterally	O
.	O

No	O
carotid	B-PROBLEM
bruits	I-PROBLEM
were	O
noted	O
.	O

White	B-TEST
count	I-TEST
5.3	O
,	O
hematocrit	B-TEST
43	O
,	O
platelets	B-TEST
200	O
.	O

Sodium	B-TEST
138	O
,	O
potassium	B-TEST
4.9	O
,	O
chloride	B-TEST
102	O
,	O
CO2	B-TEST
25	O
,	O
BUN	B-TEST
24	O
,	O
creatinine	B-TEST
0.9	O
,	O
glucose	B-TEST
309	O
.	O

Electrocardiogram	B-TEST
:	O

Rate	B-TEST
of	O
91	O
,	O
first	B-PROBLEM
degree	I-PROBLEM
AV	I-PROBLEM
block	I-PROBLEM
,	O
intervals	B-TEST
.22	O
,	O
.92	O
,	O
.36	O
,	O
with	O
left	B-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
.	O

Chest	B-TEST
x-ray	I-TEST
is	O
pending	O
at	O
the	O
time	O
of	O
physical	B-TEST
.	O

aortic	B-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
.	O

In	O
summary	O
,	O
she	O
had	O
an	B-TREATMENT
aortic	I-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
with	O
a	B-TREATMENT
#21	I-TREATMENT
mosaic	I-TREATMENT
porcine	I-TREATMENT
valve	I-TREATMENT
.	O

She	O
tolerated	O
the	B-TREATMENT
operation	I-TREATMENT
well	O
,	O
and	O
was	O
transferred	O
from	O
the	O
operating	O
room	O
to	O
the	O
Cardiothoracic	O
Intensive	O
Care	O
Unit	O
.	O

The	O
patient	O
did	O
well	O
in	O
the	O
immediate	O
postoperative	O
period	O
,	O
however	O
,	O
her	B-TEST
blood	I-TEST
pressure	I-TEST
remained	O
somewhat	B-PROBLEM
labile	I-PROBLEM
.	O

Therefore	O
,	O
she	O
was	O
continued	O
on	O
a	B-TREATMENT
Neo-Synephrine	I-TREATMENT
drip	I-TREATMENT
to	O
maintain	O
a	B-TEST
systolic	I-TEST
blood	I-TEST
pressure	I-TEST
greater	O
than	O
110	O
.	O

In	O
addition	O
,	O
she	O
was	O
slow	O
to	O
awaken	O
after	O
her	B-TREATMENT
anesthesia	I-TREATMENT
was	O
reversed	O
,	O
and	O
in	O
several	O
attempts	O
to	O
wean	O
from	O
the	B-TREATMENT
ventilator	I-TREATMENT
,	O
she	O
developed	O
a	B-PROBLEM
respiratory	I-PROBLEM
acidosis	I-PROBLEM
.	O

She	O
therefore	O
remained	O
on	O
the	B-TREATMENT
ventilator	I-TREATMENT
throughout	O
the	O
day	O
of	O
postoperative	O
day	O
one	O
.	O

Her	B-TREATMENT
Neo-Synephrine	I-TREATMENT
drip	I-TREATMENT
was	O
weaned	O
to	O
off	O
.	O

She	O
was	O
again	O
weaned	O
from	O
the	B-TREATMENT
ventilator	I-TREATMENT
,	O
and	O
successfully	O
extubated	O
.	O

Her	B-TREATMENT
chest	I-TREATMENT
tubes	I-TREATMENT
were	O
discontinued	O
and	O
,	O
at	O
the	O
end	O
of	O
the	O
day	O
,	O
she	O
was	O
transferred	O
from	O
the	O
Cardiothoracic	O
Intensive	O
Care	O
Unit	O
to	O
the	O
floor	O
for	O
continuing	B-TREATMENT
postoperative	I-TREATMENT
care	I-TREATMENT
and	O
cardiac	B-TREATMENT
rehabilitation	I-TREATMENT
.	O

Her	O
respiratory	O
condition	O
remained	O
stable	O
and	O
,	O
on	O
postoperative	O
day	O
four	O
,	O
she	O
was	O
deemed	O
stable	O
and	O
ready	O
to	O
be	O
transferred	O
to	O
rehabilitation	O
for	O
continuing	B-TREATMENT
postoperative	I-TREATMENT
care	I-TREATMENT
and	O
physical	O

therapy	B-TREATMENT
.	O

At	O
the	O
time	O
of	O
transfer	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
physical	I-TEST
examination	I-TEST
is	O
as	O
follows	O
:	O

Temperature	B-TEST
98.4	O
,	O
heart	B-TEST
rate	I-TEST
78	O
and	O
sinus	B-TEST
rhythm	I-TEST
,	O
blood	B-TEST
pressure	I-TEST
106/50	O
,	O
respiratory	B-TEST
rate	I-TEST
18	O
,	O
oxygen	B-TEST
saturation	I-TEST
97%	O
on	O
room	O
air	O
.	O

Weight	B-TEST
preoperatively	O
was	O
67	O
kg	O
,	O
at	O
discharge	O
is	O
70.9	O
kg	O
.	O

Laboratory	B-TEST
data	I-TEST
on	O
02-15	O
:	O

White	B-TEST
count	I-TEST
4.1	O
,	O
hematocrit	B-TEST
23	O
,	O
platelets	B-TEST
144	O
.	O

Sodium	B-TEST
141	O
,	O
potassium	B-TEST
4.3	O
,	O
chloride	B-TEST
108	O
,	O
CO2	B-TEST
25	O
,	O
BUN	B-TEST
24	O
,	O
creatinine	B-TEST
0.8	O
,	O
glucose	B-TEST
140	O
.	O

Scattered	B-PROBLEM
rhonchi	I-PROBLEM
with	O
diminished	B-PROBLEM
breath	I-PROBLEM
sounds	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
bases	I-PROBLEM
.	O

Regular	O
rate	O
and	O
rhythm	O
,	O
S1	O
,	O
S2	O
,	O
with	O
soft	B-PROBLEM
systolic	I-PROBLEM
ejection	I-PROBLEM
murmur	I-PROBLEM
.	O

Incision	B-PROBLEM
with	O
staples	B-TREATMENT
,	O
open	O
to	O
air	O
,	O
clean	O
and	O
dry	O
.	O

Soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
normal	O
active	O
bowel	O
sounds	O
.	O

Warm	O
and	O
well	O
perfused	O
,	O
with	O
no	O
cyanosis	B-PROBLEM
,	O
clubbing	B-PROBLEM
or	O
edema	B-PROBLEM
.	O

Ranitidine	B-TREATMENT
150	O
mg	O
twice	O
a	O
day	O
,	O
enteric-coated	B-TREATMENT
aspirin	I-TREATMENT
325	O
mg	O
once	O
daily	O
,	O
Glucovance	B-TREATMENT
5/500	O
one	O
tablet	O
twice	O
a	O
day	O
,	O
metoprolol	B-TREATMENT
25	O
mg	O
twice	O
a	O
day	O
,	O
Furosemide	B-TREATMENT
20	O
mg	O
once	O
daily	O
for	O
14	O
days	O
,	O
potassium	B-TREATMENT
chloride	I-TREATMENT
20	O
mEq	O
once	O
daily	O
for	O
14	O
days	O
,	O
Colace	B-TREATMENT
100	O
mg	O
twice	O
a	O
day	O
,	O
Niferex	B-TREATMENT
150	O
mg	O
once	O
daily	O
,	O
Percocet	B-TREATMENT
5/325	O
one	O
to	O
two	O
tablets	O
every	O
four	O
hours	O
as	O
needed	O
,	O
ibuprofen	B-TREATMENT
400	O
mg	O
every	O
six	O
hours	O
as	O
needed	O
.	O

1.	O
Aortic	B-PROBLEM
stenosis	I-PROBLEM
status	O
post	O
aortic	B-TREATMENT
valve	I-TREATMENT
replacement	I-TREATMENT
with	O
a	B-TREATMENT
#21	I-TREATMENT
mosaic	I-TREATMENT
porcine	I-TREATMENT
valve	I-TREATMENT

2.	O
Diabetes	B-PROBLEM
mellitus	I-PROBLEM
Type	I-PROBLEM
2	I-PROBLEM

3.	O
Right	B-TREATMENT
hip	I-TREATMENT
replacement	I-TREATMENT

Mitral	B-TREATMENT
valve	I-TREATMENT
repair	I-TREATMENT
.	O

The	O
patient	O
is	O
a	O
52	O
year	O
old	O
Czech	O
speaking	O
gentleman	O
with	O
a	O
history	O
of	O
severe	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
.	O

For	O
the	O
past	O
several	O
years	O
,	O
the	O
patient	O
has	O
continued	O
to	O
have	O
significant	B-PROBLEM
exercise	I-PROBLEM
intolerance	I-PROBLEM
which	O
has	O
limited	O
his	O
ability	O
to	O
work	O
.	O

He	O
reports	O
severe	B-PROBLEM
dyspnea	I-PROBLEM
on	O
exertion	O
.	O

The	O
patient	O
had	O
a	O
recent	O
admission	O
earlier	O
in	O
the	O
month	O
and	O
he	O
was	O
discharged	O
on	O
2015-09-10	O
,	O
after	O
undergoing	O
cardiac	B-TEST
catheterization	I-TEST
.	O

This	O
was	O
significant	O
for	O
demonstrating	O
no	O
flow-limited	B-PROBLEM
disease	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
coronaries	I-PROBLEM
but	O
several	B-PROBLEM
fistulae	I-PROBLEM

Several	O
of	O
these	O
were	O
coil	B-TREATMENT
embolized	I-TREATMENT
during	O
this	O
admission	O
.	O

He	O
tolerated	O
this	O
well	O
,	O
was	O
sent	O
home	O
,	O
and	O
now	O
returns	O
for	O
his	B-TREATMENT
mitral	I-TREATMENT
valve	I-TREATMENT
repair	I-TREATMENT
.	O

1.	O
Mitral	B-PROBLEM
valve	I-PROBLEM
regurgitation	I-PROBLEM
.	O

1.	O
Atenolol	B-TREATMENT
25	O
mg	O
p.o.	O
q.	O
day	O
.	O

2.	O
Enteric-coated	B-TREATMENT
aspirin	I-TREATMENT
325	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
Nitroglycerin	B-TREATMENT
sublingual	I-TREATMENT
p.r.n.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

The	O
patient	O
is	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Temperature	B-TEST
is	O
98.3	O
F.	O
;	O
pulse	B-TEST
is	O
76	O
;	O
blood	B-TEST
pressure	I-TEST
113/52	O
;	O
breathing	B-TEST
18	O
;	O
98%	O
on	O
room	O
air	O
.	O

The	O
patient	O
is	O
missing	B-PROBLEM
many	I-PROBLEM
teeth	I-PROBLEM
.	O

There	O
is	O
no	O
cervical	B-PROBLEM
lymphadenopathy	I-PROBLEM
.	O

Heart	O
is	O
regular	O
rate	O
and	O
rhythm	O
with	O
a	B-PROBLEM
III/VI	I-PROBLEM
systolic	I-PROBLEM
ejection	I-PROBLEM
murmur	I-PROBLEM
.	O

His	O
lungs	O
are	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Abdomen	O
is	O
soft	O
and	O
nontender	B-PROBLEM
.	O

The	O
patient	O
has	O
no	O
cyanosis	B-PROBLEM
,	O
clubbing	B-PROBLEM
or	O
edema	B-PROBLEM
in	I-PROBLEM
extremities	I-PROBLEM
.	O

On	O
admission	O
include	O
a	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
of	O
5.6	O
,	O
hematocrit	B-TEST
of	O
32.5	O
,	O
platelets	B-TEST
of	O
202	O
.	O

Sodium	B-TEST
of	O
140	O
,	O
potassium	B-TEST
of	O
3.5	O
,	O
BUN	B-TEST
of	O
4	O
,	O
creatinine	B-TEST
of	O
0.6	O
,	O
glucose	B-TEST
of	O
137	O
.	O

Chest	B-TEST
x-ray	I-TEST
shows	O
no	O
infiltrate	B-PROBLEM
or	O
pneumothorax	B-PROBLEM
.	O

Cardiac	B-TEST
catheterization	I-TEST
demonstrates	O
no	O
significant	B-PROBLEM
disease	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
coronary	I-PROBLEM
arteries	I-PROBLEM
.	O

Two	O
branches	O
of	O
an	B-PROBLEM
left	I-PROBLEM
anterior	I-PROBLEM
descending	I-PROBLEM
to	I-PROBLEM
PA	I-PROBLEM
fistula	I-PROBLEM
which	O
was	O
successfully	O
coiled	O
.	O

There	O
is	O
a	B-PROBLEM
persistent	I-PROBLEM
flow	I-PROBLEM
through	O
an	O
inferior	O
branch	O
of	O
the	O
left	O
anterior	O
descending	O
to	O
PA	B-PROBLEM
fistula	I-PROBLEM
and	O
a	O
persistent	O
branch	O
of	O
the	B-PROBLEM
circumflex	I-PROBLEM
to	I-PROBLEM
PA	I-PROBLEM
branch	I-PROBLEM
fistula	I-PROBLEM
which	O
anatomically	O
were	O
not	O
suitable	O
for	O
coil	B-TREATMENT
embolization	I-TREATMENT
.	O

Ejection	B-TEST
fraction	I-TEST
was	O
60%	O
.	O

mitral	B-TREATMENT
valve	I-TREATMENT
repair	I-TREATMENT
.	O

He	O
tolerated	O
this	B-TREATMENT
procedure	I-TREATMENT
well	O
.	O

The	O
patient	O
was	O
brought	O
to	O
the	O
cardiothoracic	O
Intensive	O
Care	O
Unit	O
in	O
stable	O
condition	O
on	O
minimal	B-TREATMENT
pressor	I-TREATMENT
support	I-TREATMENT
.	O

He	O
was	O
successfully	O
weaned	O
off	O
this	B-TREATMENT
support	I-TREATMENT
.	O

The	O
patient	O
was	O
fully	O
weaned	O
from	O
ventilatory	B-TREATMENT
support	I-TREATMENT
secondary	O
to	O
a	B-PROBLEM
persistent	I-PROBLEM
acidemia	I-PROBLEM
.	O

This	O
was	O
treated	O
with	O
sodium	B-TREATMENT
bicarbonate	I-TREATMENT
and	O
a	B-TREATMENT
Swan-Ganz	I-TREATMENT
was	O
placed	O
to	O
provide	O
close	B-TEST
hemodynamic	I-TEST
monitoring	I-TEST
.	O

The	O
patient	O
was	O
found	O
to	O
have	O
stable	O
hemodynamics	O
with	O
appropriate	O
mixed	O
venous	B-TEST
saturations	I-TEST
in	O
the	O
70%	O
range	O
.	O

He	O
was	O
then	O
weaned	O
off	O
of	O
ventilatory	B-TREATMENT
support	I-TREATMENT
and	O
was	O
successfully	O
extubated	O
.	O

The	O
patient	O
did	O
have	O
a	B-PROBLEM
slight	I-PROBLEM
bit	I-PROBLEM
of	I-PROBLEM
confusion	I-PROBLEM
early	O
in	O
post-extubation	O
course	O
which	O
cleared	O
.	O

In	O
addition	O
,	O
the	O
patient	O
's	O
early	O
postoperative	O
course	O
had	O
a	O
tremendous	O
urine	B-TEST
output	I-TEST
.	O

It	O
was	O
equally	O
up	O
to	O
700	O
cc.	O
an	O
hour	O
and	O
a	B-TEST
renal	I-TEST
consultation	I-TEST
was	O
obtained	O
.	O

He	O
underwent	O
a	B-TEST
head	I-TEST
CT	I-TEST
scan	I-TEST
to	O
rule	O
out	O
intracranial	B-PROBLEM
pathology	I-PROBLEM
leading	O
to	O
diabetes	B-PROBLEM
insipidus	I-PROBLEM
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
serum	I-TEST
and	O
urine	B-TEST
electrolytes	I-TEST
indicated	O
that	O
this	B-TREATMENT
diuresis	I-TREATMENT
was	O
appropriate	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
urine	I-TEST
output	I-TEST
has	O
decreased	O
and	O
his	B-TEST
BUN	I-TEST
and	O
creatinine	B-TEST
remained	O
normal	O
.	O

The	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
Foley	I-TREATMENT
was	O
discontinued	O
.	O

He	O
had	O
developed	O
some	B-PROBLEM
hematuria	I-PROBLEM
which	O
has	O
resolved	O
.	O

1.	O
Mitral	B-PROBLEM
regurgitation	I-PROBLEM
status	O
post	O
minimally	B-TREATMENT
invasive	I-TREATMENT
mitral	I-TREATMENT
valve	I-TREATMENT
repair	I-TREATMENT
.	O

1.	O
Lopressor	B-TREATMENT
75	O
mg	O
p.o.	O
twice	O
a	O
day	O
.	O

2.	O
Colace	B-TREATMENT
100	O
mg	O
p.o.	O
twice	O
a	O
day	O
.	O

3.	O
Percocet	B-TREATMENT
one	O
to	O
two	O
p.o.	O
q.	O
four	O
hours	O
p.r.n.	O

4.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
The	O
patient	O
will	O
call	O
for	O
any	B-PROBLEM
fevers	I-PROBLEM
or	O
difficulties	B-PROBLEM
with	I-PROBLEM
the	I-PROBLEM
wound	I-PROBLEM
care	I-PROBLEM
,	O
and	O
will	O
be	O
instructed	O
with	O
an	O
interpreter	O
present	O
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
requiring	O
surgical	B-TREATMENT
intervention	I-TREATMENT

CABG	B-TREATMENT
x	O
5	O

Mr.	O
Andersen	O
is	O
a	O
71-year-old	O
male	O
with	O
worsening	B-PROBLEM
anginal	I-PROBLEM
symptoms	I-PROBLEM
who	O
underwent	O
catheterization	B-TEST
that	O
showed	O
severe	B-PROBLEM
three-vessel	I-PROBLEM
disease	I-PROBLEM
.	O

He	O
is	O
presenting	O
for	O
revascularization	B-TREATMENT
.	O

DM2	B-PROBLEM
-	O
dx	O
'd	O
at	O
the	O
age	O
of	O
48	O

Arthritis	B-PROBLEM

HTN	B-PROBLEM

Tonsillectomy	B-TREATMENT
around	O
the	O
age	O
of	O
10	O

Father	O
died	O
of	O
colon	B-PROBLEM
cancer	I-PROBLEM
.	O

Mother	O
with	O
pacemaker	B-TREATMENT
,	O
alive	O
at	O
91	O
years	O
old	O
.	O

Awake	O
and	O
alert	O
,	O
NAD	B-PROBLEM

HEENT	O
:	O
PERRLA	O
,	O
no	O
carotid	B-PROBLEM
bruits	I-PROBLEM

CV	O
:	O
RRR	O
,	O
no	O
M/R/G	B-PROBLEM

Abd	O
:	O
Soft	O
,	O
NT/ND	B-PROBLEM
,	O
NABS	O

Ext	O
:	O
cool	O
,	O
no	O
varicosities	B-PROBLEM
,	O
1+	O
pedal	B-TEST
pulses	I-TEST

2013-10-29	O
11:37	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
11.4	O
*#	O
RBC	B-TEST
-	O
3.09	O
*#	O
Hgb	B-TEST
-	O
9.1	O
*#	O
Hct	B-TEST
-	O
27.5	O
*#	O
MCV	B-TEST
-	O
89	O
MCH	B-TEST
-	O
29.5	O
MCHC	B-TEST
-	O
33.3	O
RDW	B-TEST
-	O
14.6	O
Plt	B-TEST
Ct	I-TEST
-	O
180	O

2013-10-29	O
11:37	O
AM	O
BLOOD	B-TEST
PT	B-TEST
-	O
16.2	O
*	O
PTT	B-TEST
-	O
29.0	O
INR(PT)	B-TEST
-	O
1.7	O

2013-10-29	O
11:37	O
AM	O
BLOOD	B-TEST
Plt	B-TEST
Ct	I-TEST
-	O
180	O

2013-10-29	O
01:09	O
PM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
172	O
*	O
UreaN	B-TEST
-	O
11	O
Creat	B-TEST
-	O
0.9	O
Na	B-TEST
-	O
142	O
Cl	B-TEST
-	O
111	O
*	O
HCO3	B-TEST
-	O
22	O

2013-10-29	O
01:09	O
PM	O
BLOOD	B-TEST
Mg	B-TEST
-	O
2.6	O

The	O
patient	O
was	O
taken	O
to	O
the	O
operating	O
room	O
on	O
2013-10-29	O
for	O
a	B-TREATMENT
CABG	I-TREATMENT
x5	O
.	O

The	O
patient	O
tolerated	O
this	B-TREATMENT
procedure	I-TREATMENT
well	O
.	O

His	B-TREATMENT
central	I-TREATMENT
line	I-TREATMENT
and	O
chest	B-TREATMENT
tubes	I-TREATMENT
were	O
removed	O
on	O
post-op	O
day	O
#2	O
and	O
was	O
transferred	O
to	O
the	O
floor	O
in	O
stable	O
condition	O
.	O

On	O
post-op	O
day	O
#3	O
,	O
the	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
pacing	I-TREATMENT
wires	I-TREATMENT
were	O
removed	O
,	O
and	O
his	B-TREATMENT
lopressor	I-TREATMENT
was	O
started	O
.	O

On	O
post-op	O
day	O
#4	O
,	O
the	O
patient	O
failed	O
the	O
first	O
of	O
his	B-TEST
void	I-TEST
trials	I-TEST
.	O

He	O
was	O
discharged	O
home	O
on	O
post-op	O
day	O
#6	O
in	O
stable	O
condition	O
with	O
a	B-TREATMENT
foley	I-TREATMENT
catheter	I-TREATMENT
and	O
leg	B-TREATMENT
bag	I-TREATMENT
.	O

Avandia	B-TREATMENT
8	O
mg	O
daily	O

Glipizide	B-TREATMENT
10	O
mg	O
bid	O

Diovan	B-TREATMENT
160	O
mg	O
daily	O

Metformin	B-TREATMENT
500	O
mg	O
two	O
tabs	O
bid	O

Omeprazole	B-TREATMENT
20	O
mg	O
q	O
PM	O

1.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

2.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

3.	O
Oxycodone	B-TREATMENT
-	O
Acetaminophen	B-TREATMENT
5-325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
for	O
30	O
doses	O
.	O

4.	O
Atorvastatin	B-TREATMENT
Calcium	I-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

5.	O
Rosiglitazone	B-TREATMENT
Maleate	I-TREATMENT
8	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

6.	O
Glipizide	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

7.	O
Tamsulosin	B-TREATMENT
0.4	O
mg	O
Capsule	O
,	O
Sust.	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
HR	O
PO	O
HS	O
(	O
at	O
bedtime	O
).	O

8.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

9.	O
Furosemide	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
twelve	O
(	O
12	O
)	O
hours	O
.	O

10.	O
Pantoprazole	B-TREATMENT
Sodium	I-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
).	O

11.	O
Potassium	B-TREATMENT
Chloride	I-TREATMENT
10	O
mEq	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
).	O

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM

Please	O
return	O
to	O
the	O
hospital	O
or	O
call	O
Dr.	O
Alvarado	O
's	O
office	O
if	O
you	O
experience	O
chills	B-PROBLEM
or	O
fever	B-PROBLEM
greater	I-PROBLEM
than	I-PROBLEM
101	I-PROBLEM
degrees	I-PROBLEM
F.	I-PROBLEM

Please	O
call	O
if	O
you	O
notice	O
redness	B-PROBLEM
,	O
swelling	B-PROBLEM
,	O
or	O
tenderness	B-PROBLEM
of	O
your	B-PROBLEM
chest	I-PROBLEM
wound	I-PROBLEM
,	O
or	O
if	O
it	O
begins	O
to	O
drain	O
pus	B-PROBLEM
.	O

Wash	O
incision	B-PROBLEM
with	O
mild	O
soap	O
and	O
water	O
,	O
then	O
pat	O
dry	O
.	O

You	O
will	O
need	O
to	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
/	O
urologist	O
prior	O
to	O
removal	O
of	O
your	B-TREATMENT
urinary	I-TREATMENT
catheter	I-TREATMENT
.	O

Penicillins	B-TREATMENT

Transfer	O
from	O
Newton-Wellesley	O
Hospital	O
hospital	O
for	O
epidural	B-PROBLEM
abscess	I-PROBLEM

1.	O
Partial	B-TREATMENT
vertebrectomy	I-TREATMENT
of	I-TREATMENT
L3	I-TREATMENT
and	I-TREATMENT
L4	I-TREATMENT
.	O

2.	O
Fusion	B-TREATMENT
at	I-TREATMENT
L3-L4	I-TREATMENT
.	O

3.	O
Vertebral	B-TREATMENT
Spacer	I-TREATMENT
at	I-TREATMENT
L3-L4	I-TREATMENT
.	O

4.	O
Anterior	B-TREATMENT
instrumentation	I-TREATMENT
L3-L4	I-TREATMENT
.	O

5.	O
Autograft	B-TREATMENT
,	O
bone	B-TREATMENT
morphogenic	I-TREATMENT
protein	I-TREATMENT
,	O
and	O
allograft	B-TREATMENT
.	O

6.	O
Debridement	B-TREATMENT

7.	O
Incision	B-TREATMENT
and	O
drainage	B-TREATMENT

8.	O
Echocardiogram	B-TEST

73	O
yo	O
M	O
transferred	O
from	O
Newton-Wellesley	O
Hospital	O
hospital	O
for	O
epidural	B-PROBLEM
abscess	I-PROBLEM
.	O

Pt	O
has	O
h/o	O
colon	B-PROBLEM
can	I-PROBLEM
to	I-PROBLEM
liver	I-PROBLEM
,	O
s/p	O
resxn	B-TREATMENT
with	O
serosal	B-PROBLEM
implants	I-PROBLEM
in	O
9/03	O
.	O

Pt	O
states	O
he	O
has	O
been	O
receiving	O
chemotherapy	B-TREATMENT
up	O
until	O
1	O
week	O
ago	O
.	O

States	O
he	O
first	O
developed	O
back	B-PROBLEM
pain	I-PROBLEM
5	O
weeks	O
ago	O
but	O
was	O
still	O
able	O
to	O
ambulate	O
with	O
his	B-TREATMENT
cane	I-TREATMENT
.	O

An	B-TEST
MRI	I-TEST
was	O
done	O
and	O
this	O
showed	O
a	B-PROBLEM
signal	I-PROBLEM
abno	I-PROBLEM
in	I-PROBLEM
L3	I-PROBLEM
L4	I-PROBLEM
?	O
disciitis	B-PROBLEM
vs	O
osteo	B-PROBLEM
without	O
a	B-PROBLEM
definitive	I-PROBLEM
epidural	I-PROBLEM
abscess	I-PROBLEM
.	O

Initially	O
on	O
Vanc	B-TREATMENT
and	O
Cipro	B-TREATMENT
on	O
Friday	O
but	O
then	O
seen	O
by	O
ID	O
who	O
reccommended	O
no	O
abx	B-TREATMENT
but	O
a	B-TEST
bone	I-TEST
biopsy	I-TEST
,	O
blood	B-TEST
cx	I-TEST
.	O

He	O
was	O
also	O
seen	O
by	O
spine	O
who	O
repeated	O
the	B-TEST
MRI	I-TEST
and	O
this	O
showed	O
L3-4	B-PROBLEM
osteomyelitis	I-PROBLEM
and	O
discitis	B-PROBLEM
and	O
an	B-PROBLEM
epidural	I-PROBLEM
abscess	I-PROBLEM
,	O
5cm	O
.	O

He	O
was	O
subsequently	O
restared	O
on	O
Vancomycin	B-TREATMENT
for	O
Corynebacterium	B-PROBLEM
in	O
blood	B-TEST
cx	I-TEST
from	O
Fri	O
;	O
Followup	B-TEST
cx	I-TEST
has	O
been	O
NGTD	O
.	O

CXR	B-TEST
also	O
showed	O
small	B-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
and	O
attempt	O
was	O
made	O
to	O
tap	B-TREATMENT
it	O
,	O
but	O
pt	O
did	O
not	O
tolerate	O
the	B-TREATMENT
procedure	I-TREATMENT
and	O
asked	O
that	O
it	O
be	O
deferred	O
.	O

He	O
did	O
undergo	O
a	B-TEST
CT-guided	I-TEST
aspiration	I-TEST
/	I-TEST
biopsy	I-TEST
at	I-TEST
the	I-TEST
L3-4	I-TEST
disc	I-TEST
space	I-TEST
on	O
2020-03-11	O
and	O
the	O
pt	O
was	O
transferred	O
to	O
Mediplex	O
Rehab	O
Hospital	O
immediately	O
following	O
this	O
.	O

Currently	O
pt	O
denies	O
sensory	B-PROBLEM
deficits	I-PROBLEM
or	O
weakness	B-PROBLEM
.	O

States	O
he	O
is	O
not	O
able	O
to	O
walk	O
because	O
of	O
severe	B-PROBLEM
pain	I-PROBLEM
.	O

States	O
pain	B-PROBLEM
is	O
worst	O
when	O
he	O
sits	O
up	O
or	O
twists	O
his	O
back	O
.	O

No	O
bowel	B-PROBLEM
or	I-PROBLEM
bladder	I-PROBLEM
incontinence	I-PROBLEM
.	O

-	O
epidural	B-PROBLEM
abscess	I-PROBLEM

-	O
colon	B-PROBLEM
cancer	I-PROBLEM
with	O
mets	B-PROBLEM
to	I-PROBLEM
liver	I-PROBLEM
s/p	O
resection	B-TREATMENT
09-07	O
.	O

-	O
CAD	B-PROBLEM
s/p	O
CABG	B-TREATMENT
x4	O
in	O
'	O
03	O
.	O

-	O
hypercholesterolemia	B-PROBLEM

-	O
DM	B-PROBLEM
with	O
neuropathy	B-PROBLEM
.	O

-	O
persistent	B-PROBLEM
R	I-PROBLEM
foot	I-PROBLEM
ulcer	I-PROBLEM

he	O
states	O
he	O
gives	O
her	O
one	O
of	O
his	O
pensions	O
and	O
she	O
helps	O
him	O
with	O
medicines	B-TREATMENT
etc	O
.	O

Gen	O
:	O
in	O
NAD	B-PROBLEM
,	O
but	O
winces	O
in	O
pain	B-PROBLEM
with	O
movements	O
of	O
his	O
back	O
.	O

HEENT	O
:	O
Clear	O
OP	O
,	O
MM	B-PROBLEM
very	I-PROBLEM
dry	I-PROBLEM
.	O

NECK	O
:	O
Supple	O
,	O
No	O
LAD	B-PROBLEM
,	O
No	O
JVD	B-PROBLEM

CHEST	O
:	O
Port	B-TREATMENT
a	I-TREATMENT
cath	I-TREATMENT
in	I-TREATMENT
R	I-TREATMENT
chest	I-TREATMENT
,	O
no	O
erythema	B-PROBLEM
or	O
tenderness	B-PROBLEM
.	O

II/VI	B-PROBLEM
SEM	I-PROBLEM
at	I-PROBLEM
LSB	I-PROBLEM
with	O
radiation	B-PROBLEM
to	I-PROBLEM
apex	I-PROBLEM
.	O

LUNGS	O
:	O
+	O
crackles	B-PROBLEM
at	I-PROBLEM
L	I-PROBLEM
base	I-PROBLEM
>	O
R	O
base	O
.	O

ABD	O
:	O
Pt	O
very	B-PROBLEM
tense	I-PROBLEM
in	I-PROBLEM
abdomen	I-PROBLEM
(	O
states	O
belly	O
is	O
fine	O
,	O
but	O
he	O
is	O
weary	O
of	O
his	O
back	O
).	O

Well	B-PROBLEM
healed	I-PROBLEM
midline	I-PROBLEM
scar	I-PROBLEM
from	O
chest	O
down	O
to	O
pubis	O
.	O

No	O
HSM	B-PROBLEM
.	O

EXT	O
:	O
No	O
edema	B-PROBLEM
.	O

Dressing	B-TREATMENT
c/d/i	O
over	O
R	B-PROBLEM
LE	I-PROBLEM
ulcer	I-PROBLEM
.	O

1	O
+	O
DP	B-TEST
pulses	I-TEST
BL	O

Back	O
:	O
+	O
ttp	B-PROBLEM
of	I-PROBLEM
lumbar	I-PROBLEM
spine	I-PROBLEM
and	I-PROBLEM
paraspinal	I-PROBLEM
muscles	I-PROBLEM
,	O
R	O
>	O
L	O
.	O

No	O
erythema	B-PROBLEM
or	O
swelling	B-PROBLEM
noted	O
.	O

Na	B-TEST
:	O
135	O
,	O
K	B-TEST
4.5	O
,	O
Cl	B-TEST
96	O
,	O
CO2	B-TEST
27	O
,	O
BUN	B-TEST
12	O
,	O
Cr	B-TEST
0.7	O
,	O
Glu	B-TEST
167	O
,	O
Ca	B-TEST
8.4	O
,	O
Vanco	B-TEST
trough	I-TEST
13	O
,	O
WBC	B-TEST
5.3	O
,	O
Hct	B-TEST
32.0	O
,	O
plt	B-TEST
330	O
,	O
INR	B-TEST
1.0	O
.	O

No	O
culture	B-TEST
data	I-TEST
was	O
sent	O
.	O

MRI	B-TEST
lumbar	I-TEST
spine	I-TEST
(	O
Youville	O
Hospital	O
2020-03-10	O
):	O
L3-4	B-PROBLEM
osteomyelitis	I-PROBLEM
,	O
discitis	B-PROBLEM
,	O
and	O
epidural	B-PROBLEM
abscess	I-PROBLEM
.	O

Degenerative	B-PROBLEM
changes	I-PROBLEM
including	O
multilevel	B-PROBLEM
central	I-PROBLEM
spinal	I-PROBLEM
stenosis	I-PROBLEM
.	O

Impression	B-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
anterior	I-PROBLEM
aspect	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
lower	I-PROBLEM
spinal	I-PROBLEM
cord	I-PROBLEM
at	I-PROBLEM
T11-12	I-PROBLEM
by	O
disc	B-PROBLEM
bulge	I-PROBLEM
.	O

Addendum	O
:	O
Findings	O
are	O
c/w	O
paraspinous	B-PROBLEM
extension	I-PROBLEM
of	I-PROBLEM
infection	I-PROBLEM
anteriorly	O
and	O
laterally	O
into	O
the	O
medial	O
aspects	O
of	O
the	O
psoas	O
muscles	O
bilaterally	O
at	O
the	O
L3	O
and	O
L4	O
levels	O
.	O

CXR	B-TEST
(	O
Youville	O
Hospital	O
2020-03-09	O
):	O
Persistent	B-PROBLEM
unchanged	I-PROBLEM
L	I-PROBLEM
mid	I-PROBLEM
and	I-PROBLEM
lower	I-PROBLEM
lung	I-PROBLEM
field	I-PROBLEM
airspace	I-PROBLEM
disease	I-PROBLEM
with	O
moderate	B-PROBLEM
L	I-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

73	O
yo	O
M	O
transferred	O
from	O
Youville	O
Hospital	O
with	O
h/o	O
colon	B-PROBLEM
cancer	I-PROBLEM
with	O
known	B-PROBLEM
liver	I-PROBLEM
mets	I-PROBLEM
now	O
with	O
epidural	B-PROBLEM
abscess	I-PROBLEM
and	O
corynebacterium	B-PROBLEM
bacteremia	I-PROBLEM
:	O

#	O
Epidural	B-PROBLEM
abscess	I-PROBLEM
:	O
The	O
patient	O
was	O
evaluated	O
by	O
orthopedic	O
spine	O
consult	O
service	O
and	O
ID	O
.	O

He	O
was	O
continued	O
on	O
IV	B-TREATMENT
vancomycin	I-TREATMENT
throughout	O
his	O
course	O
and	O
had	O
therapeutic	O
troughs	B-TEST
.	O

Please	O
see	O
the	O
operation	O
notes	O
for	O
details	O
about	O
the	B-TREATMENT
surgeries	I-TREATMENT
.	O

The	O
patient	O
was	O
briefly	O
admitted	O
to	O
the	O
ICU	O
for	O
low	B-PROBLEM
hematocrit	I-PROBLEM
and	O
hyponatremia	B-PROBLEM
immediately	O
following	O
the	B-TREATMENT
surgery	I-TREATMENT
but	O
was	O
then	O
transferred	O
back	O
to	O
the	O
floor	O
in	O
stable	O
condition	O
.	O

The	O
patient	O
had	O
a	B-TREATMENT
PICC	I-TREATMENT
line	I-TREATMENT
placed	O
and	O
will	O
continue	O
a	B-TREATMENT
8	I-TREATMENT
week	I-TREATMENT
course	I-TREATMENT
of	I-TREATMENT
antibiotics	I-TREATMENT
.	O

The	O
patient	O
will	O
also	O
wear	O
a	B-TREATMENT
back	I-TREATMENT
brace	I-TREATMENT
at	O
all	O
times	O
while	O
out	O
of	O
bed	O
.	O

#	O
Candidemia	B-PROBLEM
:	O
The	O
patient	O
was	O
noted	O
to	O
have	O
a	O
positive	O
blood	B-TEST
culture	I-TEST
from	O
03-12	O
.	O

The	O
patient	O
was	O
started	O
on	O
Diflucan	B-TREATMENT
.	O

Ophthalmology	O
was	O
consulted	O
and	O
ruled	O
out	O
ocular	B-PROBLEM
spread	I-PROBLEM
.	O

The	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
portocath	I-TREATMENT
was	O
removed	O
.	O

The	O
tip	O
was	O
culture	B-TEST
negative	O
.	O

The	O
patient	O
will	O
get	O
a	O
total	O
of	O
a	B-TREATMENT
two	I-TREATMENT
week	I-TREATMENT
course	I-TREATMENT
of	I-TREATMENT
Diflucan	I-TREATMENT
.	O

#	O
Corynebacterium	B-PROBLEM
bacteremia	I-PROBLEM
:	O
presumably	O
Corynebacterium	B-PROBLEM
in	O
epidural	B-PROBLEM
abscess	I-PROBLEM
as	O
well	O
.	O

The	O
patient	O
had	O
no	O
blood	B-TEST
cultures	I-TEST
to	O
grow	O
corynebacterium	B-PROBLEM
while	O
hospitalized	O
.	O

#	O
Pleural	B-PROBLEM
effusion	I-PROBLEM
:	O
The	O
patient	O
was	O
noted	O
have	O
an	B-PROBLEM
effusion	I-PROBLEM
on	O
CXR	B-TEST
.	O

IP	O
was	O
consulted	O
and	O
did	O
a	B-TEST
thoracentesis	I-TEST
.	O

The	B-TEST
tap	I-TEST
was	O
negative	O
for	O
malignant	B-PROBLEM
cells	I-PROBLEM
.	O

A	B-TEST
repeat	I-TEST
CT	I-TEST
was	O
done	O
showing	O
nodular	B-PROBLEM
thickening	I-PROBLEM
along	O
the	O
right	O
major	O
and	O
minor	O
fissure	O
,	O
concerning	O
for	O
intrapleural	B-PROBLEM
tumor	I-PROBLEM
implants	I-PROBLEM
.	O

IP	O
reviewed	O
the	B-TEST
films	I-TEST
and	O
recommended	O
continue	O
oncologic	B-TREATMENT
care	I-TREATMENT
according	O
to	O

outpatient	O
course	O
and	O
pleurodesis	B-TREATMENT
if	O
the	O
pt	O
becomes	O
symptomatic	B-PROBLEM
02-07	O
fluid	B-PROBLEM
accumulation	I-PROBLEM
.	O

#	O
Foot	B-PROBLEM
ulcer	I-PROBLEM
:	O
diabetic	B-PROBLEM
ulcer	I-PROBLEM
s/p	O
surgery	B-TREATMENT
but	O
never	O
healed	O
.	O

Wound	O
care	O
was	O
consulted	O
and	O
made	O
recommendations	O
for	O
ulcer	B-TREATMENT
care	I-TREATMENT
.	O

His	B-TREATMENT
dressings	I-TREATMENT
were	O
changed	O
by	O
the	O
nursing	O
staff	O
accordingly	O
.	O

#	O
Anemia	B-PROBLEM
:	O
His	B-TEST
HCT	I-TEST
remained	O
stable	O
post-surgery	O
.	O

The	O
patient	O
was	O
continued	O
on	O
his	B-TREATMENT
iron	I-TREATMENT
supplements	I-TREATMENT
.	O

-	O
Iron	B-TREATMENT
Sulfate	I-TREATMENT
300	O
mg	O
po	O
tid	O

-	O
Procrit	B-TREATMENT
40,000	O
units	O
SC	O
q	O
Friday	O

-	O
Lovenox	B-TREATMENT
40	O
mg	O
SC	O
q24	O
for	O
DVT	O
ppx	O

-	O
Albuterol	B-TREATMENT
/	O
Atrovent	B-TREATMENT
nebs	O
q4	O

-	O
Morphine	B-TREATMENT
2-4	O
mg	O
IV	O
q3-4	O
prn	O

-	O
Mylanta	B-TREATMENT
30	O
cc	O
po	O
q6	O
prn	O

-	O
Pepcid	B-TREATMENT
20	O
mg	O
po	O
daily	O

-	O
insulin	B-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT

-	O
glipizide	B-TREATMENT
5	O
mg	O
po	O
bid	O

-	O
metformin	B-TREATMENT
500	O
mg	O
po	O
bid	O

-	O
metoprolol	B-TREATMENT
50	O
mg	O
po	O
daily	O

-	O
Vancomycin	B-TREATMENT
1.5	O
gm	O
q	O
12	O
hours	O

1.	O
Albuterol	B-TREATMENT
Sulfate	I-TREATMENT
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O

2.	O
Ipratropium	B-TREATMENT
Bromide	I-TREATMENT
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O

3.	O
Aluminum-Magnesium	B-TREATMENT
Hydroxide	I-TREATMENT
225-200	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15-30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

4.	O
Glipizide	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

5.	O
Miconazole	B-TREATMENT
Nitrate	I-TREATMENT
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

6.	O
Acetaminophen	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	B-PROBLEM
or	O
pain	B-PROBLEM
.	O

7.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

8.	O
Cepacol	B-TREATMENT
2	O
mg	O
Lozenge	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Lozenge	O
Mucous	O
membrane	O
PRN	O
(	O
as	O
needed	O
).	O

9.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

10.	O
Senna	B-TREATMENT
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

11.	O
Oxycodone	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
every	O
4-6	O
hours	O
as	O
needed	O
for	O
pain	B-PROBLEM
for	O
14	O
days	O
.	O

12.	O
Fluconazole	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
7	O
days	O
.	O

13.	O
Oxycodone	B-TREATMENT
10	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12HR	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
).	O

14.	O
Bisacodyl	B-TREATMENT
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

15.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
).	O

16.	O
Vancomycin	B-TREATMENT
in	I-TREATMENT
Dextrose	I-TREATMENT
1	O
g	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q	O
12H	O
(	O
Every	O
12	O
Hours	O
):	O
To	O
finish	O
on	O
2020-05-12	O
.	O

17.	O
Pepcid	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O

18.	O
Heparin	B-TREATMENT
Lock	I-TREATMENT
Flush	I-TREATMENT
(	I-TREATMENT
Porcine	I-TREATMENT
)	I-TREATMENT
100	O
unit	O
/	O
mL	O
Syringe	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
ML	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
:	O
10	O
ml	O
NS	B-TREATMENT
followed	O
by	O
2	O
ml	O
of	O
100	O
Units	O
/	O
ml	O
heparin	B-TREATMENT
(	O
200	O
units	O
heparin	B-TREATMENT
)	O
each	O
lumen	O
Daily	O
and	O
PRN	O
.	O

19.	O
Insulin	B-TREATMENT
Glargine	I-TREATMENT
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
units	O
Subcutaneous	O
at	O
dinner	O
time	O
.	O

20.	O
Insulin	B-TREATMENT
Lispro	I-TREATMENT
(	I-TREATMENT
Human	I-TREATMENT
)	I-TREATMENT
100	O
unit	O
/	O
mL	O
Cartridge	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
As	O
directed	O
by	O
sliding	B-TREATMENT
scale-please	I-TREATMENT
see	O
attached	O
scale	O
.	O

Primary	O
diagnosis	O
:	O
Epidural	B-PROBLEM
abscess	I-PROBLEM

-	O
colon	B-PROBLEM
cancer	I-PROBLEM
with	O
mets	B-PROBLEM
to	I-PROBLEM
liver	I-PROBLEM
s/p	O
resection	B-TREATMENT
09-07	O
.	O

-	O
CAD	B-PROBLEM
s/p	O
CABG	B-TREATMENT
x4	O
in	O
'	O
03	O
.	O

-	O
hypercholesterolemia	B-PROBLEM

-	O
DM	B-PROBLEM
with	O
neuropathy	B-PROBLEM
.	O

-	O
persistent	B-PROBLEM
R	I-PROBLEM
foot	I-PROBLEM
ulcer	I-PROBLEM

Stable	O
,	O
afebrile	B-PROBLEM

You	O
were	O
diagnosed	O
with	O
an	B-PROBLEM
epidural	I-PROBLEM
abscess	I-PROBLEM
.	O

Continue	O
to	O
take	O
the	B-TREATMENT
antibiotics	I-TREATMENT
as	O
directed	O
.	O

Take	O
the	B-TREATMENT
pain	I-TREATMENT
medication	I-TREATMENT
as	O
directed	O
and	O
do	O
not	O
drive	O
while	O
taking	O
this	B-TREATMENT
medication	I-TREATMENT
.	O

-	O
fever	B-PROBLEM
>	O
102	O

-	O
chest	B-PROBLEM
pain	I-PROBLEM
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM

-	O
worsening	B-PROBLEM
pain	I-PROBLEM
or	O
weakness	B-PROBLEM
in	I-PROBLEM
your	I-PROBLEM
legs	I-PROBLEM
,	O
loss	B-PROBLEM
of	I-PROBLEM
bowel	I-PROBLEM
or	I-PROBLEM
bladder	I-PROBLEM
function	I-PROBLEM
or	O
any	B-PROBLEM
other	I-PROBLEM
concerning	I-PROBLEM
symptoms	I-PROBLEM
.	O

Morphine	B-TREATMENT
/	O
Histamine	B-TREATMENT
H2	I-TREATMENT
Inhibitors	I-TREATMENT
/	O
Heparin	B-TREATMENT
Agents	I-TREATMENT

Increasing	B-PROBLEM
abdominal	I-PROBLEM
girth	I-PROBLEM

4u	B-TREATMENT
FFP	I-TREATMENT

Paracentesis	B-TREATMENT

47	O
female	O
with	O
h/o	O
HCV	B-PROBLEM
cirrhosis	I-PROBLEM
compocated	O
by	O
encephalopathy	B-PROBLEM
,	O
ascites	B-PROBLEM
,	O
and	O
h/o	O
portal	B-PROBLEM
vein	I-PROBLEM
thrombosis	I-PROBLEM
(	O
right	O
anterior	O
portal	O
vein	O
)	O
and	O
portalcaval	B-TREATMENT
shunt	I-TREATMENT
(	O
reversed	O
flow	O
in	O
main	O
portal	O
vein	O
)	O
presents	O
from	O
liver	O
clinic	O
with	O
increasing	B-PROBLEM
abdominal	I-PROBLEM
girth	I-PROBLEM
.	O

She	O
also	O
described	O
sob	B-PROBLEM
,	O
nausea	B-PROBLEM
,	O
worsening	B-PROBLEM
lower	I-PROBLEM
ext	I-PROBLEM
edema	I-PROBLEM
.	O

She	O
denied	O
abd	B-PROBLEM
pain	I-PROBLEM
,	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
.	O

She	O
was	O
admitted	O
for	O
a	B-TREATMENT
large	I-TREATMENT
volume	I-TREATMENT
paracentesis	I-TREATMENT
but	O
her	B-TEST
INR	I-TEST
on	O
admission	O
was	O
3.8	O
.	O

She	O
received	O
4units	O
of	O
FFP	B-TREATMENT
which	O
decreased	O
her	B-TEST
INR	I-TEST
to	O
2.2	O
and	O
then	O
2	O
more	O
units	O
during	O
the	B-TREATMENT
tap	I-TREATMENT
.	O

She	O
then	O
had	O
6L	O
of	O
non-bloody	B-PROBLEM
ascitic	I-PROBLEM
fluid	I-PROBLEM
removed	O
without	O
complication	B-PROBLEM
.	O

She	O
received	O
36gm	O
of	O
albumin	B-TREATMENT
following	O
the	B-TREATMENT
tap	I-TREATMENT
.	O

Her	B-TEST
BP	I-TEST
on	O
admission	O
was	O
120/70	O
and	O
remained	O
stable	O
following	O
the	B-TREATMENT
tap	I-TREATMENT
.	O

Over	O
the	O
next	O
several	O
hours	O
,	O
pt	O
complained	O
of	O
abd	B-PROBLEM
pain	I-PROBLEM
but	O
this	O
resolved	O
on	O
its	O
own	O
without	O
medication	B-TREATMENT
.	O

In	O
the	O
am	O
,	O
she	O
was	O
found	O
to	O
have	O
a	B-TEST
hct	I-TEST
of	O
24	O
,	O
down	O
from	O
32	O
and	O
plts	B-TEST
35	O
,	O
down	O
from	O
72	O
.	O

She	O
received	O
2	O
units	O
of	O
plts	B-TREATMENT
and	O
1	O
unit	O
of	O
PRBC	B-TREATMENT
s.	I-TREATMENT

Her	B-TEST
BP	I-TEST
was	O
then	O
noted	O
to	O
be	O
decreased	B-PROBLEM
at	O
80/40	O
which	O
improved	O
mildly	O
to	O
90/30	O
with	O
1.5L	O
of	O
NS	B-TREATMENT
.	O

Temp	B-TEST
noted	O
to	O
be	O
low	B-PROBLEM
at	O
94	O
and	O
she	O
was	O
placed	O
on	O
bear	B-TREATMENT
hugger	I-TREATMENT
which	O
improved	O
temp	B-TEST
to	O
96.7	O
.	O

Her	O
mental	O
status	O
also	O
had	O
decreased	B-PROBLEM
from	O
admission	O
and	O
her	B-TEST
urine	I-TEST
output	I-TEST
was	O
minimal	B-PROBLEM
,	O
225cc	O
over	O
the	O
past	O
12	O
hours	O
.	O

Creatinine	B-TEST
this	O
am	O
was	O
1.9	O
from	O
0.9	O
yesterday	O
.	O

She	O
was	O
recently	O
hospitalised	O
from	O
02-23	O
/	O
03-04	O
for	O
abdominal	B-PROBLEM
discomfort	I-PROBLEM
at	O
which	O
time	O
she	O
underwent	O
paracentesis	B-TREATMENT
that	O
ruled	O
out	O
SBP	B-PROBLEM
and	O
relieved	O
her	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
.	O

She	O
also	O
underwent	O
US	B-TEST
that	O
revealed	O
patent	O
portal	O
and	O
hepatic	O
vessels	O
.	O

While	O
her	O
discharge	O
summary	O
maintains	O
that	O
she	O
was	O
continued	O
on	O
Furosemide	B-TREATMENT
/	O
Spirinolactone	B-TREATMENT
/	O
Propranolol	B-TREATMENT
,	O
the	O
patient	O
did	O
not	O
receive	O
any	O
scripts	O
on	O
discharge	O
and	O
as	O
a	O
result	O
did	O
not	O
take	O
these	B-TREATMENT
medications	I-TREATMENT
.	O

Also	O
,	O
due	O
to	O
worsening	B-PROBLEM
renal	I-PROBLEM
function	I-PROBLEM
,	O
she	O
was	O
started	O
on	O
octreotide	B-TREATMENT
/	O
midodrine	B-TREATMENT
/	O
albumin	B-TREATMENT
for	O
hepatorenal	O

syndrome	B-PROBLEM
(	O
Cr	B-TEST
3.3	O
at	O
its	O
worst	O
)	O
which	O
resolved	O
prior	O
to	O
her	O
discharge	O
.	O

The	O
hospitalisation	O
was	O
also	O
significant	O
for	O
mild	B-PROBLEM
DIC	I-PROBLEM
for	O
which	O
she	O
received	O
cryoglobulins	B-TREATMENT
and	O
UTI	B-PROBLEM
(+	O
Enterococcus	B-PROBLEM
and	O
+	O
Klebsiella	B-PROBLEM
).	O

She	O
received	O
a	O
7	O
day	O
course	O
of	O
amoxicillin	B-TREATMENT
for	O
which	O
Enterococcus	B-PROBLEM
was	O
sensitive	O
but	O
Klebsiella	B-PROBLEM
unknown	O
.	O

HCV	B-PROBLEM
cirrhosis	I-PROBLEM
c/b	O
esophageal	B-PROBLEM
varices	I-PROBLEM
,	O
ascites	B-PROBLEM
,	O
partial	B-PROBLEM
portal	I-PROBLEM
vein	I-PROBLEM
thrombosis	I-PROBLEM

h/o	O
gastritis	B-PROBLEM

morbid	B-PROBLEM
obesity	I-PROBLEM

recent	O
cholecystitis	B-PROBLEM
08-10	O

sickle	B-PROBLEM
cell	I-PROBLEM
trait	I-PROBLEM

Physical	O
Exam	O
:	O
T	B-TEST
95	O
,	O
BP	B-TEST
120/70	O
,	O
HR	B-TEST
82	O
,	O
RR	B-TEST
20	O
,	O
96%	O
RA	O
Wt	B-TEST
301.6	O
lb	O

HEENT	O
:	O
+	O
scleral	B-PROBLEM
icterus	I-PROBLEM
.	O

No	O
thrush	B-PROBLEM
.	O

Cardiac	O
:	O
RRR	O
,	O
no	O
murmurs	B-PROBLEM

Abdomen	O
:	O
obese	B-PROBLEM
,	O
soft	O
,	O
mildly	B-PROBLEM
distended	I-PROBLEM
dull	B-PROBLEM
to	O
percussion	B-TEST
throughout	O
,	O
no	O
tenderness	B-PROBLEM
,	O
liver	B-PROBLEM
non-palpable	I-PROBLEM
due	O
to	O
large	B-PROBLEM
volume	I-PROBLEM
of	I-PROBLEM
ascited	I-PROBLEM

Extremities	O
:	O
05-09	O
+	O
pretibial	B-PROBLEM
edema	I-PROBLEM
extending	O
above	O
knee	O
R	O
>	O
L	O
,	O
no	O
asterixis	B-PROBLEM
.	O

No	O
palmar	B-PROBLEM
erythema	I-PROBLEM

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
8.1	O
RBC	B-TEST
-	O
3.69	O
*	O
Hgb	B-TEST
-	O
11.0	O
*	O
Hct	B-TEST
-	O
32.4	O
*	O
MCV	B-TEST
-	O
88	O
MCH	B-TEST
-	O
29.8	O
MCHC	B-TEST
-	O
33.9	O
RDW	B-TEST
-	O
26.0	O
*	O
Plt	B-TEST
Ct	I-TEST
-	O
72	O
*#	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
Neuts	B-TEST
-	O
68.3	O
Bands	B-TEST
-	O
0	O
Lymphs	B-TEST
-	O
19.8	O
Monos	B-TEST
-	O
10.6	O
Eos	B-TEST
-	O
1.1	O
Baso	B-TEST
-	O
0.2	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
Hypochr	B-TEST
-	O
1	O
+	O
Anisocy	B-TEST
-	O
2	O
+	O
Poiklo	B-TEST
-	O
2	O
+	O
Macrocy	B-TEST
-	O
2	O
+	O
Microcy	B-TEST
-	O
NORMAL	O
Polychr	B-TEST
-	O
NORMAL	O
Ovalocy	B-TEST
-	O
OCCASIONAL	O
Target	B-TEST
-	O
OCCASIONAL	O
Schisto	B-TEST
-	O
OCCASIONAL	O
Tear	O
Dr	O
Clark	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
PT	B-TEST
-	O
23.0	O
*	O
PTT	B-TEST
-	O
63.2	O
*	O
INR(PT)	B-TEST
-	O
3.8	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
76	O
UreaN	B-TEST
-	O
17	O
Creat	B-TEST
-	O
0.8	O
Na	B-TEST
-	O
129	O
*	O
K	B-TEST
-	O
3.9	O
Cl	B-TEST
-	O
101	O
HCO3	B-TEST
-	O
19	O
*	O
AnGap	B-TEST
-	O
13	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
ALT	B-TEST
-	O
33	O
AST	B-TEST
-	O
65	O
*	O
AlkPhos	B-TEST
-	O
70	O
TotBili	B-TEST
-	O
30.3	O
*	O
DirBili	B-TEST
-	O
20.8	O
*	O
IndBili	B-TEST
-	O
9.5	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
Albumin	B-TEST
-	O
3.1	O
*	O

2015-03-26	O
10:10	O
AM	O
BLOOD	B-TEST
Ammonia	B-TEST
-	O
39	O

1.	O
Small	B-PROBLEM
cirrhotic	I-PROBLEM
liver	I-PROBLEM
with	O
what	O
appears	O
to	O
be	O
a	B-TREATMENT
portocaval	I-TREATMENT
shunt	I-TREATMENT
.	O

2.	O
Moderate	B-PROBLEM
ascites	I-PROBLEM
.	O

3.	O
Cholelithiasis	B-PROBLEM
without	O
evidence	O
of	O
acute	B-PROBLEM
cholecystitis	I-PROBLEM
.	O

4.	O
No	O
hydronephrosis	B-PROBLEM
.	O

5.	O
Borderline	B-PROBLEM
splenomegaly	I-PROBLEM
.	O

A/P	O
:	O
48	O
yo	O
morbidly	O
obese	O
woman	O
with	O
HCV	B-PROBLEM
cirrhosis	I-PROBLEM
c/b	O
encephalopathy	B-PROBLEM
,	O
esophageal	B-PROBLEM
varices	I-PROBLEM
and	O
partial	B-PROBLEM
vein	I-PROBLEM
thrombosis	I-PROBLEM
(	O
but	O
no	O
hx	O
of	O
SBP	B-PROBLEM
)	O
presents	O
with	O
increasing	B-PROBLEM
abdominal	I-PROBLEM
girth	I-PROBLEM
likely	O
secondary	O
to	O
ascites	B-PROBLEM
.	O

Admitted	O
for	O
diagnostic	B-TREATMENT
/	I-TREATMENT
therapeutic	I-TREATMENT
paracentesis	I-TREATMENT
and	O
then	O
transferred	O
to	O
the	O
ICU	O
for	O
hypotension	B-PROBLEM
,	O
confusion	B-PROBLEM
and	O
anemia	B-PROBLEM
.	O

#	O
Liver	B-PROBLEM
cirrhosis	I-PROBLEM
:	O
MELD	B-TEST
score	I-TEST
of	O
34	O
on	O
admission	O
.	O

Pt	O
became	O
more	B-PROBLEM
encephalopathic	I-PROBLEM
during	O
her	O
hospital	O
course	O
.	O

She	O
was	O
not	O
a	O
transplant	O
candidate	O
due	O
to	O
her	B-PROBLEM
obesity	I-PROBLEM
.	O

After	O
it	O
was	O
explained	O
that	O
the	B-PROBLEM
pt	I-PROBLEM
's	I-PROBLEM
prognosis	I-PROBLEM
was	O
very	O
poor	O
given	O
that	O
she	O
was	O
not	O
a	B-TREATMENT
transplant	I-TREATMENT
candidate	O
,	O
the	O

decision	O
was	O
made	O
by	O
the	O
family	O
and	O
the	O
medical	O
team	O
to	O
withdraw	O
care	B-TREATMENT
.	O

#	O
Recurrent	B-PROBLEM
ascites	I-PROBLEM
:	O
On	O
the	O
medical	O
floor	O
,	O
pt	O
had	O
a	B-TREATMENT
large	I-TREATMENT
volume	I-TREATMENT
paracentesis	I-TREATMENT
(	O
6	O
liters	O
)	O
followed	O
by	O
replacement	B-TREATMENT
with	I-TREATMENT
albumin	I-TREATMENT
.	O

She	O
had	O
no	O
evidence	O
of	O
SBP	B-PROBLEM
.	O

#	O
Hypotension	B-PROBLEM
:	O
Pt	O
became	O
hypotensive	B-PROBLEM
following	O
the	B-TREATMENT
large	I-TREATMENT
volume	I-TREATMENT
paracentesis	I-TREATMENT
despite	O
replacement	B-TREATMENT
with	I-TREATMENT
albumin	I-TREATMENT
.	O

This	O
was	O
thought	O
to	O
be	O
04-09	O
the	B-TREATMENT
large	I-TREATMENT
volume	I-TREATMENT
tap	I-TREATMENT
verses	O
sepsis	B-PROBLEM
though	O
she	O
had	O
no	O
other	O
evidence	O
of	O
sepsis	B-PROBLEM
.	O

She	O
was	O
placed	O
on	O
pressors	B-TREATMENT
to	O
maintain	O
a	B-TEST
MAP	I-TEST
>	O
55	O
.	O

Once	O
the	O
decision	O
was	O
made	O
to	O
withdraw	O
care	O
,	O
the	B-TREATMENT
pressors	I-TREATMENT
were	O
discontinued	O
.	O

#	O
Anemia	B-PROBLEM
:	O
Hct	B-PROBLEM
dropped	I-PROBLEM
following	O
the	B-TREATMENT
tap	I-TREATMENT
and	O
there	O
was	O
concern	O
for	O
bleed	B-PROBLEM
into	I-PROBLEM
her	I-PROBLEM
abdomen	I-PROBLEM
.	O

She	O
received	O
one	O
unit	O
of	O
PRBC	B-TREATMENT
s.	I-TREATMENT

CT	B-TEST
of	I-TEST
the	I-TEST
abdomen	I-TEST
and	I-TEST
pelvis	I-TEST
showed	O
no	O
evidence	O
of	O
bleed	B-PROBLEM
.	O

Her	B-TEST
hematocrit	I-TEST
remained	O
stable	O
at	O
24-26	O
following	O
the	B-PROBLEM
acute	I-PROBLEM
drop.	I-PROBLEM

#	O
ARF	B-PROBLEM
:	O
Creatinine	B-TEST
has	O
increased	O
from	O
0.9	O
on	O
admission	O
to	O
1.9	O
on	O
admission	O
to	O
ICU	O
.	O

Urine	B-TEST
lytes	I-TEST
with	O
Na	B-TEST
of	O
10	O
indicating	O
either	O
pre-renal	B-PROBLEM
or	O
hepatorenal	B-PROBLEM
.	O

Fluid	B-TEST
challenge	I-TEST
with	O
36gm	O
of	O
albumin	B-TREATMENT
,	O
one	O
unit	O
of	O
PRBCs	B-TREATMENT
and	O
2L	O
of	O
NS	B-TREATMENT
.	O

Will	O
check	O
creatinine	B-TEST
this	O
afternoon	O
.	O

Pt	O
previously	O
diagnosed	O
with	O
hepatorenal	B-PROBLEM
and	O
was	O
started	O
on	O
midodrine	B-TREATMENT
,	O
octreotide	B-TREATMENT
and	O
albumin	B-TREATMENT
;	O
these	O
were	O

Her	B-TEST
creatinine	I-TEST
continued	O
to	O
increase	O
,	O
likely	O
due	O
to	O
her	B-PROBLEM
worsening	I-PROBLEM
liver	I-PROBLEM
failure	I-PROBLEM
.	O

Rifaximine	B-TREATMENT
200	O
mg	O
tid	O

Lactulose	B-TREATMENT
30	O
cc	O
qid	O
titrated	O
to	O
3-4	O
BM	O
/	O
day	O

Protonix	B-TREATMENT
40	O
mg	O
po	O
qd	O

expired	B-PROBLEM

Maternal	B-TEST
blood	I-TEST
type	I-TEST
0-positive	O
,	O
DAT	B-TEST
negative	O
,	O
negative	O
,	O
RPR	B-TEST
nonreactive	O
.	O

1.	O
Tuberculosis	B-PROBLEM
,	O
mother	O
was	O
treated	O
in	O
2001	O
according	O
to	O
chart	O
with	O
subsequent	O
negative	O
chest	B-TEST
x-ray	I-TEST
,	O
and	O

2.	O
Infertility	B-PROBLEM
.	O

The	O
pregnancy	O
was	O
complicated	O
by	O
twin	B-PROBLEM
gestation	I-PROBLEM
and	O
by	O
polyhydramnios	B-PROBLEM
with	O
apparent	O
duodenal	B-PROBLEM
atresia	I-PROBLEM
and	O
nuchal	O

thickening	B-PROBLEM
consistent	O
with	O
Trisomy	B-PROBLEM
21	I-PROBLEM
in	O
the	O
B	O
co-twin	O
.	O

Amniocentesis	B-TEST
was	O
not	O
performed	O
.	O

Maternal	B-PROBLEM
hypertension	I-PROBLEM
was	O
noted	O
in	O
the	O
doctor	O
's	O
office	O
and	O
Mom	O
was	O
referred	O
to	O
nonreassuring	B-TEST
fetal	I-TEST
tracing	I-TEST
,	O
necessitating	O
an	B-TREATMENT
urgent	I-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
.	O

Twin	O
#1	O
cried	O
spontaneously	O
at	O
birth	O
,	O
was	O
bulb	B-TREATMENT
suctioned	I-TREATMENT
and	O
received	O
Blow-by	B-TREATMENT
oxygen	I-TREATMENT
.	O

Apgars	B-TEST
were	O
8	O
at	O
one	O
minute	O
and	O
8	O
at	O
five	O
minutes	O
.	O

Twin	O
#1	O
was	O
noted	O
to	O
be	O
in	O
a	B-PROBLEM
breech	I-PROBLEM
presentation	I-PROBLEM
.	O

Sepsis	B-PROBLEM
risk	I-PROBLEM
factors	I-PROBLEM
:	O

No	O
fever	B-PROBLEM
,	O
no	O
fetal	B-PROBLEM
tachycardia	I-PROBLEM
,	O
rupture	B-PROBLEM
of	I-PROBLEM
membranes	I-PROBLEM
at	O
delivery	O
.	O

Group	B-TEST
B	I-TEST
Streptococcus	I-TEST
status	I-TEST
unknown	O
.	O

Well-appearing	O
female	O
without	O
distress	B-PROBLEM
on	O
admission	O
to	O
the	O
Newborn	O
Intensive	O
Care	O
Unit	O
.	O

The	O
patient	O
had	O
a	B-TEST
weight	I-TEST
of	O
1400	O
gm	O
,	O
length	B-TEST
41.5	O
cm	O
and	O
head	B-TEST
circumference	I-TEST
of	O
29.25	O
cm	O
.	O

Anterior	O
fontanelle	O
,	O
soft	O
and	O
flat	O
,	O
palate	O
intact	O
,	O
nondysmorphic	B-PROBLEM
features	I-PROBLEM
.	O

Lungs	O
:	O
breath	B-TEST
sounds	I-TEST
clear	O
and	O
equal	O
bilaterally	O
,	O
no	O
retractions	B-PROBLEM
.	O

Heart	O
:	O
regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmur	B-PROBLEM
,	O
normal	O
S1	O
and	O
S2	O
,	O
pulses	B-TEST
2	O
+.	O

Abdomen	O
:	O
soft	O
,	O
nondistended	B-PROBLEM
.	O

Without	O
hepatosplenomegaly	B-PROBLEM
,	O
without	O
masses	B-PROBLEM
.	O

Positive	O
suck	B-TEST
,	O
positive	O
grasp	B-TEST
.	O

1.	O
Respiratory	O
-	O
Gerardo	O
was	O
initially	O
placed	O
in	O
nasal	B-TREATMENT
cannula	I-TREATMENT
oxygen	I-TREATMENT
to	O
maintain	O
oxygen	B-TEST
saturation	I-TEST
greater	O
than	O
94	O
.	O

On	O
day	O
of	O
life	O
#1	O
,	O
caffeine	B-TREATMENT
was	O
started	O
.	O

Caffeine	B-TREATMENT
was	O
discontinued	O
on	O
day	O
of	O
life	O
#19	O
.	O

Breath	B-TEST
sounds	I-TEST
,	O
clear	O
and	O
equal	O
,	O
without	O
retractions	B-PROBLEM
,	O
respiratory	B-TEST
rate	I-TEST
30	O
s	O
to	O
60	O
s.	O

2.	O
Cardiovascular	O
-	O
The	O
patient	O
has	O
been	O
cardiovascularly	O
stable	O
without	O
murmur	B-PROBLEM
.	O

3.	O
Fluids	O
,	O
electrolytes	O
and	O
nutrition	O
-	O
Birthweight	B-TEST
was	O
1400	O
gm	O
,	O
25th	O
percentile	O
.	O

The	O
patient	O
was	O
initially	O
started	O
on	O
D10	B-TREATMENT
/	I-TREATMENT
W	I-TREATMENT
at	O
80	O
cc	O
/	O
kg	O
/	O
day	O
.	O

She	O
began	O
enteral	B-TREATMENT
feeds	I-TREATMENT
on	O
day	O
of	O
life	O
#2	O
advancing	O
to	O
mother	O
's	O
breastmilk	O
30	O
with	O
ProMod	B-TREATMENT
at	O
150	O
cc	O
/	O
kg	O
/	O
day	O
.	O

Baby	O
received	O
parenteral	B-TREATMENT
nutrition	I-TREATMENT
and	O
lipids	B-TREATMENT
for	O
four	O
days	O
.	O

No	O
hypoglycemia	B-PROBLEM
issues	I-PROBLEM
noted	O
.	O

Baby	O
is	O
presently	O
tolerating	O
mother	O
's	O
breastmilk	O
with	O
Enfamil	B-TREATMENT
powder	I-TREATMENT
to	O
make	O
24	O
cal	O
/	O
oz	O
at	O
130	O
cc	O
/	O
kg	O
/	O
day	O
.	O

4.	O
Gastrointestinal	O
,	O
genitourinary	O
-	O
Peak	B-TEST
bilirubin	I-TEST
8.5	O
,	O
phototherapy	B-TREATMENT
times	O
24	O
hours	O
.	O

Rebound	B-TEST
bilirubin	I-TEST
6.4	O
.	O

5.	O
Hematology	O
-	O
Most	O
recent	O
hematocrit	B-TEST
was	O
42.8	O
on	O
50-05-25	O
.	O

The	O
baby	O
received	O
no	O
blood	B-TREATMENT
products	I-TREATMENT
.	O

6.	O
Infectious	O
disease	O
-	O
No	O
sepsis	B-PROBLEM
risk	I-PROBLEM
factors	I-PROBLEM
.	O

Initial	B-TEST
complete	I-TEST
blood	I-TEST
count	I-TEST
with	O
white	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
14	O
,	O
hemoglobin	B-TEST
21.6	O
,	O
hematocrit	B-TEST
62.9	O
,	O
65	O
neutrophils	B-TEST
,	O
no	O
bands	B-TEST
,	O
28	O
lymphocytes	B-TEST
.	O

Blood	B-TEST
cultures	I-TEST
negative	O
.	O

8.	O
Sensory	O
-	O
Audiology	O
,	O
hearing	B-TEST
screening	I-TEST
was	O
performed	O
with	O
automated	O
auditory	O
brain	O
stem	O
responses	O
.	O

Baby	O
passed	O
hearing	B-TEST
test	I-TEST
on	O
2009-01-21	O
.	O

A	B-TEST
follow	I-TEST
up	I-TEST
examination	I-TEST
is	O
recommended	O
in	O
six	O
to	O
eight	O
months	O
.	O

1.	O
Feeds	O
-	O
Breastfeeding	O
ad	O
lib	O
,	O
supplementing	O
with	O
Enfamil	B-TREATMENT
24	O
or	O
breastmilk	O
24	O
cal	O
/	O
oz	O
made	O
with	O
1	O
tsp	O
of	O
Enfamil	B-TREATMENT
powder	I-TREATMENT
per	O
100	O
cc	O
of	O
breastmilk	O
.	O

2.	O
Medications	B-TREATMENT
-	O
Poly-Vi-James	B-TREATMENT
1	O
cc	O
p.o.	O
q.	O
day	O
;	O
Iron	B-TREATMENT
or	O
Fer-In-James	B-TREATMENT
0.2	O
cc	O
p.o.	O
q.	O
day	O
to	O
give	O
2	O
mg	O
/	O
kg	O
/	O
day	O

3.	O
Car	B-TEST
seat	I-TEST
screening	I-TEST
-	O
Passed	O
.	O

4.	O
State	B-TEST
newborn	I-TEST
screening	I-TEST
-	O
Last	O
on	O
2009-01-07	O
,	O
all	O
within	O
normal	O
range	O
.	O

5.	O
Immunizations	B-TREATMENT
received	O
-	O
Hepatitis	B-TREATMENT
B	I-TREATMENT
vaccine	I-TREATMENT
given	O
2009-01-22	O
.	O

6.	O
Immunizations	B-TREATMENT
recommended	O
-	O

Synagis	B-TREATMENT
respiratory	I-TREATMENT
syncytial	I-TREATMENT
virus	I-TREATMENT
prophylaxis	I-TREATMENT
should	O
be	O
considered	O
from	O
October	O
through	O
April	O
for	O
infants	O
who	O
meet	O

3.	O
With	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
.	O

After	O
some	O
debate	O
,	O
we	O
concluded	O
that	O
Vetrano	O
was	O
not	O
at	O
unusually	O
high	O
risk	O
from	O
RSV	B-PROBLEM
,	O
but	O
that	O
her	O
sister	O
might	O
be	O
.	O

Vetrano	O
probably	O
does	O
not	O
need	O
Synagis	B-TREATMENT
at	O
least	O
until	O
her	O
sibling	O
is	O
discharged	O
from	O
the	O
hospital	O
.	O

Influenza	B-TREATMENT
immunization	I-TREATMENT
should	O
be	O
considered	O
annually	O
in	O
the	O
fall	O
for	O
preterm	O
infants	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
once	O
they	O

reach	O
six	O
months	O
of	O
age	O
,	O
before	O
this	O
age	O
the	O
family	O
and	O
other	O
caregivers	O
should	O
be	O
considered	O
for	O
immunization	B-TREATMENT
against	O

influenza	B-PROBLEM
to	O
protect	O
the	O
infant	O
.	O

1.	O
Prematurity	B-PROBLEM
,	O
former	O
32	O
4/7	O
weeks	O
,	O
Twin	O
#1	O

2.	O
Rule	O
out	O
sepsis	B-PROBLEM

The	O
patient	O
is	O
a	O
49-year-old	O
gravida	O
III	O
,	O
para	O
II	O
,	O
who	O
was	O
sent	O
from	O
her	O
primary	O
care	O
physician	O
's	O
office	O
secondary	O
to	O
lower	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
.	O

The	O
patient	O
is	O
status	O
post	O
uterine	B-TREATMENT
artery	I-TREATMENT
embolization	I-TREATMENT
on	O
2009-01-07	O
secondary	O
to	O
fibroids	B-PROBLEM
.	O

She	O
has	O
had	O
continuing	B-PROBLEM
vaginal	I-PROBLEM
discharge	I-PROBLEM
,	O
and	O
was	O
diagnosed	O
with	O
bacterial	B-PROBLEM
vaginosis	I-PROBLEM
one	O
day	O
prior	O
to	O
admission	O
,	O
and	O
was	O
given	O
a	O
prescription	O
for	O
Flagyl	B-TREATMENT
.	O

She	O
noted	O
increasing	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
two	O
days	O
prior	O
to	O
admission	O
,	O
which	O
became	O
more	O
severe	O
on	O
the	O
day	O
prior	O
to	O
admission	O
.	O

She	O
went	O
to	O
her	O
primary	O
care	O
physician	O
's	O
office	O
on	O
the	O
day	O
of	O
admission	O
complaining	O
of	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
which	O
she	O
stated	O
was	O
constant	O
but	O
intermittently	O
sharper	O
at	O
times	O
.	O

She	O
also	O
complained	O
of	O
some	B-PROBLEM
loose	I-PROBLEM
stools	I-PROBLEM
on	O
the	O
day	O
of	O
admission	O
,	O
no	O
nausea	B-PROBLEM
or	O
vomiting	B-PROBLEM
.	O

Her	B-TEST
temperature	I-TEST
was	O
100.4	O
in	O
the	O
office	O
,	O
and	O
she	O
had	O
no	O
chills	B-PROBLEM
.	O

She	O
was	O
sent	O
for	O
a	B-TEST
CT	I-TEST
scan	I-TEST
of	I-TEST
her	I-TEST
abdomen	I-TEST
,	O
which	O
revealed	O
fluid	B-PROBLEM
and	O
question	O
of	O
gas	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
endometrial	I-PROBLEM
cavity	I-PROBLEM
,	O
and	O
she	O
was	O
sent	O
to	O
Pinewood	O
,	O
Norfolk	O
for	O
treatment	B-TREATMENT
and	O
admission	B-TREATMENT
.	O

Cesarean	B-TREATMENT
section	I-TREATMENT
x	O
2	O
,	O
spontaneous	B-PROBLEM
abortion	I-PROBLEM
x	O
1	O
.	O

Some	B-PROBLEM
spotting	I-PROBLEM
on	O
the	O
day	O
prior	O
to	O
admission	O
,	O
but	O
not	O
a	O
normal	O
period	O
.	O

Lupron	B-TREATMENT
x	O
three	O
months	O
prior	O
to	O
embolization	B-TREATMENT
.	O

Fibroid	B-PROBLEM
uterus	I-PROBLEM
status	O
post	O
embolization	B-TREATMENT
on	O
2009-01-07	O
.	O

Dilatation	B-TREATMENT
and	I-TREATMENT
curettage	I-TREATMENT
x	O
1	O
for	O
SAB	B-PROBLEM
.	O

History	O
of	O
herpes	B-PROBLEM
simplex	I-PROBLEM
virus	I-PROBLEM
,	O
last	O
outbreak	O
in	O
2000	O
.	O

No	O
history	O
of	O
abnormal	B-PROBLEM
Pap	I-PROBLEM
smears	I-PROBLEM
.	O

Cesarean	B-TREATMENT
section	I-TREATMENT
x	O
2	O
,	O
dilatation	B-TREATMENT
and	I-TREATMENT
curettage	I-TREATMENT
x	O
1	O
,	O
neck	B-TREATMENT
fusion	I-TREATMENT
after	O
motor	O
vehicle	O
accident	O
,	O
shoulder	B-TREATMENT
surgery	I-TREATMENT
after	O
motor	O
vehicle	O
accident	O
.	O

Flagyl	B-TREATMENT
.	O

Temperature	B-TEST
100.4	O
,	O
pulse	B-TEST
108	O
,	O
respirations	B-TEST
20	O
,	O
blood	B-TEST
pressure	I-TEST
110/70	O
,	O
oxygen	B-TEST
saturation	I-TEST
100%	O
on	O
room	O
air	O
.	O

In	O
general	O
,	O
she	O
was	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Her	O
abdomen	O
was	O
notable	O
for	O
voluntary	B-PROBLEM
guarding	I-PROBLEM
but	O
no	O
involuntary	B-PROBLEM
guarding	I-PROBLEM
or	O
rebound	B-PROBLEM
,	O
mild	B-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
quadrant	I-PROBLEM
tenderness	I-PROBLEM
greater	O
than	O
left	O
lower	O
quadrant	O
,	O
nondistended	B-PROBLEM
.	O

Her	B-TEST
pelvic	I-TEST
examination	I-TEST
was	O
notable	O
for	O
some	B-PROBLEM
brownish	I-PROBLEM
discharge	I-PROBLEM
.	O

Her	O
uterus	O
and	O
adnexa	O
were	O
difficult	O
to	O
assess	O
secondary	O
to	O
voluntary	B-PROBLEM
tensing	I-PROBLEM
of	I-PROBLEM
her	I-PROBLEM
abdomen	I-PROBLEM
.	O

This	O
is	O
a	O
49-year-old	O
gravida	O
III	O
,	O
para	O
II	O
,	O
status	B-TREATMENT
post	I-TREATMENT
uterine	I-TREATMENT
artery	I-TREATMENT
embolization	I-TREATMENT
on	O
2009-01-07	O
due	O
to	O
uterine	B-PROBLEM
fibroids	I-PROBLEM
,	O
with	O
continued	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
and	O
CT	B-TEST
scan	I-TEST
revealing	O
fluid	B-PROBLEM
and	I-PROBLEM
gas	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
endometrial	I-PROBLEM
cavity	I-PROBLEM
.	O

The	O
patient	O
was	O
admitted	O
and	O
was	O
initially	O
started	O
on	O
intravenous	B-TREATMENT
ampicillin	I-TREATMENT
,	O
gentamicin	B-TREATMENT
and	O
clindamycin	B-TREATMENT
.	O

Her	B-TEST
initial	I-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
was	O
11.3	O
,	O
with	O
a	O
normal	O
differential	O
.	O

Her	B-TEST
sedimentation	I-TEST
rate	I-TEST
was	O
elevated	B-PROBLEM
at	O
110	O
.	O

Her	B-TEST
electrolytes	I-TEST
were	O
within	O
normal	O
limits	O
.	O

She	O
was	O
maintained	O
on	O
intravenous	B-TREATMENT
antibiotics	I-TREATMENT
.	O

On	O
hospital	O
day	O
number	O
three	O
,	O
her	B-TEST
blood	I-TEST
cultures	I-TEST
came	O
back	O
positive	B-PROBLEM
in	O
the	B-TEST
anaerobic	I-TEST
culture	I-TEST
for	O
gram-positive	B-PROBLEM
cocci	I-PROBLEM
in	I-PROBLEM
pairs	I-PROBLEM
and	I-PROBLEM
clusters	I-PROBLEM
.	O

Further	B-TEST
identification	I-TEST
revealed	O
staphylococcus	B-PROBLEM
coag-negative	I-PROBLEM
,	O
which	O
was	O
sensitive	O
to	O
gentamicin	B-TREATMENT
and	O
clindamycin	B-TREATMENT
.	O

She	O
was	O
continued	O
on	O
her	B-TREATMENT
antibiotics	I-TREATMENT
,	O
and	O
was	O
afebrile	B-PROBLEM
until	O
hospital	O
day	O
number	O
five	O
,	O
when	O
she	O
had	O
a	B-PROBLEM
temperature	I-PROBLEM
spike	I-PROBLEM
to	O
102.3	O
.	O

Repeat	B-TEST
blood	I-TEST
cultures	I-TEST
were	O
sent	O
.	O

Her	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
was	O
12.8	O
,	O
with	O
a	O
normal	O
differential	O
.	O

At	O
this	O
time	O
,	O
an	O
Infectious	O
Disease	O
consult	O
was	O
obtained	O
,	O
and	O
the	O
recommendation	O
was	O
to	O
discontinue	O
the	B-TREATMENT
ampicillin	I-TREATMENT
,	O
gentamicin	B-TREATMENT
and	O
clindamycin	B-TREATMENT
,	O
and	O
start	O
her	O
on	O
intravenous	B-TREATMENT
Unasyn	I-TREATMENT
.	O

She	O
underwent	O
a	B-TEST
pelvic	I-TEST
ultrasound	I-TEST
and	O
an	B-TEST
abdomen	I-TEST
and	I-TEST
pelvis	I-TEST
CT	I-TEST
,	O
which	O
revealed	O
continued	B-PROBLEM
air	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
endometrial	I-PROBLEM
cavity	I-PROBLEM
vs.	O
in	O
the	B-PROBLEM
fundal	I-PROBLEM
fibroid	I-PROBLEM
.	O

Discussion	O
was	O
had	O
at	O
this	O
time	O
with	O
the	O
patient	O
regarding	O
whether	O
or	O
not	O
this	O
represented	O
an	B-PROBLEM
infected	I-PROBLEM
abscess	I-PROBLEM
vs.	O
post-surgical	B-PROBLEM
change	I-PROBLEM
.	O

possible	O
drainage	B-TREATMENT
of	O
the	B-PROBLEM
abscess	I-PROBLEM
vs.	O
hysterectomy	B-TREATMENT
.	O

The	O
patient	O
requested	O
an	O
outside	O
second	O
opinion	O
,	O
as	O
she	O
was	O
reluctant	O
to	O
undergo	O
hysterectomy	B-TREATMENT
at	O
this	O
time	O
.	O

She	O
was	O
discharged	O
to	O
home	O
on	O
hospital	O
day	O
number	O
eight	O
,	O
on	O
oral	B-TREATMENT
antibiotics	I-TREATMENT
.	O

The	O
patient	O
was	O
to	O
have	O
a	B-TEST
repeat	I-TEST
CT	I-TEST
scan	I-TEST
in	O
one	O
week	O
.	O

She	O
was	O
also	O
to	O
obtain	O
a	O
second	O
opinion	O
regarding	O
the	O
question	O
of	O
possible	O
surgical	B-TREATMENT
management	I-TREATMENT
.	O

Trazodone	B-TREATMENT
/	O
Ambien	B-TREATMENT
/	O
Sinequan	B-TREATMENT

ACQUIRED	B-PROBLEM
DEFECT	I-PROBLEM
FROM	O
BASAL	B-TREATMENT
CELL	I-TREATMENT
CARCINOMA	I-TREATMENT
RESECTION	I-TREATMENT

RIGHT	B-TREATMENT
NOSE	I-TREATMENT
/	I-TREATMENT
ALA	I-TREATMENT
RECONSTRUCTION	I-TREATMENT
USING	O
RIGHT	B-TREATMENT
CHEEK	I-TREATMENT
ADVANCEMENT	I-TREATMENT
AND	O
FOREHEAD	B-TREATMENT
LOCAL	I-TREATMENT
FLAP	I-TREATMENT

MS.	O
Marshall	O
IS	O
A	O
64-YEAR	O
OLD	O
,	O
MENTALLY	B-PROBLEM
RETARDED	I-PROBLEM
,	O
FEMALE	O
WHO	O
PRESENTED	O
WITH	O
AN	B-PROBLEM
AQUIRED	I-PROBLEM
DEFECT	I-PROBLEM
OF	I-PROBLEM
THE	I-PROBLEM
RIGHT	I-PROBLEM
NASAL	I-PROBLEM
ALA	I-PROBLEM
AND	I-PROBLEM
MEDIAL	I-PROBLEM
CHEEK	I-PROBLEM
REGION	I-PROBLEM
AFTER	O
BASAL	B-PROBLEM
CELL	I-PROBLEM
CARCINOMA	I-PROBLEM
WAS	O
RESECTED	O
BY	O
DERMATOLOGY	O
.	O

MENTAL	B-PROBLEM
RETARDATION	I-PROBLEM

DIABETES	B-PROBLEM

BIPOLAR	B-PROBLEM
DISORDER	I-PROBLEM

ON	O
PRESENTATION	O
,	O
PT	O
WAS	O
AFEBRILE	B-PROBLEM
WITH	O
NORMAL	O
VITAL	O
SIGNS	O

GEN	O
:	O
NO	O
ACUTE	B-PROBLEM
DISTRESS	I-PROBLEM
,	O
ABLE	O
TO	O
COMMUNICATE	O
AND	O
FOLLOW	O
ORDERS	O

HEAD	O
AND	O
NECK	O
:	O
5	B-PROBLEM
CM	I-PROBLEM
CIRCULAR	I-PROBLEM
FULL	I-PROBLEM
THICKNESS	I-PROBLEM
DEFECT	I-PROBLEM
AT	O
THE	O
JUNCTION	O
OF	O
THE	O
RIGHT	O
ALA	O
AND	O
CHEEK	O

LUNGS	O
:	O
CLEAR	O
TO	O
ASCULATION	B-TEST

ABDOMEN	O
:	O
SOFT	O
,	O
NON-TENDER	B-PROBLEM
,	O
NON-DISTENDED	B-PROBLEM

EXTREMITIES	O
:	O
NO	O
EDEMA	B-PROBLEM
,	O
CYANOSIS	B-PROBLEM
,	O
FULL	O
RANGE	O
OF	O
MOTION	O

UPON	O
ADMISSION	O
,	O
THE	O
PATIENT	O
WAS	O
PRE-OP	O
'D	O
AND	O
MADE	O
NPO	B-TREATMENT
/	O
IVF	B-TREATMENT
.	O

SHE	O
WENT	O
TO	O
SURGERY	B-TREATMENT
THE	O
NEXT	O
MORNING	O
AND	O
TOLERATED	O
THE	B-TREATMENT
SURGERY	I-TREATMENT
WELL	O
.	O

HOWEVER	O
,	O
SHE	O
WAS	O
SLOW	O
TO	O
AWAKE	O
FROM	O
ANESTHESIA	B-TREATMENT
,	O
AND	O
WAS	O
ADMITTED	O
TO	O
THE	O
CMED	O
CCU	O
OBSERVATION	B-TEST
.	O

SHE	O
WAS	O
TRANSFERED	O
TO	O
THE	O
FLOOR	O
POST-OP	O
DAY	O
2	O
WHERE	O
SHE	O
HAD	O
BEEN	O
AFEBRILE	B-PROBLEM
WITH	O
NORMAL	O
VITALS	O
,	O
MAKING	O
GOOD	O
URINE	O
,	O
AND	O
TOLERATING	O
A	O
REGULAR	O
DIET	O
.	O

HER	B-PROBLEM
WOUND	I-PROBLEM
HAS	O
REMAIND	O
DRY	O
AND	O
CLOSED	O
,	O
WITHOUT	O
EVIDENCE	O
OF	O
INFECTION	B-PROBLEM
OR	O
BREAKDOWN	B-PROBLEM
.	O

SHE	O
WILL	O
BE	O
DISCHARGED	O
TODAY	O
BACK	O
TO	O
HER	O
NURSING	O
HOME	O
IN	O
GOOD	O
CONDITION	O
,	O
ON	O
PAIN	B-TREATMENT
MEDS	I-TREATMENT
,	O
ANTIBIOTICS	B-TREATMENT
,	O
AND	O
WITH	O
ANTICIPATED	O
1:1	O
WATCH	O
.	O

STAGE	O
TWO	O
OF	O
HER	B-TREATMENT
SURGERY	I-TREATMENT
WILL	O
BE	O
DONE	O
IN	O
3	O
WEEKS	O
.	O

1.	O
Paroxetine	B-TREATMENT
HCl	I-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
AM	O
().	O

2.	O
Multivitamin	B-TREATMENT
Capsule	I-TREATMENT
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)).	O

3.	O
Divalproex	B-TREATMENT
Sodium	I-TREATMENT
500	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)).	O

4.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
:	O
constipation	B-PROBLEM
.	O

5.	O
Triamcinolone	B-TREATMENT
Acetonide	I-TREATMENT
0.1	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

6.	O
Divalproex	B-TREATMENT
Sodium	I-TREATMENT
Oral	O

7.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
).	O

8.	O
Oxybutynin	B-TREATMENT
Chloride	I-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QPM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
evening	O
)).	O

9.	O
Hydrocodone-Acetaminophen	B-TREATMENT
5-500	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
).	O

10.	O
Bacitracin-Polymyxin-Neosp	B-TREATMENT
HC	I-TREATMENT
Ointment	I-TREATMENT
Sig	O
:	O
One	O
(	O
1	O
)	O
Topical	O
three	O
times	O
a	O
day	O
.	O

AQUIRED	B-PROBLEM
DEFORMITY	I-PROBLEM
OF	I-PROBLEM
THE	I-PROBLEM
RIGHT	I-PROBLEM
ALA	I-PROBLEM
/	I-PROBLEM
NOSE	I-PROBLEM
AND	I-PROBLEM
MEDIAL	I-PROBLEM
CHEEK	I-PROBLEM
FROM	O
BASAL	B-TREATMENT
CELL	I-TREATMENT
CARCINOMA	I-TREATMENT
RESECTION	I-TREATMENT

PLEASE	O
GIVE	O
PATIENT	O
MEDICATIONS	B-TREATMENT
AS	O
PRESCRIBED	O
AND	O
READ	O
WARNING	O
LABELS	O
CAREFULLY	O
.	O

IF	O
SIGNS	B-PROBLEM
AND	I-PROBLEM
SYMPTOMS	I-PROBLEM
OF	O
INFECTION	B-PROBLEM
,	O
SUCH	O
AS	O
FEVERS	B-PROBLEM
/	O
CHILLS	B-PROBLEM
,	O
PURULENT	B-PROBLEM
DISCHARGE	I-PROBLEM
FROM	I-PROBLEM
WOUND	I-PROBLEM
/	I-PROBLEM
INCISION	I-PROBLEM
SITE	I-PROBLEM
,	O
INCREASED	B-PROBLEM
REDNESS	I-PROBLEM
,	O
INCREASED	B-PROBLEM
PAIN	I-PROBLEM
,	O
PLEASE	O
CALL	O
OR	O
GO	O
TO	O
THE	O
EMERGENCY	O
ROOM	O
.	O

STAGE	O
2	O
OF	O
THE	B-TREATMENT
SURGERY	I-TREATMENT
WILL	O
BE	O
DONE	O
IN	O
3	O
WEEKS	O
.	O

PLEASE	O
CLEAN	O
INCISION	B-PROBLEM
SITE	I-PROBLEM
WITH	O
NORMAL	B-TREATMENT
SALINE	I-TREATMENT
OR	O
CLEAN	O
WATER	O
THREE	O
TIMES	O
A	O
DAY	O
AND	O
PLACE	O
ANTIBIOTIC	B-TREATMENT
OINTMENT	I-TREATMENT
(	O
GIVEN	O
)	O
ON	O
TOP	O
OF	O
WOUND	B-PROBLEM
.	O

MOST	O
IMPORTANTLY	O
,	O
THE	O
PATIENT	O
MUST	O
BE	O
WATCH	O
ONE-ON-ONE	O
SO	O
THAT	O
SHE	O
DOES	O
NOT	O
PICK	O
AT	O
HER	B-PROBLEM
WOUND	I-PROBLEM
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

Hip	B-PROBLEM
fracture	I-PROBLEM

1.	O
Closed	B-TREATMENT
reduction	I-TREATMENT
of	I-TREATMENT
right	I-TREATMENT
hip	I-TREATMENT
with	O
open	B-TREATMENT
placement	I-TREATMENT
of	I-TREATMENT
dynamic	I-TREATMENT
hip	I-TREATMENT
screw	I-TREATMENT
,	I-TREATMENT
right	I-TREATMENT
hip	I-TREATMENT
.	O

2.	O
Examination	B-TEST
under	I-TEST
anesthesia	I-TEST
with	O
placement	B-TREATMENT
of	I-TREATMENT
splint	I-TREATMENT
,	I-TREATMENT
right	I-TREATMENT
elbow	I-TREATMENT
.	O

1.	O
Exploratory	B-TEST
laparotomy	I-TEST
with	O
drainage	B-TREATMENT
of	O
intra-abdominal	B-PROBLEM
abscess	I-PROBLEM
and	O
peritonitis	B-PROBLEM
with	O
gross	B-PROBLEM
soilage	I-PROBLEM
with	I-PROBLEM
bile	I-PROBLEM
and	I-PROBLEM
gastric	I-PROBLEM
contents	I-PROBLEM
.	O

2.	O
Exposure	B-TREATMENT
and	O
wide	B-TREATMENT
drainage	I-TREATMENT
of	O
perforated	B-PROBLEM
posterior	I-PROBLEM
duodenal	I-PROBLEM
ulcer	I-PROBLEM
with	O
internal	B-TREATMENT
and	I-TREATMENT
external	I-TREATMENT
drainage	I-TREATMENT
.	O

3.	O
Feeding	B-TREATMENT
jejunostomy	I-TREATMENT
.	O

4.	O
Tube	B-TREATMENT
gastrostomy	I-TREATMENT
.	O

5.	O
Placement	O
of	O
a	B-TREATMENT
right	I-TREATMENT
femoral	I-TREATMENT
arterial	I-TREATMENT
line	I-TREATMENT
.	O

90	O
yo	O
F	O
with	O
MMP	B-PROBLEM
(	O
see	O
below	O
)	O
who	O
sustained	O
a	B-PROBLEM
mechanical	I-PROBLEM
fall	I-PROBLEM
down	O
stairs	O
resulting	O
in	O
a	B-PROBLEM
hip	I-PROBLEM
and	I-PROBLEM
arm	I-PROBLEM
fracture	I-PROBLEM
.	O

Fall	B-PROBLEM
was	O
witnessed	O
by	O
daughter	O
.	O

Nicholas	B-PROBLEM
seizures	I-PROBLEM
,	O
no	O
LOC	B-PROBLEM
,	O
no	O
head	B-PROBLEM
or	I-PROBLEM
neck	I-PROBLEM
trauma	I-PROBLEM
.	O

Patient	O
denies	O
CP	B-PROBLEM
,	O
SOB	B-PROBLEM
,	O
light	B-PROBLEM
headedness	I-PROBLEM
,	O
or	O
dizziness	B-PROBLEM
prior	O
to	O
of	O
after	O
the	B-PROBLEM
fall	I-PROBLEM
.	O

She	O
fell	O
on	O
her	O
R	O
side	O
and	O
had	O
a	O
great	O
deal	O
of	O
pain	B-PROBLEM
in	I-PROBLEM
her	I-PROBLEM
R	I-PROBLEM
arm	I-PROBLEM
and	I-PROBLEM
hip	I-PROBLEM
.	O

Presented	O
to	O
Taunton	O
and	O
found	O
to	O
have	O
R	B-PROBLEM
humerus	I-PROBLEM
and	I-PROBLEM
R	I-PROBLEM
hip	I-PROBLEM
fx	I-PROBLEM
.	O

Ct	B-TEST
of	I-TEST
head	I-TEST
and	I-TEST
neck	I-TEST
neg	O
for	O
fx	B-PROBLEM
,	O
bleed	B-PROBLEM
,	O
and	O
dislocation	B-PROBLEM
.	O

1.	O
Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
status	O
post	O
non-ST-elevation	B-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
in	O
2009-05-05	O
,	O
status	O
post	O
cardiac	B-TEST
catheterization	I-TEST
with	O
left	B-TREATMENT
anterior	I-TREATMENT
descending	I-TREATMENT
artery	I-TREATMENT
stent	I-TREATMENT
placement	I-TREATMENT
in	O
05/2001	O
.	O

2.	O
CHF	B-PROBLEM
with	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
40-45%	O
02-09	O

3.	O
Diabetes	B-PROBLEM
type	I-PROBLEM
2	I-PROBLEM
.	O

4.	O
Anemia	B-PROBLEM
,	O
transfusion	B-PROBLEM
dependent	I-PROBLEM
every	O
three	O
months	O
.	O

Hct	B-TEST
28	O
b/l	O

5.	O
Polymyalgia	B-PROBLEM
rheumatica	I-PROBLEM
.	O

6.	O
Hypertension	B-PROBLEM
.	O

7.	O
Hypothyroidism	B-PROBLEM
.	O

8.	O
Chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
with	O
a	B-TEST
b/l	I-TEST
creatinine	I-TEST
of	O
1.4	O
.	O

9.	O
History	O
of	O
syncope	B-PROBLEM
and	O
first	B-PROBLEM
degree	I-PROBLEM
A-V	I-PROBLEM
heart	I-PROBLEM
block	I-PROBLEM
with	O
beta	B-TREATMENT
blocker	I-TREATMENT
therapy	I-TREATMENT
.	O

10.	O
History	O
of	O
lower	B-PROBLEM
gastrointestinal	I-PROBLEM
bleed	I-PROBLEM
in	O
2009-06-05	O
.	O

11.	O
spinal	B-PROBLEM
stenosis	I-PROBLEM

12.	O
Pacemaker	B-TREATMENT
-	O
DDD	B-TREATMENT
dual	I-TREATMENT
chamber	I-TREATMENT
rate	I-TREATMENT
response	I-TREATMENT
pacemaker	I-TREATMENT
2011-08-22	O
for	O
symptomatic	B-PROBLEM
bradycardia	I-PROBLEM

T	B-TEST
96.0	O
BP	B-TEST
177/61	O
P	B-TEST
70	O
R	B-TEST
18	O
O2	B-TEST
97	O
on	O
RA	O

Gen	O
-	O
somnolent	B-PROBLEM
,	O
confused	B-PROBLEM

Cor	O
-	O
rrr	O
,	O
no	O
m/r/g	B-PROBLEM

Abd	O
-	O
s/nt/nd	B-PROBLEM
+BS	O

Ext	O
-	O
2	O
+	O
edema	B-PROBLEM
to	I-PROBLEM
knees	I-PROBLEM
,	O
warm	O
2	O
+	O
pulses	B-TEST
,	O
pain	B-PROBLEM
in	I-PROBLEM
R	I-PROBLEM
arm	I-PROBLEM
and	I-PROBLEM
R	I-PROBLEM
hip	I-PROBLEM

2013-05-18	O
06:00	O
PM	O
GLUCOSE	B-TEST
-	O
188	O
*	O
UREA	B-TEST
N	I-TEST
-	O
48	O
*	O
CREAT	B-TEST
-	O
1.3	O
*	O
SODIUM	B-TEST
-	O
138	O
POTASSIUM	B-TEST
-	O
4.0	O
CHLORIDE	B-TEST
-	O
106	O
TOTAL	B-TEST
CO2	I-TEST
-	O
21	O
*	O
ANION	B-TEST
GAP	I-TEST
-	O
15	O

2013-05-18	O
06:00	O
PM	O
CK(CPK)	B-TEST
-	O
32	O

2013-05-18	O
06:00	O
PM	O
CK-MB	B-TEST
-	O
NotDone	O

2013-05-18	O
06:00	O
PM	O
WBC	B-TEST
-	O
14.9	O
*#	O
RBC	B-TEST
-	O
2.91	O
*	O
HGB	B-TEST
-	O
8.5	O
*	O
HCT	B-TEST
-	O
24.7	O
*	O
MCV	B-TEST
-	O
85	O
MCH	B-TEST
-	O
29.3	O
MCHC	B-TEST
-	O
34.5	O
RDW	B-TEST
-	O
14.6	O

2013-05-18	O
06:00	O
PM	O
NEUTS	B-TEST
-	O
87.9	O
*	O
BANDS	B-TEST
-	O
0	O
LYMPHS	B-TEST
-	O
6.3	O
*	O
MONOS	B-TEST
-	O
5.7	O
EOS	B-TEST
-	O
0.1	O
BASOS	B-TEST
-	O
0	O

2013-05-18	O
06:00	O
PM	O
HYPOCHROM	B-TEST
-	O
1	O
+	O
ANISOCYT	B-TEST
-	O
NORMAL	O
POIKILOCY	B-TEST
-	O
NORMAL	O
MACROCYT	B-TEST
-	O
NORMAL	O
MICROCYT	B-TEST
-	O
NORMAL	O
POLYCHROM	B-TEST
-	O
NORMAL	O

2013-05-18	O
06:00	O
PM	O
PLT	B-TEST
SMR	I-TEST
-	O
NORMAL	O
PLT	B-TEST
COUNT	I-TEST
-	O
216	O

2013-05-18	O
06:00	O
PM	O
PT	B-TEST
-	O
13.3	O
PTT	B-TEST
-	O
26.4	O
INR(PT)	B-TEST
-	O
1.2	O
EKG	B-TEST
-	O
NSR	O
64	O
,	O
1st	B-PROBLEM
deg	I-PROBLEM
block	I-PROBLEM
,	O
LAD	B-PROBLEM
,	O
new	B-PROBLEM
TWI	I-PROBLEM
inf/lat	I-PROBLEM
leads	I-PROBLEM
,	O
new	B-PROBLEM
ST	I-PROBLEM
depressions	I-PROBLEM
V4-6	I-PROBLEM

Echo	B-TEST
02-09	O

1.	O
The	O
left	O
atrium	O
is	O
moderately	B-PROBLEM
dilated	I-PROBLEM
.	O

The	O
left	O
atrium	O
is	O
elongated	B-PROBLEM
.	O

2.	O
The	B-TEST
left	I-TEST
ventricular	I-TEST
wall	I-TEST
thicknesses	I-TEST
are	O
normal	O
.	O

The	B-TEST
left	I-TEST
ventricular	I-TEST
cavity	I-TEST
size	I-TEST
is	O
normal	O
.	O

There	O
is	O
mild	B-PROBLEM
regional	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
systolic	I-PROBLEM
dysfunction	I-PROBLEM
.	O

Overall	O
left	B-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
mildly	B-PROBLEM
depressed	I-PROBLEM
.	O

Resting	B-PROBLEM
regional	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
include	O
inferolateral	B-PROBLEM
,	I-PROBLEM
inferior	I-PROBLEM
and	I-PROBLEM
mid	I-PROBLEM
septal	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

3.	O
Right	B-TEST
ventricular	I-TEST
chamber	I-TEST
size	I-TEST
is	O
normal	O
.	O

Right	B-TEST
ventricular	I-TEST
systolic	I-TEST
function	I-TEST
is	O
normal	O
.	O

4.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

No	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
present	O
.	O

5.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	B-PROBLEM
thickened	I-PROBLEM
.	O

Moderate	B-PROBLEM
(	I-PROBLEM
2	I-PROBLEM
+)	I-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

6.	O
There	O
is	O
moderate	B-PROBLEM
pulmonary	I-PROBLEM
artery	I-PROBLEM
systolic	I-PROBLEM
hypertension	I-PROBLEM
.	O

7.	O
There	O
is	O
no	O
pericardial	B-PROBLEM
effusion	I-PROBLEM
.	O

Compared	O
with	O
the	O
findings	O
of	O
the	B-TEST
prior	I-TEST
study	I-TEST
(	O
tape	O
reviewed	O
)	O
of	O
2009-06-05	O
,	O
the	B-TEST
LV	I-TEST
function	I-TEST
has	O
improved	O
with	O
an	O
improvementt	O
in	O
function	O
of	O
the	O
apex	O
,	O
septal	O
and	O
anterior	O
walls	O
.	O

New	B-PROBLEM
inferior	I-PROBLEM
and	I-PROBLEM
inferolateral	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
with	O
more	B-PROBLEM
severe	I-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
present	O
.	O

Cath	B-TEST
2001	O

1.	O
Coronary	B-TEST
angiography	I-TEST
demonstrated	O
single	B-PROBLEM
vessel	I-PROBLEM
disease	I-PROBLEM
in	I-PROBLEM
a	I-PROBLEM
right	I-PROBLEM
dominant	I-PROBLEM
system	I-PROBLEM
.	O

The	O
LAD	O
had	O
serial	B-PROBLEM
90%	I-PROBLEM
lesions	I-PROBLEM
proximally	I-PROBLEM
,	O
involving	O
the	O
origin	O
of	O
the	O
first	O
diagonal	O
,	O
which	O
was	O
occluded	B-PROBLEM
and	O
filled	O
via	O
left	O
to	O
left	O
collaterals	O
.	O

The	O
mid-distal	O
LAD	O
was	O
underfilled	B-PROBLEM
initially	O
but	O
was	O
without	O
obstructive	B-PROBLEM
disease	I-PROBLEM
.	O

The	O
non-dominant	O
circumflex	O
system	O
had	O
no	O
hemodynamically	B-PROBLEM
significant	I-PROBLEM
stenoses	I-PROBLEM
.	O

The	O
dominant	O
RCA	O
was	O
a	O
large	O
vessel	O
with	O
no	O
significant	B-PROBLEM
disease	I-PROBLEM
.	O

2.	O
Resting	B-TEST
hemodynamics	I-TEST
revealed	O
elevated	B-PROBLEM
right	I-PROBLEM
and	I-PROBLEM
left	I-PROBLEM
sided	I-PROBLEM
filling	I-PROBLEM
pressures	I-PROBLEM
with	O
a	B-TEST
mean	I-TEST
RA	I-TEST
pressure	I-TEST
of	O
12	O
mm	O
Hg	O
and	O
a	B-TEST
mean	I-TEST
wedge	I-TEST
pressure	I-TEST
24	O
mm	O
Hg	O
.	O

Moderate	B-PROBLEM
pulmonary	I-PROBLEM
hypertension	I-PROBLEM
was	O
present	O
with	O
a	B-TEST
PA	I-TEST
of	O
52/28	O
.	O

The	B-TEST
cardiac	I-TEST
index	I-TEST
was	O
preserved	O
at	O
3.0	O
L	O
/	O
min	O
/	O
m2	O
.	O

3.	O
Left	B-TEST
ventriculography	I-TEST
was	O
not	O
performed	O
due	O
to	O
the	O
presence	O
of	O
moderate	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
(	O
creatinine	B-TEST
1.6	O
).	O

4.	O
Successful	B-TREATMENT
PTCA	I-TREATMENT
and	O
stenting	B-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
proximal	I-TREATMENT
LAD	I-TREATMENT
with	O
overlapping	B-TREATMENT
2.25	I-TREATMENT
x	I-TREATMENT
13	I-TREATMENT
mm	I-TREATMENT
and	I-TREATMENT
2.25	I-TREATMENT
x	I-TREATMENT
18	I-TREATMENT
mm	I-TREATMENT
Hepacoat	I-TREATMENT
stents	I-TREATMENT
with	O
no	O
residual	B-PROBLEM
stenosis	I-PROBLEM
or	O
dissection	B-PROBLEM
and	O
normal	O
flow	O
(	O
see	O
PTCA	B-TREATMENT
comments	O
).	O

1.	O
One	B-PROBLEM
vessel	I-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

2.	O
Moderately	B-PROBLEM
elevated	I-PROBLEM
right	I-PROBLEM
and	I-PROBLEM
left	I-PROBLEM
sided	I-PROBLEM
filling	I-PROBLEM
pressures	I-PROBLEM
.	O

3.	O
Successful	B-TREATMENT
stenting	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
proximal	I-TREATMENT
LAD	I-TREATMENT
.	O

COMPLETE	B-TEST
BLOOD	I-TEST
COUNT	I-TEST
WBC	B-TEST
RBC	B-TEST
Hgb	B-TEST
Hct	B-TEST
MCV	B-TEST
MCH	B-TEST
MCHC	B-TEST
RDW	B-TEST
Plt	B-TEST
Ct	I-TEST

DIFFERENTIAL	B-TEST
Neuts	B-TEST
Bands	B-TEST
Lymphs	B-TEST
Monos	B-TEST
Eos	B-TEST
Baso	B-TEST
Atyps	B-TEST
Metas	B-TEST

RED	B-TEST
CELL	I-TEST
MORPHOLOGY	I-TEST
Hypochr	B-TEST
Anisocy	B-TEST
Poiklo	B-TEST
Macrocy	B-TEST
Microcy	B-TEST
Polychr	B-TEST

BASIC	B-TEST
COAGULATION	I-TEST
(	O
PT	B-TEST
,	O
PTT	B-TEST
,	O
PLT	B-TEST
,	O
INR	B-TEST
)	O
PT	B-TEST
PTT	B-TEST
Plt	B-TEST
Smr	I-TEST
Plt	B-TEST
Ct	I-TEST
INR(PT)	B-TEST
LPlt	B-TEST

Chemistry	B-TEST

RENAL	O
&	O
GLUCOSE	O
Glucose	B-TEST
UreaN	B-TEST
Creat	B-TEST
Na	B-TEST
K	B-TEST
Cl	B-TEST
HCO3	B-TEST
AnGap	B-TEST

ENZYMES	B-TEST
&	O
BILIRUBIN	B-TEST
ALT	B-TEST
AST	B-TEST
LD(LDH)	B-TEST
CK(CPK)	B-TEST
AlkPhos	B-TEST
Amylase	B-TEST
TotBili	B-TEST
DirBili	B-TEST

OTHER	B-TEST
ENZYMES	I-TEST
&	O
BILIRUBINS	B-TEST
Lipase	B-TEST

CPK	B-TEST
ISOENZYMES	B-TEST
CK-MB	B-TEST
MB	B-TEST
Indx	I-TEST
cTropnT	B-TEST

1	O
CTROPNT	B-TEST
>	O
0.10	O
NG/ML	O
SUGGESTS	O
ACUTE	B-PROBLEM
MI	I-PROBLEM

CHEMISTRY	B-TEST
TotProt	B-TEST
Albumin	B-TEST
Globuln	B-TEST
Calcium	B-TEST
Phos	B-TEST
Mg	B-TEST
UricAcd	B-TEST
Iron	B-TEST
Cholest	B-TEST

LIPID	B-TEST
/	O
CHOLESTEROL	B-TEST
Triglyc	B-TEST
HDL	B-TEST
CHOL/HD	B-TEST
LDLcalc	B-TEST

2013-05-19	O
09:20	O
AM	O
1603	O
-	O
5419	O
LDL(CALC)	B-TEST
INVALID	O
IF	O
TRIG	B-TEST
>	O
400	O
OR	O
NON-FASTING	O
SAMPLE	O
LAB	O
USE	O
ONLY	O
GreenHd	O

Blood	B-TEST
Gas	I-TEST

BLOOD	B-TEST
GASES	I-TEST
Type	B-TEST
Temp	B-TEST
Rates	B-TEST
Tidal	B-TEST
V	I-TEST
PEEP	B-TEST
FiO2	B-TEST
O2	B-TEST
Flow	B-TEST
pO2	B-TEST
pCO2	B-TEST
pH	B-TEST
calHCO3	B-TEST
Base	B-TEST
XS	I-TEST
AADO2	B-TEST
REQ	B-TREATMENT
O2	I-TREATMENT
Intubat	B-TREATMENT
Vent	B-TREATMENT

2013-05-24	O
07:58	O
AM	O
ART	B-TEST
102	O
36	O
7.26	O
*	O
17	O
*	O
-9	O

2013-05-24	O
04:31	O
AM	O
ART	B-TEST
36.4	O
16	O
/	O
662-15484	O
*	O
7.26	O
*	O
16	O
*	O
-10	O

ASSIST	O
/	O
CON1	O
INTUBATED	B-TREATMENT

WHOLE	O
BLOOD	O
,	O
MISCELLANEOUS	B-TEST
CHEMISTRY	I-TEST
Glucose	B-TEST
Lactate	B-TEST
Na	B-TEST
K	B-TEST
Cl	B-TEST
calHCO3	B-TEST

HEMOGLOBLIN	B-TEST
FRACTIONS	I-TEST
(	O
COOXIMETRY	B-TEST
)	O
Hgb	B-TEST
calcHCT	B-TEST
O2	B-TEST
Sat	I-TEST
COHgb	B-TEST
MetHgb	B-TEST

CALCIUM	B-TEST
freeCa	B-TEST

CT	B-TEST
ABDOMEN	I-TEST
W/O	I-TEST
CONTRAST	I-TEST
2013-05-23	O
5:46	O
PM	O

CT	B-TEST
ABDOMEN	I-TEST
W/O	I-TEST
CONTRAST	I-TEST
;	O
CT	B-TEST
PELVIS	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

Reason	O
:	O
Please	O
eval	O
for	O
perf	B-PROBLEM
/	I-PROBLEM
ischemic	I-PROBLEM
bowel	I-PROBLEM

92	O
year	O
old	O
woman	O
with	O
MS	B-PROBLEM
changes	I-PROBLEM
,	O
abd	B-PROBLEM
pain	I-PROBLEM
hypotension	B-PROBLEM
and	O
bloody	B-PROBLEM
lavage	I-PROBLEM
on	O
Lovenox+ASA	B-TREATMENT

Please	O
eval	O
for	O
perf	B-PROBLEM
/	I-PROBLEM
ischemic	I-PROBLEM
bowel	I-PROBLEM

CONTRAINDICATIONS	O
for	O
IV	B-TEST
CONTRAST	I-TEST
:	O
renal	B-PROBLEM
failure	I-PROBLEM

INDICATION	O
:	O
94-year-old	O
woman	O
with	O
mental	B-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
,	O
now	O
with	O
abdominal	B-PROBLEM
pain	I-PROBLEM
and	O
hypertension	B-PROBLEM
.	O

TECHNIQUE	O
:	O
A	O
multidetector	O
scanner	O
was	O
used	O
to	O
obtain	O
contiguous	B-TEST
axial	I-TEST
images	I-TEST
from	O
the	O
lung	O
bases	O
to	O
the	O
pubic	O
symphysis	O
.	O

Neither	O
IV	B-TEST
nor	I-TEST
oral	I-TEST
contrast	I-TEST
were	O
used	O
.	O

CT	B-TEST
OF	I-TEST
THE	I-TEST
ABDOMEN	I-TEST
WITHOUT	I-TEST
IV	I-TEST
CONTRAST	I-TEST
:	O
There	O
are	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
,	O
right	O
greater	O
the	O
left	O
;	O
there	O
is	O
compressive	B-PROBLEM
atelectasis	I-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
lung	I-PROBLEM
base	I-PROBLEM
.	O

There	O
are	O
coronary	B-PROBLEM
vascular	I-PROBLEM
calcifications	I-PROBLEM
.	O

A	B-TREATMENT
nasogastric	I-TREATMENT
tube	I-TREATMENT
is	O
seen	O
coiling	O
in	O
the	O
stomach	O
.	O

A	B-TREATMENT
dual	I-TREATMENT
chamber	I-TREATMENT
pacemaker	I-TREATMENT
is	O
seen	O
with	O
leads	O
terminating	O
in	O
the	O
right	O
atrium	O
and	O
right	O
ventricle	O
.	O

Nasogastric	B-TREATMENT
tube	I-TREATMENT
is	O
seen	O
coiling	O
in	O
the	O
stomach	O
,	O
with	O
its	O
tip	O
at	O
the	O
pylorus	O
.	O

Allowing	O
for	O
the	O
limitations	O
of	O
this	B-TEST
noncontrast	I-TEST
study	I-TEST
,	O
the	O
liver	O
,	O
pancreas	O
,	O
adrenals	O
,	O
stomach	O
are	O
unremarkable	O
.	O

A	B-PROBLEM
1.8	I-PROBLEM
cm	I-PROBLEM
exophytic	I-PROBLEM
renal	I-PROBLEM
cyst	I-PROBLEM
is	O
seen	O
on	O
the	O
left	O
.	O

A	B-PROBLEM
similar	I-PROBLEM
lesion	I-PROBLEM
is	O
seen	O
on	O
the	O
right	O
,	O
measuring	O
2.2	O
cm	O
.	O

The	O
aorta	O
is	O
normal	O
in	O
caliber	O
,	O
with	O
vascular	B-PROBLEM
calcifications	I-PROBLEM
.	O

A	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
free	I-PROBLEM
fluid	I-PROBLEM
is	O
seen	O
tracking	O
around	O
the	O
liver	O
,	O
right	O
pericolic	O
gutter	O
,	O
along	O
the	O
mesentery	O
and	O
surrounding	O
the	O
right	O
colon	O
,	O
which	O
is	O
collapsed	O
.	O

A	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
nondependent	I-PROBLEM
free	I-PROBLEM
air	I-PROBLEM
is	O
seen	O
in	O
the	O
anterior	O
aspect	O
of	O
the	O
abdomen	O
.	O

The	O
remainder	O
of	O
the	O
bowel	O
loops	O
are	O
fluid	O
filled	O
,	O
and	O
nondilated	B-PROBLEM
.	O

CT	B-TEST
OF	I-TEST
THE	I-TEST
PELVIS	I-TEST
WITHOUT	I-TEST
IV	I-TEST
CONTRAST	I-TEST
:	O
As	O
previously	O
noted	O
,	O
there	O
is	O
a	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
free	I-PROBLEM
fluid	I-PROBLEM
surrounding	O
the	O
right	O
colon	O
,	O
tracking	O
along	O
the	O
mesentery	O
and	O
into	O
the	O
pelvis	O
.	O

A	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
free	I-PROBLEM
air	I-PROBLEM
is	O
seen	O
in	O
the	O
nondependent	O
portion	O
of	O
the	O
pelvis	O
.	O

Vascular	B-PROBLEM
calcifications	I-PROBLEM
are	O
seen	O
in	O
the	O
abdominal	O
aorta	O
and	O
iliac	O
arteries	O
.	O

Subcutaneous	B-PROBLEM
edema	I-PROBLEM
is	O
noted	O
in	O
the	O
lower	O
abdomen	O
and	O
pelvis	O
.	O

A	B-TREATMENT
catheter	I-TREATMENT
is	O
seen	O
entering	O
the	O
left	O
inguinal	O
region	O
and	O
coursing	O
along	O
the	O
iliac	O
vessels	O
,	O
terminating	O
in	O
the	O
left	O
pelvis	O
.	O

Osseous	O
structures	O
are	O
remarkable	O
for	O
degenerative	B-PROBLEM
changes	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
spine	I-PROBLEM
,	O
and	O
a	B-PROBLEM
fracture	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
proximal	I-PROBLEM
right	I-PROBLEM
humerus	I-PROBLEM
,	O
with	O
orthopedic	B-TREATMENT
hardware	I-TREATMENT
causing	O
beam	B-PROBLEM
hardening	I-PROBLEM
artifact	I-PROBLEM
.	O

1.	O
A	O
small	O
amount	O
of	O
free	B-PROBLEM
air	I-PROBLEM
and	I-PROBLEM
free	I-PROBLEM
fluid	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
pelvis	I-PROBLEM
and	I-PROBLEM
abdomen	I-PROBLEM
,	O
mostly	O
along	O
the	O
right	O
pericolic	O
gutter	O
and	O
surrounding	O
the	O
ascending	O
colon	O
,	O
concerning	O
for	O
perforation	B-PROBLEM
.	O

Other	O
bowel	O
loops	O
are	O
unremarkable	O
on	O
this	B-TEST
limited	I-TEST
study	I-TEST
.	O

2.	O
Bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
,	O
right	O
greater	O
than	O
left	O
,	O
with	O
left-sided	B-PROBLEM
compressive	I-PROBLEM
atelectasis	I-PROBLEM
.	O

3.	O
Right	B-PROBLEM
proximal	I-PROBLEM
humeral	I-PROBLEM
fracture	I-PROBLEM
status	O
post	O
fixation	B-TREATMENT
.	O

The	B-TEST
study	I-TEST
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O

95	O
yo	O
F	O
with	O
MMP	B-PROBLEM
who	O
sustained	O
a	B-PROBLEM
mechanical	I-PROBLEM
fall	I-PROBLEM
down	O
stairs	O
resulting	O
in	O
a	B-PROBLEM
hip	I-PROBLEM
and	I-PROBLEM
arm	I-PROBLEM
fracture	I-PROBLEM
.	O

1)	O
s/p	O
Fall	B-PROBLEM
-	O
unlikely	O
to	O
be	O
mechanical	O
in	O
nature	O
.	O

Patient	O
has	O
injuries	B-PROBLEM
to	I-PROBLEM
her	I-PROBLEM
shoulder	I-PROBLEM
and	I-PROBLEM
hip	I-PROBLEM
.	O

2)	O
CV	O
-	O
Patient	O
has	O
CAD	B-PROBLEM
and	O
CHF	B-PROBLEM
with	O
a	B-PROBLEM
low	I-PROBLEM
hct	I-PROBLEM
and	O
major	B-PROBLEM
trauma	I-PROBLEM
.	O

She	O
also	O
has	O
new	B-PROBLEM
changes	I-PROBLEM
on	I-PROBLEM
EKG	I-PROBLEM
.	O

On	O
pressor	B-TREATMENT
to	O
hold	O
mean	O
60	O
.	O

3)	O
Anemia	B-PROBLEM
-	O
patient	O
transfusion	B-PROBLEM
dependant	I-PROBLEM
with	O
a	O
baseline	O
of	O
28	O
.	O

-	O
transfuse	O
2	O
units	O
today	O
,	O
with	O
lasix	B-TREATMENT

4)	O
GERD	B-PROBLEM
-	O
PPI	B-TREATMENT

5)	O
DM	B-PROBLEM
-	O
glipizide	B-TREATMENT
,	O
ISS	B-TREATMENT

6)	O
PMR	B-PROBLEM
-	O
cont	O
prednisone	B-TREATMENT

7)	O
GI	O
:	O
Ms.	O
Pimental	O
is	O
an	O
unfortunate	O
95	O
year	O
old	O
woman	O
,	O
status	O
post	O
a	B-PROBLEM
recent	I-PROBLEM
fall	I-PROBLEM
necessitating	O
right	B-TREATMENT
ORIF	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
hip	I-TREATMENT
and	O
right	B-PROBLEM
wrist	I-PROBLEM
fracture	I-PROBLEM
ORIF	B-TREATMENT
,	O
who	O
was	O
in	O
the	O
hospital	O
for	O
this	O
event	O
,	O
when	O
it	O
was	O
noted	O
that	O
she	O
had	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
distention	B-PROBLEM
and	O
coffee	B-PROBLEM
ground	I-PROBLEM
emesis	I-PROBLEM
with	O
worsening	B-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
and	O
renal	B-PROBLEM
failure	I-PROBLEM
.	O

CT	B-TEST
scan	I-TEST
was	O
obtained	O
and	O
this	O
revealed	O
free	B-PROBLEM
air	I-PROBLEM
and	O
massive	B-PROBLEM
ascites	I-PROBLEM
.	O

Pt	O
underwent	O
surgery	B-TREATMENT
on	O
05-23	O

1.	O
Exploratory	B-TEST
laparotomy	I-TEST
with	O
drainage	B-TREATMENT
of	O
intra-abdominal	B-PROBLEM
abscess	I-PROBLEM
and	O
peritonitis	B-PROBLEM
with	O
gross	B-PROBLEM
soilage	I-PROBLEM
with	I-PROBLEM
bile	I-PROBLEM
and	I-PROBLEM
gastric	I-PROBLEM
contents	I-PROBLEM
.	O

2.	O
Exposure	B-TREATMENT
and	O
wide	B-TREATMENT
drainage	I-TREATMENT
of	O
perforated	B-PROBLEM
posterior	I-PROBLEM
duodenal	I-PROBLEM
ulcer	I-PROBLEM
with	O
internal	B-TREATMENT
and	I-TREATMENT
external	I-TREATMENT
drainage	I-TREATMENT
.	O

3.	O
Feeding	B-TREATMENT
jejunostomy	I-TREATMENT
.	O

4.	O
Tube	B-TREATMENT
gastrostomy	I-TREATMENT
.	O

Continue	O
to	O
deteriorate	O
spiking	B-PROBLEM
fevers	I-PROBLEM
with	O
ventilatory	B-TREATMENT
support	I-TREATMENT
on	O
pressors	B-TREATMENT
to	O
hold	O
the	B-TEST
bp.	I-TEST
with	O
no	O
improvement	O
in	O
mental	O
staus	O
was	O
made	O
CMO	O
5/20/5	O
.	O

lasix	B-TREATMENT
alt	O
40	O
mg	O
and	O
20	O
mg	O
qday	O

levothyrox	B-TREATMENT
50	O
mcg	O
qday	O

lisinopril	B-TREATMENT
5	O
mg	O
qday	O

famotidine	B-TREATMENT
20	O
mg	O
qday	O

fe	B-TREATMENT
so4	I-TREATMENT
325	O
mg	O
qday	O

asa	B-TREATMENT
325	O
mg	O
qday	O

toprol	B-TREATMENT
xl	I-TREATMENT
25	O
mg	O
qday	O

glipizide	B-TREATMENT
5	O
mg	O
qday	O

imdur	B-TREATMENT
60	O
mg	O
qdau	O

prednisone	B-TREATMENT
5	O
mg	O
qday	O

tylenol	B-TREATMENT

Expired	B-PROBLEM

MULTIORGAN	B-PROBLEM
FAILURE	I-PROBLEM

DUODENAL	B-PROBLEM
PERFORATION	I-PROBLEM

MULTIPLE	B-PROBLEM
TRAUMA	I-PROBLEM

The	O
patient	O
was	O
admitted	O
originally	O
for	O
airway	B-TEST
monitoring	I-TEST
status	O
post	O
endoscopic	O
retrograde	O

cholangiopancreatography	B-TEST
with	O
adverse	B-PROBLEM
reaction	I-PROBLEM
to	O
Fentanyl	B-TREATMENT
and	O
tongue	B-PROBLEM
injury	I-PROBLEM
.	O

The	O
patient	O
is	O
a	O
59	O
year-old	O
female	O
status	O
post	O
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
on	O
the	O
day	O
of	O
admission	O
,	O
which	O
had	O
been	O
done	O
to	O
evaluate	O
for	O
possible	O
bile	B-PROBLEM
leak	I-PROBLEM
after	O
cholecystectomy	B-TREATMENT
was	O
performed	O
four	O
days	O
ago	O
.	O

The	O
patient	O
was	O
in	O
her	O
usual	O
state	O
of	O
health	O
until	O
four	O
days	O
prior	O
to	O
admission	O
when	O
she	O
had	O
a	B-TREATMENT
cholecystectomy	I-TREATMENT
.	O

Her	O
postop	O
course	O
was	O
uneventful	O
until	O
one	O
day	O
prior	O
to	O
admission	O
when	O
she	O
developed	O
abdominal	B-PROBLEM
pain	I-PROBLEM
.	O

On	O
the	O
day	O
of	O
admission	O
she	O
returned	O
to	O
the	O
outside	O
hospital	O
Emergency	O
Room	O
where	O
an	B-TEST
abdominal	I-TEST
CT	I-TEST
was	O
performed	O
,	O
which	O
showed	O
"	O
thickened	B-PROBLEM
stomach	I-PROBLEM
and	O
free	B-PROBLEM
air	I-PROBLEM
."	O

She	O
was	O
sent	O
to	O
New	O
England	O
Sinai	O
Hospital	O
&	O
Rehab	O
Center	O
for	O
an	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
and	O
possible	O
stent	B-TREATMENT
placement	I-TREATMENT
.	O

She	O
had	O
a	B-TEST
successful	I-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
,	O
which	O
showed	O
a	B-PROBLEM
bile	I-PROBLEM
leak	I-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
duct	I-PROBLEM
of	I-PROBLEM
Luschka	I-PROBLEM
.	O

A	B-TREATMENT
stent	I-TREATMENT
was	O
placed	O
successfully	O
.	O

After	O
her	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
the	O
patient	O
developed	O
"	O
jaw	B-PROBLEM
clenching	I-PROBLEM
,	O
biting	B-PROBLEM
tongue	I-PROBLEM
,	O
rigidity	B-PROBLEM
and	O
cold	B-PROBLEM
/	I-PROBLEM
chills	I-PROBLEM
."	O

The	O
patient	O
received	O
ampicillin	B-TREATMENT
,	O
Gentamycin	B-TREATMENT
and	O
Flagyl	B-TREATMENT
empirically	O
as	O
well	O
as	O
Narcan	B-TREATMENT
to	O
reverse	O
fentanyl	B-TREATMENT
.	O

Because	O
of	O
the	B-PROBLEM
tongue	I-PROBLEM
injury	I-PROBLEM
and	O
tachycardia	B-PROBLEM
as	O
well	O
as	O
possible	O
infection	B-PROBLEM
given	O
her	B-PROBLEM
fevers	I-PROBLEM
or	O
chills	B-PROBLEM
the	O
GI	O
Service	O
transferred	O
the	O
patient	O
to	O
the	O
CMED	O
CCU	O
for	O
close	O
observation	O
.	O

1.	O
Hiatal	B-PROBLEM
hernia	I-PROBLEM
.	O

2.	O
Status	O
post	O
cholecystectomy	B-TREATMENT
four	O
days	O
prior	O
to	O
admission	O
.	O

3.	O
Urinary	B-PROBLEM
frequency	I-PROBLEM
secondary	O
to	O
interstitial	B-PROBLEM
cystitis	I-PROBLEM
.	O

4.	O
Mitral	B-PROBLEM
valve	I-PROBLEM
prolapse	I-PROBLEM
.	O

5.	O
Tubal	B-TREATMENT
ligation	I-TREATMENT
many	O
years	O
ago	O
.	O

1.	O
Prempro	B-TREATMENT
.	O

2.	O
CMED	B-TREATMENT
CCU	I-TREATMENT
drops	I-TREATMENT
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
at	O
the	O
time	O
of	O
admission	O
,	O
however	O
,	O
it	O
is	O
assumed	O
that	O
her	B-PROBLEM
rigidity	I-PROBLEM
and	O
jaw	B-PROBLEM
clenching	I-PROBLEM
was	O
secondary	O
to	O
Fentanyl	B-TREATMENT
.	O

Vital	B-TEST
signs	I-TEST
temperature	B-TEST
100.6	O
.	O

Heart	B-TEST
rate	I-TEST
105	O
.	O

Blood	B-TEST
pressure	I-TEST
162/76	O
.	O

Respiratory	B-TEST
rate	I-TEST
18	O
.	O

Sating	B-TEST
98%	O
on	O
3	O
liters	O
.	O

In	O
general	O
,	O
the	O
patient	O
was	O
groggy	B-PROBLEM
status	O
post	O
anesthesia	B-TREATMENT
,	O
shivering	B-PROBLEM
,	O
but	O
awake	O
.	O

HEENT	O
showed	O
tongue	O
with	O
laceration	B-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
edge	I-PROBLEM
.	O

Lungs	O
were	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

No	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
.	O

Abdomen	O
was	O
soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
.	O

There	O
was	O
no	O
rebound	B-PROBLEM
or	O
guarding	B-PROBLEM
.	O

There	O
were	O
post	B-PROBLEM
laparoscopic	I-PROBLEM
incisions	I-PROBLEM
without	O
erythema	B-PROBLEM
with	O
Steri-Strips	B-TREATMENT
in	O
place	O
.	O

The	O
extremities	O
were	O
without	O
edema	B-PROBLEM
.	O

Dorsalis	B-TEST
pedis	I-TEST
pulses	I-TEST
were	O
intact	O
bilaterally	O
.	O

There	O
were	O
no	O
rashes	B-PROBLEM
.	O

White	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
9.0	O
,	O
hematocrit	B-TEST
39.3	O
,	O
platelets	B-TEST
296	O
,	O
neutrophil	B-TEST
count	I-TEST
82	O
,	O
lymphocytes	B-TEST
14	O
,	O
4	O
monocytes	B-TEST
,	O
troponin	B-TEST
was	O
less	O
then	O
0.3	O
.	O

Sodium	B-TEST
139	O
,	O
potassium	B-TEST
3.8	O
,	O
chloride	B-TEST
101	O
,	O
bicarb	B-TEST
26	O
,	O
BUN	B-TEST
9	O
,	O
creatinine	B-TEST
0.7	O
,	O
glucose	B-TEST
141	O
,	O
albumin	B-TEST
4.1	O
,	O
calcium	B-TEST
8.9	O
,	O
LDH	B-TEST
665	O
,	O
AST	B-TEST
44	O
,	O
ALT	B-TEST
of	O
57	O
,	O
amylase	B-TEST
41	O
,	O
CK	B-TEST
32	O
.	O

Electrocardiogram	B-TEST
showed	O
normal	O
sinus	O
rhythm	O
at	O
73	O
beats	O
per	O
minute	O
.	O

There	O
were	O
no	O
ST	B-PROBLEM
or	I-PROBLEM
T	I-PROBLEM
wave	I-PROBLEM
changes	I-PROBLEM
.	O

Abdominal	B-TEST
CT	I-TEST
showed	O
inflammation	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
upper	I-PROBLEM
quadrant	I-PROBLEM
,	O
small	B-PROBLEM
fluid	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
circumferential	I-PROBLEM
thickening	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
distal	I-PROBLEM
stomach	I-PROBLEM
.	O

There	O
was	O
a	O
question	O
of	O
a	B-PROBLEM
small	I-PROBLEM
ulcer	I-PROBLEM
.	O

There	O
was	O
a	O
tiny	O
amount	O
of	O
free	B-PROBLEM
air	I-PROBLEM
.	O

In	O
summary	O
the	O
patient	O
is	O
a	O
59	O
year-old	O
female	O
who	O
was	O
admitted	O
to	O
Quincy	O
Medical	O
Center	O
for	O
an	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
for	O
possible	O
stent	B-TREATMENT
placement	I-TREATMENT
for	O
a	B-PROBLEM
bile	I-PROBLEM
leak	I-PROBLEM
secondary	O
to	O
cholecystectomy	B-TREATMENT
performed	O
four	O
days	O
prior	O
to	O
admission	O
.	O

She	O
then	O
suffered	O
rigidity	B-PROBLEM
with	O
jaw	B-PROBLEM
clenching	I-PROBLEM
and	O
tongue	B-PROBLEM
biting	I-PROBLEM
secondary	O
to	O
Fentanyl	B-TREATMENT
administration	O
and	O
was	O
transferred	O
to	O
the	O
CMED	O
CCU	O
for	O
close	O
observation	O
.	O

She	O
was	O
started	O
on	O
Ampicillin	B-TREATMENT
,	O
Gentamycin	B-TREATMENT
and	O
Flagyl	B-TREATMENT
.	O

Her	B-TEST
liver	I-TEST
function	I-TEST
tests	I-TEST
and	O
amylase	B-TEST
and	O
lipase	B-TEST
were	O
followed	O
closely	O
.	O

As	O
stated	O
the	O
patient	O
was	O
status	O
post	O
endoscopic	B-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST
with	O
stent	O

placement	B-TREATMENT
for	O
a	B-PROBLEM
bile	I-PROBLEM
leak	I-PROBLEM
from	I-PROBLEM
the	I-PROBLEM
duct	I-PROBLEM
of	I-PROBLEM
Luschka	I-PROBLEM
.	O

The	O
patient	O
was	O
continued	O
on	O
Ampicillin	B-TREATMENT
,	O
Gentamycin	B-TREATMENT
and	O
Flagyl	B-TREATMENT
,	O
which	O
had	O
been	O
started	O
at	O
the	O
time	O
of	O
transfer	O
to	O
the	O
CMED	O
CCU	O
.	O

She	O
had	O
waxing	B-PROBLEM
and	I-PROBLEM
waning	I-PROBLEM
fevers	I-PROBLEM
.	O

However	O
,	O
her	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
was	O
never	O
really	B-PROBLEM
elevated	I-PROBLEM
and	O
she	O
did	O
not	O
have	O
a	B-PROBLEM
bandemia	I-PROBLEM
.	O

On	O
the	O
day	O
of	O
transfer	O
to	O
the	O
General	O
Medical	O
Floor	O
the	O
patient	O
had	O
received	O
clear	B-TREATMENT
liquids	I-TREATMENT
.	O

Her	B-TEST
amylase	I-TEST
and	O
lipase	B-TEST
on	O
the	O
day	O
following	O
the	B-TEST
endoscopic	I-TEST
retrograde	I-TEST
cholangiopancreatography	I-TEST

were	O
elevated	B-PROBLEM
.	O

Amylase	B-TEST
was	O
2304	O
with	O
lipase	B-TEST
being	O
7116	O
.	O

Therefore	O
she	O
was	O
made	O
NPO	B-TREATMENT
and	O
given	O
aggressive	B-TREATMENT
intravenous	I-TREATMENT
hydration	I-TREATMENT
.	O

On	O
the	O
second	O
hospital	O
day	O
on	O
the	O
General	O
Medical	O
Floor	O
the	O
patient	O
had	O
marked	B-PROBLEM
rebound	I-PROBLEM
to	O
palpation	B-TEST
of	I-TEST
her	I-TEST
abdomen	I-TEST
.	O

She	O
was	O
followed	O
closely	O
with	O
serial	B-TEST
abdominal	I-TEST
examinations	I-TEST
.	O

Her	B-TEST
amylase	I-TEST
and	O
lipase	B-TEST
were	O
trending	O
down	O
,	O
however	O
.	O

An	B-TEST
abdominal	I-TEST
CT	I-TEST
was	O
obtained	O
,	O
which	O
showed	O
only	O
mild	B-PROBLEM
pancreatitis	I-PROBLEM
.	O

There	O
were	O
no	O
intra-abdominal	B-PROBLEM
fluid	I-PROBLEM
collections	I-PROBLEM
,	O
which	O
required	O
any	B-TREATMENT
drainage	I-TREATMENT
.	O

On	O
the	O
third	O
hospital	O
day	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
pain	I-PROBLEM
was	O
improving	O
and	O
the	B-PROBLEM
rebound	I-PROBLEM
was	O
decreasing	O
.	O

Her	B-TEST
enzymes	I-TEST
continued	O
to	O
trend	O
down	O
.	O

She	O
received	O
clear	B-TREATMENT
liquids	I-TREATMENT
in	O
the	O
evening	O
and	O
tolerated	O
these	O
well	O
.	O

On	O
the	O
day	O
of	O
discharge	O
the	O
patient	O
was	O
tolerating	O
a	B-TREATMENT
BRAT	I-TREATMENT
diet	I-TREATMENT
without	O
significant	O
abdominal	O

pain	B-PROBLEM
.	O

She	O
had	O
no	O
further	B-PROBLEM
rebound	I-PROBLEM
.	O

She	O
had	O
no	O
temperature	B-PROBLEM
spikes	I-PROBLEM
in	O
greater	O
then	O
24	O
hours	O
at	O
the	O
time	O
of	O
discharge	O
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
hematocrit	I-TEST
was	O
34.8	O
at	O
the	O
time	O
of	O
admission	O
.	O

It	O
decreased	O
to	O
30	O
in	O
the	O
setting	O
of	O
aggressive	B-TREATMENT
hydration	I-TREATMENT
.	O

The	O
patient	O
was	O
aggressively	B-TREATMENT
hydrated	I-TREATMENT
given	O
that	O
she	O
was	O
NPO	B-TREATMENT
.	O

She	O
required	O
periodic	B-TREATMENT
repletion	I-TREATMENT
of	I-TREATMENT
her	I-TREATMENT
potassium	I-TREATMENT
.	O

Her	B-TEST
bicarb	I-TEST
began	O
to	O
drop	O
and	O
she	O
developed	O
an	B-PROBLEM
anion	I-PROBLEM
gap	I-PROBLEM
acidosis	I-PROBLEM
.	O

This	O
was	O
most	O
likely	O
secondary	O
to	O
ketoacidosis	B-PROBLEM
as	O
she	O
had	O
no	O
dextrose	B-TREATMENT
in	O
her	B-TREATMENT
intravenous	I-TREATMENT
fluids	I-TREATMENT
.	O

This	O
was	O
added	O
on	O
the	O
evening	O
prior	O
to	O
discharge	O
and	O
on	O
the	O
day	O
of	O
discharge	O
her	B-PROBLEM
anion	I-PROBLEM
gap	I-PROBLEM
acidosis	I-PROBLEM
had	O
resolved	O
.	O

1.	O
Levaquin	B-TREATMENT
500	O
mg	O
one	O
po	O
q	O
day	O
times	O
seven	O
days	O
.	O

2.	O
Protonix	B-TREATMENT
40	O
mg	O
po	O
q	O
day	O
.	O

3.	O
Percocet	B-TREATMENT
one	O
to	O
two	O
tablets	O
po	O
q	O
4	O
to	O
6	O
hours	O
prn	O
.	O

The	O
patient	O
was	O
given	O
a	B-TREATMENT
prescription	I-TREATMENT
for	I-TREATMENT
ten	I-TREATMENT
pills	I-TREATMENT
.	O

4.	O
Prempro	B-TREATMENT
as	O
the	O
patient	O
was	O
formerly	O
taking	O
.	O

5.	O
Trazodone	B-TREATMENT
at	O
bedtime	O
.	O

The	O
patient	O
was	O
to	O
make	O
an	O
appointment	O
with	O
Dr.	O
Nicholson	O
within	O
one	O
to	O
two	O
months	O
after	O
discharge	O
for	O
removal	B-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
stent	I-TREATMENT
.	O

She	O
was	O
to	O
continue	O
on	O
a	B-TREATMENT
BRAT	I-TREATMENT
diet	I-TREATMENT
over	O
the	O
weekend	O
and	O
two	O
days	O
after	O
discharge	O
she	O
could	O
advance	O
to	O
a	B-TREATMENT
low	I-TREATMENT
fat	I-TREATMENT
no	I-TREATMENT
dairy	I-TREATMENT
diet	I-TREATMENT
.	O

1.	O
Post	B-PROBLEM
endoscopic	I-PROBLEM
retrograde	I-PROBLEM
cholangiopancreatography	I-PROBLEM
pancreatitis	I-PROBLEM
.	O

2.	O
Anemia	B-PROBLEM
.	O

3.	O
Hypokalemia	B-PROBLEM
.	O

4.	O
Anion	B-PROBLEM
gap	I-PROBLEM
acidosis	I-PROBLEM
.	O

5.	O
Bile	B-PROBLEM
leak	I-PROBLEM
.	O

Again	O
,	O
this	O
was	O
a	O
47-year-old	O
female	O
admitted	O
with	O
Berkitt's	B-PROBLEM
lymphoma	I-PROBLEM
.	O

1.	O
Liver	B-PROBLEM
lesions	I-PROBLEM
:	O

The	O
patient	O
went	O
for	O
a	B-TEST
repeat	I-TEST
MRI	I-TEST
which	O
showed	O
no	O
change	O
in	O
the	B-PROBLEM
previously	I-PROBLEM
noted	I-PROBLEM
enumerable	I-PROBLEM
hepatic	I-PROBLEM
cyst	I-PROBLEM
in	I-PROBLEM
her	I-PROBLEM
liver	I-PROBLEM
.	O

A	O
Hepatology	O
consult	O
was	O
obtained	O
who	O
felt	O
that	O
the	O
most	O
likely	O
etiology	O
of	O
these	B-PROBLEM
cysts	I-PROBLEM
were	O
from	O
hepatic	B-PROBLEM
candidiasis	I-PROBLEM
,	O
although	O
one	O
could	O
not	O
rule	O
out	O
lymphoma	B-PROBLEM
involving	O
from	O
Burkitt's	B-PROBLEM
.	O

She	O
will	O
be	O
discharged	O
on	O
AmBisome	B-TREATMENT
300	O
mg	O
IV	O
q.d.	O
for	O
treatment	O
of	O
her	B-PROBLEM
hepatic	I-PROBLEM
candidiasis	I-PROBLEM
.	O

This	O
regimen	O
,	O
that	O
being	O
AmBisome	B-TREATMENT
,	O
was	O
recommended	O
by	O
the	O
Infectious	O
Disease	O
physicians	O
,	O
who	O
felt	O
that	O
AmBisome	B-TREATMENT
was	O
a	O
better	O
drug	O
of	O
choice	O
as	O
compared	O
to	O
fluconazole	B-TREATMENT
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
platelets	I-TEST
,	O
white	B-TEST
count	I-TEST
,	O
and	O
hematocrit	B-TEST
have	O
all	O
been	O
stable	O
.	O

Her	B-TEST
white	I-TEST
count	I-TEST
remained	O
elevated	B-PROBLEM
despite	O
discontinuing	O
her	B-TREATMENT
G-CSF	I-TREATMENT
.	O

However	O
,	O
the	O
patient	O
is	O
not	O
febrile	B-PROBLEM
and	O
her	B-TEST
white	I-TEST
count	I-TEST
should	O
be	O
continued	O
to	O
be	O
watched	O
.	O

3.	O
On	O
the	O
morning	O
of	O
12-01	O
,	O
the	O
patient	O
had	O
some	O
transient	O
episodes	O
of	O
hypotension	B-PROBLEM
with	O
SBP	B-TEST
s	I-TEST
in	O
the	O
70	O
s.	O

Her	B-TREATMENT
captopril	I-TREATMENT
was	O
discontinued	O
,	O
and	O
she	O
was	O
given	O
two	B-TREATMENT
IV	I-TREATMENT
fluid	I-TREATMENT
boluses	I-TREATMENT
with	O
appropriate	O
response	O
.	O

Her	B-TEST
blood	I-TEST
pressures	I-TEST
and	O
all	O
of	O
her	B-TEST
vital	I-TEST
signs	I-TEST
are	O
stable	O
.	O

The	O
patient	O
was	O
continued	O
on	O
TPN	B-TREATMENT
over	O
the	O
past	O
couple	O
days	O
.	O

She	O
is	O
also	O
started	O
on	O
marinol	B-TREATMENT
2.5	O
mg	O
p.o.	O
b.i.d.	O
and	O
encouraged	O
p.o.	O
intake	O
.	O

Guarded	B-PROBLEM
,	O
but	O
stable	O
.	O

1.	O
Burkitt's	B-PROBLEM
lymphoma	I-PROBLEM
.	O

2.	O
Hepatic	B-PROBLEM
candidiasis	I-PROBLEM
.	O

1.	O
AmBisome	B-TREATMENT
300	O
mg	O
IV	O
q.d.	O

2.	O
Marinol	B-TREATMENT
2.5	O
mg	O
p.o.	O
b.i.d.	O
before	O
breakfast	O
and	O
dinner	O
.	O

3.	O
Atarax	B-TREATMENT
25	O
mg	O
IV	O
/	O
p.o.	O
q.	O
4-6	O
h.	O
prn	O
for	O
itching	B-PROBLEM
.	O

4.	O
Colace	B-TREATMENT
100	O
mg	O
p.o.	O
b.i.d.	O

5.	O
Protonix	B-TREATMENT
40	O
mg	O
p.o.	O
/	O
IV	O
q.d.	O

6.	O
Nystatin	B-TREATMENT
06-18	O
mL	O
swish	O
and	O
swallow	O
q.6.	O
prn	O
.	O

7.	O
Peridex	B-TREATMENT
15	O
mL	O
swish	O
and	O
swallow	O
prn	O
.	O

Transfer	O
from	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
for	O
an	B-TEST
endoscopic	I-TEST
retrogram	I-TEST
cholangiopancreatography	I-TEST
.	O

Mr.	O
Eugene	O
is	O
a	O
67	O
year	O
old	O
male	O
with	O
a	O
remote	O
history	O
of	O
chronic	B-PROBLEM
pancreatitis	I-PROBLEM
due	O
to	O
alcohol	O
abuse	O
30	O
years	O
ago	O
,	O
who	O
is	O
transferred	O
now	O
from	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
for	O
an	B-TEST
ERCP	I-TEST
and	O
work-up	B-TEST
for	O
a	B-PROBLEM
cystic	I-PROBLEM
lesion	I-PROBLEM
at	O
the	O
head	O
of	O
his	O
pancreas	O
on	O
CT	B-TEST
scan	I-TEST
shown	O
at	O
the	O
outside	O
hospital	O
.	O

The	O
patient	O
presented	O
initially	O
to	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
at	O
the	O
end	O
of	O
December	O
for	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
and	O
was	O
found	O
to	O
have	O
pancreatitis	B-PROBLEM
.	O

During	O
this	O
admission	O
,	O
two	B-TEST
CT	I-TEST
scans	I-TEST
had	O
shown	O
a	O
question	O
of	O
an	B-PROBLEM
enlargement	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
head	I-PROBLEM
of	I-PROBLEM
his	I-PROBLEM
pancreas	I-PROBLEM

versus	O
early	B-PROBLEM
pseudocyst	I-PROBLEM
.	O

On	O
an	O
office	O
visit	O
on	O
01-14	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
significantly	B-PROBLEM
elevated	I-PROBLEM
alkaline	I-PROBLEM
phosphatase	I-PROBLEM
.	O

That	O
evening	O
,	O
the	O
patient	O
again	O
developed	O
abdominal	B-PROBLEM
pain	I-PROBLEM
"	O
like	O
his	B-PROBLEM
pancreatitis	I-PROBLEM
"	O
with	O
nausea	B-PROBLEM
and	O
vomiting	B-PROBLEM
,	O
for	O
which	O
he	O
was	O
admitted	O
to	O
the	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
.	O

His	B-TEST
complete	I-TEST
blood	I-TEST
count	I-TEST
showed	O
11%	B-PROBLEM
bandemia	I-PROBLEM
with	O
a	B-TEST
total	I-TEST
white	I-TEST
count	I-TEST
of	O
10	O
.	O

A	B-TEST
HIDA	I-TEST
scan	I-TEST
showed	O
no	B-PROBLEM
flow	I-PROBLEM
,	O
question	O
of	O
pancreatitis	B-PROBLEM
versus	O
common	B-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
obstruction	I-PROBLEM
.	O

His	B-TEST
electrocardiogram	I-TEST
showed	O
a	O
normal	O
sinus	O
rhythm	O
.	O

A	B-TEST
chest	I-TEST
x-ray	I-TEST
was	O
unremarkable	O
.	O

During	O
his	O
admission	O
to	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
,	O
the	O
patient	O
had	O
dropped	O
his	B-TEST
hematocrit	I-TEST
to	O
the	O
30	O
s	O
with	O
recorded	B-PROBLEM
melena	I-PROBLEM
.	O

He	O
received	O
an	B-TEST
MRCP	I-TEST
which	O
was	O
negative	O
for	O
evidence	O
of	O
stones	B-PROBLEM
.	O

An	B-TEST
ultrasound	I-TEST
showed	O
normal	O
gallbladder	O
with	O
no	O
wall	B-PROBLEM
thickening	I-PROBLEM
but	O
a	B-PROBLEM
dilated	I-PROBLEM
common	I-PROBLEM
bile	I-PROBLEM
duct	I-PROBLEM
of	O
8	O
mm	O
measured	O
on	O
CT	B-TEST
scan	I-TEST
.	O

The	O
patient	O
had	O
an	B-TEST
attempted	I-TEST
ERCP	I-TEST
on	O
01-18	O
,	O
which	O
was	O
unsuccessful	O
due	O
to	O
a	B-PROBLEM
long	I-PROBLEM
nipple	I-PROBLEM
like	I-PROBLEM
papilla	I-PROBLEM
.	O

He	O
was	O
therefore	O
transferred	O
to	O
Saints	O
Medical	O
Center	O
for	O
endoscopic	B-TEST
retrogram	I-TEST
cholangiopancreatography	I-TEST
.	O

The	B-TEST
patient	I-TEST
's	I-TEST
blood	I-TEST
cultures	I-TEST
at	O
outside	O
hospital	O
grew	O
out	O
Streptococcus	B-PROBLEM
sanguis-gordonii	I-PROBLEM
on	O
01-18	O
.	O

This	O
was	O
sensitive	O
to	O
Clindamycin	B-TREATMENT
,	O
Erythromycin	B-TREATMENT
,	O
penicillin	B-TREATMENT
S	I-TREATMENT
and	O
Vancomycin	B-TREATMENT
.	O

Prior	O
to	O
this	O
result	O
,	O
the	O
patient	O
had	O
already	O
been	O
on	O
Ampicillin	B-TREATMENT
,	O
Sulbactam	B-TREATMENT
and	O
Gentamycin	B-TREATMENT
.	O

It	O
appears	O
from	O
the	O
Discharge	O
summary	O
that	O
the	O
patient	O
was	O
placed	O
on	O
Unasyn	B-TREATMENT
3	O
grams	O
intravenously	O
every	O
six	O
hours	O
after	O
his	B-TEST
ERCP	I-TEST
.	O

1.	O
Type	B-PROBLEM
2	I-PROBLEM
diabetes	I-PROBLEM
mellitus	I-PROBLEM
.	O

2.	O
Right	B-PROBLEM
rotator	I-PROBLEM
cuff	I-PROBLEM
injury	I-PROBLEM
.	O

3.	O
Gastroesophageal	B-PROBLEM
reflux	I-PROBLEM
disease	I-PROBLEM
with	O
esophageal	B-TREATMENT
dilatation	I-TREATMENT
for	O
stricture	B-PROBLEM
.	O

4.	O
Recent	B-PROBLEM
pancreatitis	I-PROBLEM
;	O
prior	O
history	O
for	O
recurrent	B-PROBLEM
pancreatitis	I-PROBLEM
30	O
years	O
ago	O
from	O
alcohol	O
.	O

5.	O
History	O
of	O
Streptococcemia	B-PROBLEM
in	O
the	O
year	O
2008	O
;	O
source	O
was	O
unclear	O
but	O
presumed	O
to	O
be	O
urinary	O
.	O

6.	O
Status	O
post	O
tonsillectomy	B-TREATMENT
as	O
a	O
child	O
.	O

1.	O
Prilosec	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
day	O
.	O

2.	O
Flomax	B-TREATMENT
4	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
Humalog	B-TREATMENT
75/25	O
,	O
subcutaneously	O
.	O

4.	O
Regular	B-TREATMENT
insulin	I-TREATMENT
15	O
units	O
q.	O
a.m.	O
and	O
14	O
units	O
q.	O
p.m.	O

1.	O
Unasyn	B-TREATMENT
3	O
grams	O
intravenous	O
every	O
six	O
hours	O
.	O

2.	O
NPH	B-TREATMENT
10	O
units	O
subcutaneously	O
every	O
morning	O
and	O
8	O
units	O
subcutaneously	O
every	O
evening	O
.	O

3.	O
Flomax	B-TREATMENT
0.4	O
mg	O
p.o.	O
q.	O
day	O
.	O

4.	O
Prilosec	B-TREATMENT
30	O
mg	O
p.o.	O
q.	O
day	O
.	O

5.	O
Regular	B-TREATMENT
insulin	I-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
.	O

6.	O
Tylenol	B-TREATMENT
.	O

The	O
patient	O
is	O
allergic	B-PROBLEM
to	O
Ciprofloxacin	B-TREATMENT
,	O
morphine	B-TREATMENT
sulfate	I-TREATMENT
and	O
Droperidol	B-TREATMENT
.	O

The	O
patient	O
lives	O
with	O
his	O
disabled	O
wife	O
who	O
has	O
a	B-PROBLEM
psychiatric	I-PROBLEM
condition	I-PROBLEM
.	O

On	O
admission	O
showed	O
a	B-TEST
temperature	I-TEST
of	O
97.1	O
F.	O
;	O
heart	B-TEST
rate	I-TEST
of	O
65	O
;	O
blood	B-TEST
pressure	I-TEST
of	O
146/74	O
;	O
respiratory	B-TEST
rate	I-TEST
of	O
20	O
;	O
oxygen	B-TEST
saturation	I-TEST
98%	O
on	O
three	O
liters	O
and	O
95%	O
on	O
room	O
air	O
.	O

The	O
patient	O
was	O
alert	O
,	O
awake	O
and	O
oriented	O
,	O
pleasant	O
,	O
and	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Head	B-TEST
,	I-TEST
eyes	I-TEST
,	I-TEST
ears	I-TEST
,	I-TEST
nose	I-TEST
and	I-TEST
throat	I-TEST
examination	I-TEST
revealed	O
mucous	O
membranes	O
that	O
were	O
moist	O
.	O

He	O
had	O
no	O
icterus	B-PROBLEM
.	O

Cardiovascular	O
system	O
revealed	O
normal	O
S1	O
and	O
S2	O
,	O
no	O
murmurs	B-PROBLEM
or	O
gallops	B-PROBLEM
and	O
regular	O
rate	O
and	O
rhythm	O
.	O

Pulmonary	B-TEST
examination	I-TEST
revealed	O
lungs	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Abdominal	B-TEST
examination	I-TEST
revealed	O
an	O
abdomen	O
that	O
is	O
nondistended	B-PROBLEM
,	O
nontender	B-PROBLEM
.	O

His	B-TEST
liver	I-TEST
span	I-TEST
was	O
8	O
cm	O
.	O

There	O
was	O
no	O
rebound	B-PROBLEM
;	O
no	O
Munos	B-PROBLEM
sign	I-PROBLEM
.	O

Extremities	O
reveal	O
no	O
edema	B-PROBLEM
,	O
no	O
swelling	B-PROBLEM
.	O

Neurologic	B-TEST
examination	I-TEST
revealed	O
an	O
alert	O
and	O
oriented	O
individual	O
.	O

There	O
was	O
no	O
formal	B-TEST
strength	I-TEST
test	I-TEST
done	O
.	O

Studies	O
revealed	O
a	B-TEST
hematocrit	I-TEST
of	O
32.6	O
,	O
white	B-TEST
count	I-TEST
of	O
6.0	O
.	O

His	B-TEST
platelet	I-TEST
count	I-TEST
was	O
267	O
.	O

His	B-TEST
MCV	I-TEST
was	O
88	O
,	O
red	B-TEST
cell	I-TEST
distribution	I-TEST
was	O
13.4	O
.	O

Chemistry	O
on	O
admission	O
showed	O
a	B-TEST
sodium	I-TEST
of	O
141	O
,	O
potassium	B-TEST
of	O
4.3	O
,	O
chloride	B-TEST
of	O
107	O
,	O
bicarbonate	B-TEST
of	O
25	O
,	O
BUN	B-TEST
of	O
4	O
,	O
creatinine	B-TEST
of	O
0.6	O
and	O
a	B-TEST
sugar	I-TEST
of	O
177	O
.	O

Liver	B-TEST
function	I-TEST
tests	I-TEST
revealed	O
an	B-TEST
ALT	I-TEST
of	O
31	O
,	O
AST	B-TEST
of	O
36	O
,	O
alkaline	B-TEST
phosphatase	I-TEST
of	O
509	O
.	O

Total	B-TEST
bilirubin	I-TEST
was	O
0.8	O
.	O

Albumin	B-TEST
was	O
2.6	O
.	O

His	B-TEST
blood	I-TEST
cultures	I-TEST
were	O
drawn	O
and	O
pending	O
.	O

Urinalysis	B-TEST
revealed	O
trace	B-PROBLEM
glucose	I-PROBLEM
,	O
no	O
ketones	B-PROBLEM
,	O
no	O
red	B-PROBLEM
cells	I-PROBLEM
,	O
no	O
white	B-PROBLEM
cells	I-PROBLEM
and	O
less	O
than	O
one	O
epithelial	O
cells	O
.	O

The	O
patient	O
was	O
taken	O
down	O
to	O
the	B-TEST
endoscopic	I-TEST
retrogram	I-TEST
cholangiopancreatogram	I-TEST
upon	O
admission	O
.	O

On	O
this	B-TEST
examination	I-TEST
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
mild	B-PROBLEM
biliary	I-PROBLEM
stricture	I-PROBLEM
most	O
likely	O
secondary	O
to	O
chronic	B-PROBLEM
pancreatitis	I-PROBLEM
.	O

Cytology	B-TEST
was	O
obtained	O
.	O

He	O
was	O
also	O
found	O
to	O
have	O
dilated	B-PROBLEM
pancreatic	I-PROBLEM
ducts	I-PROBLEM
with	O
calcifications	B-PROBLEM
consistent	O
with	O
chronic	B-PROBLEM
pancreatitis	I-PROBLEM
.	O

The	O
patient	O
underwent	O
a	B-TREATMENT
percutaneous	I-TREATMENT
sphincterotomy	I-TREATMENT
extended	O
to	O
a	B-TREATMENT
full	I-TREATMENT
sphincterectomy	I-TREATMENT
.	O

He	O
also	O
had	O
successful	B-TREATMENT
extraction	I-TREATMENT
of	O
stone	B-PROBLEM
fragments	I-PROBLEM
.	O

The	O
patient	O
tolerated	O
this	B-TREATMENT
procedure	I-TREATMENT
well	O
and	O
had	O
no	O
complications	B-PROBLEM
.	O

The	O
patient	O
subsequently	O
underwent	O
a	B-TEST
CT	I-TEST
scan	I-TEST
angiogram	I-TEST
with	O
Pancreas	B-TEST
protocol	I-TEST
to	O
assess	O
the	O
pseudocyst	B-PROBLEM
versus	O
enlarged	B-PROBLEM
pancreas	I-PROBLEM
head	I-PROBLEM
.	O

The	O
results	O
of	O
this	B-TEST
study	I-TEST
indicated	O
that	O
this	O
structure	O
at	O
the	O
head	O
of	O
his	O
pancreas	O
is	O
most	O
likely	O
a	B-PROBLEM
forming	I-PROBLEM
pseudocyst	I-PROBLEM
;	O
however	O
,	O
the	O
suspicion	O
of	O
malignancy	B-PROBLEM
is	O
still	O
possible	O
and	O
the	O
patient	O
underwent	O
an	B-TEST
ultrasound	I-TEST
guided	I-TEST
biopsy	I-TEST
of	O
this	B-PROBLEM
mass	I-PROBLEM
on	O
2011-01-20	O
.	O

The	O
cytology	O
for	O
this	B-TEST
biopsy	I-TEST
is	O
still	O
pending	O
.	O

The	O
patient	O
recovered	O
well	O
status	O
post	O
these	B-TEST
two	I-TEST
procedures	I-TEST
.	O

He	O
had	O
no	O
complications	B-PROBLEM
and	O
no	O
subsequently	B-PROBLEM
pancreatitis	I-PROBLEM
.	O

His	B-TEST
alkaline	I-TEST
phosphatase	I-TEST
and	O
all	B-PROBLEM
the	I-PROBLEM
other	I-PROBLEM
abnormal	I-PROBLEM
liver	I-PROBLEM
function	I-PROBLEM
tests	I-PROBLEM
were	O
resolving	O
.	O

He	O
had	O
no	O
pain	B-PROBLEM
and	O
did	O
not	O
require	O
any	B-TREATMENT
pain	I-TREATMENT
medications	I-TREATMENT
.	O

He	O
was	O
tolerating	O
food	O
very	O
well	O
and	O
was	O
afebrile	B-PROBLEM
throughout	O
admission	O
.	O

With	O
regards	O
to	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
documented	I-PROBLEM
Strep	I-PROBLEM
septicemia	I-PROBLEM
in	O
the	O
outside	O
hospital	O
,	O
the	O
Infectious	O
Disease	O
Team	O
was	O
formally	O
consulted	O
.	O

Upon	O
obtaining	O
more	O
information	O
from	O
Rehab	O
Hospital	O
of	O
the	O
Cape	O
&	O
Islands	O
Hospital	O
,	O
it	O
appears	O
that	O
the	O
patient	O
had	O
two	O
out	O
of	O
four	O
bottles	O
growing	O
out	O
Streptococcus	B-PROBLEM
sanguis	I-PROBLEM
in	O
the	O
outside	O
hospital	O
.	O

The	O
patient	O
appeared	O
to	O
have	O
been	O
covered	O
by	O
Ampicillin	B-TREATMENT
,	O
Gentamycin	B-TREATMENT
and	O
then	O
Unasyn	B-TREATMENT
in	O
the	O
outside	O
hospital	O
.	O

The	O
patient	O
,	O
on	O
admission	O
,	O
was	O
placed	O
on	O
Ampicillin	B-TREATMENT
,	O
Gentamycin	B-TREATMENT
and	O
Flagyl	B-TREATMENT
.	O

With	O
repeated	B-TEST
blood	I-TEST
cultures	I-TEST
that	O
were	O
negative	O
,	O
the	O
patient	O
was	O
reduced	O
to	O
single	O
Mckenzie	O
of	O
intravenous	B-TREATMENT
Ampicillin	I-TREATMENT
.	O

For	O
this	B-PROBLEM
documented	I-PROBLEM
septicemia	I-PROBLEM
,	O
this	O
patient	O
went	O
for	O
a	B-TEST
endocarditis	I-TEST
work-up	I-TEST
.	O

He	O
had	O
a	B-TEST
transthoracic	I-TEST
echocardiogram	I-TEST
which	O
revealed	O
no	O
vegetations	B-PROBLEM
.	O

On	O
this	B-TEST
echocardiogram	I-TEST
,	O
he	O
was	O
found	O
to	O
have	O
mildly	B-PROBLEM
dilated	I-PROBLEM
left	I-PROBLEM
atrium	I-PROBLEM
,	O
mild	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
,	O
and	O
a	O
normal	O
ejection	O
fraction	O
of	O
greater	O
than	O
55%	O
.	O

There	O
were	O
no	O
other	B-PROBLEM
abnormalities	I-PROBLEM
noted	O
on	O
this	B-TEST
study	I-TEST
.	O

The	O
patient	O
then	O
underwent	O
a	B-TEST
transesophageal	I-TEST
echocardiogram	I-TEST
on	O
01-24	O
.	O

On	O
this	B-TEST
echocardiogram	I-TEST
,	O
he	O
was	O
again	O
noted	O
to	O
not	O
have	O
any	O
evidence	O
for	O
valvular	B-PROBLEM
vegetations	I-PROBLEM
.	O

A	B-PROBLEM
complex	I-PROBLEM
plaque	I-PROBLEM
was	O
found	O
in	O
the	O
aortic	O
arch	O
in	O
the	O
descending	O
thoracic	O
aorta	O
,	O
although	O
this	B-PROBLEM
plaque	I-PROBLEM
is	O
non-mobile	O
.	O

There	O
was	O
focal	B-PROBLEM
mitral	I-PROBLEM
valve	I-PROBLEM
prolapse	I-PROBLEM
noted	O
without	O
pathologic	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
.	O

The	O
patient	O
was	O
noted	O
to	O
have	O
trace	B-PROBLEM
aortic	I-PROBLEM
regurgitation	I-PROBLEM
.	O

A	B-TEST
Panorex	I-TEST
x-ray	I-TEST
of	O
his	O
two	O
teeth	O
were	O
obtained	O
and	O
a	B-TEST
Dental	I-TEST
Consultation	I-TEST
was	O
done	O
.	O

The	O
patient	O
was	O
thought	O
to	O
have	O
normal	O
dental	O
hygiene	O
and	O
low	O
suspicion	O
for	O
a	O
source	O
of	O
his	B-PROBLEM
alpha	I-PROBLEM
septicemia	I-PROBLEM
from	I-PROBLEM
his	I-PROBLEM
mouth	I-PROBLEM
.	O

Infectious	O
Disease	O
Department	O
as	O
well	O
as	O
Cardiology	O
had	O
recommended	O
a	O
formal	O
14	O
-	O
day	O
course	O
of	O
intravenous	B-TREATMENT
antibiotics	I-TREATMENT
to	O
treat	O
a	B-PROBLEM
documented	I-PROBLEM
alpha	I-PROBLEM
Streptococcal	I-PROBLEM
septicemia	I-PROBLEM
from	O
outside	O
hospital	O
blood	B-TEST
cultures	I-TEST
.	O

The	O
patient	O
's	O
insurance	O
company	O
,	O
however	O
,	O
would	O
not	O
pay	O
for	O
home	B-TREATMENT
antibiotics	I-TREATMENT
.	O

After	O
much	O
discussion	O
with	O
the	O
patient	O
,	O
the	O
patient	O
was	O
informed	O
of	O
the	O
risks	O
of	O
not	O
finishing	O
a	O
14	O
day	O
course	O
of	O
intravenous	B-TREATMENT
antibiotics	I-TREATMENT
and	O
chose	O
to	O
go	O
home	O
.	O

He	O
had	O
three	O
days	O
of	O
antibiotics	B-TREATMENT
remaining	O
at	O
the	O
time	O
of	O
discharge	O
.	O

It	O
was	O
discussed	O
with	O
the	O
patient	O
to	O
send	O
him	O
out	O
on	O
Augmentin	B-TREATMENT
500	O
mg	O
three	O
times	O
a	O
day	O
for	O
ten	O
more	O
days	O
.	O

He	O
was	O
to	O
follow-up	O
with	O
his	O
primary	O
care	O
physician	O
within	O
two	O
to	O
three	O
days	O
for	O
repeat	B-TEST
laboratory	I-TEST
studies	I-TEST
and	O
blood	B-TEST
cultures	I-TEST
.	O

He	O
was	O
to	O
return	O
to	O
the	O
hospital	O
with	O
any	O
signs	O
of	O
shaking	B-PROBLEM
chills	B-PROBLEM
or	O
fever	B-PROBLEM
.	O

1.	O
Pancreatitis	B-PROBLEM
status	O
post	O
endoscopic	B-TEST
retrogram	I-TEST
cholangiopancreatography	I-TEST
and	O
sphincterotomy	B-TREATMENT
.	O

2.	O
Alpha	B-PROBLEM
Streptococcus	I-PROBLEM
septicemia	I-PROBLEM
.	O

1.	O
Augmentin	B-TREATMENT
500	O
mg	O
p.o.	O
three	O
times	O
a	O
day	O
times	O
ten	O
days	O
.	O

2.	O
Flomax	B-TREATMENT
0.4	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
Prilosec	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
day	O
.	O

4.	O
Humalog	B-TREATMENT
and	O
Regular	B-TREATMENT
insulin	I-TREATMENT
subcutaneously	O
.	O

Respiratory	B-PROBLEM
distress	I-PROBLEM
-	O
On	O
10-12	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
Medicine	O
Intensive	O
Care	O
Unit	O
secondary	O
to	O
respiratory	B-PROBLEM
distress	I-PROBLEM
.	O

In	O
the	O
Medicine	O
Intensive	O
Care	O
Unit	O
,	O
the	O
patient	O
was	O
initially	O
placed	O
on	O
high-flow	B-TREATMENT
60%	I-TREATMENT
oxygen	I-TREATMENT
face	I-TREATMENT
mask	I-TREATMENT
and	O
they	O
diuresed	O
approximately	O
5	O
liters	O
off	O
into	O
the	B-TREATMENT
intravenous	I-TREATMENT
Lasix	I-TREATMENT
.	O

Since	O
then	O
the	O
patient	O
's	O
oxygenation	O
has	O
been	O
improving	O
and	O
today	O
,	O
10-17	O
,	O
she	O
is	O
requiring	O
.5	O
liters	O
of	O
keep	O
her	B-TEST
saturations	I-TEST
above	O
94	O
.	O

The	O
patient	O
continues	O
to	O
be	O
diuresed	O
with	O
approximately	O
20	O
mg	O
of	O
Lasix	B-TREATMENT
a	O
day	O
and	O
she	O
has	O
had	O
good	O
urine	O
output	O
.	O

Anemia	B-PROBLEM
-	O
The	B-TEST
patient	I-TEST
's	I-TEST
hematocrit	I-TEST
dropped	O
in	O
the	O
Intensive	O
Care	O
Unit	O
to	O
the	O
mid	O
20s	O
and	O
she	O
received	O
one	O
unit	O
of	O
packed	O

red	B-TREATMENT
blood	I-TREATMENT
cells	I-TREATMENT
with	O
a	O
good	O
response	O
up	O
to	O
30	O
.	O

Hypotension	B-PROBLEM
-	O
On	O
the	O
night	O
of	O
10-16	O
,	O
the	O
patient	O
was	O
diuresed	O
with	O
20	O
mg	O
of	O
intravenous	B-TREATMENT
Lasix	I-TREATMENT
.	O

The	O
patient	O
became	O
hypotensive	B-PROBLEM
into	O
the	O
70	O
s	O
without	O
any	B-PROBLEM
symptoms	I-PROBLEM
.	O

Her	B-TEST
oxygen	I-TEST
saturations	I-TEST
were	O
greater	O
than	O
94%	O
at	O
the	O
time	O
.	O

The	O
patient	O
was	O
given	O
250	O
cc	O
of	O
normal	B-TREATMENT
saline	I-TREATMENT
and	O
her	B-TEST
blood	I-TEST
pressure	I-TEST
responded	O
coming	O
back	O
up	O
to	O
the	O
high	O
90	O
s.	O

No	O
further	O
episodes	O
of	O
hypotension	B-PROBLEM
were	O
noted	O
.	O

Recent	B-TEST
chest	I-TEST
x-ray	I-TEST
shows	O
resolving	B-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
pneumonia	I-PROBLEM
.	O

She	O
continues	O
on	O
her	B-TREATMENT
Prednisone	I-TREATMENT
taper	I-TREATMENT
for	O
her	B-PROBLEM
asthma	I-PROBLEM
and	O
this	O
is	O
day	O
#	O
14	O
of	O
antibiotics	B-TREATMENT
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	O
Drugs	B-TREATMENT

nausea	B-PROBLEM
and	O
vomiting	B-PROBLEM

01-23	O
PORT	B-TREATMENT
line	I-TREATMENT
removal	I-TREATMENT
.	O

01-23	O
PICC	B-TREATMENT
placement	I-TREATMENT
.	O

01-24	O
PICC	B-TREATMENT
removal	I-TREATMENT
.	O

This	O
is	O
a	O
37	O
y/o	O
male	O
patient	O
with	O
PMH	O
Type	B-PROBLEM
I	I-PROBLEM
DM	I-PROBLEM
,	O
HTN	B-PROBLEM
,	O
gastroparesis	B-PROBLEM
,	O
ESRD	B-PROBLEM
on	O
HD	B-TREATMENT
(	O
last	O
in	O
12/26	O
per	O
patient	O
)	O
who	O
presents	O
to	O
CMED	O
CCU	O
with	O
hypertensive	B-PROBLEM
urgency	I-PROBLEM
unable	O
from	O
the	O
Larry	O
.	O

The	O
patient	O
early	O
this	O
morning	O
to	O
the	O
Ruthie	O
with	O
his	B-PROBLEM
usual	I-PROBLEM
nausea	I-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
abdominal	B-PROBLEM
pain	I-PROBLEM
and	O
was	O
found	O
to	O
be	O
hypertensive	B-PROBLEM
to	O
256/110	O
,	O
HR	B-TEST
102	O
,	O
T	B-TEST
99.2	O
,	O
RR	B-TEST
22	O
,	O
92%	O
RA	O
.	O

History	O
is	O
difficult	O
to	O
obtain	O
from	O
patient	O
d/t	O
somnolence	B-PROBLEM
and	O
lack	B-PROBLEM
of	I-PROBLEM
desire	I-PROBLEM
to	O
participate	O
in	O
interview	O
,	O
but	O
per	O
Frank	O
note	O
he	O
was	O
diaphoretic	B-PROBLEM
and	O
'	O
writing	O
in	O
pain	B-PROBLEM
',	O
vomiting	O
clear	O
substance	O
.	O

He	O
was	O
given	O
ativan	B-TREATMENT
a	O
total	O
of	O
4	O
mg	O
of	O
ativan	B-TREATMENT
,	O
6	O
mg	O
of	O
dilaudid	B-TREATMENT
,	O
labetolol	B-TREATMENT
20	O
mg	O
IV	O
x	O
1	O
and	O
hydralazine	B-TREATMENT
10	O
mg	O
IV	O
x	O
1	O
without	O
good	O
response	O
(	O
200/99	O
).	O

He	O
recieved	O
2L	B-TREATMENT
NS	I-TREATMENT
and	O
was	O
started	O
on	O
labetolol	B-TREATMENT
gtt	I-TREATMENT
and	O
BP	B-TEST
decreased	O
to	O
161/79	O
.	O

Tranferred	O
to	O
CMED	O
CCU	O
for	O
further	O
management	O
while	O
on	O
labetolol	B-TREATMENT
gtt	I-TREATMENT
.	O

At	O
that	O
time	O
BP	B-TEST
was	O
attributed	O
to	O
abdominal	B-PROBLEM
pain	I-PROBLEM
and	O
inability	O
to	O
take	O
PO	O
meds	O
d/t	O
nausea	B-PROBLEM
/	O
vomiting	B-PROBLEM
.	O

Also	O
had	O
labile	B-PROBLEM
blood	I-PROBLEM
sugars	I-PROBLEM
with	O
repeated	O
episodes	O
of	O
hypoglycemia	B-PROBLEM
,	O
and	O
Strickland	O
recommended	O
sugars	B-TEST
in	O
the	O
range	O
of	O
150-200	O
.	O

He	O
eloped	O
prior	O
to	O
formal	O
discharge	O
when	O
his	B-TEST
FS	I-TEST
was	O
found	O
to	O
be	O
critically	B-PROBLEM
high	I-PROBLEM
-	O
recommended	O
to	O
patient	O
that	O
he	O
stay	O
for	O
repeat	O
,	O
but	O
left	O
AMA	O
without	O
signing	O
any	O
forms	O
.	O

Upon	O
transfer	O
to	O
the	O
CMED	O
CCU	O
the	O
patient	O
appears	O
somewhat	B-PROBLEM
uncomfortable	I-PROBLEM
,	O
reporting	O
nausea	B-PROBLEM
and	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
but	O
when	O
questioned	O
he	O
was	O
unable	O
/	O
unwilling	O
to	O
participate	O
in	O
HPI	O
or	O
exam	B-TEST
d/t	O
sleepiness	B-PROBLEM
.	O

He	O
denied	O
CP	B-PROBLEM
,	O
SOB	B-PROBLEM
,	O
HA	B-PROBLEM
,	O
vision	B-PROBLEM
changes	I-PROBLEM
,	O
neck	B-PROBLEM
stiffness	I-PROBLEM
,	O
dysuria	B-PROBLEM
,	O
or	O
other	B-PROBLEM
symptoms	I-PROBLEM
.	O

In	O
the	O
CMED	O
CCU	O
he	O
became	O
hypotensive	B-PROBLEM
to	O
SBP	B-TEST
80	O
s.	O

Labetalol	B-TREATMENT
was	O
stopped	O
and	O
he	O
received	O
a	B-TREATMENT
500	I-TREATMENT
cc	I-TREATMENT
fluid	I-TREATMENT
bolus	I-TREATMENT
and	O
his	B-TEST
blood	I-TEST
pressure	I-TEST
rose	O
to	O
SBP	B-TEST
90	O
s.	O

Cardiac	O
and	O
infectious	O
sources	O
of	O
hypotension	B-PROBLEM
were	O
considered	O
,	O
but	O
cardiac	B-TEST
enzymes	I-TEST
were	O
not	O
changed	O
from	O
prior	O
studies	O
and	O
he	O
had	O
no	O
localizing	B-PROBLEM
signs	I-PROBLEM
of	I-PROBLEM
infection	I-PROBLEM
;	O
blood	B-TEST
cultures	I-TEST
were	O
sent	O
and	O
a	B-TEST
ultrasound	I-TEST
of	O
the	B-TREATMENT
L	I-TREATMENT
arm	I-TREATMENT
AVF	I-TREATMENT
ordered	O
to	O
rule	O
out	O
abscess	B-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
site	I-PROBLEM
.	O

He	O
received	O
a	B-TREATMENT
partial	I-TREATMENT
HD	I-TREATMENT
session	I-TREATMENT
,	O
limited	O
by	O
hypotension	B-PROBLEM
.	O

Over	O
night	O
,	O
his	B-TEST
blood	I-TEST
pressure	I-TEST
trended	O
up	O
to	O
130	O
s	O
systolic	O
.	O

He	O
was	O
restarted	O
on	O
his	B-TREATMENT
home	I-TREATMENT
blood	I-TREATMENT
pressure	I-TREATMENT
regimen	I-TREATMENT
.	O

He	O
was	O
to	O
be	O
called	O
out	O
to	O
the	O
medical	O
floor	O
on	O
2019-01-20	O
but	O
became	O
somnolent	B-PROBLEM
after	O
receiving	O
pain	B-TREATMENT
and	I-TREATMENT
anti-nausea	I-TREATMENT
meds	I-TREATMENT
,	O
so	O
he	O
stayed	O
in	O
the	O
ICU	O
for	O
closer	O
monitoring	O
of	O
respiratory	O
status	O
,	O
which	O
spontaneously	O
improved	O
.	O

His	B-TEST
blood	I-TEST
sugar	I-TEST
at	O
10	O
pm	O
was	O
low	O
at	O
22	O
and	O
he	O
was	O
disoriented	B-PROBLEM
,	O
which	O
resolved	O
with	O
two	O
glasses	O
of	O
juice	O
;	O
he	O
did	O
not	O
receive	O
his	O
standing	O
dose	O
of	O
NPH	B-TREATMENT
that	O
evening	O
.	O

Blood	B-TEST
cultures	I-TEST
returned	O
positive	O
with	O
GPC	B-PROBLEM
in	I-PROBLEM
pairs	I-PROBLEM
and	I-PROBLEM
clusters	I-PROBLEM
,	O
so	O
a	B-TEST
TTE	I-TEST
and	O
surveillance	B-TEST
cultures	I-TEST
were	O
ordered	O
and	O
vancomycin	B-TREATMENT
was	O
started	O
.	O

1.	O
DM	B-PROBLEM
type	I-PROBLEM
I	O

2.	O
ESRD	B-PROBLEM
on	O
hemodialysis	B-TREATMENT
started	O
2017-01-07	O
on	O
Tu	O
,	O
Th	O
,	O
Sat	O

3.	O
Severe	B-PROBLEM
autonomic	I-PROBLEM
dysfunction	I-PROBLEM
with	O
multiple	O
hospitalizations	O
for	O
hypertensive	B-PROBLEM
emergency	I-PROBLEM
,	O
gastroparesis	B-PROBLEM
,	O
and	O
orthostatic	B-PROBLEM
hypotension	I-PROBLEM
.	O

4.	O
History	O
of	O
esophageal	B-PROBLEM
erosion	I-PROBLEM
,	O
MW	B-PROBLEM
tear	I-PROBLEM

5.	O
CAD	B-PROBLEM
with	O
1-vessel	B-PROBLEM
disease	I-PROBLEM
(	O
50%	B-PROBLEM
stenosis	I-PROBLEM
D1	I-PROBLEM
in	O
2014-06-07	O
),	O
normal	O
stress	O

6.	O
hx	O
of	O
Foot	B-PROBLEM
Ulcer	I-PROBLEM

7.	O
h/o	O
clot	B-PROBLEM
in	O
AV	B-TREATMENT
graft	I-TREATMENT
x2	O
(	O
March	O
and	O
2018-07-07	O
)	O

His	O
father	O
recently	O
died	O
of	O
ESRD	B-PROBLEM
and	O
diabetes	B-PROBLEM
.	O

His	O
mother	O
is	O
in	O
her	O
50	O
s	O
and	O
has	O
hypertension	B-PROBLEM
.	O

He	O
has	O
two	O
sisters	O
,	O
one	O
with	O
diabetes	B-PROBLEM
,	O
and	O
six	O
brothers	O
,	O
one	O
with	O
diabetes	B-PROBLEM
.	O

Vitals	B-TEST
:	O
97.4	O
,	O
164/90	O
,	O
102	O
,	O
10	O
,	O
97%	O
4L	O

General	O
:	O
sleepy	B-PROBLEM
,	O
arouses	O
to	O
voice	O
but	O
limited	O
participation	O
with	O
physical	B-TEST
exam	I-TEST

HEENT	O
:	O
PERRL	O
,	O
left	B-PROBLEM
pupil	I-PROBLEM
smaller	I-PROBLEM
than	I-PROBLEM
right	I-PROBLEM
,	O
pt	O
will	O
not	O
participate	O
in	O
EOMI	O
,	O
sclera	O
anicteric	B-PROBLEM
,	O
MM	B-PROBLEM
dry	I-PROBLEM
,	O
No	O
OP	B-PROBLEM
lesions	I-PROBLEM

Neck	O
:	O
Supple	O
,	O
no	O
JVD	B-PROBLEM

CV	O
:	O
RRR	O
,	O
nl	O
S1	O
,	O
S2	O
,	O
2/6	B-PROBLEM
systolic	I-PROBLEM
murmur	I-PROBLEM
at	I-PROBLEM
LUSB	I-PROBLEM

Chest	O
:	O
HD	B-TREATMENT
line	I-TREATMENT
in	O
place	O
without	O
erythema	B-PROBLEM

Abd	O
:	O
Soft	O
,	O
ND	B-PROBLEM
,	O
nontender	B-PROBLEM
,	O
+	O
BS	O
,	O
no	O
guarding	B-PROBLEM
,	O
no	O
rebound	B-PROBLEM
,	O
multiple	B-PROBLEM
well	I-PROBLEM
healed	I-PROBLEM
scars	I-PROBLEM

Ext	O
:	O
no	O
c/c/e	B-PROBLEM
,	O
left	B-PROBLEM
arm	I-PROBLEM
with	I-PROBLEM
fistula	I-PROBLEM
with	O
good	O
thrill	O

Skin	O
:	O
no	O
rashes	B-PROBLEM

Pt	O
admitted	O
to	O
medical	O
floor	O
in	O
hemodynamically	O
stable	O
condition	O
without	O
specific	B-PROBLEM
complaints	I-PROBLEM
.	O

#	O
hypertensive	B-PROBLEM
urgency	I-PROBLEM
:	O

Upon	O
presentation	O
it	O
was	O
unclear	O
when	O
last	O
time	O
was	O
that	O
patient	O
took	O
meds	B-TREATMENT
,	O
but	O
hypertension	B-PROBLEM
likely	O
d/t	O
inability	B-PROBLEM
to	I-PROBLEM
take	I-PROBLEM
meds	I-PROBLEM
in	O
setting	O
of	O
N/V	B-PROBLEM
.	O

Also	O
contribution	O
of	O
autonomic	B-PROBLEM
dysfunction	I-PROBLEM
.	O

No	O
evidence	O
of	O
active	B-PROBLEM
end	I-PROBLEM
organ	I-PROBLEM
damage	I-PROBLEM
.	O

Pt	O
was	O
treated	O
with	O
labetalol	B-TREATMENT
gtt	I-TREATMENT
in	O
CMED	O
CCU	O
which	O
was	O
weaned	O
off	O
on	O
01-20	O
.	O

carduac	B-PROBLEM
enzymes	I-PROBLEM
mildly	I-PROBLEM
elevated	I-PROBLEM
,	O
felt	O
02-08	O
demand	B-PROBLEM
ischemia	I-PROBLEM
in	O
setting	O
of	O
hypertensive	B-PROBLEM
urgency	I-PROBLEM
,	O
CK	B-TEST
and	O
MB	B-TEST
trended	O
Mcewen	O
at	O
time	O
of	O
admission	O
to	O
medical	O
floor	O
.	O

Pt	B-PROBLEM
's	I-PROBLEM
hypertensive	I-PROBLEM
urgency	I-PROBLEM
was	O
resolved	O
upon	O
admission	O
to	O
the	O
medical	O
floor	O
.	O

His	B-TEST
SBP	I-TEST
s	I-TEST
ranged	O
140	O
s-	O
170	O
s	O
.	O

He	O
was	O
restarted	O
on	O
his	O
home	O
regimen	O
of	O
antihypertensives	B-TREATMENT
without	O
difficulty	O
(	O
metoprolol	B-TREATMENT
75	O
tid	O
,	O
clonidine	B-TREATMENT
patch	I-TREATMENT
and	I-TREATMENT
oral	I-TREATMENT
,	O
nifedipine	B-TREATMENT
30	O
SR	O
q	O
daily	O
).	O

#	O
bacteremia	B-PROBLEM
:	O

pt	O
with	O
2/4	O
bottles	O
coag	B-PROBLEM
neg	I-PROBLEM
staph	I-PROBLEM
on	O
01-19	O
and	O
again	O
on	O
01-20	O
.	O

PORT	B-TREATMENT
was	O
felt	O
most	O
likely	O
source	O
,	O
and	O
pt	O
has	O
had	O
at	O
least	O
2	O
sets	O
of	O
+	B-PROBLEM
blood	I-PROBLEM
cultures	I-PROBLEM
since	O
it	O
was	O
placed	O
.	O

TTE	B-TEST
was	O
obtained	O
which	O
was	O
not	O
concerning	O
for	O
endocarditis	B-PROBLEM
.	O

pt	O
without	O
stigmata	B-PROBLEM
of	I-PROBLEM
SBE	I-PROBLEM
.	O

ID	O
consult	O
obtained	O
which	O
recommended	O
removal	B-TREATMENT
of	I-TREATMENT
PORT	I-TREATMENT
,	O
which	O
was	O
taken	O
out	O
on	O
01-23	O
.	O

Pt	O
will	O
compelete	O
a	O
2	O
week	O
course	O
of	O
vancomycin	B-TREATMENT
at	O
hemodialysis	B-TREATMENT
,	O
which	O
has	O
been	O
arranged	O
by	O
renal	O
service	O
.	O

A	B-TREATMENT
PICC	I-TREATMENT
was	O
breifly	O
placed	O
,	O
however	O
removed	O
as	O
it	O
is	O
unclear	O
if	O
pt	O
can	O
reliably	O
flush	O
this	O
.	O

PORT	B-TREATMENT
will	O
be	O
replaced	O
on	O
2019-02-11	O
per	O
IR	O
(	O
Dr.	O
Welsh	O
placed	O
last	O
PORT	B-TREATMENT
,	O
then	O
removed	O
it	O
on	O
01-23	O
),	O
ordered	O
placed	O
in	O
OMR	O
.	O

diabetic	B-PROBLEM
gastropathy	I-PROBLEM
causing	O
inability	B-PROBLEM
to	I-PROBLEM
toleral	I-PROBLEM
oral	I-PROBLEM
antihypertensive	I-PROBLEM
medication	I-PROBLEM
prompting	O
repeated	O
Donald	O
presentation	O
for	O
hypertensive	B-PROBLEM
urgency	I-PROBLEM
.	O

Pt	O
with	O
surveillance	B-TEST
cultures	I-TEST
and	O
port	B-TEST
tip	I-TEST
cultures	I-TEST
showing	O
NGTD	O
on	O
01-24	O
,	O
he	O
will	O
have	O
futher	B-TEST
surveillance	I-TEST
cultures	I-TEST
drawn	O
at	O
hemodialysis	B-TREATMENT
and	O
followed	O
by	O
his	O
nephrologist	O
.	O

#	O
n/v/	B-PROBLEM
abdominal	B-PROBLEM
pain	I-PROBLEM
:	O
pt	O
with	O
multiple	O
admissions	O
with	O
similar	B-PROBLEM
complaints	I-PROBLEM
,	O
etiology	O
02-08	O
gastroparesis	B-PROBLEM
,	O
improves	O
considerably	O
with	O
ativan	B-TREATMENT
,	O
dilaudid	B-TREATMENT
,	O
reglan	B-TREATMENT
,	O
pt	O
was	O
tolerating	O
PO	B-TREATMENT
meds	I-TREATMENT
/	O
diet	O
at	O
time	O
of	O
admission	O
to	O
medical	O
service	O
and	O
was	O
restarted	O
on	O
oral	B-TREATMENT
reglan	I-TREATMENT
.	O

#	O
DMI	B-PROBLEM
:	O
Pt	O
on	O
sliding	B-TREATMENT
scale	I-TREATMENT
as	O
inpatient	O
and	O
taking	O
NPH	B-TREATMENT
2	O
units	O
BID	O
at	O
home	O
.	O

pt	O
with	O
two	O
episodes	O
of	O
hypoglycemia	B-PROBLEM
(	O
FSBS	B-TEST
22	O
and	O
27	O
),	O
etiology	O
unclear	O
,	O
pt	O
followed	O
by	O
Strickland	O
,	O
who	O
recommend	O
no	O
changes	O
to	O
current	B-TREATMENT
insulin	I-TREATMENT
regimen	I-TREATMENT
.	O

will	O
discharge	O
pt	O
with	O
instructions	O
to	O
continue	O
NPH	B-TREATMENT
2	O
UNITS	O
BID	O
as	O
Frederick	O
Tracey	O
recs	O
.	O

#	O
CAD	B-PROBLEM
-	O
pt	O
denied	O
cp	B-PROBLEM
/	O
sob	B-PROBLEM
throughout	O
hospitalization	O
.	O

Troponins	B-TEST
rose	O
at	O
admission	O
,	O
however	O
CK	B-TEST
and	O
MB	B-TEST
trending	O
Mcewen	O
wat	O
time	O
of	O
admission	O
to	O
medical	O
service	O
.	O

Etiology	O
felt	O
most	O
likely	O
demand	B-PROBLEM
ischemia	I-PROBLEM
in	O
setting	O
of	O
original	B-PROBLEM
hypertensive	I-PROBLEM
urgency	I-PROBLEM
with	O
persistent	B-PROBLEM
elevation	I-PROBLEM
of	I-PROBLEM
trop	I-PROBLEM
02-08	O
ESRD	B-PROBLEM
.	O

Pt	O
was	O
continued	O
on	O
aspirin	B-TREATMENT
,	O
metoprolol	B-TREATMENT
,	O
nifedipine	B-TREATMENT
.	O

#	O
ESRD	B-PROBLEM
:	O
etiology	O
likely	O
02-08	O
DM	B-PROBLEM
and	O
HTN	B-PROBLEM
,	O
pt	O
tolerating	O
HD	B-TREATMENT
well	O
,	O
and	O
underwent	O
dialysis	B-TREATMENT
without	O
difficulty	B-PROBLEM
on	O
01-24	O
.	O

pt	O
will	O
be	O
discharged	O
home	O
with	O
plan	O
to	O
continue	O
current	B-TREATMENT
dialysis	I-TREATMENT
schedule	I-TREATMENT
(	O
Tue	O
/	O
Th	O
/	O
Sat	O
).	O

In	O
addition	O
pt	O
will	O
be	O
given	O
vancomycin	B-TREATMENT
at	O
dialysis	O
x	O
2	O
week	O
course	O
(	O
last	O
day	O
2019-02-05	O
)	O
given	O
his	B-PROBLEM
PORT	I-PROBLEM
line	I-PROBLEM
infection	I-PROBLEM
.	O

He	O
will	O
have	O
levels	B-TEST
drawn	O
at	O
dialysis	B-TREATMENT
and	O
be	O
dosed	O
with	O
vancomycin	B-TREATMENT
as	O
appropriate	O
.	O

Plan	O
is	O
for	O
surveillance	B-TEST
cultures	I-TEST
to	O
be	O
drawn	O
at	O
dialysis	B-TREATMENT
.	O

If	O
negative	O
,	O
pt	O
is	O
scheduled	O
for	O
presumptively	B-TREATMENT
replacement	I-TREATMENT
of	I-TREATMENT
PORT	I-TREATMENT
on	O
2019-02-11	O
with	O
interventional	B-TREATMENT
radiology	I-TREATMENT
(	O
dr.	O
Arevalo	O
).	O

Pt	O
continued	O
on	O
home	O
regimen	O
of	O
calcium	B-TREATMENT
acetate	I-TREATMENT
667	O
mg	O
,	O
3	O
capsules	O
TID	O
.	O

#	O
AV	B-TREATMENT
fistula	I-TREATMENT
:	O
pt	O
with	O
h/o	O
numerous	B-PROBLEM
clots	I-PROBLEM
in	O
AV	B-TREATMENT
fistula	I-TREATMENT
.	O

No	O
signs	O
of	O
infection	B-PROBLEM
presently	O
,	O
and	O
tolerating	O
dialysis	B-TREATMENT
without	O
difficulty	B-PROBLEM
.	O

Pt	O
was	O
subtherapeuticon	B-PROBLEM
INR	I-PROBLEM
on	O
admission	O
,	O
thus	O
treated	O
with	O
heparin	B-TREATMENT
gtt	I-TREATMENT
.	O

coumadin	B-TREATMENT
held	O
on	O
01-22	O
for	O
PORT	B-TREATMENT
removal	I-TREATMENT
,	O
and	O
restarted	O
on	O
01-24	O
.	O

Pt	O
discharged	O
with	O
instructions	O
to	O
continue	O
coumadin	B-TREATMENT
1.5	O
mg	O
po	O
q	O
daily	O
with	O
goal	B-TEST
INR	I-TEST
02-09	O
.	O

pt	O
discharged	O
home	O
on	O
01-24	O
with	O
instructions	O
to	O
complete	O
2	O
week	O
course	O
of	O
vancomycin	B-TREATMENT
at	O
hemodialysis	B-TREATMENT
for	O
his	B-PROBLEM
PORT	I-PROBLEM
line	I-PROBLEM
infection	I-PROBLEM
.	O

an	O
appointment	O
was	O
made	O
with	O
interventional	O
radiology	O
on	O
2019-02-11	O
to	O
replace	O
his	B-TREATMENT
PORT	I-TREATMENT
,	O
under	O
the	O
assumption	O
that	O
his	B-TEST
surveillance	I-TEST
cultures	I-TEST
from	O
dialysis	B-TREATMENT
remain	O
negative	O
.	O

Metoclopramide	B-TREATMENT
10	O
mg	O
PO	O
Q6	O

Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
75	O
mg	O
PO	O
TID	O

Calcium	B-TREATMENT
Acetate	I-TREATMENT
1340	O
mg	O
tid	O
with	O
meals	O

Anzemet	B-TREATMENT
12.5	O
IV	O
prn	O

Prochlorperazine	B-TREATMENT
10	O
mg	O
IV	O
Q6H	O
prn	O

Ativan	B-TREATMENT
1	O
mg	O
PO	O
Q6H	O
prn	O

Dilaudid	B-TREATMENT
4mg	O
PO	O
Q3-4H	O
prn	O

Insulin	B-TREATMENT
NPH	I-TREATMENT
2	O
units	O
Subcutaneous	O
twice	O
a	O
day	O
.	O

Clonidine	B-TREATMENT
0.3	O
mg	O
/	O
24	O
hr	O
Patch	O
Weekly	O
Transdermal	O
QTHUR	O

Clonidine	B-TREATMENT
0.2	O
mg	O
PO	O
TID	O

Prochlorperazine	B-TREATMENT
10	O
mg	O
q	O
6	O
h	O

Coumadin	B-TREATMENT
1.5	O
mg	O
PO	O
QHS	O

Nifedipine	B-TREATMENT
30	O
SR	O
mg	O
PO	O
QD	O

Bisacodyl	B-TREATMENT
prn	O

Protonix	B-TREATMENT
40	O
QD	O

1.	O
Metoclopramide	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
).	O

2.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

3.	O
Calcium	B-TREATMENT
Acetate	I-TREATMENT
667	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
TID	O
W/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
).	O

4.	O
Ativan	B-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
q6h	O
prn	O
.	O

5.	O
Dilaudid	B-TREATMENT
4	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
q3-4hr	O
prn	O
.	O

6.	O
Clonidine	B-TREATMENT
0.3	O
mg	O
/	O
24	O
hr	O
Patch	O
Weekly	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
Weekly	O
Transdermal	O
Q	O
WED	O
(	O
every	O
Wednesday	O
).	O

7.	O
Clonidine	B-TREATMENT
0.2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

8.	O
Warfarin	B-TREATMENT
1	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
).	O

9.	O
Nifedipine	B-TREATMENT
30	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
).	O

10.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
).	O

11.	O
Bisacodyl	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

12.	O
Vancomycin	B-TREATMENT
in	I-TREATMENT
Dextrose	I-TREATMENT
1	O
g	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
QHD	O
(	O
each	O
hemodialysis	B-TREATMENT
):	O
2	O
week	O
course	O
to	O
be	O
given	O
at	O
dialysis	O
,	O
last	O
day	O
2019-02-05	O
.	O

13.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O

14.	O
Humalog	B-TREATMENT
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
USE	O
AS	O
DIRECTED	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
please	O
use	O
attached	O
sliding	B-TREATMENT
scale	I-TREATMENT
.	O

15.	O
Insulin	B-TREATMENT
NPH	I-TREATMENT
Human	I-TREATMENT
Recomb	I-TREATMENT
100	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
2	O
UNITS	O
Subcutaneous	O
twice	O
a	O
day	O
.	O

bacteremia	B-PROBLEM
02-08	O
PORT	B-PROBLEM
line	I-PROBLEM
infection	I-PROBLEM

hypertensive	B-PROBLEM
urgency	I-PROBLEM

diabetic	B-PROBLEM
gastropathy	I-PROBLEM

please	O
continue	O
to	O
take	O
all	O
of	O
your	B-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

you	O
were	O
started	O
on	O
a	O
2	O
week	O
course	O
of	O
vancomycin	B-TREATMENT
to	O
be	O
given	O
at	O
hemodialysis	B-TREATMENT
for	O
your	B-PROBLEM
line	I-PROBLEM
infection	I-PROBLEM
.	O

you	O
will	O
have	O
your	B-TREATMENT
PORT	I-TREATMENT
replaced	O
after	O
2	O
weeks	O
of	O
antibiotics	B-TREATMENT
if	O
your	B-TEST
blood	I-TEST
cultures	I-TEST
remain	O
negative	O
.	O

if	O
you	O
have	O
recurrent	B-PROBLEM
fevers	I-PROBLEM
,	O
chills	B-PROBLEM
,	O
naseau	B-PROBLEM
,	O
vomitting	B-PROBLEM
,	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
or	O
other	B-PROBLEM
worrisome	I-PROBLEM
symptoms	I-PROBLEM
,	O
please	O
contact	O
your	O
primary	O
care	O
physician	O
or	O
the	O
emergency	O
department	O
.	O

please	O
follow-up	O
with	O
your	O
dialysis	O
physician	O
regarding	O
replacing	O
your	B-TREATMENT
PORT	I-TREATMENT
.	O

The	O
patient	O
had	O
stage	B-PROBLEM
1	I-PROBLEM
sacral	I-PROBLEM
decubitus	I-PROBLEM
on	I-PROBLEM
her	I-PROBLEM
buttocks	I-PROBLEM
.	O

This	O
was	O
treated	O
with	O
wound	B-TREATMENT
care	I-TREATMENT
using	O
Eucerin	B-TREATMENT
cream	I-TREATMENT
and	O
also	O
patient	O
was	O
treated	O
with	O
lidocaine	B-TREATMENT
jelly	I-TREATMENT
for	O
pain	B-TREATMENT
control	I-TREATMENT
.	O

The	O
patient	O
was	O
seen	O
by	O
the	O
wound	O
care	O
nurse	O
and	O
the	B-PROBLEM
decubitus	I-PROBLEM
ulcer	I-PROBLEM
was	O
felt	O
to	O
be	O
mild	O
,	O
but	O
was	O
causing	O
the	O
patient	O
a	O
lot	O
of	O
discomfort	B-PROBLEM
and	O
the	O
wound	O
care	O
nurse	O
Ivy	O
Rose	O
lidocaine	B-TREATMENT
jelly	I-TREATMENT
.	O

With	O
regard	O
to	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
chronic	I-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
,	O
the	O
patient	O
's	O
respiratory	O
status	O
improved	O
throughout	O
the	O
remainder	O
of	O
her	O
hospital	O
course	O
.	O

The	O
patient	O
had	O
no	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
or	O
cough	B-PROBLEM
on	O
discharge	O
.	O

The	O
patient	O
was	O
oxygenating	O
well	O
on	O
her	B-TREATMENT
home	I-TREATMENT
O2	I-TREATMENT
dose	I-TREATMENT
of	O
2	O
liters	O
per	O
minute	O
.	O

The	O
patient	O
overall	O
continued	O
to	O
improve	O
,	O
but	O
remained	O
physically	B-PROBLEM
decompensated	I-PROBLEM
and	O
the	O
patient	O
was	O
transferred	O
to	O
Waltham/Weston	O
Hospital	O
Rehabilitation	O
Hospital	O
for	O
intensive	B-TREATMENT
physical	I-TREATMENT
therapy	I-TREATMENT
.	O

DISCHARGE	B-TREATMENT
MEDICATIONS	I-TREATMENT
are	O
the	O
same	O
with	O
the	O
addition	O
of	O
viscous	B-TREATMENT
lidocaine	I-TREATMENT
jelly	I-TREATMENT
to	O
be	O
applied	O
to	O
buttock	O
prn	O
and	O
viscous	B-TREATMENT
lidocaine	I-TREATMENT
swish	I-TREATMENT
and	I-TREATMENT
swallow	I-TREATMENT
tid	O
prn	O
before	O
meals	O
.	O

This	O
is	O
an	O
86-year-old	O
female	O
with	O
a	O
past	O
medical	O
history	O
of	O
diabetes	B-PROBLEM
and	O
hypertension	B-PROBLEM
who	O
presented	O
to	O
the	O
Emergency	O
Department	O
with	O
a	O
two	O
day	O
history	O
of	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
easy	B-PROBLEM
fatigability	I-PROBLEM
.	O

She	O
also	O
noted	O
increased	B-PROBLEM
dyspnea	I-PROBLEM
on	O
exertion	O
.	O

She	O
denies	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
orthopnea	B-PROBLEM
,	O
paroxysmal	B-PROBLEM
nocturnal	I-PROBLEM
dyspnea	I-PROBLEM
.	O

However	O
,	O
the	O
patient	O
has	O
noted	O
some	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
,	O
intermittent	O
times	O
a	O
couple	O
of	O
days	O
,	O
none	O
on	O
the	O
day	O
of	O
admission	O
.	O

Denied	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
diaphoresis	B-PROBLEM
,	O
bowel	B-PROBLEM
movement	I-PROBLEM
changes	I-PROBLEM
.	O

She	O
has	O
noted	O
increased	B-PROBLEM
urinary	I-PROBLEM
frequency	I-PROBLEM
.	O

Denies	O
fever	B-PROBLEM
or	O
chills	B-PROBLEM
.	O

Of	O
note	O
,	O
she	O
has	O
had	O
recent	B-TREATMENT
medication	I-TREATMENT
changes	I-TREATMENT
which	O
included	O
discontinuing	O
Diovan	B-TREATMENT
and	O
starting	O
terazosin	B-TREATMENT
.	O

1.	O
Diabetes	B-PROBLEM
mellitus	I-PROBLEM
.	O

2.	O
Hypertension	B-PROBLEM
.	O

3.	O
Osteoarthritis	B-PROBLEM
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

1.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.	O
day	O
.	O

2.	O
Norvasc	B-TREATMENT
10	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
Isosorbide	B-TREATMENT
mononitrate	I-TREATMENT
30	O
q.	O
day	O
.	O

4.	O
Terazosin	B-TREATMENT
1	O
mg	O
p.o.	O
q.	O
day	O
.	O

Positive	O
for	O
diabetes	B-PROBLEM
.	O

No	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

On	O
admission	O
,	O
blood	B-TEST
pressure	I-TEST
151/61	O
,	O
heart	B-TEST
rate	I-TEST
75	O
,	O
SaO2	B-TEST
93%	O
on	O
room	O
air	O
.	O

In	O
general	O
,	O
patient	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Jugular	B-TEST
venous	I-TEST
pressure	I-TEST
notable	O
at	O
the	O
mid	O
neck	O
upright	O
about	O
80	O
degree	O
angles	O
.	O

Cardiovascular	O
regular	O
rate	O
and	O
rhythm	O
with	O
a	B-PROBLEM
1-2/6	I-PROBLEM
holosystolic	I-PROBLEM
murmur	I-PROBLEM
.	O

Crackles	B-PROBLEM
bilaterally	I-PROBLEM
one-third	O
to	O
one-half	O
the	O
way	O
up	O
.	O

Bowel	B-TEST
sounds	I-TEST
positive	O
,	O
soft	O
,	O
non-tender	B-PROBLEM
,	O
non-distended	B-PROBLEM
.	O

1+	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
edema	I-PROBLEM
.	O

Included	O
normal	O
CBC	O
,	O
BUN	B-TEST
47	O
,	O
creatinine	B-TEST
2.4	O
up	O
from	O
baseline	O
of	O
about	O
1.5	O
.	O

Troponin	B-TEST
4.7	O
,	O
CK	B-TEST
101	O
,	O
MB	B-TEST
3	O
.	O

Chest	B-TEST
x-ray	I-TEST
showed	O
patient	O
was	O
in	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

ELECTROCARDIOGRAM	B-TEST
:	O

Showed	O
normal	O
sinus	O
rhythm	O
at	O
107	O
beats	O
per	O
minute	O
with	O
left	B-PROBLEM
axis	I-PROBLEM
deviation	I-PROBLEM
and	O
poor	B-PROBLEM
R-wave	I-PROBLEM
progression	I-PROBLEM
.	O

However	O
,	O
no	O
acute	B-PROBLEM
changes	I-PROBLEM
were	O
apparent	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
Cardiac	O
Medicine	O
Service	O
and	O
treated	O
for	O
presumed	O
diastolic	B-PROBLEM
and	I-PROBLEM
systolic	I-PROBLEM
dysfunction	I-PROBLEM
.	O

Echocardiogram	B-TEST
was	O
obtained	O
which	O
showed	O
moderately	B-PROBLEM
depressed	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
systolic	I-PROBLEM
function	I-PROBLEM
as	O
well	O
as	O
hypokinesis	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
lower	I-PROBLEM
half	I-PROBLEM
of	I-PROBLEM
septum	I-PROBLEM
and	I-PROBLEM
apex	I-PROBLEM
.	O

Also	O
of	O
note	O
was	O
the	B-PROBLEM
distal	I-PROBLEM
lateral	I-PROBLEM
wall	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

The	B-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
were	O
noted	O
to	O
be	O
new	O
.	O

It	O
was	O
believed	O
that	O
a	B-TEST
troponin	I-TEST
on	O
admission	O
in	O
addition	O
to	O
the	B-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
she	O
underwent	O
a	B-PROBLEM
non-Q	I-PROBLEM
wave	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
prior	O
to	O
resulted	O
in	O
her	B-PROBLEM
current	I-PROBLEM
cardiac	I-PROBLEM
failure	I-PROBLEM
.	O

Throughout	O
hospital	O
course	O
patient	B-TEST
's	I-TEST
troponin	I-TEST
trended	O
down	O
to	O
less	O
than	O
0.3	O
.	O

She	O
was	O
continued	O
with	O
aggressive	B-TREATMENT
diuresis	I-TREATMENT
.	O

She	O
was	O
started	O
on	O
_________	O
with	O
excellent	O
diuresis	O
,	O
however	O
,	O
her	B-PROBLEM
renal	I-PROBLEM
functioning	I-PROBLEM
worsening	I-PROBLEM
.	O

A	B-TEST
cardiac	I-TEST
catheterization	I-TEST
was	O
deferred	O
until	O
the	B-PROBLEM
renal	I-PROBLEM
issue	I-PROBLEM
could	O
be	O
resolved	O
.	O

However	O
,	O
her	B-TEST
creatinine	I-TEST
continued	O
to	O
increase	O
.	O

Diuresis	B-TREATMENT
was	O
halted	O
and	O
without	O
improvement	O
in	O
creatinine	B-TEST
.	O

A	B-TEST
renal	I-TEST
ultrasound	I-TEST
was	O
obtained	O
.	O

It	O
showed	O
a	B-TEST
right	I-TEST
kidney	I-TEST
size	I-TEST
of	O
6.3	O
cm	O
and	O
a	B-TEST
left	I-TEST
kidney	I-TEST
size	I-TEST
of	O
8.4	O
cm	O
.	O

Given	O
her	B-PROBLEM
hypertension	I-PROBLEM
which	O
was	O
very	O
difficult	O
to	O
control	O
,	O
it	O
was	O
felt	O
that	O
she	O
had	O
renal	B-PROBLEM
artery	I-PROBLEM
stenosis	I-PROBLEM
and	O
thus	O
she	O
underwent	O
MRA	B-TEST
of	I-TEST
the	I-TEST
kidney	I-TEST
which	O
showed	O
severe	B-PROBLEM
right	I-PROBLEM
renal	I-PROBLEM
artery	I-PROBLEM
stenosis	I-PROBLEM
at	I-PROBLEM
its	I-PROBLEM
origin	I-PROBLEM
.	O

There	O
was	O
also	O
moderate	B-PROBLEM
to	I-PROBLEM
severe	I-PROBLEM
focal	I-PROBLEM
stenosis	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
renal	I-PROBLEM
artery	I-PROBLEM
approximately	O
1.3	O
cm	O
from	O
its	O
origin	O
.	O

She	O
was	O
transferred	O
to	O
the	O
unit	O
overnight	O
to	O
assess	O
volume	B-TEST
which	O
was	O
noted	O
to	O
be	O
optimal	O
.	O

On	O
05-25	O
she	O
underwent	O
catheterization	B-TEST
and	O
subsequent	B-TREATMENT
stenting	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
left	I-TREATMENT
renal	I-TREATMENT
artery	I-TREATMENT
.	O

Due	O
to	O
dye	B-TREATMENT
load	I-TREATMENT
required	O
to	O
assess	O
the	B-PROBLEM
coronary	I-PROBLEM
disease	I-PROBLEM
were	O
not	O
visualized	O
.	O

After	O
the	B-TREATMENT
procedure	I-TREATMENT
the	O
patient	O
did	O
well	O
.	O

However	O
,	O
her	B-TEST
creatinine	I-TEST
has	O
worsened	B-PROBLEM
up	O
to	O
4.2	O
.	O

However	O
,	O
her	B-TEST
urine	I-TEST
output	I-TEST
has	O
improved	O
.	O

She	O
has	O
not	O
required	O
hemodialysis	B-TREATMENT
at	O
this	O
time	O
.	O

1.	O
Non-Q	B-PROBLEM
wave	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
.	O

2.	O
Systolic	B-PROBLEM
and	I-PROBLEM
diastolic	I-PROBLEM
congestive	I-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
.	O

3.	O
Bilateral	B-PROBLEM
renal	I-PROBLEM
artery	I-PROBLEM
stenosis	I-PROBLEM
status	O
post	O
stent	B-TREATMENT
left	I-TREATMENT
renal	I-TREATMENT
artery	I-TREATMENT
.	O

4.	O
Acute	B-PROBLEM
renal	I-PROBLEM
failure	I-PROBLEM
.	O

5.	O
Hypertension	B-PROBLEM
.	O

1.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.	O
day	O
.	O

2.	O
Norvasc	B-TREATMENT
10	O
mg	O
p.o.	O
q.	O
day	O
.	O

3.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
p.o.	O
q.	O
day	O
.	O

4.	O
Protonix	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
day	O
.	O

5.	O
Multivitamin	B-TREATMENT
one	O
p.o.	O
q.	O
day	O
.	O

6.	O
Carvedilol	B-TREATMENT
3.125	O
p.o.	O
b.i.d.	O

7.	O
___________	O
dinitrate	B-TREATMENT
20	O
mg	O
p.o.	O
t.i.d.	O

8.	O
Erythropoietin	B-TREATMENT
10,000	O
units	O
two	O
times	O
a	O
week	O
Tuesday	O
and	O
Saturday	O
.	O

9.	O
Calcium	B-TREATMENT
acetate	I-TREATMENT
Tums	I-TREATMENT
one	O
p.o.	O
t.i.d.	O
with	O
meals	O
.	O

10.	O
Tylenol	B-TREATMENT
325	O
mg	O
p.o.	O
q.	O
4-6	O
h.	O
p.r.n.	O

11.	O
Iron	B-TREATMENT
sulfate	I-TREATMENT
325	O
mg	O
p.o.	O
q.	O
day	O
.	O

12.	O
Colace	B-TREATMENT
100	O
mg	O
p.o.	O
b.i.d.	O

13.	O
Hydralazine	B-TREATMENT
10	O
mg	O
p.o.	O
q.	O
6h.	O

14.	O
Plavix	B-TREATMENT
75	O
mg	O
p.o.	O
q.	O
day	O
times	O
30	O
days	O
.	O

22	O
year	O
old	O
female	O
transfer	O
from	O
outside	O
hospital	O
after	O
a	O
motor	O
vehicle	O
accident	O
with	O
diagnosed	B-PROBLEM
liver	I-PROBLEM
laceration	I-PROBLEM
by	O
CT	B-TEST
scan	I-TEST
.	O

Neck	O
with	O
cervical	B-TREATMENT
collar	I-TREATMENT
.	O

Left	B-PROBLEM
forarm	I-PROBLEM
and	I-PROBLEM
right	I-PROBLEM
knee	I-PROBLEM
abrasions	I-PROBLEM
.	O

Chest	O
clear	O
to	O
auscultation	B-TEST
bilateral	O
,	O
S1	O
S2	O
normal	O
and	O
with	O
no	O
murmors	B-PROBLEM
.	O

Abdominal	B-PROBLEM
pain	I-PROBLEM
predominally	O
on	O
the	O
right	O
upper	O
quadrant	O
,	O
no	O
signs	O
of	O
peritoneal	B-PROBLEM
irritation	I-PROBLEM
.	O

GLUCOSE	B-TEST
-	O
74	O
UREA	B-TEST
N	I-TEST
-	O
9	O
CREAT	B-TEST
-	O
0.7	O
SODIUM	B-TEST
-	O
139	O
POTASSIUM	B-TEST
-	O
3.5	O
CHLORIDE	B-TEST
-	O
106	O
TOTAL	B-TEST
CO2	I-TEST
-	O
23	O
ANION	B-TEST
GAP	I-TEST
-	O
14	O

ALT(SGPT)	B-TEST
-	O
241	O
*	O
AST(SGOT)	B-TEST
-	O
207	O
*	O
ALK	B-TEST
PHOS	I-TEST
-	O
51	O
TOT	B-TEST
BILI	I-TEST
-	O
0.8	O

CALCIUM	B-TEST
-	O
8.2	O
*	O
PHOSPHATE	B-TEST
-	O
3.1	O
MAGNESIUM	B-TEST
-	O
2.2	O

GLUCOSE	B-TEST
-	O
75	O
UREA	B-TEST
N	I-TEST
-	O
10	O
CREAT	B-TEST
-	O
0.6	O
SODIUM	B-TEST
-	O
137	O
POTASSIUM	B-TEST
-	O
3.7	O
CHLORIDE	B-TEST
-	O
103	O
TOTAL	B-TEST
CO2	I-TEST
-	O
23	O
ANION	B-TEST
GAP	I-TEST
-	O
15	O

ALT(SGPT)	B-TEST
-	O
318	O
*	O
AST(SGOT)	B-TEST
-	O
307	O
*	O
ALK	B-TEST
PHOS	I-TEST
-	O
61	O
TOT	B-TEST
BILI	I-TEST
-	O
0.9	O

WBC	B-TEST
-	O
8.3	O
RBC	B-TEST
-	O
3.64	O
*	O
HGB	B-TEST
-	O
12.6	O
HCT	B-TEST
-	O
36.1	O
MCV	B-TEST
-	O
99	O
*	O
MCH	B-TEST
-	O
34.7	O
*	O
MCHC	B-TEST
-	O
35.0	O
RDW	B-TEST
-	O
12.4	O

PT	B-TEST
-	O
11.6	O
PTT	B-TEST
-	O
26.0	O
INR(PT)	B-TEST
-	O
0.9	O

Patient	O
was	O
admited	O
,	O
pain	B-PROBLEM
was	O
managed	O
with	O
a	B-TREATMENT
PCA	I-TREATMENT
and	O
later	O
with	O
PO	B-TREATMENT
medication	I-TREATMENT
.	O

The	B-PROBLEM
liver	I-PROBLEM
laceration	I-PROBLEM
was	O
stable	O
,	O
no	O
sign	O
of	O
rupture	B-PROBLEM
or	O
further	B-PROBLEM
complication	I-PROBLEM
,	O
did	O
not	O
required	O
surgical	B-TREATMENT
managment	I-TREATMENT
.	O

The	B-TEST
liver	I-TEST
enzimes	I-TEST
come	O
down	O
,	O
no	O
signs	O
of	O
biliary	B-PROBLEM
stasis	I-PROBLEM
.	O

1.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
4	O
days	O
.	O

2.	O
Hydromorphone	B-TREATMENT
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q2H	O
(	O
every	O
2	O
hours	O
)	O
as	O
needed	O
for	O
Pain	B-PROBLEM
for	O
4	O
days	O
.	O

-	O
Follow	O
up	O
with	O
Trauma	O
Surgery	O
Clinic	O
with	O
the	O
Result	O
from	O
the	B-TEST
CT	I-TEST
scan	I-TEST
abdomen	I-TEST

-	O
Call	O
for	O
appointment	O
to	O
(	O
289	O
)	O
411-5387	O
for	O
the	O
Trauma	O
Clinic	O
and	O
Abdominal	B-TEST
CT	I-TEST
scan	I-TEST
of	I-TEST
the	I-TEST
Abdomen	I-TEST
in	O
4	O
weeks	O

-	O
If	O
any	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
,	O
fever	B-PROBLEM
or	O
dizziness	B-PROBLEM
,	O
go	O
to	O
the	O
Emergency	O
Room	O

-	O
Analgesic	B-TREATMENT
(	I-TREATMENT
Percocet	I-TREATMENT
)	I-TREATMENT
as	O
needed	O

-	O
Trauma	O
Surgery	O
Clinic	O
in	O
four	O
weeks	O
with	O
CT	B-TEST
abdomen	I-TEST
results	O
.	O

Call	O
Trauma	O
Clinic	O
to	O
coordinate	O
the	B-TEST
study	I-TEST
,	O
result	O
and	O
appointment	O
dates	O
((	O
289	O
)	O
411-5387	O
).	O

He	O
is	O
a	O
39	O
year-old	O
gentleman	O
with	O
hyperlipidemia	B-PROBLEM
and	O
smoking	O
who	O
presented	O
with	O
acute	O
onset	O
of	O
chest	B-PROBLEM
pain	I-PROBLEM
since	O
five	O
in	O
the	O
morning	O
with	O
radiation	O
to	O
the	O
left	O
arm	O
and	O
nausea	B-PROBLEM
.	O

Symptoms	B-PROBLEM
resolved	O
spontaneously	O
.	O

Cath	O
Lab	O
at	O
the	O
Pinewood	O
,	O
Norfolk	O
that	O
evening	O
where	O
a	B-TREATMENT
stent	I-TREATMENT
procedure	I-TREATMENT
to	I-TREATMENT
the	I-TREATMENT
RCA	I-TREATMENT
was	O
complicated	O
by	O
guidewire	O
entrapment	O
inside	O
of	O
a	B-TREATMENT
stent	I-TREATMENT
requiring	O
CT	B-TREATMENT
surgery	I-TREATMENT
to	O
do	O
a	B-TREATMENT
thoracotomy	I-TREATMENT
with	O
bypass	B-TREATMENT
and	O
excision	B-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
wire	I-TREATMENT
.	O

The	O
case	O
was	O
complicated	O
by	O
an	O
episode	O
of	O
coffee	B-PROBLEM
ground	I-PROBLEM
emesis	I-PROBLEM
and	O
a	B-PROBLEM
bleed	I-PROBLEM
from	I-PROBLEM
femoral	I-PROBLEM
access	I-PROBLEM
site	I-PROBLEM
prior	O
to	O
CT	B-TREATMENT
surgery	I-TREATMENT
.	O

Gastroenterology	O
was	O
consulted	O
and	O
they	O
recommended	O
Protonix	B-TREATMENT
and	O
felt	O
it	O
was	O
due	O
to	O
peptic	B-PROBLEM
ulcer	I-PROBLEM
disease	I-PROBLEM
.	O

1.	O
Hepatitis	B-PROBLEM
B	I-PROBLEM
.	O

2.	O
Hypercholesterolemia	B-PROBLEM
.	O

3.	O
Fatty	B-PROBLEM
liver	I-PROBLEM
resolved	O
.	O

Relatively	O
unknown	O
other	O
than	O
Lipitor	B-TREATMENT
.	O

ALLERGIES	O
:	O
He	O
had	O
no	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

FAMILY	O
HISTORY	O
:	O
Not	O
significant	O
for	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

The	O
patient	O
was	O
diagnosed	O
as	O
having	O
an	B-PROBLEM
acute	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
.	O

The	O
patient	O
was	O
taken	O
emergently	O
to	O
the	O
operating	O
room	O
on	O
2009-05-02	O
for	O
his	B-TREATMENT
CABG	I-TREATMENT
,	O
right	B-TREATMENT
coronary	I-TREATMENT
endarterectomy	I-TREATMENT
,	O
removal	B-TREATMENT
of	I-TREATMENT
RCA	I-TREATMENT
stents	I-TREATMENT
and	O
retrieval	B-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
aortic	I-TREATMENT
guidewire	I-TREATMENT
.	O

Postoperatively	O
he	O
did	O
well	O
and	O
was	O
transferred	O
to	O
the	O
Cardiac	O
Surgery	O
Intensive	O
Care	O
Unit	O
where	O
he	O
was	O
on	O
pressor	B-TREATMENT
support	I-TREATMENT
of	O
Neo-Synephrine	B-TREATMENT
and	O
he	O
was	O
extubated	O
.	O

The	O
patient	O
slowly	O
weaned	O
off	O
Neo-Synephrine	B-TREATMENT
as	O
tolerated	O
.	O

His	B-TREATMENT
chest	I-TREATMENT
tube	I-TREATMENT
had	O
been	O
discontinued	O
.	O

Upon	O
arrival	O
to	O
the	O
floor	O
the	B-TREATMENT
patient	I-TREATMENT
's	I-TREATMENT
wires	I-TREATMENT
were	O
discontinued	O
on	O
2009-05-05	O
and	O
his	B-TREATMENT
Foley	I-TREATMENT
catheter	I-TREATMENT
was	O
discontinued	O
.	O

His	B-TEST
electrolytes	I-TEST
were	O
repleted	O
and	O
the	O
patient	O
was	O
discharged	O
home	O
on	O
2009-05-06	O
after	O
tolerating	O
a	O
level	O
V	O
.	O

MEDICATIONS	O
:	O
His	B-TREATMENT
prescriptions	I-TREATMENT
shall	O
include	O

1.	O
Lopressor	B-TREATMENT
25	O
milligrams	O
po	O
bid	O
.	O

2.	O
Lipitor	B-TREATMENT
20	O
milligrams	O
po	O
q	O
HS	O
.	O

3.	O
Niferex	B-TREATMENT
150	O
milligrams	O
caplet	O
one	O
cap	O
per	O
day	O
.	O

4.	O
Protonix	B-TREATMENT
40	O
milligrams	O
po	O
q	O
day	O
.	O

5.	O
Colace	B-TREATMENT
100	O
milligrams	O
po	O
bid	O
.	O

6.	O
Percocet	B-TREATMENT
one	O
to	O
two	O
tablets	O
q	O
four	O
H	O
prn	O
for	O
pain	B-PROBLEM
.	O

7.	O
Plavix	B-TREATMENT
75	O
milligrams	O
po	O
q	O
day	O
times	O
three	O
months	O
.	O

8.	O
Aspirin	B-TREATMENT
325	O
milligrams	O
po	O
q	O
day	O
.	O

9.	O
Lasix	B-TREATMENT
20	O
milligrams	O
po	O
times	O
30	O
days	O
.	O

10.	O
KCL	B-TREATMENT
20	O
milliequivalents	O
po	O
q	O
d	O
times	O
three	O
days	O
.	O

Prostate	B-PROBLEM
cancer	I-PROBLEM
.	O

Status	O
post	O
radical	B-TREATMENT
retropubic	I-TREATMENT
prostatectomy	I-TREATMENT
.	O

The	O
patient	O
is	O
a	O
64	O
year	O
old	O
gentleman	O
with	O
a	O
history	O
of	O
elevated	B-PROBLEM
PSA	I-PROBLEM
,	O
prostate	B-PROBLEM
cancer	I-PROBLEM
.	O

He	O
was	O
diagnosed	O
with	O
needle	B-TEST
biopsy	I-TEST
on	O
either	O
side	O
of	O
the	O
prostate	O
with	O
3+3	O
equals	O
6	O
on	O
the	O
right	O
side	O
and	O
3+4	O
equals	O
7	O
on	O
the	O
left	O
side	O
.	O

The	O
patient	O
underwent	O
radical	B-TREATMENT
retropubic	I-TREATMENT
prostatectomy	I-TREATMENT
on	O
2012-01-20	O
.	O

Dr.	O
Marie	O
Anderson	O
performed	O
the	B-TREATMENT
surgery	I-TREATMENT
.	O

The	O
patient	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
well	O
.	O

On	O
postoperative	O
day	O
number	O
one	O
,	O
he	O
was	O
administered	O
1	B-TREATMENT
mg	I-TREATMENT
Coumadin	I-TREATMENT
per	O
protocol	O
as	O
well	O
as	O
on	O
the	O
operative	O
day	O
1	O
mg	O
of	O
Coumadin	B-TREATMENT
.	O

His	B-TEST
laboratories	I-TEST
were	O
checked	O
and	O
his	B-TEST
hematocrit	I-TEST
was	O
noted	O
to	O
be	O
stable	O
.	O

His	B-PROBLEM
pain	I-PROBLEM
was	O
well	O
controlled	O
with	O
oral	B-TREATMENT
medication	I-TREATMENT
at	O
this	O
time	O
.	O

His	B-TREATMENT
intravenous	I-TREATMENT
fluids	I-TREATMENT
were	O
discontinued	O
at	O
this	O
time	O
.	O

His	B-TREATMENT
Penrose	I-TREATMENT
drain	I-TREATMENT
was	O
discontinued	O
at	O
this	O
time	O
.	O

He	O
was	O
discharged	O
home	O
with	O
a	B-TREATMENT
Foley	I-TREATMENT
catheter	I-TREATMENT
and	O
he	O
will	O
follow-up	O
with	O
Dr.	O
Ross	O
in	O
one	O
to	O
two	O
weeks	O
.	O

Iodine	B-TREATMENT
;	O
Iodine	B-TREATMENT
Containing	I-TREATMENT

Tracheostomy	B-TREATMENT
2014-11-11	O

Bronchoscopy	B-TEST
2014-11-05	O

Atrial	B-PROBLEM
fibrillation	I-PROBLEM
(	O
on	O
Coumadin	B-TREATMENT
)	O

Coronary	B-PROBLEM
Artery	I-PROBLEM
Disease	I-PROBLEM

Ulcerative	B-PROBLEM
Colitis	I-PROBLEM
w/	O
colostomy	B-TREATMENT

Hypertension	B-PROBLEM

Pacemaker	B-TREATMENT

CVA	B-PROBLEM
2012	O
w/	O
right	B-PROBLEM
sided	I-PROBLEM
weakness	I-PROBLEM

Cataracts	B-PROBLEM
,	O
s/p	O
cataract	B-TREATMENT
surgery	I-TREATMENT

s/p	O
TURP	B-TREATMENT

GLUCOSE	B-TEST
-	O
126	O
*	O
UREA	B-TEST
N	I-TEST
-	O
9	O
CREAT	B-TEST
-	O
0.8	O
SODIUM	B-TEST
-	O
135	O
POTASSIUM	B-TEST
-	O
3.4	O
CHLORIDE	B-TEST
-	O
99	O
TOTAL	B-TEST
CO2	I-TEST
-	O
25	O
ANION	B-TEST
GAP	I-TEST
-	O
14	O

CALCIUM	B-TEST
-	O
8.2	O
*	O
PHOSPHATE	B-TEST
-	O
2.1	O
*	O
MAGNESIUM	B-TEST
-	O
1.9	O

WBC	B-TEST
-	O
6.5	O
RBC	B-TEST
-	O
3.68	O
*	O
HGB	B-TEST
-	O
11.6	O
*	O
HCT	B-TEST
-	O
32.5	O
*	O
MCV	B-TEST
-	O
88	O
MCH	B-TEST
-	O
31.5	O
MCHC	B-TEST
-	O
35.6	O
*	O
RDW	B-TEST
-	O
13.6	O

PLT	B-TEST
COUNT	I-TEST
-	O
207	O

PT	B-TEST
-	O
15.0	O
*	O
PTT	B-TEST
-	O
31.3	O
INR(PT)	B-TEST
-	O
1.5	O

TYPE	O
-	O
ART	O
TEMP	B-TEST
-	O
36.6	O
RATES	B-TEST
-	O
14	O
/	O
TIDAL	B-TEST
VOL	I-TEST
-	O
550	O
PEEP	B-TREATMENT
-	O
5	O
O2	B-TREATMENT
-	O
100	O
PO2	B-TEST
-	O
416	O
*	O
PCO2	B-TEST
-	O
39	O
PH	B-TEST
-	O
7.41	O
TOTAL	B-TEST
CO2	I-TEST
-	O
26	O
BASE	B-TEST
XS	I-TEST
-	O
0	O
AADO2	B-TEST
-	O
279	O
REQ	B-TEST
O2	I-TEST
-	O
52	O
-	O
ASSIST	O
/	O
CON	O
INTUBATED	O
-	O
INTUBATED	O

ASA	B-TEST
-	O
NEG	O
ETHANOL	B-TEST
-	O
NEG	O
ACETMNPHN	B-TEST
-	O
NEG	O
bnzodzpn	B-TEST
-	O
NEG	O
barbitrt	B-TEST
-	O
NEG	O
tricyclic	B-TEST
-	O
NEG	O

2014-10-21	O
09:35	O
AM	O
URINE	B-TEST

bnzodzpn	B-TEST
-	O
NEG	O
barbitrt	B-TEST
-	O
NEG	O
opiates	B-TEST
-	O
NEG	O
cocaine	B-TEST
-	O
NEG	O
amphetmn	B-TEST
-	O
NEG	O
mthdone	B-TEST
-	O
NEG	O

CT	B-TEST
C	I-TEST
-	I-TEST
SPINE	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

CT	B-TEST
C	I-TEST
-	I-TEST
SPINE	I-TEST
W/O	I-TEST
CONTRAST	I-TEST
;	O
CT	O
RECONSTRUCTION	O

TECHNIQUE	O
:	O
Noncontrast	B-TEST
cervical	I-TEST
spine	I-TEST
CT	I-TEST
.	O

NOTE	O
:	O
This	B-TEST
study	I-TEST
was	O
initially	O
performed	O
on	O
2014-10-21	O
.	O

Findings	O
were	O
discussed	O
with	O
Dr.	O
Leanne	O
Vazquez	O
at	O
the	O
time	O
this	B-TEST
study	I-TEST
was	O
performed	O
,	O
but	O
the	B-TEST
study	I-TEST
was	O
not	O
dictated	O
until	O
the	O
morning	O
of	O
2014-10-22	O
,	O
due	O
to	O
PACS	O
malfunction	O
.	O

NONCONTRAST	B-TEST
CERVICAL	I-TEST
SPINE	I-TEST
CT	I-TEST
:	O
There	O
are	O
minimally	B-PROBLEM
displaced	I-PROBLEM
and	I-PROBLEM
comminuted	I-PROBLEM
fractures	I-PROBLEM
through	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
C7	I-PROBLEM
and	I-PROBLEM
T1	I-PROBLEM
transverse	I-PROBLEM
processes	I-PROBLEM
.	O

Positioning	O
limits	O
assessment	B-TEST
of	I-TEST
alignment	I-TEST
due	O
to	O
extreme	B-PROBLEM
head	I-PROBLEM
tilting	I-PROBLEM
to	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
,	O
but	O
this	O
is	O
likely	O
the	O
best	O
obtainable	O
secondary	O
to	O
intubation	B-TREATMENT
and	O
nasogastric	B-TREATMENT
tube	I-TREATMENT
placement	I-TREATMENT
.	O

There	O
is	O
no	O
atlantoaxial	B-PROBLEM
subluxation	I-PROBLEM
.	O

Prevertebral	B-PROBLEM
soft	I-PROBLEM
tissue	I-PROBLEM
swelling	I-PROBLEM
cannot	O
be	O
excluded	O
secondary	O
to	O
intubation	B-TREATMENT
.	O

Extensive	B-PROBLEM
carotid	I-PROBLEM
arterial	I-PROBLEM
calcifications	I-PROBLEM
are	O
present	O
in	O
the	O
bulb	O
regions	O
bilaterally	O
.	O

Biapical	B-PROBLEM
lung	I-PROBLEM
scarring	I-PROBLEM
and	O
mild	B-PROBLEM
bronchiectasis	I-PROBLEM
are	O
present	O
.	O

Also	O
noted	O
is	O
sclerosis	B-PROBLEM
and	O
opacification	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
visualized	I-PROBLEM
left	I-PROBLEM
mastoid	I-PROBLEM
air	I-PROBLEM
cells	I-PROBLEM
and	I-PROBLEM
mastoid	I-PROBLEM
tip	I-PROBLEM
,	O
likely	O
chronic	O
inflammatory	O

disease	B-PROBLEM
.	O

IMPRESSION	O
:	O
Minimally	B-PROBLEM
displaced	I-PROBLEM
,	I-PROBLEM
comminuted	I-PROBLEM
fractures	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
C7	I-PROBLEM
and	I-PROBLEM
T1	I-PROBLEM
transverse	I-PROBLEM
processes	I-PROBLEM
.	O

No	O
evidence	O
of	O
extension	B-PROBLEM
into	I-PROBLEM
the	I-PROBLEM
foramina	I-PROBLEM
transversaria	I-PROBLEM
.	O

CT	B-TEST
HEAD	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

CT	B-TEST
HEAD	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

Reason	O
:	O
bleed	B-PROBLEM
?	O

72	O
year	O
old	O
man	O
with	O
intraparenchymal	B-PROBLEM
bleed	I-PROBLEM
s/p	O
fall	O

bleed	B-PROBLEM
?	O

INDICATION	O
:	O
Intraparenchymal	B-PROBLEM
hemorrhage	I-PROBLEM
after	O
fall	O
.	O

Assess	O
for	O
hemorrhage	B-PROBLEM
.	O

TECHNIQUE	O
:	O
Non-contrast	B-TEST
head	I-TEST
CT	I-TEST
.	O

COMPARISON	O
:	O
No	O
prior	B-TEST
studies	I-TEST
are	O
available	O
.	O

By	O
report	O
,	O
the	O
patient	O
has	O
an	B-TEST
outside	I-TEST
study	I-TEST
.	O

Should	O
this	O
become	O
available	O
,	O
an	O
addendum	O
will	O
be	O
issued	O
to	O
this	O
report	O
following	O
the	O
comparison	O
with	O
the	B-TEST
outside	I-TEST
examination	I-TEST
.	O

NOTE	O
:	O
This	B-TEST
study	I-TEST
was	O
initially	O
performed	O
on	O
the	O
morning	O
of	O
10-21	O
,	O
and	O
is	O
being	O
dictated	O
on	O
the	O
morning	O
of	O
10-22	O
due	O
to	O
PACS	O
malfunction	O
.	O

NON-CONTRAST	B-TEST
HEAD	I-TEST
CT	I-TEST
:	O
There	O
is	O
a	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
hemorrhage	I-PROBLEM
within	O
the	O
occipital	O
horns	O
of	O
both	O
lateral	O
ventricles	O
,	O
right	O
greater	O
than	O
left	O
.	O

Located	O
within	O
the	O
atrium	O
of	O
the	O
right	O
lateral	O
ventricle	O
is	O
an	B-PROBLEM
18	I-PROBLEM
x	I-PROBLEM
10	I-PROBLEM
mm	I-PROBLEM
nodular	I-PROBLEM
area	I-PROBLEM
of	I-PROBLEM
increased	I-PROBLEM
density	I-PROBLEM
which	O
is	O
separate	O
from	O
the	O
choroid	O
plexus	O
.	O

There	O
is	O
no	O
evidence	O
of	O
surrounding	B-PROBLEM
edema	I-PROBLEM
.	O

There	O
is	O
diffuse	B-PROBLEM
brain	I-PROBLEM
atrophy	I-PROBLEM
and	O
chronic	B-PROBLEM
microvascular	I-PROBLEM
infarction	I-PROBLEM
throughout	I-PROBLEM
the	I-PROBLEM
white	I-PROBLEM
matter	I-PROBLEM
.	O

There	O
is	O
a	B-PROBLEM
remote	I-PROBLEM
right	I-PROBLEM
frontal	I-PROBLEM
infarct	I-PROBLEM
.	O

There	O
is	O
no	O
evidence	O
of	O
subarachnoid	B-PROBLEM
hemorrhage	I-PROBLEM
or	O
acute	B-PROBLEM
major	I-PROBLEM
vascular	I-PROBLEM
territorial	I-PROBLEM
infarction	I-PROBLEM
.	O

The	O
ventricles	O
do	O
not	O
appear	O
dilated	O
relative	O
to	O
the	O
sulci	O
,	O
and	O
there	O
is	O
no	O
shift	B-PROBLEM
of	I-PROBLEM
normally	I-PROBLEM
midline	I-PROBLEM
structures	I-PROBLEM
.	O

There	O
is	O
no	O
skull	B-PROBLEM
fracture	I-PROBLEM
.	O

There	O
is	O
opacification	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
posterior	I-PROBLEM
nasal	I-PROBLEM
cavity	I-PROBLEM
and	I-PROBLEM
nasopharynx	I-PROBLEM
but	O
an	B-TREATMENT
NG	I-TREATMENT
tube	I-TREATMENT
is	O
present	O
,	O
and	O
the	O
patient	O
is	O
intubated	O
.	O

Opacified	B-PROBLEM
and	I-PROBLEM
sclerotic	I-PROBLEM
left	I-PROBLEM
mastoid	I-PROBLEM
air	I-PROBLEM
cells	I-PROBLEM
are	O
noted	O
.	O

1.	O
Small	O
amount	O
of	O
intraventricular	B-PROBLEM
hemorrhage	I-PROBLEM
.	O

2.	O
Ovoid	B-PROBLEM
18	I-PROBLEM
-	I-PROBLEM
mm	I-PROBLEM
density	I-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
atrium	I-PROBLEM
of	O
the	O
right	O
lateral	O
ventricle	O
.	O

This	O
could	O
represent	O
either	O
an	B-PROBLEM
atypically	I-PROBLEM
located	I-PROBLEM
blood	I-PROBLEM
clot	I-PROBLEM
or	O
an	B-PROBLEM
intraventricular	I-PROBLEM
mass	I-PROBLEM
,	O
and	O
further	O
evaluation	O
with	O
contrast	B-TEST
-	I-TEST
enhanced	I-TEST
MRI	I-TEST
of	I-TEST
the	I-TEST
brain	I-TEST
,	O
when	O
clinically	O
feasible	O
,	O
is	O
recommended	O
.	O

CT	B-TEST
HEAD	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

CT	B-TEST
HEAD	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

Reason	O
:	O
altered	B-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM

altered	B-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM

INDICATION	O
:	O
72-year-old	O
male	O
with	O
altered	B-PROBLEM
mental	I-PROBLEM
status	I-PROBLEM
.	O

TECHNIQUE	O
:	O
Axial	B-TEST
noncontrast	I-TEST
CT	I-TEST
scans	I-TEST
of	I-TEST
the	I-TEST
brain	I-TEST
were	O
obtained	O
.	O

Comparison	O
is	O
made	O
to	O
a	B-TEST
previous	I-TEST
study	I-TEST
from	O
2014-10-27	O
.	O

There	O
are	O
numerous	O
areas	O
of	O
decreased	B-PROBLEM
attenuation	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
periventricular	I-PROBLEM
and	I-PROBLEM
subcortical	I-PROBLEM
white	I-PROBLEM
matter	I-PROBLEM
of	O
both	O
cerebral	O
hemispheres	O
,	O
indicating	O
chronic	B-PROBLEM
microvascular	I-PROBLEM
infarction	I-PROBLEM
.	O

There	O
is	O
also	O
an	B-PROBLEM
old	I-PROBLEM
right	I-PROBLEM
frontal	I-PROBLEM
lobe	I-PROBLEM
cortical	I-PROBLEM
infarction	I-PROBLEM
.	O

A	B-PROBLEM
small	I-PROBLEM
right	I-PROBLEM
occipital	I-PROBLEM
lobe	I-PROBLEM
chronic	I-PROBLEM
infarction	I-PROBLEM
is	O
also	O
evident	O
.	O

There	O
is	O
a	B-PROBLEM
small	I-PROBLEM
amount	I-PROBLEM
of	I-PROBLEM
blood	I-PROBLEM
layering	I-PROBLEM
in	I-PROBLEM
both	I-PROBLEM
lateral	I-PROBLEM
ventricles	I-PROBLEM
,	O
and	O
this	O
has	O
decreased	O
since	O
the	B-TEST
previous	I-TEST
study	I-TEST
.	O

No	O
new	B-PROBLEM
hemorrhage	I-PROBLEM
is	O
observed	O
.	O

There	O
is	O
opacification	B-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
mastoid	I-PROBLEM
air	I-PROBLEM
cells	I-PROBLEM
,	O
greater	O
on	O
the	O
left	O
than	O
the	O
right	O
.	O

There	O
is	O
some	B-PROBLEM
fluid	I-PROBLEM
or	O
mucosal	B-PROBLEM
thickening	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
ethmoid	I-PROBLEM
and	I-PROBLEM
sphenoid	I-PROBLEM
sinuses	I-PROBLEM
.	O

IMPRESSION	O
:	O
No	O
new	B-PROBLEM
cortical	I-PROBLEM
territorial	I-PROBLEM
infarction	I-PROBLEM
or	O
hemorrhage	B-PROBLEM
is	O
identified	O
.	O

There	O
is	O
decreased	B-PROBLEM
intraventricular	I-PROBLEM
blood	I-PROBLEM
,	O
compared	O
to	O
the	B-TEST
previous	I-TEST
study	I-TEST
,	O
and	O
there	O
are	O
no	O
signs	O
of	O
hydrocephalus	B-PROBLEM
.	O

CHEST	B-TEST
(	I-TEST
PORTABLE	I-TEST
AP	I-TEST
)	I-TEST

CHEST	B-TEST
(	I-TEST
PORTABLE	I-TEST
AP	I-TEST
)	I-TEST

Reason	O
:	O
Fever	B-PROBLEM
,	O
f/u	O
infiltrte	B-PROBLEM

72	O
yo	O
M	O
with	O
rib	B-PROBLEM
fx	I-PROBLEM
s/p	O
trauma	B-PROBLEM
,	O
failure	O
on	O
previous	B-TEST
CXR	I-TEST
,	O
now	O
with	O
fever	B-PROBLEM
.	O

Fever	B-PROBLEM
,	O
f/u	O
infiltrte	B-PROBLEM

HISTORY	O
:	O
Trauma	B-PROBLEM
,	O
congestive	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
,	O
fever	B-PROBLEM
,	O
pneumonia	B-PROBLEM
.	O

Portable	B-TEST
supine	I-TEST
chest	I-TEST
radiograph	I-TEST
shows	O
improvement	O
in	O
edema	B-PROBLEM
compared	O
to	O
studies	B-TEST
from	O
four	O
and	O
five	O
days	O
earlier	O
with	O
no	O
significant	B-PROBLEM
radiographic	I-PROBLEM
change	I-PROBLEM
in	O
right	B-PROBLEM
upper	I-PROBLEM
lobe	I-PROBLEM
consolidation	I-PROBLEM
consistent	O
with	O
pneumonia	B-PROBLEM
.	O

Some	B-PROBLEM
interstitial	I-PROBLEM
edema	I-PROBLEM
still	O
persists	O
,	O
but	O
there	O
is	O
no	O
central	B-PROBLEM
pulmonary	I-PROBLEM
vascular	I-PROBLEM
congestion	I-PROBLEM
.	O

Cardiac	B-TEST
size	I-TEST
is	O
unchanged	O
.	O

The	O
amount	O
of	O
fluid	B-PROBLEM
layering	I-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
apices	I-PROBLEM
and	I-PROBLEM
the	I-PROBLEM
pleural	I-PROBLEM
spaces	I-PROBLEM
appear	O
slightly	O
decreased	O
.	O

Multiple	B-PROBLEM
left-sided	I-PROBLEM
rib	I-PROBLEM
fractures	I-PROBLEM
are	O
seen	O
.	O

Supporting	B-TREATMENT
tubes	I-TREATMENT
and	I-TREATMENT
lines	I-TREATMENT
are	O
in	O
unchanged	O
position	O
and	O
the	O
patient	O
has	O
a	B-TREATMENT
single	I-TREATMENT
lead	I-TREATMENT
pacemaker	I-TREATMENT
projected	O
on	O
the	O
left	O
.	O

Calcification	B-PROBLEM
is	O
seen	O
at	O
both	O
carotid	O
bifurcations	O
.	O

CONCLUSION	O
:	O
Improvement	O
in	O
congestion	B-PROBLEM
from	O
edema	B-PROBLEM
with	O
no	O
worsening	O
,	O
but	O
no	O
significant	O
improvement	O
,	O
in	O
the	B-PROBLEM
right	I-PROBLEM
upper	I-PROBLEM
lobe	I-PROBLEM
pneumonia	I-PROBLEM
.	O

Supporting	B-TREATMENT
lines	I-TREATMENT
and	I-TREATMENT
tubes	I-TREATMENT
in	O
unchanged	O
position	O
.	O

Admitted	O
to	O
TSICU	O
for	O
subarachnoid	B-PROBLEM
hemorrhage	I-PROBLEM
and	O
multiple	B-PROBLEM
spinal	I-PROBLEM
fractures	I-PROBLEM
.	O

Intubated	B-TREATMENT
and	O
sedated	B-TREATMENT
for	O
desats	B-PROBLEM
on	O
2014-10-27	O
.	O

CT	B-TEST
head	I-TEST
remained	O
stable	O
for	O
SAH	B-PROBLEM
.	O

Evaluated	O
by	O
orthopedic	O
spine	O
surgeons	O
with	O
recommendations	O
for	O
soft	B-TREATMENT
c-collar	I-TREATMENT
for	O
comfort	O
.	O

In	O
TSICU	O
,	O
developed	O
MRSA	B-PROBLEM
pneumonia	I-PROBLEM
with	O
question	O
of	O
aspiration	B-PROBLEM
,	O
treated	O
Zosyn	B-TREATMENT
-->	O
vanc	B-TREATMENT
/	O
levo	B-TREATMENT
-->	O
then	O
2	O
week	O
course	O
of	O
Linazolid	B-TREATMENT
with	O
resolution	O
of	O
fevers	B-PROBLEM
and	O
decreased	B-PROBLEM
pulmonary	I-PROBLEM
secretions	I-PROBLEM
.	O

2014-11-11	O
:	O
Tracheostomy	B-TREATMENT
performed	O
without	O
complication	B-PROBLEM
.	O

Patient	O
tolerated	O
decreasing	B-TREATMENT
ventillary	I-TREATMENT
support.	I-TREATMENT

Mental	O
status	O
improved	O
with	O
the	O
discontinuation	O
of	O
his	B-TREATMENT
bensodiazapines	I-TREATMENT
.	O

Failed	B-PROBLEM
swallow	I-PROBLEM
study	I-PROBLEM
x	O
2	O
in	O
early	O
November	O
.	O

Decision	O
to	O
continue	O
Dobhoff	B-TREATMENT
at	O
rehab	O
given	O
continued	O
clinical	O
improvement	O
and	O
his	O
poor	O
candidacy	O
for	O
G/J	B-TREATMENT
tube	I-TREATMENT
.	O

Communicating	O
by	O
speech	O
s/p	O
PMV	B-TREATMENT
placement	I-TREATMENT
.	O

Occasionally	O
required	O
Haldol	B-TREATMENT
/	O
ativan	B-TREATMENT
at	O
night	O
for	O
agitation	B-PROBLEM
.	O

Progressed	O
adequately	O
with	O
physical	B-TREATMENT
/	I-TREATMENT
occupational	I-TREATMENT
therapy	I-TREATMENT
,	O
however	O
was	O
noted	O
to	O
develop	O
an	B-PROBLEM
early	I-PROBLEM
bilateral	I-PROBLEM
upper	I-PROBLEM
extermity	I-PROBLEM
contracture	I-PROBLEM
at	I-PROBLEM
the	I-PROBLEM
elbows	I-PROBLEM
and	I-PROBLEM
wrists	I-PROBLEM
.	O

Serial	B-TEST
CT	I-TEST
head	I-TEST
revealed	O
decreased	B-PROBLEM
blood	I-PROBLEM
through	O
2014-11-14	O
.	O

1.	O
Heparin	B-TREATMENT
(	I-TREATMENT
Porcine	I-TREATMENT
)	I-TREATMENT
5,000	O
unit/mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

2.	O
Lisinopril	B-TREATMENT
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

3.	O
Lansoprazole	B-TREATMENT
30	O
mg	O
Susp	O
,	O
Delayed	O
Release	O
for	O
Recon	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

4.	O
Linezolid	B-TREATMENT
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
):	O
Last	O
dose	O
2014-11-20	O
.	O

5.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
).	O

6.	O
Digoxin	B-TREATMENT
125	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

7.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
150	O
mg	O
/	O
15	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

8.	O
Bisacodyl	B-TREATMENT
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

9.	O
Magnesium	B-TREATMENT
Hydroxide	I-TREATMENT
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
consitpation	B-PROBLEM
.	O

Subarachnoid	B-PROBLEM
hemorrhage	I-PROBLEM
w/	O
bilateral	B-PROBLEM
intraventricular	I-PROBLEM
hemorrhage	I-PROBLEM

Left	B-PROBLEM
T1	I-PROBLEM
transverse	I-PROBLEM
process	I-PROBLEM
fracture	I-PROBLEM

C7	B-PROBLEM
&	I-PROBLEM
T1	I-PROBLEM
mimimally	I-PROBLEM
displaced	I-PROBLEM
transverse	I-PROBLEM
process	I-PROBLEM
fracture	I-PROBLEM

Left	B-PROBLEM
rib	I-PROBLEM
fractures	I-PROBLEM
05-22	O

You	O
must	O
continue	O
to	O
wear	O
your	B-TREATMENT
cervical	I-TREATMENT
collar	I-TREATMENT
for	O
the	O
next	O
4	O
weeks	O
(	O
through	O
12-11	O
).	O

SURGERY	B-TREATMENT

Sulfa	B-TREATMENT
(	I-TREATMENT
Sulfonamides	I-TREATMENT
)	I-TREATMENT
/	O
Penicillins	B-TREATMENT

2015-10-27	O
Open	B-TREATMENT
reduction	I-TREATMENT
and	O
internal	B-TREATMENT
fixation	I-TREATMENT
of	O
right	B-PROBLEM
tib/fib	I-PROBLEM
fractures	I-PROBLEM

17	O
yo	O
male	O
pedestrian	O
who	O
was	O
struck	O
by	O
auto	O
at	O
unknown	O
speed	O
;	O
+LOC	B-PROBLEM
.	O

He	O
was	O
medflighted	O
to	O
The	O
Hospital	O
for	O
Orthopedics	O
for	O
ongoing	B-TREATMENT
trauma	I-TREATMENT
care	I-TREATMENT
.	O

Upon	O
arrival	O
GCS	B-TEST
15	O
,	O
alert	O
and	O
oriented	O
x3	O
.	O

Attention	B-PROBLEM
deficit	I-PROBLEM
disorder	I-PROBLEM
(	O
diagnosed	O
@	O
14	O
yrs	O
of	O
age	O
)	O

GLUCOSE	B-TEST
-	O
101	O
LACTATE	B-TEST
-	O
2.9	O
*	O
NA+	B-TEST
-	O
142	O
K+	B-TEST
-	O
3.6	O
CL-	B-TEST
-	O
102	O
TCO2	B-TEST
-	O
26	O

UREA	B-TEST
N	I-TEST
-	O
12	O
CREAT	B-TEST
-	O
1.0	O

AMYLASE	B-TEST
-	O
44	O

ASA	B-TEST
-	O
NEG	O
ETHANOL	B-TEST
-	O
NEG	O
ACETMNPHN	B-TEST
-	O
NEG	O
bnzodzpn	B-TEST
-	O
NEG	O
barbitrt	B-TEST
-	O
NEG	O
tricyclic	B-TEST
-	O
NEG	O

WBC	B-TEST
-	O
16.0	O
*	O
RBC	B-TEST
-	O
4.89	O
HGB	B-TEST
-	O
14.5	O
HCT	B-TEST
-	O
40.4	O
MCV	B-TEST
-	O
83	O
MCH	B-TEST
-	O
29.7	O
MCHC	B-TEST
-	O
35.9	O
*	O
RDW	B-TEST
-	O
13.4	O

PLT	B-TEST
COUNT	I-TEST
-	O
247	O

PT	B-TEST
-	O
12.7	O
PTT	B-TEST
-	O
23.8	O
INR(PT)	B-TEST
-	O
1.1	O

CT	B-TEST
HEAD	I-TEST
W/O	I-TEST
CONTRAST	I-TEST

eval	B-TEST
for	O
bleed	B-PROBLEM

TECHNIQUE	O
:	O
Axial	B-TEST
MDCT	I-TEST
images	I-TEST
of	I-TEST
the	I-TEST
brain	I-TEST
without	O
IV	O
contrast	O
.	O

FINDINGS	O
:	O
There	O
is	O
a	B-PROBLEM
linear	I-PROBLEM
nondepressed	I-PROBLEM
right	I-PROBLEM
temporal	I-PROBLEM
calvarial	I-PROBLEM
fracture	I-PROBLEM
extending	O
into	O
the	O
mastoid	O
process	O
.	O

There	O
is	O
a	B-PROBLEM
small	I-PROBLEM
subdural	I-PROBLEM
hematoma	I-PROBLEM
with	O
components	O
of	O
pneumocephalus	B-PROBLEM
tracking	O
from	O
the	O
mastoid	O
air	O
cells	O
.	O

There	O
is	O
no	O
shift	B-PROBLEM
of	I-PROBLEM
normally	I-PROBLEM
midline	I-PROBLEM
structures	I-PROBLEM
.	O

There	O
is	O
also	O
a	B-PROBLEM
left	I-PROBLEM
occipital	I-PROBLEM
scalp	I-PROBLEM
contusion	I-PROBLEM
but	O
no	O
associated	B-PROBLEM
skull	I-PROBLEM
fracture	I-PROBLEM
.	O

Prominent	B-TREATMENT
sutures	I-TREATMENT
in	O
this	O
young	O
patient	O
,	O
the	B-TREATMENT
right	I-TREATMENT
calvarial	I-TREATMENT
suture	I-TREATMENT
extending	O
into	O
the	O
right	O
temporal	O
bones	O
appears	O
more	O
prominent	O
than	O
its	O
counterpart	O
on	O
the	O
left	O
,	O
however	O
,	O
does	O
not	O
appear	O
to	O
represent	O
an	B-PROBLEM
acute	I-PROBLEM
fracture	I-PROBLEM
.	O

No	O
other	B-PROBLEM
acute	I-PROBLEM
fractures	I-PROBLEM
are	O
appreciated	O
.	O

There	O
is	O
small	O
amount	O
of	O
mucosal	B-PROBLEM
thickening	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
sphenoid	I-PROBLEM
sinuses	I-PROBLEM
.	O

No	O
air-fluid	B-TEST
levels	I-TEST
to	O
suggest	O
occult	B-PROBLEM
facial	I-PROBLEM
fractures	I-PROBLEM
.	O

IMPRESSION	O
:	O
Linear	B-PROBLEM
right	I-PROBLEM
temporal	I-PROBLEM
calvarial	I-PROBLEM
fracture	I-PROBLEM
extending	O
into	O
the	O
mastoid	O
process	O
with	O
small	B-PROBLEM
associated	I-PROBLEM
right	I-PROBLEM
posterior	I-PROBLEM
convexity	I-PROBLEM
subdural	I-PROBLEM
hematoma	I-PROBLEM
and	O
pneumocephalus	B-PROBLEM
.	O

Discussed	O
with	O
trauma	O
team	O
during	O
the	B-TEST
study	I-TEST
.	O

CT	B-TEST
C-SPINE	I-TEST
W/O	O
CONTRAST	O

eval	B-TEST
for	O
fx	B-PROBLEM

Head	B-PROBLEM
injury	I-PROBLEM
to	I-PROBLEM
the	I-PROBLEM
occiput	I-PROBLEM
.	O

TECHNIQUE	O
:	O
Axial	B-TEST
MDCT	I-TEST
images	I-TEST
of	I-TEST
the	I-TEST
cervical	I-TEST
spine	I-TEST
with	O
coronal	O
and	O
sagittal	O
reformats	O
without	O
IV	O
contrast	O
.	O

There	O
is	O
normal	O
alignment	O
of	O
the	O
cervical	O
vertebral	O
bodies	O
without	O
acute	B-PROBLEM
fracture	I-PROBLEM
or	O
traumatic	B-PROBLEM
malalignment	I-PROBLEM
.	O

There	O
is	O
no	O
significant	B-PROBLEM
prevertebral	I-PROBLEM
soft	I-PROBLEM
tissue	I-PROBLEM
swelling	I-PROBLEM
.	O

The	O
lung	O
apices	O
are	O
clear	O
without	O
pneumothorax	B-PROBLEM
.	O

There	O
is	O
a	B-PROBLEM
linear	I-PROBLEM
right	I-PROBLEM
temporal	I-PROBLEM
calvarial	I-PROBLEM
fracture	I-PROBLEM
extending	O
into	O
the	O
right	O
temporal	O
bones	O
.	O

Multiple	O
posterior	O
right	O
-	O
sided	O
mastoid	O
air	O
cells	O
are	O
opacified	B-PROBLEM
with	I-PROBLEM
blood	I-PROBLEM
.	O

1)	O
No	O
acute	B-PROBLEM
cervical	I-PROBLEM
spine	I-PROBLEM
fracture	I-PROBLEM
.	O

2)	O
Linear	B-PROBLEM
right	I-PROBLEM
temporal	I-PROBLEM
calvarial	I-PROBLEM
fracture	I-PROBLEM
extending	O
into	O
the	O
mastoid	O
with	O
a	B-PROBLEM
small	I-PROBLEM
right	I-PROBLEM
posterior	I-PROBLEM
convexity	I-PROBLEM
subdural	I-PROBLEM
hematoma	I-PROBLEM
and	O
pneumocephalus	B-PROBLEM
;	O
see	O
head	B-TEST
CT	I-TEST
report	O
.	O

CHEST	B-TEST
(	I-TEST
PA	I-TEST
&	I-TEST
LAT	I-TEST
)	I-TEST

Reason	O
:	O
Please	O
r/o	O
acute	B-PROBLEM
process	I-PROBLEM
.	O

17	O
year	O
old	O
man	O
with	O
post-op	B-PROBLEM
fever	I-PROBLEM
.	O

Please	O
r/o	O
acute	B-PROBLEM
process	I-PROBLEM
.	O

INDICATION	O
:	O
Postoperative	B-PROBLEM
fever	I-PROBLEM
.	O

TECHNIQUE	O
:	O
PA	B-TEST
and	I-TEST
lateral	I-TEST
views	I-TEST
of	I-TEST
the	I-TEST
chest	I-TEST
.	O

There	O
are	O
no	O
pleural	B-PROBLEM
effusions	I-PROBLEM
or	O
focal	B-PROBLEM
consolidations	I-PROBLEM
.	O

There	O
is	O
no	O
evidence	O
of	O
CHF	B-PROBLEM
.	O

IMPRESSION	O
:	O
No	O
evidence	O
of	O
significant	B-PROBLEM
abnormality	I-PROBLEM
.	O

TIB	B-TEST
/	I-TEST
FIB	I-TEST
(	I-TEST
AP	I-TEST
&	I-TEST
LAT	I-TEST
)	I-TEST
SOFT	O
TISSUE	O

Reason	O
:	O
eval	B-TEST
for	I-TEST
alignment	I-TEST
,	I-TEST
post	I-TEST
op	I-TEST
changes	I-TEST

56	O
year	O
old	O
man	O
with	O
open	B-PROBLEM
RLE	I-PROBLEM
fx	I-PROBLEM
now	O
s/p	B-TREATMENT
fixation	I-TREATMENT

eval	B-TEST
for	I-TEST
alignment	I-TEST
,	I-TEST
post	I-TEST
op	I-TEST
changes	I-TEST

INDICATION	O
:	O
Fracture	B-PROBLEM
.	O
Assess	O
for	O
alignment	O
.	O

RIGHT	B-TEST
TIBIA	I-TEST
/	I-TEST
FIBULA	I-TEST
,	I-TEST
AP	I-TEST
AND	I-TEST
LATERAL	I-TEST
VIEWS	I-TEST
:	O
An	B-TREATMENT
intramedullary	I-TREATMENT
rod	I-TREATMENT
is	O
seen	O
fixating	O
a	B-PROBLEM
proximal	I-PROBLEM
diaphyseal	I-PROBLEM
comminuted	I-PROBLEM
tibial	I-PROBLEM
fracture	I-PROBLEM
with	O
six	B-TREATMENT
proximal	I-TREATMENT
and	I-TREATMENT
two	I-TREATMENT
distal	I-TREATMENT
screws	I-TREATMENT
.	O

Additionally	O
,	O
a	B-TREATMENT
side	I-TREATMENT
plate	I-TREATMENT
is	O
seen	O
medially	O
fixating	O
the	B-PROBLEM
fracture	I-PROBLEM
.	O

There	O
is	O
a	B-PROBLEM
non-displaced	I-PROBLEM
comminuted	I-PROBLEM
fracture	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
proximal	I-PROBLEM
fibular	I-PROBLEM
diaphysis	I-PROBLEM
.	O

There	O
is	O
surrounding	O
soft	B-PROBLEM
tissue	I-PROBLEM
swelling	I-PROBLEM
.	O

IMPRESSION	O
:	O
Comminuted	B-PROBLEM
proximal	I-PROBLEM
tibiofibular	I-PROBLEM
fractures	I-PROBLEM
status	B-TREATMENT
post	I-TREATMENT
ORIF	I-TREATMENT
of	I-TREATMENT
the	I-TREATMENT
tibia	I-TREATMENT
with	O
an	B-TREATMENT
intramedullary	I-TREATMENT
rod	I-TREATMENT
and	I-TREATMENT
side	I-TREATMENT
plate	I-TREATMENT
.	O

No	O
evidence	O
of	O
immediate	B-PROBLEM
hardware	I-PROBLEM
complication	I-PROBLEM
.	O

CT	B-TEST
HEAD	I-TEST
W/O	O
CONTRAST	O

Reason	O
:	O
follow	B-TEST
up	I-TEST
ct	I-TEST

17	O
year	O
old	O
man	O
with	O
pneumocephalus	B-PROBLEM
s/p	O
CMED	O
CCU	O
v.	O
mvc	O

follow	B-TEST
up	I-TEST
ct	I-TEST

CLINICAL	O
HISTORY	O
:	O
History	O
of	O
pneumocephalus	B-PROBLEM
status	O
post	O
pedestrian	O
versus	O
motor	O
vehicle	O
collision	O
.	O

Follow	B-TEST
up	I-TEST
CT	I-TEST
scan	I-TEST
.	O

COMPARISON	O
:	O
Non-contrast	B-TEST
head	I-TEST
CT	I-TEST
from	O
2015-10-27	O
.	O

TECHNIQUE	O
:	O
Non-contrast	B-TEST
head	I-TEST
CT	I-TEST
.	O

FINDINGS	O
:	O
The	O
previously	O
noted	O
subdural	B-PROBLEM
hemorrhage	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
posterior	I-PROBLEM
fossa	I-PROBLEM
appears	O
less	O
conspicuous	O
.	O

The	O
pneumocephalus	B-PROBLEM
adjacent	O
to	O
the	B-PROBLEM
linear	I-PROBLEM
skull	I-PROBLEM
fracture	I-PROBLEM
appears	O
to	O
have	O
decreased	O
in	O
size	O
.	O

There	O
are	O
persistent	B-PROBLEM
bifrontal	I-PROBLEM
and	I-PROBLEM
right	I-PROBLEM
parietal	I-PROBLEM
hemorrhagic	I-PROBLEM
contusions	I-PROBLEM
with	O
surrounding	B-PROBLEM
edema	I-PROBLEM
and	O
possible	O
small	B-PROBLEM
left	I-PROBLEM
frontal	I-PROBLEM
subarachnoid	I-PROBLEM
hemorrhage	I-PROBLEM
(	O
adjacent	O
to	O
falx	O
)	O
which	O
are	O
largely	O
unchanged	O
.	O

There	O
is	O
no	O
shift	B-PROBLEM
of	I-PROBLEM
normally	I-PROBLEM
midline	I-PROBLEM
structures	I-PROBLEM
or	O
hydrocephalus	B-PROBLEM
.	O

The	B-TEST
air-	I-TEST
fluid	I-TEST
level	I-TEST
in	I-TEST
the	I-TEST
right	I-TEST
sphenoid	I-TEST
sinus	I-TEST
and	O
bilateral	B-PROBLEM
opacification	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
mastoid	I-PROBLEM
air	I-PROBLEM
cells	I-PROBLEM
are	O
unchanged	O
.	O

1.	O
Decreased	O
size	O
of	O
right	B-PROBLEM
posterior	I-PROBLEM
subdural	I-PROBLEM
hemorrhage	I-PROBLEM
.	O

2.	O
Multifocal	B-PROBLEM
hemorrhagic	I-PROBLEM
contusions	I-PROBLEM
and	O
surrounding	B-PROBLEM
edema	I-PROBLEM
are	O
largely	O
unchanged	O
.	O

He	O
was	O
admitted	O
to	O
the	O
trauma	O
service	O
.	O
Orthopedics	O
and	O
Neurosurgery	O
were	O
consulted	O
because	O
of	O
his	B-PROBLEM
injuries	I-PROBLEM
.	O

His	B-PROBLEM
Neurosurgical	I-PROBLEM
issues	I-PROBLEM
were	O
nonoperative	O
;	O
he	O
was	O
loaded	O
with	O
Dilantin	B-TREATMENT
;	O
serial	B-TEST
head	I-TEST
CT	I-TEST
scans	I-TEST
were	O
performed	O
and	O
were	O
stable	O
.	O

He	O
will	O
need	O
to	O
follow	O
up	O
with	O
Dr.	O
Mckinney	O
in	O
4	O
weeks	O
for	O
repeat	B-TEST
head	I-TEST
imaging	I-TEST
and	O
continue	O
with	O
Dilantin	B-TREATMENT
for	O
one	O
month	O
.	O

His	B-PROBLEM
right	I-PROBLEM
tib	I-PROBLEM
/	I-PROBLEM
fib	I-PROBLEM
fracture	I-PROBLEM
was	O
repaired	O
by	O
Orthopedics	O
on	O
10-27	O
;	O
postoperatively	O
there	O
were	O
no	O
complications	B-PROBLEM
.	O

He	O
was	O
fitted	O
with	O
a	B-TREATMENT
hinged	I-TREATMENT
Mcdonald	I-TREATMENT
brace	I-TREATMENT
for	O
his	B-PROBLEM
LLE	I-PROBLEM
.	O

He	O
will	O
need	O
to	O
continue	O
on	O
Lovenox	B-TREATMENT
injections	I-TREATMENT
for	O
at	O
least	O
4-6	O
weeks	O
.	O

He	O
was	O
transfused	O
with	O
3	B-TREATMENT
u	I-TREATMENT
packed	I-TREATMENT
cells	I-TREATMENT
for	O
a	B-TEST
hematocrit	I-TEST
of	O
21	O
,	O
post	B-TEST
transfusion	I-TEST
HCT	I-TEST
was	O
26.1	O
;	O
there	O
was	O
a	O
questionable	O
transfusion	B-PROBLEM
reaction	I-PROBLEM
at	O
the	O
end	O
of	O
his	B-TREATMENT
first	I-TREATMENT
unit	I-TREATMENT
of	I-TREATMENT
packed	I-TREATMENT
cells	I-TREATMENT
;	O
he	O
did	O
subsequently	O
receive	O
the	B-TREATMENT
remaining	I-TREATMENT
2	I-TREATMENT
units	I-TREATMENT
without	O
any	B-PROBLEM
further	I-PROBLEM
reaction	I-PROBLEM
.	O

Allergic	B-PROBLEM
to	O
PCN	B-TREATMENT
and	O
Sulfa	B-TREATMENT

1.	O
Phenytoin	B-TREATMENT
50	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
three	O
times	O
a	O
day	O
for	O
1	O
months	O
.	O

2.	O
Oxycodone	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

3.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

4.	O
Magnesium	B-TREATMENT
Hydroxide	I-TREATMENT
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
constipation	B-PROBLEM
.	O

5.	O
Lovenox	B-TREATMENT
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
0.4	O
ML	O
's	O
Subcutaneous	O
once	O
a	O
day	O
for	O
30	O
days	O
.	O

Subdural	B-PROBLEM
hematoma	I-PROBLEM

Skull	B-PROBLEM
fracture	I-PROBLEM

Right	B-PROBLEM
comminuted	I-PROBLEM
tibia	I-PROBLEM
/	I-PROBLEM
fibula	I-PROBLEM
fracture	I-PROBLEM

Return	O
to	O
the	O
emergency	O
room	O
if	O
you	O
develop	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
severe	B-PROBLEM
headaches	I-PROBLEM
,	O
visual	B-PROBLEM
disturbances	I-PROBLEM
,	O
nause	B-PROBLEM
,	O
vomiting	B-PROBLEM
and	O
/	O
or	O
any	B-PROBLEM
other	I-PROBLEM
symptoms	I-PROBLEM
that	O
are	O
concerning	O
to	O
you	O
.	O

You	O
will	O
need	O
to	O
conrtinue	O
with	O
your	B-TREATMENT
Lovenox	I-TREATMENT
injections	I-TREATMENT
for	O
at	O
least	O
4-6	O
weeks	O
as	O
instructed	O
by	O
Orthopedics	O

Inform	O
the	O
office	O
that	O
you	O
will	O
need	O
a	B-TEST
repeat	I-TEST
head	I-TEST
CT	I-TEST
scan	I-TEST
for	O
this	O
appointment	O
.	O

Liver	B-TREATMENT
Transplant	I-TREATMENT
Surgery	I-TREATMENT
Service	O

Hepatitis	B-PROBLEM
C	I-PROBLEM
cirrhosis	I-PROBLEM
.	O

The	O
patient	O
is	O
a	O
49	O
year-old	O
man	O
with	O
hepatitis	B-PROBLEM
C	I-PROBLEM
cirrhosis	I-PROBLEM
complicated	O
by	O
encephalopathy	B-PROBLEM
,	O
positive	B-PROBLEM
esophageal	I-PROBLEM
varices	I-PROBLEM
,	O
now	O
with	O
worsening	B-PROBLEM
confusion	I-PROBLEM
and	O
lethargy	B-PROBLEM
.	O

The	O
patient	O
has	O
been	O
admitted	O
5	O
x	O
in	O
the	O
past	O
to	O
Nantucket	O
Cottage	O
Hospital	O
since	O
11-30	O
for	O
encephalopathy	B-PROBLEM
.	O

Infectious	B-TEST
work-up	I-TEST
was	O
negative	O
.	O

Trazodone	B-TREATMENT
stopped	O
.	O

Patient	O
was	O
started	O
on	O
Lactulose	B-TREATMENT
and	O
Rifaximine	B-TREATMENT
which	O
improved	O
his	O
mental	O
status	O
.	O

Today	O
,	O
on	O
2014-03-03	O
,	O
the	O
patient	O
was	O
seen	O
in	O
clinic	O
with	O
increased	B-PROBLEM
lethargy	I-PROBLEM
,	O
confusion	B-PROBLEM
.	O

Wife	O
reports	O
that	O
the	O
patient	O
has	O
a	O
history	O
of	O
lethargy	B-PROBLEM
and	O
confusion	B-PROBLEM
,	O
similar	O
to	O
the	B-PROBLEM
symptoms	I-PROBLEM
for	O
which	O
the	O
patient	O
was	O
recently	O
admitted	O
.	O

The	O
patient	O
also	O
reports	O
that	O
he	O
has	O
had	O
"	O
yellowish	B-PROBLEM
eyes	I-PROBLEM
,	O
some	B-PROBLEM
shaking	I-PROBLEM
and	O
his	O
breath	O
smelled	O
more	O
like	O
ammonia	O
over	O
the	O
past	O
3	O
days	O
."	O

The	O
patient	O
has	O
been	O
compliant	O
with	O
his	B-TREATMENT
medications	I-TREATMENT
.	O

He	O
has	O
had	O
night	B-PROBLEM
sweats	I-PROBLEM
for	O
the	O
past	O
2	O
weeks	O
.	O

He	O
denies	O
any	B-PROBLEM
abdominal	I-PROBLEM
pain	I-PROBLEM
.	O

He	O
gets	O
cold	B-PROBLEM
easily	O
but	O
denies	O
fevers	B-PROBLEM
.	O

HCV	B-PROBLEM
cirrhosis	I-PROBLEM
.	O

Underwent	O
treatment	B-TREATMENT
with	O
Interferon	B-TREATMENT
10	O
years	O
ago	O
.	O

He	O
stopped	O
secondary	O
to	O
aggressive	B-PROBLEM
behavior	I-PROBLEM
.	O

History	O
of	O
hepatic	B-PROBLEM
encephalopathy	I-PROBLEM
.	O

Esophageal	B-PROBLEM
varices	I-PROBLEM
.	O

EGD	B-TEST
on	O
2013-12-08	O
demonstrated	O
5	B-PROBLEM
cores	I-PROBLEM
of	I-PROBLEM
varices	I-PROBLEM
,	O
grade	O
1	O
to	O
2	O
at	O
the	O
lower	O
third	O
of	O
the	O
esophagus	O
.	O

Four	B-TREATMENT
bands	I-TREATMENT
were	O
placed	O
without	O
difficulty	O
.	O

Also	O
,	O
the	O
patient	O
has	O
a	O
past	O
medical	O
history	O
of	O
hypertension	B-PROBLEM
,	O
glucose	B-PROBLEM
intolerance	I-PROBLEM
,	O
peripheral	B-PROBLEM
neuropathy	I-PROBLEM
.	O

The	O
patient	O
was	O
taken	O
off	O
of	O
Neurontin	B-TREATMENT
because	O
it	O
started	O
to	O
worsen	O
his	O
mental	O
status	O
.	O

Nadolol	B-TREATMENT
20	O
mg	O
q.	O
Day	O
.	O

Protonix	B-TREATMENT
20	O
mg	O
q.	O
24	O
hours	O
.	O

Osamine	B-TREATMENT
200	O
mg	O
t.i.d.	O

Lactulose	B-TREATMENT
30	O
mg	O
q.i.d.	O

Lasix	B-TREATMENT
40	O
mg	O
q.	O
Day	O
.	O

Insulin	B-TREATMENT
regular	I-TREATMENT
.	O

Amlodipine	B-TREATMENT
5	O
mg	O
q.	O
Day	O
.	O

Retazepine	B-TREATMENT
50	O
mg	O
q	O
h.s.	O

Testosterone	B-TREATMENT
4	O
mg	O
q.	O
24	O
hours	O
.	O

No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

The	O
patient	O
contracted	O
HCV	B-PROBLEM
20	O
years	O
ago	O
secondary	O
to	O
IV	O
drug	O
use	O
.	O

FAMILY	O
HISTORY	O
:	O
Father	O
died	O
of	O
metastatic	B-PROBLEM
colon	I-PROBLEM
cancer	I-PROBLEM
.	O

Mother	O
died	O
of	O
end	B-PROBLEM
stage	I-PROBLEM
renal	I-PROBLEM
disease	I-PROBLEM
.	O

Vital	B-TEST
signs	I-TEST
were	O
stable	O
.	O

Weight	B-TEST
was	O
122.5	O
.	O

General	O
:	O
Patient	O
is	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Lethargic	B-PROBLEM
,	O
occasionally	O
falling	O
asleep	O
.	O

Sclera	B-PROBLEM
mildly	I-PROBLEM
icteric	I-PROBLEM
.	O

Neck	O
:	O
No	O
LAD	B-PROBLEM
.	O

Lungs	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Normal	O
S1	O
and	O
S2	O
without	O
murmurs	B-PROBLEM
or	O
rubs	B-PROBLEM
.	O

Positive	B-PROBLEM
gynecomastia	I-PROBLEM
.	O

Abdomen	O
:	O
Positive	O
bowel	O
sounds	O
,	O
soft	O
,	O
nondistended	B-PROBLEM
,	O
nontender	B-PROBLEM
.	O

Obvious	B-PROBLEM
ascites	I-PROBLEM
.	O

1+	B-PROBLEM
edema	I-PROBLEM
bilaterally	I-PROBLEM
.	O

There	O
was	O
mild	B-PROBLEM
asterixis	I-PROBLEM
.	O

Patient	O
continued	O
on	O
Lactulose	B-TREATMENT
.	O

Continue	O
on	O
Rifaximine	B-TREATMENT
.	O

Continue	O
Lasix	B-TREATMENT
.	O

On	O
2014-04-02	O
,	O
the	O
patient	O
was	O
awake	O
,	O
alert	O
and	O
oriented	O
,	O
taking	O
Lactulose	B-TREATMENT
.	O

Difficulty	B-PROBLEM
with	I-PROBLEM
word	I-PROBLEM
finding	I-PROBLEM
at	O
times	O
.	O

Denies	O
any	B-PROBLEM
pain	I-PROBLEM
or	O
discomfort	B-PROBLEM
.	O

Abdomen	O
:	O
Slightly	B-PROBLEM
distended	I-PROBLEM
,	O
nontender	B-PROBLEM
.	O

Ultrasound	B-TEST
was	O
performed	O
on	O
2014-04-01	O
demonstrating	O
severe	B-PROBLEM
portal	I-PROBLEM
hypertension	I-PROBLEM
with	O
massive	B-PROBLEM
peri	I-PROBLEM
splenic	I-PROBLEM
varices	I-PROBLEM
and	O
splenorenal	B-TREATMENT
shunt	I-TREATMENT
.	O

Repeat	B-PROBLEM
hepato	I-PROBLEM
fungal	I-PROBLEM
flare	I-PROBLEM
.	O

On	O
2014-04-04	O
,	O
the	O
transplant	O
service	O
was	O
consulted	O
because	O
the	O
patient	O
was	O
possibly	O
going	O
to	O
the	O
operating	O
room	O
for	O
transplant	B-TREATMENT
on	O
2014-04-04	O
.	O

The	O
patient	O
did	O
go	O
to	O
operating	O
room	O
on	O
2014-04-04	O
and	O
the	O
patient	O
had	O
cadaveric	B-TREATMENT
liver	I-TREATMENT
transplant	I-TREATMENT
performed	O
by	O
Dr.	O
Michael	O
Sanders	O
.	O

Please	O
see	O
detailed	O
operative	O
note	O
for	O
more	O
information	O
about	O
the	B-TREATMENT
procedure	I-TREATMENT
.	O

The	O
patient	O
received	O
MMF	B-TREATMENT
1	O
gram	O
b.i.d.	O
,	O
Flagyl	B-TREATMENT
500	O
mg	O
IV	O
x1	O
.	O

The	O
patient	O
also	O
received	O
Unasyn	B-TREATMENT
for	O
2	O
days	O
,	O
Fluconazole	B-TREATMENT
,	O
heparin	B-TREATMENT
,	O
Protonix	B-TREATMENT
,	O
insulin	B-TREATMENT
,	O
morphine	B-TREATMENT
,	O
Bactrim	B-TREATMENT
.	O

The	O
patient	O
was	O
on	O
Propofol	B-TREATMENT
for	O
2	O
days	O
.	O

On	O
2014-04-04	O
,	O
labs	B-TEST
were	O
as	O
follows	O
:	O

WBC	B-TEST
of	O
8.3	O
;	O
hematocrit	B-TEST
of	O
30.6	O
;	O
platelets	B-TEST
69	O
;	O
sodium	B-TEST
132	O
;	O
3.9	O
,	O
102	O
,	O
22	O
,	O
serum	B-TEST
creatinine	I-TEST
of	O
13	O
and	O
1.1	O
.	O

Glucose	B-TEST
114	O
.	O

AST	B-TEST
87	O
.	O

ALT	B-TEST
44	O
.	O

Alkaline	B-TEST
phosphatase	I-TEST
169	O
.	O

PT	B-TEST
of	O
20.6	O
.	O

PTT	B-TEST
of	O
38.7	O
.	O

INR	B-TEST
of	O
2.0	O
.	O

On	O
postoperative	O
day	O
number	O
1	O
,	O
duplex	B-TEST
ultrasound	I-TEST
of	I-TEST
the	I-TEST
patient	I-TEST
's	I-TEST
liver	I-TEST
was	O
performed	O
demonstrating	O
normal	O
appearing	O
portal	O
veins	O
and	O
hepatic	O
arteries	O
.	O

There	O
appears	O
to	O
be	O
a	B-PROBLEM
decreased	I-PROBLEM
and	I-PROBLEM
sluggish	I-PROBLEM
flow	I-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
and	I-PROBLEM
left	I-PROBLEM
hepatic	I-PROBLEM
veins	I-PROBLEM
with	O
loss	B-PROBLEM
of	I-PROBLEM
normal	I-PROBLEM
respiratory	I-PROBLEM
variations	I-PROBLEM
,	I-PROBLEM
wave	I-PROBLEM
forms	I-PROBLEM
and	I-PROBLEM
the	I-PROBLEM
intrahepatic	I-PROBLEM
portion	I-PROBLEM
.	O

Additionally	O
,	O
there	O
is	O
diminished	B-PROBLEM
color	I-PROBLEM
flow	I-PROBLEM
with	O
confluence	O
of	O
the	O
hepatic	O
veins	O
.	O

These	O
findings	O
may	O
reflect	O
thrombus	B-PROBLEM
within	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
and	I-PROBLEM
right	I-PROBLEM
hepatic	I-PROBLEM
veins	I-PROBLEM
.	O

Caval	B-PROBLEM
narrowing	I-PROBLEM
is	O
seen	O
,	O
most	O
likely	O
correlation	O
to	O
clinical	O
history	O
is	O
recommended	O
and	O
further	O
evaluation	O
of	O
the	B-TEST
CT	I-TEST
or	O
short-term	B-TEST
ultrasounds	I-TEST
for	O
follow-up	O
was	O
recommended	O
.	O

The	B-TREATMENT
Feeney	I-TREATMENT
Gann-Burlington	I-TREATMENT
drain	I-TREATMENT
on	O
postoperative	O
day	O
number	O
demonstrated	O
medial	B-TEST
output	I-TEST
of	O
780	O
with	O
lateral	B-TEST
output	I-TEST
of	O
150	O
.	O

Patient	O
continued	O
getting	O
Acyclovir	B-TREATMENT
,	O
Prednisone	B-TREATMENT
,	O
MMF	B-TREATMENT
one	O
gram	O
b.i.d	O
.	O

The	O
patient	O
was	O
on	O
FK	B-TREATMENT
2	I-TREATMENT
and	O
2	O
that	O
was	O
started	O
on	O
postoperative	O
day	O
number	O
2	O
.	O

Waltham-Ludlow	B-TREATMENT
drains	I-TREATMENT
put	O
out	O
on	O
the	O
13th	O
620	O
and	O
380	O
.	O

Omalley	O
was	O
consulted	O
on	O
2014-04-08	O
for	O
better	O
glucose	B-TREATMENT
control	I-TREATMENT
since	O
the	O
patient	O
was	O
on	O
steroids	B-TREATMENT
.	O

Patient	O
was	O
transfused	O
1	B-TREATMENT
unit	I-TREATMENT
of	I-TREATMENT
platelets	I-TREATMENT
on	O
2014-04-08	O
for	O
platelet	B-TEST
count	I-TEST
of	O
66	O
.	O

A	B-TEST
heparin	I-TEST
independent	I-TEST
antibody	I-TEST
was	O
sent	O
off	O
on	O
2014-04-07	O
which	O
was	O
unremarkable	O
.	O

On	O
2014-04-09	O
,	O
patient	O
continued	O
to	O
do	O
very	O
well	O
,	O
ambulating	O
,	O
tolerating	O
a	O
diet	O
,	O
urinating	O
without	O
difficulty	B-PROBLEM
.	O

Drains	B-TREATMENT
continued	O
to	O
put	O
out	O
significant	O
amount	O
of	O
fluid	O
.	O

Patient	B-TEST
's	I-TEST
labs	I-TEST
from	O
2014-04-10	O
were	O
the	O
following	O
:	O

7.1	O
,	O
hematocrit	B-TEST
of	O
30.8	O
,	O
platelets	B-TEST
90	O
.	O

Sodium	B-TEST
of	O
138	O
;	O
potassium	B-TEST
3.5	O
;	O
106	O
,	O
28	O
,	O
31	O
,	O
1.0	O
,	O
glucose	B-TEST
134	O
.	O

AST	B-TEST
82	O
.	O

ALT	B-TEST
176	O
.	O

Alkaline	B-TEST
phosphatase	I-TEST
78	O
which	O
all	O
have	O
significantly	O
decreased	O
since	O
postoperative	O
day	O
number	O
1	O
.	O

Total	B-TEST
bilirubin	I-TEST
was	O
0.9	O
.	O

On	O
2014-04-09	O
,	O
FK	B-TEST
level	I-TEST
was	O
10.3	O
.	O

Protonix	B-TREATMENT
40	O
mg	O
q.	O
24	O
.	O

Moltipine	B-TREATMENT
5	O
mg	O
q.	O
Day	O
.	O

Fluconazole	B-TREATMENT
400	O
mg	O
q.	O
24	O
hours	O
.	O

Prednisone	B-TREATMENT
20	O
mg	O
q.	O
Day	O
.	O

MMF	B-TREATMENT
1000	O
mg	O
b.i.d.	O
.	O

Lopressor	B-TREATMENT
50	O
m	O
b.i.d.	O

Percocet	B-TREATMENT
1	O
to	O
2	O
tabs	O
q.	O
4	O
to	O
6	O
hours	O
prn	O
.	O

Colace	B-TREATMENT
100	O
mg	O
b.i.d.	O

Bactrim	B-TREATMENT
SS	O
1	O
tab	O
q.	O
Day	O
.	O

Tacrolimus	B-TREATMENT
3	O
mg	O
b.i.d.	O

Lasix	B-TREATMENT
20	O
mg	O
b.i.d.	O

Valcyte	B-TREATMENT
900	O
mg	O
q.	O
Day	O
.	O

Patient	O
is	O
on	O
insulin	B-TREATMENT
sliding	I-TREATMENT
scale	I-TREATMENT
with	O
fixed	O
dose	O
.	O

The	O
patient	O
is	O
to	O
call	O
787-984-9608	O
if	O
any	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
nausea	B-PROBLEM
and	O
vomiting	B-PROBLEM
,	O
abdominal	B-PROBLEM
pain	I-PROBLEM
,	O
inability	B-PROBLEM
to	I-PROBLEM
take	I-PROBLEM
medications	I-PROBLEM
,	O
inability	B-PROBLEM
to	I-PROBLEM
eat	I-PROBLEM
or	I-PROBLEM
drink	I-PROBLEM
.	O

Patient	O
needs	O
to	O
have	O
labs	B-TEST
every	O
Monday	O
and	O
Thursday	O
including	O
a	B-TEST
CBC	I-TEST
,	O
chem-10	B-TEST
,	O
AST	B-TEST
,	O
ALT	B-TEST
,	O
alkaline	B-TEST
phosphatase	I-TEST
,	O
albumin	B-TEST
,	O
total	B-TEST
bilirubin	I-TEST
and	O
Prograf	B-TEST
level	I-TEST
need	O
to	O
be	O
obtained	O
.	O

All	B-TEST
cultures	I-TEST
have	O
been	O
unremarkable	O
.	O

Cultures	B-TEST
were	O
obtained	O
on	O
2014-03-31	O
.	O

Urine	B-TEST
culture	I-TEST
and	O
blood	B-TEST
culture	I-TEST
have	O
been	O
unremarkable	O
on	O
2014-04-03	O
.	O

Hepatitis	B-TEST
viral	I-TEST
load	I-TEST
was	O
76,500	O
.	O

Pathology	O
demonstrates	O
that	O
the	B-TEST
pathology	I-TEST
results	I-TEST
of	I-TEST
the	I-TEST
liver	I-TEST
were	O
not	O
finalized	O
.	O

Fetal	B-TEST
screens	I-TEST
,	O
O	O
positive	O
,	O
antibody	B-TEST
negative	O
,	O
RPR	B-TEST
nonreactive	O
,	O
rubella	B-TEST
immune	O
,	O
hepatitis	B-TEST
surface	I-TEST
antigen	I-TEST
negative	O
,	O
GBS	B-TEST
unknown	O
.	O

IVF	B-PROBLEM
pregnancy	I-PROBLEM
complicated	O
by	O
IUGR	B-PROBLEM
,	O
2	B-PROBLEM
vessel	I-PROBLEM
cord	I-PROBLEM
,	O
normal	O
fetal	O
echo	O
reverse	O
diastolic	O
flow	O
and	O
demise	B-PROBLEM
of	I-PROBLEM
twin	I-PROBLEM
A	I-PROBLEM
at	O
27	O
weeks	O
.	O

Twin	O
B	O
with	O
normal	O
fetal	O
survey	O
was	O
transferred	O
to	O
Boston	O
Medical	O
Center	O
at	O
26	O
and	O
2/7	O
weeks	O
with	O
IUGR	B-PROBLEM
of	I-PROBLEM
twin	I-PROBLEM
A	I-PROBLEM
was	O
first	O
noted	O
,	O
presented	O
with	O
preterm	B-PROBLEM
labor	I-PROBLEM
at	O
31	O
weeks	O
.	O

Betamethasone	B-TREATMENT
complete	O
at	O
approximately	O
26	O
weeks	O
and	O
31	O
weeks	O
.	O

Mother	O
was	O
on	O
clindamycin	B-TREATMENT
since	O
11-04	O
.	O

PPROM	B-PROBLEM
with	O
bleeding	B-PROBLEM
and	O
transverse	B-PROBLEM
lie	I-PROBLEM
prompted	O
cesarean	B-TREATMENT
section	I-TREATMENT
.	O

Abruption	B-PROBLEM
noted	O
.	O

Apgars	B-TEST
were	O
6	O
and	O
9	O
.	O

On	O
admission	O
weight	B-TEST
1670	O
grams	O
approximately	O
50	O
th	O
percentile	O
,	O
length	B-TEST
43	O
cm	O
50	O
th	O
percentile	O
,	O
head	B-TEST
circumference	I-TEST
not	O
done	O
.	O

Anterior	O
fontanel	O
soft	O
,	O
flat	O
,	O
cap	O
and	O
prong	B-TREATMENT
CPAP	I-TREATMENT
in	O
place	O
.	O

Nondysmorphic	B-PROBLEM
intact	O
Veliz	O
.	O

No	O
murmur	B-PROBLEM
.	O

No	O
hepatosplenomegaly	B-PROBLEM
.	O

Positive	O
vaginal	B-PROBLEM
tag	I-PROBLEM
.	O

No	O
hip	B-PROBLEM
click	I-PROBLEM
.	O

No	O
sacral	B-PROBLEM
dimple	I-PROBLEM
.	O

Decrease	B-PROBLEM
tone	I-PROBLEM
,	O
ruddy	O
,	O
warm	O
,	O
well	O
perfused	O
with	O
peripheral	B-TREATMENT
IV	I-TREATMENT
in	I-TREATMENT
left	I-TREATMENT
hand	I-TREATMENT
.	O

Mills	O
was	O
admitted	O
to	O
the	O
newborn	O
intensive	O
care	O
unit	O
with	O
moderate	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
.	O

Infant	O
placed	O
on	O
CPAP	B-TREATMENT
.	O

X-ray	B-TEST
revealed	O
mild	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
syndrome	I-PROBLEM
.	O

She	O
remained	O
on	O
CPAP	B-TREATMENT
for	O
a	O
total	O
of	O
24	O
hours	O
at	O
which	O
time	O
she	O
transitioned	O
to	O
room	O
air	O
and	O
continues	O
to	O
be	O
stable	O
in	O
room	O
air	O
.	O

Caffeine	B-TREATMENT
citrate	I-TREATMENT
was	O
initiated	O
on	O
11-14	O
for	O
apnea	B-PROBLEM
and	O
bradycardia	B-PROBLEM
of	I-PROBLEM
prematurity	I-PROBLEM
.	O

Heart	B-TEST
ranges	I-TEST
130	O
s	O
to	O
160	O
s.	O

Blood	B-TEST
pressure	I-TEST
most	O
recently	O
60/37	O
with	O
a	O
mean	O
of	O
44	O
.	O

Birth	B-TEST
weight	I-TEST
was	O
1670	O
grams	O
50	O
th	O
percentile	O
,	O
length	B-TEST
43	O
cm	O
50	O
th	O
percentile	O
.	O

Head	B-TEST
circumference	I-TEST
not	O
done	O
.	O

Infant	O
was	O
initially	O
started	O
on	O
80	O
cc	O
per	O
kilo	O
per	O
day	O
of	O
D10W	B-TREATMENT
.	O

Enteral	B-TREATMENT
feedings	I-TREATMENT
were	O
initiated	O
on	O
day	O
of	O
life	O
#1	O
.	O

Infant	O
achieved	O
full	B-TREATMENT
enteral	I-TREATMENT
feedings	I-TREATMENT
by	O
day	O
of	O
life	O
6	O
.	O

She	O
is	O
currently	O
receiving	O
150	O
cc	O
per	O
kilo	O
per	O
day	O
of	O
Special	B-TREATMENT
Care	I-TREATMENT
20	I-TREATMENT
.	O

Her	B-TEST
discharge	I-TEST
weight	I-TEST
is	O
1477	O
gm	O
.	O

Her	O
most	O
recent	O
set	O
of	O
electrolytes	O
were	O
on	O
2015-11-13	O
with	O
a	B-TEST
sodium	I-TEST
of	O
143	O
,	O
a	B-TEST
potassium	I-TEST
of	O
6.3	O
hemolyzed	O
,	O
a	B-TEST
chloride	I-TEST
of	O
113	O
and	O
a	B-TEST
total	I-TEST
CO2	I-TEST
of	O
17	O
.	O

She	O
will	O
need	O
advance	B-TREATMENT
calorie	I-TREATMENT
density	I-TREATMENT
for	O
better	O
growth	O
.	O

GI	B-TEST
.	I-TEST
Bilirubin	I-TEST
peaked	O
on	O
day	O
of	O
life	O
#2	O
of	O
9.0	O
/	O
0.3	O
.	O

Infant	O
is	O
under	O
phototherapy	B-TREATMENT
,	O
which	O
was	O
discontinued	O
on	O
11-13	O
.	O

Most	B-TEST
recent	I-TEST
bilirubin	I-TEST
was	O
on	O
11-14	O
of	O
4.8	O
/	O
0.3	O
.	O

Hematocrit	B-TEST
on	O
admission	O
was	O
53.7	O
.	O

She	O
has	O
not	O
required	O
any	B-TREATMENT
blood	I-TREATMENT
transfusions	I-TREATMENT
.	O

A	B-TEST
CBC	I-TEST
and	O
blood	B-TEST
culture	I-TEST
obtained	O
on	O
admission	O
.	O

CBC	B-TEST
had	O
a	B-TEST
white	I-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
of	O
9	O
,	O
17	O
polys	B-TEST
,	O
0	O
bands	B-TEST
,	O
platelets	B-TEST
of	O
326	O
.	O

She	O
received	O
48	O
hours	O
of	O
ampicillin	B-TREATMENT
and	O
gentamycin	B-TREATMENT
with	O
negative	O
blood	B-TEST
cultures	I-TEST
and	O
antibiotics	B-TREATMENT
were	O
discontinued	O
.	O

Head	B-TEST
ultrasound	I-TEST
was	O
performed	O
on	O
2015-11-16	O
and	O
was	O
normal	O
.	O

Sensory	B-TEST
,	I-TEST
hearing	I-TEST
screen	I-TEST
has	O
not	O
yet	O
been	O
performed	O
,	O
but	O
should	O
be	O
done	O
prior	O
to	O
discharge	O
.	O

Continue	O
150	O
cc	O
per	O
kilo	O
per	O
day	O
of	O
Special	B-TREATMENT
Care	I-TREATMENT
20	I-TREATMENT
calories	I-TREATMENT
advancing	O
caloric	O
intake	O
as	O
required	O
to	O
maintain	O
weight	O
gain	O
of	O
3	O
grams	O
per	O
kilogram	O
per	O
day	O
.	O

Medications	B-TREATMENT
,	O
continue	O
caffeine	B-TREATMENT
citrate	I-TREATMENT
of	O
11	O
mg	O
po	O
every	O
day	O
.	O

Car	B-TEST
seat	I-TEST
position	I-TEST
screening	I-TEST
has	O
not	O
yet	O
been	O
done	O
.	O

State	B-TEST
newborn	I-TEST
screen	I-TEST
was	O
sent	O
on	O
day	O
of	O
life	O
#3	O
and	O
at	O
discharge	O
.	O

Immunizations	B-TREATMENT
received	O
,	O
infant	O
has	O
not	O
received	O
any	B-TREATMENT
immunizations	I-TREATMENT
to	O
date	O
.	O

State	B-TEST
newborn	I-TEST
screen	I-TEST
was	O
sent	O
on	O
2015-11-12	O
.	O

Immunizations	B-TREATMENT
:	O
recommended	O
Synagis	B-TREATMENT
RSV	I-TREATMENT
prophylaxis	I-TREATMENT
should	O
be	O
considered	O
from	O
November	O
through	O
March	O
for	O
infants	O
who	O
meet	O
any	O
of	O
the	O
following	O
3	O
criteria	O
,	O
born	O
at	O
less	O
than	O
32	O
weeks	O
,	O
born	O
between	O
32	O
and	O
35	O
weeks	O
with	O
2	O
of	O
the	O
following	O
,	O
daycare	O
during	O
RSV	O
season	O
,	O
a	O
smoker	O
in	O
the	O
household	O
,	O
neuromuscular	B-PROBLEM
disease	I-PROBLEM
and	O
weight	B-PROBLEM
abnormalities	I-PROBLEM
or	O
school	O
age	O
siblings	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
.	O

Influenza	B-TREATMENT
immunization	I-TREATMENT
is	O
recommended	O
annually	O
in	O
the	O
fall	O
for	O
all	O
infants	O
once	O
they	O
reach	O
6	O
months	O
of	O
age	O
.	O

Before	O
this	O
age	O
and	O
for	O
the	O
first	O
24	O
months	O
of	O
the	B-TREATMENT
child	I-TREATMENT
's	I-TREATMENT
life	I-TREATMENT
immunizations	I-TREATMENT
against	O
influenza	B-PROBLEM
is	O
recommended	O
for	O
household	O
contacts	O
and	O
out	O
of	O
home	O
care	O
givers	O
.	O

Premature	B-PROBLEM
infant	I-PROBLEM
born	O
at	O
31	O
and	O
6/7	O
weeks	O
gestation	O
,	O
resolved	O
respiratory	B-PROBLEM
distress	I-PROBLEM
syndrome	I-PROBLEM
.	O

Rule	O
out	O
sepsis	B-PROBLEM
with	O
antibiotic	B-TREATMENT
.	O

Hyperbilirubinemia	B-PROBLEM
resolving	O
.	O

Apnea	B-PROBLEM
and	O
bradycardia	B-PROBLEM
of	I-PROBLEM
prematurity	I-PROBLEM
.	O

Codeine	B-TREATMENT
/	O
Iodine	B-TREATMENT

large	B-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
,	O
transfer	O
from	O
OSH	O

Thoracentesis	B-TREATMENT
2018-05-27	O

82	O
F	O
with	O
h/o	O
COPD	B-PROBLEM
,	O
CAD	B-PROBLEM
,	O
pafib	B-PROBLEM
and	O
SSS	B-PROBLEM
s/p	O
pacer	B-TREATMENT
on	O
05-08	O
for	O
symptomatic	B-PROBLEM
pauses	I-PROBLEM
is	O
transferred	O
for	O
large	B-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
?	O
needing	O
drainage	B-TREATMENT
and	O
CHF	B-PROBLEM
.	O

She	O
was	O
admitted	O
to	O
Cambridge	O
Hospital	O
2018-05-24	O
with	O
ARF	B-PROBLEM
(	O
Cr	B-TEST
3.5	O
up	O
from	O
0.9	O
)	O
and	O
SOB	B-PROBLEM
.	O

According	O
to	O
her	O
guardian	O
she	O
was	O
discharged	O
to	O
her	O
NH	O
for	O
a	O
few	O
days	O
after	O
her	B-TREATMENT
pacer	I-TREATMENT
was	O
placed	O
05-08	O
,	O
which	O
was	O
complicated	O
by	O
a	B-PROBLEM
PTX	I-PROBLEM
requiring	O
CT	B-TREATMENT
placement	I-TREATMENT
which	O
had	O
been	O
d/c	O
'd	O
in	O
the	O
hospital	O
after	O
resolution	O
of	O
her	B-PROBLEM
PTX	I-PROBLEM
.	O

She	O
had	O
some	O
nausea	B-PROBLEM
/	O
vomiting	B-PROBLEM
and	O
generally	O
was	O
taking	O
poor	O
pos	O
at	O
her	O
NH	O
.	O

There	O
had	O
been	O
some	O
concern	O
her	B-PROBLEM
nausea	I-PROBLEM
was	O
due	O
to	O
her	B-TREATMENT
amiodarone	I-TREATMENT
which	O
had	O
been	O
discontinued	O
about	O
1	O
week	O
ago	O
.	O

She	O
was	O
then	O
sent	O
to	O
Franklin	O
Medical	O
Center	O
05-24	O
with	O
lethargy	B-PROBLEM
and	O
n/v	B-PROBLEM
.	O

At	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
she	O
was	O
discovered	O
to	O
have	O
ARF	B-PROBLEM
,	O
a	B-PROBLEM
large	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
,	O
and	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
.	O

She	O
was	O
treated	O
with	O
IVF	B-TREATMENT
for	O
her	B-PROBLEM
ARF	I-PROBLEM
.	O

She	O
underwent	O
a	B-TEST
TTE	I-TEST
at	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
today	O
(	O
05-26	O
)	O
showing	O
mod-lg	B-PROBLEM
circumferential	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
without	O
evidence	O
of	O
RV	B-PROBLEM
diastolic	I-PROBLEM
collapse	I-PROBLEM
and	O
no	O
MV	O
inflow	O
evidence	O
of	O
tamponade	B-PROBLEM
,	O
pacer	B-TREATMENT
wire	I-TREATMENT
located	O
in	O
RV	O
apex	O
.	O

There	O
was	O
still	O
concern	O
for	O
her	B-PROBLEM
effusion	I-PROBLEM
contributing	O
to	O
her	B-PROBLEM
SOB	I-PROBLEM
at	O
the	O
OSH	O
so	O
she	O
was	O
transferred	O
for	O
drainage	B-TREATMENT
and	O
treatment	B-TREATMENT
of	O
CHF	B-PROBLEM
.	O

Today	O
she	O
only	O
complains	O
of	O
some	B-PROBLEM
SOB	I-PROBLEM
,	O
which	O
she	O
says	O
remains	O
largely	O
unchanged	O
over	O
the	O
past	O
few	O
days	O
.	O

She	O
denies	O
any	B-PROBLEM
CP	I-PROBLEM
/	O
cough	B-PROBLEM
/	O
fever	B-PROBLEM
/	O
abd	B-PROBLEM
pain	I-PROBLEM
/	O
diarrhea	B-PROBLEM
/	O
black	B-PROBLEM
or	I-PROBLEM
bloody	I-PROBLEM
stools	I-PROBLEM
/	O
headache	B-PROBLEM
.	O

htn	B-PROBLEM

afib	B-PROBLEM
,	O
SSS	B-PROBLEM

COPD	B-PROBLEM

CAD	B-PROBLEM

pacer	B-TREATMENT
DDDR	I-TREATMENT
(	I-TREATMENT
Vitatron	I-TREATMENT
CL860	I-TREATMENT
)	I-TREATMENT
placed	O
05-08	O
for	O
SSS	B-PROBLEM
with	O
symptomatic	B-PROBLEM
bradycardia	I-PROBLEM
,	O
c/b	O
R	B-PROBLEM
PTX	I-PROBLEM
requiring	O
chest	B-TREATMENT
tube	I-TREATMENT

GERD	B-PROBLEM

CVA	B-PROBLEM

hypothyroidism	B-PROBLEM

legally	B-PROBLEM
blind	I-PROBLEM

Exam	O
:	O
T	B-TEST
96.2	O
HR	B-TEST
70	O
BP	B-TEST
118/46	O
R	B-TEST
24	O
sat	B-TEST
90%	O
on	O
60%FM	B-TREATMENT

pulsus	B-PROBLEM
parodoxus	I-PROBLEM
=	O
6-8	O
mm	O

gen	O
:	O
mild	B-PROBLEM
resp	I-PROBLEM
distress	I-PROBLEM
speaking	O
in	O
full	O
sentences	O
but	O
using	O
accessory	O
muscles	O

HEENT	O
:	O
mmm	O
,	O
JVP	B-TEST
at	O
14	O
cm	O
,	O
no	O
bruits	B-PROBLEM
,	O
supple	O

pulm	O
:	O
no	O
BS	B-TEST
01-15	O
way	O
up	O
bilat	O
,	O
no	O
consolidation	B-PROBLEM

abd	O
:	O
s/nt/slightly	O
distended	B-PROBLEM
,	O
dec	B-PROBLEM
BS	I-PROBLEM
,	O
no	O
CVA	B-PROBLEM
tenderness	I-PROBLEM

ext	O
:	O
1+	B-PROBLEM
LE	I-PROBLEM
edema	I-PROBLEM

ECG	B-TEST
:	O
a	O
paced	O
at	O
70	O
bpm	O
/	O
nml	O
axis	O
,	O
LBBB	B-PROBLEM
,	O
no	O
ST	B-PROBLEM
or	I-PROBLEM
TW	I-PROBLEM
changes	I-PROBLEM

CXR	B-TEST
at	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
05-26	O
:	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
eff	I-PROBLEM
and	O
pericardial	B-PROBLEM
eff	I-PROBLEM

CT	B-TEST
chest	I-TEST
at	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
05-25	O
:	O
large	B-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
,	O
bilat	B-PROBLEM
pleural	I-PROBLEM
eff	I-PROBLEM
with	O
underlying	B-PROBLEM
consolidation	I-PROBLEM
which	O
could	O
represent	O
PNA	B-PROBLEM
vs.	O
atelectasis	B-PROBLEM

TTE	B-TEST
at	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
05-26	O
:	O
mod-lg	B-PROBLEM
circumferential	I-PROBLEM
pericardial	I-PROBLEM
eff	I-PROBLEM
,	O
no	O
evidence	O
of	O
RV	B-PROBLEM
diastolic	I-PROBLEM
collapse	I-PROBLEM
,	O
no	O
MV	O
inflow	O
evidence	O
of	O
tamponade	B-PROBLEM
,	O
pacer	B-TREATMENT
lead	I-TREATMENT
located	O
in	O
RV	O
apex	O

head	B-TEST
CT	I-TEST
at	O
Erich	O
Lindemann	O
Mental	O
Health	O
Center	O
05-24	O
:	O
atrophy	B-PROBLEM
,	O
dense	B-PROBLEM
calcification	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
tentorium	I-PROBLEM
,	O
most	O
likely	O
of	O
metabolic	O
etiology	O

IMAGING	B-TEST
AT	O
Providence	O
Behavioral	O
Health	O
Hospital	O
:	O

ECHO	B-TEST
2018-05-28	O

IMPRESSION	O
:	O
Moderate	B-PROBLEM
to	I-PROBLEM
large	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
(	O
minimal	B-PROBLEM
fluid	I-PROBLEM
anteriorly	I-PROBLEM
(	O
1cm	O
),	O
?	O
bloody	B-PROBLEM
).	O

No	O
definite	B-PROBLEM
tamponade	I-PROBLEM
physiology	I-PROBLEM
.	O

Pacer	B-TREATMENT
seen	O
in	O
RV	O
apex	O
,	O
but	O
cannot	O
exclude	O
perforation	B-PROBLEM
.	O

CXR	B-TEST
2018-05-30	O

FINDINGS	O
:	O
The	B-TEST
lung	I-TEST
volumes	I-TEST
are	O
Moderate	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
are	O
unchanged	O
.	O

Mild	B-PROBLEM
pulmonary	I-PROBLEM
edema	I-PROBLEM
is	O
unchanged	O
.	O

Lung	B-TEST
volumes	I-TEST
are	O
low	B-PROBLEM
.	O

Bibasilar	B-PROBLEM
atelectasis	I-PROBLEM
is	O
unchanged	O
.	O

IMPRESSION	O
:	O
Unchanged	B-PROBLEM
moderate	I-PROBLEM
bilateral	I-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
and	O
mild	B-PROBLEM
CHF	I-PROBLEM
.	O

RENAL	B-TEST
US	I-TEST
2018-05-28	O

FINDINGS	O
:	O
The	O
right	O
kidney	O
measures	O
11	O
cm	O
in	O
length	B-TEST
,	O
the	O
left	O
kidney	O
measures	O
9.7	O
cm	O
in	O
length	B-TEST
.	O

No	O
hydronephrosis	B-PROBLEM
is	O
seen	O
.	O

No	O
urinary	B-PROBLEM
calculi	I-PROBLEM
are	O
seen	O
.	O

The	O
bladder	O
appears	O
unremarkable	O
and	O
contains	O
a	B-TREATMENT
Foley	I-TREATMENT
catheter	I-TREATMENT
.	O

IMPRESSION	O
:	O
No	O
evidence	O
of	O
hydronephrosis	B-PROBLEM
.	O

82	O
y/o	O
f	O
w	O
h/o	O
afib	B-PROBLEM
,	O
SSS	B-PROBLEM
s/p	O
pacer	B-TREATMENT
05-08	O
c/b	O
PTX	B-PROBLEM
requiring	O
CT	B-TREATMENT
,	O
CAD	B-PROBLEM
,	O
who	O
was	O
readmitted	O
05-24	O
with	O
ARF	B-PROBLEM
and	O
lethargy	B-PROBLEM
,	O
found	O
to	O
have	O
a	B-PROBLEM
large	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
and	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
,	O
with	O
echo	B-TEST
showing	O
no	O
evidence	O
of	O
tamponade	B-PROBLEM
,	O
who	O
is	O
transferred	O
for	O
possible	O
pericardial	B-TREATMENT
effusion	I-TREATMENT
drainage	I-TREATMENT
and	O
treatment	B-TREATMENT
of	O
CHF	B-PROBLEM
,	O
as	O
well	O
as	O
drainage	B-TREATMENT
of	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
.	O

She	O
had	O
a	B-TEST
BNP	I-TEST
of	O
>	O
5000	O
on	O
admission	O
.	O

Since	O
admission	O
,	O
she	O
ruled	O
out	O
for	O
MI	B-PROBLEM
by	O
enzymes	B-TEST
,	O
and	O
had	O
a	B-TEST
right	I-TEST
sided	I-TEST
thoracentesis	I-TEST
which	O
yielded	O
transudative	B-PROBLEM
fluid	I-PROBLEM
.	O

WBC	B-TEST
s	I-TEST
since	O
admission	O
were	O
as	O
high	O
as	O
14,000	O
but	O
normalized	O
.	O

She	O
also	O
had	O
2	B-TEST
echocardiograms	I-TEST
which	O
revealed	O
persistent	B-PROBLEM
pericardial	I-PROBLEM
effusions	I-PROBLEM
.	O

She	O
has	O
been	O
gently	O
diuresed	O
but	O
has	O
worsening	B-PROBLEM
ARF	I-PROBLEM
.	O

Her	B-PROBLEM
O2	I-PROBLEM
requirement	I-PROBLEM
has	O
increased	O
despite	O
diuresis	B-TREATMENT
.	O

She	O
denies	O
any	O
CP	B-PROBLEM
/	O
cough	B-PROBLEM
/	O
fever	B-PROBLEM
,	O
abdominal	B-PROBLEM
pain	I-PROBLEM
/	O
diarrhea	B-PROBLEM
,	O
black	B-PROBLEM
or	I-PROBLEM
bloody	I-PROBLEM
stools	I-PROBLEM
or	O
headache	B-PROBLEM
.	O

Her	B-TEST
urine	I-TEST
output	I-TEST
decreased	B-PROBLEM
to	O
nearly	O
zero	O
.	O

In	O
the	O
setting	O
of	O
her	B-PROBLEM
ongoing	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
,	O
she	O
was	O
transferred	O
for	O
closer	O
observation	O
to	O
the	O
CCU	O
.	O

The	O
CCU	O
fellow	O
and	O
team	O
declined	O
to	O
do	O
pericardial	B-TREATMENT
drainage	I-TREATMENT
,	O
as	O
the	O
pt	O
was	O
hemodynamically	O
stable	O
,	O
without	O
change	B-PROBLEM
in	I-PROBLEM
appearance	I-PROBLEM
of	I-PROBLEM
effusion	I-PROBLEM
by	O
echo	B-TEST
performed	O
at	O
bedside	O
by	O
cards	O
fellow	O
.	O

As	O
she	O
was	O
felt	O
by	O
the	O
CCU	O
to	O
be	O
a	O
poor	O
candidate	O
for	O
right	B-TEST
heart	I-TEST
cath	I-TEST
,	O
was	O
hemodynamically	O
stable	O
with	O
blood	B-TEST
pressure	I-TEST
110	O
s-	O
120	O
s	O
systolic	B-TEST
and	O
pulse	B-TEST
70	O
s-	O
80	O
s	O
,	O
she	O
was	O
called	O
out	O
of	O
the	O
CCU	O
and	O
back	O
to	O
the	O
cardiac	O
floor	O
without	O
intervention	B-TREATMENT
.	O

The	O
procedure	O
team	O
was	O
called	O
to	O
consider	O
doing	O
a	B-TREATMENT
left	I-TREATMENT
thoracentesis	I-TREATMENT
,	O
but	O
she	O
was	O
declined	O
because	O
it	O
was	O
felt	O
that	O
her	B-PROBLEM
effusions	I-PROBLEM
were	O
transudative	B-PROBLEM
,	O
secondary	O
to	O
CHF	B-PROBLEM
,	O
and	O
it	O
was	O
recommended	O
to	O
treat	O
CHF	B-PROBLEM
.	O

The	O
pt	O
continued	O
to	O
have	O
low	B-PROBLEM
urine	I-PROBLEM
output	I-PROBLEM
.	O

She	O
was	O
given	O
a	B-TREATMENT
lasix	I-TREATMENT
drip	I-TREATMENT
IV	I-TREATMENT
upon	O
call-out	O
of	O
the	O
ICU	O
,	O
and	O
additional	O
boluses	B-TREATMENT
of	I-TREATMENT
IV	I-TREATMENT
lasix	I-TREATMENT
,	O
200	O
mg	O
then	O
300	O
mg	O
IV	O
were	O
given	O
with	O
a	O
good	O
response	O
,	O
however	O
,	O
she	O
remained	O
net	B-PROBLEM
positive	I-PROBLEM
fluid	I-PROBLEM
balance	I-PROBLEM
.	O

Renal	O
consultants	O
did	O
not	O
feel	O
there	O
was	O
an	O
emergent	O
need	O
for	O
dialysis	B-TREATMENT
.	O

A	B-TREATMENT
nitro	I-TREATMENT
drip	I-TREATMENT
was	O
started	O
in	O
an	O
effort	O
to	O
decrease	O
her	O
preload	B-TEST
and	O
afterload	B-TEST
.	O

On	O
call	O
out	O
from	O
the	O
CCU	O
,	O
the	O
pt	O
was	O
satting	B-TEST
93%	O
on	O
4-5L	O
NC	B-TREATMENT
,	O
and	O
through	O
the	O
following	O
night	O
,	O
her	B-PROBLEM
oxygen	I-PROBLEM
requirement	I-PROBLEM
increased	O
to	O
NRB	B-TREATMENT
,	O
wherein	O
she	O
was	O
satting	B-TEST
upper	O
80	O
s-	O
low	O
90	O
s.	O

ABG	B-TEST
that	O
evening	O
was	O
7.29/51/56	O
on	O
4L	O
NC	B-TREATMENT
and	O
early	O
the	O
next	O
morning	O
,	O
was	O
7.25/62/64	O
on	O
NRB	B-TREATMENT
.	O

A	B-TEST
CXR	I-TEST
was	O
performed	O
the	O
evening	O
of	O
5/16	O
,	O
showing	O
moderate	B-PROBLEM
sized	I-PROBLEM
bilateral	I-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
,	O
stable	B-PROBLEM
cardiomegaly	I-PROBLEM
and	O
a	O
possible	O
RLL	B-PROBLEM
infiltrate	I-PROBLEM
.	O

Vancomycin	B-TREATMENT
and	O
Zosyn	B-TREATMENT
were	O
started	O
.	O

She	O
was	O
afebrile	B-PROBLEM
.	O

The	O
morning	O
of	O
5/17	O
,	O
her	B-TEST
pulsus	I-TEST
parodoxicus	I-TEST
was	O
12	O
.	O

Because	O
of	O
her	B-TEST
ABG	I-TEST
,	O
and	O
declining	O
clinical	O
status	O
,	O
the	O
CCU	O
was	O
notified	O
for	O
possible	O
transfer	O
.	O

It	O
was	O
felt	O
that	O
given	O
her	O
age	O
,	O
multiple	B-PROBLEM
co-morbidities	I-PROBLEM
,	O
that	O
her	O
prognosis	O
was	O
poor	O
even	O
prior	O
to	O
CCU	O
admission	O
,	O
possible	O
pericardial	B-TREATMENT
drainage	I-TREATMENT
or	O
repeat	B-TREATMENT
thoracenteses	I-TREATMENT
.	O

Explained	O
to	O
Lewin	O
that	O
pt	O
will	O
likely	O
need	O
to	O
be	O
intubated	O
,	O
as	O
she	O
cannot	O
lie	O
flat	O
,	O
and	O
most	O
likely	O
cannot	O
undergo	O
pericardial	B-TREATMENT
drainage	I-TREATMENT
,	O
thoracentesis	B-TREATMENT
,	O
or	O
right	B-TREATMENT
heart	I-TREATMENT
cath	I-TREATMENT
with	O
BiPAP	B-TREATMENT
(	O
which	O
would	O
have	O
been	O
the	O
next	O
measure	O
after	O
NRB	B-TREATMENT
,	O
and	O
prior	O
to	O
intubation	B-TREATMENT
).	O

Explained	O
that	O
despite	O
these	B-TREATMENT
invasive	I-TREATMENT
measures	I-TREATMENT
,	O
she	O
still	O
has	O
a	O
very	O
poor	O
prognosis	O
.	O

Odell	O
does	O
not	O
believe	O
the	O
pt	O
would	O
want	O
to	O
be	O
intubated	O
,	O
with	O
central	B-TREATMENT
line	I-TREATMENT
,	O
right	B-TREATMENT
heart	I-TREATMENT
cath	I-TREATMENT
,	O
in	O
the	O
CCU	O
.	O

She	O
requested	O
the	O
patient	O
be	O
made	O
Comfort	B-TREATMENT
Measures	I-TREATMENT
Only	O
.	O

The	O
pt	O
will	O
be	O
made	O
comfortable	O
,	O
with	O
goals	O
of	O
care	O
shifted	O
towards	O
suppressing	O
her	B-PROBLEM
air	I-PROBLEM
hunger	I-PROBLEM
and	O
pain	B-PROBLEM
.	O

#.	O
SOB	B-PROBLEM
:	O
Most	O
consistent	O
with	O
CHF	B-PROBLEM
by	O
exam	B-TEST
,	O
although	O
unknown	O
what	O
the	O
severity	O
of	O
her	B-PROBLEM
COPD	I-PROBLEM
is	O
currently	O
.	O

TTE	B-TEST
revealed	O
large	B-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
.	O

Pt	O
is	O
now	O
s/p	O
drainage	B-TREATMENT
of	O
right	B-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
,	O
diagnostic	O
and	O
therapeutic	O
,	O
with	O
studies	B-TEST
consistent	O
with	O
transudate	B-PROBLEM
,	O
etiology	O
most	O
likely	O
02-15	O
CHF	B-PROBLEM
.	O

We	O
continued	O
her	B-TREATMENT
albuterol	I-TREATMENT
/	O
atrovent	B-TREATMENT
nebs	I-TREATMENT
,	O
diuresis	B-TREATMENT
with	O
IV	B-TREATMENT
lasix	I-TREATMENT
drip	I-TREATMENT
and	O
boluses	B-TREATMENT
.	O

Her	B-TEST
05-27	I-TEST
CXR	I-TEST
post	O
procedure	O
w/o	O
PNX	B-PROBLEM
,	O
effusion	B-PROBLEM
much	O
improved	O
,	O
yet	O
her	B-TEST
05-28	I-TEST
CXR	I-TEST
worse	O
than	O
05-27	O
with	O
some	O
reaccumulation	O
of	O
right	B-PROBLEM
pleural	I-PROBLEM
effusion	I-PROBLEM
.	O

Then	O
,	O
on	O
05-29	O
,	O
she	O
demonstrated	O
bilateral	B-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM
(	O
reaccumulated	O
),	O
right	B-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
infiltrate	I-PROBLEM
(	O
started	O
on	O
vanco	B-TREATMENT
/	O
zosyn	B-TREATMENT
)->	O
put	O
on	O
face	B-TREATMENT
mask	I-TREATMENT
,	O
given	O
lasix	B-TREATMENT
x	O
1	O
bolus	O
100	O
mg	O
,	O
responded	O
somewhat	O
and	O
o2	B-TEST
sat	I-TEST
stable	O
in	O
low	O
90	O
s.	O

She	O
was	O
given	O
200	B-TREATMENT
mg	I-TREATMENT
IV	I-TREATMENT
lasix	I-TREATMENT
X	O
1	O
with	O
an	O
additional	O
100	O
cc	O
of	O
urine	B-TEST
output	I-TEST
the	O
evening	O
of	O
5/16	O
.	O

Her	B-TREATMENT
lasix	I-TREATMENT
gtt	I-TREATMENT
continued	O
during	O
this	O
time	O
.	O

Her	B-TEST
oxygen	I-TEST
sats	I-TEST
did	O
not	O
improve	O
.	O

#.	O
Pericardial	B-PROBLEM
effusion	I-PROBLEM
:	O
unclear	O
etiology	O
,	O
OSH	O
had	O
raised	O
question	O
of	O
RV	B-PROBLEM
perforation	I-PROBLEM
from	O
pacer	B-TREATMENT
,	O
however	O
she	O
had	O
a	O
normal	O
echo	O
appearance	O
of	O
lead	O
,	O
no	O
tamponade	B-PROBLEM
by	O
exam	B-TEST
.	O

This	O
has	O
still	O
be	O
known	O
to	O
occur	O
during	O
the	B-TREATMENT
placement	I-TREATMENT
of	I-TREATMENT
pacemaker	I-TREATMENT
.	O

It	O
was	O
felt	O
posthumously	O
that	O
her	B-PROBLEM
large	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
was	O
most	O
likely	O
secondary	O
to	O
a	B-PROBLEM
complication	I-PROBLEM
of	O
pacer	B-TREATMENT
placement	I-TREATMENT
,	O
although	O
this	O
was	O
not	O
seen	O
on	O
imaging	B-TEST
.	O

In	O
the	O
last	O
12	O
hours	O
of	O
her	O
life	O
,	O
her	B-TEST
pulsus	I-TEST
was	O
12	O
,	O
and	O
she	O
was	O
felt	O
to	O
likely	O
to	O
have	O
aspect	O
of	O
tamponade	B-PROBLEM
physiology	I-PROBLEM
,	O
since	O
her	B-TEST
preload	I-TEST
was	O
reduced	O
.	O

#.	O
CHF	B-PROBLEM
:	O
normal	O
EF	O
on	O
TTE	B-TEST
so	O
possibly	O
with	O
diastolic	B-PROBLEM
dysfunction	I-PROBLEM
,	O
ruled	O
out	O
for	O
MI	B-PROBLEM

-	O
See	O
course	O
of	O
diuresis	B-TREATMENT
above	O
.	O

-	O
We	O
continued	O
ASA	B-TREATMENT
/	O
imdur	B-TREATMENT
/	O
CCB	B-TREATMENT
/	O
hold	O
diovan	B-TREATMENT
until	O
pt	O
was	O
made	O
CMO	O
.	O

#.	O
Pleural	B-PROBLEM
effusions	I-PROBLEM
:	O
Likely	O
due	O
to	O
CHF	B-PROBLEM
although	O
had	O
some	B-PROBLEM
leukocytosis	I-PROBLEM
at	O
admission	O
to	O
OSH	O
.	O

Mary	B-TEST
studies	I-TEST
c/w	O
transudate	B-PROBLEM
.	O

-	O
After	O
she	O
was	O
made	O
CMO	O
,	O
the	O
pt	O
was	O
started	O
on	O
Morphine	B-TREATMENT
gtt	I-TREATMENT
to	O
maximize	O
comfort	O
and	O
minimize	O
air	B-PROBLEM
hunger	I-PROBLEM
.	O

#.	O
Afib/SSS	B-PROBLEM
:	O
She	O
was	O
A-paced	B-TREATMENT
,	O
pacer	B-TREATMENT
placed	O
05-08	O
in	O
DDDR	B-TREATMENT
mode	I-TREATMENT
,	O
complicated	O
by	O
PTX	B-PROBLEM
requiring	O
chest	B-TREATMENT
tube	I-TREATMENT
which	O
resolved	O
and	O
tube	B-TREATMENT
was	O
removed	O
during	O
admit	O
for	O
pacer	B-TREATMENT
,	O
no	O
evidence	O
of	O
PTX	B-PROBLEM
on	O
most	B-TEST
recent	I-TEST
CXR	I-TEST
.	O

Her	B-TREATMENT
pacer	I-TREATMENT
wires	I-TREATMENT
in	O
correct	O
position	O
.	O

We	O
continued	O
amiodarone	B-TREATMENT
until	O
pt	O
was	O
made	O
CMO	O
.	O

Anticoagulation	B-TREATMENT
has	O
not	O
been	O
given	O
this	O
admission	O
.	O

We	O
started	O
her	O
on	O
dilt	B-TREATMENT
for	O
additional	B-TREATMENT
a	I-TREATMENT
fib	I-TREATMENT
control	I-TREATMENT
(	O
revert	O
back	O
to	O
a	B-PROBLEM
fib	I-PROBLEM
on	O
05-29	O
),	O
which	O
was	O
stopped	O
when	O
the	O
pt	O
was	O
made	O
CMO	O
.	O

#.	O
Oliguric	B-PROBLEM
ARF	I-PROBLEM
:	O
likely	O
prerenal	O
due	O
to	O
n/v	B-PROBLEM
poor	B-PROBLEM
po	I-PROBLEM
intake	I-PROBLEM
and	O
poor	B-PROBLEM
forward	I-PROBLEM
flow	I-PROBLEM
,	O
However	O
,	O
need	O
to	O
continue	O
diuresis	B-TREATMENT
.	O

Her	B-TEST
urine	I-TEST
lytes	I-TEST
consistent	O
with	O
ATN	B-PROBLEM
,	O
FENA	B-TEST
4%	O
.	O

Renal	B-TEST
u/s	I-TEST
negative	O
for	O
hydronephrosis	B-PROBLEM
.	O

Renal	O
consultants	O
did	O
not	O
feel	O
that	O
there	O
was	O
an	O
indication	O
for	O
urgent	B-TREATMENT
hemodialysis	I-TREATMENT
.	O

She	O
continued	O
to	O
put	O
out	O
low	B-PROBLEM
amounts	I-PROBLEM
of	I-PROBLEM
urine	I-PROBLEM
throughout	O
the	O
admission	O
,	O
despite	O
aggressive	B-TREATMENT
diuresis	I-TREATMENT
with	O
IV	B-TREATMENT
lasix	I-TREATMENT
gtt	I-TREATMENT
and	O
boluses	B-TREATMENT
.	O

#.	O
ID	O
:	O
initially	O
had	O
leukocytosis	B-PROBLEM
at	O
admission	O
,	O
with	O
chest	B-TEST
CT	I-TEST
showing	O
possible	O
underlying	B-PROBLEM
consolidations	I-PROBLEM
vs.	O
atelectasis	B-PROBLEM
,	O
levoflox	B-TREATMENT
started	O
05-24	O
and	O
subsequently	O
stopped	O
(	O
no	O
consolidations	B-PROBLEM
on	O
CXR	B-TEST
and	O
afebrile	B-PROBLEM
).	O

U/A	B-TEST
on	O
05-27	O
c/w	O
UTI	B-PROBLEM
.	O

Pt	O
now	O
on	O
IV	B-TREATMENT
Ceftriaxone	I-TREATMENT
(	O
was	O
on	O
levoflox	B-TREATMENT
since	O
05-24	O
however	O
UA	B-TEST
now	O
floridly	B-PROBLEM
positive	I-PROBLEM
(	O
more	O
so	O
than	O
UA	B-TEST
at	O
OSH	O
)	O
so	O
felt	O
possibly	O
levo-resistant	B-PROBLEM
.	O

Pt	O
started	O
on	O
CTX	B-TREATMENT
05-27	O
.	O

She	O
was	O
empirically	O
started	O
on	O
vanco/zosyn	B-TREATMENT
for	O
empiric	B-TREATMENT
hosp	I-TREATMENT
acquired	I-TREATMENT
pna	I-TREATMENT
coverage	I-TREATMENT

-	O
possible	O
opacity	B-PROBLEM
on	O
CXR	B-TEST
-	O
along	O
w/	O
leukocytosis	B-PROBLEM
.	O

#.	O
Anemia	B-PROBLEM
:	O
Unclear	O
source	O
.	O

She	O
was	O
guiaic	B-TEST
negative	O
.	O

-	O
no	O
transfusions	B-TREATMENT
,	O
CMO/DNR/DNI	O

#.	O
FEN	O
:	O
check	O
lytes	B-TEST
,	O
most	O
recently	O
normal	O
.	O

cardiac/renal	B-TREATMENT
diet	I-TREATMENT

#.	O
Access	O
:	O
PIV	B-TREATMENT

aranesp	B-TREATMENT
100	O
mcg	O
(	O
X1	O
05-26	O
)	O

diltiazem	B-TREATMENT
CD	I-TREATMENT
240	O
mg	O

paxil	B-TREATMENT
20	O
mg	O
daily	O

detrol	B-TREATMENT
LA	I-TREATMENT
4	O
mg	O
daily	O

EC	B-TREATMENT
ASA	I-TREATMENT
81	O
mg	O
daily	O

pepcid	B-TREATMENT
20	O
mg	O
daily	O

amiodarone	B-TREATMENT
200	O
mg	O
daily	O

levofloxacin	B-TREATMENT
250	O
mg	O
IV	O
daily	O
(	O
started	O
05-24	O
)	O

levothyroxine	B-TREATMENT
50	O
mcg	O
daily	O

diovan	B-TREATMENT
160	O
mg	O
daily	O

imdur	B-TREATMENT
60	O
mg	O
daily	O

albuterol-ipratroprium	B-TREATMENT
INH	O
2	O
sprays	O
tid	O
prn	O

1.	O
Pulmonary	B-PROBLEM
Edema	I-PROBLEM
and	O
Hypoxic	B-PROBLEM
Respiratory	I-PROBLEM
Failure	I-PROBLEM

2.	O
Large	B-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM

3.	O
Moderate	B-PROBLEM
bilateral	I-PROBLEM
pleural	I-PROBLEM
effusions	I-PROBLEM

4.	O
Congestive	B-PROBLEM
Heart	I-PROBLEM
Failure	I-PROBLEM

5.	O
Paroxysmal	B-PROBLEM
Atrial	I-PROBLEM
Fibrillation	I-PROBLEM

6.	O
Sick	B-PROBLEM
sinus	I-PROBLEM
syndrome	I-PROBLEM
status	O
post	O
pacer	B-TREATMENT
placement	I-TREATMENT

7.	O
Coronary	B-PROBLEM
Artery	I-PROBLEM
Disease	I-PROBLEM

Penicillins	B-TREATMENT

Dyspnea	B-PROBLEM

46	O
-	O
yo-man	O
w/	O
active	O
cocaine	O
use	O
presents	O
w/	O
LE	B-PROBLEM
edema	I-PROBLEM
.	O

10	O
days	O
ago	O
,	O
he	O
developed	O
b/l	B-PROBLEM
LE	I-PROBLEM
edema	I-PROBLEM
that	O
has	O
gotten	O
progressively	O
worse	O
until	O
now	O
.	O

Three	O
days	O
ago	O
,	O
he	O
developed	O
dyspnea	B-PROBLEM
on	O
exertion	O
when	O
climbing	O
stairs	O
,	O
assoc	O
w/	O
2-pillow	B-PROBLEM
orthopnea	I-PROBLEM
and	O
PND	B-PROBLEM
.	O

He	O
denies	O
any	B-PROBLEM
recent	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
palpitations	B-PROBLEM
,	O
headache	B-PROBLEM
,	O
confusion	B-PROBLEM
,	O
weakness	B-PROBLEM
,	O
numbness	B-PROBLEM
,	O
abd	B-PROBLEM
pain	I-PROBLEM
,	O
or	O
hematuria	B-PROBLEM
.	O

No	O
recent	B-PROBLEM
viral	I-PROBLEM
syndromes	I-PROBLEM
or	O
URI	B-PROBLEM
s.	I-PROBLEM

Today	O
,	O
his	O
wife	O
convinced	O
him	O
to	O
present	O
to	O
the	O
Deanna	O
for	O
evaluation	B-TEST
.	O

In	O
the	O
Deanna	O
,	O
his	B-TEST
BP	I-TEST
was	O
230/170	O
.	O

BNP	B-TEST
was	O
elevated	O
at	O
7500	O
.	O

CXR	B-TEST
revealed	O
evidence	O
of	O
cardiomegaly	B-PROBLEM
and	O
pulm	B-PROBLEM
edema	I-PROBLEM
.	O

He	O
was	O
treated	O
w/	O
ASA	B-TREATMENT
325	O
mg	O
,	O
lasix	B-TREATMENT
10	O
mg	O
IV	O
,	O
and	O
hydralazine	B-TREATMENT
10	O
mg	O
IV	O
x	O
2	O
.	O

He	O
responded	O
well	O
to	O
lasix	B-TREATMENT
w/	O
good	O
UOP	B-TEST
,	O
but	O
diastolic	B-TEST
BP	I-TEST
remained	O
elevated	B-PROBLEM
at	O
170	O
,	O
prompting	O
initiation	O
of	O
nitroprusside	B-TREATMENT
gtt	I-TREATMENT
.	O

Drinks	O
3-4	O
beers	O
a	O
few	O
times	O
weekly	O
,	O
no	O
h/o	O
withdrawal	B-PROBLEM
symptoms	I-PROBLEM
,	O
seizures	B-PROBLEM
or	O
DT	B-PROBLEM
s.	I-PROBLEM

There	O
is	O
no	O
family	O
history	O
of	O
premature	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
or	O
sudden	B-PROBLEM
death	I-PROBLEM
.	O

VS	B-TEST
:	O
T,	B-TEST
BP	B-TEST
181/122	O
,	O
HR	B-TEST
84	O
,	O
RR	B-TEST
12	O
,	O
O2	B-TEST
98%	O
2L/m	O

Gen	O
:	O
lying	O
flat	O
in	O
bed	O
,	O
pleasant	O
and	O
conversational	O
,	O
NAD	B-PROBLEM

HEENT	O
:	O
NCAT	B-PROBLEM
.	O

Sclera	B-PROBLEM
anicteric	I-PROBLEM
.	O

Neck	O
:	O
Supple	O
with	O
JVP	B-TEST
of	O
8	O
cm	O
.	O

CV	O
:	O
reg	O
s1	O
,	O
loud	B-PROBLEM
s2	I-PROBLEM
,	O
+	O
2/6	B-PROBLEM
systolic	I-PROBLEM
murmur	I-PROBLEM
radiating	I-PROBLEM
to	I-PROBLEM
axilla	I-PROBLEM
,	O
no	O
s3/s4/r	B-PROBLEM

Pulm	O
:	O
CTA	O
b/l	O
w/	O
no	O
crackles	B-PROBLEM
or	O
wheezing	B-PROBLEM

Abd	O
:	O
obese	B-PROBLEM
,	O
+BS	O
,	O
soft	O
,	O
NTND	B-PROBLEM
.	O

Ext	O
:	O
warm	O
,	O
2+	O
DP	B-TEST
b/l	O
,	O
2+	B-PROBLEM
pitting	I-PROBLEM
edema	I-PROBLEM
to	I-PROBLEM
knees	I-PROBLEM
b/l	I-PROBLEM

WBC	B-TEST
-	O
7.7	O
RBC	B-TEST
-	O
5.00	O
HGB	B-TEST
-	O
15.0	O
HCT	B-TEST
-	O
42.8	O
MCV	B-TEST
-	O
86	O
MCH	B-TEST
-	O
30.0	O
MCHC	B-TEST
-	O
35.0	O
RDW	B-TEST
-	O
14.6	O

PLT	B-TEST
COUNT	I-TEST
-	O
315	O

CK-MB	B-TEST
-	O
4	O
proBNP	B-TEST
-	O
7489	O
*	O

cTropnT	B-TEST
-	O
0.02	O
*	O

ALT(SGPT)	B-TEST
-	O
77	O
*	O
AST(SGOT)	B-TEST
-	O
60	O
*	O
CK(CPK)	B-TEST
-	O
195	O
*	O
ALK	B-TEST
PHOS	I-TEST
-	O
104	O
AMYLASE	B-TEST
-	O
100	O
TOT	B-TEST
BILI	I-TEST
-	O
0.4	O

EKG	B-TEST
demonstrated	O
NSR	O
at	O
87	O
bpm	O
,	O
nl	O
axis	O
,	O
nl	O
int	O
,	O
LVH	B-PROBLEM
w/	O
strain	B-PROBLEM
pattern	I-PROBLEM
,	O
no	O
ischemic	B-PROBLEM
changes	I-PROBLEM
.	O

CXR	B-TEST
:	O

Moderate	B-PROBLEM
to	I-PROBLEM
severe	I-PROBLEM
enlargement	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
cardiac	I-PROBLEM
silhouette	I-PROBLEM
,	O
and	O
particularly	O
the	O
left	O
atrium	O
accompanied	O
by	O
pulmonary	B-PROBLEM
vascular	I-PROBLEM
congestion	I-PROBLEM
and	O
mild	B-PROBLEM
pulmonary	I-PROBLEM
edema	I-PROBLEM
consistent	O
with	O
heart	B-PROBLEM
failure	I-PROBLEM
.	O

The	O
left	O
atrium	O
is	O
moderately	B-PROBLEM
dilated	I-PROBLEM
.	O

There	O
is	O
moderate	B-PROBLEM
symmetric	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
with	O
mild	B-PROBLEM
cavity	I-PROBLEM
dilation	I-PROBLEM
and	O
severe	B-PROBLEM
global	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

No	O
left	B-PROBLEM
ventricular	I-PROBLEM
thrombus	I-PROBLEM
is	O
seen	O
.	O

Tissue	B-TEST
Doppler	I-TEST
imaging	I-TEST
suggests	O
an	B-PROBLEM
increased	I-PROBLEM
left	I-PROBLEM
ventricular	I-PROBLEM
filling	I-PROBLEM
pressure	I-PROBLEM
(	O
PCWP	B-TEST
>	O
18	O
mmHg	O
).	O

The	O
right	O
ventricular	O
cavity	O
is	O
mildly	B-PROBLEM
dilated	I-PROBLEM
with	O
severe	B-PROBLEM
free	I-PROBLEM
wall	I-PROBLEM
hypokinesis	I-PROBLEM
.	O

The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
minimally	B-PROBLEM
thickened	I-PROBLEM
.	O

No	O
aortic	B-PROBLEM
stenosis	I-PROBLEM
or	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

There	O
is	O
no	O
mitral	B-PROBLEM
valve	I-PROBLEM
prolapse	I-PROBLEM
.	O

Mild	B-PROBLEM
(	I-PROBLEM
1+	I-PROBLEM
)	I-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
is	O
seen	O
.	O

There	O
is	O
moderate	B-PROBLEM
pulmonary	I-PROBLEM
artery	I-PROBLEM
systolic	I-PROBLEM
hypertension	I-PROBLEM
.	O

There	O
is	O
a	B-PROBLEM
very	I-PROBLEM
small	I-PROBLEM
circumferential	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
.	O

IMPRESSION	O
:	O
Moderate	B-PROBLEM
symmetric	I-PROBLEM
eft	I-PROBLEM
ventricular	I-PROBLEM
hypertrophy	I-PROBLEM
with	O
severe	B-PROBLEM
global	I-PROBLEM
biventricular	I-PROBLEM
hypokinesis	I-PROBLEM
c/w	O
diffuse	B-PROBLEM
process	I-PROBLEM
(	O
toxin	B-PROBLEM
,	O
metabolic	O
,	O
cannot	O
exclude	O
myocarditis	B-PROBLEM
;	O
in	O
the	O
absence	O
of	O
LVH	B-PROBLEM
on	O
ECG	B-TEST
,	O
an	B-PROBLEM
infiltrative	I-PROBLEM
process	I-PROBLEM
should	O
also	O
be	O
considered	O
).	O

Mild	B-PROBLEM
mitral	I-PROBLEM
regurgitation	I-PROBLEM
.	O

Moderate	B-PROBLEM
pulmonary	I-PROBLEM
arterial	I-PROBLEM
hypertension	I-PROBLEM
.	O

Very	B-PROBLEM
small	I-PROBLEM
circumferential	I-PROBLEM
pericardial	I-PROBLEM
effusion	I-PROBLEM
.	O

Possible	O
abnormality	B-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
aortic	I-PROBLEM
valve	I-PROBLEM
as	O
described	O
above	O
without	O
aortic	B-PROBLEM
regurgitation	I-PROBLEM
.	O

If	O
clinically	O
indicated	O
a	B-TEST
TEE	I-TEST
would	O
be	O
better	O
able	O
to	O
define	O
an	B-PROBLEM
abnormality	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
aortic	I-PROBLEM
valve	I-PROBLEM
.	O

46	O
-	O
yo-man	O
w/	O
cocaine	O
abuse	O
presents	O
w/	O
LE	B-PROBLEM
edema	I-PROBLEM
and	O
DOE	B-PROBLEM
likely	O
from	O
diastolic	B-PROBLEM
heart	I-PROBLEM
failure	I-PROBLEM
in	O
the	O
setting	O
of	O
cocaine	O
use	O
complicated	O
by	O
hypertensive	B-PROBLEM
urgency	I-PROBLEM
.	O

Hypertensive	B-PROBLEM
urgency	I-PROBLEM
:	O

BP	B-TEST
230/170	O
on	O
presentation	O
,	O
most	O
likely	O
from	O
chronic	B-PROBLEM
HTN	I-PROBLEM
exacerbated	O
by	O
cocaine	O
use	O
.	O

No	O
signs	O
of	O
end-organ	B-PROBLEM
damage	I-PROBLEM
at	O
present	O
except	O
for	O
elevated	B-PROBLEM
creatinine	I-PROBLEM
,	O
which	O
is	O
more	O
likely	O
a	B-PROBLEM
chronic	I-PROBLEM
problem	I-PROBLEM
.	O

The	O
patient	O
was	O
started	O
on	O
labetalol	B-TREATMENT
and	O
Lisinopril	B-TREATMENT
.	O

His	B-TEST
blood	I-TEST
pressure	I-TEST
was	O
taken	O
down	O
from	O
230	O
systolic	B-TEST
to	O
approx	O
160	O
systolic	B-TEST
/	O
100	O
diastolic	B-TEST
on	O
discharge	O
.	O

His	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
edema	I-PROBLEM
improved	O
with	O
diuresis	B-TREATMENT
.	O

An	B-TEST
echo	I-TEST
performed	O
on	O
admission	O
showed	O
an	B-TEST
LF	I-TEST
EF	I-TEST
of	O
25%	O
.	O

It	O
is	O
hoped	O
with	O
good	B-TREATMENT
blood	I-TREATMENT
pressure	I-TREATMENT
control	I-TREATMENT
and	O
use	O
of	O
an	B-TREATMENT
ACE-I	I-TREATMENT
with	O
follow	O
up	O
in	O
addition	O
to	O
cocaine	O
abstaining	O
will	O
improved	O
his	O
cardiac	O
function	O
.	O

Renal	B-PROBLEM
Failure	I-PROBLEM
:	O
creatinine	B-TEST
on	O
admission	O
was	O
1.6	O
Likely	O
acute	B-PROBLEM
hypertensive	I-PROBLEM
nephropathy	I-PROBLEM
plus	O
probalbe	O
long-standing	B-PROBLEM
hypertensive	I-PROBLEM
disease	I-PROBLEM
.	O

discharged	O
on	O
ACE-I	B-TREATMENT
.	O

1.	O
Aspirin	B-TREATMENT
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Hydrochlorothiazide	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

3.	O
Labetalol	B-TREATMENT
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

4.	O
Lisinopril	B-TREATMENT
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

-	O
hypertensive	B-PROBLEM
emergency	I-PROBLEM

-	O
ARF	B-PROBLEM

-	O
mild	B-PROBLEM
transaminitis	I-PROBLEM
likely	O
03-25	O
etoh	O
and	O
cocaine	O
abuse	O

-	O
lower	B-PROBLEM
extremity	I-PROBLEM
edema	I-PROBLEM
improved	O

You	O
came	O
in	O
with	O
hypertensive	B-PROBLEM
emergency	I-PROBLEM
.	O

You	O
were	O
treated	O
with	O
medications	B-TREATMENT
to	O
improve	O
your	B-TEST
blood	I-TEST
pressure	I-TEST
.	O

1.	O
Lisinopril	B-TREATMENT
20	O
mg	O
daily	O

2.	O
HCTZ	B-TREATMENT
25	O
mg	O
daily	O

3.	O
Labetalol	B-TREATMENT
400	O
mg	O
bid	O

4.	O
ASA	B-TREATMENT
162mg	O
daily	O

It	O
is	O
extremely	O
important	O
for	O
you	O
to	O
take	O
these	B-TREATMENT
medications	I-TREATMENT
.	O

Please	O
return	O
to	O
the	O
Deanna	O
if	O
you	O
experience	O
SOB	B-PROBLEM
,	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
fevers	B-PROBLEM
,	O
chills	B-PROBLEM
,	O
dizziness	B-PROBLEM
,	O
decreased	B-PROBLEM
urine	I-PROBLEM
output	I-PROBLEM
.	O

Ken	O
Nansteel-Miller	O
is	O
the	O
triplet	O
#3	O
of	O
a	B-PROBLEM
spontaneous	I-PROBLEM
triamniotic-trichorionic	I-PROBLEM
triplet	I-PROBLEM
pregnancy	I-PROBLEM
born	O
to	O
a	O
39-year-old	O
G4	O
P1	O
spontaneous	O
abortion	O
2	O
woman	O
.	O

Blood	B-TEST
type	I-TEST
A	O
positive	O
,	O
antibody	B-TEST
negative	O
,	O
rubella	B-TEST
immune	O
,	O
RPR	B-TEST
nonreactive	O
,	O
hepatitis	B-TEST
B	I-TEST
surface	I-TEST
antigen	I-TEST
negative	O
,	O
group	B-TEST
beta	I-TEST
Strep	I-TEST
status	I-TEST
unknown	O
.	O

The	O
mother	O
was	O
followed	O
closely	O
and	O
received	O
betamethasone	B-TREATMENT
2011-08-22	O
.	O

She	O
was	O
admitted	O
on	O
2011-08-25	O
for	O
nausea	B-PROBLEM
,	O
vomiting	B-PROBLEM
,	O
and	O
a	B-PROBLEM
shortened	I-PROBLEM
cervix	I-PROBLEM
.	O

She	O
was	O
treated	O
with	O
bed	B-TREATMENT
rest	I-TREATMENT
and	O
prn	O
terbutaline	B-TREATMENT
.	O

Other	B-TREATMENT
medications	I-TREATMENT
including	O
Prozac	B-TREATMENT
.	O

The	O
babies	O
were	O
born	O
by	O
elective	B-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
at	O
34	O
weeks	O
gestation	O
.	O

This	O
triplet	O
#3	O
emerged	O
with	O
spontaneous	O
respirations	O
,	O
and	O
required	O
blow-by	B-TREATMENT
oxygen	I-TREATMENT
in	O
the	O
delivery	O
room	O
.	O

Apgars	B-TEST
were	O
seven	O
at	O
one	O
minute	O
and	O
eight	O
at	O
five	O
minutes	O
.	O

He	O
was	O
admitted	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
for	O
treatment	B-TREATMENT
of	O
prematurity	B-PROBLEM
.	O

Weight	B-TEST
1.7	O
kg	O
,	O
length	B-TEST
41.5	O
cm	O
,	O
head	B-TEST
circumference	I-TEST
29	O
cm	O
,	O
all	O
10th-25th	O
percentile	O
for	O
34	O
weeks	O
.	O

General	O
:	O
Nondysmorphic	B-PROBLEM
preterm	O
male	O
in	O
mild	B-PROBLEM
respiratory	I-PROBLEM
distress	I-PROBLEM
.	O

Positive	O
red	B-TEST
reflex	I-TEST
bilaterally	O
.	O

Chest	O
:	O
Mild	B-PROBLEM
intercostal	I-PROBLEM
and	I-PROBLEM
sternal	I-PROBLEM
retractions	I-PROBLEM
.	O

Breath	B-TEST
sounds	I-TEST
equal	O
with	O
fair	O
aeration	O
.	O

Cardiovascular	O
:	O
Regular	O
,	O
rate	O
,	O
and	O
rhythm	O
,	O
no	O
murmur	B-PROBLEM
.	O

Femoral	B-TEST
pulses	I-TEST
+2	O
.	O

Abdomen	O
is	O
soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
no	O
masses	B-PROBLEM
,	O
positive	O
bowel	O
sounds	O
.	O

1.	O
Respiratory	O
:	O
Lincoln	O
required	O
nasal	B-TREATMENT
cannula	I-TREATMENT
O2	I-TREATMENT
for	O
approximately	O
the	O
first	O
8-12	O
hours	O
of	O
life	O
.	O

He	O
has	O
had	O
no	O
episodes	O
of	O
spontaneous	B-PROBLEM
apnea	I-PROBLEM
during	O
admission	O
.	O

2.	O
Cardiovascular	O
:	O
Falmouth	O
has	O
maintained	O
normal	O
heart	O
rates	O
and	O
blood	B-TEST
pressures	I-TEST
.	O

No	O
murmurs	B-PROBLEM
have	O
been	O
noted	O
.	O

Beverly	O
was	O
initially	O
NPO	B-TREATMENT
and	O
maintained	O
on	O
intravenous	B-TREATMENT
fluids	I-TREATMENT
.	O

Enteral	B-TREATMENT
feeds	I-TREATMENT
were	O
started	O
on	O
day	O
of	O
life	O
#1	O
,	O
and	O
gradually	O
advanced	O
to	O
full	O
volume	O
.	O

Discharge	B-TEST
weight	I-TEST
is	O
1.89	O
kg	O
.	O

4.	O
Gastrointestinal	O
:	O
Boston	O
required	O
treatment	B-TREATMENT
for	O
unconjungated	B-PROBLEM
hyperbilirubinemia	I-PROBLEM
with	O
phototherapy	B-TREATMENT
.	O

His	B-TEST
peak	I-TEST
serum	I-TEST
bilirubin	I-TEST
occurred	O
on	O
day	O
of	O
life	O
three	O
with	O
a	O
total	O
of	O
8.3	O
/	O
0.2	O
direct	O
,	O
8.1	O
indirect	O
mg/dl	O
.	O

He	O
received	O
phototherapy	B-TREATMENT
for	O
approximately	O
72	O
hours	O
.	O

Rebound	B-TEST
bilirubin	I-TEST
on	O
day	O
of	O
life	O
#7	O
was	O
6.6	O
,	O
and	O
total	O
was	O
0.2	O
direct	O
.	O

Throughout	O
admission	O
,	O
there	O
are	O
no	O
neurological	B-PROBLEM
concerns	I-PROBLEM
at	O
the	O
time	O
of	O
discharge	O
.	O

Audiology	O
:	O
Hearing	B-TEST
screening	I-TEST
was	O
performed	O
with	O
automated	O
auditory	O
brain	O
stem	O
responses	O
.	O

2.	O
Medications	B-TREATMENT
:	O
Ferrous	B-TREATMENT
sulfate	I-TREATMENT
0.15	O
cc	O
po	O
q	O
day	O
25	O
mg	O
/	O
ml	O
dilution	O
.	O

3.	O
Car	B-TEST
seat	I-TEST
position	I-TEST
screening	I-TEST
was	O
performed	O
.	O

Waltham	O
was	O
monitored	O
for	O
90	O
minutes	O
without	O
any	O
episodes	O
of	O
apnea	B-PROBLEM
or	O
oxygen	B-PROBLEM
desaturation	I-PROBLEM
.	O

4.	O
State	B-TEST
Newborn	I-TEST
Screens	I-TEST
were	O
sent	O
on	O
09-27	O
and	O
2011-10-05	O
with	O
no	O
notification	O
of	O
abnormal	B-PROBLEM
results	I-PROBLEM
to	O
date	O
.	O

5.	O
No	O
immunizations	B-TREATMENT
administered	O
.	O

Plan	O
is	O
to	O
receive	O
hepatitis	B-TREATMENT
B	I-TREATMENT
in	O
the	O
pediatrician	O
's	O
office	O
,	O
once	O
he	O
reaches	O
a	O
weight	O
of	O
2	O
kg	O
.	O

6.	O
Immunizations	B-TREATMENT
recommended	O
:	O
Synagis	B-TREATMENT
RSV	I-TREATMENT
prophylaxis	I-TREATMENT
should	O
be	O
considered	O
from	O
October	O
through	O
April	O
for	O
infants	O
who	O
meet	O
any	O
of	O
the	O
following	O
three	O
criteria	O
:	O

3)	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
.	O

Influenza	B-TREATMENT
immunization	I-TREATMENT
should	O
be	O
considered	O
annually	O
in	O
the	O
fall	O
for	O
preterm	O
infants	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
once	O
they	O
reach	O
six	O
months	O
of	O
age	O
.	O

Before	O
this	O
age	O
,	O
the	O
family	O
and	O
other	O
caregivers	O
should	O
be	O
considered	O
for	O
immunization	B-TREATMENT
against	O
influenza	B-PROBLEM
to	O
protect	O
the	O
infant	O
.	O

1.	O
Prematurity	B-PROBLEM
at	I-PROBLEM
34	I-PROBLEM
weeks	I-PROBLEM
gestation	I-PROBLEM
.	O

3.	O
Unconjugated	B-PROBLEM
hyperbilirubinemia	I-PROBLEM
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	I-PROBLEM
Drugs	I-PROBLEM

exertional	B-PROBLEM
angina	I-PROBLEM

10-01	O
CABG	B-TREATMENT
x	O
3	O

60	O
yo	O
M	O
with	O
exertional	B-PROBLEM
angina	I-PROBLEM
->	O
positive	B-PROBLEM
ETT	I-PROBLEM
->	O
cath	B-TEST
with	O
severe	B-PROBLEM
3VD	I-PROBLEM

HTN	B-PROBLEM

DM	B-PROBLEM

cataracts	B-PROBLEM
s/p	O
removal	B-TREATMENT
of	O
in	O
Mayotte	O
c/b	O
enucleated	O
CMED	O
CSRU	O

urinary	B-PROBLEM
incontinence	I-PROBLEM

father	O
with	O
?	O
Mi	B-PROBLEM
at	O
unknown	O
age	O

NAD	B-TEST
76	O
184/87	O
18	O

Teeth	B-PROBLEM
in	I-PROBLEM
poor	I-PROBLEM
repair	I-PROBLEM

distant	B-PROBLEM
heart	I-PROBLEM
sounds	I-PROBLEM
,	O
RRR	O

extrem	B-PROBLEM
warm	I-PROBLEM
,	O
no	O
edema	B-PROBLEM
,	O
no	O
varicosities	B-PROBLEM
,	O
2+	O
pedal	B-TEST
pulses	I-TEST

2019-10-07	O
05:30	O
AM	O
BLOOD	B-TEST
WBC	B-TEST
-	O
6.5	O
RBC	B-TEST
-	O
3.23	O
*	O
Hgb	B-TEST
-	O
9.5	O
*	O
Hct	B-TEST
-	O
27.6	O
*	O
MCV	B-TEST
-	O
86	O
MCH	B-TEST
-	O
29.4	O
MCHC	B-TEST
-	O
34.4	O
RDW	B-TEST
-	O
14.0	O
Plt	B-TEST
Ct	I-TEST
-	O
356	O
#	O

2019-10-07	O
05:30	O
AM	O
BLOOD	B-TEST
Plt	B-TEST
Ct	I-TEST
-	O
356	O
#	O

2019-10-04	O
06:50	O
AM	O
BLOOD	B-TEST
PT	B-TEST
-	O
13.2	O
*	O
PTT	B-TEST
-	O
32.1	O
INR(PT)	B-TEST
-	O
1.2	O
*	O

2019-10-07	O
05:30	O
AM	O
BLOOD	B-TEST
Glucose	B-TEST
-	O
156	O
*	O
UreaN	B-TEST
-	O
20	O
Creat	B-TEST
-	O
1.0	O
Na	B-TEST
-	O
140	O
K	B-TEST
-	O
3.8	O
Cl	B-TEST
-	O
99	O
HCO3	B-TEST
-	O
31	O
AnGap	B-TEST
-	O
14	O

He	O
was	O
taken	O
to	O
the	O
operating	O
room	O
on	O
2019-10-01	O
where	O
he	O
underwent	O
a	B-TREATMENT
CABG	I-TREATMENT
x	O
3	O
.	O

He	O
was	O
weaned	O
from	O
his	B-TREATMENT
vasoactive	I-TREATMENT
drips	I-TREATMENT
and	O
transferred	O
to	O
the	O
floor	O
on	O
POD	O
#2	O
.	O

He	O
was	O
seen	O
by	O
speech	O
and	O
swallowing	O
who	O
recommended	O
NPO	B-TREATMENT
,	O
he	O
then	O
underwent	O
a	B-TEST
video	I-TEST
swallow	I-TEST
after	O
which	O
he	O
was	O
changed	O
to	O
a	B-TREATMENT
diet	I-TREATMENT
of	I-TREATMENT
thin	I-TREATMENT
liquids	I-TREATMENT
and	I-TREATMENT
soft	I-TREATMENT
solids	I-TREATMENT
,	O
and	O
felt	O
that	O
his	O
eeating	O
may	O
be	O
limited	O
by	O
his	B-PROBLEM
loose	I-PROBLEM
teeth	I-PROBLEM
.	O

lisinopril	B-TREATMENT
,	O
protonix	B-TREATMENT
,	O
glipizide	B-TREATMENT
,	O
metformin	B-TREATMENT
,	O
asa	B-TREATMENT

1.	O
Aspirin	B-TREATMENT
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
).	O

3.	O
Metoprolol	B-TREATMENT
Tartrate	I-TREATMENT
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

4.	O
Docusate	B-TREATMENT
Sodium	I-TREATMENT
150	O
mg	O
/	O
15	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

5.	O
Oxycodone	B-TREATMENT
-	O
Acetaminophen	B-TREATMENT
5-325	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
every	O
4-6	O
hours	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

6.	O
Clopidogrel	B-TREATMENT
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

7.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

8.	O
Glipizide	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

9.	O
Lisinopril	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

10.	O
Hydrochlorothiazide	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O

CAD	B-PROBLEM

HTN	B-PROBLEM

DM	B-PROBLEM

cataracts	B-PROBLEM
s/p	O
removal	B-TREATMENT
c/b	O
enucleated	O
left	O
CMED	O
CSRU	O

urinary	B-PROBLEM
incontinence	I-PROBLEM

?	O
TIA	B-PROBLEM

Call	O
with	O
fever	B-PROBLEM
,	O
redness	B-PROBLEM
or	O
drainage	B-PROBLEM
from	I-PROBLEM
incision	I-PROBLEM
or	O
weight	B-PROBLEM
gain	I-PROBLEM
more	O
than	O
2	O
pounds	O
in	O
one	O
day	O
or	O
five	O
in	O
one	O
week	O
.	O

Shower	O
,	O
no	O
baths	O
,	O
no	O
lotions	B-TREATMENT
,	O
creams	B-TREATMENT
or	O
powders	B-TREATMENT
to	O
incisions	B-PROBLEM
.	O

The	O
patient	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
FOUND	B-PROBLEM
DOWN	I-PROBLEM
.	O

Following	O
evaluation	B-TEST
and	O
treatment	B-TREATMENT
,	O
the	O
patient	O
's	O
disposition	O
at	O
the	O
end	O
of	O
the	O
visit	O
was	O
ADMITTED	O
AS	O
AN	O
INPATIENT	O
TO	O
BRI	O
HEALTH	O
.	O

Your	O
patient	O
was	O
admitted	O
under	O
the	O
care	O
of	O
REEFRAUP	O
,	O
JA	O
Y	O
with	O
a	O
preliminary	O
diagnosis	O
of	O
SYNCOPE	B-PROBLEM
.	O

The	O
patient	O
is	O
a	O
57	O
-	O
year-old	O
female	O
with	O
a	O
history	O
of	O
hypertension	B-PROBLEM
and	O
hypercholesterolemia	B-PROBLEM
but	O
no	O
prior	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
history	I-PROBLEM
who	O
presented	O
with	O
chest	B-PROBLEM
pain	I-PROBLEM
.	O

The	O
patient	O
reports	O
the	B-PROBLEM
pain	I-PROBLEM
began	O
at	O
4:00	O
p.m.	O
on	O
the	O
day	O
of	O
admission	O
.	O

She	O
reports	O
that	O
it	O
had	O
essentially	O
started	O
earlier	O
in	O
the	O
day	O
with	O
some	B-PROBLEM
GERD-like	I-PROBLEM
symptoms	I-PROBLEM
.	O

She	O
had	O
taken	O
Maalox	B-TREATMENT
but	O
had	O
no	O
relief	O
with	O
this	O
.	O

The	B-PROBLEM
pain	I-PROBLEM
was	O
intermittent	O
through	O
the	O
day	O
and	O
then	O
at	O
4:00	O
p.m.	O
increased	O
and	O
was	O
also	O
associated	O
with	O
nausea	B-PROBLEM
and	O
diaphoresis	B-PROBLEM
.	O

She	O
reports	O
that	O
the	B-PROBLEM
pain	I-PROBLEM
shot	O
through	O
her	O
back	O
.	O

The	O
patient	O
has	O
never	O
had	O
these	B-PROBLEM
symptoms	I-PROBLEM
in	O
the	O
past	O
.	O

At	O
that	O
time	O
,	O
the	B-PROBLEM
pain	I-PROBLEM
was	O
unremitting	O
.	O

In	O
the	O
Emergency	O
Room	O
,	O
the	O
patient	O
was	O
given	O
Lopressor	B-TREATMENT
,	O
nitroglycerin	B-TREATMENT
,	O
and	O
aspirin	B-TREATMENT
.	O

A	B-TREATMENT
TP3A	I-TREATMENT
inhibitor	I-TREATMENT
was	O
not	O
given	O
for	O
concern	O
for	O
dissection	B-PROBLEM
.	O

The	O
patient	O
was	O
found	O
to	O
have	O
5057	O
E.	O
Sixth	O
Blvd.	O
elevations	B-PROBLEM
in	I-PROBLEM
I	I-PROBLEM
,	I-PROBLEM
aVL	I-PROBLEM
,	I-PROBLEM
and	I-PROBLEM
V1	I-PROBLEM
through	I-PROBLEM
V2	I-PROBLEM
and	O
ST	B-PROBLEM
depressions	I-PROBLEM
in	I-PROBLEM
II	I-PROBLEM
,	I-PROBLEM
III	I-PROBLEM
,	I-PROBLEM
and	I-PROBLEM
aVF	I-PROBLEM
.	O

1.	O
Hypertension	B-PROBLEM
.	O

2.	O
Hypercholesterolemia	B-PROBLEM
.	O

3.	O
Chondrocalcinosis	B-PROBLEM
.	O

4.	O
Carpal	B-PROBLEM
tunnel	I-PROBLEM
syndrome	I-PROBLEM
.	O

5.	O
GERD	B-PROBLEM
.	O

1.	O
Atenolol	B-TREATMENT
25	O
.	O

2.	O
Crestor	B-TREATMENT
10	O
q.d.	O

3.	O
Uniretic	B-TREATMENT
15/25	O
.	O

ALLERGIES	O
:	O
The	O
patient	O
has	O
no	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

On	O
admission	O
,	O
the	O
patient	O
was	O
afebrile	B-PROBLEM
,	O
blood	B-TEST
pressure	I-TEST
146/88	O
,	O
pulse	B-TEST
71	O
,	O
respirations	B-TEST
18	O
.	O

General	O
:	O
The	O
patient	O
was	O
a	O
well	O
appearing	O
female	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

No	O
murmurs	B-PROBLEM
were	O
appreciated	O
.	O

Lungs	O
:	O
Clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Abdomen	O
:	O
Soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
good	O
bowel	O
sounds	O
.	O

Extremities	O
:	O
There	O
was	O
no	O
edema	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
extremities	I-PROBLEM
.	O

The	B-TEST
dorsalis	I-TEST
pedis	I-TEST
pulses	I-TEST
were	O
2+	O
bilaterally	O
.	O

LABORATORY	O
AND	O
RADIOLOGIC	O
DATA	O
:	O
On	O
admission	O
,	O
white	B-TEST
count	I-TEST
10.8	O
,	O
hematocrit	B-TEST
38.2	O
,	O
platelets	B-TEST
324,000	O
.	O

1.	O
CORONARY	B-PROBLEM
ARTERY	I-PROBLEM
DISEASE	I-PROBLEM
:	O
The	O
patient	O
was	O
taken	O
to	O
Cardiac	B-TEST
Catheterization	I-TEST
where	O
she	O
was	O
found	O
to	O
have	O
two	B-PROBLEM
vessel	I-PROBLEM
disease	I-PROBLEM
.	O

The	O
proximal	O
LAD	O
was	O
found	O
to	O
have	O
a	B-PROBLEM
90%	I-PROBLEM
lesion	I-PROBLEM
with	O
a	O
septal	O
branch	O
with	O
a	B-PROBLEM
95%	I-PROBLEM
stenosis	I-PROBLEM
and	O
a	O
diagonal	O
branch	O
with	O
99%	B-PROBLEM
stenosis	I-PROBLEM
.	O

The	O
patient	O
had	O
twin	B-TREATMENT
LAD	I-TREATMENT
stents	I-TREATMENT
to	O
the	O
LAD	O
diagonal	O
and	O
LAD	O
septal	O
branches	O
with	O
Taxus	B-TREATMENT
stents	I-TREATMENT
.	O

The	O
patient	O
also	O
had	O
proximal	B-PROBLEM
RCA	I-PROBLEM
lesion	I-PROBLEM
of	I-PROBLEM
80%	I-PROBLEM
and	O
a	B-PROBLEM
mid	I-PROBLEM
RCA	I-PROBLEM
lesion	I-PROBLEM
of	I-PROBLEM
80-90%	I-PROBLEM
which	O
were	O
not	O
intervened	O
upon	O
.	O

The	O
patient	O
was	O
given	O
an	B-TREATMENT
aspirin	I-TREATMENT
and	O
Plavix	B-TREATMENT
and	O
in	O
addition	O
started	O
on	O
a	B-TREATMENT
beta	I-TREATMENT
Elmore	I-TREATMENT
,	O
Maxine	B-TREATMENT
ACE	I-TREATMENT
inhibitor	I-TREATMENT
,	O
and	O
these	O
were	O
titrated	O
up	O
as	O
her	B-TEST
blood	I-TEST
pressure	I-TEST
tolerated	O
.	O

Given	O
the	O
fact	O
that	O
the	O
patient	O
had	O
issues	O
with	O
muscle	B-PROBLEM
cramping	I-PROBLEM
with	O
Atorvastatin	B-TREATMENT
in	O
the	O
past	O
,	O
she	O
was	O
started	O
on	O
Pravastatin	B-TREATMENT
which	O
should	O
give	O
less	O
of	O
these	B-PROBLEM
side	I-PROBLEM
effects	I-PROBLEM
.	O

The	O
patient	O
will	O
follow-up	O
with	O
Cardiology	O
in	O
one	O
months	O
time	O
for	O
further	B-TREATMENT
management	I-TREATMENT
of	O
her	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
and	O
further	B-TEST
evaluation	I-TEST
of	O
her	B-PROBLEM
remaining	I-PROBLEM
RCA	I-PROBLEM
lesions	I-PROBLEM
.	O

2.	O
PUMP	O
:	O
The	O
patient	O
had	O
an	B-TEST
echocardiogram	I-TEST
to	O
assess	O
her	O
LV	O
function	O
.	O

She	O
was	O
found	O
to	O
have	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
30-35%	O
as	O
well	O
as	O
an	B-PROBLEM
akinetic	I-PROBLEM
apex	I-PROBLEM
and	O
apical	B-PROBLEM
mid	I-PROBLEM
and	I-PROBLEM
septal	I-PROBLEM
akinesis	I-PROBLEM
.	O

Given	O
the	O
fact	O
that	O
the	O
patient	O
had	O
significant	B-PROBLEM
apical	I-PROBLEM
akinesis	I-PROBLEM
,	O
she	O
was	O
started	O
on	O
heparin	B-TREATMENT
with	O
a	O
transition	O
to	O
Coumadin	B-TREATMENT
for	O
anticoagulation	B-TREATMENT
for	O
stroke	B-TREATMENT
prevention	I-TREATMENT
in	O
the	O
setting	O
of	O
apical	B-PROBLEM
akinesis	I-PROBLEM
.	O

On	O
discharge	O
,	O
the	O
patient	O
was	O
given	O
Lovenox	B-TREATMENT
injections	I-TREATMENT
which	O
should	O
be	O
continued	O
until	O
the	O
patient	O
reaches	O
a	O
therapeutic	O
dose	O
of	O
Coumadin	B-TREATMENT
.	O

3.	O
RHYTHM	O
:	O
The	O
patient	O
was	O
monitored	O
on	O
telemetry	B-TEST
throughout	O
her	O
hospitalization	O
with	O
no	O
significant	B-PROBLEM
events	I-PROBLEM
.	O

The	O
patient	O
had	O
an	B-TEST
EP	I-TEST
evaluation	I-TEST
and	O
will	O
be	O
followed-up	O
by	O
Dr.	O
Welch	O
.	O

14-087	O
,	O
the	O
patient	O
had	O
a	B-TEST
signal-averaged	I-TEST
EKG	I-TEST
.	O

She	O
will	O
follow-up	O
with	O
Dr.	O
Welch	O
with	O
an	B-TEST
echocardiogram	I-TEST
on	O
2015-07-24	O
in	O
a	O
meeting	O
to	O
discuss	O
risk	O
stratification	O
for	O
sudden	B-PROBLEM
cardiac	I-PROBLEM
death	I-PROBLEM
and	O
possible	O
ICD	B-TREATMENT
placement	I-TREATMENT
.	O

4.	O
NEUROLOGY	O
:	O
The	O
patient	O
complained	O
of	O
left	B-PROBLEM
lower	I-PROBLEM
extremity	I-PROBLEM
weakness	I-PROBLEM
with	O
ambulation	O
two	O
days	O
after	O
her	B-TEST
cardiac	I-TEST
catheterization	I-TEST
.	O

The	O
patient	O
had	O
no	O
evidence	O
for	O
weakness	B-PROBLEM
on	O
examination	B-TEST
with	O
good	O
proximal	O
and	O
distal	O
strength	O
in	O
the	O
lower	O
extremities	O
as	O
well	O
as	O
intact	O
sensation	O
.	O

She	O
was	O
also	O
able	O
to	O
ascend	O
stairs	O
without	O
difficulty	B-PROBLEM
.	O

The	O
patient	O
was	O
already	O
on	O
an	B-TREATMENT
aspirin	I-TREATMENT
and	O
Plavix	B-TREATMENT
should	O
this	O
represent	O
a	B-PROBLEM
small	I-PROBLEM
stroke	I-PROBLEM
.	O

However	O
,	O
there	O
was	O
no	O
evidence	O
for	O
neurologic	B-PROBLEM
deficit	I-PROBLEM
on	O
examination	B-TEST
and	O
this	O
will	O
be	O
followed-up	O
by	O
her	O
primary	O
care	O
physician	O
.	O

5.	O
HEMATOLOGY	O
:	O
The	O
patient	O
was	O
discharged	O
on	O
Coumadin	B-TREATMENT
for	O
apical	B-PROBLEM
akinesis	I-PROBLEM
and	O
stroke	B-PROBLEM
risk	I-PROBLEM
.	O

This	O
will	O
be	O
further	O
monitored	O
by	O
her	O
primary	O
care	O
physician	O
,	O
Dr.	O
Banks	O
,	O
who	O
will	O
adjust	O
her	B-TREATMENT
Coumadin	I-TREATMENT
dose	I-TREATMENT
.	O

DISCHARGE	O
DIAGNOSIS	O
:	O
ST	B-PROBLEM
elevation	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
,	O
status	O
post	O
left	B-TREATMENT
anterior	I-TREATMENT
descending	I-TREATMENT
artery	I-TREATMENT
stent	I-TREATMENT
.	O

1.	O
Aspirin	B-TREATMENT
325	O
q.d.	O

2.	O
Lisinopril	B-TREATMENT
5	O
q.d.	O

3.	O
Toprol	B-TREATMENT
XL	I-TREATMENT
100	O
q.d.	O

4.	O
Coumadin	B-TREATMENT
5	O
q.d.	O

5.	O
Plavix	B-TREATMENT
75	O
q.d.	O

6.	O
Lovenox	B-TREATMENT
60	O
mg	O
b.i.d.	O
until	O
therapeutic	O
on	O
Coumadin	B-TREATMENT
.	O

7.	O
Pravastatin	B-TREATMENT
80	O
q.d.	O

FOLLOW-UP	O
PLANS	O
:	O
The	O
patient	O
will	O
follow-up	O
with	O
her	O
primary	O
care	O
physician	O
in	O
the	O
week	O
following	O
discharge	O
for	O
further	O
monitoring	O
of	O
her	B-TEST
INR	I-TEST
and	O
adjustment	O
of	O
her	B-TREATMENT
Coumadin	I-TREATMENT
dose	I-TREATMENT
.	O

In	O
addition	O
to	O
this	O
,	O
the	O
patient	O
will	O
follow-up	O
with	O
Cardiology	O
,	O
Dr.	O
Foster	O
,	O
and	O
Dr.	O
Upshaw	O
,	O
on	O
2015-07-06	O
for	O
further	B-TEST
monitoring	I-TEST
.	O

Richard	O
Williams	O
,	O
Twin	O
number	O
II	O
,	O
was	O
born	O
at	O
31-6/7	O
weeks	O
gestation	O
by	O
cesarean	B-TREATMENT
section	I-TREATMENT
for	O
rupture	B-PROBLEM
of	I-PROBLEM
membranes	I-PROBLEM
of	O
Twin	O
number	O
I	O
and	O
progressive	B-PROBLEM
preterm	I-PROBLEM
labor	I-PROBLEM
.	O

Mother	O
is	O
a	O
37	O
year	O
old	O
Gravida	O
1	O
,	O
Para	O
0	O
now	O
2	O
woman	O
whose	O
blood	B-TEST
type	I-TEST
is	O
A	O
negative	O
,	O
antibody	B-TEST
negative	O
,	O
rubella	B-TEST
immune	O
,	O
RPR	B-TEST
nonreactive	O
,	O
hepatitis	B-TEST
B	I-TEST
surface	I-TEST
antigen	I-TEST
negative	O
and	O
Group	B-TEST
B	I-TEST
Streptococcus	I-TEST
unknown	O
.	O

The	O
mother	O
had	O
received	O
a	O
complete	O
course	O
of	O
betamethasone	B-TREATMENT
prior	O
to	O
delivery	O
.	O

This	O
pregnancy	O
was	O
achieved	O
with	O
in	O
Bartley	B-TREATMENT
fertilization	I-TREATMENT
.	O

A	B-TREATMENT
cerclage	I-TREATMENT
was	O
placed	O
at	O
18	O
weeks	O
gestation	O
.	O

Cesarean	B-TREATMENT
section	I-TREATMENT
was	O
performed	O
under	O
spinal	B-TREATMENT
anesthesia	I-TREATMENT
.	O

This	O
infant	O
emerged	O
with	O
Apgars	B-TEST
of	O
8	O
at	O
one	O
minute	O
and	O
8	O
at	O
five	O
minutes	O
.	O

On	O
admission	O
,	O
revealed	O
a	O
vigorous	O
non-dysmorphic	O
premature	O
infant	O
,	O
with	O
moderate	B-PROBLEM
subcostal	I-PROBLEM
retractions	I-PROBLEM
and	O
some	B-PROBLEM
occasional	I-PROBLEM
grunting	I-PROBLEM
,	O
normal	O
S1	O
,	O
S2	O
heart	O
sounds	O
,	O
no	O
murmur	B-PROBLEM
.	O

The	B-TEST
birth	I-TEST
weight	I-TEST
was	O
1,980	O
grams	O
,	O
80th	O
percentile	O
.	O

The	B-TEST
birth	I-TEST
length	I-TEST
was	O
44	O
centimeters	O
,	O
the	O
75th	O
percentile	O
and	O
the	B-TEST
birth	I-TEST
head	I-TEST
circumference	I-TEST
was	O
30.6	O
centimeters	O
,	O
in	O
the	O
65th	O
percentile	O

The	O
infant	O
was	O
intubated	O
soon	O
after	O
admission	O
to	O
the	O
CMED	O
CSRU	O
and	O
received	O
two	O
doses	O
of	O
surfactant	B-TREATMENT
.	O

Her	B-TEST
respirations	I-TEST
are	O
comfortable	O
.	O

Her	B-TEST
lung	I-TEST
sounds	I-TEST
are	O
clear	O
and	O
equal	O
.	O

She	O
has	O
had	O
no	O
apnea	B-PROBLEM
,	O
bradycardia	B-PROBLEM
or	O
desaturation	B-PROBLEM
.	O

She	O
has	O
a	O
normal	O
S1	O
,	O
S2	O
heart	O
sound	O
and	O
no	O
murmur	B-PROBLEM
.	O

She	O
started	O
on	O
enteral	B-TREATMENT
feeds	I-TREATMENT
on	O
day	O
of	O
life	O
number	O
two	O
and	O
progressed	O
without	O
difficulty	O
to	O
full	B-TREATMENT
volume	I-TREATMENT
feedings	I-TREATMENT
by	O
day	O
of	O
life	O
five	O
and	O
then	O
was	O
advanced	O
to	O
calorie	B-TREATMENT
enhanced	I-TREATMENT
breast	I-TREATMENT
milk	I-TREATMENT
of	O
24	O
calories	O
per	O
ounce	O
.	O

She	O
has	O
been	O
taking	O
from	O
130	O
to	O
160	O
cc.	O
per	O
kilo	O
per	O
day	O
on	O
an	B-TREATMENT
ad	I-TREATMENT
lib	I-TREATMENT
feeding	I-TREATMENT
plan	I-TREATMENT
.	O

At	O
the	O
time	O
of	O
discharge	O
,	O
her	B-TEST
weight	I-TEST
is	O
2,200	O
grams	O
;	O
her	B-TEST
length	I-TEST
is	O
49.5	O
centimeters	O
(	O
19.5	O
inches	O
)	O
and	O
her	B-TEST
head	I-TEST
circumference	I-TEST
is	O
30.5	O
centimeters	O
.	O

Her	B-TEST
peak	I-TEST
bilirubin	I-TEST
occurred	O
on	O
day	O
of	O
life	O
five	O
and	O
was	O
total	B-TEST
12.1	O
,	O
direct	B-TEST
0.3	O
;	O
the	B-TEST
last	I-TEST
bilirubin	I-TEST
on	O
day	O
of	O
life	O
six	O
was	O
total	B-TEST
11.1	O
,	O
direct	B-TEST
0.4	O
.	O

She	O
never	O
required	O
phototherapy	B-TREATMENT
.	O

Her	B-TEST
hematocrit	I-TEST
at	O
the	O
time	O
of	O
admission	O
was	O
45.4	O
,	O
platelets	B-TEST
were	O
360,000	O
.	O

She	O
is	O
receiving	O
supplemental	B-TREATMENT
iron	I-TREATMENT
to	O
provide	O
2	O
mg	O
per	O
kilo	O
per	O
day	O
as	O
elemental	B-TREATMENT
iron	I-TREATMENT
.	O

She	O
has	O
never	O
received	O
any	O
blood	B-TREATMENT
products	I-TREATMENT
during	O
this	O
CMED	O
CSRU	O
stay	O
.	O

The	O
infant	O
was	O
started	O
on	O
Ampicillin	B-TREATMENT
and	O
Gentamycin	B-TREATMENT
at	O
the	O
time	O
of	O
admission	O
for	O
sepsis	B-PROBLEM
risk	I-PROBLEM
factor	I-PROBLEM
.	O

The	B-TREATMENT
antibiotics	I-TREATMENT
were	O
discontinued	O
after	O
48	O
hours	O
when	O
the	O
infant	O
was	O
clinically	O
well	O
and	O
the	B-TEST
blood	I-TEST
cultures	I-TEST
remained	O
negative	O
.	O

She	O
had	O
a	B-TEST
head	I-TEST
ultrasound	I-TEST
on	O
2013-05-02	O
,	O
that	O
was	O
completely	O
within	O
normal	O
limits	O
.	O

The	O
infant	O
is	O
on	O
breast	B-TREATMENT
milk	I-TREATMENT
with	I-TREATMENT
Enfamil	I-TREATMENT
Powder	I-TREATMENT
to	O
provide	O
24	O
calories	O
per	O
ounce	O
and	O
on	O
an	B-TREATMENT
ad	I-TREATMENT
lib	I-TREATMENT
feeding	I-TREATMENT
schedule	I-TREATMENT
.	O

Ferinsol	B-TREATMENT
0.2	O
cc.	O
to	O
provide	O
5	O
mg	O
a	O
day	O
.	O

3.	O
The	O
infant	O
passed	O
a	B-TEST
car	I-TEST
seat	I-TEST
positioning	I-TEST
test	I-TEST
on	O
2013-05-11	O
.	O

4.	O
State	B-TEST
Screens	I-TEST
were	O
sent	O
on	O
04-27	O
and	O
2013-05-08	O
.	O

5.	O
The	O
infant	O
received	O
the	B-TREATMENT
hepatitis	I-TREATMENT
B	I-TREATMENT
vaccine	I-TREATMENT
on	O
2013-05-09	O
,	O
and	O
Synagis	B-TREATMENT
on	O
2013-05-11	O
.	O

1)	O
Synagis	B-TREATMENT
RSV	I-TREATMENT
prophylaxis	I-TREATMENT
should	O
be	O
considered	O
from	O
October	O
through	O
April	O
for	O
infants	O
who	O
meet	O
any	O
of	O
the	O
following	O
three	O
criteria	O
:	O

smoker	O
in	O
the	O
household	O
,	O
with	O
preschool	O
siblings	O
,	O
or	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
;	O

2)	O
Influenza	B-TREATMENT
immunization	I-TREATMENT
should	O
be	O
considered	O
annually	O
in	O
the	O
Fall	O
for	O
preterm	O
infants	O
with	O
chronic	B-PROBLEM
lung	I-PROBLEM
disease	I-PROBLEM
once	O
they	O
reach	O
six	O
months	O
of	O
age	O
.	O

Before	O
this	O
age	O
,	O
the	O
family	O
and	O
other	O
care	O
givers	O
should	O
be	O
considered	O
for	O
immunization	B-TREATMENT
against	O
influenza	B-PROBLEM
to	O
protect	O
the	O
infant	O
.	O

1.	O
Prematurity	B-PROBLEM
at	O
31-6/7	O
weeks	O
gestation	O
.	O

3.	O
Sepsis	B-PROBLEM
,	O
ruled	O
out	O
.	O

4.	O
Status	O
post	O
respiratory	B-PROBLEM
distress	I-PROBLEM
syndrome	I-PROBLEM
.	O

Patient	O
recorded	O
as	O
having	O
No	O
Known	B-PROBLEM
Allergies	I-PROBLEM
to	O
Drugs	B-TREATMENT

bright	B-PROBLEM
red	I-PROBLEM
blood	I-PROBLEM
per	I-PROBLEM
rectum	I-PROBLEM

Colonoscopy	B-TREATMENT

Virtual	B-TREATMENT
colonoscopy	I-TREATMENT

55	O
yo	O
M	O
w/	O
h/o	O
recurrent	B-PROBLEM
bladder	I-PROBLEM
ca	I-PROBLEM
s/p	O
cystectomy	B-TREATMENT
w/	O
ileal	B-TREATMENT
conduit	I-TREATMENT
p/w	O
BRBPR	B-PROBLEM
to	O
OSH	O
.	O

Hct	B-TEST
dropped	O
34	O
->	O
22	O
.	O

EGD	B-TEST
normal	O
.	O

Cscope	B-TEST
unable	O
to	O
complete	O
due	O
to	O
blood	B-PROBLEM
but	O
tics	B-PROBLEM
seen	O
.	O

Tagged	O
RBC	B-TEST
+	O
activity	O
in	O
RLQ	O
.	O

Transferred	O
to	O
Mediplex	O
Rehab	O
Hospital	O
ICU	O
where	O
Hct	B-TEST
has	O
remained	O
stable	O
.	O

Seen	O
by	O
GI	O
and	O
plan	O
is	O
to	O
continue	O
holding	O
anticoagulation	B-TREATMENT
and	O
repeat	B-TEST
scope	I-TEST
on	O
Monday	O
.	O

Pt	O
feeling	O
well	O
,	O
denies	O
abd	B-PROBLEM
pain	I-PROBLEM
,	O
N/V	B-PROBLEM
,	O
LH	B-PROBLEM
,	O
SOB	B-PROBLEM
,	O
CP	B-PROBLEM
.	O

Metastatic	B-PROBLEM
bladder	I-PROBLEM
CA	I-PROBLEM
now	O
in	O
remission	O
s/p	O
chemo/xrt	B-TREATMENT
s/p	O
cystectomy	B-TREATMENT
and	O
ileal	B-TREATMENT
loop	I-TREATMENT
urinary	I-TREATMENT
diversion	I-TREATMENT
and	O
also	O
radical	B-TREATMENT
prstatectomy	I-TREATMENT
with	O
bilateral	B-TREATMENT
pelvic	I-TREATMENT
lymph	I-TREATMENT
node	I-TREATMENT
dissection	I-TREATMENT
.	O

b/l	B-PROBLEM
DVT	I-PROBLEM
s,	O
most	O
recent	O
seen	O
in	O
IVC	O
to	O
right	O
femoral	O
vein	O
s/p	O
IVC	B-TREATMENT
filter	I-TREATMENT
2015-01-15	O

Nephrolithiasis	B-PROBLEM
.	O

Anemia	B-PROBLEM
-	O
baseline	O
mid	O
30	O
s.	O

denies	O
fh	O
of	O
bleeding	B-PROBLEM
or	O
clotting	B-PROBLEM
disorders	I-PROBLEM
.	O

T	B-TEST
97.4	O
BP	B-TEST
100/62	O
P	B-TEST
56	O
RR	B-TEST
16	O

Mid	O
aged	O
man	O
in	O
NAD	B-PROBLEM

sclera	B-PROBLEM
anicteric	I-PROBLEM
,	O
MMM	O

supple	O
,	O
no	O
LAD	B-PROBLEM

RRR	O
S1/S2	O
no	O
M	B-PROBLEM

soft	O
,	O
+BS	O
,	O
NT	B-PROBLEM
,	O
Midline	B-PROBLEM
surgical	I-PROBLEM
scar	I-PROBLEM
,	O
nephrostomy	B-TREATMENT
bag	I-TREATMENT
draining	O

yellowish	B-PROBLEM
urine	I-PROBLEM
in	I-PROBLEM
RLQ	I-PROBLEM

no	O
edema	B-PROBLEM
,	O
no	O
clubbing	B-PROBLEM

2015-12-03	O
10:27	O
PM	O
GLUCOSE	B-TEST
-	O
88	O
UREA	B-TEST
N	I-TEST
-	O
12	O
CREAT	B-TEST
-	O
1.0	O
SODIUM	B-TEST
-	O
138	O
POTASSIUM	B-TEST
-	O
3.3	O
CHLORIDE	B-TEST
-	O
107	O
TOTAL	B-TEST
CO2	I-TEST
-	O
25	O
ANION	B-TEST
GAP	I-TEST
-	O
9	O

2015-12-03	O
10:27	O
PM	O
estGFR	B-TEST
-	O
Using	O
this	O

2015-12-03	O
10:27	O
PM	O
CALCIUM	B-TEST
-	O
8.7	O
PHOSPHATE	B-TEST
-	O
2.4	O
*	O
MAGNESIUM	B-TEST
-	O
1.5	O
*	O

2015-12-03	O
10:27	O
PM	O
WBC	B-TEST
-	O
8.4	O
RBC	B-TEST
-	O
2.98	O
*	O
HGB	B-TEST
-	O
9.3	O
*	O
HCT	B-TEST
-	O
26.3	O
*	O
MCV	B-TEST
-	O
88	O
MCH	B-TEST
-	O
31.1	O
MCHC	B-TEST
-	O
35.3	O
*	O
RDW	B-TEST
-	O
14.4	O

2015-12-03	O
10:27	O
PM	O
PLT	B-TEST
COUNT	I-TEST
-	O
164	O

2015-12-03	O
10:27	O
PM	O
PT	B-TEST
-	O
11.4	O
PTT	B-TEST
-	O
27.5	O
INR(PT)	B-TEST
-	O
1.0	O

55	O
year	O
old	O
man	O
with	O
history	O
of	O
metastatic	B-PROBLEM
bladder	I-PROBLEM
cancer	I-PROBLEM
and	O
recurrent	B-PROBLEM
DVT	I-PROBLEM
s	I-PROBLEM
on	O
Lovenox	B-TREATMENT
admitted	O
with	O
lower	B-PROBLEM
GI	I-PROBLEM
bleeding	I-PROBLEM
.	O

Right	B-PROBLEM
lower	I-PROBLEM
quadrant	I-PROBLEM
source	I-PROBLEM
of	I-PROBLEM
bleed	I-PROBLEM
on	O
red	B-TEST
blood	I-TEST
cell	I-TEST
scan	I-TEST
.	O

Attempts	O
to	O
visualize	O
colon	O
by	O
conventional	B-TEST
and	I-TEST
CT	I-TEST
virtual	I-TEST
colonoscopy	I-TEST
failed	O
because	O
of	O
sigmoid	B-PROBLEM
angulation	I-PROBLEM
and	O
inadequate	O
preparation	O
,	O
respectively	O
.	O

On	O
Ct	B-TEST
scan	I-TEST
,	O
a	B-PROBLEM
right	I-PROBLEM
psoas	I-PROBLEM
mass	I-PROBLEM
,	O
most	O
consistent	O
with	O
a	B-PROBLEM
hematoma	I-PROBLEM
,	O
was	O
seen	O
.	O

Since	O
the	B-TEST
hematocrit	I-TEST
of	O
the	O
patient	O
was	O
stable	O
and	O
outside	O
records	O
from	O
2015-03-28	O
mentioned	O
a	B-PROBLEM
mass	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
pelvis	I-PROBLEM
,	O
the	O
patient	O
was	O
discharged	O
.	O

Lovenox	B-TREATMENT
was	O
held	O
until	O
follow-up	O
with	O
primary	O
care	O
doctor	O
.	O

Also	O
,	O
a	B-TEST
repeat	I-TEST
outpatient	I-TEST
CT	I-TEST
colonoscopy	I-TEST
with	O
better	O
preparation	O
should	O
be	O
considered	O
.	O

Lovenox	B-TREATMENT
0.6	O
mg	O
/	O
kg	O
SC	O
BID	O

1.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O

cbc	B-TEST
,	O
creatinine	B-TEST

GIB	B-PROBLEM

Metastatic	B-PROBLEM
,	I-PROBLEM
recurrent	I-PROBLEM
bladder	I-PROBLEM
cancer	I-PROBLEM

h/o	O
DVT	B-PROBLEM
s	I-PROBLEM

We	O
recommend	O
that	O
you	O
do	O
NOT	O
resume	O
your	B-TREATMENT
lovenox	I-TREATMENT
until	O
talking	O
to	O
your	O
PCP	O
,	O
Dr.	O
Jessie	O
.	O

You	O
likely	O
have	O
a	B-PROBLEM
bleeding	I-PROBLEM
source	I-PROBLEM
in	I-PROBLEM
your	I-PROBLEM
colon	I-PROBLEM
that	O
we	O
have	O
been	O
unable	O
to	O
visualize	O
.	O

The	B-PROBLEM
bleeding	I-PROBLEM
has	O
stopped	O
and	O
you	O
have	O
remained	O
hemodynamically	O
stable	O
and	O
your	B-TEST
hematocrit	I-TEST
is	O
stable	O
,	O
but	O
you	O
are	O
at	O
risk	O
of	O
bleeding	B-PROBLEM
from	O
this	O
source	O
again	O
with	O
anticoagulation	B-TREATMENT
.	O

A	B-TEST
CT	I-TEST
scan	I-TEST
of	I-TEST
your	I-TEST
abdomen	I-TEST
showed	O
a	B-PROBLEM
right	I-PROBLEM
pelvic	I-PROBLEM
mass	I-PROBLEM
,	O
most	O
likely	O
a	B-PROBLEM
hematoma	I-PROBLEM
,	O
which	O
had	O
been	O
described	O
previously	O
in	O
2015-03-28	O
.	O

Please	O
continue	O
to	O
take	O
your	B-TREATMENT
other	I-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

Please	O
see	O
a	O
doctor	O
if	O
you	O
feel	O
dizzy	B-PROBLEM
,	O
or	O
have	O
blood	B-PROBLEM
in	I-PROBLEM
your	I-PROBLEM
stool	I-PROBLEM
again	O
.	O

Please	O
go	O
to	O
Dr.	O
Colombo	O
office	O
later	O
this	O
week	O
to	O
have	O
your	B-TEST
labs	I-TEST
drawn	O
and	O
sent	O
to	O
Dr.	O
Powell	O
.	O

Cardiothoracic	B-TREATMENT
Surgery	I-TREATMENT

This	O
is	O
a	O
67	O
-	O
year-old	O
male	O
with	O
a	O
history	O
of	O
high	B-PROBLEM
cholesterol	I-PROBLEM
who	O
was	O
in	O
his	O
usual	O
state	O
of	O
health	O
until	O
2016-04-03	O
.	O

He	O
was	O
raking	O
leaves	O
on	O
04-02	O
and	O
then	O
developed	O
episodes	O
of	O
mid	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
and	O
burning	B-PROBLEM
which	O
radiated	O
to	O
the	O
left	O
arm	O
.	O

That	O
night	O
he	O
reportedly	O
stopped	O
breathing	B-PROBLEM
and	O
was	O
unresponsive	B-PROBLEM
.	O

His	O
wife	O
gave	O
him	O
mouth-to-mouth	B-TREATMENT
resuscitation	I-TREATMENT
and	O
he	O
regained	O
consciousness	O
.	O

He	O
presented	O
to	O
an	O
outside	O
hospital	O
with	O
an	B-PROBLEM
acute	I-PROBLEM
inferior	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
and	O
was	O
treated	O
with	O
thrombolytic	B-TREATMENT
therapy	I-TREATMENT
.	O

His	B-TEST
troponin	I-TEST
was	O
20	O
and	O
he	O
had	O
EKG	B-PROBLEM
changes	I-PROBLEM
.	O

He	O
underwent	O
catheterization	B-TEST
on	O
2016-04-05	O
which	O
revealed	O
a	B-TEST
left	I-TEST
ventricular	I-TEST
ejection	I-TEST
fraction	I-TEST
of	O
50%	O
,	O
no	O
mitral	B-PROBLEM
regurgitation	I-PROBLEM
,	O
insufficiency	B-PROBLEM
or	O
hypokinesis	B-PROBLEM
.	O

Left	O
main	O
coronary	O
artery	O
was	O
narrowed	B-PROBLEM
50-60%	O
,	O
left	O
anterior	O
descending	O
coronary	O
artery	O
70%	O
proximally	O
,	O
right	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
dominant	I-PROBLEM
diseased	I-PROBLEM
up	O
to	O
90%	O
proximally	O
in	O
the	O
midportion	O
,	O
70%	O
distally	O
.	O

1.	O
History	O
of	O
high	B-PROBLEM
cholesterol	I-PROBLEM
.	O

2.	O
Hemorrhoidectomy	B-TREATMENT
.	O

3.	O
Carotid	B-PROBLEM
disease	I-PROBLEM
.	O

1.	O
Lipitor	B-TREATMENT
20	O
mg	O
p.o.	O
q.d.	O

2.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.d.	O

3.	O
Lopressor	B-TREATMENT
25	O
mg	O
p.o.	O
b.i.d.	O

4.	O
Plavix	B-TREATMENT
75	O
mg	O
p.o.	O
q.d.	O
which	O
has	O
been	O
discontinued	O
prior	O
to	O
surgery	B-TREATMENT
.	O

Positive	O
for	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
.	O

In	O
general	O
the	O
patient	O
was	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
,	O
afebrile	B-PROBLEM
,	O
vital	B-TEST
signs	I-TEST
stable	O
.	O

HEENT	O
:	O
Normocephalic	O
,	O
atraumatic	B-PROBLEM
.	O

Neck	O
:	O
Supple	O
with	O
full	O
range	O
of	O
motion	O
,	O
no	O
lymphadenopathy	B-PROBLEM
nor	O
thyromegaly	B-PROBLEM
.	O

Carotids	B-TEST
were	O
1+	O
bilaterally	O
.	O

Positive	O
right	B-PROBLEM
carotid	I-PROBLEM
bruits	I-PROBLEM
.	O

Lungs	O
:	O
Clear	O
to	O
auscultation	B-TEST
bilaterally	O
.	O

Cardiovascular	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmurs	B-PROBLEM
.	O

Abdomen	O
:	O
Positive	O
bowel	O
sounds	O
,	O
soft	O
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
no	O
masses	B-PROBLEM
,	O
no	O
hepatosplenomegaly	B-PROBLEM
.	O

Extremities	O
:	O
Without	O
cyanosis	B-PROBLEM
,	O
clubbing	B-PROBLEM
or	O
edema	B-PROBLEM
.	O

Pulses	B-TEST
were	O
2+	O
bilaterally	O
throughout	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
and	O
on	O
2016-04-06	O
the	O
patient	O
underwent	O
coronary	B-TREATMENT
artery	I-TREATMENT
bypass	I-TREATMENT
grafting	I-TREATMENT
x	O
4	O
with	O
left	O
internal	O
mammary	O
artery	O
to	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
,	O
saphenous	B-TREATMENT
vein	I-TREATMENT
graft	I-TREATMENT
to	I-TREATMENT
the	I-TREATMENT
diagonal	I-TREATMENT
,	O
saphenous	B-TREATMENT
vein	I-TREATMENT
graft	I-TREATMENT
to	I-TREATMENT
obtuse	I-TREATMENT
marginal	I-TREATMENT
,	O
saphenous	B-TREATMENT
vein	I-TREATMENT
graft	I-TREATMENT
to	I-TREATMENT
right	I-TREATMENT
coronary	I-TREATMENT
artery	I-TREATMENT
,	O
posterior	O
descending	O
coronary	O
artery	O
.	O

The	O
patient	O
appeared	O
to	O
have	O
tolerated	O
the	B-TREATMENT
procedure	I-TREATMENT
and	O
was	O
transferred	O
to	O
the	O
cardiac	O
intensive	O
care	O
unit	O
for	O
postoperative	B-TREATMENT
management	I-TREATMENT
.	O

He	O
was	O
started	O
on	O
beta	B-TREATMENT
blockers	I-TREATMENT
.	O

The	O
patient	O
had	O
pacing	B-TREATMENT
wires	I-TREATMENT
and	O
chest	B-TREATMENT
tubes	I-TREATMENT
in	O
place	O
,	O
both	O
of	O
which	O
over	O
the	O
course	O
of	O
his	O
stay	O
were	O
removed	O
successfully	O
.	O

They	O
requested	O
that	O
he	O
follow	O
up	O
in	O
three	O
to	O
five	O
weeks	O
for	O
endurance	B-TREATMENT
training	I-TREATMENT
,	O
however	O
then	O
physical	O
therapy	O
followed	O
him	O
a	O
number	O
of	O
times	O
afterward	O
and	O
decided	O
that	O
he	O
was	O
in	O
good	O
condition	O
and	O
did	O
not	O
need	O
further	O
physical	B-TREATMENT
therapy	I-TREATMENT
.	O

He	O
may	O
observe	O
regular	O
activity	O
although	O
he	O
should	O
avoid	O
strenuous	O
activity	O
and	O
should	O
not	O
drive	O
while	O
on	O
pain	B-TREATMENT
medications	I-TREATMENT
.	O

1.	O
Lasix	B-TREATMENT
20	O
mg	O
p.o.	O
q.	O
12	O
.	O

2.	O
Potassium	B-TREATMENT
20	O
mEq	O
p.o.	O
q.	O
12	O
.	O

3.	O
Colace	B-TREATMENT
100	O
mg	O
p.o.	O
b.i.d.	O

4.	O
Aspirin	B-TREATMENT
325	O
mg	O
p.o.	O
q.d.	O

5.	O
Percocet	B-TREATMENT
1-2	O
tablets	O
p.o.	O
q.	O
4	O
p.r.n.	O
pain	B-PROBLEM
.	O

6.	O
Lopressor	B-TREATMENT
12.5	O
mg	O
p.o.	O
b.i.d.	O

Peggy	O
Hammock	O
is	O
a	O
full	O
term	O
baby	O
boy	O
born	O
at	O
38	O
1/7	O
weeks	O
by	O
repeat	B-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
to	O
a	O
34	O
year	O
old	O
gravida	O
III	O
,	O
now	O
para	O
II	O
mother	O
.	O

Serologies	B-TEST
include	O
blood	B-TEST
type	I-TEST
O	O
negative	O
,	O
antibody	B-TEST
negative	O
,	O
RPR	B-TEST
nonreactive	O
.	O

Hepatitis	B-TEST
B	I-TEST
surface	I-TEST
antigen	I-TEST
negative	O
,	O
rubella	B-TEST
immune	O
.	O

Group	B-TEST
B	I-TEST
strep	I-TEST
screening	I-TEST
was	O
negative	O
.	O

Pregnancy	O
was	O
uncomplicated	B-PROBLEM
until	O
an	O
occurrence	O
of	O
HSV	B-PROBLEM
outbreak	I-PROBLEM
occurred	O
on	O
2017-09-13	O
approximately	O
one	O
week	O
prior	O
to	O
delivery	B-TREATMENT
.	O

Pregnancy	O
was	O
also	O
complicated	O
by	O
maternal	O
history	O
of	O
depression	B-PROBLEM
for	O
which	O
mother	O
received	O
Zoloft	B-TREATMENT
.	O

On	O
day	O
of	O
delivery	B-TREATMENT
mother	O
presented	O
in	O
spontaneous	B-PROBLEM
labor	I-PROBLEM
.	O

There	O
were	O
no	O
sepsis	B-PROBLEM
risk	I-PROBLEM
factors	I-PROBLEM
.	O

GBS	B-TEST
negative	O
.	O

No	O
maternal	B-PROBLEM
fever	I-PROBLEM
.	O

Rupture	B-PROBLEM
of	I-PROBLEM
membranes	I-PROBLEM
at	O
time	O
of	O
delivery	B-TREATMENT
.	O

Delivery	B-TREATMENT
was	O
by	O
repeat	B-TREATMENT
cesarean	I-TREATMENT
section	I-TREATMENT
and	O
Apgars	B-TEST
of	O
8	O
and	O
9	O
were	O
given	O
at	O
one	O
and	O
five	O
minutes	O
respectively	O
.	O

Baby	O
appeared	O
well	O
and	O
went	O
to	O
the	O
newborn	O
nursery	O
and	O
was	O
breast	O
feeding	O
and	O
undergoing	O
routine	B-TREATMENT
newborn	I-TREATMENT
care	I-TREATMENT
.	O

On	O
the	O
newborn	O
nursery	O
the	O
mother	O
called	O
the	O
nurse	O
for	O
concern	O
of	O
baby	O
turning	O
dusky	B-PROBLEM
while	O
feeding	O
.	O

This	B-PROBLEM
episode	I-PROBLEM
was	O
also	O
accompanied	O
by	O
gagging	B-PROBLEM
motions	I-PROBLEM
noted	O
of	O
the	O
infant	O
.	O

A	B-PROBLEM
second	I-PROBLEM
episode	I-PROBLEM
occurred	O
where	O
the	O
baby	O
turned	O
pale	B-PROBLEM
.	O

The	O
baby	O
did	O
not	O
turn	O
blue	B-PROBLEM
at	O
that	O
time	O
.	O

The	O
Neonatal	O
Intensive	O
Care	O
Unit	O
was	O
notified	O
and	O
the	O
baby	O
was	O
transferred	O
to	O
the	O
Newborn	O
Intensive	O
Care	O
Unit	O
for	O
further	B-TEST
evaluation	I-TEST
.	O

Full	O
term	O
well	O
appearing	O
infant	O
with	O
some	B-PROBLEM
facial	I-PROBLEM
jaundice	I-PROBLEM
,	O
overall	O
pink	O
,	O
warm	O
and	O
well	O
perfused	O
,	O
alert	O
and	O
responsive	O
.	O

Red	B-TEST
reflexes	I-TEST
noted	O
bilaterally	O
.	O

He	O
had	O
a	O
left	O
pupil	O
that	O
was	O
in	O
unequal	B-PROBLEM
in	I-PROBLEM
size	I-PROBLEM
with	O
a	B-PROBLEM
keyhole	I-PROBLEM
appearance	I-PROBLEM
consistent	O
with	O
a	B-PROBLEM
coloboma	I-PROBLEM
.	O

His	O
neck	O
was	O
supple	O
without	O
masses	B-PROBLEM
or	O
bruits	B-PROBLEM
.	O

Lungs	O
were	O
clear	O
to	O
auscultation	B-TEST
and	O
equal	O
.	O

Regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmur	B-PROBLEM
.	O

2	O
plus	O
femoral	B-TEST
pulses	I-TEST
were	O
noted	O
.	O

Infant	O
was	O
circumcised	B-TREATMENT
in	O
the	O
newborn	O
nursery	O
which	O
was	O
healing	O
well	O
.	O

Tone	B-TEST
was	O
appropriate	O
for	O
gestational	O
age	O
with	O
equal	O
strength	B-TEST
,	O
symmetric	O
reflexes	B-TEST
.	O

The	O
infant	O
was	O
placed	O
on	O
a	B-TEST
cardiopulmonary	I-TEST
monitor	I-TEST
upon	O
admission	O
to	O
the	O
Newborn	O
Intensive	O
Care	O
Unit	O
with	O
pulse	B-TEST
oximetry	I-TEST
.	O

He	O
was	O
noted	O
to	O
have	O
an	O
episode	O
of	O
desaturation	B-PROBLEM
related	O
to	O
feeding	O
with	O
desaturations	B-PROBLEM
in	O
the	O
70	O
percent	O
.	O

Jule	O
remained	O
in	O
room	O
air	O
without	O
any	O
evidence	O
of	O
respiratory	B-PROBLEM
distress	I-PROBLEM
and	O
was	O
without	O
any	B-PROBLEM
further	I-PROBLEM
dusky	I-PROBLEM
spells	I-PROBLEM
or	O
pale	B-PROBLEM
episodes	I-PROBLEM
in	O
the	O
48	O
hours	O
prior	O
to	O
discharge	O
.	O

Renee	O
remained	O
cardiovascularly	O
stable	O
with	O
AP	B-TEST
s	I-TEST
noted	O
to	O
be	O
120	O
to	O
130	O
s.	O

Blood	B-TEST
pressure	I-TEST
84/43	O
with	O
a	B-TEST
mean	I-TEST
of	O
59	O
.	O

He	O
was	O
fed	O
with	O
a	O
bottle	O
occasionally	O
by	O
his	O
dad	O
and	O
had	O
a	O
vigorous	O
suck	O
and	O
was	O
noted	O
to	O
have	O
some	B-PROBLEM
discoordination	I-PROBLEM
of	I-PROBLEM
his	I-PROBLEM
suck	I-PROBLEM
while	O
breathing	O
at	O
the	O
initial	O
onset	O
of	O
feeding	O
time	O
.	O

Breast	O
feeding	O
was	O
limited	O
to	O
four	O
to	O
five	O
minutes	O
on	O
each	O
side	O
per	O
recommendation	O
of	O
neurology	O
after	O
their	B-TEST
evaluation	I-TEST
to	O
try	O
and	O
minimize	O
incidence	O
of	O
gastroesophageal	B-PROBLEM
reflux	I-PROBLEM
.	O

Weight	B-TEST
at	O
time	O
of	O
discharge	O
is	O
3.13	O
kilograms	O
.	O

Birth	B-TEST
weight	I-TEST
was	O
3.29	O
kilograms	O
in	O
the	O
75th	O
percentile	O
.	O

Head	B-TEST
circumference	I-TEST
was	O
34.5	O
cm	O
,	O
75th	O
percentile	O
,	O
and	O
length	B-TEST
was	O
50.7	O
cm	O
,	O
also	O
the	O
75th	O
percentile	O
.	O

Baby	O
was	O
noted	O
to	O
have	O
frequent	B-PROBLEM
spitting	I-PROBLEM
episodes	I-PROBLEM
.	O

This	O
was	O
minimized	O
with	O
limitation	B-TREATMENT
of	I-TREATMENT
volume	I-TREATMENT
at	I-TREATMENT
each	I-TREATMENT
feed	I-TREATMENT
with	O
frequent	B-TREATMENT
feeding	I-TREATMENT
.	O

The	O
baby	O
demonstrated	O
mild	B-PROBLEM
physiologic	I-PROBLEM
jaundice	I-PROBLEM
with	O
a	B-TEST
serum	I-TEST
bilirubin	I-TEST
obtained	O
on	O
day	O
of	O
life	O
three	O
which	O
was	O
6.7	O
with	O
a	O
direct	O
of	O
0.2	O
.	O

Mother	B-TEST
's	I-TEST
blood	I-TEST
type	I-TEST
is	O
O	O
negative	O
.	O

Infant	B-TEST
's	I-TEST
blood	I-TEST
type	I-TEST
was	O
O	O
positive	O
and	O
Coombs	B-TEST
was	O
noted	O
to	O
be	O
negative	O
.	O

In	O
addition	O
a	B-TEST
complete	I-TEST
blood	I-TEST
count	I-TEST
was	O
obtained	O
on	O
admission	O
with	O
a	B-TEST
white	I-TEST
count	I-TEST
of	O
10.1	O
with	O
43	O
polys	B-TEST
and	O
0	O
bands	B-TEST
.	I-TEST

Hematocrit	B-TEST
was	O
noted	O
to	O
47.5	O
with	O
platelets	B-TEST
of	O
257,000	O
.	O

There	O
were	O
no	O
blood	B-TREATMENT
products	I-TREATMENT
received	O
during	O
hospitalization	O
.	O

A	B-TEST
blood	I-TEST
culture	I-TEST
was	O
obtained	O
upon	O
admission	O
and	O
Ampicillin	B-TREATMENT
and	O
Gentamicin	B-TREATMENT
were	O
given	O
for	O
48	O
hours	O
with	O
blood	B-TEST
cultures	I-TEST
remaining	O
sterile	O
.	O

Antibiotics	B-TREATMENT
were	O
discontinued	O
on	O
day	O
of	O
life	O
three	O
and	O
infant	O
has	O
remained	O
clinically	O
well	O
off	O
antibiotics	B-TREATMENT
.	O

Neurology	O
was	O
consulted	O
due	O
to	O
the	O
concern	O
for	O
seizures	B-PROBLEM
in	O
the	O
setting	O
of	O
dusky	B-PROBLEM
episodes	I-PROBLEM
.	O

An	B-TEST
EEG	I-TEST
was	O
performed	O
.	O

The	B-TEST
EEG	I-TEST
showed	O
transient	B-PROBLEM
sharp	I-PROBLEM
waves	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
front	I-PROBLEM
,	O
left	O
occipital	O
and	O
right	O
parietal	O
regions	O
.	O

There	O
was	O
no	O
electrographic	B-TEST
evidence	I-TEST
of	O
seizure	B-PROBLEM
activity	I-PROBLEM
noted	O
.	O

Hearing	B-TEST
screening	I-TEST
was	O
performed	O
with	O
automated	O
auditory	O
brain	O
stem	O
responses	O
.	O

Ophthalmology	O
was	O
consulted	O
due	O
to	O
the	O
presence	O
of	O
a	B-PROBLEM
coloboma	I-PROBLEM
into	O
the	O
left	O
CMED	O
.	O

Ophthalmology	O
noted	O
that	O
this	B-PROBLEM
left	I-PROBLEM
Martha	I-PROBLEM
coloboma	I-PROBLEM
was	O
likely	O
an	B-PROBLEM
isolated	I-PROBLEM
anomaly	I-PROBLEM
in	O
the	O
absence	O
of	O
other	B-PROBLEM
pathology	I-PROBLEM
.	O

Medications	B-TREATMENT
are	O
Tri-Vi-Michael	B-TREATMENT
1	O
cc	O
by	O
mouth	O
each	O
day	O
.	O

Newborn	B-TEST
state	I-TEST
screen	I-TEST
was	O
sent	O
on	O
day	O
of	O
life	O
three	O
.	O

Immunizations	B-TREATMENT
received	O
are	O
hepatitis	B-TREATMENT
B	I-TREATMENT
vaccine	I-TREATMENT
given	O
on	O
09-26	O
.	O

Full	O
term	O
male	O
infant	O
with	O
cyanosis	B-PROBLEM
episodes	I-PROBLEM
.	O

Rule	O
out	O
sepsis	B-PROBLEM
.	O

Left	B-PROBLEM
coloboma	I-PROBLEM
.	O

Rule	O
out	O
seizures	B-PROBLEM
.	O

Mr.	O
Pohl	O
is	O
a	O
53	O
-	O
year-old	O
male	O
with	O
history	O
of	O
alcohol	O
use	O
and	O
hypertension	B-PROBLEM
.	O

He	O
was	O
found	O
in	O
his	O
apartment	O
lobby	O
"	O
shouting	O
"	O
and	O
very	B-PROBLEM
agitated	I-PROBLEM
.	O

He	O
by	O
emergency	O
room	O
report	O
,	O
was	O
found	O
in	O
his	O
apartment	O
lobby	O
agitated	B-PROBLEM
.	O

Blood	B-TEST
alcohol	I-TEST
level	I-TEST
was	O
383	O
.	O

Agitated	B-PROBLEM
in	O
emergency	O
room	O
requiring	O
4	B-TREATMENT
leather	I-TREATMENT
restraints	I-TREATMENT
,	O
received	O
5	O
mg	O
of	O
Haldol	B-TREATMENT
,	O
2	O
mg	O
of	O
Ativan	B-TREATMENT
.	O

He	O
became	O
hypotensive	B-PROBLEM
in	O
the	O
emergency	O
room	O
with	O
a	B-TEST
systolic	I-TEST
blood	I-TEST
pressure	I-TEST
in	O
the	O
80	O
's	O
and	O
had	O
decreased	B-PROBLEM
respiratory	I-PROBLEM
rate	I-PROBLEM
.	O

He	O
received	O
a	B-TREATMENT
normal	I-TREATMENT
saline	I-TREATMENT
bolus	I-TREATMENT
of	O
2	O
liters	O
of	O
good	O
blood	O
pressure	O
response	O
.	O

The	O
patient	O
was	O
then	O
admitted	O
to	O
the	O
medical	O
Intensive	O
Care	O
Unit	O
for	O
observation	O
of	O
his	B-TEST
blood	I-TEST
pressure	I-TEST
and	O
then	O
transferred	O
to	O
our	O
service	O
on	O
medicine	O
when	O
the	B-TEST
blood	I-TEST
pressures	I-TEST
remained	O
stable	O
overnight	O
.	O

The	O
patient	O
denies	O
any	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
dysuria	B-PROBLEM
,	O
diarrhea	B-PROBLEM
,	O
bright	B-PROBLEM
red	I-PROBLEM
blood	I-PROBLEM
per	I-PROBLEM
rectum	I-PROBLEM
.	O

He	O
does	O
complain	O
of	O
cold	B-PROBLEM
symptoms	I-PROBLEM
times	O
one	O
week	O
.	O

The	O
patient	O
states	O
in	O
the	O
past	O
that	O
he	O
has	O
participated	O
in	O
several	O
alcohol	B-TREATMENT
treatment	I-TREATMENT
programs	I-TREATMENT
,	O
most	O
recently	O
Star	O
which	O
is	O
similar	O
Alcoholics	O
Anonymous	O
.	O

His	O
brother	O
is	O
mentally	B-PROBLEM
handicapped	I-PROBLEM
and	O
might	O
be	O
sent	O
away	O
from	O
his	O
instate	O
institution	O
.	O

In	O
the	O
past	O
,	O
he	O
has	O
been	O
very	B-PROBLEM
depressed	I-PROBLEM
and	O
has	O
seen	O
a	B-TREATMENT
counselor	I-TREATMENT
at	O
Greenfield	O
Community	O
College	O
Community	O
Health	O
.	O

1.	O
Hypertension	B-PROBLEM
.	O

2.	O
History	O
of	O
colonic	B-PROBLEM
polyps	I-PROBLEM
times	O
3	O
,	O
benign	O
in	O
2007	O
,	O
repeat	B-TEST
colonoscopy	I-TEST
due	O
to	O
in	O
2010	O
.	O

3.	O
History	O
of	O
right	B-PROBLEM
inguinal	I-PROBLEM
hernia	I-PROBLEM
in	O
2002	O
.	O

Positive	O
tobacco	O
,	O
10	O
pack	O
year	O
history	O
,	O
quit	O
for	O
8	O
years	O
in	O
his	O
40	O
's	O
and	O
now	O
no	O
cigarettes	O
for	O
one	O
week	O
using	O
no	O
pharmacal	B-TREATMENT
therapy	I-TREATMENT
.	O

The	O
patient	O
has	O
only	O
male	O
sexual	O
partners	O
and	O
in	O
the	O
last	O
six	O
months	O
has	O
two	O
regular	O
partners	O
who	O
reportedly	O
are	O
human	B-PROBLEM
immunodeficiency	I-PROBLEM
virus	I-PROBLEM
negative	O
and	O
no	O
IV	O
drug	O
use	O
.	O

He	O
uses	O
condoms	B-TREATMENT
consistently	O
.	O

Major	O
stressors	O
in	O
his	O
life	O
include	O
unstable	O
job	O
,	O
brother	O
is	O
mentally	B-PROBLEM
handicapped	I-PROBLEM
,	O
war	O
.	O

ALLERGIES	O
:	O
No	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

1.	O
Lisinopril	B-TREATMENT
5	O
mg	O
p.o.	O
q.d.	O

2.	O
Mavik	B-TREATMENT
question	O
of	O
dosage	O
.	O

3.	O
Hydrochlorothiazide	B-TREATMENT
question	O
of	O
dosage	O
.	O

1.	O
Ranitidine	B-TREATMENT
150	O
mg	O
b.i.d.	O

2.	O
Thiamine	B-TREATMENT
100	O
mg	O
q.d.	O

3.	O
Folic	B-TREATMENT
acid	I-TREATMENT
1	O
mg	O
q.	O
d.	O

4.	O
Multivitamin	B-TREATMENT

Vitals	B-TEST
on	I-TEST
admission	I-TEST
:	O
Please	O
refer	O
to	O
addendum	O
.	O

Vital	B-TEST
signs	I-TEST
were	O
stable	O
.	O

Systolic	B-TEST
blood	I-TEST
pressure	I-TEST
in	O
the	O
120	O
's	O
to	O
130	O
's.	O

Pulse	B-TEST
in	O
the	O
60	O
's	O
to	O
70	O
's.	O

The	O
patient	O
was	O
a	O
thin	O
well-appearing	O
man	O
who	O
was	O
visibly	B-PROBLEM
restless	I-PROBLEM
in	O
bed	O
.	O

He	O
was	O
alert	O
and	O
oriented	O
times	O
3	O
and	O
with	O
slightly	B-PROBLEM
pressured	I-PROBLEM
speech	I-PROBLEM
.	O

He	O
states	O
that	O
mood	O
is	O
depressed	B-PROBLEM
.	O

He	O
denies	O
auditory	B-PROBLEM
,	I-PROBLEM
visual	I-PROBLEM
or	I-PROBLEM
tactile	I-PROBLEM
hallucinations	I-PROBLEM
.	O

Cranial	B-TEST
nerves	I-TEST
II-XII	I-TEST
are	O
grossly	O
intact	O
,	O
5/5	O
strength	B-TEST
in	I-TEST
all	I-TEST
extremities	I-TEST
,	O
sensation	B-TEST
is	O
intact	O
in	O
all	O
extremities	O
.	O

Head	B-TEST
,	I-TEST
ears	I-TEST
,	I-TEST
eyes	I-TEST
,	I-TEST
nose	I-TEST
and	I-TEST
throat	I-TEST
:	O
Atraumatic	B-PROBLEM
and	O
normocephalic	O
.	O

Sclerae	O
were	O
anicteric	B-PROBLEM
.	O

Oropharynx	O
was	O
benign	O
without	O
exudate	B-PROBLEM
.	O

NO	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
.	O

Rare	B-PROBLEM
crackles	I-PROBLEM
on	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
base	I-PROBLEM
,	O
otherwise	O
clear	O
to	O
auscultation	B-TEST
bilaterally	I-TEST
.	O

Positive	O
bowel	O
sounds	O
,	O
nontender	B-PROBLEM
and	O
nondistended	B-PROBLEM
.	O

No	O
hepatosplenomegaly	B-PROBLEM
.	O

He	O
had	O
Dorsalis	B-TEST
pedis	I-TEST
in	O
radial	B-TEST
pulses	I-TEST
,	O
hands	B-PROBLEM
and	I-PROBLEM
feet	I-PROBLEM
notably	I-PROBLEM
tremulous	I-PROBLEM
without	O
asterixis	B-PROBLEM
.	O

No	O
stigmata	B-PROBLEM
of	O
IV	O
drug	O
use	O
.	O

CBC	B-TEST
:	O
White	B-TEST
blood	I-TEST
cell	I-TEST
count	I-TEST
is	O
8.8	O
,	O
hematocrit	B-TEST
35.5	O
platelets	B-TEST
266	O
,	O
PT	B-TEST
13	O
,	O
PT-T	B-TEST
23.3	O
,	O
INR	B-TEST
was	O
1.1	O
.	O

Chem-7	B-TEST
:	O
Sodium	B-TEST
145	O
,	O
potassium	B-TEST
3.4	O
,	O
chloride	B-TEST
116	O
,	O
bicarb	B-TEST
21	O
,	O
BUN	B-TEST
12	O
,	O
creatinine	B-TEST
0.6	O
,	O
glucose	B-TEST
96	O
,	O
calcium	B-TEST
7.2	O
,	O
phos	B-TEST
3.6	O
,	O
magnesium	B-TEST
1.7	O
.	O

Liver	B-TEST
function	I-TEST
tests	I-TEST
:	O
ALT	B-TEST
38	O
,	O
AST	B-TEST
34	O
,	O
alk	B-TEST
phos	I-TEST
is	I-TEST
107	O
,	O
albumin	B-TEST
is	O
3.2	O
,	O
peak	B-TEST
bili	I-TEST
is	I-TEST
0.3	O
,	O
amylase	B-TEST
31	O
,	O
and	O
lipase	B-TEST
is	O
32	O
.	O

UA	B-TEST
was	O
negative	O
.	O

Urine	B-TEST
tox	I-TEST
was	O
negative	O
.	O

Serum	B-TEST
tox	I-TEST
was	O
positive	O
for	O
ETOH	B-TEST
at	O
383	O
,	O
otherwise	O
negative	O
.	O

Serum	B-TEST
osmolality	I-TEST
was	O
38397	O
,	O
calculated	B-TEST
osmolality	I-TEST
gap	I-TEST
was	O
21	O
.	O

chest	B-TEST
x-ray	I-TEST
from	O
02-07	O
had	O
linear	B-PROBLEM
atelectasis	I-PROBLEM
in	I-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
with	O
no	O
evidence	O
of	O
a	B-PROBLEM
band-like	I-PROBLEM
opacity	I-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
left	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
which	O
was	O
evident	O
on	O
the	B-TEST
chest	I-TEST
x-ray	I-TEST
on	O
02-06	O
.	O

CT	B-TEST
of	I-TEST
the	I-TEST
head	I-TEST
on	O
02-06	O
was	O
negative	O
for	O
hemorrhage	B-PROBLEM
.	O

There	O
was	O
bran	B-PROBLEM
atrophy	I-PROBLEM
and	O
right	B-PROBLEM
temporal	I-PROBLEM
encephalomalacia	I-PROBLEM
.	O

Mr.	O
Pohl	O
is	O
a	O
53	O
-	O
year-old	O
male	O
with	O
a	O
history	O
of	O
ETOH	O
,	O
hypertension	B-PROBLEM
who	O
presented	O
int	O
he	O
emergency	O
room	O
with	O
increased	B-PROBLEM
agitation	I-PROBLEM
,	O
like	O
secondary	O
to	O
ETOH	B-PROBLEM
intoxication	I-PROBLEM
and	O
developed	O
subsequent	B-PROBLEM
hypotension	I-PROBLEM
,	O
systolic	B-TEST
blood	I-TEST
pressures	I-TEST
in	O
the	O
80	O
's,	O
status	O
post	O
Ativan	B-TREATMENT
and	O
Haldol	B-TREATMENT
,	O
but	O
was	O
responsive	O

to	O
fluid	B-TREATMENT
resuscitation	I-TREATMENT
at	O
4	O
liters	O
and	O
was	O
admitted	O
to	O
the	O
CMED	O
CCU	O
for	O
hemodynamic	B-TEST
monitoring	I-TEST
.	O

Plan	O
for	O
patient	O
regarding	O
cardiac	O
,	O
unlike	O
hypotension	B-PROBLEM
of	I-PROBLEM
cardiac	I-PROBLEM
origin	I-PROBLEM
.	O

The	O
patient	O
responded	O
well	O
to	O
fluid	B-TREATMENT
resuscitation	I-TREATMENT
.	O

Elevated	B-PROBLEM
CK	I-PROBLEM
on	O
02-07	O
is	O
likely	O
secondary	O
to	O
mild	B-PROBLEM
rhabdomyolysis	I-PROBLEM
.	O

We	O
decided	O
to	O
discontinue	O
telemetry	B-TEST
and	O
held	O
all	B-TREATMENT
hypertension	I-TREATMENT
medications	I-TREATMENT
including	O
Lisinopril	B-TREATMENT
,	O
Mavik	B-TREATMENT
,	O
hydrochlorothiazide	B-TREATMENT
.	O

2.	O
For	O
pulmonary	O
,	O
the	O
patient	O
had	O
a	O
good	O
O2	B-TEST
saturations	I-TEST
on	O
room	O
air	O
.	O

He	O
had	O
atelectasis	B-PROBLEM
in	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
lower	I-PROBLEM
lobe	I-PROBLEM
by	O
chest	B-TEST
x-ray	I-TEST
.	O

The	O
patient	O
on	O
ranitidine	B-TREATMENT
150	O
mg	O
p.o.	O
b.i.d.	O
for	O
gastrointestinal	B-TREATMENT
prophylaxis	I-TREATMENT
.	O

4.	O
Urology	O
:	O
Foley	B-TREATMENT
was	O
discontinued	O
in	O
the	O
CMED	O
CCU	O
at	O
12	O
p.m.	O

The	O
patient	O
was	O
urinating	O
without	O
difficulty	B-PROBLEM
.	O

We	O
continued	O
IV	B-TREATMENT
fluids	I-TREATMENT
at	O
100	O
cc	O
per	O
hour	O
for	O
one	O
liter	O
secondary	O
to	O
a	O
concern	O
for	O
rhabdomyolysis	B-PROBLEM
plus	O
kidney	B-TREATMENT
protective	I-TREATMENT
effects	I-TREATMENT
.	O

K	B-TEST
was	O
3.4	O
,	O
repleted	O
,	O
potassium	B-TREATMENT
chloride	I-TREATMENT
40	O
mEq	O
times	O
1	O
dose	O
p.o.	O

Calcium	B-TEST
with	O
7.2	O
corrected	O
to	O
less	O
than	O
8.0,	O
completed	O
calcium	B-TREATMENT
carbonate	I-TREATMENT
at	O
500	O
mg	O
blood	B-TEST
pressure.o.	I-TEST
t.i.d.	O
while	O
in	O
the	O
hospital	O
.	O

Mag	B-TEST
was	O
1.7	O
,	O
repleted	O
with	O
magnesium	B-TREATMENT
oxide	I-TREATMENT
with	O
400	O
mg	O
p.o.	O
times	O
one	O
dose	O
.	O

The	O
patient	O
seemed	O
notably	B-PROBLEM
anxious	I-PROBLEM
and	O
depressed	B-PROBLEM
.	O

It	O
is	O
possible	O
that	O
the	O
patient	O
is	O
self	O
medicating	O
for	O
underlying	B-PROBLEM
psychiatric	I-PROBLEM
disorder	I-PROBLEM
.	O

We	O
will	O
monitor	B-TEST
for	O
signs	O
of	O
alcohol	B-PROBLEM
withdrawal	I-PROBLEM
according	O
to	O
the	B-TEST
CIWA	I-TEST
scale	I-TEST
.	O

We	O
will	O
given	O
valium	B-TREATMENT
5	O
mg	O
p.o.	O
q.	O
3	O
hours	O
for	O
withdrawal	B-PROBLEM
.	O

We	O
will	O
consider	O
psychiatry	O
consult	O
in	O
the	O
future	O
to	O
assess	O
for	O
underlying	B-PROBLEM
anxiety	I-PROBLEM
disorder	I-PROBLEM
or	O
depression	B-PROBLEM
.	O

The	O
patient	O
may	O
be	O
discharge	O
Harry	O
02-08	O
pending	O
observations	B-TEST
for	O
delirium	B-PROBLEM
tremens	I-PROBLEM
after	O
discussion	O
with	O
primary	O
care	O
physician	O
,	O
Dr.	O
Blue	O
who	O
knows	O
the	O
patient	O
well	O
.	O

1.	O
Blood	B-TEST
pressure	I-TEST
:	O

The	B-TEST
patient	I-TEST
's	I-TEST
blood	I-TEST
pressure	I-TEST
remained	O
stable	O
on	O
hospital	O
day	O
#2	O
through	O
hospital	O
day	O
#3	O
status	O
post	O
IV	B-TREATMENT
hydration	I-TREATMENT
with	O
systolic	B-TEST
blood	I-TEST
pressures	I-TEST
in	O
the	O
120	O
's	O
to	O
130	O
's.	O

We	O
continued	O
to	O
hold	O
the	O
patient	O
's	O
home	B-TREATMENT
blood	I-TREATMENT
pressure	I-TREATMENT
medications	I-TREATMENT
.	O

The	O
patient	O
was	O
asymptomatic	B-PROBLEM
without	O
chest	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
no	O
mental	B-PROBLEM
status	I-PROBLEM
changes	I-PROBLEM
.	O

On	O
Hospital	O
day	O
#2	O
through	O
hospital	O
day	O
#3	O
,	O
the	O
patient	O
had	O
mild	B-PROBLEM
tremor	I-PROBLEM
on	I-PROBLEM
hands	I-PROBLEM
,	O
but	O
improved	O
over	O
hospital	O
course	O
.	O

The	O
patient	O
became	O
notably	B-PROBLEM
less	I-PROBLEM
anxious	I-PROBLEM
throughout	O
hospital	O
stay	O
.	O

CIWA	B-TEST
scale	I-TEST
over	O
night	O
was	O
1	O
for	O
tremor	B-PROBLEM
and	O
the	O
patient	O
did	O
not	O
require	O
any	O
Valium	B-TREATMENT
for	O
alcohol	B-PROBLEM
withdrawal	I-PROBLEM
.	O

Calcium	B-TREATMENT
carbonate	I-TREATMENT
500	O
mg	O
p.o.	O
t.i.d.	O
,	O
Mag	B-TREATMENT
oxide	I-TREATMENT
400	O
mg	O
p.o.	O
times	O
one	O
dose	O
,	O
potassium	B-TREATMENT
chloride	I-TREATMENT
repleted	O
40	O
mEq	O
times	O
one	O
dose	O
.	O

1.	O
ETOH	B-PROBLEM
intoxication	I-PROBLEM
.	O

2.	O
Hypertension	B-PROBLEM
.	O

3.	O
History	O
of	O
colonic	B-PROBLEM
polyp	I-PROBLEM
times	O
3	O
,	O
benign	O
in	O
2007	O
,	O
repeat	B-TEST
colonoscopy	I-TEST
due	O
in	O
2010	O
.	O

4.	O
History	B-PROBLEM
of	I-PROBLEM
right	I-PROBLEM
inguinal	I-PROBLEM
hernia	I-PROBLEM
in	O
2002	O
.	O

Return	O
to	O
home	B-TREATMENT
medications	I-TREATMENT
:	O

1.	O
Lisinopril	B-TREATMENT
5	O
mg	O
p.o.q.d.	O

2.	O
Mavik	B-TREATMENT
unknown	O
dosage	O
.	O

3.	O
Hydrochlorothiazide	B-TREATMENT
unknown	O
dosage	O
.	O

The	O
patient	O
is	O
an	O
82	O
-	O
year-old	O
male	O
with	O
a	O
history	O
of	O
hypertension	B-PROBLEM
,	O
remote	O
tobacco	O
abuse	O
,	O
chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
,	O
and	O
a	O
history	O
of	O
a	B-PROBLEM
TIA	I-PROBLEM
who	O
was	O
in	O
his	O
usual	O
state	O
of	O
health	O
until	O
five	O
nights	O
prior	O
to	O
admission	O
when	O
he	O
awoke	O
at	O
midnight	O
with	O
severe	B-PROBLEM
epigastric	I-PROBLEM
pain	I-PROBLEM
radiating	O
to	O
both	O
arms	O
.	O

He	O
also	O
had	O
bilateral	B-PROBLEM
arm	I-PROBLEM
numbness	I-PROBLEM
.	O

The	B-PROBLEM
symptoms	I-PROBLEM
were	O
associated	O
with	O
diaphoresis	B-PROBLEM
and	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
but	O
no	O
nausea	B-PROBLEM
or	O
vomiting	B-PROBLEM
.	O

After	O
approximately	O
one	O
hour	O
,	O
he	O
presented	O
to	O
the	O
Bristol	O
County	O
Tuberculosis	O
Hospital	O
Dana-Farber	O
Cancer	O
Institute	O
Campus	O
where	O
he	O
ruled	O
in	O
for	O
a	B-PROBLEM
non-ST	I-PROBLEM
elevation	I-PROBLEM
MI	I-PROBLEM
with	O
a	B-TEST
CK	I-TEST
of	O
438	O
with	O
a	B-TEST
peak	I-TEST
CK	I-TEST
MB	I-TEST
of	O
19.8	O
and	O
troponin	B-TEST
that	O
peaked	O
at	O
10.2	O
.	O

He	O
was	O
started	O
on	O
nitrates	B-TREATMENT
there	O
as	O
well	O
as	O
heparin	B-TREATMENT
and	O
Integrelin	B-TREATMENT
and	O
remained	O
pain-free	B-PROBLEM
.	O

He	O
denied	O
any	O
history	O
of	O
similar	B-PROBLEM
symptoms	I-PROBLEM
in	O
the	O
past	O
and	O
has	O
had	O
no	O
prior	O
history	O
of	O
angina	B-PROBLEM
or	O
myocardial	B-PROBLEM
infarction	I-PROBLEM
.	O

The	O
patient	O
was	O
subsequently	O
transferred	O
to	O
Youville	O
Hospital	O
for	O
cardiac	B-TEST
catheterization	I-TEST
.	O

At	O
the	O
time	O
of	O
transfer	O
,	O
he	O
was	O
initially	O
admitted	O
to	O
the	O
CMI	O
Service	O
after	O
undergoing	O
cardiac	B-TEST
catheterization	I-TEST
which	O
revealed	O
a	B-PROBLEM
long	I-PROBLEM
LAD	I-PROBLEM
lesion	I-PROBLEM
that	O
was	O
angioplastied	O
without	O
stent	B-TREATMENT
placement	I-TREATMENT
,	O
and	O
a	B-PROBLEM
total	I-PROBLEM
occlusion	I-PROBLEM
of	I-PROBLEM
the	I-PROBLEM
RCA	I-PROBLEM
with	O
collaterals	O
.	O

He	O
subsequently	O
became	O
hypotensive	B-PROBLEM
and	O
bradycardiac	B-PROBLEM
in	O
the	O
Catheterization	O
Laboratory	O
which	O
responded	O
to	O
IV	B-TREATMENT
fluids	I-TREATMENT
,	O
dopamine	B-TREATMENT
,	O
Atropine	B-TREATMENT
,	O
and	O
he	O
was	O
then	O
transferred	O
to	O
the	O
CCU	O
for	O
further	B-TEST
monitoring	I-TEST
.	O

He	O
had	O
a	B-TEST
bedside	I-TEST
transthoracic	I-TEST
echocardiogram	I-TEST
done	O
in	O
the	O
Cardiac	O
Catheterization	O
laboratory	O
without	O
evidence	O
of	O
an	B-PROBLEM
effusion	I-PROBLEM
.	O

A	B-TREATMENT
Swan	I-TREATMENT
was	O
also	O
placed	O
.	O

There	O
were	O
no	O
stents	B-TREATMENT
deployed	O
at	O
all	O
throughout	O
the	B-TEST
catheterization	I-TEST
.	O

By	O
the	O
time	O
he	O
was	O
admitted	O
,	O
he	O
was	O
off	O
pressors	B-TREATMENT
and	O
hemodynamically	O
stable	O
and	O
pain-free	B-PROBLEM
.	O

TIA	B-PROBLEM
in	O
1998	O
.	O

COPD	B-PROBLEM
with	O
2	O
liters	O
dependence	O
of	O
home	B-TREATMENT
02	I-TREATMENT
.	O

BPH	B-PROBLEM
.	O

Chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
.	O

Gastritis	B-PROBLEM
.	O

Asthma	B-PROBLEM
.	O

He	O
uses	O
a	B-TREATMENT
cane	I-TREATMENT
p.r.n.	O
for	O
walking	O
.	O

The	O
patient	O
has	O
no	O
known	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

1.	O
Aspirin	B-TREATMENT
325	O
mg	O
q.d.	O

2.	O
Metoprolol	B-TREATMENT
50	O
mg	O
b.i.d.	O

3.	O
Lipitor	B-TREATMENT
10	O
mg	O
q.d.	O

4.	O
MDI	B-TREATMENT
p.r.n.	O

5.	O
Heparin	B-TREATMENT
drip	I-TREATMENT
on	O
transfer	O
.	O

6.	O
Integrelin	B-TREATMENT
drip	I-TREATMENT
on	O
transfer	O
.	O

Vital	B-TEST
signs	I-TEST
:	O

Heart	B-TEST
rate	I-TEST
91	O
,	O
regular	O
,	O
blood	B-TEST
pressure	I-TEST
169/81	O
from	O
a	B-TREATMENT
right	I-TREATMENT
groin	I-TREATMENT
A	I-TREATMENT
line	I-TREATMENT
,	O
respirations	B-TEST
12	O
,	O
oxygen	B-TEST
saturation	I-TEST
of	O
97	O
percent	O
on	O
2	B-TREATMENT
liters	I-TREATMENT
nasal	I-TREATMENT
cannula	I-TREATMENT
.	O

He	O
was	O
a	O
well	O
appearing	O
male	O
in	O
no	O
acute	B-PROBLEM
distress	I-PROBLEM
.	O

Crusting	B-PROBLEM
around	I-PROBLEM
the	I-PROBLEM
right	I-PROBLEM
eyelid	I-PROBLEM
but	O
the	O
pupils	O
were	O
equal	O
,	O
round	O
,	O
and	O
reactive	O
to	O
light	O
.	O

He	O
was	O
edentulous	B-PROBLEM
.	O

The	O
neck	O
was	O
supple	O
without	O
lymphadenopathy	B-PROBLEM
or	O
thyromegaly	B-PROBLEM
.	O

He	O
had	O
no	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
,	O
or	O
gallops	B-PROBLEM
.	O

His	O
lungs	O
were	O
clear	O
to	O
auscultation	B-TEST
bilaterally	O
Anteriorly	O
and	O
laterally	O
.	O

Soft	O
,	O
obese	B-PROBLEM
,	O
nontender	B-PROBLEM
,	O
nondistended	B-PROBLEM
.	O

He	O
had	O
normoactive	O
bowel	B-TEST
sounds	I-TEST
.	O

There	O
was	O
a	B-TREATMENT
right	I-TREATMENT
groin	I-TREATMENT
A	I-TREATMENT
line	I-TREATMENT
and	O
a	B-TREATMENT
left	I-TREATMENT
groin	I-TREATMENT
venous	I-TREATMENT
sheath	I-TREATMENT
with	O
a	B-TREATMENT
Swan	I-TREATMENT
.	O

He	O
had	O
no	O
evident	B-PROBLEM
edema	I-PROBLEM
.	O

He	O
had	O
2+	O
dorsalis	B-TEST
pedis	I-TEST
and	O
posterior	B-TEST
tibial	I-TEST
pulses	I-TEST
bilaterally	O
.	O

On	O
admission	O
,	O
the	B-TEST
CBC	I-TEST
revealed	O
a	B-TEST
white	I-TEST
count	I-TEST
of	O
7.4	O
,	O
hematocrit	B-TEST
39.7	O
,	O
and	O
platelets	B-TEST
of	O
217,000	O
.	O

Serum	B-TEST
chemistries	I-TEST
revealed	O
a	B-TEST
sodium	I-TEST
of	O
135,	O
potassium	B-TEST
4.0	O
,	O
chloride	B-TEST
102	O
,	O
bicarbonate	B-TEST
26	O
,	O
BUN	B-TEST
29	O
,	O
creatinine	B-TEST
1.6	O
,	O
and	O
glucose	B-TEST
of	O
111	O
.	O

The	B-TEST
initial	I-TEST
EKG	I-TEST
showed	O
normal	O
sinus	B-TEST
rhythm	I-TEST
at	O
a	B-TEST
rate	I-TEST
of	O
71	O
with	O
a	O
normal	O
axis	B-TEST
and	O
evidence	O
of	O
first-degree	B-PROBLEM
AV	I-PROBLEM
block	I-PROBLEM
with	O
prolonged	B-PROBLEM
PR	I-PROBLEM
interval	I-PROBLEM
of	O
238	O
milliseconds	O
.	O

He	O
also	O
had	O
a	B-PROBLEM
widened	I-PROBLEM
QRS	I-PROBLEM
of	O
153	O
milliseconds	O
,	O
an	B-PROBLEM
old	I-PROBLEM
right	I-PROBLEM
bundle	I-PROBLEM
branch	I-PROBLEM
block	I-PROBLEM
,	O
and	O
no	O
acute	B-PROBLEM
ST	I-PROBLEM
or	I-PROBLEM
T	I-PROBLEM
wave	I-PROBLEM
changes	I-PROBLEM
.	O

The	B-TEST
EKG	I-TEST
was	O
prior	O
to	O
catheterization	B-TEST
and	O
the	O
one	O
post	O
PTCA	B-TREATMENT
was	O
no	O
different	O
.	O

He	O
had	O
a	B-TEST
bedside	I-TEST
echocardiogram	I-TEST
done	O
in	O
the	O
Catheterization	O
Laboratory	O
which	O
showed	O
normal	O
LV	O
wall	O
thickness	O
and	O
normal	O
LV	O
cavity	O
size	O
.	O

There	O
was	O
no	O
evidence	O
of	O
effusion	B-PROBLEM
.	O

Cardiac	B-TEST
catheterization	I-TEST
revealed	O
a	B-PROBLEM
totally	I-PROBLEM
occluded	I-PROBLEM
RCA	I-PROBLEM
with	O
collaterals	O
,	O
an	B-PROBLEM
80	I-PROBLEM
percent	I-PROBLEM
LAD	I-PROBLEM
lesion	I-PROBLEM
extending	O
distally	O
which	O
was	O
angioplastied	O
but	O
no	O
stent	B-TREATMENT
was	O
placed	O
.	O

The	B-TEST
right	I-TEST
heart	I-TEST
catheterization	I-TEST
revealed	O
pulmonary	B-TEST
capillary	I-TEST
wedge	I-TEST
pressure	I-TEST
of	O
4	O
,	O
cardiac	B-TEST
output	I-TEST
of	O
8	O
,	O
and	O
cardiac	B-TEST
index	I-TEST
of	O
3.8	O
,	O
he	O
had	O
an	B-TEST
RA	I-TEST
pressure	I-TEST
of	O
10	O
,	O
RV	B-TEST
pressure	I-TEST
of	O
43/4	O
,	O
PA	B-TEST
pressure	I-TEST
of	O
37/10	O
.	O

This	O
is	O
an	O
82	O
-	O
year-old	O
male	O
with	O
a	O
history	O
of	O
prior	O
tobacco	O
use	O
,	O
hypertension	B-PROBLEM
,	O
chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
,	O
COPD	B-PROBLEM
,	O
gastritis	B-PROBLEM
,	O
and	O
TIA	B-PROBLEM
who	O
initially	O
presented	O
to	O
Braintree	O
with	O
a	B-PROBLEM
non-ST	I-PROBLEM
elevation	I-PROBLEM
MI	I-PROBLEM
and	O
Guaiac	B-PROBLEM
positive	I-PROBLEM
stools	I-PROBLEM
,	O
transferred	O
to	O
St.	O
Margaret's	O
Center	O
for	O
Women	O
&	O
Infants	O
for	O
cardiac	B-TEST
catheterization	I-TEST
with	O
PTCA	B-TREATMENT
to	O
mid	B-PROBLEM
LAD	I-PROBLEM
lesion	I-PROBLEM
complicated	O
by	O
hypotension	B-PROBLEM
and	O
bradycardia	B-PROBLEM
requiring	O
Atropine	B-TREATMENT
,	O
IV	B-TREATMENT
fluids	I-TREATMENT
and	O
transient	B-TREATMENT
dopamine	I-TREATMENT
possibly	O
secondary	O
to	O
vagal	B-PROBLEM
reaction	I-PROBLEM
,	O
subsequently	O
transferred	O
to	O
CCU	O
for	O
close	B-TEST
monitoring	I-TEST
,	O
hemodynamically	O
stable	O
at	O
the	O
time	O
of	O
admission	O
to	O
the	O
CCU	O
.	O

As	O
summarized	O
above	O
,	O
the	O
patient	O
had	O
a	B-PROBLEM
non-ST	I-PROBLEM
elevation	I-PROBLEM
MI	I-PROBLEM
with	O
evidence	O
of	O
an	B-PROBLEM
80	I-PROBLEM
percent	I-PROBLEM
mid	I-PROBLEM
LAD	I-PROBLEM
lesion	I-PROBLEM
for	O
which	O
he	O
underwent	O
angioplasty	B-TREATMENT
without	O
stent	B-TREATMENT
placement	I-TREATMENT
.	O

He	O
was	O
initially	O
continued	O
on	O
aspirin	B-TREATMENT
,	O
Plavix	B-TREATMENT
,	O
beta	B-TREATMENT
blocker	I-TREATMENT
,	O
statin	B-TREATMENT
,	O
and	O
ACE	B-TREATMENT
inhibitor	I-TREATMENT
.	O

At	O
the	O
time	O
of	O
discharge	O
,	O
his	B-TREATMENT
Plavix	I-TREATMENT
was	O
held	O
due	O
to	O
Guaiac	B-PROBLEM
positive	I-PROBLEM
stools	I-PROBLEM
and	O
hematocrit	B-PROBLEM
drop	I-PROBLEM
throughout	O
admission	O
.	O

He	O
had	O
a	B-TEST
transthoracic	I-TEST
echocardiogram	I-TEST
the	O
day	O
after	O
admission	O
showing	O
an	B-TEST
ejection	I-TEST
fraction	I-TEST
of	O
greater	O
than	O
60	O
percent	O
.	O

No	O
focal	B-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormalities	I-PROBLEM
.	O

He	O
had	O
no	O
recurrent	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
throughout	O
admission	O
.	O

In	O
regards	O
to	O
his	O
rhythm	O
,	O
he	O
has	O
an	B-PROBLEM
underlying	I-PROBLEM
right	I-PROBLEM
bundle	I-PROBLEM
branch	I-PROBLEM
block	I-PROBLEM
and	O
first-degree	B-PROBLEM
AV	I-PROBLEM
block	I-PROBLEM
which	O
were	O
stable	O
throughout	O
this	O
admission	O
.	O

He	O
had	O
a	O
history	O
of	O
COPD	B-PROBLEM
for	O
which	O
he	O
is	O
on	O
baseline	O
2	O
liters	O
of	O
02	B-TREATMENT
by	O
nasal	B-TREATMENT
cannula	I-TREATMENT
at	O
home	O
and	O
Albuterol	B-TREATMENT
and	O
Atrovent	B-TREATMENT
MDI	I-TREATMENT
s	O
p.r.n.	O
at	O
home	O
.	O

He	O
is	O
also	O
on	O
Flovent	B-TREATMENT
MDI	I-TREATMENT
at	O
home	O
as	O
well	O
.	O

He	O
was	O
continued	O
on	O
his	B-TREATMENT
MDI	I-TREATMENT
and	O
was	O
at	O
his	B-PROBLEM
baseline	I-PROBLEM
02	I-PROBLEM
requirement	I-PROBLEM
throughout	O
admission	O
.	O

He	O
has	O
a	O
history	O
of	O
chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
likely	O
secondary	O
to	O
hypertension	B-PROBLEM
and	O
was	O
admitted	O
with	O
a	B-TEST
creatinine	I-TEST
of	O
1.6	O
.	O

His	B-TREATMENT
ACE	I-TREATMENT
inhibitor	I-TREATMENT
post	O
MI	B-PROBLEM
was	O
initially	O
held	O
due	O
to	O
his	B-TEST
creatinine	I-TEST
.	O

However	O
,	O
this	O
responded	O
to	O
IV	B-TREATMENT
fluids	I-TREATMENT
and	O
his	B-TREATMENT
ACE	I-TREATMENT
inhibitor	I-TREATMENT
was	O
restarted	O
at	O
the	O
time	O
of	O
discharge	O
.	O

He	O
will	O
need	O
close	B-TEST
monitoring	I-TEST
of	O
his	B-TEST
creatinine	I-TEST
post	O
discharge	O
in	O
the	O
setting	O
of	O
reinstitution	O
of	O
his	B-TREATMENT
ACE	I-TREATMENT
inhibitor	I-TREATMENT
.	O

His	O
stools	O
were	O
noted	O
to	O
be	O
Guaiac	B-PROBLEM
positive	I-PROBLEM
at	O
the	O
outside	O
hospital	O
and	O
there	O
was	O
still	O
concern	O
for	O
possible	O
GI	B-PROBLEM
bleed	I-PROBLEM
given	O
continued	O
Guaiac	B-PROBLEM
positive	I-PROBLEM
stools	I-PROBLEM
during	O
this	O
admission	O
and	O
a	B-PROBLEM
slight	I-PROBLEM
drop	I-PROBLEM
in	I-PROBLEM
his	I-PROBLEM
hematocrit	I-PROBLEM
from	O
39	O
to	O
33	O
.	O

It	O
was	O
felt	O
most	O
appropriate	O
for	O
him	O
to	O
have	O
an	B-TEST
outpatient	I-TEST
GI	I-TEST
workup	I-TEST
,	O
and	O
his	O
PCP	O
was	O
contacted	O
and	O
will	O
arrange	O
for	O
outpatient	B-TEST
colonoscopy	I-TEST
.	O

His	B-TREATMENT
Plavix	I-TREATMENT
was	O
held	O
at	O
the	O
time	O
of	O
discharge	O
due	O
to	O
a	O
question	O
of	O
GI	B-PROBLEM
bleed	I-PROBLEM
and	O
in	O
the	O
setting	O
of	O
not	O
having	O
a	B-TREATMENT
stent	I-TREATMENT
placed	O
at	O
the	O
time	O
of	O
catheterization	B-TEST
.	O

He	O
was	O
continued	O
on	O
his	B-TREATMENT
aspirin	I-TREATMENT
,	O
however	O
.	O

Coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
status	O
post	O
non-ST	B-PROBLEM
elevation	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
with	O
80	B-PROBLEM
percent	I-PROBLEM
mid	I-PROBLEM
LAD	I-PROBLEM
lesion	I-PROBLEM
,	O
now	O
status	O
post	O
angioplasty	B-TREATMENT
.	O

Hypertension	B-PROBLEM
.	O

Chronic	B-PROBLEM
renal	I-PROBLEM
insufficiency	I-PROBLEM
.	O

Chronic	B-PROBLEM
obstructive	I-PROBLEM
pulmonary	I-PROBLEM
disease	I-PROBLEM
.	O

Guaiac	B-PROBLEM
positive	I-PROBLEM
stools	I-PROBLEM
.	O

Anemia	B-PROBLEM
.	O

1.	O
Lipitor	B-TREATMENT
10	O
mg	O
q.d.	O

2.	O
Lisinopril	B-TREATMENT
2.5	O
mg	O
q.d.	O

3.	O
Flovent	B-TREATMENT
110	O
micrograms	O
aerosol	O
two	O
puffs	O
b.i.d.	O

4.	O
Aspirin	B-TREATMENT
325	O
mg	O
q.d.	O

5.	O
Combivent	B-TREATMENT
MDI	O
p.r.n.	O

6.	O
Toprol	B-TREATMENT
XL	I-TREATMENT
100	O
mg	O
q.d.	O

At	O
the	O
time	O
of	O
discharge	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
vital	I-TEST
signs	I-TEST
were	O
stable	O
and	O
he	O
was	O
without	O
complaints	B-PROBLEM
.	O

It	O
was	O
discussed	O
with	O
him	O
the	O
need	O
to	O
schedule	O
follow-up	O
for	O
colonoscopy	B-TEST
with	O
his	O
PCP	O
as	O
well	O
.	O

Sulfa	B-TREATMENT
(	I-TREATMENT
Sulfonamides	I-TREATMENT
)	O
/	O
Penicillins	B-TREATMENT
/	O
Macrodantin	B-TREATMENT
/	O
Ivp	B-TREATMENT
Dye	I-TREATMENT
,	O
Iodine	B-TREATMENT
Containing	I-TREATMENT

Just	O
prior	O
to	O
discharge	O
on	O
11-14	O
,	O
pt	B-TEST
's	I-TEST
BP	I-TEST
was	O
found	O
to	O
be	O
70/40	O
P70	O
s	O
just	O
after	O
receiving	O
her	B-TREATMENT
am	I-TREATMENT
BP	I-TREATMENT
meds	I-TREATMENT
.	O

She	O
was	O
asymptomatic	B-PROBLEM
.	O

1.	O
Hypotension	B-PROBLEM
:	O
The	B-TREATMENT
patient	I-TREATMENT
'd	I-TREATMENT
pm	I-TREATMENT
BP	I-TREATMENT
meds	I-TREATMENT
were	O
held	O
11-14	O
and	O
she	O
was	O
administered	O
1.5L	O
NS	B-TREATMENT
over	O
the	O
course	O
of	O
the	O
day	O
with	O
subsequent	O
SBP	B-TEST
s	I-TEST
in	O
the	O
high	O
90	O
s,	O
low	O
100	O
s,.	O

The	B-PROBLEM
hypotension	I-PROBLEM
was	O
likely	O
due	O
to	O
volume	B-PROBLEM
depletion	I-PROBLEM
caused	O
by	O
her	B-PROBLEM
diarrhea	I-PROBLEM
/	O
loose	B-PROBLEM
stools	I-PROBLEM
in	O
addition	O
to	O
decreased	B-PROBLEM
PO	I-PROBLEM
intake	I-PROBLEM
secondary	O
to	O
her	B-PROBLEM
GERD	I-PROBLEM
and	O
thrush	B-PROBLEM
.	O

All	O
of	O
this	O
occurred	O
in	O
the	O
setting	O
of	O
aggressive	B-TREATMENT
BP	I-TREATMENT
management	I-TREATMENT
with	O
metoprolol	B-TREATMENT
25	O
BID	O
,	O
HCTZ	B-TREATMENT
/	O
Triampterene	B-TREATMENT
(	O
as	O
a	O
replacment	O
for	O
lasix	B-TREATMENT
due	O
to	O
recurrent	B-PROBLEM
hypokalemia	I-PROBLEM
),	O
Benicar	B-TREATMENT
20	O
mg	O
QD	O
,	O
and	O
Imdur	B-TREATMENT
30	O
mg	O
QD	O
.	O

Infection	B-PROBLEM
/	O
sepsis	B-PROBLEM
was	O
not	O
likely	O
given	O
she	O
was	O
afebrile	B-PROBLEM
and	O
had	O
no	O
localizing	B-PROBLEM
sx	I-PROBLEM
with	O
an	O
improving	O
lung	B-TEST
exam	I-TEST
and	O
02	B-PROBLEM
requirement	I-PROBLEM
.	O

Given	O
the	B-PROBLEM
patient	I-PROBLEM
's	I-PROBLEM
recent	I-PROBLEM
RP	I-PROBLEM
bleed	I-PROBLEM
,	O
there	O
was	O
concern	O
for	O
a	B-PROBLEM
recurrent	I-PROBLEM
bleed	I-PROBLEM
.	O

Her	B-TEST
groin	I-TEST
exam	I-TEST
was	O
unchanged	O
.	O

Her	B-TEST
Hct	I-TEST
dropped	O
from	O
Hct	B-TEST
38.9	O
before	O
fluids	B-TREATMENT
to	O
35.5	O
s/p	O
1.5L	O
NS	B-TREATMENT
and	O
was	O
thought	O
to	O
be	O
dilutional	O
.	O

Repeat	B-TEST
hcts	I-TEST
were	O
stable	O
.	O

The	O
patient	O
was	O
kept	O
an	O
additional	O
two	O
days	O
to	O
follow	O
her	B-TEST
hcts	I-TEST
and	O
titrate	O
her	B-TREATMENT
BP	I-TREATMENT
meds	I-TREATMENT
.	O

As	O
volume	B-PROBLEM
depletion	I-PROBLEM
was	O
thought	O
to	O
be	O
the	O
cause	O
of	O
her	B-PROBLEM
low	I-PROBLEM
BP	I-PROBLEM
,	O
only	O
the	B-TREATMENT
BBlocker	I-TREATMENT
was	O
restarted	O
.	O

She	O
was	O
also	O
placed	O
on	O
on	O
low	B-TREATMENT
dose	I-TREATMENT
spironolactone	I-TREATMENT
as	O
a	B-TREATMENT
K	I-TREATMENT
sparing	I-TREATMENT
diuretic	I-TREATMENT
and	O
for	O
BP	B-TREATMENT
control	I-TREATMENT
in	O
addition	O
to	O
Toprol	B-TREATMENT
XL	I-TREATMENT
25	O
mg	O
QD	O
for	O
her	B-PROBLEM
coronary	I-PROBLEM
disease	I-PROBLEM
.	O

She	O
tolerated	O
these	B-TREATMENT
meds	I-TREATMENT
with	O
SBP	B-TEST
s	I-TEST
in	O
the	O
high	O
90	O
s	O
to	O
100	O
s	O
and	O
was	O
therefore	O
discharged	O
on	O
this	B-TREATMENT
regimen	I-TREATMENT
.	O

She	O
will	O
need	O
follow	O
up	O
with	O
her	O
PCP	O
within	O
B	O
week	O
after	O
discharge	O
from	O
the	O
extended	O
care	O
facility	O
for	O
further	B-TREATMENT
BP	I-TREATMENT
titration	I-TREATMENT
and	O
monitoring	B-TEST
of	I-TEST
her	I-TEST
electrolytes	I-TEST
.	O

2.	O
Thrush	B-PROBLEM
:	O
This	O
is	O
likely	O
secondary	O
to	O
her	B-TREATMENT
steroid	I-TREATMENT
inhalers	I-TREATMENT
and	O
PO	B-TREATMENT
prednisone	I-TREATMENT
for	O
COPD	B-PROBLEM
exacerbation	I-PROBLEM
.	O

She	O
was	O
started	O
on	O
nystatin	B-TREATMENT
swish	O
and	O
swallow	O
QID	O
.	O

The	O
patient	O
was	O
encouraged	O
to	O
take	B-TREATMENT
PO	I-TREATMENT
liquids	I-TREATMENT
to	O
prevent	O
volume	B-PROBLEM
depletion	I-PROBLEM
.	O

3.	O
diarrhea	B-PROBLEM
:	O
The	O
patient	O
has	O
been	O
having	O
loose	B-PROBLEM
stools	I-PROBLEM
at	O
night	O
and	O
was	O
guiac	B-PROBLEM
pos	I-PROBLEM
x	O
2	O
.	O

Stool	B-TEST
for	I-TEST
C.diff	I-TEST
toxin	I-TEST
was	O
sent	O
x	O
1	O
and	O
was	O
negative	O
.	O

Her	B-TREATMENT
bowel	I-TREATMENT
regimen	I-TREATMENT
is	O
prn	O
.	O

Gastroenteritis	B-PROBLEM
is	O
possible	O
but	O
she	O
has	O
no	O
vomiting	B-PROBLEM
and	O
only	O
occ	B-PROBLEM
nausea	I-PROBLEM
with	O
meds	B-TREATMENT
.	O

There	O
is	O
no	O
evidence	O
of	O
obstruction	B-PROBLEM
on	O
AXR	B-TEST
.	O

Therefore	O
,	O
the	O
cause	O
of	O
her	B-PROBLEM
mild	I-PROBLEM
diarrhea	I-PROBLEM
(	O
few	B-PROBLEM
loose	I-PROBLEM
BM	I-PROBLEM
/	O
liquid	B-PROBLEM
stool	I-PROBLEM
/	O
night	O
)	O
may	O
be	O
either	O
viral	B-PROBLEM
or	O
secondary	O
to	O
resolving	B-PROBLEM
abdominal	I-PROBLEM
hematoma	I-PROBLEM
with	O
resultant	O
irritation	B-PROBLEM
of	I-PROBLEM
GI	I-PROBLEM
system	I-PROBLEM
.	O

We	O
have	O
advised	O
a	B-TREATMENT
BRAT	I-TREATMENT
diet	I-TREATMENT
.	O

4.	O
guiac	B-PROBLEM
pos	I-PROBLEM
stool	I-PROBLEM
:	O
Given	O
the	O
patient	O
's	O
sx	O
of	O
GERD	B-PROBLEM
,	O
current	O
PO	B-TREATMENT
steroid	I-TREATMENT
regimen	I-TREATMENT
,	O
and	O
ASA	B-TREATMENT
for	O
her	B-TREATMENT
stents	I-TREATMENT
,	O
the	O
ddx	O
for	O
her	B-PROBLEM
guiac	I-PROBLEM
positive	I-PROBLEM
stools	I-PROBLEM
would	O
include	O
gastritis	B-PROBLEM
/	O
gastric	B-PROBLEM
ulcer	I-PROBLEM
in	O
addition	O
to	O
lower	B-PROBLEM
GI	I-PROBLEM
pathology	I-PROBLEM
.	O

However	O
,	O
she	O
has	O
no	O
vomiting	B-PROBLEM
and	O
only	B-PROBLEM
mild	I-PROBLEM
nausea	I-PROBLEM
with	O
medications	B-TREATMENT
.	O

She	O
also	O
has	O
no	O
gross	B-PROBLEM
blood	I-PROBLEM
per	I-PROBLEM
rectum	I-PROBLEM
and	O
her	B-TEST
hct	I-TEST
is	O
stable	O
.	O

Upon	O
discharge	O
the	O
patient	O
was	O
changed	O
to	O
a	B-TREATMENT
BID	I-TREATMENT
protonix	I-TREATMENT
regimen	I-TREATMENT
.	O

She	O
will	O
need	O
outpatient	O
follow	O
up	O
for	O
her	B-PROBLEM
guiac	I-PROBLEM
pos	I-PROBLEM
stools	I-PROBLEM
with	O
endoscopy	B-TEST
vs	O
EGD	B-TEST
+/-	O
H.pylori	B-TEST
serologies	I-TEST
.	O

1.	O
Atorvastatin	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

2.	O
Pantoprazole	B-TREATMENT
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
twice	O
a	O
day	O
.	O

3.	O
Acetaminophen	B-TREATMENT
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
).	O

4.	O
Oxycodone	B-TREATMENT
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-PROBLEM
.	O

5.	O
Fluticasone	B-TREATMENT
50	O
mcg	O
/	O
Actuation	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Spray	O
Nasal	O
DAILY	O
(	O
Daily	O
).	O

6.	O
Fluticasone	B-TREATMENT
110	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
BID	O
(	O
2	O
times	O
a	O
day	O
).	O

7.	O
Tiotropium	B-TREATMENT
Bromide	I-TREATMENT
18	O
mcg	O
Capsule	O
,	O
w/	O
Inhalation	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
Inhalation	O
DAILY	O
(	O
Daily	O
).	O

8.	O
Clopidogrel	B-TREATMENT
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

9.	O
Albuterol	B-TREATMENT
Sulfate	I-TREATMENT
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
or	O
wheezing	B-PROBLEM
.	O

10.	O
Aluminum	B-TREATMENT
-	I-TREATMENT
Magnesium	I-TREATMENT
Hydroxide	I-TREATMENT
225-200	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15-30	O
ML	O
s	O
PO	O
PRN	O
(	O
as	O
needed	O
).	O

11.	O
Senna	B-TREATMENT
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O

12.	O
Prednisone	B-TREATMENT
10	O
mg	O
Tablet	O
Sig	O
:	O
1-2	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
4	O
days	O
:	O
Please	O
take	O
two	O
pills	O
for	O
one	O
day	O
starting	O
11-17	O
,	O
then	O
take	O
one	O
pill	O
for	O
three	O
days	O
.	O

13.	O
oxygen	B-TREATMENT
continue	O
02	B-TREATMENT
at	O
1L/min	O
continuous	O
to	O
keep	O
sats	B-TEST
in	O
90	O
's.	O

14.	O
Spironolactone	B-TREATMENT
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
).	O

15.	O
Metoprolol	B-TREATMENT
Succinate	I-TREATMENT
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24HR	O
PO	O
DAILY	O
(	O
Daily	O
).	O

16.	O
Nystatin	B-TREATMENT
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
for	O
7	O
days	O
.	O

17.	O
Aspirin	B-TREATMENT
325	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
).	O

1)	O
Rapid	B-PROBLEM
atrial	I-PROBLEM
fibrillation	I-PROBLEM
with	O
demand	B-PROBLEM
ischemia	I-PROBLEM

2)	O
Retroperitoneal	B-PROBLEM
bleed	I-PROBLEM

If	O
you	O
experience	O
CP	B-PROBLEM
,	O
SOB	B-PROBLEM
,	O
dizzyness	B-PROBLEM
,	O
or	O
any	B-PROBLEM
other	I-PROBLEM
symptoms	I-PROBLEM
that	O
concern	O
you	O
please	O
call	O
your	O
PCP	O
or	O
return	O
to	O
the	O
ER	O
.	O

Note	O
:	O
you	O
have	O
had	O
a	B-TREATMENT
cardiac	I-TREATMENT
stent	I-TREATMENT
placed	O
during	O
this	O
admission	O
.	O

You	O
must	O
take	O
your	B-TREATMENT
aspirin	I-TREATMENT
and	O
plavix	B-TREATMENT
every	O
day	O
to	O
prevent	O
failure	B-PROBLEM
of	I-PROBLEM
these	I-PROBLEM
stents	I-PROBLEM
which	O
could	O
be	O
life	O
threatening	O
.	O

Please	O
take	O
all	B-TREATMENT
medications	I-TREATMENT
as	O
prescribed	O
.	O

2)	O
You	O
are	O
scheduled	O
to	O
have	O
your	B-TREATMENT
staples	I-TREATMENT
removed	O
on	O
2013-11-20	O
3:00	O
with	O
provider	O
:	O
Leah	O
,	O
Paula	O
G.	O
Wilson	O
SURGERY	O
(	O
NHB	O
)	O

This	O
is	O
a	O
55	O
-	O
year-old	O
Caucasian	O
speaking	O
male	O
who	O
is	O
a	O
smoker	O
and	O
has	O
a	O
family	O
history	O
of	O
coronary	B-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
as	O
well	O
as	O
a	O
personal	O
history	O
of	O
hypertension	B-PROBLEM
,	O
who	O
experienced	O
multiple	O
episodes	O
of	O
10/10	B-PROBLEM
substernal	I-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
radiating	O
down	O
his	O
left	O
arm	O
last	O
night	O
with	O
his	O
daily	O
activities	O
.	O

Each	B-PROBLEM
episode	I-PROBLEM
lasted	O
approximately	O
15	O
minutes	O
in	O
duration	O
and	O
resolved	O
on	O
their	O
own	O
.	O

This	O
morning	O
while	O
landscaping	O
the	O
patient	O
had	O
unremitting	B-PROBLEM
12-05	I-PROBLEM
pain	I-PROBLEM
with	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
and	O
diaphoresis	B-PROBLEM
.	O

He	O
presented	O
to	O
Deaconess-Nashoba	O
Hospital	O
Hospital	O
and	O
the	B-TEST
first	I-TEST
EKG	I-TEST
was	O
found	O
to	O
have	O
ST	B-PROBLEM
elevations	I-PROBLEM
in	I-PROBLEM
V1-V3	I-PROBLEM
of	O
1-2	O
mm	O
with	O
T	B-PROBLEM
wave	I-PROBLEM
inversions	I-PROBLEM
in	O
V4-6	O
,	O
I	O
and	O
L	O
,	O
which	O
progressed	O
to	O
3-0167	O
W.	O
Seventh	O
Ave.	O
elevations	O
within	O
20	O
minutes	O
.	O

Heparin	B-TREATMENT
and	O
nitroglycerin	B-TREATMENT
drip	I-TREATMENT
were	O
started	O
with	O
10	O
mg	O
of	O
IV	B-TREATMENT
Retavase	I-TREATMENT
half	O
dose	O
.	O

He	O
was	O
transferred	O
to	O
the	O
North	O
Adams	O
Regional	O
Hospital	O
for	O
catheterization	B-TEST
.	O

Once	O
at	O
Hahnemann	O
General	O
Hospital	O
he	O
received	O
heparin	B-TREATMENT
and	O
Integrilin	B-TREATMENT
.	O

Coronary	B-TEST
angiography	I-TEST
revealed	O
left	O
main	O
,	O
left	O
circumflex	O
and	O
RCA	O
normal	O
and	O
left	B-PROBLEM
LAD	I-PROBLEM
with	I-PROBLEM
99%	I-PROBLEM
midstenosis	I-PROBLEM
.	O

A	B-TREATMENT
Hepacoat	I-TREATMENT
stent	I-TREATMENT
was	O
placed	O
with	O
no	O
residuals	B-TEST
but	O
good	O
flow	O
after	O
nitroglycerin	B-TREATMENT
and	O
diltiazem	B-TREATMENT
.	O

The	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
persisted	O
afterwards	O
and	O
a	B-TEST
relook	I-TEST
catheterization	I-TEST
was	O
performed	O
that	O
revealed	O
no	O
occlusions	B-PROBLEM
.	O

The	B-TEST
right	I-TEST
heart	I-TEST
catheterization	I-TEST
revealed	O
a	B-TEST
cardiac	I-TEST
output	I-TEST
index	I-TEST
of	O
4.11	O
and	O
2.15	O
respectively	O
.	O

RA	B-TEST
pressure	I-TEST
was	O
13	O
,	O
RV	B-TEST
pressure	I-TEST
45/7	O
,	O
wedge	B-TEST
27	O
and	O
PA	B-TEST
pressures	I-TEST
of	O
42/21	O
.	O

He	O
was	O
transferred	O
to	O
the	O
CC	O
for	O
monitoring	B-TEST
and	O
he	O
denied	O
having	O
further	B-PROBLEM
pain	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
nausea	B-PROBLEM
or	O
vomiting	B-PROBLEM
.	O

At	O
baseline	O
the	O
patient	O
denies	O
any	O
previous	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
pressure	B-PROBLEM
,	O
dyspnea	B-PROBLEM
on	O
exertion	O
,	O
orthopnea	B-PROBLEM
,	O
PND	B-PROBLEM
or	O
palpitations	B-PROBLEM
.	O

Only	O
hypertension	B-PROBLEM
.	O

Antihypertensive	B-TREATMENT
medications	I-TREATMENT
that	O
the	O
patient	O
could	O
not	O
identify	O
.	O

The	O
patient	O
denies	O
having	O
any	B-PROBLEM
drug	I-PROBLEM
allergies	I-PROBLEM
.	O

Significant	O
for	O
a	O
brother	O
who	O
had	O
an	B-PROBLEM
MI	I-PROBLEM
at	O
age	O
61	O
.	O

The	O
patient	O
was	O
afebrile	B-PROBLEM
.	O

Blood	B-TEST
pressure	I-TEST
156/67	O
,	O
pulse	B-TEST
80	O
and	O
respiratory	B-TEST
rate	I-TEST
14	O
.	O

He	O
was	O
laying	O
flat	O
,	O
very	B-PROBLEM
tense	I-PROBLEM
.	O

Skin	O
was	O
strong	O
build	O
and	O
was	O
in	O
no	O
apparent	B-PROBLEM
distress	I-PROBLEM
.	O

He	O
was	O
anicteric	B-PROBLEM
with	O
moist	O
mucous	O
membranes	O
.	O

No	O
JVD	B-PROBLEM
or	O
increased	B-PROBLEM
JVP	I-PROBLEM
was	O
appreciated	O
at	O
0	O
degrees	O
.	O

The	O
patient	O
did	O
not	O
have	O
any	B-PROBLEM
carotid	I-PROBLEM
bruits	I-PROBLEM
,	O
abdominal	B-PROBLEM
bruits	I-PROBLEM
or	O
femoral	B-PROBLEM
bruits	I-PROBLEM
.	O

His	B-TEST
PMI	I-TEST
was	O
two	O
finger	B-TEST
breath	I-TEST
width	I-TEST
in	O
the	O
fifth	O
intercostal	O
space	O
lateral	O
to	O
the	O
midclavicular	O
line	O
.	O

There	O
were	O
no	O
lifts	B-PROBLEM
or	O
heaves	B-PROBLEM
on	O
examination	B-TEST
.	O

His	O
heart	O
was	O
regular	O
with	O
no	O
murmurs	B-PROBLEM
,	O
rubs	B-PROBLEM
or	O
gallops	B-PROBLEM
and	O
his	B-TEST
radial	I-TEST
and	I-TEST
DP	I-TEST
pulses	I-TEST
were	O
both	O
2+	O
bilaterally	O
and	O
equal	O
.	O

His	O
lungs	O
were	O
clear	O
to	O
auscultation	B-TEST
.	O

His	O
abdomen	O
was	O
scaphoid	B-PROBLEM
,	O
nondistended	B-PROBLEM
,	O
nontender	B-PROBLEM
with	O
positive	O
bowel	O
sounds	O
.	O

His	O
extremities	O
were	O
warm	O
,	O
pink	O
with	O
no	O
edema	B-PROBLEM
.	O

The	O
right	O
calf	O
site	O
had	O
minimal	B-PROBLEM
ooze	I-PROBLEM
and	O
no	O
hematomas	B-PROBLEM
or	O
bruits	B-PROBLEM
.	O

This	O
is	O
a	O
54	O
-	O
year-old	O
man	O
with	O
significant	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
risk	I-PROBLEM
factors	I-PROBLEM
,	O
positive	O
family	O
history	O
,	O
smoking	O
history	O
,	O
hypertension	B-PROBLEM
and	O
gender	O
who	O
presented	O
with	O
an	B-PROBLEM
ST	I-PROBLEM
elevation	I-PROBLEM
MI	I-PROBLEM
status	O
post	O
LAD	B-TREATMENT
stent	I-TREATMENT
,	O
complicated	O
by	O
no	O
residuals	B-PROBLEM
requiring	O
nitroglycerin	B-TREATMENT
and	O
diltiazem	B-TREATMENT
for	O
good	O
flow	O
.	O

The	O
patient	O
was	O
pain	B-PROBLEM
free	O
and	O
doing	O
well	O
.	O

For	O
his	B-PROBLEM
coronary	I-PROBLEM
artery	I-PROBLEM
disease	I-PROBLEM
,	O
aspirin	B-TREATMENT
was	O
started	O
at	O
325	O
.	O

Plavix	B-TREATMENT
was	O
started	O
at	O
75	O
mg	O
a	O
day	O
,	O
Lipitor	B-TREATMENT
20	O
mg	O
per	O
day	O
,	O
metoprolol	B-TREATMENT
25	O
mg	O
twice	O
a	O
day	O
to	O
be	O
titrated	O
up	O
as	O
tolerated	O
and	O
on	O
day	O
two	O
of	O
admission	O
an	B-TREATMENT
ACE	I-TREATMENT
inhibitor	I-TREATMENT
was	O
started	O
.	O

Captopril	B-TREATMENT
6.2	O
3	O
x	O
a	O
day	O
and	O
titrated	O
up	O
.	O

A	B-TEST
lipid	I-TEST
panel	I-TEST
was	O
checked	O
and	O
found	O
to	O
be	O
within	O
normal	O
limits	O
,	O
although	O
it	O
was	O
noted	O
this	O
was	O
in	O
the	O
post	O
MI	O
setting	O
and	O
the	B-TEST
lipid	I-TEST
panel	I-TEST
could	O
be	O
falsely	O
low	O
.	O

Serial	B-TEST
CK	I-TEST
s	I-TEST
were	O
followed	O
with	O
a	B-TEST
CK	I-TEST
peak	I-TEST
of	O
433	O
.	O

Hypertension	B-PROBLEM
was	O
managed	O
with	O
beta	B-TREATMENT
blocker	I-TREATMENT
and	O
ACE	B-TREATMENT
inhibitor	I-TREATMENT
and	O
Integrilin	B-TREATMENT
was	O
continued	O
post	O
MI	B-PROBLEM
for	O
18	O
hours	O
.	O

Rhythm	O
was	O
maintained	O
at	O
normal	O
sinus	O
,	O
monitored	O
on	O
telemetry	B-TEST
without	O
ectopy	B-PROBLEM
.	O

EKG	B-TEST
s	I-TEST
were	O
followed	O
for	O
normalization	O
.	O

The	O
patient	O
had	O
an	B-TEST
echocardiogram	I-TEST
on	O
day	O
two	O
of	O
admission	O
,	O
which	O
revealed	O
a	B-PROBLEM
mildly	I-PROBLEM
dilated	I-PROBLEM
left	I-PROBLEM
atrium	I-PROBLEM
,	O
mild	B-PROBLEM
symmetric	I-PROBLEM
LVH	I-PROBLEM
,	O
normal	O
LV	O
cavity	O
size	O
,	O
mild	B-PROBLEM
region	I-PROBLEM
LV	I-PROBLEM
systolic	I-PROBLEM
dysfunction	I-PROBLEM
,	O
arresting	B-PROBLEM
regional	I-PROBLEM
wall	I-PROBLEM
motion	I-PROBLEM
abnormality	I-PROBLEM
including	O
focal	B-PROBLEM
apical	I-PROBLEM
hypokinesis	I-PROBLEM
,	O
a	O
normal	O
right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
,	O
a	B-PROBLEM
moderately	I-PROBLEM
dilated	I-PROBLEM
aortic	I-PROBLEM
root	I-PROBLEM
,	O
a	B-PROBLEM
mildly	I-PROBLEM
dilated	I-PROBLEM
ascending	I-PROBLEM
aorta	I-PROBLEM
,	O
normal	O
aortic	O
valve	O
leaflet	O
,	O
normal	O
mitral	O
valve	O
leaflet	O
and	O
no	O
pericardial	B-PROBLEM
effusions	I-PROBLEM
.	O

The	O
patient	O
was	O
normal	O
volume	O
and	O
displayed	O
no	O
evidence	O
CHF	B-PROBLEM
signs	I-PROBLEM
or	I-PROBLEM
symptoms	I-PROBLEM
.	O

The	B-PROBLEM
risk	I-PROBLEM
factors	I-PROBLEM
were	O
addressed	O
.	O

The	O
patient	O
was	O
told	O
repeatedly	O
that	O
he	O
needed	O
to	O
stop	O
smoking	O
and	O
was	O
given	O
a	B-TREATMENT
nicotine	I-TREATMENT
patch	I-TREATMENT
and	O
his	O
primary	O
care	O
provider	O
was	O
called	O
to	O
discuss	O
outpatient	O
plans	O
to	O
help	O
the	O
patient	O
stop	O
smoking	O
.	O

The	O
patient	O
was	O
advised	O
to	O
have	O
a	B-TREATMENT
low	I-TREATMENT
fat	I-TREATMENT
/	I-TREATMENT
low	I-TREATMENT
cholesterol	I-TREATMENT
diet	I-TREATMENT
,	O
was	O
cleared	O
by	O
PT	O
and	O
advised	O
to	O
do	O
cardiac	B-TREATMENT
rehabilitation	I-TREATMENT
.	O

He	O
was	O
advised	O
the	O
importance	O
of	O
each	O
of	O
his	O
and	O
compliance	O
with	O
each	O
of	O
these	B-TREATMENT
medications	I-TREATMENT
and	O
was	O
told	O
he	O
needed	O
close	O
followup	O
with	O
a	O
cardiologist	O
.	O

For	O
renal	O
,	O
his	B-TEST
creatinine	I-TEST
was	O
monitored	O
and	O
the	B-TEST
dye	I-TEST
load	I-TEST
and	O
the	B-TEST
catheterization	I-TEST
.	O

The	O
patient	O
was	O
given	O
a	B-TREATMENT
low	I-TREATMENT
fat	I-TREATMENT
/	I-TREATMENT
low	I-TREATMENT
cholesterol	I-TREATMENT
diet	I-TREATMENT
.	O

His	B-TEST
electrolytes	I-TEST
were	O
monitored	O
and	O
repleted	O
carefully	O
.	O

He	O
had	O
normal	O
bowel	O
movements	O
and	O
had	O
GI	B-TREATMENT
prophylaxis	I-TREATMENT
throughout	O
his	O
stay	O
.	O

For	O
hematology	O
,	O
the	B-TEST
patient	I-TEST
's	I-TEST
hematocrit	I-TEST
and	O
platelets	B-TEST
were	O
monitored	O
after	O
the	B-TEST
catheterization	I-TEST
.	O

They	O
were	O
normal	O
and	O
did	O
not	O
change	O
and	O
the	O
patient	O
received	O
pneumatic	B-TREATMENT
boots	I-TREATMENT
for	O
DVT	B-TREATMENT
prophylaxis	I-TREATMENT
.	O

On	O
day	O
two	O
of	O
admission	O
,	O
the	O
patient	O
ambulated	O
with	O
PT	B-TREATMENT
and	O
was	O
moved	O
to	O
the	O
regular	O
floor	O
.	O

He	O
denied	O
ever	O
having	O
any	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
chest	B-PROBLEM
pressure	I-PROBLEM
,	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
dyspnea	B-PROBLEM
on	O
exertion	O
and	O
he	O
was	O
discharged	O
to	O
home	O
.	O

He	O
was	O
told	O
to	O
return	O
to	O
the	O
emergency	O
department	O
if	O
he	O
had	O
any	B-PROBLEM
chest	I-PROBLEM
pain	I-PROBLEM
,	O
pressure	B-PROBLEM
,	O
difficulty	B-PROBLEM
breathing	I-PROBLEM
,	O
nausea	B-PROBLEM
,	O
light-headiness	B-PROBLEM
or	O
dizziness	B-PROBLEM
.	O

He	O
was	O
advised	O
to	O
take	O
all	O
of	O
his	B-TREATMENT
medications	I-TREATMENT
.	O

1.	O
ST	B-PROBLEM
elevation	I-PROBLEM
myocardial	I-PROBLEM
infarction	I-PROBLEM
.	O

2.	O
Hypertension	B-PROBLEM
.	O

Cardiac	B-TEST
catheterization	I-TEST
and	O
stent	B-TREATMENT
placement	I-TREATMENT
in	I-TREATMENT
the	I-TREATMENT
mid	I-TREATMENT
left	I-TREATMENT
anterior	I-TREATMENT
descending	I-TREATMENT
artery	I-TREATMENT
.	O

Aspirin	B-TREATMENT
325	O
mg	O
q.d.	O
,	O
Plavix	B-TREATMENT
75	O
mg	O
q.d.	O
,	O
Lipitor	B-TREATMENT
20	O
mg	O
q.d.	O
,	O
nitroglycerin	B-TREATMENT
0.3	O
mg	O
sublingually	O
p.r.n.	O
chest	B-PROBLEM
pain	I-PROBLEM
or	O
pressure	B-PROBLEM
or	O
shortness	B-PROBLEM
of	I-PROBLEM
breath	I-PROBLEM
,	O
lisinopril	B-TREATMENT
hydrochlorothiazide	B-TREATMENT
20	O
/	O
12.5	O
mg	O
q.d.	O
,	O
atenolol	B-TREATMENT
25	O
mg	O
q.d.	O

The	O
patient	O
was	O
told	O
he	O
could	O
return	O
to	O
work	O
after	O
two	O
weeks	O
of	O
rest	B-TREATMENT
,	O
given	O
that	O
his	O
work	O
required	O
a	O
high	O
level	O
of	O
exertion	O
and	O
the	O
patient	O
was	O
also	O
given	O
a	O
prescription	O
for	O
a	B-TREATMENT
transdermal	I-TREATMENT
nicotine	I-TREATMENT
patch	I-TREATMENT
14	O
mg	O
the	O
be	O
used	O
for	O
up	O
to	O
2	O
weeks	O
until	O
cravings	B-PROBLEM
remitted	O
.	O
